FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Faubel, S AF Faubel, Sarah TI Renal Relevant Radiology: Introduction SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material C1 [Faubel, Sarah] Univ Colorado, Div Internal Med, Denver, CO 80202 USA. [Faubel, Sarah] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Faubel, S (reprint author), Univ Colorado Denver, Div Nephrol, 12700 East 19th Ave,Box C281, Aurora, CO 80045 USA. EM sarah.faubel@ucdenver.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD FEB 7 PY 2014 VL 9 IS 2 BP 371 EP 372 DI 10.2215/CJN.10211013 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA AI9FY UT WOS:000337238400022 PM 24510108 ER PT J AU Faubel, S Patel, NU Lockhart, ME Cadnapaphornchai, MA AF Faubel, Sarah Patel, Nayana U. Lockhart, Mark E. Cadnapaphornchai, Melissa A. TI Renal Relevant Radiology: Use of Ultrasonography in Patients with AKI SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE TUBULAR-NECROSIS; ACUTE KIDNEY INJURY; HEMOLYTIC-UREMIC SYNDROME; RESISTIVE INDEX; HEALTHY-CHILDREN; SONOGRAPHIC MEASUREMENTS; ADULT VOLUNTEERS; DUPLEX-DOPPLER; FOLLOW-UP; ULTRASOUND AB As judged by the American College of Radiology Appropriateness Criteria, renal Doppler ultrasonography is the most appropriate imaging test in the evaluation of AKI and has the highest level of recommendation. Unfortunately, nephrologists are rarely specifically trained in ultrasonography technique and interpretation, and important clinical information obtained from renal ultrasonography may not be appreciated. In this review, the strengths and limitations of grayscale ultrasonography in the evaluation of patients with AKI will be discussed with attention to its use for (1) assessment of intrinsic causes of AKI, (2) distinguishing acute from chronic kidney diseases, and (3) detection of obstruction. The use of Doppler imaging and the resistive index in patients with AKI will be reviewed with attention to its use for (1) predicting the development of AKI, (2) predicting the prognosis of AKI, and (3) distinguishing prerenal azotemia from intrinsic AKI. Finally, pediatric considerations in the use of ultrasonography in AKI will be reviewed. C1 [Faubel, Sarah] Univ Colorado, Div Internal Med, Denver, CO 80202 USA. [Faubel, Sarah] Denver Vet Affairs Med Ctr, Denver, CO USA. [Patel, Nayana U.] Univ Colorado Denver, Dept Radiol, Denver, CO USA. [Cadnapaphornchai, Melissa A.] Univ Colorado Denver, Dept Internal Med, Denver, CO USA. [Lockhart, Mark E.] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA. RP Faubel, S (reprint author), Univ Colorado Denver, Denver Vet Adm Med Ctr, Div Nephrol, 12700 East 19th Ave,Box C281, Aurora, CO 80045 USA. EM sarah.faubel@ucdenver.edu NR 62 TC 9 Z9 10 U1 1 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD FEB 7 PY 2014 VL 9 IS 2 BP 382 EP 394 DI 10.2215/CJN.04840513 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA AI9FY UT WOS:000337238400024 PM 24235286 ER PT J AU Katolik, A Johnsson, R Montemayor, E Lackey, JG Hart, PJ Damha, MJ AF Katolik, Adam Johnsson, Richard Montemayor, Eric Lackey, Jeremy G. Hart, P. John Damha, Masad J. TI Regiospecific Solid-Phase Synthesis of Branched Oligoribonucleotides That Mimic Intronic Lariat RNA Intermediates SO JOURNAL OF ORGANIC CHEMISTRY LA English DT Article ID YEAST DEBRANCHING ENZYME; SINGLE-STRANDED-DNA; IN-VITRO; MYXOCOCCUS-XANTHUS; SELF-CLEAVAGE; INHIBITION; FRAGMENTS; OLIGODEOXYNUCLEOTIDES; OLIGONUCLEOTIDES; CEREVISIAE AB We have developed new solid phase methods for the synthesis of branched RNAs that mimic intronic lariat RNA intermediates. These methods produce branched oligoribonucleotide sequences of arbitrary length, base composition, and regiochemistry at the branchpoint junction. The methods utilize branching monomers that allow for the growth of each branch regioselectively from any of the hydroxyl positions (5', 3', or 2') at the branch-point junction. The integrity and branchpoint connectivity of the synthetic products have been confirmed by HPLC and MS analysis, and cleavage of the 2',5' linkage by recombinant debranching enzyme. Nonhydrolyzable branched RNA analogues containing arabinose instead of ribose at the branchpoint junction were shown to inhibit debranching activity and, hence, represent "decoys" for sequestering RNA binding proteins thought to drive amyotrophic lateral sclerosis (ALS). C1 [Katolik, Adam; Johnsson, Richard; Lackey, Jeremy G.; Damha, Masad J.] McGill Univ, Montreal, PQ H3A 0B8, Canada. [Montemayor, Eric; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Damha, MJ (reprint author), McGill Univ, 801 Sherbrooke St W, Montreal, PQ H3A 0B8, Canada. EM masad.damha@mcgill.ca RI Johnsson, Richard/B-8954-2011 FU National Science and Engineering Council of Canada; Robert A. Welch Foundation [AQ-1399]; National Science Foundation [DBI-0905865]; Swedish Research Council FX This work was supported by grants from the National Science and Engineering Council of Canada (Discovery Grant to AID.), the Robert A. Welch Foundation (AQ-1399) (P.J.H.), the National Science Foundation (DBI-0905865) (E.M.), and the Swedish Research Council (R.J.). NR 45 TC 13 Z9 13 U1 0 U2 7 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-3263 J9 J ORG CHEM JI J. Org. Chem. PD FEB 7 PY 2014 VL 79 IS 3 BP 963 EP 975 DI 10.1021/jo4024182 PG 13 WC Chemistry, Organic SC Chemistry GA AA5TZ UT WOS:000331163800014 PM 24401015 ER PT J AU Abdel-Kader, K Jhamb, M Mandich, LA Yabes, J Keene, RM Beach, S Buysse, DJ Unruh, ML AF Abdel-Kader, Khaled Jhamb, Manisha Mandich, Lee Anne Yabes, Jonathan Keene, Robert M. Beach, Scott Buysse, Daniel J. Unruh, Mark L. TI Ecological momentary assessment of fatigue, sleepiness, and exhaustion in ESKD SO BMC NEPHROLOGY LA English DT Article DE End-stage renal disease; Alertness; Fatigue; Symptoms; Ecological momentary assessment ID QUALITY-OF-LIFE; CHRONIC KIDNEY-DISEASE; POSTDIALYSIS FATIGUE; MAINTENANCE DIALYSIS; PHYSICAL-ACTIVITY; HEMODIALYSIS; EXPERIENCE; SYMPTOMS; ASSOCIATION; IMPACT AB Background: Many patients on maintenance dialysis experience significant sleepiness and fatigue. However, the influence of the hemodialysis (HD) day and circadian rhythms on patients' symptoms have not been well characterized. We sought to use ecological momentary assessment to evaluate day-to-day and diurnal variability of fatigue, sleepiness, exhaustion and related symptoms in thrice-weekly maintenance HD patients. Methods: Subjects used a modified cellular phone to access an interactive voice response system that administered the Daytime Insomnia Symptom Scale (DISS). The DISS assessed subjective vitality, mood, and alertness through 19 questions using 7-point Likert scales. Subjects completed the DISS 4 times daily for 7 consecutive days. Factor analysis was conducted and a mean composite score of fatigue-sleepiness-exhaustion was created. Linear mixed regression models (LMM) were used to examine the association of time of day, dialysis day and fatigue, sleepiness, and exhaustion composite scores. Results: The 55 participants completed 1,252 of 1,540 (81%) possible assessments over the 7 day period. Multiple symptoms related to mood (e.g., feeling sad, feeling tense), cognition (e. g., difficulty concentrating), and fatigue (e.g., exhaustion, feeling sleepy) demonstrated significant daily and diurnal variation, with higher overall symptom scores noted on hemodialysis days and later in the day. In factor analysis, 4 factors explained the majority of the observed variance for DISS symptoms. Fatigue, sleepiness, and exhaustion loaded onto the same factor and were highly intercorrelated. In LMM, mean composite fatigue-sleepiness-exhaustion scores were associated with dialysis day (coefficient and 95% confidence interval [CI] 0.21 [0.02 - 0.39]) and time of day (coefficient and 95% CI 0.33 [0.25 - 0.41]. Observed associations were minimally affected by adjustment for demographics and common confounders. Conclusions: Maintenance HD patients experience fatigue-sleepiness-exhaustion symptoms that demonstrate significant daily and diurnal variation. The variability in symptoms may contribute to poor symptom awareness by providers and greater misclassification bias of fatigue related symptoms in clinical studies. C1 [Abdel-Kader, Khaled] Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, Nashville, TN 37232 USA. [Jhamb, Manisha] Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA USA. [Mandich, Lee Anne] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Yabes, Jonathan] Univ Pittsburgh, Ctr Res Hlth Care, Div Gen Internal Med, Pittsburgh, PA USA. [Keene, Robert M.; Beach, Scott] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA USA. [Buysse, Daniel J.] Univ Pittsburgh, Sleep Med Inst, Dept Psychiat, Pittsburgh, PA USA. [Unruh, Mark L.] Univ New Mexico, Div Nephrol, Albuquerque, NM 87131 USA. RP Abdel-Kader, K (reprint author), Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, 1161 21st Ave South,MCN S-3223, Nashville, TN 37232 USA. EM khaled.abdel-kader@vanderbilt.edu OI Abdel-Kader, Khaled/0000-0002-6412-8498 FU National Institutes of Health [K23DK090304, R01DK077785]; American Heart Association [11FTF7520014] FX This work was supported by National Institutes of Health grants K23DK090304 (Abdel-Kader) and R01DK077785 (Unruh) and American Heart Association grant 11FTF7520014 (Jhamb). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 47 TC 5 Z9 5 U1 1 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD FEB 6 PY 2014 VL 15 AR 29 DI 10.1186/1471-2369-15-29 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AB9PV UT WOS:000332128500001 PM 24502751 ER PT J AU Humphrey, LL Deffebach, M Pappas, M Zakher, B Slatore, CG AF Humphrey, Linda L. Deffebach, Mark Pappas, Miranda Zakher, Bernadette Slatore, Christopher G. TI Screening for Lung Cancer With Low-Dose Computed Tomography Response SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID CT C1 [Humphrey, Linda L.; Deffebach, Mark; Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR 97239 USA. [Pappas, Miranda; Zakher, Bernadette] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Humphrey, LL (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. NR 4 TC 3 Z9 3 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 4 PY 2014 VL 160 IS 3 BP 212 EP 212 DI 10.7326/L14-5003-3 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AA2VE UT WOS:000330951500015 PM 24493448 ER PT J AU Kwon, OJ Zhang, L Ittmann, MM Xin, L AF Kwon, Oh-Joon Zhang, Li Ittmann, Michael M. Xin, Li TI Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE prostate stem cells; cells-of-origin for cancer ID ACUTE BACTERIAL PROSTATITIS; EPITHELIAL STEM-CELLS; MURINE PROSTATE; AUTOIMMUNE PROSTATITIS; MOUSE PROSTATE; IN-VITRO; MODEL; TISSUE; CARCINOGENESIS; EXPRESSION AB Chronic inflammation has been shown to promote the initiation and progression of diverse malignancies by inducing genetic and epigenetic alterations. In this study, we investigate an alternative mechanism through which inflammation promotes the initiation of prostate cancer. Adult murine prostate epithelia are composed predominantly of basal and luminal cells. Previous studies revealed that the two lineages are largely self-sustained when residing in their native microenvironment. To interrogate whether tissue inflammation alters the differentiation program of basal cells, we conducted lineage tracing of basal cells using a K14-CreER; mTmG model in concert with a murine model of prostatitis induced by infection from the uropathogenic bacteria CP9. We show that acute prostatitis causes tissue damage and creates a tissue microenvironment that induces the differentiation of basal cells into luminal cells, an alteration that rarely occurs under normal physiological conditions. Previously we showed that a mouse model with prostate basal cell-specific deletion of Phosphatase and tensin homolog (K14-CreER; Ptenfl/fl) develops prostate cancer with a long latency, because disease initiation in this model requires and is limited by the differentiation of transformation-resistant basal cells into transformation-competent luminal cells. Here, we show that CP9-induced prostatitis significantly accelerates the initiation of prostatic intraepithelial neoplasia in this model. Our results demonstrate that inflammation results in a tissue microenvironment that alters the normal prostate epithelial cell differentiation program and that through this cellular process inflammation accelerates the initiation of prostate cancer with a basal cell origin. C1 [Kwon, Oh-Joon; Zhang, Li; Xin, Li] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Ittmann, Michael M.; Xin, Li] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Xin, Li] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Ittmann, Michael M.] Michael E DeBakey VA Med Ctr, US Dept Vet Affairs, Houston, TX 77030 USA. RP Xin, L (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. EM xin@bcm.edu FU National Institutes of Health (NIH) [AI036211, CA125123, RR024574]; NIH [R00 CA125937, R01 DK092202, U01 CA141497, P20DK097775]; NIH Cancer Center Shared Resources [P30 CA125123] FX We thank Dr. Allison O'Brien for providing the CP9 bacterial strain; Drs. Julienne Carstens and Jonathan Levitt for technical advice on transurethral instillation of bacteria; Drs. Jeffrey Rosen and Amy Shore for critical comments; Joel M. Sederstrom for expert assistance with flow cytometry; and the Cytometry and Cell Sorting Core at Baylor College of Medicine [National Institutes of Health (NIH) Grants AI036211, CA125123, and RR024574] for technical support. This work was supported by NIH Grants R00 CA125937 and R01 DK092202 (to L.X.), U01 CA141497 and P20DK097775 (to M.M.I.), and NIH Cancer Center Shared Resources Grant P30 CA125123. NR 64 TC 39 Z9 39 U1 0 U2 12 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 4 PY 2014 VL 111 IS 5 BP E592 EP E600 DI 10.1073/pnas.1318157111 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 302FL UT WOS:000330587600012 PM 24367088 ER PT J AU Mitsis, EM Bender, HA Kostakoglu, L Machac, J Martin, J Woehr, JL Sewell, MC Aloysi, A Goldstein, MA Li, C Sano, M Gandy, S AF Mitsis, Effie M. Bender, Heidi A. Kostakoglu, Lale Machac, Josef Martin, Jane Woehr, Jennifer L. Sewell, Margaret C. Aloysi, Amy Goldstein, Martin A. Li, Clara Sano, Mary Gandy, Sam TI A consecutive case series experience with [F-18] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition SO MOLECULAR NEURODEGENERATION LA English DT Article DE Amyvid (TM); Florbetapir; PET; Clinical series; Alzheimer's disease; Neuroimaging ID POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; ALZHEIMER-DISEASE; F 18; AMYLOID DEPOSITION; INDIVIDUALS; F-18-AV-45; MEMORY; CARE AB Background: Identification and quantification of fibrillar amyloid in brain using positron emission tomography (PET) imaging and Amyvid (TM) ([F-18] Amyvid, [F-18] florbetapir, F-18-AV-45) was recently approved by the US Food and Drug Administration as a clinical tool to estimate brain amyloid burden in patients being evaluated for cognitive impairment or dementia. Imaging with [F-18] florbetapir offers in vivo confirmation of the presence of cerebral amyloidosis and may increase the accuracy of the diagnosis and likely cause of cognitive impairment (CI) or dementia. Most importantly, amyloid imaging may improve certainty of etiology in situations where the differential diagnosis cannot be resolved on the basis of standard clinical and laboratory criteria. Results: A consecutive case series of 30 patients (age 50-89; 16 M/14 F) were clinically evaluated at a cognitive evaluation center of urban dementia center and referred for [F-18] florbetapir PET imaging as part of a comprehensive dementia workup. Evaluation included neurological examination and neuropsychological assessment by dementia experts. [F-18] florbetapir PET scans were read by trained nuclear medicine physicians using the qualitative binary approach. Scans were rated as either positive or negative for the presence of cerebral amyloidosis. In addition to a comprehensive dementia evaluation, post [F-18] florbetapir PET imaging results caused diagnoses to be changed in 10 patients and clarified in 9 patients. Four patients presenting with SCI were negative for amyloidosis. These results show that [F-18] florbetapir PET imaging added diagnostic clarification and discrimination in over half of the patients evaluated. Conclusions: Amyloid imaging provided novel and essential data that: (1) caused diagnosis to be revised; and/or (2) prevented the initiation of incorrect or suboptimal treatment; and/or (3) avoided inappropriate referral to an anti-amyloid clinical trial. C1 [Mitsis, Effie M.; Bender, Heidi A.; Martin, Jane; Sewell, Margaret C.; Aloysi, Amy; Li, Clara; Sano, Mary; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Bender, Heidi A.; Woehr, Jennifer L.; Aloysi, Amy; Goldstein, Martin A.; Gandy, Sam] Mt Sinai Med Ctr, Dept Neurol, New York, NY 10029 USA. [Kostakoglu, Lale; Machac, Josef] Dept Nucl Med, New York, NY 10029 USA. [Mitsis, Effie M.; Sewell, Margaret C.; Li, Clara; Sano, Mary; Gandy, Sam] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Mitsis, Effie M.; Gandy, Sam] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Mitsis, EM (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM effie.mitsis@mssm.edu FU Baxter Pharmaceuticals; Polyphenolics, Inc.; Amicus Pharmaceuticals; Icahn School of Medicine Alzheimer's Disease Research Center [P50 AG05138] FX The Authors gratefully acknowledge Ash Rafique and Corey Fernandez for technical and administrative support, respectively. SG thanks NIA, NINDS, the Cure Alzheimer's Fund, the Department of Veteran Affairs, the Gideon and Sarah Gartner Foundation, and the Louis B. Mayer Foundation. Within the past 5 years, SG has received grants from Baxter Pharmaceuticals, Polyphenolics, Inc., and Amicus Pharmaceuticals. He has served as a member of the Data and Safety Monitoring Board for the Pfizer-Janssen Alzheimer's Immunotherapy Alliance, as a member of the Scientific Advisory Board of DiaGenic, and as a consultant to Amicus Pharmaceuticals and to Cerora, Inc. This research was supported in part by the Icahn School of Medicine Alzheimer's Disease Research Center grant P50 AG05138. NR 20 TC 9 Z9 9 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD FEB 3 PY 2014 VL 9 AR 10 DI 10.1186/1750-1326-9-10 PG 6 WC Neurosciences SC Neurosciences & Neurology GA AB1JX UT WOS:000331548800001 PM 24484858 ER PT J AU Lange, RA Levine, GN AF Lange, Richard A. Levine, Glenn N. TI Sexual Activity and Ischemic Heart Disease SO CURRENT CARDIOLOGY REPORTS LA English DT Article DE Sexual activity; Coital angina; Coital MI; Ischemic heart disease ID CORONARY-ARTERY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; CASE-CROSSOVER ANALYSIS; ERECTILE DYSFUNCTION; SILDENAFIL-CITRATE; CARDIOVASCULAR-DISEASE; HYPERTENSIVE MEN; CARDIAC RISK; ANTIHYPERTENSIVE DRUGS; DEPRESSIVE SYMPTOMS AB Human sexuality is an important aspect of health and quality of life. Many patients with ischemic heart disease - and their partners - are concerned that sexual activity could exacerbate their cardiac condition, possibly causing myocardial infarction or cardiac death. Patients with ischemic heart disease who wish to initiate or resume sexual activity should be evaluated with a thorough medical history and physical examination. Sexual activity is reasonable for individuals with no or mild angina and those who can exercise >= 3-5 METS without angina, excessive dyspnea, or ischemic ST segment changes. For the patient who is considered not be at low cardiovascular (CV) risk or in whom the CV risk is unknown, an exercise stress test is reasonable in order to determine his or her exercise capacity and to ascertain if symptoms or ischemia may occur. Regular exercise and cardiac rehabilitation can be effective in reducing the risk of CV complications associated with sexual activity for the patient with ischemic heart disease. C1 [Lange, Richard A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Levine, Glenn N.] Baylor Coll Med, Dept Med, Michael E DeBakey Med Ctr, Cardiol Sect, Houston, TX 77030 USA. RP Lange, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7870, San Antonio, TX 78229 USA. EM Langera@uthscsa.edu NR 97 TC 6 Z9 8 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3782 EI 1534-3170 J9 CURR CARDIOL REP JI Curr. Cardiol. Rep. PD FEB PY 2014 VL 16 IS 2 AR 445 DI 10.1007/s11886-013-0445-4 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AT6ZC UT WOS:000345084500002 PM 24408673 ER PT J AU Guichard, JL Benavides, G Ballinger, S Dell'Italia, L AF Guichard, J. L. Benavides, G. Ballinger, S. Dell'Italia, L. TI MITOCHONDRIAL DNA HAPLOTYPE CONTRIBUTES TO THE CYTOSKELETAL AND MITOCHONDRIAL RESPONSES TO CYCLICAL STRETCH IN ISOLATED CARDIOMYOCYTES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 [Guichard, J. L.; Benavides, G.; Ballinger, S.; Dell'Italia, L.] Univ Alabama Birmingham, Birmingham, AL USA. [Dell'Italia, L.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2014 VL 62 IS 2 MA 358 BP 513 EP 513 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AL3SH UT WOS:000339048800367 ER PT J AU Musgrove, JL Estrada, C Morris, J Kraemer, R AF Musgrove, J. L. Estrada, C. Morris, J. Kraemer, R. TI PRIORITIZING DOMAINS OF CLINICAL REASONING TO INCLUDE IN A CURRICULUM SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 [Musgrove, J. L.; Estrada, C.; Morris, J.; Kraemer, R.] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2014 VL 62 IS 2 MA 585 BP 582 EP 583 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AL3SH UT WOS:000339048800594 ER PT J AU Kertesz, S Austin, E Holmes, S Lukas, CV Pollio, D White, B Schumacher, J AF Kertesz, S. Austin, E. Holmes, S. Lukas, Van Deusen C. Pollio, D. White, B. Schumacher, J. TI ENDING HOMELESSNESS FOR 48,000 VETERANS: ORGANIZATIONAL AND CLINICAL CHALLENGES FOR VA MEDICAL CENTERS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 [Kertesz, S.; Austin, E.] Birmingham VA Med Ctr, Birmingham, AL USA. [Kertesz, S.; Schumacher, J.] Univ Alabama Birmingham, Birmingham, AL USA. [Holmes, S.; Lukas, Van Deusen C.; White, B.] Boston VAMC, Boston, MA USA. [Pollio, D.] Univ Alabama, Tuscaloosa, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2014 VL 62 IS 2 MA 590 BP 584 EP 584 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AL3SH UT WOS:000339048800599 ER PT J AU Johansen, KL Dalrymple, LS Delgado, C Kaysen, GA Kornak, J Grimes, B Chertow, GM AF Johansen, Kirsten L. Dalrymple, Lorien S. Delgado, Cynthia Kaysen, George A. Kornak, John Grimes, Barbara Chertow, Glenn M. TI Association between Body Composition and Frailty among Prevalent Hemodialysis Patients: A US Renal Data System Special Study SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; DIALYSIS PATIENTS; FLUID VOLUME; MORTALITY; HEALTH; OLDER; CONSEQUENCES; PREDICTOR; OUTCOMES; OBESITY AB Studies of frailty among patients on hemodialysis have relied on definitions that substitute self-reported functioning for measures of physical performance and omit weight loss or substitute alternate criteria. We examined the association between body composition and a definition of frailty that includes measured physical performance and weight loss in a cross-sectional analysis of 638 adult patients receiving maintenance hemodialysis at 14 centers. Frailty was defined as having three of following characteristics: weight loss, weakness, exhaustion, low physical activity, and slow gait speed. We performed logistic regression with body mass index (BMI) and bioelectrical impedance spectroscopy (BIS)-derived estimates of intracellular water (ICW), fat mass, and extracellular water (ECW) as the main predictors, and age, sex, race, and comorbidity as covariates. Overall, 30% of participants were frail. Older age (odds ratio [OR], 1.31 per 10 years; 95% confidence interval [95% CI], 1.14 to 1.50), diabetes (OR, 1.65; 95% CI, 1.13 to 2.40), higher fat mass (OR, 1.18; 95% CI, 1.02 to 1.37), and higher ECW(OR, 1.33; 95% CI, 1.20 to 1.47) associated with higher odds of frailty. Higher ICW associated with lower odds of frailty (OR, 0.80 per kg; 95% CI, 0.73 to 0.87). The addition of BMI data did not change the area under the receiver operating characteristics curve (AUC; AUC=0.66 versus 0.66; P=0.71), but the addition of BIS data did change the AUC (AUC=0.72; P < 0.001). Thus, individual components of body composition but not BMI associate strongly with frailty in this cohort of patients receiving hemodialysis. C1 [Johansen, Kirsten L.; Delgado, Cynthia] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA. [Johansen, Kirsten L.; Kornak, John; Grimes, Barbara] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Johansen, Kirsten L.; Delgado, Cynthia] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Dalrymple, Lorien S.; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. [Chertow, Glenn M.] Stanford Univ, Dept Med, Sch Med, Div Nephrol, Stanford, CA 94305 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM Kirsten.Johansen@ucsf.edu FU National Institutes of Health [N01-DK-0005, N01-DK-2450] FX This work was supported by National Institutes of Health Grants N01-DK-0005 (to K.L.J.) and N01-DK-2450 (to G.M.C.). NR 28 TC 32 Z9 32 U1 2 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB 1 PY 2014 VL 25 IS 2 BP 381 EP 389 DI 10.1681/ASN.2013040431 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA AJ8QM UT WOS:000337971700020 PM 24158987 ER PT J AU Robinson-Cohen, C Littman, AJ Duncan, GE Weiss, NS Sachs, MC Ruzinski, J Kundzins, J Rock, D de Boer, IH Ikizler, TA Himmelfarb, J Kestenbaum, BR AF Robinson-Cohen, Cassianne Littman, Alyson J. Duncan, Glen E. Weiss, Noel S. Sachs, Michael C. Ruzinski, John Kundzins, John Rock, Denise de Boer, Ian H. Ikizler, T. Alp Himmelfarb, Jonathan Kestenbaum, Bryan R. TI Physical Activity and Change in Estimated GFR among Persons with CKD SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; RISK-FACTOR; RENAL-INSUFFICIENCY; INSULIN-RESISTANCE; OLDER-ADULTS; CYSTATIN-C AB Physical activity may counteract metabolic disturbances that promote the progression of CKD. To address this concept, we performed a longitudinal cohort study of 256 participants in the Seattle Kidney Study, a clinic-based study of CKD. Participants with an estimated GFR (eGFR) of 15-59 ml/min per 1.73 m(2) at baseline were eligible for the study. Physical activity was quantified using the Four-Week Physical Activity History Questionnaire. We used generalized estimating equations to test associations of physical activity with change in eGFR determined by longitudinal measurements of serum cystatin C. Mean baseline eGFR was 42 ml/min per 1.73 m(2). During a median 3.7 years of follow-up, the mean change in eGFR(cystatin) (C) was -7.6% per year (interquartile range, -16.8%, 4.9% per year). Participants who reported >150 minutes of physical activity per week had the lowest rate of eGFR(cystatin C) loss (mean -6.2% per year compared with -9.6% per year among inactive participants). In adjusted analyses, each 60-minute increment in weekly physical activity duration associated with a 0.5% slower decline per year in eGFR (95% confidence interval, 0.02 to 0.98; P=0.04). Results were similar in sensitivity analyses restricted to participants without cardiovascular disease or diabetes, or to participants with moderate/high physical function. After adjustment for eGFR at the time of questionnaire completion, physical activity did not associate with the incidence of ESRD(n=34 events). In summary, higher physical activity levels associated with slower rates of eGFR loss in persons with established CKD. C1 [Robinson-Cohen, Cassianne; Sachs, Michael C.; Ruzinski, John; Kundzins, John; Rock, Denise; de Boer, Ian H.; Himmelfarb, Jonathan; Kestenbaum, Bryan R.] Univ Washington, Kidney Res Inst, Seattle, WA 98104 USA. [Robinson-Cohen, Cassianne; Littman, Alyson J.; Duncan, Glen E.; Weiss, Noel S.; de Boer, Ian H.; Kestenbaum, Bryan R.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Littman, Alyson J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Duncan, Glen E.] Univ Washington, Nutr Sci Program, Seattle, WA 98104 USA. [de Boer, Ian H.; Kestenbaum, Bryan R.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98104 USA. [Ikizler, T. Alp; Himmelfarb, Jonathan] Vet Affairs Tennessee Valley Healthcare Syst Nash, Nashville, TN USA. [Ikizler, T. Alp] Vanderbilt Univ, Div Nephrol, Nashville, TN 37235 USA. RP Robinson-Cohen, C (reprint author), Univ Washington, Kidney Res Inst, 325 Ninth Ave,Box 359606, Seattle, WA 98104 USA. EM cassyrc@uw.edu RI Duncan, Glen/A-3771-2008 OI Duncan, Glen/0000-0001-6909-1869; Robinson-Cohen, Cassianne/0000-0003-4783-7046 FU Kidney Research Institute (Seattle, WA); National Institutes of Health National Heart, Lung, and Blood Institute [2R01HL070938]; Department of Veterans Affairs (Rehabilitation Research & Development Career Development Award) [6982] FX This article is the result of work supported by the Kidney Research Institute (Seattle, WA). This research was also supported by the National Institutes of Health National Heart, Lung, and Blood Institute (Grant 2R01HL070938 to J.H.) and the Department of Veterans Affairs (Rehabilitation Research & Development Career Development Award 6982 to A.J.L.). NR 53 TC 23 Z9 23 U1 1 U2 10 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB 1 PY 2014 VL 25 IS 2 BP 399 EP 406 DI 10.1681/ASN.2013040392 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AJ8QM UT WOS:000337971700022 PM 24335971 ER PT J AU Meeks, DW Takian, A Sittig, DF Singh, H Barber, N AF Meeks, Derek W. Takian, Amirhossein Sittig, Dean F. Singh, Hardeep Barber, Nick TI Exploring the sociotechnical intersection of patient safety and electronic health record implementation SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID ORDER ENTRY SYSTEMS; INFORMATION-TECHNOLOGY; FOLLOW-UP; MEDICAL-RECORD; UNINTENDED CONSEQUENCES; CARE; ERRORS; MANAGEMENT; ADOPTION; CLASSIFICATION AB Objective The intersection of electronic health records (EHR) and patient safety is complex. To examine the applicability of two previously developed conceptual models comprehensively to understand safety implications of EHR implementation in the English National Health Service (NHS). Methods We conducted a secondary analysis of interview data from a 30-month longitudinal, prospective, case study-based evaluation of EHR implementation in 12 NHS hospitals. We used a framework analysis approach to apply conceptual models developed by Sittig and Singh to understand better EHR implementation and use: an eight-dimension sociotechnical model and a three-phase patient safety model (safe technology, safe use of technology, and use of technology to improve safety). Results The intersection of patient safety and EHR implementation and use was characterized by risks involving technology (hardware and software, clinical content, and human-computer interfaces), the interaction of technology with non-technological factors, and improper or unsafe use of technology. Our data support that patient safety improvement activities as well as patient safety hazards change as an organization evolves from concerns about safe EHR functionality, ensuring safe and appropriate EHR use, to using the EHR itself to provide ongoing surveillance and monitoring of patient safety. Discussion We demonstrate the face validity of two models for understanding the sociotechnical aspects of safe EHR implementation and the complex interactions of technology within a healthcare system evolving from paper to integrated EHR. Conclusions Using sociotechnical models, including those presented in this paper, may be beneficial to help stakeholders understand, synthesize, and anticipate risks at the intersection of patient safety and health information technology. C1 [Meeks, Derek W.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, VA HSR&D Ctr Excellence, Dept Family & Community Med, Houston, TX 77030 USA. [Takian, Amirhossein] Brunel Univ, Sch Hlth Sci & Social Care, Div Hlth Studies, Uxbridge UB8 3PH, Middx, England. [Sittig, Dean F.] Univ Texas Sch Biomed Informat, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston VA HSR&D Ctr Excellence,Sect Hlth Serv Re, Houston, TX 77030 USA. [Barber, Nick] UCL Sch Pharm, Dept Practice & Policy, London, England. RP Meeks, DW (reprint author), Houston VA HSR&D Ctr Excellence 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM derek.meeks@bcm.edu FU NHS Connecting for Health Evaluation Programme [005 08/S0709/97]; VA National Center of Patient Safety, Agency for Health Care Research and Quality; Houston VA HSR&D Center of Excellence [HFP90-020]; Baylor College of Medicine Department of Family and Community Medicine; Ruth L. Kirschstein national research service award [T32HP10031] FX This paper is independent research commissioned by the NHS Connecting for Health Evaluation Programme (005 08/S0709/97) led by Professor Richard Lilford. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. HS is supported by the VA National Center of Patient Safety, Agency for Health Care Research and Quality, and in part by the Houston VA HSR&D Center of Excellence (HFP90-020). DWM is supported by the Baylor College of Medicine Department of Family and Community Medicine post-doctoral fellowship program and the Ruth L. Kirschstein national research service award (T32HP10031). These sources had no role in the preparation, review, or approval of the manuscript. NR 51 TC 13 Z9 13 U1 1 U2 16 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD FEB PY 2014 VL 21 IS E1 BP E28 EP E34 DI 10.1136/amiajnl-2013-001762 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA AJ4UM UT WOS:000337672800006 PM 24052536 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Arthroplasty Outcomes Are Improving, but Why Isn't My Patient With Rheumatoid Arthritis Doing as Well? SO ARTHRITIS & RHEUMATOLOGY LA English DT Editorial Material ID TOTAL KNEE ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; RISK-FACTORS; MEDICARE PATIENTS; INFECTION; MORTALITY C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Rochester, MN USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Rochester, MN USA. [Singh, Jasvinder A.] Mayo Clin, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU NIA NIH HHS [U01 AG018947] NR 14 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2014 VL 66 IS 2 BP 250 EP 253 DI 10.1002/art.38236 PG 4 WC Rheumatology SC Rheumatology GA AJ0PQ UT WOS:000337357900004 PM 24504796 ER PT J AU Mohan, D Fischhoff, B Farris, C Switzer, GE Rosengart, MR Yealy, DM Saul, M Angus, DC Barnato, AE AF Mohan, Deepika Fischhoff, Baruch Farris, Coreen Switzer, Galen E. Rosengart, Matthew R. Yealy, Donald M. Saul, Melissa Angus, Derek C. Barnato, Amber E. TI Validating a Vignette-Based Instrument to Study Physician Decision Making in Trauma Triage SO MEDICAL DECISION MAKING LA English DT Article DE survey methods; psychometric/scaling; performance measures ID SIGNAL-DETECTION ANALYSIS; PRIMARY-CARE PHYSICIANS; STANDARDIZED PATIENTS; CLINICAL VIGNETTES; UNITED-STATES; QUALITY; SYSTEM; ABSTRACTION; MORTALITY; CASELOAD AB Background. The evidence supporting the use of vignettes to study physician decision making comes primarily from the study of low-risk decisions and the demonstration of good agreement at the group level between vignettes and actual practice. The validity of using vignettes to predict decision making in more complex, high-risk contexts and at the individual level remains unknown. Methods. We had previously developed a vignette-based instrument to study physician decision making in trauma triage. Here, we measured the retest reliability, internal consistency, known-groups performance, and criterion validity of the instrument. Thirty-two emergency physicians, recruited at a national academic meeting, participated in reliability testing. Twenty-eight trauma surgeons, recruited using personal contacts, participated in known-groups testing. Twenty-eight emergency physicians, recruited from physicians working at hospitals for which we had access to medical records, participated in criterion validity testing. We measured rates of undertriage (the proportion of severely injured patients not transferred to trauma centers) and overtriage (the proportion of patients transferred with minor injuries) on the instrument. For physicians participating in criterion validity testing, we compared rates of triage on the instrument with rates in practice, based on chart review. Results. Physicians made similar transfer decisions for cases (k = 0.42, P < 0.01) on 2 administrations of the instrument. Responses were internally consistent (Kuder-Richardson, 0.71-0.91). Surgeons had lower rates of undertriage than emergency physicians (13% v. 70%, P < 0.01). No correlation existed between individual rates of under-or overtriage on the vignettes and in practice (r = -0.17, P = 0.4; r = -0.03, P = 0.85). Conclusions. The instrument developed to assess trauma triage decision making performed reliably and detected known group differences. However, it did not predict individual physician performance. C1 [Mohan, Deepika; Rosengart, Matthew R.; Angus, Derek C.] Univ Pittsburgh, CRISMA Clin Res Invest & Syst Modeling Acute Illn, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15261 USA. [Mohan, Deepika; Rosengart, Matthew R.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA. [Fischhoff, Baruch] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA. [Switzer, Galen E.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15261 USA. [Switzer, Galen E.; Barnato, Amber E.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA. [Switzer, Galen E.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA. [Farris, Coreen] RAND Corp, Pittsburgh, PA USA. [Yealy, Donald M.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15261 USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15261 USA. [Saul, Melissa] Univ Pittsburgh, Dept Biomed Informat, Sch Med, Pittsburgh, PA 15261 USA. RP Mohan, D (reprint author), Univ Pittsburgh, CRISMA Lab, Room 637 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM mohand@upmc.edu RI Angus, Derek/E-9671-2012 FU NIGMS NIH HHS [1K23 GM101292-01, K23 GM101292] NR 38 TC 10 Z9 10 U1 0 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X EI 1552-681X J9 MED DECIS MAKING JI Med. Decis. Mak. PD FEB PY 2014 VL 34 IS 2 BP 242 EP 252 PG 11 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA AI8QH UT WOS:000337185600011 PM 24125789 ER PT J AU Cheng, G Alavi, A Werner, TJ Del Bello, CV Akers, SR AF Cheng, Gang Alavi, Abass Werner, Thomas J. Del Bello, Catherine V. Akers, Scott R. TI Serial Changes of FDG Uptake and Diagnosis of Suspected Lung Malignancy A Lesion-Based Analysis SO CLINICAL NUCLEAR MEDICINE LA English DT Article DE FDG PET; delayed imaging; lung cancer; diagnosis ID DUAL-TIME-POINT; POSITRON-EMISSION-TOMOGRAPHY; TUBERCULOSIS-ENDEMIC COUNTRY; SOLITARY PULMONARY NODULES; PHASE F-18-FDG PET; LYMPH-NODES; CANCER; BENIGN; DIFFERENTIATION; IMPACT AB Objective: This study prospectively evaluates the serial change of FDG uptake and its diagnostic value in malignant versus benign lung lesions in patients with suspected lung cancer. Patients and Methods: Patients with suspected lung malignancy underwent whole-body FDG PET/CT at 1, 2, and 3 hours after an IV injection of F-18-FDG. The SUVs of FDG in lung nodules and hilar/mediastinal nodes at each time point were correlated with biopsy/surgical pathologic findings. Results: There were a total of 45 malignant lesions and 80 benign lesions from 43 patients with pathologic diagnosis that were included for analysis. The SUVmax had an average of 25.5% increase in all tumor-positive lesions from 1 to 2 hours (vs 1.6% decrease in all tumor-negative lesions, P < 0.0001) and an average of 39.1% increase from 1 to 3 hours (vs 4.5% increase in all tumor-negative lesions, P G 0.0001). The receiver operating characteristic analysis showed that the 2-hour and 3-hour SUVmax had similar area under the curve and outperformed the SUVmax on the 1-hour initial imaging or retention index (RI). The optimal cutoff values to differentiate malignancy from benign lesions were 3.24 for 1-hour SUVmax, 3.67 for 2-hour SUVmax, and 4.21 for 3-hour SUVmax, with 11.6% for 1- to 2-hour RI and 23.9% for 1-to 3-hour RI. The 3-hour delayed SUVmax of 4.21 provided the best overall performance (accuracy of 88.8%). The analysis of the lesion-to-background ratio revealed that delayed imaging improved the image quality significantly, leading to much easier detection of either malignant or benign lesions. Conclusions: Multiple time point FDG PET/CT imaging moderately improves the diagnostic accuracy of lung cancer and significantly improves the image quality. C1 [Cheng, Gang; Del Bello, Catherine V.; Akers, Scott R.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. [Cheng, Gang; Alavi, Abass; Werner, Thomas J.] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. RP Akers, SR (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM gangcheng99@yahoo.com; akerssco@me.com FU Department of Veterans Affairs FX Supported in part by a pilot grant from the Department of Veterans Affairs (VISN 4 CPPF grant). NR 28 TC 5 Z9 5 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-9762 EI 1536-0229 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD FEB PY 2014 VL 39 IS 2 BP 147 EP 155 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AI3DB UT WOS:000336738100022 PM 24368534 ER PT J AU Cheng, G Morley, JF AF Cheng, Gang Morley, James F. TI Complete and Readily Reversible Blocking of Striatal DaTscan Binding by Methylphenidate SO CLINICAL NUCLEAR MEDICINE LA English DT Editorial Material DE DaTscan; I-123 ioflupane; SPECT; methylphenidate; parkinsonian syndrome; striatum; blocking effect ID DOPAMINE TRANSPORTERS; SPECT; ABSTINENCE C1 [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA. [Morley, James F.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Morley, James F.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM gangcheng99@yahoo.com NR 11 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-9762 EI 1536-0229 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD FEB PY 2014 VL 39 IS 2 BP 211 EP 213 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA AI3DB UT WOS:000336738100041 PM 24300364 ER PT J AU Cummings, DE Cohen, RV AF Cummings, David E. Cohen, Ricardo V. TI Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery SO LANCET DIABETES & ENDOCRINOLOGY LA English DT Article ID TYPE-2 DIABETES-MELLITUS; SWEDISH OBESE SUBJECTS; VERTICAL BANDED GASTROPLASTY; GASTRIC BYPASS-SURGERY; LAPAROSCOPIC SLEEVE GASTRECTOMY; RANDOMIZED-CONTROLLED-TRIAL; CARDIOVASCULAR RISK-FACTORS; LIFE-STYLE INTERVENTION; LONG-TERM MORTALITY; BODY-MASS INDEX AB Bariatric surgery use is largely governed worldwide by a 1991 National Institutes of Health consensus statement that advocates BMI as the primary operative criterion and restricts surgery to severely obese patients. These guidelines have been enormously valuable in standardising practice, thereby facilitating accumulation of a copious database of information regarding long-term surgical benefits and risks, from vast clinical experience and research. However, the National Institutes of Health recommendations had important limitations from the outset and are now gravely outdated. They do not account for remarkable advances in minimally invasive surgical techniques or the development of entirely new procedures. In the two decades since they were crafted, we have gained far greater understanding of the dramatic, weight-independent benefits of some operations on metabolic diseases, especially type 2 diabetes, and of the inadequacy of BMI as a primary criterion for surgical selection. Furthermore, there is now a substantial and rapidly burgeoning body of level-1 evidence from randomised trials comparing surgical versus non-surgical approaches to obesity, type 2 diabetes, and other metabolic diseases, including among only mildly obese or merely overweight patients. Herein, we present arguments to impel the development of new guidelines for the use of bariatric and so-called metabolic surgery to inform clinical practice and insurance compensation. C1 [Cummings, David E.] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. [Cummings, David E.] Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Cohen, Ricardo V.] Oswaldo Cruz Hosp, Ctr Excellence Bariatr & Metab Surg, Sao Paulo, Brazil. RP Cummings, DE (reprint author), Univ Washington, Diabet & Obes Ctr Excellence, Box 358280 Mail Stop 111, Seattle, WA 98195 USA. EM davidec@u.washington.edu FU Johnson Johnson; Johnson & Johnson Medical Brasil; Oswaldo Cruz Hospital; NIH [RO1 DK517498, RO1 DK61516, RO1 DK089528, UO1 DK66568, P30 DK17047] FX DEC is a principal investigator on the COSMID trial, which is funded by Johnson & Johnson. RVC is a principal investigator for the MOMS trial, which is funded by Johnson & Johnson Medical Brasil and Oswaldo Cruz Hospital. DEC is supported by NIH grants RO1 DK517498, RO1 DK61516, RO1 DK089528, UO1 DK66568, and P30 DK17047. NR 76 TC 26 Z9 30 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2213-8587 J9 LANCET DIABETES ENDO JI Lancet Diabetes Endocrinol. PD FEB PY 2014 VL 2 IS 2 BP 175 EP 181 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AI2XQ UT WOS:000336722900025 PM 24622721 ER PT J AU Heneghan, AF Pierre, JF Gosain, A Kudsk, KA AF Heneghan, Aaron F. Pierre, Joseph F. Gosain, Ankush Kudsk, Kenneth A. TI IL-25 Improves Luminal Innate Immunity and Barrier Function During Parenteral Nutrition SO ANNALS OF SURGERY LA English DT Article DE innate immunity; parenteral nutrition; Paneth cells; goblet cells; secretory phospholipase A(2); small intestine ID UPPER RESPIRATORY-TRACT; MAJOR ABDOMINAL-TRAUMA; IIA PHOSPHOLIPASE A(2); LYMPHOID-TISSUE; MUCOSAL IMMUNITY; STAPHYLOCOCCUS-AUREUS; INFLAMMATORY FLUID; SEPTIC MORBIDITY; MESSENGER-RNA; CELL-WALL AB Background: Parenteral nutrition (PN) increases risks of infections in critically injured patients. Recently, PN was shown to reduce intestine luminal levels of the Paneth cell antimicrobial molecule secretory phospholipase A(2) (sPLA(2)) and the goblet cell glycoprotein mucin2 (MUC2). These molecules are critical factors for innate mucosal immunity and provide barrier protection. Interleukin-4 (IL-4) and IL-13 regulate sPLA(2) and MUC2 production through the IL-13 receptor. Because IL-25 stimulates IL-4 and IL-13 release and PN reduces luminal sPLA(2) and MUC2, we hypothesized that adding IL-25 to PN would restore these innate immune factors and maintain barrier function. Methods: Two days after venous cannulation, male ICR (Institute of Cancer Research) mice were randomized to receive chow (n = 12), PN (n = 9), or PN + 0.7 g of exogenous IL-25 (n = 11) daily for 5 days. Small-intestine wash fluid (SIWF) was collected for analysis of sPLA(2) activity, MUC2 density, and luminal levels of IL-4 and IL-13. Small-intestinal tissue was harvested for analysis of tissue sPLA(2) activity or immediate use in an ex-vivo intestinal segment culture (EVISC) to assess susceptibility of the tissue segments to enteroinvasive Escherichia coli. Results: PN reduced luminal sPLA(2) (P < 0.0001) and MUC2 (P <0.002) compared with chow, whereas the addition of IL-25 to PN increased luminal sPLA(2) (P < 0.0001) and MUC2 (P < 0.02) compared with PN. Tissue IL-4 and IL-13 decreased with PN compared with chow (IL-4: P < 0.0001, IL-13: P < 0.002), whereas IL-25 increased both cytokines compared with PN (IL-4: P < 0.03, IL-13: P < 0.02). Tissue levels of sPLA(2) were significantly decreased with PN compared with chow, whereas IL-25 significantly increased tissue sPLA(2) levels compared with PN alone. Functionally, more bacteria invaded the PN-treated tissue compared with chow (P < 0.01), and the addition of IL-25 to PN decreased enteroinvasion to chow levels (P < 0.01). Conclusions: PN impairs innate mucosal immunity by suppressing luminal sPLA(2) activity and MUC2 density compared with chow. PN also increases bacterial invasion in ex-vivo tissue. Administration of exogenous IL-25 reverses this dysfunction and increases luminal sPLA(2) and MUC2. PN tissue treated with IL-25 was significantly more resistant to bacterial invasion than with PN alone, suggesting that IL-25-induced effects augment the barrier defense mechanisms. C1 [Heneghan, Aaron F.; Pierre, Joseph F.; Gosain, Ankush; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave H4-736, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu OI Gosain, Ankush/0000-0002-0428-1503 FU National Institutes of Health (NIH) [R01 GM 53439]; Biomedical Laboratory Research & Development Service of the VA Office of Research and Development, Washington, DC [I01BX001672] FX Supported by the National Institutes of Health (NIH) grant R01 GM 53439 and Award number I01BX001672 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development, Washington, DC. NR 54 TC 10 Z9 10 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD FEB PY 2014 VL 259 IS 2 BP 394 EP 400 DI 10.1097/SLA.0b013e318284f510 PG 7 WC Surgery SC Surgery GA AH6NM UT WOS:000336247600049 PM 23426341 ER PT J AU Dunham, RM Vujkovic-Cvijin, I Yukl, SA Broadhurst, MJ Loke, P Albright, RG Wong, JK Lederman, MM Somsouk, M Hunt, PW Martin, JN Deeks, SG McCune, JM AF Dunham, Richard M. Vujkovic-Cvijin, Ivan Yukl, Steven A. Broadhurst, Mara J. Loke, P'ng Albright, Rebecca G. Wong, Joseph K. Lederman, Michael M. Somsouk, Ma Hunt, Peter W. Martin, Jeffrey N. Deeks, Steven G. McCune, Joseph M. TI Discordance Between Peripheral and Colonic Markers of Inflammation During Suppressive ART SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE colon biopsy; ART; microbial translocation; inflammation; HIV; CD4 T-cell recovery ID ACTIVE ANTIRETROVIRAL THERAPY; VIRUS TYPE-1 INFECTION; T-CELL-ACTIVATION; IMMUNE ACTIVATION; HIV-INFECTION; MICROBIAL TRANSLOCATION; LYMPHOID-TISSUE; I INTERFERON; CD4(+); IMMUNODEFICIENCY AB Objective: Persistent systemic inflammation is associated with the inability of some HIV-infected patients to normalize circulating CD4(+) T-cell levels after years of suppressive antiretroviral therapy. In this study, we sought to understand whether such systemic inflammation is also associated with detectable signs of inflammation in biopsies from the rectosigmoid colon. Design: Immunologic and virological parameters were studied in the peripheral blood and in rectosigmoid colon biopsies from individuals with viral suppression for at least 2 years and with peripheral CD4(+) T-cell levels of <350 cells per cubic millimeter (immunologic nonresponders, n = 18) or >500 cells per cubic millimeter (immunologic responders, n = 16). Methods: Peripheral blood and rectosigmoid colon biopsies were analyzed by flow cytometry, enzyme-linked immunosorbent assay, and quantitative polymerase chain reaction. Results: Nonresponders had elevated T-cell activation and inflammatory cytokines in the circulation, but inflammatory gene expression in colon biopsies was not different as compared with responders, and there was little relationship between blood and colon markers of inflammation. Blood inflammatory markers were positively associated with soluble CD14 levels indicative of monocyte activation. Conclusions: These findings demonstrate that, in the context of treated HIV disease, it is easier to detect parameters of inflammation (including blood monocyte activation) in the peripheral blood than in isolated rectosigmoid colon biopsies. Accordingly, interventions to block such inflammation in this population might be most conveniently and accurately assessed in blood. C1 [Dunham, Richard M.] GlaxoSmithKline, HIV Discovery Performance Unit, Res Triangle Pk, NC USA. [Vujkovic-Cvijin, Ivan; Broadhurst, Mara J.; Loke, P'ng; Albright, Rebecca G.; McCune, Joseph M.] Univ Calif San Francisco, Dept Med, Div Expt Med, San Francisco, CA 94143 USA. [Vujkovic-Cvijin, Ivan; Broadhurst, Mara J.] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA. [Yukl, Steven A.; Wong, Joseph K.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA. [Yukl, Steven A.; Wong, Joseph K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lederman, Michael M.] Case Western Reserve Univ, Dept Med, Div Infect Dis & HIV Med, Cleveland, OH 44106 USA. [Somsouk, Ma] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA. [Hunt, Peter W.; Martin, Jeffrey N.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA 94143 USA. RP McCune, JM (reprint author), Univ Calif San Francisco, Dept Med, Div Expt Med, Box 1234, San Francisco, CA 94143 USA. EM mike.mccune@ucsf.edu OI Vujkovic-Cvijin, Ivan/0000-0002-8611-4900 FU American Foundation for AIDS Research [107854-48-RGRL]; University of California, San Francisco (UCSF)/Gladstone Center for AIDS Research [P30 AI27763]; Hurlbut-Johnson Fund; UCSF/GIVI Center for AIDS Research; NIAID [U19 AI096109, R37 AI040312, K23 CA157929, R24 AI067039, F32 AI091534]; California HIV/AIDS Research Program [ID09-SF-067]; UCSF Clinical and Translational Science Institute [RR024131-01]; US Department of Veterans Affairs [1 IK2 CX000520-01] FX Supported by the American Foundation for AIDS Research (107854-48-RGRL to J.M.M. and S.G.D.). Additional support was provided by in part by the University of California, San Francisco (UCSF)/Gladstone Center for AIDS Research (P30 AI27763), the Hurlbut-Johnson Fund administered by the AIDS Research Institute at UCSF (to R. M. D.), the UCSF/GIVI Center for AIDS Research (to R. M. D. and S.A.Y.), NIAID (U19 AI096109 to J.M.M. and S. G. D.), R37 AI040312 (to J.M.M.), K23 CA157929 (to M. S.), R24 AI067039 (to J.N.M.), and F32 AI091534 (to R. M. D.), the California HIV/AIDS Research Program (ID09-SF-067 to P.W.H.), the UCSF Clinical and Translational Science Institute (RR024131-01), and the US Department of Veterans Affairs (1 IK2 CX000520-01 to S.A.Y.). NR 42 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2014 VL 65 IS 2 BP 133 EP 141 DI 10.1097/01.qai.0000437172.08127.0b PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG8DZ UT WOS:000335650300015 PM 24121758 ER PT J AU Taylor, BS Liang, YY Garduno, LS Walter, EA Gerardi, MB Anstead, GM Bullock, D Turner, BJ AF Taylor, Barbara S. Liang, Yuanyuan Garduno, L. Sergio Walter, Elizabeth A. Gerardi, Margit B. Anstead, Gregory M. Bullock, Delia Turner, Barbara J. TI High Risk of Obesity and Weight Gain for HIV-Infected Uninsured Minorities SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE obesity; health disparities; weight gain; HIV; observational cohort ID BODY-MASS INDEX; HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-HEART-DISEASE; ACTIVE ANTIRETROVIRAL THERAPY; LIFE-STYLE INTERVENTION; HEALTH-INSURANCE STATUS; IMMUNE CELL COUNTS; UNITED-STATES; SOCIOECONOMIC-STATUS; US ADULTS AB Background: Obesity and HIV disproportionately affect minorities and have significant health risks, but few studies have examined disparities in weight change in HIV-seropositive (HIV+) cohorts. Objective: To determine racial and health insurance disparities in significant weight gain in a predominately Hispanic HIV+ cohort. Methods: Our observational cohort study of 1214 nonunderweight HIV+ adults from 2007 to 2010 had significant weight gain [>= 3% annual body mass index (BMI) increase] as the primary outcome. The secondary outcome was continuous BMI over time. A 4-level race-ethnicity/insurance predictor reflected the interaction between race-ethnicity and insurance: insured white (non-Hispanic), uninsured white, insured minority (Hispanic or black), or uninsured minority. Logistic and mixed-effects models adjusted for baseline BMI, age, gender, household income, HIV transmission category, antiretroviral therapy type, CD4(+) count, plasma HIV-1 RNA, observation months, and visit frequency. Results: The cohort was 63% Hispanic and 14% black; 13.3% were insured white, 10.0% uninsured white, 40.9% insured minority, and 35.7% uninsured minority. At baseline, 37.5% were overweight, 22.1% obese. Median observation was 3.25 years. Twenty-four percent of the cohort had significant weight gain, which was more likely for uninsured minority patients than insured whites [adjusted odds ratio = 2.85, 95% confidence intervals (CIs): 1.66 to 4.90]. The rate of BMI increase in mixed-effects models was greatest for uninsured minorities. Of 455 overweight at baseline, 29% were projected to become obese in 4 years. Conclusions and Relevance: In this majority Hispanic HIV+ cohort, 60% were overweight or obese at baseline, and uninsured minority patients gained weight more rapidly. These data should prompt greater attention by HIV providers for prevention of obesity. C1 [Taylor, Barbara S.; Garduno, L. Sergio; Walter, Elizabeth A.; Gerardi, Margit B.; Anstead, Gregory M.; Bullock, Delia] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA. [Taylor, Barbara S.; Liang, Yuanyuan; Turner, Barbara J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Taylor, Barbara S.; Liang, Yuanyuan; Turner, Barbara J.] Univ Texas Sch Publ Hlth, San Antonio, TX USA. [Liang, Yuanyuan] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Walter, Elizabeth A.; Anstead, Gregory M.] South Texas Vet Hlth Care Syst, Dept Med, Div Infect Dis, San Antonio, TX USA. [Gerardi, Margit B.] Univ Texas Hlth Sci Ctr San Antonio, Sch Nursing, Dept Family & Community Hlth Syst, San Antonio, TX 78229 USA. RP Taylor, BS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Infect Dis, 7703 Floyd Curl Dr,MSC 7881, San Antonio, TX 78229 USA. EM taylorb4@uthscsa.edu FU University Health System (UHS) FX The authors gratefully recognize University Health System (UHS) for their support of this project. Specific thanks are due to Lisa Wammack, Tracy Jeffers, and Michelle Silva of UHS for their assistance in developing the data repository for the South Texas HIV Cohort, and all of the patients and providers at the UHS Family Focused AIDS Clinical Treatment & Services clinic. NR 67 TC 14 Z9 14 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2014 VL 65 IS 2 BP E33 EP E40 DI 10.1097/QAI.0000000000000010 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA AG8DZ UT WOS:000335650300001 PM 24121754 ER PT J AU Joshi, A Teng, E Tassniyom, K Mendez, MF AF Joshi, Aditi Teng, Edmond Tassniyom, Kanida Mendez, Mario F. TI Hippocampal and Mesial Temporal Sclerosis in Early-Onset Frontotemporal Lobar Degeneration Versus Alzheimer's Disease SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article ID REPEAT EXPANSION; DEMENTIA; TDP-43; PATHOLOGY; VARIANT; TAU C1 [Joshi, Aditi; Teng, Edmond; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Teng, Edmond; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tassniyom, Kanida] Khon Kaen Univ, Dept Psychiat, Khon Kaen, Thailand. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu FU NIA [R01AG034499-03]; VA Merit Review; Alzheimer's Disease Research Center [NIA P50 AG-16570]; NACC [UO1 AG016976]; NIA; AFAR; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; Alzheimer's Disease Research Centers of California; Sidell-Kagan Foundation; [K08 AG 34628] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: NIA Grant #R01AG034499-03, a VA Merit Review, Alzheimer's Disease Research Center Grant NIA P50 AG-16570 and the NACC grant UO1 AG016976. K08 AG 34628 (to ET; jointly sponsored by NIA, AFAR, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation and an anonymous donor), the Alzheimer's Disease Research Centers of California, and the Sidell-Kagan Foundation. NR 21 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 EI 1938-2731 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD FEB PY 2014 VL 29 IS 1 BP 45 EP 49 PG 5 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA AB0DW UT WOS:000331463000007 PM 24085254 ER PT J AU Verma, SM Okawa, J Propert, KJ Werth, VP AF Verma, S. M. Okawa, J. Propert, K. J. Werth, V. P. TI The impact of skin damage due to cutaneous lupus on quality of life SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID SEVERITY INDEX; DISEASE SEVERITY; REVISED CRITERIA; ERYTHEMATOSUS; COHORT; RESPONSIVENESS; CLASSIFICATION; RHEUMATOLOGY; INSTRUMENT; VITILIGO C1 [Verma, S. M.; Okawa, J.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. [Verma, S. M.; Okawa, J.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Propert, K. J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Philadelphia Vet Affairs Med Ctr, Dept Dermatol, Philadelphia, PA USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development); National Institutes of Health [NIH K24-AR 02207] FX This material is based upon work supported by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development) and by the National Institutes of Health (NIH K24-AR 02207) to V.P.W. NR 22 TC 7 Z9 7 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD FEB PY 2014 VL 170 IS 2 BP 315 EP 321 PG 7 WC Dermatology SC Dermatology GA AA8QA UT WOS:000331358800013 PM 24111880 ER PT J AU Kabbinavar, FF Zomorodian, N Rettig, M Khan, F Greenwald, DR DiCarlo, B Davidson, SJ Patel, R Pandit, L Chandraratna, R Sanders, M AF Kabbinavar, Fairooz F. Zomorodian, Nazy Rettig, Matthew Khan, Faraz Greenwald, Daniel Reif DiCarlo, Brian Davidson, Sheldon J. Patel, Ravindranath Pandit, Lalita Chandraratna, Rosh Sanders, Martin TI An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC). SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Genitourinary Cancers Symposium CY JAN 30-FEB 01, 2014 CL San Francisco, CA C1 Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Dept Med, West Los Angeles, CA USA. Tanslat Res Oncol US, Los Angeles, CA USA. Translat Oncol Res Int, Santa Maria, CA USA. Lalita Pandit MD Inc, Fountain Valley, CA USA. Therapeut Inc, Santa Ana, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2014 VL 32 IS 4 SU S MA 169 PG 1 WC Oncology SC Oncology GA AG3LF UT WOS:000335318100172 ER PT J AU Eng, JA Hunter, CJ Handley, MA Boscardin, CK Gonzales, R Ackerman, SL AF Eng, Jessica A. Hunter, Cecily J. Handley, Margaret A. Boscardin, Christy K. Gonzales, Ralph Ackerman, Sara L. TI Patient Attitudes About Specialty Follow-up Care by Telephone SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Letter C1 [Eng, Jessica A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Eng, Jessica A.] Univ Calif San Francisco, Sch Med, Div Geriatr, San Francisco, CA 94143 USA. [Hunter, Cecily J.; Handley, Margaret A.] Univ Calif San Francisco, Sch Med, Div Gen Internal Med, San Francisco, CA 94143 USA. [Handley, Margaret A.; Boscardin, Christy K.; Gonzales, Ralph] Univ Calif San Francisco, Sch Med, Dept Biostat & Epidemiol, San Francisco, CA 94143 USA. [Ackerman, Sara L.] Univ Calif San Francisco, Sch Nursing, Dept Social & Behav Sci, San Francisco, CA 94143 USA. RP Eng, JA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,181G, San Francisco, CA 94121 USA. EM jes-sica.eng@ucsf.edu FU NCATS NIH HHS [UL1 TR000004] NR 4 TC 0 Z9 0 U1 1 U2 1 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2014 VL 20 IS 2 BP 164 EP 167 PG 4 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AE5CJ UT WOS:000334005100011 PM 24738534 ER PT J AU Datta, J Gupta, M Lewis, RS Mamtani, R Stripp, D Kelz, RR Drebin, JA Fraker, DL Karakousis, GC Roses, RE AF Datta, J. Gupta, M. Lewis, R. S. Mamtani, R. Stripp, D. Kelz, R. R. Drebin, J. A. Fraker, D. L. Karakousis, G. C. Roses, R. E. TI Does Inadequate Lymph Node Staging Impact Survival in Resected Gastric Cancer? SO ANNALS OF SURGICAL ONCOLOGY LA English DT Meeting Abstract CT 67th Annual Cancer Symposium of the Society-of-Surgical-Oncology CY MAR 12-15, 2014 CL Phoenix, AZ SP Soc Surg Oncol C1 [Datta, J.; Gupta, M.; Lewis, R. S.; Kelz, R. R.; Drebin, J. A.; Fraker, D. L.; Karakousis, G. C.; Roses, R. E.] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Mamtani, R.] Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Stripp, D.] Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 EI 1534-4681 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD FEB PY 2014 VL 21 SU 1 BP S165 EP S166 PG 2 WC Oncology; Surgery SC Oncology; Surgery GA AE7WC UT WOS:000334209100466 ER PT J AU Mandell, D Siegle, GJ Shutt, L Feldmiller, J Thase, ME AF Mandell, Darcy Siegle, Greg J. Shutt, Luann Feldmiller, Josh Thase, Michael E. TI Neural Substrates of Trait Ruminations in Depression SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE rumination; depression; fMRI; emotion; amygdala ID WORKING-MEMORY; EMOTIONAL INFORMATION; UNIPOLAR DEPRESSION; CINGULATE ACTIVITY; PREFRONTAL CORTEX; COGNITIVE THERAPY; MAJOR DEPRESSION; ANGRY RUMINATION; PUPIL-DILATION; DEFAULT-MODE AB Rumination in depression is a risk factor for longer, more intense, and harder-to-treat depressions. But there appear to be multiple types of depressive rumination-whether they all share these vulnerability mechanisms, and thus would benefit from the same types of clinical attention is unclear. In the current study, we examined neural correlates of empirically derived dimensions of trait rumination in 35 depressed participants. These individuals and 29 never-depressed controls completed 17 self-report measures of rumination and an alternating emotion-processing/executive-control task during functional MRI (fMRI) assessment. We examined associations of regions of interest-the amygdala and other cortical regions subserving a potential role in deficient cognitive control and elaborative emotion-processing-with trait rumination. Rumination of all types was generally associated with increased sustained amygdala reactivity. When controlling for amygdala reactivity, distinct activity patterns in hippocampus were also associated with specific dimensions of rumination. We discuss the possibly utility of targeting more basic biological substrates of emotional reactivity in depressed patients who frequently ruminate. C1 [Mandell, Darcy; Siegle, Greg J.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Siegle, Greg J.; Shutt, Luann; Feldmiller, Josh] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Siegle, GJ (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM gsiegle@pitt.edu FU NIMH NIH HHS [MH60473, K01 MH064159, K02 MH082998, MH064159, MH082998, MH55762, MH58356, R01 MH055762, R01 MH058356, R01 MH096334, R25 MH060473] NR 81 TC 23 Z9 26 U1 7 U2 33 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2014 VL 123 IS 1 BP 35 EP 48 DI 10.1037/a0035834 PG 14 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA AD7RL UT WOS:000333462800005 PM 24661157 ER PT J AU Simpson, TL Stappenbeck, CA Luterek, JA Lehavot, K Kaysen, DL AF Simpson, Tracy L. Stappenbeck, Cynthia A. Luterek, Jane A. Lehavot, Keren Kaysen, Debra L. TI Drinking Motives Moderate Daily Relationships Between PTSD Symptoms and Alcohol Use SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE alcohol use; daily monitoring; drinking motives; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSIS; NATIONAL COMORBIDITY SURVEY; FEMALE CRIME VICTIMS; SUBSTANCE USE; SEXUAL ASSAULT; TRAUMATIC EVENT; BINGE-DRINKING; GUARD SOLDIERS; ABUSE AB Posttraumatic stress disorder (PTSD) and alcohol dependence (AD) frequently co-occur, although results of both cross-sectional and longitudinal studies evaluating the nature of their relationship have been mixed. There has been varied support for competing models explaining how these conditions influence one another. To assess both the self-medication and mutual maintenance models, as well as examine the potential moderating role of drinking motives, the current study used Generalized Estimating Equations to evaluate daily associations for an average of 7.3 days between PTSD symptoms and alcohol use in a mixed-gender sample of individuals who met criteria for both PTSD and AD. Results generally supported a self-medication model with elevated PTSD symptoms predictive of greater alcohol use on that same day and on the following day. Contrary to a mutual maintenance model prediction, drinking did not predict next-day PTSD symptoms. Results also indicated that both coping and enhancement drinking motives were significant moderators of the PTSD and drinking relationships, suggesting that these relationships may be more or less salient depending on an individual's particular drinking motivations. For example, among those higher on coping drinking motives, a 1-unit increase in PTSD symptom severity was associated with a 35% increase in amount of alcohol consumed the same day, while among those low on coping drinking motives, a 1-unit PTSD increase was associated with only a 10% increase in alcohol consumption. We discuss implications of these findings for the larger literature on the associations between PTSD and alcohol use as well as for clinical interventions. C1 [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA 98108 USA. [Simpson, Tracy L.; Stappenbeck, Cynthia A.; Luterek, Jane A.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Lehavot, Keren] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA 98108 USA. [Kaysen, Debra L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Simpson, TL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way 116 CESATE, Seattle, WA 98108 USA. EM tracy.simpson@va.gov FU NIAAA NIH HHS [1 R21 AA 17130-01, R21 AA017130] NR 59 TC 21 Z9 21 U1 3 U2 14 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2014 VL 123 IS 1 BP 237 EP 247 DI 10.1037/a0035193 PG 11 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA AD7RL UT WOS:000333462800024 PM 24661174 ER PT J AU Pekary, AE Sattin, A AF Pekary, A. E. Sattin, Albert TI Increased TRH and TRH-like peptide release in rat brain and peripheral tissues during proestrus/estrus SO PEPTIDES LA English DT Article DE Thyrotropin-releasing hormone; Estrus cycle; Limbic system; Depression treatment ID ESTROGEN-RECEPTOR-BETA; GLUTAMATE-INDUCED TOXICITY; HORMONE TRH; HIPPOCAMPAL-NEURONS; VAGINOCERVICAL STIMULATION; REPRODUCTIVE TISSUES; HOMOLOGOUS PEPTIDE; RAPID MODULATION; MESSENGER-RNA; ESTRUS CYCLE AB Women are at greater risk for major depression, PTSD, and other anxiety disorders. ER beta-selective agonists for the treatment of these disorders are the focus of pharmacologic development and clinical testing. Estradiol and its metabolites contribute to the neuroprotective effects of this steroid class, particularly in men, due to local conversion of testosterone to estiradiol in key brain regions which are predisposed to neurodegenerative diseases. We have used young adult female Sprague-Dawley rats to assess the role of TRH and TRH-like peptides, with the general structure pGlu-X-Pro-NH2 where "X" can be any amino acid residue, as mediators of the neurobiochemical effects of estradiol. The neuroprotective TRH and TRH-like peptides are coreleased with excitotoxic glutamate by glutamatergic neurons which contribute importantly to the regulation of the estrus cycle. The levels of TRH and TRH-like peptides during proestrus and/or estrus in the 12 brain regions analyzed were significantly decreased (due to accelerated release) 106 times but increased only 25 times when compared to the corresponding levels during diestrus days 1 and 2. These changes, listed by brain region in the order of decreasing number of significant decreases (down arrow) and/or increases (up arrow), were: striatum (20 down arrow,1 up arrow), medulla oblongata (16 down arrow,2 up arrow), amygdala (14 down arrow,1 up arrow), cerebellum (13 down arrow,1 up arrow), hypothalamus (12 down arrow,1 up arrow), entorhinal cortex (6 down arrow,6 up arrow), posterior cingulate (10 down arrow,1 up arrow), frontal cortex (3 down arrow,5 up arrow), nucleus accumbens (5 down arrow,3 up arrow), hippocampus (5 down arrow,2 up arrow), anterior cingulate (2 down arrow,1 up arrow), and piriform cortex (1 up arrow). In peripheral tissues the corresponding changes were: ovaries (23 down arrow), uterus (16 down arrow,1 up arrow), adrenals (11 down arrow,3 up arrow), and pancreas (1 down arrow,6 up arrow). We conclude that these peptides may be downstream mediators of some of the therapeutic effects of estrogen. Published by Elsevier Inc. C1 [Pekary, A. E.; Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Sattin, Albert] VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. [Pekary, A. E.] VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. [Pekary, A. E.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. RP Pekary, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Eugene.Pekary@va.gov FU Department of Veterans Affairs Medical Research Funds; Pekary Family Trust FX This work was supported by the Department of Veterans Affairs Medical Research Funds (AEP and AS) and the Pekary Family Trust. NR 80 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 EI 1873-5169 J9 PEPTIDES JI Peptides PD FEB PY 2014 VL 52 BP 1 EP 10 DI 10.1016/j.peptides.2013.11.018 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA AD5EU UT WOS:000333275400001 PM 24296042 ER PT J AU Ho, PM Lambert-Kerzner, A Carey, EP Fahdi, IE Bryson, CL Melnyk, SD Bosworth, HB Radcliff, T Davis, R Mun, H Weaver, J Barnett, C Baron, A Del Giacco, EJ AF Ho, P. Michael Lambert-Kerzner, Anne Carey, Evan P. Fahdi, Ibrahim E. Bryson, Chris L. Melnyk, S. Dee Bosworth, Hayden B. Radcliff, Tiffany Davis, Ryan Mun, Howard Weaver, Jennifer Barnett, Casey Baron, Anna Del Giacco, Eric J. TI Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures After Acute Coronary Syndrome Hospital Discharge A Randomized Clinical Trial SO JAMA INTERNAL MEDICINE LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; THERAPY; OUTCOMES; DISCONTINUATION; PREVALENCE; PREDICTORS; MORTALITY; DISEASE AB IMPORTANCE Adherence to cardioprotective medication regimens in the year after hospitalization for acute coronary syndrome (ACS) is poor. OBJECTIVE To test a multifaceted intervention to improve adherence to cardiac medications. DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial, 253 patients from 4 Department of Veterans Affairs medical centers located in Denver (Colorado), Seattle (Washington); Durham (North Carolina), and Little Rock (Arkansas) admitted with ACS were randomized to the multifaceted intervention (INT) or usual care (UC) prior to discharge. INTERVENTIONS The INT lasted for 1 year following discharge and comprised (1) pharmacist-led medication reconciliation and tailoring; (2) patient education; (3) collaborative care between pharmacist and a patient's primary care clinician and/or cardiologist; and (4) 2 types of voice messaging (educational and medication refill reminder calls). MAIN OUTCOMES AND MEASURES The primary outcome of interest was proportion of patients adherent to medication regimens based on a mean proportion of days covered (PDC) greater than 0.80 in the year after hospital discharge using pharmacy refill data for 4 cardioprotective medications (clopidogrel, beta-blockers, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors [statins], and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers [ACEI/ARB]). Secondary outcomes included achievement of blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) level targets. RESULTS Of 253 patients, 241 (95.3%) completed the study (122 in INT and 119 in UC). In the INT group, 89.3% of patients were adherent compared with 73.9% in the UC group (P =.003). Mean PDC was higher in the INT group (0.94 vs 0.87; P<.001). A greater proportion of intervention patients were adherent to clopidogrel (86.8% vs 70.7%; P=.03), statins (93.2% vs 71.3%; P<.001), and ACEI/ARB (93.1% vs 81.7%; P=.03) but not beta-blockers (88.1% vs 84.8%; P=.59). There were no statistically significant differences in the proportion of patients who achieved BP and LDL-C level goals. CONCLUSIONS AND RELEVANCE A multifaceted intervention comprising pharmacist-led medication reconciliation and tailoring, patient education, collaborative care between pharmacist and patients' primary care clinician and/or cardiologist, and voice messaging increased adherence to medication regimens in the year after ACS hospital discharge without improving BP and LDL-C levels. Understanding the impact of such improvement in adherence on clinical outcomes is needed prior to broader dissemination of the program. C1 [Ho, P. Michael; Lambert-Kerzner, Anne; Carey, Evan P.; Davis, Ryan; Baron, Anna] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Dept Med, Denver, CO USA. [Ho, P. Michael] Colorado Cardiovasc Outcomes Res Grp, Denver, CO USA. [Carey, Evan P.; Baron, Anna] Univ Colorado, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Fahdi, Ibrahim E.; Weaver, Jennifer; Barnett, Casey; Del Giacco, Eric J.] John L McClellan Mem Vet Adm Med Ctr, Little Rock, AR USA. [Bryson, Chris L.; Mun, Howard] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Melnyk, S. Dee; Bosworth, Hayden B.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Sch Nursing, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Dept Med, Div Gen Internal Med, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA. [Radcliff, Tiffany] Texas A&M Sch Rural Publ Hlth, Dept Hlth Policy & Management, College Stn, TX USA. RP Ho, PM (reprint author), Denver VA Med Ctr, Dept Med, 1055 Clermont St 111B, Denver, CO 80220 USA. EM Michael.ho@va.gov FU Veterans Health Administration Health Service Research & Development (HSR&D) Investigator initiated Award [IIR 08-302]; senior career scientist award (Research Career Scientist Award VA HSRD) [08-027] FX This study was funded by a Veterans Health Administration Health Service Research & Development (HSR&D) Investigator initiated Award (grant IIR 08-302). Dr Bosworth was supported by a senior career scientist award (Research Career Scientist Award VA HSR&D 08-027). NR 16 TC 46 Z9 46 U1 2 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2014 VL 174 IS 2 BP 186 EP 193 DI 10.1001/jamainternmed.2013.12944 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA AD2FM UT WOS:000333049200008 PM 24247275 ER PT J AU Saha, S AF Saha, Somnath TI Taking Diversity Seriously: The Merits of Increasing Minority Representation in Medicine SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID RACE; CARE C1 Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97239 USA. RP Saha, S (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sahas@ohsu.edu NR 5 TC 6 Z9 6 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2014 VL 174 IS 2 BP 291 EP 292 DI 10.1001/jamainternmed.2013.12736 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AD2FM UT WOS:000333049200028 PM 24378744 ER PT J AU Morton, GJ Kaiyala, KJ Foster-Schubert, KE Cummings, DE Schwartz, MW AF Morton, Gregory J. Kaiyala, Karl J. Foster-Schubert, Karen E. Cummings, David E. Schwartz, Michael W. TI Carbohydrate Feeding Dissociates the Postprandial FGF19 Response From Circulating Bile Acid Levels in Humans SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID Y GASTRIC BYPASS; GROWTH-FACTOR 19; DIURNAL-VARIATION; FIBROBLAST-GROWTH-FACTOR-19; FGF15/19; GHRELIN; PROTEIN; WEIGHT; FAMILY AB Context: Fibroblast growth factor 19 (FGF19) improves glycemic control in diabetic animals and is secreted from the gastrointestinal tract after meals in response to bile acid stimulation. Objective: We sought to understand how ingestion of carbohydrates, protein or lipids affect both FGF19 and bile acid concentrations in human plasma, with the hypothesis that variation in the bile acid response to different macronutrients would predict differences in plasma FGF19 levels. Design: This was a randomized, within-subjects crossover study. Setting: The study was conducted at a university clinical research center. Participants: There were 16 healthy human subjects included in the study. Interventions: Isocaloric, isovolemic beverages composed primarily of carbohydrates, proteins, or lipids were provided to each participant on 3 separate occasions. Main Outcome Measures: The magnitudes of postprandial rises of plasma FGF19 and total bile acid levels were determined. Results: All beverages induced an initial transient decline of plasma FGF19 levels during the first 60 minutes after consumption. For FGF19, the ingestion of carbohydrate was associated with the fastest and highest increase of plasma levels, returning to baseline at 5 hours. By comparison, the protein beverage induced a modest but significant elevation of FGF19 levels that peaked at the end of the 6-hour sampling interval, whereas a lipid beverage was without effect. In contrast, total bile acid levels increased in plasma only in response to a high-lipid beverage, demonstrating a marked divergence between the FGF19 and bile acid response to lipid vs carbohydrate. Conclusions: Abile acid-independent mechanism is implicated in the effect of meals to raise plasma FGF19 concentrations. C1 [Morton, Gregory J.; Foster-Schubert, Karen E.; Cummings, David E.; Schwartz, Michael W.] Univ Washington, Sch Dent, Dept Med, Seattle, WA 98195 USA. [Kaiyala, Karl J.] Univ Washington, Sch Dent, Dept Dent Publ Hlth Sci, Seattle, WA 98195 USA. [Foster-Schubert, Karen E.; Cummings, David E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Schwartz, MW (reprint author), Univ Washing South Lake Union, Dept Med, 850 Republican St,N335,Box 358055, Seattle, WA 98195 USA. EM mschwart@u.washington.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [DK068384, DK083042, DK090320, DK089056, DK052989, DK61516]; Nutrition Obesity Research Center [DK035816]; Diabetes Research Center at the University of Washington [DK17047] FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Grants DK068384, DK083042, DK090320, DK089056, DK052989, and DK61516; the Nutrition Obesity Research Center (DK035816); and the Diabetes Research Center (DK17047) at the University of Washington. NR 22 TC 6 Z9 6 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2014 VL 99 IS 2 BP E241 EP E245 DI 10.1210/jc.2013-3129 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AD7QS UT WOS:000333460300007 PM 24297792 ER PT J AU Karam, EG Friedman, MJ Hill, ED Kessler, RC McLaughlin, KA Petukhova, M Sampson, L Shahly, V Angermeyer, MC Bromet, EJ de Girolamo, G de Graaf, R Demyttenaere, K Ferry, F Florescu, SE Haro, JM He, YL Karam, AN Kawakami, N Kovess-Masfety, V Medina-Mora, ME Browne, MAO Posada-Villa, JA Shalev, AY Stein, DJ Viana, MC Zarkov, Z Koenen, KC AF Karam, Elie G. Friedman, Matthew J. Hill, Eric D. Kessler, Ronald C. McLaughlin, Katie A. Petukhova, Maria Sampson, Laura Shahly, Victoria Angermeyer, Matthias C. Bromet, Evelyn J. de Girolamo, Giovanni de Graaf, Ron Demyttenaere, Koen Ferry, Finola Florescu, Silvia E. Haro, Josep Maria He, Yanling Karam, Aimee N. Kawakami, Norito Kovess-Masfety, Viviane Medina-Mora, Maria Elena Browne, Mark A. Oakley Posada-Villa, Jose A. Shalev, Arieh Y. Stein, Dan J. Viana, Maria Carmen Zarkov, Zahari Koenen, Karestan C. TI CUMULATIVE TRAUMAS AND RISK THRESHOLDS: 12-MONTH PTSD IN THE WORLD MENTAL HEALTH (WMH) SURVEYS SO DEPRESSION AND ANXIETY LA English DT Article DE PTSD; functional impairment; comorbidity; World Mental Health Surveys; epidemiology ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-PROCESSING THERAPY; RANDOMIZED CONTROLLED-TRIAL; NATIONAL COMORBIDITY SURVEY; COMPLEX PTSD; PROLONGED EXPOSURE; CHILDHOOD ABUSE; DISSOCIATION; DEPRESSION; ANXIETY AB BackgroundClinical research suggests that posttraumatic stress disorder (PTSD) patients exposed to multiple traumatic events (TEs) rather than a single TE have increased morbidity and dysfunction. Although epidemiological surveys in the United States and Europe also document high rates of multiple TE exposure, no population-based cross-national data have examined this issue. MethodsData were analyzed from 20 population surveys in the World Health Organization World Mental Health Survey Initiative (n = 51,295 aged 18+). The Composite International Diagnostic Interview (3.0) assessed 12-month PTSD and other common DSM-IV disorders. Respondents with 12-month PTSD were assessed for single versus multiple TEs implicated in their symptoms. Associations were examined with age of onset (AOO), functional impairment, comorbidity, and PTSD symptom counts. Results19.8% of respondents with 12-month PTSD reported that their symptoms were associated with multiple TEs. Cases who associated their PTSD with four or more TEs had greater functional impairment, an earlier AOO, longer duration, higher comorbidity with mood and anxiety disorders, elevated hyperarousal symptoms, higher proportional exposures to partner physical abuse and other types of physical assault, and lower proportional exposure to unexpected death of a loved one than cases with fewer associated TEs. ConclusionsA risk threshold was observed in this large-scale cross-national database wherein cases who associated their PTSD with four or more TEs presented a more complex clinical picture with substantially greater functional impairment and greater morbidity than other cases of PTSD. PTSD cases associated with four or more TEs may merit specific and targeted intervention strategies. (C) 2013 Wiley Periodicals, Inc. C1 [Karam, Elie G.; Karam, Aimee N.] St George Hosp Univ Med Ctr, IDRAAC, Dept Psychiat & Clin Psychol, Beirut, Lebanon. [Friedman, Matthew J.] Geisel Sch Med Dartmouth, Natl Ctr PTSD, US Dept Vet Affairs, Hanover, NH USA. [Hill, Eric D.; Kessler, Ronald C.; Petukhova, Maria; Sampson, Laura; Shahly, Victoria] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [McLaughlin, Katie A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. [Angermeyer, Matthias C.] Ctr Publ Mental Hlth, Gosing Am Wagram, Austria. [Bromet, Evelyn J.] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. [de Girolamo, Giovanni] IRCCS Ctr S Giovanni di Dio Fatebenefratelli, Bologna, Italy. [Demyttenaere, Koen] Katholieke Univ Leuven Hosp, Univ Hosp Gasthuisberg, Dept Psychiat, Leuven, Belgium. [Ferry, Finola] Univ Ulster, Bamford Ctr Mental Hlth & Wellbeing, MRC Trial Methodol Hub, Coleraine BT52 1SA, Londonderry, North Ireland. [Florescu, Silvia E.] Natl Sch Publ Hlth & Hlth Serv Management, Publ Hlth Res & Evidence Based Med Dept, Bucharest, Romania. [Haro, Josep Maria] Univ Barcelona, CIBERSAM, Parc Sanitari St Joan de Deu, Barcelona, Spain. [He, Yanling] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Dept Clin Epidemiol, Shanghai 200030, Peoples R China. [Kawakami, Norito] Univ Tokyo, Grad Sch Med, Dept Mental Hlth, Tokyo, Japan. [Kovess-Masfety, Viviane] Univ Paris 05, EHESP Sch Publ Hlth, Dept Epidemiol, Paris, France. [Medina-Mora, Maria Elena] Natl Inst Psychiat, Mexico City, DF, Mexico. [Posada-Villa, Jose A.] Inst Colombiano Sistema Nervioso, Bogota, DC, Colombia. [Shalev, Arieh Y.] Hadassah Univ Hosp, Dept Psychiat, IL-91120 Jerusalem, Israel. [Stein, Dan J.] Univ Cape Town, Dept Psychiat, ZA-7925 Cape Town, South Africa. [Viana, Maria Carmen] Univ Fed Espirito Santo, Dept Social Med, Vitoria, ES, Brazil. [Zarkov, Zahari] Natl Ctr Publ Hlth & Anal, Dept Mental Hlth, Sofia, Bulgaria. [Koenen, Karestan C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, Psychiat Neurol Epidemiol Cluster, New York, NY 10032 USA. RP Koenen, KC (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, 722 West 168th St,Room 720G, New York, NY 10032 USA. EM kck5@mail.cumc.columbia.edu RI Haro, Josep Maria/D-1423-2011; Stein, Dan/A-1752-2008 OI Haro, Josep Maria/0000-0002-3984-277X; Stein, Dan/0000-0001-7218-7810; Viana, Maria Carmen/0000-0002-0464-4845; Ferry, Finola/0000-0003-1875-5180; Shalev, Arieh/0000-0001-9425-050X; McLaughlin, Katie/0000-0002-1362-2410 FU National Institute of Mental Health (NIMH) [R01 MH070884]; John D. and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558, R01-MH093612]; Fogarty International Center [FIRCA R03-TW006481]; Pan American Health Organization; Eli Lilly and Company; Ortho-McNeil Pharmaceutical; GlaxoSmithKline; Bristol-Myers Squibb; State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]; Ministry of Social Protection; European Commission [QLG5-1999-01042, SANCO 2004123]; Piedmont Region (Italy); Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]; Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]; Ministry of Health; Israel National Institute for Health Policy and Health Services Research; National Insurance Institute of Israel; Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; Lebanese Ministry of Public Health; WHO (Lebanon); National Institute of Health/Fogarty International Center [R03 TW006481-01]; AstraZeneca; Eli Lilly; Hikma Pharm; Janssen Cilag; Pfizer; Roche; Sanofi-Aventis; Servier; Novartis; National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]; National Council on Science and Technology [CONACyT-G30544-H]; PanAmerican Health Organization (PAHO); New Zealand Ministry of Health; Alcohol Advisory Council; Health Research Council; Health & Social Care Research & Development Division of the Public Health Agency; Ministry of Public Health; Eli Lilly Romania SRL; US National Institute of Mental Health [R01-MH059575, RO1-MH61905, RO2-MH51806, RO3-MH61905]; South African Department of Health; University of Michigan; National Institute of Mental Health [U01-MH60220]; National Institute of Drug Abuse (NIDA); Substance Abuse and Mental Health Services Administration (SAMHSA); Robert Wood Johnson Foundation (RWJF) [044708]; John W. Alden Trust; Departament de Salut, Generalitat de Catalunya, Spain FX The World Health Organization World Mental Health (WMH) Survey Initiative was supported by the National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, R01 DA016558, and R01-MH093612), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, GlaxoSmithKline, and Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis. None of the funders had any role in the design, analysis, interpretation of results, or preparation of this paper. A complete list of all within-country and cross-national WMH publications can be found at . The Sao Paulo Megacity Mental Health Survey is supported by the State of Sao Paulo Research Foundation (FAPESP) Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Beijing, People's Republic of China World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Colombian National Study of Mental Health (NSMH) is supported by the Ministry of Social Protection. The ESEMeD project is funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123), the Piedmont Region (Italy), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnologia, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour and Welfare. The Lebanese National Mental Health Survey (LEBANON) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health/Fogarty International Center (R03 TW006481-01), Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences, anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from AstraZeneca, Eli Lilly, GlaxoSmithKline, Hikma Pharm, Janssen Cilag, Pfizer, Roche, Sanofi-Aventis, Servier, and Novartis. The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544-H), with supplemental support from the PanAmerican Health Organization (PAHO). Te Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency.; The Romania WMH study projects "Policies in Mental Health Area" and "National Study regarding Mental Health and Services Use" were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health), with technical support of Metro Media Transilvania, the National Institute of Statistics-National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The South Africa Stress and Health Study (SASH) is supported by the US National Institute of Mental Health (R01-MH059575) and National Institute of Drug Abuse with supplemental funding from the South African Department of Health and the University of Michigan. The Ukraine Comorbid Mental Disorders during Periods of Social Disruption (CMDPSD) study is funded by the US National Institute of Mental Health (RO1-MH61905). The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. These surveys were carried out in conjunction with the World Health Organization WMH Survey Initiative. We thank the WMH staff for assistance with instrumentation, fieldwork, and data analysis. A complete list of WMH publications can be found at www.hcp.med.harvard.edu/wmh NR 42 TC 40 Z9 40 U1 7 U2 37 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD FEB PY 2014 VL 31 IS 2 BP 130 EP 142 DI 10.1002/da.22169 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AA6EA UT WOS:000331190400005 PM 23983056 ER PT J AU Maguen, S Madden, E Cohen, B Bertenthal, D Seal, K AF Maguen, Shira Madden, Erin Cohen, Beth Bertenthal, Daniel Seal, Karen TI ASSOCIATION OF MENTAL HEALTH PROBLEMS WITH GASTROINTESTINAL DISORDERS IN IRAQ AND AFGHANISTAN VETERANS SO DEPRESSION AND ANXIETY LA English DT Article DE gastrointestinal disorders; veteran; mental health; posttraumatic stress disorder; irritable bowel syndrome ID IRRITABLE-BOWEL-SYNDROME; POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; UNITED-STATES; DIGESTIVE DISEASES; WOMEN VETERANS; SYMPTOMS; POPULATION; PREVALENCE; ANXIETY AB BackgroundGastrointestinal disorders (GIDs) represent a large public health burden, affecting an estimated 60-70 million Americans annually. Our goal was to examine the relationship between GID and the most common mental health disorders in a national group of newly returning veterans. We also evaluated gender differences in the association of mental health disorders and GID. MethodsWe utilized a retrospective, longitudinal cohort analysis of veterans' health records. Participants were 603,221 Iraq and Afghanistan veterans who were new users of VA healthcare from October 7, 2001 (start of the war in Afghanistan) to December 31, 2010. ResultsThe prevalence of GID in newly returning veterans was nearly 20%, and veterans with a mental health disorder were at least twice as likely to have a GID as those without mental health disorders. For women, the increased risk of all GIDs was greatest among those with depression. Among men, the increased risk of irritable bowel syndrome (IBS) was greatest among those with posttraumatic stress disorder. IBS was the GID most strongly associated with mental health conditions among both genders. ConclusionsThe large proportion of newly returning veterans with GIDs and comorbid mental health diagnoses is concerning. Successful detection and treatment of GIDs associated with mental health disorders will require integrated efforts from primary care and mental health. (C) 2013 Wiley Periodicals, Inc. C1 [Maguen, Shira; Madden, Erin; Cohen, Beth; Bertenthal, Daniel; Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Maguen, Shira; Seal, Karen] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Cohen, Beth; Seal, Karen] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bertenthal, Daniel] Mental Illness Res Educ & Clin Ctr, San Francisco, CA USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov FU VA Health Sciences Research and Development (HSR&D) Career Development Award; National Institutes of Health [K23 HL 094765-01]; Mental Illness Research and Education Clinical Center of the US Veterans Health Administration FX Contract grant sponsor: VA Health Sciences Research and Development (HSR&D) Career Development Award; Contract grant sponsor: National Institutes of Health; Contract grant number: K23 HL 094765-01; Contract grant sponsor: Mental Illness Research and Education Clinical Center of the US Veterans Health Administration. NR 32 TC 8 Z9 8 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD FEB PY 2014 VL 31 IS 2 BP 160 EP 165 DI 10.1002/da.22072 PG 6 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA AA6EA UT WOS:000331190400008 PM 23494973 ER PT J AU Hoffler, EF Dekle, JW Sheets, C AF Hoffler, Elizabeth F. Dekle, Judith Ward Sheets, Carol TI Social Work with Service Members, Veterans, and Their Families SO HEALTH & SOCIAL WORK LA English DT Editorial Material C1 [Hoffler, Elizabeth F.] Prevent Canc Fdn, Alexandria, VA 22314 USA. [Dekle, Judith Ward] US Dept Def, Alexandria, VA USA. [Sheets, Carol] US Dept Vet Affairs, Washington, DC USA. RP Hoffler, EF (reprint author), Prevent Canc Fdn, 1600 Duke St,Suite 500, Alexandria, VA 22314 USA. EM elizabeth.hoffler@gmail.com NR 15 TC 0 Z9 0 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0360-7283 EI 1545-6854 J9 HEALTH SOC WORK JI Health Soc. Work PD FEB PY 2014 VL 39 IS 1 SI SI BP 3 EP 5 DI 10.1093/hsw/hlu007 PG 3 WC Social Work SC Social Work GA AC7XC UT WOS:000332745700001 PM 24693598 ER PT J AU Strong, J Ray, K Findley, PA Torres, R Pickett, L Byrne, RJ AF Strong, Jessica Ray, Kathleen Findley, Patricia A. Torres, Rita Pickett, Lisa Byrne, Richard J. TI Psychosocial Concerns of Veterans of Operation Enduring Freedom/Operation Iraqi Freedom SO HEALTH & SOCIAL WORK LA English DT Article DE mental health; psychosocial factors; social work; veterans ID RETURNING COMBAT VETERANS; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH; WAR VETERANS; US MILITARY; AFGHANISTAN; CARE; PAIN; ASSOCIATION; DEPLOYMENT AB U.S. veterans present with complex medical and psychosocial concerns postdeployment. Identification of psychosocial concerns is necessary for appropriate and targeted social work interventions to improve delivery and receipt of health care through the U.S. Department of Veterans Affairs. The purpose of this article is to identify specific psychosocial concerns of veterans of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) presenting at the War Related Illness and Injury Study Center. A retrospective chart review of psychosocial concerns from all OIF/OEF veterans seen from June 2008 to June 2010 provided data for this mixed methods study. Veterans in the sample (N = 356) reported an average of 5.2 psychosocial concerns (SD = 2.32, range = 0 to 11). The most commonly reported concerns were pain (72 percent), sleep (62 percent), cognition (61 percent), vocational issues (53 percent), education (49 percent), finances (42 percent), relationships (37 percent), anger (30 percent), substance abuse (23 percent), and social support (20 percent), though these categories were not exclusive and many veterans endorsed more than one category. Multiple psychosocial concerns reported by veterans suggest the need for targeted social work intervention. C1 [Strong, Jessica] Univ N Carolina, Wilmington, NC 28403 USA. [Ray, Kathleen; Torres, Rita] US Dept Vet Affairs, War Related Illness & Injury Study Ctr, E Orange, NJ USA. [Findley, Patricia A.] Rutgers State Univ, Sch Social Work, New Brunswick, NJ 08903 USA. [Pickett, Lisa] US Dept Vet Affairs, Extended Care Serv, VA New Jersey Hlth Care Syst, Lyons, NJ USA. [Byrne, Richard J.] Family Intervent Serv, Sparta, NJ USA. RP Strong, J (reprint author), Univ N Carolina, Wilmington, NC 28403 USA. EM strongj@uncw.edu NR 32 TC 2 Z9 2 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0360-7283 EI 1545-6854 J9 HEALTH SOC WORK JI Health Soc. Work PD FEB PY 2014 VL 39 IS 1 SI SI BP 17 EP 24 DI 10.1093/hsw/hlu002 PG 8 WC Social Work SC Social Work GA AC7XC UT WOS:000332745700003 PM 24693600 ER PT J AU Lanctot, KL Chau, SA Herrmann, N Drye, LT Rosenberg, PB Scherer, RW Black, SE Vaidya, V Bachman, DL Mintzer, JE AF Lanctot, Krista L. Chau, Sarah A. Herrmann, Nathan Drye, Lea T. Rosenberg, Paul B. Scherer, Roberta W. Black, Sandra E. Vaidya, Vijay Bachman, David L. Mintzer, Jacobo E. CA ADMET Investigators TI Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE psychopharmacology; neuropharmacology; apathy; behavioral and psychological symptoms of dementia (BPSD); Alzheimer's disease ID DEFICIT HYPERACTIVITY DISORDER; ALZHEIMERS-DISEASE; DEXTROAMPHETAMINE CHALLENGE; PARKINSONS-DISEASE; DEMENTIA; DOPAMINE; GALANTAMINE; MOTIVATION; MEMORY; SPECT AB Background: Little is known about the effect of methylphenidate (MPH) on attention in Alzheimer's disease (AD). MPH has shown to improve apathy in AD, and both apathy and attention have been related to dopaminergic function. The goal was to investigate MPH effects on attention in AD and assess the relationship between attention and apathy responses. Methods: MPH (10 mg PO twice daily) or placebo was administered for six weeks in a randomized, double-blind trial in mild-to-moderate AD outpatients with apathy (Neuropsychiatric Inventory (NPI) Apathy >= 4). Attention was measured with the Wechsler Adult Intelligence Scale - Digit Span (DS) subtest (DS forward, selective attention) and apathy with the Apathy Evaluation Scale (AES). A mixed effects linear regression estimated the difference in change from baseline between treatment groups, defined as delta (MPH (DS week 6-DS baseline)) - (placebo (DS week 6-DS baseline)). Results: In 60 patients (37 females, age = 76 +/- 8, Mini-Mental State Examination (MMSE) = 20 +/- 5, NPI Apathy = 7 +/- 2), the change in DS forward (delta = 0.87 (95% CI: 0.06-1.68), p = 0.03) and DS total (delta = 1.01 (95% CI: 0.09-1.93), p = 0.03) favored MPH over placebo. Of 57 completers, 17 patients had improved apathy (>= 3.3 points on the AES from baseline to end point) and 40 did not. There were no significant associations between AES and NPI Apathy with DS change scores in the MPH, placebo, AES responder, or non-responder groups. DS scores did not predict apathy response to MPH treatment. Conclusion: These results suggest MPH can improve attention and apathy in AD; however, the effects appear independent in this population. C1 [Lanctot, Krista L.; Chau, Sarah A.; Herrmann, Nathan; Black, Sandra E.] Univ Toronto, Dept Psychiat, Toronto, ON M5S 1A1, Canada. [Lanctot, Krista L.; Chau, Sarah A.; Herrmann, Nathan; Black, Sandra E.] Univ Toronto, Dept Med Neurol, Toronto, ON M5S 1A1, Canada. [Lanctot, Krista L.; Chau, Sarah A.; Herrmann, Nathan; Black, Sandra E.] Univ Toronto, Brain Sci Res Program, Sunnybrook Res Inst, Dept Psychiat, Toronto, ON M5S 1A1, Canada. [Lanctot, Krista L.; Chau, Sarah A.; Herrmann, Nathan; Black, Sandra E.] Univ Toronto, Brain Sci Res Program, Sunnybrook Res Inst, Dept Pharmacol Toxicol, Toronto, ON M5S 1A1, Canada. [Lanctot, Krista L.; Chau, Sarah A.; Herrmann, Nathan; Black, Sandra E.] Univ Toronto, Brain Sci Res Program, Sunnybrook Res Inst, Dept Med Neurol, Toronto, ON M5S 1A1, Canada. [Drye, Lea T.; Scherer, Roberta W.; Vaidya, Vijay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Rosenberg, Paul B.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Bachman, David L.; Mintzer, Jacobo E.] Med Univ S Carolina, Dept Neurosci, Alzheimers Res Program, Charleston, SC USA. [Bachman, David L.; Mintzer, Jacobo E.] Med Univ S Carolina, Dept Neurosci, Alzheimers Clin Program, Charleston, SC USA. [Bachman, David L.; Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Lanctot, KL (reprint author), 2075 Bayview Ave Room FG-08, Toronto, ON M4N 3M5, Canada. EM Krista.lanctot@sunnybrook.ca OI Drye, Lea/0000-0002-2964-1878 FU National Institute on Aging (NIA) [R01 AG033032-01, 1 K08 AG029157-01A1] FX This research was supported by funding from the sponsor National Institute on Aging (NIA) R01 AG033032-01 and 1 K08 AG029157-01A1. The NIA had no role in data collection, analysis, or drafting of the paper. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. NR 38 TC 9 Z9 9 U1 2 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD FEB PY 2014 VL 26 IS 2 BP 239 EP 246 DI 10.1017/S1041610213001762 PG 8 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA AD0QS UT WOS:000332939800008 PM 24169147 ER PT J AU Zhang, YQ Bokov, A Gelfond, J Soto, V Ikeno, Y Hubbard, G Diaz, V Sloane, L Maslin, K Treaster, S Rendon, S van Remmen, H Ward, W Javors, M Richardson, A Austad, SN Fischer, K AF Zhang, Yiqiang Bokov, Alex Gelfond, John Soto, Vanessa Ikeno, Yuji Hubbard, Gene Diaz, Vivian Sloane, Lauren Maslin, Keith Treaster, Stephen Rendon, Samantha van Remmen, Holly Ward, Walter Javors, Martin Richardson, Arlan Austad, Steven N. Fischer, Kathleen TI Rapamycin Extends Life and Health in C57BL/6 Mice SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Aging; Health span; Rapamycin; Sex differences ID GENETICALLY HETEROGENEOUS MICE; MAMMALIAN TARGET; COGNITIVE DEFICITS; AMYLOID-BETA; TOR PATHWAY; SPAN; AUTOPHAGY; MTOR; PROTEIN; P62/SQSTM1 AB Target of rapamycin inhibition by rapamycin feeding has previously been shown to extend life in genetically heterogeneous mice. To examine whether it similarly affected mouse health, we fed encapsulated rapamycin or a control diet to C57BL/6Nia mice of both sexes starting at 19 months of age. We performed a range of health assessments 6 and 12 months later. Rapamycin feeding significantly reduced mTOR activity in most but not all tissues. It also reduced total and resting metabolic rate during the light (inactive) phase of the light: dark cycle in females only but had no effect on spontaneous activity or metabolism during the dark (active) phase of either sex. Males only had less fragmented sleep when fed rapamycin, whereas stride length and rotarod performance were improved in both sexes. Survival was also improved by this late-life rapamycin feeding, and some pathological lesions were delayed. We found no adverse health consequences associated with rapamycin treatment. C1 [Zhang, Yiqiang; Bokov, Alex; Gelfond, John; Soto, Vanessa; Ikeno, Yuji; Hubbard, Gene; Diaz, Vivian; Sloane, Lauren; Rendon, Samantha; van Remmen, Holly; Ward, Walter; Richardson, Arlan; Austad, Steven N.; Fischer, Kathleen] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Zhang, Yiqiang; Maslin, Keith; Treaster, Stephen; Austad, Steven N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA. [Bokov, Alex; Gelfond, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78245 USA. [Ikeno, Yuji; Hubbard, Gene] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78245 USA. [Ikeno, Yuji] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Rendon, Samantha; van Remmen, Holly; Austad, Steven N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Ward, Walter; Richardson, Arlan; Fischer, Kathleen] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA. [Javors, Martin; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78245 USA. RP Fischer, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM fischerke@uthscsa.edu FU National Institutes of Health [RC2 AG036613]; University of Texas Health Science Center at San Antonio Nathan Shock Center of Excellence in the Biology of Aging [P30 AG13319] FX This work was supported by National Institutes of Health grant RC2 AG036613 and the University of Texas Health Science Center at San Antonio Nathan Shock Center of Excellence in the Biology of Aging (P30 AG13319). NR 55 TC 72 Z9 73 U1 2 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD FEB PY 2014 VL 69 IS 2 BP 119 EP 130 DI 10.1093/gerona/glt056 PG 12 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AD6QA UT WOS:000333384700001 PM 23682161 ER PT J AU Talbot, LS Maguen, S Metzler, TJ Schmitz, M McCaslin, SE Richards, A Perlis, ML Posner, DA Weiss, B Ruoff, L Varbel, J Neylan, TC AF Talbot, Lisa S. Maguen, Shira Metzler, Thomas J. Schmitz, Martha McCaslin, Shannon E. Richards, Anne Perlis, Michael L. Posner, Donn A. Weiss, Brandon Ruoff, Leslie Varbel, Jonathan Neylan, Thomas C. TI Cognitive Behavioral Therapy for Insomnia in Posttraumatic Stress Disorder: A Randomized Controlled Trial SO SLEEP LA English DT Article DE Insomnia; cognitive behavioral therapy; posttraumatic stress disorder ID BECK DEPRESSION INVENTORY; SLEEP QUALITY INDEX; NATIONALLY REPRESENTATIVE SAMPLE; ADMINISTERED PTSD SCALE; TEST-RETEST RELIABILITY; MALE VIETNAM VETERANS; PSYCHIATRIC-DISORDERS; NONPHARMACOLOGIC TREATMENT; PSYCHOMETRIC PROPERTIES; PERSISTENT INSOMNIA AB Study Objectives: Examine whether cognitive behavioral therapy for insomnia (CBT-I) improves sleep in posttraumatic stress disorder (PTSD) as well as nightmares, nonsleep PTSD symptoms, depression symptoms, and psychosocial functioning. Design: Randomized controlled trial with two arms: CBT-I and monitor-only waitlist control. Setting: Department of Veterans Affairs (VA) Medical Center. Participants: Forty-five adults (31 females: [mean age 37 y (22-59 y)] with PTSD meeting research diagnostic criteria for insomnia, randomly assigned to CBT-I (n = 29; 22 females) or monitor-only waitlist control (n = 16; nine females). Interventions: Eight-session weekly individual CBT-I delivered by a licensed clinical psychologist or a board-certified psychiatrist. Measurements and Results: Measures included continuous monitoring of sleep with diary and actigraphy; prepolysomnography and postpolysomnography and Clinician-Administered PTSD Scale (CAPS); and pre, mid, and post self-report questionnaires, with follow-up of CBT-I participants 6 mo later. CBT-I was superior to the waitlist control condition in all sleep diary outcomes and in polysomnography-measured total sleep time. Compared to waitlist participants, CBT-I participants reported improved subjective sleep (41% full remission versus 0%), disruptive nocturnal behaviors (based on the Pittsburgh Sleep Quality Index-Addendum), and overall work and interpersonal functioning. These effects were maintained at 6-mo follow-up. Both CBT-I and waitlist control participants reported reductions in PTSD symptoms and CAPS-measured nightmares. Conclusions: Cognitive behavioral therapy for insomnia (CBT-I) improved sleep in individuals with posttraumatic stress disorder, with durable gains at 6 mo. Overall psychosocial functioning improved following CBT-I. The initial evidence regarding CBT-I and nightmares is promising but further research is needed. Results suggest that a comprehensive approach to treatment of posttraumatic stress disorder should include behavioral sleep medicine. C1 [Talbot, Lisa S.; Maguen, Shira; Metzler, Thomas J.; Schmitz, Martha; McCaslin, Shannon E.; Richards, Anne; Weiss, Brandon; Ruoff, Leslie; Varbel, Jonathan; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Talbot, Lisa S.; Maguen, Shira; Schmitz, Martha; McCaslin, Shannon E.; Richards, Anne; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [McCaslin, Shannon E.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA. [Perlis, Michael L.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Posner, Donn A.] Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA. RP Talbot, LS (reprint author), San Francisco VA Med Ctr 116H, 4150 Clement St, San Francisco, CA 94121 USA. EM lisa.talbot@gmail.com FU National Institute for Mental Health [TCN: 5R01MH073978-04, 5R34MH077667-03]; Mental Illness Research and Education Clinical Center of the US Veterans Health Administration FX This was not an industry supported study. The authors have indicated no financial conflicts of interest. This project was supported by grants from the National Institute for Mental Health (TCN: 5R01MH073978-04, 5R34MH077667-03) and the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. This material is the result of work supported with resources and the use of facilities at the Veterans Administration Medical Center, San Francisco, CA. NR 101 TC 40 Z9 40 U1 0 U2 27 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD FEB 1 PY 2014 VL 37 IS 2 BP 327 EP 341 DI 10.5665/sleep.3408 PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AC4VL UT WOS:000332519100013 PM 24497661 ER PT J AU Williams, EC Rubinsky, AD Lapham, GT Chavez, LJ Rittmueller, SE Hawkins, EJ Grossbard, JR Kivlahan, DR Bradley, KA AF Williams, Emily C. Rubinsky, Anna D. Lapham, Gwen T. Chavez, Laura J. Rittmueller, Stacey E. Hawkins, Eric J. Grossbard, Joel R. Kivlahan, Daniel R. Bradley, Katharine A. TI Prevalence of clinically recognized alcohol and other substance use disorders among VA outpatients with unhealthy alcohol use identified by routine alcohol screening SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcohol use disorders; Alcohol screening; Substance use disorders ID RANDOMIZED-CONTROLLED-TRIAL; PRIMARY-CARE SETTINGS; AUDIT-C; GENDER-DIFFERENCES; BRIEF INTERVENTION; OPIOID DEPENDENCE; RISK DRINKING; PREVENTIVE SERVICES; CHRONIC DISEASE; UNITED-STATES AB Objective: The purpose of routine alcohol screening is to identify patients who may benefit from brief intervention, but patients who also have alcohol and other substance use disorders (AUD/SUD) likely require more intensive interventions. This study sought to determine the prevalence of clinically documented AUD/SUD among VA outpatients with unhealthy alcohol use identified by routine screening. Methods: VA patients 18-90 years who screened positive for unhealthy alcohol use (AUDIT-C >= 3 women; >= 4 men) and were randomly selected for quality improvement standardized medical record review (6/06-6/10) were included. Gender-stratified prevalences of clinically documented AUD/SUD (diagnosis of AUD, SUD, or alcohol-specific medical conditions, or VA specialty addictions treatment on the date of or 365 days prior to screening) were estimated and compared across AUDIT-C risk groups, and then repeated across groups further stratified by age. Results: Among 63,397 eligible patients with unhealthy alcohol use, 25% (n = 2109) women and 28% (n = 15,199) men had documented AUD/SUD (p <0.001). The prevalence of AUD/SUD increased with increasing AUDIT-C risk, ranging from 13% (95% Cl 13-14%) to 82% (79-85%) for women and 12% (11-12%) to 69% (68-71%) for men in the lowest and highest AUDIT-C risk groups, respectively. Patterns were similar across age groups. Conclusions: One-quarter of all patients with unhealthy alcohol use, and a majority of those with the highest alcohol screening scores, had clinically recognized AUD/SUD. Healthcare systems implementing evidence-based alcohol-related care should be prepared to offer more intensive interventions and/or effective pharmacotherapies for these patients. Published by Elsevier Ireland Ltd. C1 [Williams, Emily C.; Rubinsky, Anna D.; Lapham, Gwen T.; Chavez, Laura J.; Rittmueller, Stacey E.; Hawkins, Eric J.; Grossbard, Joel R.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Denver Seattle Ctr Innovat Veteran Centered & Val, Hlth Serv Res Ca Dev, Seattle, WA 98101 USA. [Rubinsky, Anna D.; Hawkins, Eric J.; Grossbard, Joel R.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ, Seattle, WA 98101 USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Williams, Emily C.; Rubinsky, Anna D.; Chavez, Laura J.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM emily.williams3@va.gov FU VA Substance Use Disorders Quality Enhancement Research Initiative; VA Puget Sound HSRD; AHRQ/NRSA T-32 training grant at the University of Washington; VA Health Services Research Development [CDA 12-276]; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI) FX Data for this study were provided by the VA Office of Analytics and Business Intelligence. This work was supported by the VA Substance Use Disorders Quality Enhancement Research Initiative and VA Puget Sound HSR&D. Dr. Rubinsky was also supported by an AHRQ/NRSA T-32 training grant at the University of Washington. Dr. Williams is supported by a Career Development Award from VA Health Services Research & Development (CDA 12-276). Dr. Williams is also an investigator with the Implementation Research Institute (IRI) at the George Warren Brown School of Social Work at Washington University in St. Louis. IRI is supported through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). NR 71 TC 8 Z9 9 U1 1 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD FEB 1 PY 2014 VL 135 BP 95 EP 103 DI 10.1016/j.drugalcdep.2013.11.016 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA AC7YH UT WOS:000332749700013 PM 24360928 ER PT J AU Whellan, DJ Goodlin, SJ Dickinson, MG Heidenreich, PA Jaenicke, C Stough, WG Rich, MW AF Whellan, David J. Goodlin, Sarah J. Dickinson, Michael G. Heidenreich, Paul A. Jaenicke, Connie Stough, Wendy Gattis Rich, Michael W. CA Quality Care Comm Heart Failure TI End-of-Life Care in Patients With Heart Failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Advanced heart failure; end-of-life care; hospice; palliative care ID CARDIAC-RESYNCHRONIZATION THERAPY; VENTRICULAR ASSIST DEVICE; IMPLANTABLE ELECTRONIC DEVICES; EXPERT CONSENSUS STATEMENT; PATIENTS NEARING END; HOME OXYGEN-THERAPY; CENTRAL SLEEP-APNEA; LAST 6 MONTHS; DESTINATION THERAPY; PALLIATIVE CARE AB Stage D heart failure (HF) is associated with poor prognosis, yet little consensus exists on the care of patients with HF approaching the end of life. Treatment options for end-stage HF range from continuation of guideline-directed medical therapy to device interventions and cardiac transplantation. However, patients approaching the end of life may elect to forego therapies or procedures perceived as burdensome, or to deactivate devices that were implanted earlier in the disease course. Although discussing end-of-life issues such as advance directives, palliative care, or hospice can be difficult, such conversations are critical to understanding patient and family expectations and to developing mutually agreed-on goals of care. Because patients with HF are at risk for rapid clinical deterioration or sudden cardiac death, end-of-life issues should be discussed early in the course of management. As patients progress to advanced HF, the need for such discussions increases, especially among patients who have declined, failed, or been deemed to be ineligible for advanced HF therapies. Communication to define goals of care for the individual patient and then to design therapy concordant with these goals is fundamental to patient-centered care. The objectives of this white paper are to highlight key end-of-life considerations in patients with HF, to provide direction for clinicians on strategies for addressing end-of-life issues and providing optimal patient care, and to draw attention to the need for more research focusing on end-of-life care for the HF population. C1 [Whellan, David J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA. [Goodlin, Sarah J.] Portland VA Med Ctr, Div Gen Internal Med & Geriatr, Portland, OR USA. [Dickinson, Michael G.] Spectrum Hlth, Frederik Meijer Heart & Vasc Inst, Grand Rapids, MI USA. [Heidenreich, Paul A.] Vet Affairs Palo Alto Med Ctr, Ctr Primacy Care & Outcomes Res, Ctr Hlth Policy, Palo Alto, CA USA. [Jaenicke, Connie] Vet Affairs Med Ctr, Minneapolis, MN USA. [Stough, Wendy Gattis] Campbell Univ, Coll Pharm & Hlth Sci, Bales Creek, NC USA. [Rich, Michael W.] Washington Univ, Sch Med, St Louis, MO USA. RP Whellan, DJ (reprint author), Thomas Jefferson Univ, 925 Chestnut St, Philadelphia, PA 19107 USA. EM djw150@jefferson.edu RI Stough, Wendy/R-4287-2016 OI Stough, Wendy/0000-0001-8290-1205; Heidenreich, Paul/0000-0001-7730-8490 FU Medtronic; Heart Failure Society of America FX Sarah J. Goodlin, MD, reports research support from Medtronic. Wendy Gattis Stough, PharmD reports support from the Heart Failure Society of America. None of the other authors report any potential conflict of interest. NR 109 TC 26 Z9 27 U1 1 U2 13 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD FEB PY 2014 VL 20 IS 2 BP 121 EP 134 DI 10.1016/j.cardfail.2013.12.003 PG 14 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AC3QC UT WOS:000332435300006 PM 24556532 ER PT J AU Vickrey, BG Thrift, AG AF Vickrey, Barbara G. Thrift, Amanda G. TI Advances in Stroke Health Policy/Outcomes Research 2013 SO STROKE LA English DT Editorial Material DE mortality; point-of-care systems; quality of healthcare ID CARE; MORTALITY; OUTCOMES C1 [Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Vickrey, Barbara G.] Greater Los Angeles VA HealthCare Syst, Dept Neurol, Los Angeles, CA USA. [Thrift, Amanda G.] Monash Univ, Epidemiol & Prevent Unit, Stroke & Ageing Res Ctr STARC, Dept Med,Monash Med Ctr,Southern Clin Sch, Melbourne, Vic 3004, Australia. [Thrift, Amanda G.] Florey Neurosci Inst, Natl Stroke Res Inst, Heidelberg, Vic, Australia. RP Vickrey, BG (reprint author), Univ Calif Los Angeles, Dept Neurol, C109 RNRC,710 Westwood Plaza, Los Angeles, CA 90095 USA. EM bvickrey@ucla.edu RI Thrift, Amanda/I-6251-2012 OI Thrift, Amanda/0000-0001-8533-4170 NR 11 TC 1 Z9 1 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2014 VL 45 IS 2 BP 361 EP 362 DI 10.1161/STROKEAHA.113.004224 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 298GP UT WOS:000330312500015 PM 24436232 ER PT J AU Cruz-Oliver, DM Talamantes, M Sanchez-Reilly, S AF Cruz-Oliver, Dulce M. Talamantes, Melissa Sanchez-Reilly, Sandra TI What Evidence is Available on End-of-life (EOL) Care and Latino Elders? A Literature Review SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Review DE Latino; Hispanic; elder; end of life; palliative; hospice ID ETHNIC-DIFFERENCES; PALLIATIVE CARE; AFRICAN-AMERICAN; DECISION-MAKING; OLDER LATINOS; HEALTH-CARE; HOSPICE; PREFERENCES; SUPPORT; DEATH AB Background: Low-income and minority persons, such as Latinos, encounter substantial barriers in accessing effective end-of-life (EOL) care. This study intends to review current evidence on how to deliver EOL care to Latino elders. Methods: Literature search in PubMed and Ovid Web sites of articles indexed in Medline (1948-2011), Cochrane (2005-2011), Embase, and PsychInfo (1967-2011) databases. Articles were included if they contained (1) study participants' race/ethnicity, (2) adults or population older than 60 years, and (3) information related to EOL care. Results: A total of 64 abstracts were reviewed, and 38 articles met the inclusion criteria. After reviewing the quality of evidence, 4 themes were identified and summarized: EOL preferences, hospice, Latino culture, and caregiving. Conclusion: Latino elders have traditional acculturation practices, face EOL decisions with family support, and, if educated, are receptive toward hospice and caregiver support. C1 [Cruz-Oliver, Dulce M.] St Louis Univ, Dept Internal Med, Div Geriatr, St Louis, MO 63104 USA. [Talamantes, Melissa] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, South Texas Vet Hlth Care Syst, GEC, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78229 USA. RP Cruz-Oliver, DM (reprint author), St Louis Univ, Dept Internal Med, Div Geriatr, 1402 South Grand Blvd M238, St Louis, MO 63104 USA. EM dcruzoli@slu.edu FU NIA NIH HHS [T35 AG038048] NR 56 TC 10 Z9 10 U1 3 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD FEB PY 2014 VL 31 IS 1 BP 87 EP 97 DI 10.1177/1049909113480841 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AA6ID UT WOS:000331201100012 PM 23503564 ER PT J AU Doi, H Tanoue, S Kaplan, DE AF Doi, Hiroyoshi Tanoue, Shiroh Kaplan, David E. TI Peripheral CD27(-)CD21(-) B-cells represent an exhausted lymphocyte population in hepatitis C cirrhosis SO CLINICAL IMMUNOLOGY LA English DT Article DE Human; B-cell; Lymphocyte; Hepatitis C; Anergy; CD21 ID MARGINAL ZONE-LIKE; VIRUS-INFECTION; MIXED CRYOGLOBULINEMIA; LIVER-TRANSPLANTATION; HIV-INFECTION; MICROBIAL TRANSLOCATION; IMMUNE ACTIVATION; EXPANSION; RECEPTOR; BLOOD AB Hepatitis C cirrhosis is associated with a profound disappearance of memory B-cells. We sought to determine if this loss is associated with the expansion of the CD27(-)CD21(-) tissue-like memory B-cells with features of B-cell exhaustion. To this end, we quantified the frequency of CD27(-) CD21(-) B-cells in healthy, non-cirrhotic HCV-infected, and cirrhotic patients. We examined the expression of putative inhibitory receptors, the proliferative and immunoglobulin-secreting capacity of CD27/CD21-defined B-cell subsets upon B-cell receptor and/or CD40 stimulation. We found that CD27(-)CD21(-) B-cells are significantly increased in frequency relative to healthy donors in HCV-infected patients. CD2(-)CD21(-) B-cells were hypoproliferative relative to nave and resting Memory B-cells upon agonistic stimulation, but retained similar capacity for antibody secretion. Conclusion: CD2(-)CD21(-) tissue-like memory B-cells with exhausted proliferation circulate at increased frequency in cirrhotic and non-cirrhotic HCV-infected patients. This B-cell subset does not appear anergic, exhibiting immunoglobulin-secreting capacity on CD40 agonism indistinguishable from other CD27/CD21-defined B-cell subsets. Published by Elsevier Inc. C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA. [Doi, Hiroyoshi; Tanoue, Shiroh; Kaplan, David E.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. RP Kaplan, DE (reprint author), Philadelphia VA Med Ctr, Res Bldg 21,A402A,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM dakaplan@mail.med.upenn.edu OI Kaplan, David E./0000-0002-3839-336X FU Schering-Plough Research Institute; Merck Sharp Et Dohme Corp FX This work was supported by an unrestricted scientific grant from the Schering-Plough Research Institute affiliated with Merck Sharp Et Dohme Corp (DEK). The authors would also like to thank the patients and volunteers who contributed samples. The content of this article does not reflect the views of the VA or of the US Government. NR 44 TC 18 Z9 18 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 EI 1521-7035 J9 CLIN IMMUNOL JI Clin. Immunol. PD FEB PY 2014 VL 150 IS 2 BP 184 EP 191 DI 10.1016/j.clim.2013.12.001 PG 8 WC Immunology SC Immunology GA AC0OH UT WOS:000332194100009 PM 24434272 ER PT J AU Kanwal, F Hoang, T Chrusciel, T Kramer, JR El-Serag, HB Durfee, J Dominitz, JA Yano, EM Asch, SM AF Kanwal, Fasiha Tuyen Hoang Chrusciel, Timothy Kramer, Jennifer R. El-Serag, Hashem B. Durfee, Janet Dominitz, Jason A. Yano, Elizabeth M. Asch, Steven M. TI Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Process of care; Structure of care; Health services; Chronic hepatitis C; Quality improvement ID GEOGRAPHIC-VARIATION; UNITED-STATES; ANTIVIRAL THERAPY; US VETERANS; PREDICTORS; HOSPITALS; MANAGEMENT; QUALITY; DISEASE; COHORT AB Available data suggest problems in the process of care provided to patients with chronic hepatitis C (HCV). However, the solutions to these problems are less obvious. Healthcare facility factors are potentially modifiable and may enhance process quality in HCV treatment. We evaluated the relationship between the process of HCV care and facility factors including number of weekly half-day HCV clinics per 1,000 HCV patients, HCV-specific quality-improvement initiatives, and administrative service of the HCV clinic (gastroenterology, infectious disease, primary care) for a cohort of 34,258 patients who sought care in 126 Veterans Affairs facilities during 2003-2006. We measured HCV care on the basis of 23 HCV-specific process measures capturing pretreatment (seven measures), preventive and/or comorbid (seven measures), and treatment and treatment monitoring care (nine measures). Patients seen at a facility with > 8 half-day clinics were 52 % more likely to receive overall indicated care (OR 1.52, 95 % CI 1.13-2.05). Patients seen at a facility with > 3 HCV quality improvement initiatives were more likely to receive better preventive and/or comorbid care (OR 1.32, 95 % CI 1.00-1.74). Compared with patients in facilities with no dedicated HCV clinic, patients at facilities with gastroenterology-based clinics received better pretreatment care (OR 1.36, 95 % CI 1.01-1.85) and more antiviral treatment (OR 1.45, 95 % CI 1.06-1.97) whereas those at facilities with infectious disease-based or primary care-based clinics received better preventive and/or comorbid care (OR 1.59, 95 % CI 1.06-2.39 and 1.84, 95 % CI 1.21-2.79 respectively). Several facility factors affected the process of HCV care. These factors may serve as targets for quality-improvement efforts. C1 [Kanwal, Fasiha; Kramer, Jennifer R.; El-Serag, Hashem B.] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. [Kanwal, Fasiha; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Gastroenterol Sect, Houston, TX 77030 USA. [Tuyen Hoang; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Chrusciel, Timothy] John Cochran VA Med Ctr, St Louis, MO USA. [Durfee, Janet] Off Publ Hlth Clin Publ Hlth, Washington, DC USA. [Dominitz, Jason A.] VA Puget Hlth Care Syst, Seattle, WA USA. [Yano, Elizabeth M.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. [Yano, Elizabeth M.] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Asch, Steven M.] VA Palo Alto, Hlth Serv Res & Dev Serv, VA HSR&D Ctr Excellence, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ, Coll Med, Dept Med, Palo Alto, CA 94304 USA. RP Kanwal, F (reprint author), Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Hlth Serv Res & Dev Serv, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM fasiha.kanwal@va.gov OI Dominitz, Jason/0000-0002-8070-7086 FU Health Services Research and Development Service, the Office of Research and Development, the Department of Veterans Affairs [IIR-07-111]; VA HSR&D Senior Research Career Scientist Award [05-195]; VA HSRD [06-087, 09-082] FX This material is based on work supported, in part, by the Health Services Research and Development Service, the Office of Research and Development, the Department of Veterans Affairs grant IIR-07-111 to Dr Kanwal. The authors are indebted to the Veterans Health Administration Hepatitis C Clinical Case Registry, Clinical Public Health, and Healthcare Analysis and Information Group for the data used in this study. Dr. Yano's time was covered by a VA HSR&D Senior Research Career Scientist Award (Project #05-195). VA organizational data were obtained from VA HSR&D-funded studies (Projects #06-087 and #09-082). NR 26 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD FEB PY 2014 VL 59 IS 2 BP 273 EP 281 DI 10.1007/s10620-013-2773-z PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AB2WD UT WOS:000331651900008 PM 23934366 ER PT J AU Interian, A Kline, A Janal, M Glynn, S Losonczy, M AF Interian, Alejandro Kline, Anna Janal, Malvin Glynn, Shirley Losonczy, Miklos TI Multiple Deployments and Combat Trauma: Do Homefront Stressors Increase the Risk for Posttraumatic Stress Symptoms? SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID NATIONAL-GUARD SOLDIERS; MENTAL-HEALTH; DEPLOYED SOLDIERS; IRAQI FREEDOM; GULF-WAR; VETERANS; PTSD; FAMILY; RESILIENCE; AFGHANISTAN AB Multiple deployments are common among military personnel who served in Operation Enduring Freedom and Operation Iraqi Freedom and are associated with greater posttraumatic stress symptoms (PTSS). Homefront stressors (i.e., family, occupational problems) resulting from deployments may increase the risk of PTSS. Moreover, with multiple deployments, a new deployment may occur while still experiencing homefront stressors from previous tours. This prospective study assessed whether homefront stressors from a previous tour increased the risk of PTSS after a new deployment. It also examined the effects of homefront stressors at postdeployment. Survey data were obtained from U.S. National Guard soldiers with previous deployments prior to (Wave 1) and after (Wave 2) a new deployment to Iraq (N = 196). Homefront stressors reported at Wave 1 ( = .154, p = .015) and Wave 2 ( = .214, p = .002) were both significantly predictive of PTSS at postdeployment, even after adjusting for warzone stressors, predeployment PTSS, and other variables. A pattern of chronic homefront stressors (i.e., homefront stressors at pre- and postdeployment) was associated with higher levels of PTSS at postdeployment ( = .220, p = .002). Service members with multiple deployments are at greater risk for PTSS if deployed with homefront stressors from previous tours and/or face these stressors at postdeployment. C1 [Interian, Alejandro; Kline, Anna] VA New Jersey Hlth Care Syst, E Orange, NJ USA. [Interian, Alejandro; Kline, Anna] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA. [Janal, Malvin] NYU, New York, NY USA. [Glynn, Shirley] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Glynn, Shirley] Univ Calif Los Angeles, Los Angeles, CA USA. [Losonczy, Miklos] Lincoln Med & Mental Hlth Ctr, Bronx, NY 10451 USA. RP Interian, A (reprint author), VA New Jersey Hlth Care Syst Mental Hlth & Behav, 151 Knollcroff Rd 116A, Lyons, NJ 07939 USA. EM alejandro.interian@va.gov NR 35 TC 6 Z9 6 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD FEB PY 2014 VL 27 IS 1 BP 90 EP 97 DI 10.1002/jts.21885 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AA7NR UT WOS:000331284600012 PM 24464407 ER PT J AU Findlay, VJ Moretz, RE Wang, C Vaena, SG Bandurraga, SG Ashenafi, M Marshall, DT Watson, DK Camp, ER AF Findlay, Victoria J. Moretz, R. Eric Wang, Cindy Vaena, Silvia G. Bandurraga, Savannah G. Ashenafi, Michael Marshall, David T. Watson, Dennis K. Camp, E. Ramsay TI Slug Expression Inhibits Calcitriol-Mediated Sensitivity to Radiation in Colorectal Cancer SO MOLECULAR CARCINOGENESIS LA English DT Article DE vitamin D; radiation; colorectal; cancer; EMT; Slug ID HUMAN-COLON-CANCER; TRANSCRIPTION FACTOR SNAIL; VITAMIN-D-RECEPTOR; ACTIVITY IN-VITRO; PROSTATE-CANCER; CELL-LINES; RECTAL-CANCER; E-CADHERIN; CARCINOMA; MODEL AB Recently, a reciprocal relationship between calcitriol and epithelial-to-mesenchymal transition has been described. Therefore, we hypothesized that calcitriol (1,25-dihydroxyvitamin D-3) would enhance radiation sensitivity in colorectal cancer regulated by epithelial mesenchymal transition. Vitamin-D receptor, E-cadherin and vimentin protein as well as E-cadherin, Snail and Slug mRNA levels were assessed in a panel of human colorectal cancer cell lines at baseline and in response calcitriol. We defined cell lines as calcitriol sensitive based on demonstrating an enhanced epithelial phenotype with increased E-cadherin, reduced vimentin and decreased expression of Snail and Slug as well as decreased cellular migration in response to calcitriol. In calcitriol sensitive cells, including DLD-1 and HCT116, 24h calcitriol pre-treatment enhanced the radiation sensitivity by 2.3- and 2.6-fold, respectively, at 4Gy (P<0.05). In contrast, SW620 cells with high baseline mesenchymal features including high Slug and vimentin expression with low E-cadherin expression demonstrated no significant radiation sensitizing response to calcitriol treatment. Similarly, transfection of Slug in the calcitriol sensitive colon cancer cell lines, DLD-1 and HCT 116, completely inhibited the radiation sensitizing effect of calcitriol. Collectively, we demonstrate that calcitriol can enhance the therapeutic effects of radiation in colon cancer cells and Slug expression mitigates this observed effect potentially representing an effective biomarker for calcitriol therapy. (c) 2013 Wiley Periodicals, Inc. C1 [Findlay, Victoria J.; Bandurraga, Savannah G.; Watson, Dennis K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Moretz, R. Eric; Wang, Cindy; Vaena, Silvia G.; Camp, E. Ramsay] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Ashenafi, Michael; Marshall, David T.] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Watson, Dennis K.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Camp, E. Ramsay] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Findlay, VJ (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 39 Sabin St,WRB,RS-310, Charleston, SC 29425 USA. FU SCTR NIH/NCRR [UL1RR029882]; NIH [1K08CA142904] FX Grant sponsor: SCTR NIH/NCRR; Grant number: UL1RR029882; Grant sponsor: NIH; Grant number: 1K08CA142904 NR 29 TC 5 Z9 5 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 EI 1098-2744 J9 MOL CARCINOGEN JI Mol. Carcinog. PD FEB PY 2014 VL 53 SU 1 SI SI BP E130 EP E139 DI 10.1002/mc.22054 PG 10 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA AB3QK UT WOS:000331705100014 PM 23996472 ER PT J AU Wong, K Boone, T Munoz, A AF Wong, Kelvin Boone, Timothy Munoz, Alvaro TI FUNCTIONAL-MRI DURING BLADDER CYSTOMETRY IN SPINAL CORD-INJURED AND INTACT FEMALE RATS SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion (SUFU) CY FEB 25-MAR 01, 2014 CL Miami, FL SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Wong, Kelvin; Munoz, Alvaro] Houston Methodist Res Inst, Houston, TX USA. [Boone, Timothy] Houston Methodist Hosp, MHRI, Houston, TX USA. [Boone, Timothy] VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2014 VL 33 IS 2 BP 194 EP 194 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AA3SO UT WOS:000331012800073 ER PT J AU Boone, T Munoz, A AF Boone, Timothy Munoz, Alvaro TI INHIBITION OF P2 x 7 RECEPTORS AFTER DORSAL-HORN TRANSECTION IMPROVES NEUROGENIC BLADDER DYSFUNCTION IN FEMALE RATS SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion (SUFU) CY FEB 25-MAR 01, 2014 CL Miami, FL SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Boone, Timothy] Houston Methodist Hosp, HMRI, Houston, TX USA. [Boone, Timothy] VA Med Ctr, Houston, TX USA. [Munoz, Alvaro] Houston Methodist Res Inst, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2014 VL 33 IS 2 BP 198 EP 198 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AA3SO UT WOS:000331012800081 ER PT J AU Ferguson, A Sutton, B Boone, T Ford, A Munoz, A AF Ferguson, Andrew Sutton, Broderick Boone, Timothy Ford, Anthony Munoz, Alvaro TI EFFECTS OF UROTHELIAL P2 x 3 RECEPTOR INHIBITION ON RAT BLADDER CONTRACTILITY SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT Annual Winter Meeting of the Society-of-Urodynamics-Female-Pelvic-Medicine-and-Urogenital-Reconstruct ion (SUFU) CY FEB 25-MAR 01, 2014 CL Miami, FL SP Soc Urodynam, Female Pelv Med & Urogenital Reconstruct C1 [Ferguson, Andrew; Sutton, Broderick; Munoz, Alvaro] Houston Methodist Res Inst, Houston, TX USA. [Boone, Timothy] Houston Methodist Hosp, MHRI, Houston, TX USA. [Boone, Timothy] VA Med Ctr, Houston, TX USA. [Ford, Anthony] Afferent Pharmaceut, San Mateo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0733-2467 EI 1520-6777 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PD FEB PY 2014 VL 33 IS 2 BP 203 EP 203 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA AA3SO UT WOS:000331012800093 ER PT J AU Shah, NR Chokshi, DA AF Shah, Nirav R. Chokshi, Dave A. TI Should Health Care Systems Become Insurers? SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB Incentives under the Affordable Care Act are making more health care systems assume the risk of paying for patient care, making boundaries between care delivery organizations and insurers less clear-cut. Bundled payments, value-based purchasing, and accountable care organizations transfer financial risk from payers to health care systems. The goal of health care systems that adopt risk contracts is to contain costs due to the increase in financial pressures as Medicaid expands and reimbursements for Medicare and fee-for-service care shrink. Accountable care organization contracts have shown promise in slowing the increase in medical expenditures for public and private payers. Some health care systems hold ownership in an associated health plan, with increasing numbers of systems developing new ways of engaging with health plans. Physicians and hospitals must distinguish between different types of arrangements. A full ownership partnership encompasses joint governance between the insurance plan and health care system; all participants in the plan receive care from the associated health system. In partial ownership, the health care system owns a stake in the insurer, but governance and care relationships are not totally overlapping. In a partnership, the formal relationship with the insurance plan preferentially refers patients to the health care system, and the system enters into risk contracts for the patients. Finally, in contractual arrangements, health systems enter into risk-bearing contracts with insurance plans for specific patient populations. For health systems that assume risk, the arrangement drives integration, such that most of a patient's health care needs and associated payments are addressed by a single network, allowing care to be better coordinated. Care provided outside the network is paid for by the insurer. Cost savings are generated by decreasing volume-based incentives in fee-for-service payment systems that can create overuse. Linking health care systems and payers can also overcome a lack of price transparency. One challenge is whether health care system-insurer partnerships will conflict with existing state and federal regulations designed to maintain a competitive marketplace. These include antitrust regulations, bans on the corporate practice of medicine, and prohibitions on fee-splitting. Another concern is that the health care system and insurers do not necessarily have the same goals and human resources. Merging these models will require significant investments of energy and capital that may distract from core activities. In addition, most health systems are ill-equipped to handle the complex operations of the insurance business. Systems must maintain adequate capital reserves to be a financially viable health plan. Therefore, health systems must be more judicious about assuming risk and managing population health and costs. Successful partnerships between health care systems and insurers will require certain components. (1) The integrated arrangement must rest on a foundation of high-functioning primary health care. (2) It must incorporate system-wide processes for quality improvement. (3) It must engage patients with outreach initiatives for disease self-management and preventive care. (4) Systems must be able to manage costs of care. With care delivery transformation as the ultimate goal, the leaders of health systems must nurture and build on momentum in a sustainable way. C1 [Shah, Nirav R.] New York State Dept Hlth, Albany, NY 12201 USA. US Dept Vet Affairs, Washington, DC USA. RP Shah, NR (reprint author), New York State Dept Hlth, Albany, NY 12201 USA. OI Chokshi, Dave/0000-0001-7467-4591 NR 0 TC 0 Z9 0 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD FEB PY 2014 VL 69 IS 2 BP 69 EP 70 DI 10.1097/01.ogx.0000444674.43584.fc PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA AB1HK UT WOS:000331541900005 ER PT J AU Carrion, I Nedjat-Haiem, F Estrada, LF AF Carrion, Iraida Nedjat-Haiem, Frances Estrada, Lucia Franco TI Understanding Factors That Facilitate Treatment Decisions Among Latinos With Cancer SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Carrion, Iraida; Estrada, Lucia Franco] Univ S Florida, Tampa, FL 33620 USA. [Nedjat-Haiem, Frances] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2014 VL 23 SU 1 SI SI BP 77 EP 77 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA AA4TI UT WOS:000331088700136 ER PT J AU Golier, JA Caramanica, K Makotkine, L Sher, L Yehuda, R AF Golier, Julia A. Caramanica, Kimberly Makotkine, Louri Sher, Leo Yehuda, Rachel TI Cortisol response to cosyntropin administration in military veterans with or without posttraumatic stress disorder SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Post-traumatic stress disorder (PTSD); Veterans; Cosyntropin; Cortisol; ACTH ID CORTICOTROPIN-RELEASING HORMONE; CHILDHOOD ABUSE; MAJOR DEPRESSION; GULF-WAR; PTSD; STIMULATION; SENSITIVITY; SUPPRESSION; HYDROCORTISONE; CHALLENGE AB Studies have demonstrated altered sensitivity of the hypothalamic-pituitary-adrenal (HPA) axis to its direct regulators in veterans with posttraumatic stress disorder (PTSD), but little is known about the adrenal response to hormonal stimulation in PTSD. An increased cortisol response to synthetic corticotropin-releasing factor (CRF) was recently found to be associated with war-zone deployment and not PTSD specifically. To more accurately assess whether there is altered adrenocortical responsivity to hormonal stimulation in relation to war-zone deployment or PTSD, we performed the low-dose cosyntropin stimulation test in a sample of 45 male veterans: 13 war-zone exposed veterans with chronic PTSD (PTSD+), 22 war-zone exposed veterans without chronic PTSD (PTSD-), and 10 veterans not exposed to a war-zone and without chronic PTSD (nonexposed). Plasma cortisol and ACTH were measured at baseline and at intervals over a one hour period following intravenous administration of 1 mu g of cosyntropin. A significant main effect of group (PTSD+, PTSD-, non-exposed) on the cortisol response to cosyntropin was observed. Cosyntropin-stimulated plasma cortisol levels were significantly higher in the PTSD+ and PTSD-groups compared to the non-exposed group. A significant main effect of group was also observed on peak cortisol levels. These findings suggest that war-zone exposure itself has persistent effects on adrenocortical activity. Published by Elsevier Ltd. C1 [Golier, Julia A.; Caramanica, Kimberly; Makotkine, Louri; Sher, Leo; Yehuda, Rachel] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. [Golier, Julia A.; Makotkine, Louri; Sher, Leo; Yehuda, Rachel] Mt Sinai Hosp, New York, NY USA. RP Golier, JA (reprint author), James J Peters VA Med Ctr, OOMH 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM julia.golier@va.gov FU VA MERIT award; National Institute of Health (NIH) [5 M01 RR00071] FX Funding for this study was provided by a VA MERIT award to Dr. Golier and by a grant (5 M01 RR00071) for the Mount Sinai General Clinical Research Center from the National Institute of Health (NIH). The VA and NIH had no further rote in the study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication. NR 30 TC 2 Z9 3 U1 3 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD FEB PY 2014 VL 40 BP 151 EP 158 DI 10.1016/j.psyneuen.2013.10.020 PG 8 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA AB6TB UT WOS:000331921300018 PM 24485487 ER PT J AU Lehrner, A Bierer, LM Passarelli, V Pratchett, LC Flory, JD Bader, HN Harris, IR Bedi, A Daskalakis, NP Makotkine, I Yehuda, R AF Lehrner, Amy Bierer, Linda M. Passarelli, Vincent Pratchett, Laura C. Flory, Janine D. Bader, Heather N. Harris, Iris R. Bedi, Aarti Daskalakis, Nikolaos P. Makotkine, Iouri Yehuda, Rachel TI Maternal PTSD associates with greater glucocorticoid sensitivity in offspring of Holocaust survivors SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE PTSD; Risk factor; Glucocorticoid receptor; Cortisol; Dexamethasone suppression test; Intergenerational; Holocaust; Trauma ID POSTTRAUMATIC-STRESS-DISORDER; PERIPHERAL MONONUCLEAR LEUKOCYTES; PARENTAL PTSD; RECEPTOR RESPONSE; CHILDHOOD TRAUMA; LOW CORTISOL; DEPRESSION; DEXAMETHASONE; RISK; VULNERABILITY AB Intergenerational effects of trauma have been observed clinically in a wide range of populations, and parental PTSD has been associated with an increased risk for psychopathology in offspring. In studies of Holocaust survivor offspring, parental PTSD, and particularly maternal PTSD, has been associated with increased risk for PTSD, low basal urinary cortisol excretion and enhanced cortisol suppression in response to dexamethasone. Such findings implicate maternally derived glucocorticoid programming in the intergenerational transmission of trauma-related consequences, potentially resulting from in utero influences or early life experiences. This study investigated the relative influence of Holocaust exposure and PTSD in mothers and fathers on glucocorticoid sensitivity in offspring. Eighty Holocaust offspring and 15 offspring of non-exposed Jewish parents completed evaluations and provided blood and urine samples. Glucocorticoid sensitivity was evaluated using the lysozyme suppression test (LST), an in vitro measure of glucocorticoid receptor sensitivity in a peripheral tissue, the dexamethasone suppression test (DST), and 24-h urinary cortisol excretion. Maternal PTSD was associated with greater glucocorticoid sensitivity in offspring across all three measures of glucocorticoid function. An interaction of maternal and paternal PTSD on the DST and 24-h urinary cortisol showed an effect of decreased glucocorticoid sensitivity in offspring with paternal, but not maternal, PTSD. Although indirect, these findings are consistent with the hypothesis that epigenetic programming may be involved in the intergenerational transmission of trauma-related effects on glucocorticoid regulation. Published by Elsevier Ltd. C1 [Lehrner, Amy; Bierer, Linda M.; Passarelli, Vincent; Pratchett, Laura C.; Flory, Janine D.; Harris, Iris R.; Daskalakis, Nikolaos P.; Makotkine, Iouri; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, PTSD Program, Bronx, NY 10468 USA. [Bierer, Linda M.; Pratchett, Laura C.; Flory, Janine D.; Bader, Heather N.; Bedi, Aarti; Daskalakis, Nikolaos P.; Makotkine, Iouri; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. RP Lehrner, A (reprint author), James J Peters Vet Affairs Med Ctr, PTSD Program, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM amy.lehrner@va.gov RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 FU Identification of an Epigenetic Risk Marker for PTSD [1RC1MH088101-01]; National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1TR000067] FX This work was supported by 1RC1MH088101-01 "Identification of an Epigenetic Risk Marker for PTSD" and Grant Number #UL1TR000067 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The NIMH and NIH had no further role in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication. NR 48 TC 24 Z9 24 U1 6 U2 27 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD FEB PY 2014 VL 40 BP 213 EP 220 DI 10.1016/j.psyneuen.2013.11.019 PG 8 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA AB6TB UT WOS:000331921300024 PM 24485493 ER PT J AU Hall, MR McGillicuddy, E Kaplan, LJ AF Hall, Michael R. McGillicuddy, Edward Kaplan, Lewis J. TI Biofilm: Basic Principles, Pathophysiology, and Implications for Clinicians SO SURGICAL INFECTIONS LA English DT Article ID PSEUDOMONAS-AERUGINOSA BIOFILMS; BACTERIAL BIOFILMS; PHYSIOLOGICAL HETEROGENEITY; HELICOBACTER-PYLORI; RANDOMIZED-TRIAL; PERSISTER CELLS; INFECTIONS; ANTIBIOTICS; SURVIVAL; COMMUNITIES AB Background: Biofilm is ubiquitous throughout nature including bacteria, fungi, protozoa-associated bacteriophages, and viruses. Whereas it is adaptive for certain organisms in a variety of environments, biofilm is important in understanding and treating clinically relevant infections, especially those involving temporarily or durably implanted devices. Methods: Review of pertinent English-language literature. Results: Important advances have been made in understanding biofilm structure and function that elucidate key events in biofilm-based infectious processes. Wounds, oral cavity, urinary tract, gastrointestinal tract, and device-associated biofilm-based infections dominate clinically relevant infections. Criteria have been articulated to detect and diagnose biofilm-associated infection but there are hurdles to overcome to treat effectively such infection. Native biofilm resistance mechanisms as well as incompletely effective human immune system responses impede successful infection resolution. Biofilm-appropriate education appears under-represented in standardized surgical education curriculum. Conclusion: Several potential methods of enabling primary prevention as well as treatment of biofilm-associated infection are on the near horizon. There is an opportunity to enhance surgical education regarding biofilm prevention, diagnosis, and therapy. C1 [Hall, Michael R.; McGillicuddy, Edward] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Kaplan, LJ (reprint author), Philadelphia VAMC, Surg Serv, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Lewis.Kaplan@va.gov NR 60 TC 24 Z9 24 U1 3 U2 22 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 EI 1557-8674 J9 SURG INFECT JI Surg. Infect. PD FEB 1 PY 2014 VL 15 IS 1 BP 1 EP 7 DI 10.1089/sur.2012.129 PG 7 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA AA9BE UT WOS:000331387900001 PM 24476019 ER PT J AU Ullrich, PM Sahay, A Stetler, CB AF Ullrich, Philip M. Sahay, Anju Stetler, Cheryl B. TI Use of Implementation Theory: A Focus on PARIHS SO WORLDVIEWS ON EVIDENCE-BASED NURSING LA English DT Article DE PARIHS; implementation; theory; health services; framework; evidence; context; facilitation; translation; effectiveness ID QUALITATIVE CONTENT-ANALYSIS; CONCEPTUAL-FRAMEWORK; INTERVENTIONS; STRATEGIES; MODELS AB BackgroundLimited understanding and application of theory in implementation research contributes to variable effectiveness of implementation studies. Better understanding of direct experiences with theory could improve implementation research and the potency of interventions. AimsThis study was a conceptual exercise aimed at characterizing experiences with and applications of the Promoting Action on Research Implementation in Health Services (PARIHS) framework. MethodsThis was a structured, qualitative study involving document reviews and interviews used to answer the following overarching questions about nine implementation research centers: Why and how was PARIHS used? What strengths and weaknesses were identified for PARIHS? FindingsPARIHS was being used for varied purposes, at varied levels, in varied ways, and to a varying extent within and across centers. Lack of implementation theory use in investigators' early years was common. Variability in the nature of theory use was attributable to characteristics of the centers, individual investigators, and features of PARIHS. Strengths and weaknesses of the PARIHS framework were identified. Linking Evidence to ActionThe study provides information to researchers and theorists about the use of one well-known implementation framework. The information suggests areas for improvements in PARIHS as well as theory use in general, and should assist in the development of theory-based programs of research. C1 [Ullrich, Philip M.] VA Puget Sound Hlth Care Syst, Spinal Cord Injury QUERI, Seattle, WA 98108 USA. [Sahay, Anju] VA Palo Alto Hlth Care Syst, Chron Heart Failure QUERI Ctr, Palo Alto, CA USA. [Stetler, Cheryl B.] Boston Univ, Sch Publ Hlth, Dept Hlth Serv, Boston, MA USA. RP Ullrich, PM (reprint author), VA Puget Sound Hlth Care Syst, Spinal Cord Injury QUERI, 1600 S Columbian Way, Seattle, WA 98108 USA. EM philip.ullrich@va.gov FU U.S. Department of Veterans Affairs, Office of Research, and Development Health Services RD Program FX This material is based upon work supported by the U.S. Department of Veterans Affairs, Office of Research, and Development Health Services R&D Program. We wish to acknowledge the important contributions of Jeffrey Smith to the paper. The views expressed in this article are the authors' and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 25 TC 7 Z9 8 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-102X EI 1741-6787 J9 WORLDV EVID-BASED NU JI Worldviews Evid.-Based Nurs. PD FEB PY 2014 VL 11 IS 1 BP 26 EP 34 DI 10.1111/wvn.12016 PG 9 WC Nursing SC Nursing GA AB3OV UT WOS:000331701000004 PM 24103045 ER PT J AU Bhattacharya, A Hamilton, R Jernigan, A Zhang, YQ Sabia, M Rahnian, MM Li, Y Wei, R Chaudhuri, A Van Remmen, H AF Bhattacharya, Arunabh Hamilton, Ryan Jernigan, Amanda Zhang, Yiqiang Sabia, Marian Rahnian, Md. M. Li, Yan Wei, Rochelle Chaudhuri, Asish Van Remmen, Holly TI Genetic ablation of 12/15-lipoxygenase but not 5-lipoxygenase protects against denervation-induced muscle atrophy SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE 12/15-Lipoxygenase; 5-Lipoxygenase; NADPH oxidase; Denervation; Muscle atrophy; Free radicals ID AMYOTROPHIC-LATERAL-SCLEROSIS; UBIQUITIN-PROTEASOME PATHWAY; FATTY LIVER-DISEASE; SKELETAL-MUSCLE; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; MOUSE MODEL; TRANSCRIPTION FACTOR; NITROSATIVE STRESS AB Skeletal muscle atrophy is a debilitating outcome of a number of chronic diseases and conditions associated with loss of muscle innervation by motor neurons, such as aging and neurodegenerative diseases. We previously reported that denervation-induced loss of muscle mass is associated with activation of cytosolic phospholipase A(2) (cPLA(2)), the rate-limiting step for the release of arachidonic acid from membrane phospholipids, which then acts as a substrate for metabolic pathways that generate bioactive lipid mediators. In this study, we asked whether 5- and 12/15-lipoxygenase (LO) lipid metabolic pathways downstream of cPLA2 mediate denervation-induced muscle atrophy in mice. Both 5- and 12/15-LO were activated in response to surgical denervation; however, 12/15-LO activity was increased similar to 2.5-fold versus an similar to 1.5-fold increase in activity of 5-LO. Genetic and pharmacological inhibition of 12/15-LO (but not 5-LO) significantly protected against denervation-induced muscle atrophy, suggesting a selective role for the 12/15-LO pathway in neurogenic muscle atrophy. The activation of the 12/15-LO pathway (but not 5-LO) during muscle atrophy increased NADPH oxidase activity, protein ubiquitination, and ubiquitin-proteasome-mediated proteolytic degradation. In conclusion, this study reveals a novel pathway for neurogenic muscle atrophy and suggests that 12/15-LO may be a potential therapeutic target in diseases associated with loss of innervation and muscle atrophy. (C) 2013 Published by Elsevier Inc. C1 [Bhattacharya, Arunabh; Hamilton, Ryan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Bhattacharya, Arunabh; Hamilton, Ryan; Jernigan, Amanda; Zhang, Yiqiang; Sabia, Marian; Rahnian, Md. M.; Li, Yan; Wei, Rochelle; Chaudhuri, Asish; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Zhang, Yiqiang; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Rahnian, Md. M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Chaudhuri, Asish; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Bhattacharya, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Cellular & Struct Biol, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM bhattacharya@uthscsa.edu FU National Institutes of Health [K01AG038555]; American Federation for Aging Research; Muscular Dystrophy Association FX This work was supported by grants to A.B. from the National Institutes of Health (K01AG038555) and the American Federation for Aging Research and by a Muscular Dystrophy Association grant to H.V.R. NR 57 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD FEB PY 2014 VL 67 BP 30 EP 40 DI 10.1016/j.freeradbiomed.2013.10.002 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA AB5UM UT WOS:000331854200004 PM 24121057 ER PT J AU Chaiswing, L Zhong, WX Oberley, TD AF Chaiswing, Luksana Zhong, Weixiong Oberley, Terry D. TI Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE ECSOD; MnSOD; Prx; Trx1; Prostate cancer; Posttranslational modifications; Redox balance; Free radicals ID MANGANESE SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; CYSTEINE OXIDATION; BREAST-CANCER; CELL INVASION; THIOREDOXIN; DAMAGE; GROWTH; TISSUE; PEROXIREDOXINS AB A metabolomics study demonstrated a decrease in glutathione and an increase in cysteine (Cys) levels in human prostate cancer (PCa) tissues as Gleason scores increased, indicating redox imbalance with PCa progression. These results were extended in the present study by analyzing the redox state of the protein thioredoxin 1 (Trx1) and sulfinylation (SO3) of peroxiredoxins (Prxs) (PrxSO(3)) in PCa tissues and cell lines. Lysates of paired human PCa tissues with varying degrees of aggressiveness and adjacent benign (BN) tissues were used for analysis. Redox Western blot analysis of Trx1 demonstrated low levels of reduced and high levels of oxidized Trx1 (functional and nonfunctional, respectively) in high-grade PCa (Gleason scores 4+4 to 4+5) in comparison to intermediate-grade PCa (Gleason scores 3+3 to 3+4) or BN tissues. PrxSO(3) were increased in high-grade PCa. Oxidized Trx1 and PrxSO(3) are indicators of oxidative stress. To study whether redox imbalance may potentially affect enzyme activities of antioxidant proteins (APs), we determined the levels of selected APs in PCa tissues by Western blot analysis and found that mitochondrial manganese superoxide dismutase (MnSOD), Prx3, and Trx1 were increased in high-grade PCa tissues compared with BN tissues. Enzyme activities of MnSOD in high-grade PCa tissues were significantly increased but at a lower magnitude compared with the levels of MnSOD protein (0.5-fold vs 2-fold increase). Trx1 activity was not changed in high-grade PCa tissues despite a large. increase in Trx1 protein expression. Further studies demonstrated a significant increase in posttranslational modifications of tyrosine and lysine residues in MnSOD protein and oxidation of Cys at the active site (Cys32 and Cys35) and the regulatory site (Cys62 and Cys69) of Trx1 in high-grade PCa compared to BN tissues. These discordant changes between protein levels and enzyme activities are consistent with protein inactivation by redox imbalance and/or posttranslational modifications. In contrast, the protein level and activity of extracellular superoxide dismutase were significantly decreased in high-grade PCa compared with adjacent BN tissues. Results from cell lines mirror those from PCa tissues. Knowledge of redox-state profiles in specific cancers may help to predict the behavior and response of each cancer to chemotherapeutic drugs and radiation. (C) 2013 Elsevier Inc. All rights reserved. C1 [Chaiswing, Luksana; Zhong, Weixiong; Oberley, Terry D.] Dept Pathol & Lab Med, Madison, WI 53705 USA. [Zhong, Weixiong; Oberley, Terry D.] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. RP Chaiswing, L (reprint author), 1111 Highland Ave WIMR Bldg Rm 7168a, Madison, WI 53705 USA. EM lchaiswing@wisc.edu; toberley@wisc.edu FU University of Wisconsin; Department of Pathology Research and Development Committee, University of Wisconsin at Madison Graduate School; UW Carbone Cancer Center (NIH) [P30 CA014520]; NIH [RO1 CA07359902, RO1 CA09485301]; Society for Free Radical Biology Medicine FX The contents do not represent the views of the U.S. Department of Veterans Affairs. This work was supported in part by funds from the University of Wisconsin, Department of Pathology Research and Development Committee, University of Wisconsin at Madison Graduate School, UW Carbone Cancer Center (NIH Grant P30 CA014520), NIH Grants RO1 CA07359902 and RO1 CA09485301 to Daret St. Clair (T.D.O.; Co-I), and a 2010 mini-fellowship award from the Society for Free Radical Biology & Medicine. We acknowledge Weihua Shan for her technical assistance in redox Western experiments and the use of resources and facilities at the William S. Middleton Memorial Veterans Hospital (Madison, WI, USA). We would like to dedicate this article to the memory of Dr. Terry D. Oberley. His dedication to the field of free radical biology and medicine was an inspiration to all of us. NR 46 TC 13 Z9 13 U1 2 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD FEB PY 2014 VL 67 BP 342 EP 352 DI 10.1016/j.freeradbiomed.2013.11.006 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA AB5UM UT WOS:000331854200032 PM 24269899 ER PT J AU DeNicola, M Phan, RT Nham, P Moatamed, NA AF DeNicola, M. Phan, R. T. Nham, P. Moatamed, N. A. TI Deletion of EGFR Exon 19 in Invasive Lobular Breast Carcinoma SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2014 VL 94 SU 1 MA 168 BP 44A EP 44A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA AA5QX UT WOS:000331155800169 ER PT J AU DeNicola, M Phan, RT Nham, P Moatamed, NA AF DeNicola, M. Phan, R. T. Nham, P. Moatamed, N. A. TI Deletion of EGFR Exon 19 in Invasive Lobular Breast Carcinoma SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 103rd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 01-07, 2014 CL San Diego, CA SP US & Canadian Acad Pathol, Dako, Biocare Med, Leica Biosystems, LabCorp Specialty Testing Grp, Integrated Oncol, GenomOncology, Nephropath, Ventana, Diagnost BioSystems C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2014 VL 27 SU 2 MA 168 BP 44A EP 44A PG 1 WC Pathology SC Pathology GA AB0SK UT WOS:000331502200169 ER PT J AU Clark, DG Wadley, VG Kapur, P DeRamus, TP Singletary, B Nicholas, AP Blanton, PD Lokken, K Deshpande, H Marson, D Deutsch, G AF Clark, D. G. Wadley, V. G. Kapur, P. DeRamus, T. P. Singletary, B. Nicholas, A. P. Blanton, P. D. Lokken, K. Deshpande, H. Marson, D. Deutsch, G. TI Lexical factors and cerebral regions influencing verbal fluency performance in MCI SO NEUROPSYCHOLOGIA LA English DT Article DE Alzheimer's disease; Mild cognitive impairment; Verbal fluency; Semantic memory; Natural language processing ID MILD COGNITIVE IMPAIRMENT; SURFACE-BASED ANALYSIS; TEMPORAL-LOBE LESIONS; ALZHEIMERS-DISEASE; SEMANTIC DEMENTIA; CORTICAL SURFACE; HUNTINGTONS-DISEASE; COORDINATE SYSTEM; NORMATIVE DATA; NEURAL BASIS AB Objective: To evaluate assumptions regarding semantic (noun), verb, and letter fluency in mild cognitive impairment (MCI) and Alzheimer disease (AD) using novel techniques for measuring word similarity in fluency lists and a region of interest (ROI) analysis of gray matter correlates. Method: Fifty-eight individuals with normal cognition (NC, n=25), MCI (n=23), or AD (n=10) underwent neuropsychological tests, including 10 verbal fluency tasks (three letter tasks [F, A, S], six noun categories [animals, water creatures, fruits and vegetables, tools, vehicles, boats], and verbs). All pairs of words generated by each participant on each task were compared in terms of semantic (meaning), orthographic (spelling), and phonemic (pronunciation) similarity. We used mixed-effects logistic regression to determine which lexical factors were predictive of word adjacency within the lists. Associations between each fluency raw score and gray matter volumes in sixteen ROIs were identified by means of multiple linear regression. We evaluated causal models for both types of analyses to specify the contributions of diagnosis and various mediator variables to the outcomes of word adjacency and fluency raw score. Results: Semantic similarity between words emerged as the strongest predictor of word adjacency for all fluency tasks, including the letter fluency tasks. Seman.tic similarity mediated the effect of cognitive impairment on word adjacency only for three fluency tasks employing a biological cue. Orthographic similarity was predictive of word adjacency for the A and S tasks, while phonemic similarity was predictive only for the S task and one semantic task (vehicles). The ROI analysis revealed different patterns of correlations among the various fluency tasks, with the most common associations in the right lower temporal and bilateral dorsal frontal regions. Following correction with gray matter volumes from the opposite hemisphere, significant associations persisted for animals, vehicles, and a composite nouns score in the left inferior frontal gyrus, but for letter A, letter S, and a composite FAS score in the right inferior frontal gyrus. These regressions also revealed a lateralized association of the left subcortical nuclei with all letter fluency scores and fruits and vegetables fluency, and an association of the right lower temporal ROI with letter A, FAS, and verb fluency. Gray matter volume in several bihemispheric ROIs (left dorsal frontal, right lower temporal, right occipital, and bilateral mesial temporal) mediated the relationship between cognitive impairment and fluency for fruits and vegetables. Gray matter volume in the right lower temporal ROI mediated the relationship between cognitive impairment and five fluency raw scores (animals, fruits and vegetables, tools, verbs, and the composite nouns score). Conclusion: Semantic memory exerts the strongest influence on word adjacency in letter fluency as well as semantic verbal fluency tasks. Orthography is a stronger influence than pronunciation. All types of fluency task raw scores (letter, noun, and verb) correlate with cerebral regions known to support verbal or nonverbal semantic memory. The findings emphasize the contribution of right hemisphere regions to fluency task performance, particularly for verb and letter fluency. The relationship between diagnosis and semantic fluency performance is mediated by semantic similarity of words and by gray matter volume in the right lower temporal region. Published by Elsevier Ltd. C1 [Clark, D. G.; Nicholas, A. P.; Blanton, P. D.; Lokken, K.] Birmingham VA Med Ctr, Birmingham, AL USA. [Clark, D. G.; Nicholas, A. P.; Marson, D.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA. [Wadley, V. G.] Univ Alabama Birmingham, Dept Med, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Kapur, P.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [DeRamus, T. P.] Univ Alabama Birmingham, Dept Psychol & Behav Neurosci, Birmingham, AL USA. [Singletary, B.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL USA. [Deshpande, H.; Deutsch, G.] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA. RP Clark, DG (reprint author), 1720,7th Ave South,SC 620C, Birmingham, AL 35294 USA. EM dgclark@uab.edu FU VA [E6553W] FX VA (E6553W). NR 78 TC 5 Z9 7 U1 4 U2 23 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 EI 1873-3514 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD FEB PY 2014 VL 54 BP 98 EP 111 DI 10.1016/j.neuropsychologia.2013.12.010 PG 14 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA AB3IT UT WOS:000331685200011 PM 24384308 ER PT J AU Park, LG Howie-Esquivel, J Chung, ML Dracup, K AF Park, Linda G. Howie-Esquivel, Jill Chung, Misook L. Dracup, Kathleen TI A text messaging intervention to promote medication adherence for patients with coronary heart disease: A randomized controlled trial SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Text messaging; Mobile phone; Medication adherence; Antiplatelets; Statins; Coronary heart disease ID IMPROVE ADHERENCE; STENT THROMBOSIS; OUTCOMES; PREDICTORS; CONTINUATION; METAANALYSIS; PREVENTION; PROGRAM; SCALE; RATES AB Objective: Pharmacologic treatment for secondary prevention of coronary heart disease (CHD) is critical to prevent adverse clinical outcomes. In a randomized controlled trial, we compared antiplatelet and statin adherence among patients with CHD who received: (1) text messages (TM) for medication reminders and education, (2) educational TM only, or (3) No TM. Methods: A mobile health intervention delivered customized TM for 30 days. We assessed and analyzed medication adherence with electronic monitoring devices [Medication Event Monitoring System (MEMS)] by one-way ANOVA and Welch tests, two-way TM response rates by t-tests, and self-reported adherence (Morisky Medication Adherence Scale) by Repeated Measures ANOVA. Results: Among 90 patients (76% male, mean age 59.2 years), MEMS revealed patients who received TM for antiplatelets had a higher percentage of correct doses taken (p = 0.02), percentage number of doses taken (p = 0.01), and percentage of prescribed doses taken on schedule (p = 0.01). TM response rates were higher for antiplatelets than statins (p = 0.005). Self-reported adherence revealed no significant differences among groups. Conclusion: TM increased adherence to antiplatelet therapy demonstrated by MEMS and TM responses. Practice implications: Feasibility and high satisfaction were established. Mobile health interventions show promise in promoting medication adherence. Published by Elsevier Ireland Ltd. C1 [Park, Linda G.] San Francisco VA Med Ctr, Div Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA. [Howie-Esquivel, Jill; Dracup, Kathleen] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA. [Chung, Misook L.] Univ Kentucky, Coll Nursing, Lexington, KY 40506 USA. RP Park, LG (reprint author), San Francisco VA Med Ctr, Div Geriatr Palliat & Extended Care, 4150 Clement St,Bldg 1 207 181G, San Francisco, CA 94121 USA. EM linda.park@ucsf.edu RI Emchi, Karma/Q-1952-2016 FU Graduate Division of University of California, San Francisco; UCSF/Hartford Center of Geriatric Nursing Excellence FX Funding for research materials was provided by a grant from the Graduate Division of University of California, San Francisco and a scholarship from the UCSF/Hartford Center of Geriatric Nursing Excellence. CareSpeak Communications provided the use of the mobile Health manager platform, which is designed to improve medical therapy adherence using two-way text messaging. NR 43 TC 35 Z9 37 U1 5 U2 29 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD FEB PY 2014 VL 94 IS 2 BP 261 EP 268 DI 10.1016/j.pec.2013.10.027 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA AB6TZ UT WOS:000331923700018 PM 24321403 ER PT J AU Garcia, HA McGeary, CA McGeary, DD Finley, EP Peterson, AL AF Garcia, Hector A. McGeary, Cindy A. McGeary, Donald D. Finley, Erin P. Peterson, Alan L. TI Burnout in Veterans Health Administration Mental Health Providers in Posttraumatic Stress Clinics SO PSYCHOLOGICAL SERVICES LA English DT Article DE burnout; Veterans Health Administration; posttraumatic stress disorder; workplace stressors; absenteeism ID JOB BURNOUT; SATISFACTION; TURNOVER; PSYCHOLOGISTS; STAFF; WORK; CARE; DISSEMINATION; PREDICTORS; CONSTRUCT AB The purpose of this study was to conduct the first assessment of burnout among Veterans Health Administration (VHA) mental health clinicians providing evidence-based posttraumatic stress disorder (PTSD) care. This study consisted of 138 participants and the sample was mostly female (67%), Caucasian (non-Hispanic; 81%), and married (70%) with a mean age of 44.3 years (SD = 11.2). Recruitment was directed through VHA PTSD Clinical Teams (PCT) throughout the United States based on a nationwide mailing list of PCT Clinic Directors. Participants completed an electronic survey that assessed demographics, organizational work factors, absenteeism, and burnout (assessed through the Maslach Burnout Inventory-General Survey, MBI-GS). Twelve percent of the sample reported low Professional Efficacy, 50% reported high levels of Exhaustion, and 47% reported high levels of Cynicism as determined by the MBI-GS cut-off scores. Only workplace characteristics were significantly associated with provider scores on all 3 scales. Exhaustion and Cynicism were most impacted by perceptions of organizational politics/bureaucracy, increased clinical workload, and control over how work is done. Organizational factors were also significantly associated with provider absenteeism and intent to leave his or her job. Findings suggest that providers in VHA specialty PTSD-care settings may benefit from programs or supports aimed at preventing and/or ameliorating burnout. C1 [Garcia, Hector A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Garcia, Hector A.; McGeary, Donald D.; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [McGeary, Cindy A.] Univ Texas Arlington, Dept Psychol, Arlington, TX USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Garcia, HA (reprint author), Frank Tejeda Outpatient Clin, 5788 Eckhert Rd, San Antonio, TX 78240 USA. EM Hector.Garcia2@va.gov OI Finley, Erin/0000-0003-4497-7721 FU NIMH NIH HHS [R25 MH080916, R25 MH080916-01A2] NR 50 TC 7 Z9 7 U1 4 U2 12 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2014 VL 11 IS 1 BP 50 EP 59 DI 10.1037/a0035643 PG 10 WC Psychology, Clinical SC Psychology GA AB6AL UT WOS:000331869700006 PM 24564443 ER PT J AU Mariappan, MM DeSilva, K Sorice, GP Muscogiuri, G Jimenez, F Ahuja, S Barnes, JL Choudhury, GG Musi, N DeFronzo, R Kasinath, BS AF Mariappan, Meenalakshmi M. DeSilva, Kristin Sorice, Gian Pio Muscogiuri, Giovanna Jimenez, Fabio Ahuja, Seema Barnes, Jefferey L. Choudhury, Goutam Ghosh Musi, Nicolas DeFronzo, Ralph Kasinath, Balakuntalam S. TI Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE hyperglycemia; hyperinsulinemia; renal fibrosis; TGF-beta; mTOR; laminin ID MESSENGER-RNA TRANSLATION; RENAL EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; DIABETIC-NEPHROPATHY; HIGH GLUCOSE; TGF-BETA; POSTPRANDIAL HYPERGLYCEMIA; CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS AB Increase in matrix protein content in the kidney is a cardinal feature of diabetic kidney disease. While renal matrix protein content is increased by chronic hyperglycemia, whether it is regulated by acute elevation of glucose and insulin has not been addressed. In this study, we aimed to evaluate whether short duration of combined hyperglycemia and hyperinsulinemia, mimicking the metabolic environment of prediabetes and early type 2 diabetes, induces kidney injury. Normal rats were subjected to either saline infusion (control, n = 4) or 7 h of combined hyperglycemic-hyperinsulinemic clamp (HG + HI clamp; n = 6). During the clamp, plasma glucose and plasma insulin were maintained at about 350 mg/dl and 16 ng/ml, respectively. HG + HI clamp increased the expression of renal cortical transforming growth factor-beta (TGF-alpha) and renal matrix proteins, laminin and fibronectin. This was associated with the activation of SMAD3, Akt, mammalian target of rapamycin (mTOR) complexes, and ERK signaling pathways and their downstream target events in the initiation and elongation phases of mRNA translation, an important step in protein synthesis. Additionally, HG + HI clamp provoked renal inflammation as shown by the activation of Toll-like receptor 4 (TLR4) and infiltration of CD68-positive monocytes. Urinary F2t isoprostane excretion, an index of renal oxidant stress, was increased in the HG + HI clamp rats. We conclude that even a short duration of hyperglycemia and hyperinsulinemia contributes to activation of pathways that regulate matrix protein synthesis, inflammation, and oxidative stress in the kidney. This finding could have implications for the control of short-term rises in blood glucose in diabetic individuals at risk of developing kidney disease. C1 [Mariappan, Meenalakshmi M.; DeSilva, Kristin; Jimenez, Fabio; Ahuja, Seema; Barnes, Jefferey L.; Choudhury, Goutam Ghosh; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Sorice, Gian Pio; Muscogiuri, Giovanna; Musi, Nicolas; DeFronzo, Ralph] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabetes, San Antonio, TX 78229 USA. [Mariappan, Meenalakshmi M.; Jimenez, Fabio; Ahuja, Seema; Barnes, Jefferey L.; Choudhury, Goutam Ghosh; Musi, Nicolas; DeFronzo, Ralph; Kasinath, Balakuntalam S.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Mariappan, MM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM malini@uthscsa.edu FU National Institutes of Health (NIH) [DK-077295, RC2 AG-036613]; VA Merit Review Program and American Diabetes Association; Juvenile Diabetes Research Foundation and the National Kidney Foundation of South and Central Texas; VA Senior Research Career Scientist Award [NIH-R01 (DK-050190)] FX This work was supported by National Institutes of Health (NIH) Grants DK-077295 and RC2 AG-036613 (B. S. Kasinath), VA Merit Review Program and American Diabetes Association (B. S. Kasinath), and Juvenile Diabetes Research Foundation and the National Kidney Foundation of South and Central Texas (M. M. Mariappan). G. G. Choudhury is supported by NIH-R01 (DK-050190) and VA Merit Review Grants and is a recipient of the VA Senior Research Career Scientist Award. NR 52 TC 6 Z9 6 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD FEB PY 2014 VL 306 IS 3 BP C202 EP C211 DI 10.1152/ajpcell.00144.2013 PG 10 WC Cell Biology; Physiology SC Cell Biology; Physiology GA AA9YU UT WOS:000331449800004 PM 24108867 ER PT J AU Pasquini, MC Le Rademacher, J Flowers, C Lill, M Costa, LJ Shore, TB Vaughan, W Craig, M Freytes, CO Shea, TC Horwitz, ME Fay, JW Mineishi, S Rondelli, D Mason, J Reddy, V Braunschweig, I Ai, WY Armstrong, E Smith, A Zhao, C Elekes, A Carreras, J Kato, K Waller, EK AF Pasquini, Marcelo C. Le Rademacher, Jennifer Flowers, Christopher Lill, Michael Costa, Luciano J. Shore, Tsiporah B. Vaughan, William Craig, Michael Freytes, Cesar O. Shea, Thomas C. Horwitz, Mitchell E. Fay, Joseph W. Mineishi, Shin Rondelli, Damiano Mason, James Reddy, Vijay Braunschweig, Ira Ai, Weiyun Armstrong, Elizabeth Smith, Angela Zhao, Cathy Elekes, Agnes Carreras, Jeanette Kato, Kazunobu Waller, Edmund K. TI Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Pasquini, Marcelo C.; Carreras, Jeanette] Med Coll Wisconsin, CIBMTR, Milwaukee, WI 53226 USA. [Le Rademacher, Jennifer] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Flowers, Christopher; Waller, Edmund K.] Emory Univ, Div BMT, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. [Lill, Michael] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Costa, Luciano J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Shore, Tsiporah B.] New York Hosp, Cornell Med Ctr Hematol Oncol, New York, NY 10021 USA. [Vaughan, William] Univ Alabama Birmingham, Bone Marrow Transplantat & Cell Therapy Program, Birmingham, AL USA. [Craig, Michael] W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Shea, Thomas C.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA. [Horwitz, Mitchell E.] Duke Univ, Med Ctr, Dept Med, Adult Stem Cell Transplant Program,Div Cellular T, Durham, NC 27710 USA. [Fay, Joseph W.] Baylor Univ, Med Ctr, Dallas, TX USA. [Mineishi, Shin] Univ Alabama Birmingham, Bone Marrow Transplantat Program, Birmingham, AL USA. [Rondelli, Damiano] Univ Illinois Hosp & Hlth Sci Syst, Dept Med, Sect Hematol Oncol, Chicago, IL USA. [Mason, James] Scripps Clin, La Jolla, CA 92037 USA. [Reddy, Vijay] Univ Florida, Gainesville, FL USA. [Braunschweig, Ira] Montefiore Med Ctr, Bronx, NY 10467 USA. [Ai, Weiyun] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Armstrong, Elizabeth; Smith, Angela; Zhao, Cathy; Elekes, Agnes; Kato, Kazunobu] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. RI Flowers, Christopher/F-1953-2010 OI Flowers, Christopher/0000-0002-9524-3990 NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 232 BP S162 EP S162 PG 1 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400237 ER PT J AU Toro, JJ Schneider, D Alonzo, R Hasan, A Lee, S Gushiken, F Haile, DJ Freytes, CO AF Toro, Juan J. Schneider, Deanna Alonzo, Rosalinda Hasan, Abida Lee, Shuko Gushiken, Francisco Haile, David J. Freytes, Cesar O. TI A Prospective, Randomized Clinical Trial of Cryotherapy Vs. Supersaturated Calcium Phosphate Rinses Vs. Saline Rinses for the Prevention of Oral Mucositis in Patients with Multiple Myeloma (MM) Receiving High-Dose Melphalan (HDM) and Autotransplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Meeting Abstract CT BMT Tandem Meetings CY FEB 26-MAR 02, 2014 CL Grapevine, TX C1 [Toro, Juan J.; Schneider, Deanna; Alonzo, Rosalinda; Hasan, Abida; Lee, Shuko; Gushiken, Francisco; Haile, David J.; Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2014 VL 20 IS 2 SU 1 MA 309 BP S204 EP S205 PG 2 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA AA5QT UT WOS:000331155400314 ER PT J AU Fisher, MB Henning, EA Soegaard, NB Dodge, GR Steinberg, DR Mauck, RL AF Fisher, Matthew B. Henning, Elizabeth A. Soeegaard, Nicole B. Dodge, George R. Steinberg, David R. Mauck, Robert L. TI Maximizing cartilage formation and integration via a trajectory-based tissue engineering approach SO BIOMATERIALS LA English DT Article DE Tissue engineering; Hyaluronic acid; Hydrogels; Cartilage; Integration; Maturation ID AUTOLOGOUS CHONDROCYTE IMPLANTATION; MESENCHYMAL STEM-CELLS; CHONDROGENIC DIFFERENTIATION; EXTRACELLULAR-MATRIX; AGAROSE CULTURE; GOAT MODEL; FOLLOW-UP; REPAIR; KNEE; TRANSPLANTATION AB Given the limitations of current surgical approaches to treat articular cartilage injuries, tissue engineering (TE) approaches have been aggressively pursued. Despite reproduction of key mechanical attributes of native tissue, the ability of TE cartilage constructs to integrate with native tissue must also be optimized for clinical success. In this paper, we propose a "trajectory-based" tissue engineering (TB-TE) approach, based on the hypothesis that time-dependent increases in construct maturation in-vitro prior to implantation (i.e. positive rates) may provide a reliable predictor of in-vivo success. As an example TE system, we utilized hyaluronic acid hydrogels laden with mesenchymal stem cells. We first modeled the maturation of these constructs in-vitro to capture time-dependent changes. We then performed a sensitivity analysis of the model to optimize the timing and amount of data collection. Finally, we showed that integration to cartilage in-vitro is not correlated to the maturation state of TE constructs, but rather their maturation rate, providing a proof-of-concept for the use of TB-TE to enhance treatment outcomes following cartilage injury. This new approach challenges the traditional TE paradigm of matching only native state parameters of maturity and emphasizes the importance of also establishing an in-vitro trajectory in constructs in order to improve the chance of in-vivo success. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Fisher, Matthew B.; Henning, Elizabeth A.; Soeegaard, Nicole B.; Dodge, George R.; Steinberg, David R.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Henning, Elizabeth A.; Dodge, George R.; Steinberg, David R.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Dept Orthopaed Surg, Perelman Sch Med, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01 EB008722, F32 AR062971]; Department of Veterans Affairs [101 RX000700] FX This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (R01 EB008722 and F32 AR062971) and the Department of Veterans Affairs (101 RX000700). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. The authors would like to thank Dr. Jason Burdick for providing the hyaluronic acid. NR 46 TC 13 Z9 13 U1 1 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0142-9612 EI 1878-5905 J9 BIOMATERIALS JI Biomaterials PD FEB PY 2014 VL 35 IS 7 BP 2140 EP 2148 DI 10.1016/j.biomaterials.2013.11.031 PG 9 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA AB0SL UT WOS:000331502300007 PM 24314553 ER PT J AU Shore, S Borgerding, JA Gylys-Colwell, I McDermott, K Ho, PM Tillquist, MN Lowy, E McGuire, DK Stolker, JM Arnold, SV Kosiborod, M Maddox, TM AF Shore, Supriya Borgerding, Joleen A. Gylys-Colwell, Ina McDermott, Kelly Ho, P. Michael Tillquist, Maggie N. Lowy, Elliott McGuire, Darren K. Stolker, Joshua M. Arnold, Suzanne V. Kosiborod, Mikhail Maddox, Thomas M. TI Association Between Hyperglycemia at Admission During Hospitalization for Acute Myocardial Infarction and Subsequent Diabetes: Insights From the Veterans Administration Cardiac Care Follow-up Clinical Study SO DIABETES CARE LA English DT Article ID ACUTE CORONARY SYNDROME; BLOOD-GLUCOSE CONTROL; TIMI RISK SCORE; STRESS HYPERGLYCEMIA; NONDIABETIC PATIENTS; THROMBOLYTIC ERA; MELLITUS; PREVALENCE; OUTCOMES; AFFAIRS AB OBJECTIVEAmong patients with acute myocardial infarction (AMI) without known diabetes, hyperglycemia at admission is common and associated with worse outcomes. It may represent developing diabetes, but this association is unclear. Therefore, we examined the association between hyperglycemia (140 mg/dL) at admission and evidence of diabetes among patients with AMI without known diabetes within 6 months of their hospitalization.RESEARCH DESIGN AND METHODSWe studied a national cohort of consecutive patients with AMI without known diabetes presenting at 127 Veterans Affairs hospitals between October 2005 and March 2011. Evidence of diabetes either at discharge or in the following 6 months was ascertained using diagnostic codes, medication prescriptions, and/or elevated hemoglobin A(1c). Association between hyperglycemia at admission and evidence of diabetes was evaluated using regression modeling.RESULTSAmong 10,499 patients with AMI without known diabetes, 98% were men and 1,761 (16.8%) had hyperglycemia at admission. Within 6 months following their index hospitalization, 208 patients (11.8%) with hyperglycemia at admission had evidence of diabetes compared with 443 patients (5.1%) without hyperglycemia at admission (P < 0.001). After multivariable adjustment, hyperglycemia at admission was significantly associated with subsequent diabetes odds ratio 2.56 (95% CI 2.15-3.06). Among those with new evidence of diabetes, 41% patients (267 of 651) had a hemoglobin A(1c) 6.5% without accompanying diagnostic codes or medication prescriptions, suggesting they had unrecognized diabetes.CONCLUSIONSHyperglycemia at admission occurred in one of six patients with AMI without known diabetes and was significantly associated with new evidence of diabetes in the 6 months following hospitalization. In addition, two of five patients with evidence of diabetes were potentially unrecognized. Accordingly, diabetes-screening programs for hyperglycemic patients with AMI may be an important component of optimal care. C1 [Shore, Supriya] Univ Colorado, Sch Publ Hlth, Denver, CO 80202 USA. [Borgerding, Joleen A.; Gylys-Colwell, Ina; Lowy, Elliott] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Northwest Ctr Excellence, Seattle, WA USA. [McDermott, Kelly] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. [Ho, P. Michael; Maddox, Thomas M.] VA Eastern Colorado Hlth Care Syst, Cardiol Sect, Denver, CO USA. [Ho, P. Michael; Tillquist, Maggie N.; Maddox, Thomas M.] Univ Colorado, Sch Med, Dept Med, Div Cardiol, Denver, CO USA. [McGuire, Darren K.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Stolker, Joshua M.] St Louis Univ, Dept Med, Div Cardiol, St Louis, MO 63103 USA. [Arnold, Suzanne V.; Kosiborod, Mikhail] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA. RP Maddox, TM (reprint author), St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA. EM thomas.maddox@va.gov FU VA Health Services Research and Development Career Development Award FX T.M.M. is supported by a VA Health Services Research and Development Career Development Award. NR 32 TC 10 Z9 10 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2014 VL 37 IS 2 BP 409 EP 418 DI 10.2337/dc13-1125 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA4NM UT WOS:000331072800028 PM 24089537 ER PT J AU Karras, E Stephens, B Kemp, JE Bossarte, RM AF Karras, Elizabeth Stephens, Brady Kemp, Janet E. Bossarte, Robert M. TI Using media to promote suicide prevention hotlines to Veteran households SO INJURY PREVENTION LA English DT Article ID CAMPAIGNS; HEALTH; ATTITUDES; BEHAVIOR; STIGMA AB This article presents preliminary evidence that media campaigns are valuable in promoting suicide prevention hotlines to Veteran households by reporting data from 2526 telephone surveys. Findings from this study underscore the need for further investigation of the use of media campaigns to support suicide prevention initiatives aimed at Veteran populations. C1 [Karras, Elizabeth; Stephens, Brady; Bossarte, Robert M.] VISN 2 Ctr Excellence Suicide Prevent, Dept Vet Affairs, Canandaigua, NY 14424 USA. [Kemp, Janet E.] US Dept Vet Affairs, Natl Mental Hlth Program, Washington, DE USA. [Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP Karras, E (reprint author), VISN 2 Ctr Excellence Suicide Prevent, Dept Vet Affairs, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM Elizabeth.karras@va.gov FU VISN 2 Center of Excellence for Suicide Prevention at the Canandaigua VA Medical Center FX This material is the result of work supported with resources and the use of facilities at the VISN 2 Center of Excellence for Suicide Prevention at the Canandaigua VA Medical Center. We thank all of the Center of Excellence survey Center staff who participated in the data collection process. NR 19 TC 1 Z9 1 U1 4 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD FEB PY 2014 VL 20 IS 1 DI 10.1136/injuryprev-2012-040742 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA6EG UT WOS:000331191000016 ER PT J AU Rubenstein, L Khodyakov, D Hempel, S Danz, M Salem-Schatz, S Foy, R O'Neill, S Dalal, S Shekelle, P AF Rubenstein, Lisa Khodyakov, Dmitry Hempel, Susanne Danz, Margie Salem-Schatz, Susanne Foy, Robbie O'Neill, Sean Dalal, Siddhartha Shekelle, Paul TI How can we recognize continuous quality improvement? SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE continuous quality improvement; quality improvement; consultants; health care organization ID HEALTH-CARE; INTERVENTION PUBLICATIONS; CONSENSUS; DEPRESSION; COMPETENCE; STRATEGIES; GUIDELINES AB Continuous quality improvement (CQI) methods are foundational approaches to improving healthcare delivery. Publications using the term CQI, however, are methodologically heterogeneous, and labels other than CQI are used to signify relevant approaches. Standards for identifying the use of CQI based on its key methodological features could enable more effective learning across quality improvement (QI) efforts. The objective was to identify essential methodological features for recognizing CQI. Previous work with a 12-member international expert panel identified reliably abstracted CQI methodological features. We tested which features met rigorous a priori standards as essential features of CQI using a three-phase online modified-Delphi process. Primarily United States and Canada. 119 QI experts randomly assigned into four on-line panels. Participants rated CQI features and discussed their answers using online, anonymous and asynchronous discussion boards. We analyzed ratings quantitatively and discussion threads qualitatively. Panel consensus on definitional CQI features. Seventy-nine (66) panelists completed the process. Thirty-three completers self-identified as QI researchers, 18 as QI practitioners and 28 as both equally. The features systematic data guided activities, designing with local conditions in mind and iterative development and testing met a priori standards as essential CQI features. Qualitative analyses showed cross-cutting themes focused on differences between QI and CQI. We found consensus among a broad group of CQI researchers and practitioners on three features as essential for identifying QI work more specifically as CQI. All three features are needed as a minimum standard for recognizing CQI methods. C1 [Rubenstein, Lisa; Khodyakov, Dmitry; Hempel, Susanne; Danz, Margie; O'Neill, Sean; Dalal, Siddhartha; Shekelle, Paul] RAND Corp, Santa Monica, CA 90401 USA. [Rubenstein, Lisa; Danz, Margie] Vet Affairs Greater Los Angeles Sepulveda, North Hills, CA 91343 USA. [Rubenstein, Lisa] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Rubenstein, Lisa] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Salem-Schatz, Susanne] HealthCare Qual Initiat, Newton, MA 02459 USA. [Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9JT, W Yorkshire, England. [O'Neill, Sean] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Hempel, S (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90401 USA. EM susanne_hempel@rand.org OI O'Neill, Sean/0000-0001-7759-8942 FU Robert Wood Johnson Foundation [65113, 67890]; RAND Corporation; VA Health Services Research and Development Center for Implementation Practice and Research Support; Department of Veterans Affairs FX This work was supported by the Robert Wood Johnson Foundation (Grant ID 65113: Advancing the science of continuous quality improvement: a framework for identifying, classifying and evaluating continuous quality improvement studies and Grant ID 67890: Providing a framework for the identification, classification and evaluation of quality improvement initiatives) and the RAND Corporation, with additional funding provided by the VA Health Services Research and Development Center for Implementation Practice and Research Support. Funding to pay the Open Access publication charges for this article was provided by the Department of Veterans Affairs. NR 33 TC 13 Z9 13 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 EI 1464-3677 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD FEB PY 2014 VL 26 IS 1 BP 6 EP 15 DI 10.1093/intqhc/mzt085 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA AA7SF UT WOS:000331296500002 PM 24311732 ER PT J AU Menda, SA Driver, TH Neiman, AE Naseri, A Stewart, JM AF Menda, Shivali A. Driver, Todd H. Neiman, Alexandra E. Naseri, Ayman Stewart, Jay M. TI Return to the Operating Room After Resident-Performed Cataract Surgery SO JAMA OPHTHALMOLOGY LA English DT Letter ID QUALITY INDICATOR C1 [Menda, Shivali A.; Driver, Todd H.; Neiman, Alexandra E.; Naseri, Ayman; Stewart, Jay M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Neiman, Alexandra E.; Stewart, Jay M.] San Francisco Gen Hosp, Dept Ophthalmol, San Francisco, CA 94110 USA. [Naseri, Ayman] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA USA. RP Stewart, JM (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,K301, San Francisco, CA 94143 USA. EM stewartj@vision.ucsf.edu NR 6 TC 5 Z9 5 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD FEB PY 2014 VL 132 IS 2 BP 223 EP 224 DI 10.1001/jamaophthalmol.2013.5675 PG 2 WC Ophthalmology SC Ophthalmology GA AA8TJ UT WOS:000331367600015 PM 24288082 ER PT J AU Lin, CA Takemoto, S Kandemir, U Kuo, AC AF Lin, Carol A. Takemoto, Steven Kandemir, Utku Kuo, Alfred C. TI Mid-Term Outcomes in HIV-Positive Patients After Primary Total Hip or Knee Arthroplasty SO JOURNAL OF ARTHROPLASTY LA English DT Article DE HIV/AIDS; THA; TKA; HAART ID HUMAN-IMMUNODEFICIENCY-VIRUS; TOTAL JOINT ARTHROPLASTY; HEMOPHILIC ARTHROPATHY; ANTIRETROVIRAL THERAPY; INFECTED HEMOPHILIACS; SOCIOECONOMIC-STATUS; NATURAL-HISTORY; REPLACEMENT; COUNTS; COMORBIDITIES AB We hypothesized that infection rates following total joint arthroplasty (TJA) in those with the human immunodeficiency virus (HIV) without hemophilia or drug use would be similar to rates in HIV-negative patients. Records at an urban HIV referral hospital were searched for patients who underwent primary total hip and knee arthroplasty from 2003 to 2010. The primary outcome was revision for infection. 372 HIV-negative and 22 HIV-positive TJA patients met inclusion criteria. The HIV-positive group had more deep infections than the HIV-negative group (9.1% v 2.2%, P = 0.102). There were no infections in those with AIDS-defining CD4 counts. Those with HIV may have a higher risk of developing a deep infection. A low CD4 count is not an absolute contraindication to TJA in HIV positive patients. Published by Elsevier Inc. C1 [Lin, Carol A.] Hennepin Cty Med Ctr, Dept Orthopaed Surg, Minneapolis, MN 55415 USA. [Takemoto, Steven; Kuo, Alfred C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kandemir, Utku; Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. [Kandemir, Utku] San Francisco Gen Hosp, Dept Orthopaed Surg, San Francisco, CA 94110 USA. RP Kuo, AC (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 500 Parnassus Ave,MUW 320, San Francisco, CA 94143 USA. FU Orthopaedic Research and Education Foundation; Clinical and Translational Science Institute at the University of California, San Francisco FX This project was supported by a Resident Research Grant from the Orthopaedic Research and Education Foundation and the Clinical and Translational Science Institute at the University of California, San Francisco. These organizations played no role in the study other than in providing funding. NR 45 TC 14 Z9 14 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD FEB PY 2014 VL 29 IS 2 BP 277 EP 282 DI 10.1016/j.arth.2013.06.015 PG 6 WC Orthopedics SC Orthopedics GA AA8KY UT WOS:000331345600006 PM 23867663 ER PT J AU Moghanaki, D Cheuk, A Fosmire, H Dawson, G Anscher, M Lutz, S AF Moghanaki, Drew Cheuk, Alice Fosmire, Helen Dawson, George Anscher, Mitchell Lutz, Stephen TI Availability of Single Fraction Palliative Radiotherapy for Cancer Patients Receiving End-of-Life Care Within the Veterans Healthcare Administration SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Moghanaki, Drew] Virginia Commonwealth Univ, Richmond, VA USA. [Cheuk, Alice] James J Peters VA Med Ctr, Bronx, NY USA. [Fosmire, Helen] Roudebush VA Hosp, Zionsville, IN USA. [Dawson, George] VA Med Ctr, Bronx, NY USA. [Anscher, Mitchell] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. [Lutz, Stephen] Blanchard Valley Hlth Syst, Findlay, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 393 EP 394 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000057 ER PT J AU Healy, J Lee, SK Ross, J Sanchez-Reilly, S Chappell, P Villarreal, D AF Healy, Jennifer Lee, Shuko Ross, Jeanette Sanchez-Reilly, Sandra Chappell, Phylliss Villarreal, Deborah TI The Double Parallel Curriculum in Palliative Care(DP-PC): Using a Double Parallel Education Strategy with Multimedia to Enhance Learners Knowledge and Skills in End of Life Palliative Care (EOL-PC) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Healy, Jennifer; Ross, Jeanette; Sanchez-Reilly, Sandra; Chappell, Phylliss; Villarreal, Deborah] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ross, Jeanette; Sanchez-Reilly, Sandra] South Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 403 EP 403 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000071 ER PT J AU Rotella, J Smith, TJ Widera, E AF Rotella, Joseph Smith, Thomas J. Widera, Eric TI Leading the Way to Wiser Choices: Communicating with Your Team, Institution, and Community About AAHPM's List of "Five Things Physicians and Patients Should Question in HPM" SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Rotella, Joseph] Hosparus, Louisville, KY USA. [Rotella, Joseph] Univ Louisville, Louisville, KY 40292 USA. [Smith, Thomas J.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Smith, Thomas J.] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Widera, Eric] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Widera, Eric] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 408 EP 409 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000080 ER PT J AU Ahluwalia, S Ettner, S Pantoja, P Lorenz, K Tisnado, D Walling, A AF Ahluwalia, Sangeeta Ettner, Susan Pantoja, Philip Lorenz, Karl Tisnado, Diana Walling, Anne TI Early Care Planning Discussions Are Associated with Less Hospital Care at the End of Life in Veterans with Advanced Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ahluwalia, Sangeeta; Tisnado, Diana; Walling, Anne] Univ Calif Los Angeles, Los Angeles, CA USA. [Ettner, Susan] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Pantoja, Philip] Dept Vet Affairs, North Hills, CA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 410 EP 411 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000083 ER PT J AU Singer, A Lynn, J Teno, J Lunney, J Meeker, D Lorenz, K AF Singer, Adam Lynn, Joanne Teno, Joan Lunney, June Meeker, Daniella Lorenz, Karl TI Going Less Gently into That Good Night? Symptom Trends in the Last Year of Life, 1998-2010 SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Singer, Adam; Meeker, Daniella] RAND Corp, Santa Monica, CA USA. [Lynn, Joanne] Altarum Inst, Chevy Chase, MD USA. [Teno, Joan] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA. [Lunney, June] Hosp & Palliat Nurses Assoc, Kennett Sq, PA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 411 EP 412 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000084 ER PT J AU Ahluwalia, S Prendergast, T Lorenz, K Schreibeis-Baum, H AF Ahluwalia, Sangeeta Prendergast, Thomas Lorenz, Karl Schreibeis-Baum, Hannah TI Nursing Roles, Experiences and Perspectives on Family Meetings: "We're the Most Consistent Person with Our Patients" SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ahluwalia, Sangeeta] Univ Calif Los Angeles, Los Angeles, CA USA. [Prendergast, Thomas] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Schreibeis-Baum, Hannah] Vet Adm, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 420 EP 421 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000099 ER PT J AU Cooke, K Franklin, J Painter, J Weinstein, S Rodgers, J AF Cooke, Kelly Franklin, John Painter, John Weinstein, Sharon Rodgers, James TI Effects of Combat and Military Training on End of Life Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Cooke, Kelly] ProHlth Care, Waukesha, WI USA. [Franklin, John; Painter, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Weinstein, Sharon] Univ Utah, Salt Lake City, UT USA. [Rodgers, James] Vet Affairs Healthcare, Temple, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 431 EP 431 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000114 ER PT J AU Binney, Z Garrido, M Quest, T AF Binney, Zachary Garrido, Melissa Quest, Tammie TI Impact of Inpatient Palliative Care Consultation on 30-day Hospital Readmissions and Near Misses SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Binney, Zachary; Quest, Tammie] Emory Univ, Atlanta, GA 30322 USA. [Garrido, Melissa] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 438 EP 439 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000126 ER PT J AU Garcia, J Davila, NF Cruz-Oliver, D Parikh, M Sanchez-Reilly, S Ortiz, JR AF Garcia, Jessica Davila, Natalia Fernandez Cruz-Oliver, Dulce Parikh, Manas Sanchez-Reilly, Sandra Ortiz, Jesus Roberto TI Caregivers Like Me: Cuidadores Como Yo SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Davila, Natalia Fernandez] Univ Puerto Rico, Jayuya, PR USA. [Cruz-Oliver, Dulce] St Louis Univ, Sch Med, St Louis, MO USA. [Parikh, Manas] St Louis Univ, St Louis, MO 63103 USA. [Sanchez-Reilly, Sandra; Ortiz, Jesus Roberto] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ortiz, Jesus Roberto] VA Hosp Audie Murphie, Brownsville, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 450 EP 451 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000144 ER PT J AU Schreibeis-Baum, H Lynn, J Xenakis, L Lorenz, K Brown, G AF Schreibeis-Baum, Hannah Lynn, Joanne Xenakis, Lea Lorenz, Karl Brown, Gina TI Systematic Review of Recent Federal and State Policy in Palliative and End-of-Life Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Schreibeis-Baum, Hannah] Vet Adm, Santa Monica, CA USA. [Lynn, Joanne] Altarum Inst, Chevy Chase, MD USA. [Xenakis, Lea] Samueli Inst, New York, NY USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Brown, Gina] VA Greater Los Angeles Hlth Care Syst, Claremont, CA USA. OI Schreibeis-Baum, Hannah/0000-0001-7798-9804 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 453 EP 454 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000149 ER PT J AU Chappell, P Lee, S Ross, J Healy, J Sanchez-Reilly, S AF Chappell, Phylliss Lee, Shuko Ross, Jeanette Healy, Jennifer Sanchez-Reilly, Sandra TI Communicating with Dying Patients and Their Families: Multimedia Training in End-of-Life Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Chappell, Phylliss; Ross, Jeanette; Healy, Jennifer; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko; Ross, Jeanette; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 460 EP 461 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000160 ER PT J AU Kvale, E Lisovicz, N Rocque, G Mona, F Taylor, R Martin, M AF Kvale, Elizabeth Lisovicz, Nedra Rocque, Gabrielle Mona, Fouad Taylor, Richard Martin, Michelle TI Extending Palliative Care Principles to Impact Public Health: Evaluation of a Training Program for Community Health Advisors (Lay Navigators) in Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Kvale, Elizabeth; Lisovicz, Nedra; Rocque, Gabrielle; Mona, Fouad; Taylor, Richard; Martin, Michelle] Univ Alabama Birmingham, Birmingham, AL USA. [Kvale, Elizabeth] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 489 EP 489 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000202 ER PT J AU Lendon, J Meeker, D Lorenz, K Lynne, J AF Lendon, Jessica Meeker, Daniella Lorenz, Karl Lynne, Joanne TI Trends in Caregiving Near End of Life, 2000-2008 SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Lendon, Jessica; Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Meeker, Daniella] RAND Corp, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 490 EP 491 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000205 ER PT J AU Meeker, D Lynn, J Leaf, D Lorenz, K AF Meeker, Daniella Lynn, Joanne Leaf, Duncan Lorenz, Karl TI Disability, Recovery, and Expenditures Among the Frail Elderly in the United States: Characteristics of an Objectively Defined Population SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Meeker, Daniella] RAND Corp, Santa Monica, CA USA. [Lynn, Joanne] Altarum Inst, Chevy Chase, MD USA. [Leaf, Duncan] Univ So Calif, Los Angeles, CA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 492 EP 493 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000208 ER PT J AU Mirmiran, A Lee, S Healy, J Sanchez-Reilly, S Mishaw, S Aziz, W AF Mirmiran, Ahmadreza Lee, Shuko Healy, Jennifer Sanchez-Reilly, Sandra Mishaw, Stephanie Aziz, Wesam TI Tertiary Hospital Cost Analysis for Palliative Care Consultation Service (T-HOPE) Study SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Lee, Shuko; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Healy, Jennifer; Sanchez-Reilly, Sandra; Aziz, Wesam] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Mishaw, Stephanie] Univ Texas Hlth Sci Ctr San Antonio, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 493 EP 494 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000209 ER PT J AU O'Riordan, D Lindenauer, P Ferrell, B Pantilat, S Burke, R Lorenz, K AF O'Riordan, David Lindenauer, Peter Ferrell, Betty Pantilat, Steven Burke, Rebecca Lorenz, Karl TI Palliative Care Quality Network: Identifying Core Data to Drive Quality Improvement SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [O'Riordan, David] Div Hosp Med, San Francisco, CA USA. [Lindenauer, Peter] Baystate Med Ctr, Springfield, MA USA. [Ferrell, Betty] City Hope Natl Med Ctr, Duarte, CA USA. [Pantilat, Steven] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA. [Burke, Rebecca] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 496 EP 497 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000214 ER PT J AU Schreibeis-Baum, H Cary, M Casarett, D Streim, J Lorenz, K AF Schreibeis-Baum, Hannah Cary, Mark Casarett, David Streim, Joel Lorenz, Karl TI Identifying Preferences for Palliative Home Care Services Among Veterans with HF and COPD and Their Caregivers: An Adaptive Conjoint Analysis SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Schreibeis-Baum, Hannah] Vet Adm, Santa Monica, CA USA. [Cary, Mark] Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA. [Casarett, David; Streim, Joel] Univ Penn, Philadelphia, PA 19104 USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. OI Schreibeis-Baum, Hannah/0000-0001-7798-9804 NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 502 EP 503 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000223 ER PT J AU Wachterman, M Keating, N Lorenz, K Simon, S Lipsitz, S AF Wachterman, Melissa Keating, Nancy Lorenz, Karl Simon, Steven Lipsitz, Stuart TI Patterns of Hospice Care Among Military Veterans and Non-Veterans SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Keating, Nancy] Harvard Univ, Sch Med, Boston, MA USA. [Lorenz, Karl] VA Greater Los Angeles, Los Angeles, CA USA. [Simon, Steven] VA Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 506 EP 507 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000230 ER PT J AU Wiesenthal, A Ross, J Cai, K Sanchez-Reilly, S Lin, L AF Wiesenthal, Alison Ross, Jeanette Cai, Kerrington, Jr. Sanchez-Reilly, Sandra Lin, Lin TI When Cancer Blogging Helps with Healing More than One SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 12-15, 2014 CL San Diego, CA SP Amer Acad Hosp and Palliat Med, Hosp and Palliat Nurses Assoc C1 [Ross, Jeanette; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ross, Jeanette; Sanchez-Reilly, Sandra; Lin, Lin] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Cai, Kerrington, Jr.] VA Hosp, High Sch, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2014 VL 47 IS 2 BP 511 EP 512 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA AA5OS UT WOS:000331150000237 ER PT J AU Bekelman, DB Hooker, S Nowels, CT Main, DS Meek, P McBryde, C Hattler, B Lorenz, KA Heidenreich, PA AF Bekelman, David B. Hooker, Stephanie Nowels, Carolyn T. Main, Deborah S. Meek, Paula McBryde, Connor Hattler, Brack Lorenz, Karl A. Heidenreich, Paul A. TI Feasibility and Acceptability of a Collaborative Care Intervention To Improve Symptoms and Quality of Life in Chronic Heart Failure: Mixed Methods Pilot Trial SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; PALLIATIVE CARE; DISEASE MANAGEMENT; ASSESSMENT SYSTEM; CHRONIC ILLNESS; DEPRESSION; OUTCOMES; POPULATION; IMPAIRMENT; THERAPY AB Background: People with chronic heart failure (HF) suffer from numerous symptoms that worsen quality of life. The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention was designed to improve symptoms and quality of life by integrating palliative and psychosocial care into chronic care. Objective: Our aim was to determine the feasibility and acceptability of CASA and identify necessary improvements. Methods: We conducted a prospective mixed-methods pilot trial. The CASA intervention included (1) nurse phone visits involving structured symptom assessments and guidelines to alleviate breathlessness, fatigue, pain, or depression; (2) structured phone counseling targeting adjustment to illness and depression if present; and (3) weekly team meetings with a palliative care specialist, cardiologist, and primary care physician focused on medical recommendations to primary care providers (PCPs, physician or nurse practioners) to improve symptoms. Study subjects were outpatients with chronic HF from a Veteran's Affairs hospital (n=15) and a university hospital (n=2). Measurements included feasibility (cohort retention rate, medical recommendation implementation rate, missing data, quality of care) and acceptability (an end-of-study semi-structured participant interview). Results: Participants were male with a median age of 63 years. One withdrew early and there were <5% missing data. Overall, 85% of 87 collaborative care team medical recommendations were implemented. All participants who screened positive for depression were either treated for depression or thought to not have a depressive disorder. In the qualitative interviews, patients reported a positive experience and provided several constructive critiques. Conclusions: The CASA intervention was feasible based on participant enrollment, cohort retention, implementation of medical recommendations, minimal missing data, and acceptability. Several intervention changes were made based on participant feedback. C1 [Bekelman, David B.; McBryde, Connor; Hattler, Brack] Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Denver, CO USA. [Bekelman, David B.; Nowels, Carolyn T.; McBryde, Connor; Hattler, Brack] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Meek, Paula] Univ Colorado, Sch Med, Coll Nursing, Aurora, CO USA. [Hooker, Stephanie] Univ Colorado, Dept Psychol, Denver, CO 80202 USA. [Main, Deborah S.] Univ Colorado, Dept Hlth & Behav Sci, Denver, CO 80202 USA. [Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Heidenreich, Paul A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Bekelman, DB (reprint author), VA Eastern Colorado Hlth Care Syst, 1055 Clermont Ave Res 151, Denver, CO 80220 USA. EM david.bekelman@va.gov OI Heidenreich, Paul/0000-0001-7730-8490; Hooker, Stephanie/0000-0003-4222-7046 FU Department of Veterans Affairs [RRP 11-239, CDA 08-022] FX No competing financial interests exist. This study was funded by the Department of Veterans Affairs, RRP 11-239. Dr. Bekelman is also funded by the Department of Veterans Affairs, CDA 08-022. NR 38 TC 9 Z9 9 U1 4 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB 1 PY 2014 VL 17 IS 2 BP 145 EP 151 DI 10.1089/jpm.2013.0143 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AA6TG UT WOS:000331230400008 PM 24329424 ER PT J AU Bays, AM Engelberg, RA Back, AL Ford, DW Downey, L Shannon, SE Doorenbos, AZ Edlund, B Christianson, P Arnold, RW O'Connor, K Kross, EK Reinke, LF Feemster, LC Fryer-Edwards, K Alexander, SC Tulsky, JA Curtis, JR AF Bays, Alison M. Engelberg, Ruth A. Back, Anthony L. Ford, Dee W. Downey, Lois Shannon, Sarah E. Doorenbos, Ardith Z. Edlund, Barbara Christianson, Phyllis Arnold, Richard W. O'Connor, Kim Kross, Erin K. Reinke, Lynn F. Feemster, Laura Cecere Fryer-Edwards, Kelly Alexander, Stewart C. Tulsky, James A. Curtis, J. Randall TI Interprofessional Communication Skills Training for Serious Illness: Evaluation of a Small-Group, Simulated Patient Intervention SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; BREAKING BAD-NEWS; EARLY PALLIATIVE CARE; CELL LUNG-CANCER; STANDARDIZED PATIENTS; MEDICAL-STUDENTS; RANDOMIZED-TRIAL; ROLE-PLAY; END; EDUCATION AB Background: Communication with patients and families is an essential component of high-quality care in serious illness. Small-group skills training can result in new communication behaviors, but past studies have used facilitators with extensive experience, raising concerns this is not scalable. Objective: The objective was to investigate the effect of an experiential communication skills building workshop (Codetalk), led by newly trained facilitators, on internal medicine trainees' and nurse practitioner students' ability to communicate bad news and express empathy. Design: Trainees participated in Codetalk; skill improvement was evaluated through pre- and post- standardized patient (SP) encounters. Setting and subjects: The subjects were internal medicine residents and nurse practitioner students at two universities. Intervention and measurements: The study was carried out in anywhere from five to eight half-day sessions over a month. The first and last sessions included audiotaped trainee SP encounters coded for effective communication behaviors. The primary outcome was change in communication scores from pre-intervention to post-intervention. We also measured trainee characteristics to identify predictors of performance and change in performance over time. Results: We enrolled 145 trainees who completed pre- and post-intervention SP interviewswith participation rates of 52% for physicians and 14% for nurse practitioners. Trainees' scores improved in 8 of 11 coded behaviors (p<0.05). The only significant predictors of performance were having participated in the intervention (p<0.001) and study site (p<0.003). The only predictor of improvement in performance over time was participating in the intervention (p<0.001). Conclusions: A communication skills intervention using newly trained facilitators was associated with improvement in trainees' skills in giving bad news and expressing empathy. Improvement in communication skills did not vary by trainee characteristics. C1 [Bays, Alison M.; Arnold, Richard W.; O'Connor, Kim] Univ Washington, Sch Nursing, Dept Med, Seattle, WA 98104 USA. [Engelberg, Ruth A.; Downey, Lois; Kross, Erin K.; Feemster, Laura Cecere; Curtis, J. Randall] Univ Washington, Sch Nursing, Dept Med, Div Pulm & Crit Care, Seattle, WA 98104 USA. [Shannon, Sarah E.; Doorenbos, Ardith Z.; Christianson, Phyllis; Reinke, Lynn F.; Curtis, J. Randall] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98104 USA. [Fryer-Edwards, Kelly; Curtis, J. Randall] Univ Washington, Sch Med, Dept Bioeth & Humanities, Seattle, WA 98104 USA. [Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Div Med Oncol,Dept Med, Seattle, WA 98104 USA. [Ford, Dee W.] Med Univ S Carolina, Dept Med, Div Pulm & Crit Care, Charleston, SC 29425 USA. [Edlund, Barbara] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Reinke, Lynn F.; Feemster, Laura Cecere] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Alexander, Stewart C.; Tulsky, James A.] Duke Univ, Dept Med, Durham, NC USA. [Alexander, Stewart C.; Tulsky, James A.] Duke Univ, Duke Palliat Care, Durham, NC USA. RP Curtis, JR (reprint author), Univ Washington, Div Pulm & Crit Care Med, 325 Ninth Ave, Seattle, WA 98104 USA. EM jrc@uw.edu FU NHLBI NIH HHS [K23 HL111116, K23 HL098745] NR 35 TC 24 Z9 24 U1 4 U2 26 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB 1 PY 2014 VL 17 IS 2 BP 159 EP 166 DI 10.1089/jpm.2013.0318 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA AA6TG UT WOS:000331230400010 PM 24180700 ER PT J AU Marcum, ZA Driessen, J Thorpe, CT Gellad, WF Donohue, JM AF Marcum, Zachary A. Driessen, Julia Thorpe, Carolyn T. Gellad, Walid F. Donohue, Julie M. TI Effect of Multiple Pharmacy Use on Medication Adherence and Drug-Drug Interactions in Older Adults with Medicare Part D SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pharmacy; medication adherence; drug interactions; Medicare ID PROPENSITY SCORE; ELDERLY-PATIENTS; DOSE-RESPONSE; PRESCRIPTION; MANAGEMENT; COMPLEXITY; THERAPY; ACCESS AB ObjectivesTo assess the association between multiple pharmacy use and medication adherence and potential drug-drug interactions (DDIs) in older adults. DesignCross-sectional propensity score-weighted analysis. Setting2009 claims data. ParticipantsA nationally representative sample of 926,956 Medicare Part D beneficiaries aged 65 and older continuously enrolled in fee-for-service Medicare and Part D that year who filled one or more prescriptions at a community retail or mail order pharmacy. MeasurementsMultiple pharmacy use was defined as concurrent (overlapping time periods) or sequential use (non-overlapping time periods) of 2 pharmacies in the year. Medication adherence was calculated using a proportion of days covered of 0.80 or greater for eight therapeutic categories (beta-blockers, renin angiotensin system antagonists, calcium channel blockers, statins, sulfonylureas, biguanides (metformin), thiazolidinediones, and dipeptidyl peptidase-IV inhibitors). Potential DDIs arising from use of certain drugs across a broad set of classes were defined as the concurrent filling of two interacting drugs. ResultsOverall, 38.1% of the sample used multiple pharmacies. Those using multiple pharmacies (concurrently or sequentially) consistently had higher adjusted odds of nonadherence (ranging from 1.10 to 1.31, P<.001) across all chronic medication classes assessed after controlling for sociodemographic, health status, and access to care factors than single pharmacy users. The adjusted predicted probability of exposure to a DDI was also slightly higher for those using multiple pharmacies concurrently (3.6%) than for single pharmacy users (3.2%, adjusted odds ratio (AOR)=1.11, 95% confidence interval (CI)=1.08-1.15) but lower in individuals using multiple pharmacies sequentially (2.8%, AOR=0.85, 95% CI=0.81-0.91). ConclusionsFilling prescriptions at multiple pharmacies was associated with lower medication adherence across multiple chronic medications and a small but statistically significant greater likelihood of DDIs in concurrent pharmacy users. C1 [Marcum, Zachary A.] Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Driessen, Julia; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Thorpe, Carolyn T.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Gen Internal Med, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA. RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med, Div Geriatr Med, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM zam12@pitt.edu OI Donohue, Julie/0000-0003-2418-6017 FU National Institute on Aging [P30AG024827, K07AG033174, R01AG027017]; Agency for Healthcare Research and Quality [R01HS018721]; Veterans Affairs Health Services Research and Development Service Career Development Award [CDA 09-207] FX This research was funded by National Institute on Aging Grants P30AG024827, K07AG033174, and R01AG027017 and Agency for Healthcare Research and Quality Grant R01HS018721. Dr. Gellad was supported by Veterans Affairs Health Services Research and Development Service Career Development Award CDA 09-207. NR 29 TC 6 Z9 6 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 244 EP 252 DI 10.1111/jgs.12645 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100005 PM 24521363 ER PT J AU Pugh, JA Wang, CP Espinoza, SE Noel, PH Bollinger, M Amuan, M Finley, E Pugh, MJ AF Pugh, Jacqueline A. Wang, Chen-Pin Espinoza, Sara E. Noel, Polly H. Bollinger, Mary Amuan, Megan Finley, Erin Pugh, Mary Jo TI Influence of Frailty-Related Diagnoses, High-Risk Prescribing in Elderly Adults, and Primary Care Use on Readmissions in Fewer than 30 Days for Veterans Aged 65 and Older SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE early readmissions; high-risk prescribing in the elderly; frailty; primary care ID WOMENS-HEALTH; INAPPROPRIATE MEDICATIONS; HOSPITAL READMISSIONS; 30-DAY READMISSION; QUALITY; OUTCOMES; AFFAIRS; IMPACT; PREDICTION; EXPERIENCE AB ObjectivesTo determine the effect of two variables not previously studied in the readmissions literature (frailty-related diagnoses and high-risk medications in the elderly (HRME)) and one understudied variable (volume of primary care visits in the prior year). DesignRetrospective cohort study using data from a study designed to examine outcomes associated with inappropriate prescribing in elderly adults. SettingAll Veterans Affairs (VA) facilities with acute inpatient beds in fiscal year 2006 (FY06). ParticipantsAll veterans aged 65 and older by October 1, 2005, who received VA care at least once per year between October 1, 2004, and September 30, 2006, and were hospitalized at least once during FY06 on a medical or surgical unit. MeasurementsA generalized linear interactive risk prediction model included demographic and clinical characteristics (mental health and chronic medical conditions, frailty-related diagnoses, number of medications) in FY05; incident HRME in FY06 before index hospitalization or readmission; chronic HRME in FY05; and FY05 emergency department (ED), hospital, geriatric, palliative, or primary care use. Facility-level variables were complexity, rural versus urban, and FY06 admission rate. ResultsThe mean adjusted readmission rate was 18.3%. The new frailty-related diagnoses variable is a risk factor for readmission in addition to Charlson comorbidity score. Incident HRME use was associated with lower rates of readmission, as were higher numbers of primary care visits in the prior year. ConclusionFrailty-related diagnoses may help to target individuals at higher risk of readmission to receive more-intensive care transition services. HRME use does not help in this targeting. A higher number of face-to-face primary care visits in the prior year, unlike ED and hospital use, correlates with fewer readmissions and may be another avenue for targeting prevention strategies. C1 [Pugh, Jacqueline A.; Wang, Chen-Pin; Noel, Polly H.; Bollinger, Mary; Finley, Erin; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Pugh, Jacqueline A.; Espinoza, Sara E.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, San Antonio, TX 78229 USA. [Wang, Chen-Pin; Bollinger, Mary; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Espinoza, Sara E.; Noel, Polly H.; Finley, Erin] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Espinoza, Sara E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr Gerontol & Palliat Med, San Antonio, TX 78229 USA. [Amuan, Megan] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. RP Pugh, JA (reprint author), STVHCS, VERDICT 11C-6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM pugh@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Pugh, Mary Jo/0000-0003-4196-7763; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR-06-062]; Veterans Evidence-based Research, Dissemination, and Implementation Center, Audie L. Murphy VA Hospital, San Antonio, Texas; Edith Nourse Rogers Memorial VA Medical Center; Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts FX This study was funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR-06-062; Mary Jo V. Pugh, PhD). Dr. Pugh is a Research Health Scientist at the Veterans Evidence-based Research, Dissemination, and Implementation Center, San Antonio, TX. We acknowledge the support of the Veterans Evidence-based Research, Dissemination, and Implementation Center, Audie L. Murphy VA Hospital, San Antonio, Texas, and the Edith Nourse Rogers Memorial VA Medical Center, the Center for Health Quality, Outcomes, and Economic Research, Bedford, Massachusetts. NR 52 TC 6 Z9 6 U1 4 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 291 EP 298 DI 10.1111/jgs.12656 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100011 PM 24521365 ER PT J AU Segelman, M Szydlowski, J Kinosian, B McNabney, M Raziano, DB Eng, C van Reenen, C Greener, HT AF Segelman, Micah Szydlowski, Jill Kinosian, Bruce McNabney, Matthew Raziano, Donna B. Eng, Catherine van Reenen, Christine Greener, Helena Temkin TI Hospitalizations in the Program of All-Inclusive Care for the Elderly SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE potentially avoidable hospitalizations; dual eligible beneficiaries; home- and community-based services; long-term services and supports; PACE ID LONG-TERM-CARE; MEDICARE; PACE; MODEL AB ObjectivesTo measure the rates of hospitalization, readmission, and potentially avoidable hospitalization (PAH) in the Program of All-Inclusive Care for the Elderly (PACE). DesignRetrospective study. SettingPACE. ParticipantsPACE enrollees. MeasurementsHospitalization and PAH rates were measured per 1,000 person-years. Readmission was defined as any return to the hospital within 30days of prior hospital discharge. PAHs were defined as hospitalizations for conditions that previously established criteria have identified as possibly preventable or manageable without hospitalization. ResultsRate of hospitalization was 539/1,000, vs 962/1,000 for dually eligible aged or disabled waiver (ADW) enrollees. Thirty-day readmission was 19.3%, compared with 22.9% for the national population of dually eligible older enrollees. PAH rate was 100/1,000, compared with 250/1,000 for dually eligible ADW enrollees. Considerable variation was observed between sites. ConclusionPACE enrollees experienced lower rates of hospitalization, readmission, and PAH than similar populations. Variations in hospitalization rates between PACE sites suggest opportunities for quality improvement. C1 [Segelman, Micah; Szydlowski, Jill; Greener, Helena Temkin] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY USA. [Kinosian, Bruce] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Kinosian, Bruce] Univ Penn, Sch Med, Div Geriatr, Philadelphia, PA 19104 USA. [Kinosian, Bruce] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [McNabney, Matthew] Johns Hopkins Univ, Sch Med, Hopkins ElderPlus, Baltimore, MD USA. [Raziano, Donna B.] Catholic Hlth East Trinity Inc, Mercy Hlth Syst, Mercy LIFE, Mercy Home & Community Based Serv, Philadelphia, PA USA. [Eng, Catherine] Lok Senior Hlth Serv, San Francisco, CA USA. [Eng, Catherine] Univ Calif San Francisco, Sch Med, Dept Med, Div Geriatr, San Francisco, CA USA. [van Reenen, Christine] Natl PACE Assoc, Alexandria, VA USA. RP Segelman, M (reprint author), Dept Publ Hlth Sci, 265 Crittenden Blvd,CU 420644, Rochester, NY 14642 USA. EM micah_segelman@urmc.rochester.edu FU National PACE Association FX Support provided by the National PACE Association. NR 23 TC 6 Z9 6 U1 9 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 320 EP 324 DI 10.1111/jgs.12637 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100015 PM 24417503 ER PT J AU Maust, DT Oslin, DW Marcus, SC AF Maust, Donovan T. Oslin, David W. Marcus, Steven C. TI Effect of Age on the Profile of Psychotropic Users: Results from the 2010 National Ambulatory Medical Care Survey SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pharmacoepidemiology; psychotropic prescribing; National Ambulatory Medical Care Survey ID OLDER-ADULTS; MENTAL-ILLNESS; NURSING-HOMES; UNITED-STATES; HEALTH-CARE; TRENDS; RISK; ANTIPSYCHOTICS; ANTIDEPRESSANTS; POLYPHARMACY AB ObjectivesTo describe the effect of age on psychotropic coprescribing, psychiatric diagnoses, and other clinical characteristics. DesignAnalysis of the National Ambulatory Medical Care Survey. SettingA national sample of outpatient visits to physicians (N=2,406) in office-based practice in 2010. ParticipantsAdults prescribed psychotropic medication (N=31,229). MeasurementsOffice visits at which antidepressant, anxiolytic, sedative, hypnotic, antipsychotic, or mood stabilizer medications were prescribed were grouped according to participant age (21-64, 65) and then compared within each medication class on visit characteristics. and then compared according to variables including provider type, sex, and race; presence of diagnosed mental illness; prescription of other psychotropic agents; total number of chronic conditions; time spent with physician; and total number of medications. ResultsIn 2010, there were 90.3million antidepressant office visits; 77.7million anxiolytic/sedative/hypnotic visits; 15.5million antipsychotic visits; and 9.5million mood stabilizer visits. Nonpsychiatrists prescribed the majority of psychotropic medications for every class and age group; 17.3% of older adult antipsychotic visits and 44.9% of younger adult antipsychotic visits were to a psychiatrist (chi-square=19.58, P=.001). Older adults in every medication class were less likely to have a diagnosed mental disorder. ConclusionOlder adults prescribed psychotropic medication were less likely to have a diagnosed mental disorder than their younger counterparts. Efforts to promote quality prescribing should seek to minimize nonspecific use of psychotropic medication. C1 [Maust, Donovan T.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Maust, Donovan T.] Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Oslin, David W.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Oslin, David W.] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Networks Mental Illness Res E, Philadelphia, PA USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Maust, DT (reprint author), Univ Michigan, Dept Psychiat, NCRC 016-217W,2800 Plymouth Rd, Ann Arbor, MI 48109 USA. EM maustd@umich.edu NR 30 TC 9 Z9 9 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 358 EP 364 DI 10.1111/jgs.12640 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100022 PM 24417590 ER PT J AU Kumar, A Gumaste, P Lam, C Dostal, P Stoopler, ET Schwab, EP AF Kumar, Avishek Gumaste, Purva Lam, Carly Dostal, Patrick Stoopler, Eric T. Schwab, Edna P. TI AN UNUSUAL INGESTION IN AN OLDER PERSON: DENTURES SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Kumar, Avishek; Gumaste, Purva; Lam, Carly; Dostal, Patrick] Univ Penn, Div Geriatr Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kumar, Avishek; Gumaste, Purva; Lam, Carly; Dostal, Patrick; Stoopler, Eric T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Stoopler, Eric T.] Univ Penn, Sch Dent Med, Dept Oral Med, Philadelphia, PA 19104 USA. [Schwab, Edna P.] Univ Penn, Div Geriatr, Perelman Sch Med, Dept Clin Med, Philadelphia, PA 19104 USA. RP Kumar, A (reprint author), Univ Penn, Div Geriatr Med, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2014 VL 62 IS 2 BP 399 EP 400 DI 10.1111/jgs.12642 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA AA6KL UT WOS:000331207100037 PM 24521379 ER PT J AU Katon, J Cypel, Y Raza, M Zephyrin, L Reiber, G Yano, EM Barth, S Schneiderman, A AF Katon, Jodie Cypel, Yasmin Raza, Mubashra Zephyrin, Laurie Reiber, Gayle Yano, Elizabeth M. Barth, Shannon Schneiderman, Aaron TI Self-Reported Infertility Among Male and Female Veterans Serving During Operation Enduring Freedom/Operation Iraqi Freedom SO JOURNAL OF WOMENS HEALTH LA English DT Article ID GULF-WAR VETERANS; AFFAIRS HEALTH-CARE; UNITED-STATES; REPRODUCTIVE HEALTH; COHORT; WOMEN; PREVALENCE; FERTILITY; PREGNANCY; PERSPECTIVE AB Background: Infertility is associated with psychosocial distress and is a growing public health concern. Our objective was to report the prevalence of lifetime history of infertility among men and women Veterans. Methods: We used data from the U.S. Department of Veterans Affairs National Health Study for a New Generation of U.S. Veterans, a nationally representative survey of Veterans serving during Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). The primary dependent variables were self-reported lifetime history of infertility among Veterans and their partners, defined as trying unsuccessfully to become pregnant for at least 12 months, and seeking medical help for infertility. Multiple logistic regression was used to determine whether gender was associated with lifetime history of infertility or seeking medical help for infertility, after adjusting for sociodemographic and military characteristics. All analyses were weighted to account for the complex survey design and nonresponse. Results: Among the 20,370 Veterans (16,056 men; 4,314 women) in our final analytic sample, the prevalence of lifetime history of infertility was 15.8% for women and 13.8% for men. After adjusting for age, ever married, education, race/ethnicity, component, branch of service, and deployment to OEF/OIF, compared with men, women Veterans had similar odds of lifetime history of infertility (odds ratio [OR] 1.07; 95% confidence interval [CI] 0.94, 1.20), but increased odds of seeking medical help for infertility (OR 1.35; 95% CI 1.06, 1.72). Conclusions: Women Veterans are more likely than their male counterparts to seek care for infertility, and given their increasing numbers, the demand for infertility evaluation and care within Veteran's Affairs may increase. C1 [Katon, Jodie; Zephyrin, Laurie] Dept Vet Affairs VA Cent Off, Off Womens Hlth Serv, Washington, DC USA. [Katon, Jodie; Reiber, Gayle] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Katon, Jodie; Reiber, Gayle] Univ Washington Sch Publ Hlth, Dept Hlth Serv, Seattle, WA USA. [Reiber, Gayle] Univ Washington Sch Publ Hlth, Dept Epidemiol, Seattle, WA USA. [Cypel, Yasmin; Raza, Mubashra; Barth, Shannon; Schneiderman, Aaron] VA Off Publ Hlth, Post Deployment Hlth Strateg Healthcare Grp, Washington, DC USA. [Zephyrin, Laurie] New York Harbor VA Healthcare Syst, New York, NY USA. [Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Study Healthcare Innovat Implementat & Policy, Hlth Serv Res & Dev Ctr, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Katon, J (reprint author), VA Med Ctr, Dept Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM jkaton@u.washington.edu FU Department of Veterans Affairs, Office of Public Health; Office of Academic Affiliations' Associated Health Post-doctoral Fellowship [TTP 61-026, RCS-98-353, RCS-05-195]; VA HSR&D Senior Research Career Scientist awards FX This study was funded by the Department of Veterans Affairs, Office of Public Health. Dr. Katon was supported by an Office of Academic Affiliations' Associated Health Post-doctoral Fellowship (No. TTP 61-026). Drs. Reiber (No. RCS-98-353) and Yano (No. RCS-05-195) are supported by VA HSR&D Senior Research Career Scientist awards. The views expressed within are solely those of the authors, and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 41 TC 3 Z9 3 U1 1 U2 6 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD FEB 1 PY 2014 VL 23 IS 2 BP 175 EP 183 DI 10.1089/jwh.2013.4468 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA AA7HC UT WOS:000331267300011 PM 24261648 ER PT J AU Wong, ES Hebert, PL Hernandez, SE Batten, A Lo, S Lemon, JM Fihn, SD Liu, CF AF Wong, Edwin S. Hebert, Paul L. Hernandez, Susan E. Batten, Adam Lo, Sophie Lemon, Jaclyn M. Fihn, Stephan D. Liu, Chuan-Fen TI Association Between Local Area Unemployment Rates and Use of Veterans Affairs Outpatient Health Services SO MEDICAL CARE LA English DT Article DE outpatient utilization; unemployment rate; enabling resources; Department of Veterans Affairs ID CARE; MEDICARE; RECESSIONS; ACCESS AB Background:Prior research indicates that federal spending on Medicare, Medicaid, and other government health programs accelerated during the Great Recession.Objectives:To examine whether local unemployment was associated with utilization of Veterans Affairs Health Care System (VA) primary care, specialty care, and mental health services during 2004-2012.Research Design:We analyzed utilization of VA health services at the clinic level using fixed-effects negative binomial models. We stratified analyses by veterans' copayment status (exempt and nonexempt) and age (under 65 and 65+) to account for differences in VA utilization because of Medicare eligibility.Subjects:A total of 11,041,855 veterans assigned to 892 clinics identified in the VA Primary Care Management Module, representing nearly all veterans receiving primary care from VA, were included.Measures:Clinic-level utilization was calculated quarterly as the total number of visits for patients assigned to a clinic. Local area unemployment rates were defined as quarterly unemployment rates within VA geographical planning sectors.Results:Higher local unemployment was associated with greater use of VA care in all categories among veterans exempt from copayments. The association between local unemployment and utilization differed by age group among veterans subject to copayments. Higher local unemployment was associated with lower use of primary and specialty care among Medicare-eligible veterans aged 65+, but greater use of primary care among veterans under age 65.Conclusions:Our findings highlight the importance of the state of the economy in interpreting and forecasting demand for government health programs including VA, particularly during periods focused on deficit reduction. C1 [Wong, Edwin S.; Hebert, Paul L.; Batten, Adam; Lemon, Jaclyn M.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA. [Wong, Edwin S.; Hebert, Paul L.; Hernandez, Susan E.; Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Lo, Sophie; Fihn, Stephan D.] Vet Hlth Adm, Off Analyt & Business Intelligence, Seattle, WA USA. RP Wong, ES (reprint author), VA Puget Sound Hlth Care Syst, Northwest Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eswong@uw.edu FU Veterans Health Administration Patient Centered Medical Home Demonstration Laboratory Coordination Center [XVA-61-041]; VA HSR&D Career Development Award [CDA 13-024] FX Supported by the Veterans Health Administration Patient Centered Medical Home Demonstration Laboratory Coordination Center (XVA-61-041). E. S. W. supported by a VA HSR&D Career Development Award (CDA 13-024). NR 39 TC 4 Z9 4 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2014 VL 52 IS 2 BP 137 EP 143 DI 10.1097/MLR.0000000000000079 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AA4SS UT WOS:000331087100009 PM 24374409 ER PT J AU Pugh, MJV Finley, EP Copeland, LA Wang, CP Noel, PH Amuan, ME Parsons, HM Wells, M Elizondo, B Pugh, JA AF Pugh, Mary Jo V. Finley, Erin P. Copeland, Laurel A. Wang, Chen-Pin Noel, Polly H. Amuan, Megan E. Parsons, Helen M. Wells, Margaret Elizondo, Barbara Pugh, Jacqueline A. TI Complex Comorbidity Clusters in OEF/OIF Veterans The Polytrauma Clinical Triad and Beyond SO MEDICAL CARE LA English DT Article DE Afghan Campaign 2001 (Operation Enduring Freedom); comorbidity; Iraq War 2003 (Operation Iraqi Freedom); veterans ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH DISORDERS; OPERATION-IRAQI-FREEDOM; ENDURING FREEDOM; US VETERANS; WAR; AFGHANISTAN; PAIN; CARE AB Background:A growing body of research on US Veterans from Afghanistan and Iraq [Operations Enduring and Iraqi Freedom, and Operation New Dawn (OEF/OIF)] has described the polytrauma clinical triad (PCT): traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and pain. Extant research has not explored comorbidity clusters in this population more broadly, particularly co-occurring chronic diseases.Objectives:The aim of the study was to identify comorbidity clusters among diagnoses of deployment-specific (TBI, PTSD, pain) and chronic (eg, hypertension, diabetes) conditions, and to examine the association of these clusters with health care utilization and adverse outcomes.Research Design:This was a retrospective cohort study.Subjects:The cohort comprised OEF/OIF Veterans who received care in the Veterans Health Administration in fiscal years (FY) 2008-2010.Measures:We identified comorbidity using validated ICD-9-CM code-based algorithms and FY08-09 data, followed by which we applied latent class analysis to identify the most statistically distinct and clinically meaningful patterns of comorbidity. We examined the association of these clusters with process measures/outcomes using logistic regression to correlate medication use, acute health care utilization, and adverse outcomes in FY10.Results:In this cohort (N=191,797), we found 6 comorbidity clusters. Cluster 1: PCT+Chronic Disease (5%); Cluster 2: PCT (9%); Cluster 3: Mental Health+Substance Abuse (24%); Cluster 4: Sleep, Amputation, Chronic Disease (4%); Cluster 5: Pain, Moderate PTSD (6%); and Cluster 6: Relatively Healthy (53%). Subsequent health care utilization patterns and adverse events were consistent with disease patterns.Conclusions:These comorbidity clusters extend beyond the PCT and may be used as a foundation to examine coordination/quality of care and outcomes for OEF/OIF Veterans with different patterns of comorbidity. C1 [Pugh, Mary Jo V.; Finley, Erin P.; Wang, Chen-Pin; Noel, Polly H.; Wells, Margaret; Elizondo, Barbara; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.; Wang, Chen-Pin; Parsons, Helen M.; Wells, Margaret; Elizondo, Barbara] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.; Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Bryan, TX USA. [Finley, Erin P.; Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA. [Copeland, Laurel A.] Scott & White Healthcare Syst, Temple, TX USA. [Amuan, Megan E.] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA. RP Pugh, MJV (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Maryjo.pughm@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237] FX Funded by the Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). NR 34 TC 16 Z9 16 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2014 VL 52 IS 2 BP 172 EP 181 DI 10.1097/MLR.0000000000000059 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA AA4SS UT WOS:000331087100014 PM 24374417 ER PT J AU O'Connell, BP Schlosser, RJ Wentzel, JL Nagel, W Mulligan, JK AF O'Connell, Brendan P. Schlosser, Rodney J. Wentzel, Jennifer L. Nagel, Whitney Mulligan, Jennifer K. TI Systemic Monocyte-Derived Dendritic Cells and Associated Th2 Skewing in Chronic Rhinosinusitis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE chronic rhinosinusitis; nasal polyposis; dendritic cells; t-helper cells; Th2 inflammation ID ALLERGIC FUNGAL RHINOSINUSITIS; AIRWAY EPITHELIAL-CELLS; DUST MITE ALLERGEN; NASAL POLYPS; CHEMOKINE RECEPTORS; CHRONIC SINUSITIS; PERIPHERAL-BLOOD; CUTTING EDGE; IMMUNITY; EXPRESSION AB Introduction Monocyte-derived dendritic cells (moDCs) are antigen-presenting cells capable of directing immune responses toward T-helper 1 (Th1) or T-helper 2 (Th2) phenotypes. The systemic profile of moDCs and their association with Th1/Th2 skewing in chronic rhinosinusitis (CRS) is unclear. The purpose of this study is to characterize circulating moDCs in controls, CRS without nasal polyps (CRSsNP), and CRS with nasal polyps (CRSwNP) and correlate moDCs with Th1/Th2 skewing, mucosal inflammation on computed tomography (CT), and quality of life (QoL). Study Design Cross-sectional study. Setting Tertiary care hospital. Subjects Blood was drawn from control (n = 12), CRSsNP (n = 18), and CRSwNP (n = 15) patients during endoscopic sinus surgery. Methods Peripheral blood moDCs were analyzed with flow cytometry for expression of HLA-DR, CD209, and CD14. Th1 and Th2 cells were identified by CXCR3 and CCR8 expression, respectively. Lund-Mackay CT scores were assigned by blinded graders. Sino-Nasal Outcome Test 22 (SNOT-22) surveys were completed by patients before surgery. Results CRSsNP and CRSwNP displayed elevations in systemic moDCs compared with controls. In CRSwNP, systemic Th2 skewing was observed and circulating CD4+ Th2 cells correlated with percent moDCs. MoDCs strongly correlated with higher Lund-Mackay CT scores in CRSsNP but not in CRSwNP. No relationship between moDCs and SNOT-22 scores was observed for either subset of CRS. Conclusion These data support that CRSwNP and CRSsNP display alterations in systemic immune profiles. CRSwNP is characterized by significant elevations in circulating moDCs, which is associated with systemic Th2-biased inflammation. Circulating moDCs are associated with mucosal inflammation on CT imaging in CRSsNP. No association between moDCs and QoL is evident in either CRS subset. C1 [O'Connell, Brendan P.; Schlosser, Rodney J.; Wentzel, Jennifer L.; Nagel, Whitney; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Mulligan, JK (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu FU American Academy of Otolaryngology-Head and Neck Surgery Resident Research Award, CORE grant [277809]; Flight Attendant Medical Research Institute [092401, 113039]; Clinical Sciences Research and Development Program of the Department of Veterans Affairs [1 I01 CX000377] FX American Academy of Otolaryngology-Head and Neck Surgery Resident Research Award, CORE grant (277809 [B.P.O.]), Flight Attendant Medical Research Institute (092401 [J.K.M.] and 113039 [R.J.S.]), and Merit-review award from Clinical Sciences Research and Development Program of the Department of Veterans Affairs (1 I01 CX000377). NR 44 TC 5 Z9 5 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2014 VL 150 IS 2 BP 312 EP 320 DI 10.1177/0194599813516277 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA AA6PH UT WOS:000331219800024 PM 24367054 ER PT J AU Pompili, M Innamorati, M Di Vittorio, C Sher, L Girardi, P Amore, M AF Pompili, Maurizio Innamorati, Marco Di Vittorio, Cristina Sher, Leo Girardi, Paolo Amore, Mario TI Sociodemographic and Clinical Differences Between Suicide Ideators and Attempters: A Study of Mood Disordered Patients 50 Years and Older SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID LATE-ONSET DEPRESSION; TOWER-OF-BABEL; BIPOLAR-DISORDER; GENERAL-POPULATION; MAJOR DEPRESSION; LIFE EVENTS; PSYCHOMETRIC PROPERTIES; GERIATRIC DEPRESSION; REVISED NOMENCLATURE; LITHIUM TREATMENT AB Our study sought to characterize mood disordered suicide ideators and attempters 50years and older admitted to a psychiatric ward either for a recent suicide attempt or for ongoing suicidal ideation. We enrolled 50 patients with suicide ideation consecutively admitted to an inpatient department and 50 patients admitted for a suicide attempt made in the last 48hours. Suicide attempters more frequently had low social support and an age of onset of mood disorder of 46years and older, and less frequently had a history of suicidal behaviors in the family members and pharmacological treatment, despite the fact that the groups did not differ with regard to antidepressants prescribed. The groups were not distinguishable based on several variables assumed to be risk factors for suicide behavior, such as proximal life events and stressors or alcohol use disorders. In both samples, comorbidity with organic diseases, the presence of stressful life events in the past 12months, and a diagnosis of major depression were frequently reported. In conclusion, the presence of low social support and the absence of a pharmacotherapy may increase suicidal behaviors in patients at risk. C1 [Pompili, Maurizio; Girardi, Paolo] Univ Roma La Sapienza, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, I-00185 Rome, Italy. [Innamorati, Marco; Di Vittorio, Cristina] Univ Parma, Dept Neurosci, Div Psychiat, I-43100 Parma, Italy. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Amore, Mario] Univ Genoa, Sect Psychiat, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy. RP Pompili, M (reprint author), St Andrea Hosp, Dept Psychiat, 1035,Via Grottarossa,1035, Rome, Italy. EM maurizio.pompili@uniroma1.it OI Innamorati, Marco/0000-0003-1389-2290; Pompili, Maurizio/0000-0003-1886-4977 NR 75 TC 6 Z9 6 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD FEB PY 2014 VL 44 IS 1 BP 34 EP 45 DI 10.1111/sltb.12051 PG 12 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA AA7CQ UT WOS:000331255100004 PM 23937195 ER PT J AU Lackner, JM Gudleski, GD Thakur, ER Stewart, TJ Iacobucci, GJ Spiegel, BMR AF Lackner, Jeffrey M. Gudleski, Gregory D. Thakur, Elyse R. Stewart, Travis J. Iacobucci, Gary J. Spiegel, Brennan M. R. CA IBS Outcome Study Research Grp TI The Impact of Physical Complaints, Social Environment, and Psychological Functioning on IBS Patients' Health Perceptions: Looking Beyond GI Symptom Severity SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; REPORTED OUTCOME MEASURES; SELF-RATED HEALTH; QUALITY-OF-LIFE; GASTROINTESTINAL SYMPTOMS; CLINICAL-TRIALS; UNITED-STATES; DISEASE; ILLNESS; ASSESSMENTS AB OBJECTIVES: In the absence of a reliable biomarker, clinical decisions for a functional gastrointestinal (GI) disorder like irritable bowel syndrome (IBS) depend on asking patients to appraise and communicate their health status. Self-ratings of health (SRH) have proven a powerful and consistent predictor of health outcomes, but little is known about how they relate to those relevant to IBS (e. g., quality of life (QOL), IBS symptom severity). This study examined what psychosocial factors, if any, predict SRH among a cohort of more severe IBS patients. METHODS: Subjects included 234 Rome III-positive IBS patients (mean age = 41 years, female = 78%) without comorbid organic GI disease. Subjects were administered a test battery that included the IBS Symptom Severity Scale, Screening for Somatoform Symptoms, IBS Medical Comorbidity Inventory, SF-12 Vitality Scale, Perceived Stress Scale, Beck Depression Inventory, Trait Anxiety Inventory, and Negative Interactions Scale. RESULTS: Partial correlations identified somatization, depression, fatigue, stress, anxiety, and medical comorbidities as variables with the strongest correlations with SRH (r values = 0.36-0.41, P values < 0.05). IBS symptom severity was weakly associated with SRH (r = 0.18, P < 0.05). The final regression model explained 41.3% of the variance in SRH scores (F = 8.49, P < 0.001) with significant predictors including fatigue, medical comorbidities, somatization, and negative social interactions. CONCLUSIONS: SRH are associated with psychological (anxiety, stress, depression), social (negative interactions), and extraintestinal somatic factors (fatigue, somatization, medical comorbidities). The severity of IBS symptoms appears to have a relatively modest role in how IBS patients describe their health in general. C1 [Lackner, Jeffrey M.; Gudleski, Gregory D.; Stewart, Travis J.; Iacobucci, Gary J.] SUNY Buffalo, Sch Med, Dept Med, Behav Med Clin, Buffalo, NY 14215 USA. [Thakur, Elyse R.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA. [Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Lackner, JM (reprint author), SUNY Buffalo, Sch Med, ECMC, Behav Med Clin,Dept Med, 462 Grider St, Buffalo, NY 14215 USA. EM lackner@buffalo.edu FU NIH [DK77738] FX This study was funded by NIH grant DK77738. NR 61 TC 18 Z9 19 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2014 VL 109 IS 2 BP 224 EP 233 DI 10.1038/ajg.2013.410 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AA4IF UT WOS:000331058600011 PM 24419481 ER PT J AU Khanna, P Agarwal, N Khanna, D Hays, RD Chang, L Bolus, R Melmed, G Whitman, CB Kaplan, RM Ogawa, R Snyder, B Spiegel, BMR AF Khanna, Puja Agarwal, Nikhil Khanna, Dinesh Hays, Ron D. Chang, Lin Bolus, Roger Melmed, Gil Whitman, Cynthia B. Kaplan, Robert M. Ogawa, Rikke Snyder, Bradley Spiegel, Brennan M. R. TI Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID QUALITY-OF-LIFE; GASTROESOPHAGEAL-REFLUX DISEASE; IRRITABLE-BOWEL-SYNDROME; TREATMENT SATISFACTION QUESTIONNAIRE; GASTROINTESTINAL-TRACT INSTRUMENT; RANDOMIZED CONTROLLED-TRIAL; SYMPTOM-RATING-SCALE; LAPAROSCOPIC NISSEN FUNDOPLICATION; FECAL INCONTINENCE QUESTIONNAIRE; VISCERAL SENSITIVITY INDEX AB OBJECTIVES: Because gastrointestinal (GI) illnesses can cause physical, emotional, and social distress, patient-reported outcomes (PROs) are used to guide clinical decision making, conduct research, and seek drug approval. It is important to develop a mechanism for identifying, categorizing, and evaluating the over 100 GI PROs that exist. Here we describe a new, National Institutes of Health (NIH)-supported, online PRO clearinghouse-the GI-PRO database. METHODS: Using a protocol developed by the NIH Patient-Reported Outcome Measurement Information System (PROMIS (R)), we performed a systematic review to identify English-language GI PROs. We abstracted PRO items and developed an online searchable item database. We categorized symptoms into content "bins" to evaluate a framework for GI symptom reporting. Finally, we assigned a score for the methodological quality of each PRO represented in the published literature (0-20 range; higher indicates better). RESULTS: We reviewed 15,697 titles (kappa > 0.6 for title and abstract selection), from which we identified 126 PROs. Review of the PROs revealed eight GI symptom "bins" : (i) abdominal pain, (ii) bloat/gas, (iii) diarrhea, (iv) constipation, (v) bowel incontinence/soilage, (vi) heartburn/reflux, (vii) swallowing, and (viii) nausea/vomiting. In addition to these symptoms, the PROs covered four psychosocial domains: (i) behaviors, (ii) cognitions, (iii) emotions, and (iv) psychosocial impact. The quality scores were generally low (mean 8.88 +/- 4.19; 0 (min)-20 (max)). In addition, 51% did not include patient input in developing the PRO, and 41% provided no information on score interpretation. CONCLUSIONS: GI PROs cover a wide range of biopsychosocial symptoms. Although plentiful, GI PROs are limited by low methodological quality. Our online PRO library (www.researchcore.org/gipro/) can help in selecting PROs for clinical and research purposes. C1 [Khanna, Puja; Khanna, Dinesh] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Agarwal, Nikhil; Spiegel, Brennan M. R.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA 90073 USA. [Agarwal, Nikhil; Melmed, Gil] Cedars Sinai Med Ctr, Dept Gastroenterol, Los Angeles, CA 90048 USA. [Hays, Ron D.; Kaplan, Robert M.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Hays, Ron D.; Kaplan, Robert M.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Chang, Lin; Bolus, Roger; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Bolus, Roger; Whitman, Cynthia B.; Snyder, Bradley; Spiegel, Brennan M. R.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Ogawa, Rikke] Univ Calif Los Angeles, Biomed Lib Hlth Sci, Los Angeles, CA USA. RP Spiegel, BMR (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU National Institutes of Health through the NIH Roadmap for Medical Research [AR052177]; ACR Research and Education Foundation; NIAMS [K24AR063120-02]; NIH/NIA [P30-AG028748, P30-AG021684]; NCMHD [2P20MD000182]; Ironwood; Movetis; Shire Pharmaceuticals; Prometheus; Rose Pharma; Takeda; NIH/NIAMS [U01 AR057936A] FX NIH/NIAMS U01 AR057936A, the National Institutes of Health through the NIH Roadmap for Medical Research Grant (AR052177). Puja Khanna was supported by ACR Research and Education Foundation Career Development Bridge Funding Award 2011-12. Dinesh Khanna was also supported by NIAMS K24AR063120-02. Ron Hays was supported by NIH/NIA grants P30-AG028748 and P30-AG021684, and NCMHD grant 2P20MD000182. Brennan Spiegel has received grant support from Ironwood, Movetis, and Shire Pharmaceuticals. Lin Chang has received grant support from Prometheus, Rose Pharma, and Takeda. NR 169 TC 5 Z9 5 U1 3 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2014 VL 109 IS 2 BP 234 EP 248 DI 10.1038/ajg.2013.401 PG 15 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AA4IF UT WOS:000331058600012 PM 24343547 ER PT J AU Ramanathan, S Johnson, S Burns, SP Kralovic, SM Goldstein, B Smith, B Gerding, DN Evans, CT AF Ramanathan, Swetha Johnson, Stuart Burns, Stephen P. Kralovic, Stephen M. Goldstein, Barry Smith, Bridget Gerding, Dale N. Evans, Charlesnika T. TI Recurrence of Clostridium difficile infection among veterans with spinal cord injury and disorder SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE C difficile infection; First recurrence; Veterans Affairs; Concomitant antibiotics; Length of stay ID PROTON PUMP INHIBITORS; 1ST RECURRENCE; RISK-FACTOR; DIARRHEA; EPIDEMIOLOGY; FIDAXOMICIN; VANCOMYCIN; DISEASE; MANAGEMENT; OUTCOMES AB Background: Recurrent Clostridiumdifficile (CDI) infection is a growing concern; however, there are little data on impact of recurrent CDI on those with spinal cord injury and disorder (SCI/D). Therefore, the objective of this study was to identify risk factors associated with recurrence of CDI among Veterans with SCI/D. Methods: This was a retrospective cohort study with data from outpatient, inpatient, and extended care settings at 83 Department of Veterans Affairs facilities from 2002 to 2009. Results: Of 1,464 cases of CDI analyzed, 315 cases (21.5%) had a first recurrence of CDI. Multivariable regression demonstrated that risk factors significantly associated with increased recurrence were concomitant fluoroquinolone use (odds ratio [OR], 1.39; 95% confidence interval [CI]: 1.08-1.80), whereas concomitant tetracycline use (OR, 0.35; 95% CI: 0.14-0.90), and cerebrovascular accident (OR, 0.46; 95% CI: 0.25-0.85) were associated with decreased recurrence. A subanalysis in those with health care facility-onset CDI showed that increased length of stay postinitial CDI was a significant risk factor for recurrence as was concomitant use of fluoroquinolones and that tetracycline remained protective for recurrence. Conclusion: Concomitant fluoroquinolone use was a risk factor for the recurrence of CDI. In contrast, tetracyclines and cerebrovascular accident were protective. Length of stay greater than 90 days from the initial CDI episode was also a risk factor for recurrence among those with health care facility-onset CDI. Future studies should focus on effective strategies to prevent these risk factors among the SCI/D population. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Ramanathan, Swetha; Smith, Bridget; Evans, Charlesnika T.] Vet Affairs Edward Hines Jr Hosp, Ctr Innovat Complex Chron Healthcare & Spinal Cor, Dept Vet Affairs, Hines, IL 60141 USA. [Ramanathan, Swetha] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Johnson, Stuart; Gerding, Dale N.] Vet Affairs Edward Hines Jr Hosp, Dept Vet Affairs, Res Serv, Hines, IL 60141 USA. [Johnson, Stuart; Smith, Bridget; Gerding, Dale N.] Loyola Univ, Med Ctr, Dept Med, Maywood, IL 60153 USA. [Burns, Stephen P.; Goldstein, Barry] SCI QUERI, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Burns, Stephen P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Kralovic, Stephen M.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Kralovic, Stephen M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Evans, Charlesnika T.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Evans, Charlesnika T.] Northwestern Univ, Ctr Healthcare Studies, Chicago, IL 60611 USA. RP Ramanathan, S (reprint author), Vet Affairs Edward Hines Jr Hosp, 5th & Roosevelt Rd 151H,Room C306,POB 5000, Hines, IL 60141 USA. EM Swetha.Ramanathan@va.gov FU VA Health Services Research and Development Service [IIR-10-148] FX Supported by VA Health Services Research and Development Service (IIR-10-148). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 39 TC 5 Z9 5 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2014 VL 42 IS 2 BP 168 EP 173 DI 10.1016/j.ajic.2013.08.009 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA AA2VO UT WOS:000330952500018 PM 24485372 ER PT J AU Goebel-Stengel, M Stengel, A Wang, LX Tache, Y AF Goebel-Stengel, Miriam Stengel, Andreas Wang, Lixin Tache, Yvette TI Orexigenic response to tail pinch: role of brain NPY1 and corticotropin releasing factor receptors SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE body weight; corticotropin releasing factor; fecal pellet output; food intake; Fos; ghrelin; neuropeptide Y; stress-induced eating; somatostatin receptor 2 antagonist; tail pinch ID STRESS-RELATED ALTERATIONS; FOOD-INTAKE; NEUROPEPTIDE-Y; BODY-WEIGHT; PARAVENTRICULAR NUCLEUS; NIGROSTRIATAL DOPAMINE; ENDOGENOUS OPIATES; INDUCED INHIBITION; ABDOMINAL-SURGERY; CENTRAL INJECTION AB Tail pinch stimulates food intake in rats. We investigated brain mechanisms of this response and the influence of repeated exposure. Sprague-Dawley rats received acute (5 min) or repeated (5 min/ day for 14 days) tail pinch using a padded clip. Acute tail pinch increased 5-min food intake compared with control (0.92 +/- 0.2 vs. 0.03 +/- 0.01 g, P < 0.01). This response was inhibited by 76% by intracerebroventricular injection of BIBP-3226, a neuropeptide Y-1 (NPY1) receptor antagonist, increased by 48% by astressin-B, a corticotropin-releasing factor (CRF) receptor antagonist, and not modified by S-406-028, a somatostatin subtype 2 antagonist. After the 5-min tail pinch without food, blood glucose rose by 21% (P < 0.01) while changes in plasma acyl ghrelin (+41%) and adrenocorticotropic hormone (+7%) were not significant. Two tail pinches (45 min apart) activate pontine and hindbrain catecholaminergic and hypothalamic paraventricular CRF neurons. After 14 days of repeated tail pinch, the 5-min orexigenic response was not significantly different from days 2 to 11 but reduced by 50% thereafter (P < 0.001). Simultaneously, the 5-min fecal pellet output increased during the last 5 days compared with the first 5 days (+8%, P < 05). At day 14, the body weight gain was reduced by 22%, with a 99% inhibition of fat gain and a 25% reduction in lean mass (P < 0.05). The orexigenic response to acute 5-min tail pinch is likely to involve the activation of brain NPY1 signaling, whereas that of CRF tends to dampen the acute response and may contribute to increased defecation and decreased body weight gain induced by repeated tail pinch. C1 [Goebel-Stengel, Miriam; Stengel, Andreas; Wang, Lixin; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Ctr Neurobiol Stress, CURE Digest Dis Res Ctr,Digest Dis Div, Los Angeles, CA 90024 USA. [Goebel-Stengel, Miriam; Stengel, Andreas; Wang, Lixin; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goebel-Stengel, Miriam] Martin Luther Krankenhaus Berlin, Dept Internal Med, Berlin, Germany. [Goebel-Stengel, Miriam] Martin Luther Krankenhaus Berlin, Inst Neurogastroenterol, Berlin, Germany. [Stengel, Andreas] Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, Berlin, Germany. [Stengel, Andreas] Charite, D-13353 Berlin, Germany. RP Tache, Y (reprint author), VA GLA Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Rm 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU National Institutes of Health (NIH) [R01 DK-33061, DK-41301]; Veterans Affairs Merit Award [F219-R]; Research Career Scientist Award FX This study was supported by National Institutes of Health (NIH) Grant R01 DK-33061, NIH Center Grant DK-41301 (Animal Core), and Veterans Affairs Merit Award Project F219-R, and Research Career Scientist Award. NR 72 TC 8 Z9 8 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 EI 1522-1490 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD FEB PY 2014 VL 306 IS 3 BP R164 EP R174 DI 10.1152/ajpregu.00335.2013 PG 11 WC Physiology SC Physiology GA AA4NO UT WOS:000331073000002 PM 24338440 ER PT J AU Bersohn, MM Shapiro, S AF Bersohn, Malcolm M. Shapiro, Shelley TI Systolic BP and Heart Rate in Pulmonary Hypertension Response SO CHEST LA English DT Letter C1 [Bersohn, Malcolm M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Bersohn, MM (reprint author), VA Greater Los Angeles Healthcare Syst, Cardiol 111E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mbersohn@ucla.edu NR 2 TC 0 Z9 0 U1 1 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2014 VL 145 IS 2 BP 414 EP 415 DI 10.1378/chest.13-2401 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AA2WO UT WOS:000330955100039 PM 24493520 ER PT J AU Jefferson, JA Escudero, E Johnson, RJ Swenson, ER Hurtado, A AF Jefferson, J. Ashley Escudero, Elizabeth Johnson, Richard J. Swenson, Erik R. Hurtado, Abdias TI Increased Oxidative Stress at Altitude SO CHEST LA English DT Letter ID HYPOXIA C1 [Jefferson, J. Ashley] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Escudero, Elizabeth; Hurtado, Abdias] Univ Cayetano Heredia, Carlos Monge Cassinelli Nephrol Ctr, Lima, Peru. [Johnson, Richard J.] Univ Colorado, Div Nephrol, Aurora, CO USA. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98195 USA. RP Jefferson, JA (reprint author), Univ Washington, Div Nephrol, 1959 NE Pacific St,Box 356174, Seattle, WA 98195 USA. EM jashleyj@u.washington.edu NR 7 TC 1 Z9 1 U1 1 U2 3 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2014 VL 145 IS 2 BP 423 EP 423 DI 10.1378/chest.13-2062 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AA2WO UT WOS:000330955100051 PM 24493532 ER PT J AU Ersek, M Sefcik, JS Lin, FC Lee, TJ Gilliam, R Hanson, LC AF Ersek, Mary Sefcik, Justine S. Lin, Feng-Chang Lee, Tae Joon Gilliam, Robin Hanson, Laura C. TI Provider Staffing Effect on a Decision Aid Intervention SO CLINICAL NURSING RESEARCH LA English DT Article ID NURSING-HOME RESIDENTS; ADVANCED PRACTICE NURSES; OLDER PERSONS; PHYSICIAN ASSISTANTS; ADVANCED DEMENTIA; CONFLICT SCALE; CARE; TRIAL; DEATH C1 [Ersek, Mary] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Ersek, Mary; Sefcik, Justine S.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Lin, Feng-Chang] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Lee, Tae Joon] E Carolina Univ, Brody Sch Med, Greenville, NC USA. [Gilliam, Robin; Hanson, Laura C.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. [Hanson, Laura C.] Univ N Carolina, Div Geriatr Med, Chapel Hill, NC USA. RP Ersek, M (reprint author), Univ Penn, Sch Nursing, Philadelphia Vet Affairs Med Ctr, Natl PROMISE Performance Reporting & Outcomes Mea, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM ersekm@nursing.upenn.edu FU National Institute of Nursing Research [RO1NR009826]; Jonas Hartford Scholarship FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by Award Number RO1NR009826 from the National Institute of Nursing Research. JSS was supported by a Jonas Hartford Scholarship. NR 30 TC 1 Z9 1 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1054-7738 EI 1552-3799 J9 CLIN NURS RES JI Clin. Nurs. Res. PD FEB PY 2014 VL 23 IS 1 BP 36 EP 53 PG 18 WC Nursing SC Nursing GA AA5CL UT WOS:000331113200004 PM 23291316 ER PT J AU Wang, J Gong, B Zhao, W Tang, C Varghese, M Nguyen, T Bi, WN Bilski, A Begum, S Vempati, P Knable, L Ho, L Pasinetti, GM AF Wang, Jun Gong, Bing Zhao, Wei Tang, Cheuk Varghese, Merina Tuyen Nguyen Bi, Weina Bilski, Amanda Begum, Shimul Vempati, Prashant Knable, Lindsay Ho, Lap Pasinetti, Giulio M. TI Epigenetic Mechanisms Linking Diabetes and Synaptic Impairments SO DIABETES LA English DT Article ID HISTONE DEACETYLASE INHIBITORS; INDEPENDENT COMPONENT ANALYSIS; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; METABOLIC SYNDROME; MEMORY FORMATION; DNA METHYLATION; MOUSE MODEL; BRAIN MRI; MELLITUS AB Diabetes is one of the major risk factors for dementia. However, the molecular mechanism underlying the risk of diabetes for dementia is largely unknown. Recent studies revealed that epigenetic modifications may play a role in the pathogenesis of diabetes. We hypothesized that diabetes may cause epigenetic changes in the brain that may adversely affect synaptic function. We found significant elevation in the expression of histone deacetylases (HDACs) class IIa in the brains of diabetic subjects compared with control subjects, and these changes coincide with altered expression of synaptic proteins. In a mouse model of diet-induced type 2 diabetes (T2D), we found that, similar to humans, T2D mice also showed increased expression of HDAC IIa in the brain, and these alterations were associated with increased susceptibility to oligomeric A-induced synaptic impairments in the hippocampal formation and eventually led to synaptic dysfunction. Pharmacological inhibition of HDAC IIa restored synaptic plasticity. Our study demonstrates that diabetes may induce epigenetic modifications affecting neuropathological mechanisms in the brain leading to increased susceptibility to insults associated with neurodegenerative or vascular impairments. Our study provides, for the first time, an epigenetic explanation for the increased risk of diabetic patients developing dementia. C1 [Wang, Jun; Gong, Bing; Zhao, Wei; Varghese, Merina; Bi, Weina; Bilski, Amanda; Begum, Shimul; Vempati, Prashant; Knable, Lindsay; Ho, Lap; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Tang, Cheuk; Tuyen Nguyen] Mt Sinai Sch Med, Dept Radiol, New York, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 NR 50 TC 13 Z9 13 U1 0 U2 11 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2014 VL 63 IS 2 BP 645 EP 654 DI 10.2337/db13-1063 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA5BG UT WOS:000331110000031 PM 24154559 ER PT J AU Thalacker-Mercer, AE Ingram, KH Guo, FJ Ilkayeva, O Newgard, CB Garvey, WT AF Thalacker-Mercer, Anna E. Ingram, Katherine H. Guo, Fangjian Ilkayeva, Olga Newgard, Christopher B. Garvey, W. Timothy TI BMI, RQ, Diabetes, and Sex Affect the Relationships Between Amino Acids and Clamp Measures of Insulin Action in Humans SO DIABETES LA English DT Article ID RESISTANCE SYNDROME; AFRICAN-AMERICANS; SKELETAL-MUSCLE; WEIGHT-LOSS; GLUCOSE; SENSITIVITY; SECRETION; OBESITY; FAT; METABOLISM AB Previous studies have used indirect measures of insulin sensitivity to link circulating amino acids with insulin resistance and identify potential biomarkers of diabetes risk. Using direct measures (i.e., hyperinsulinemic-euglycemic clamps), we examined the relationships between the metabolomic amino acid profile and insulin action (i.e., glucose disposal rate [GDR]). Relationships between GDR and serum amino acids were determined among insulin-sensitive, insulin-resistant, and type 2 diabetic (T2DM) individuals. In all subjects, glycine (Gly) had the strongest correlation with GDR (positive association), followed by leucine/isoleucine (Leu/Ile) (negative association). These relationships were dramatically influenced by BMI, the resting respiratory quotient (RQ), T2DM, and sex. Gly had a strong positive correlation with GDR regardless of BMI, RQ, or sex but became nonsignificant in T2DM. In contrast, Leu/Ile was negatively associated with GDR in nonobese and T2DM subjects. Increased resting fat metabolism (i.e., low RQ) and obesity were observed to independently promote and negate the association between Leu/Ile and insulin resistance, respectively. Additionally, the relationship between Leu/Ile and GDR was magnified in T2DM males. Future studies are needed to determine whether Gly has a mechanistic role in glucose homeostasis and whether dietary Gly enrichment may be an effective intervention in diseases characterized by insulin resistance. C1 [Thalacker-Mercer, Anna E.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [Thalacker-Mercer, Anna E.; Ingram, Katherine H.; Guo, Fangjian; Garvey, W. Timothy] Univ Alabama Birmingham, Birmingham, AL USA. [Thalacker-Mercer, Anna E.; Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Thalacker-Mercer, Anna E.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA. [Ingram, Katherine H.] Kennesaw State Univ, Dept Exercise Sci & Sport Management, Kennesaw, GA USA. [Ilkayeva, Olga; Newgard, Christopher B.] Duke Univ, Dept Med, Durham, NC USA. [Newgard, Christopher B.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. EM garveyt@uab.edu RI Guo, Fangjian/B-7705-2015 OI Guo, Fangjian/0000-0003-3729-2724 FU National Institutes of Health [DK-038765, DK-083562, P01 HL-55782, P01 DK58398]; Merit Review program of the Department of Veterans Affairs; University of Alabama at Birmingham (UAB) Center for Clinical and Translational Science [UL1 RR025777]; Nutrition and Obesity Research Center [P30-DK-56336]; UAB Diabetes Research and Training Center [P60 DK-079626] FX This work was supported by grants from the National Institutes of Health (DK-038765, DK-083562, P01 HL-55782, and P01 DK58398 to W.T.G.) and the Merit Review program (to W.T.G.) of the Department of Veterans Affairs. The authors also acknowledge support from the University of Alabama at Birmingham (UAB) Center for Clinical and Translational Science (UL1 RR025777), the Nutrition and Obesity Research Center (P30-DK-56336), and the UAB Diabetes Research and Training Center (P60 DK-079626). NR 36 TC 19 Z9 19 U1 0 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2014 VL 63 IS 2 BP 791 EP 800 DI 10.2337/db13-0396 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AA5BG UT WOS:000331110000044 PM 24130332 ER PT J AU Gellad, WF AF Gellad, Walid F. TI Targeted Cancer Therapy: From Bench to Bedside to Patient SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID CHRONIC MYELOID-LEUKEMIA; MEDICATION ADHERENCE; BREAST-CANCER; NONADHERENCE; IMATINIB; COST; IBRUTINIB; OUTCOMES; AGENTS; WOMEN C1 Univ Pittsburgh, Ctr Hlth Equity Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. RP Gellad, WF (reprint author), Univ Pittsburgh, Ctr Hlth Equity Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. EM walid.gellad@va.gov NR 28 TC 1 Z9 1 U1 0 U2 8 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2014 VL 32 IS 4 BP 268 EP 270 DI 10.1200/JCO.2013.53.8413 PG 3 WC Oncology SC Oncology GA AA4LH UT WOS:000331066600002 PM 24366939 ER PT J AU Fenske, TS Zhang, MJ Carreras, J Ayala, E Burns, LJ Cashen, A Costa, LJ Freytes, CO Gale, RP Hamadani, M Holmberg, LA Inwards, DJ Lazarus, HM Maziarz, RT Munker, R Perales, MA Rizzieri, DA Schouten, HC Smith, SM Waller, EK Wirk, BM Laport, GG Maloney, DG Montoto, S Hari, PN AF Fenske, Timothy S. Zhang, Mei-Jie Carreras, Jeanette Ayala, Ernesto Burns, Linda J. Cashen, Amanda Costa, Luciano J. Freytes, Cesar O. Gale, Robert P. Hamadani, Mehdi Holmberg, Leona A. Inwards, David J. Lazarus, Hillard M. Maziarz, Richard T. Munker, Reinhold Perales, Miguel-Angel Rizzieri, David A. Schouten, Harry C. Smith, Sonali M. Waller, Edmund K. Wirk, Baldeep M. Laport, Ginna G. Maloney, David G. Montoto, Silvia Hari, Parameswaran N. TI Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID INTERNATIONAL PROGNOSTIC INDEX; PROSPECTIVE RANDOMIZED-TRIAL; MARROW TRANSPLANT; INDUCTION REGIMEN; IMPROVES RESPONSE; FOLLOW-UP; PHASE-II; SURVIVAL; RITUXIMAB; IMMUNOCHEMOTHERAPY AB Purpose To examine the outcomes of patients with chemotherapy-sensitive mantle-cell lymphoma (MCL) following a first hematopoietic stem-cell transplantation (HCT), comparing outcomes with autologous (auto) versus reduced-intensity conditioning allogeneic (RIC allo) HCT and with transplantation applied at different times in the disease course. Patients and Methods In all, 519 patients who received transplantations between 1996 and 2007 and were reported to the Center for International Blood and Marrow Transplant Research were analyzed. The early transplantation cohort was defined as those patients in first partial or complete remission with no more than two lines of chemotherapy. The late transplantation cohort was defined as all the remaining patients. Results Auto-HCT and RIC allo-HCT resulted in similar overall survival from transplantation for both the early (at 5 years: 61% auto-HCT v 62% RIC allo-HCT; P = .951) and late cohorts (at 5 years: 44% auto-HCT v 31% RIC allo-HCT; P = .202). In both early and late transplantation cohorts, progression/relapse was lower and nonrelapse mortality was higher in the allo-HCT group. Overall survival and progression-free survival were highest in patients who underwent auto-HCT in first complete response. Multivariate analysis of survival from diagnosis identified a survival benefit favoring early HCT for both auto-HCT and RIC allo-HCT. Conclusion For patients with chemotherapy-sensitive MCL, the optimal timing for HCT is early in the disease course. Outcomes are particularly favorable for patients undergoing auto-HCT in first complete remission. For those unable to achieve complete remission after two lines of chemotherapy or those with relapsed disease, either auto-HCT or RIC allo-HCT may be effective, although the chance for long-term remission and survival is lower. C1 [Fenske, Timothy S.; Hamadani, Mehdi] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Zhang, Mei-Jie; Carreras, Jeanette; Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Ayala, Ernesto] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Wirk, Baldeep M.] Shands Healthcare, Gainesville, FL USA. [Wirk, Baldeep M.] Univ Florida, Gainesville, FL USA. [Burns, Linda J.] Univ Minnesota, Med Ctr, Fairview, Minneapolis, MN 55455 USA. [Inwards, David J.] Mayo Clin Rochester, Rochester, MN USA. [Cashen, Amanda] Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO USA. [Costa, Luciano J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Freytes, Cesar O.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Gale, Robert P.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England. [Montoto, Silvia] Queen Mary Univ London, Barts Canc Inst, London, England. [Holmberg, Leona A.; Maloney, David G.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Munker, Reinhold] Louisiana State Univ, Hlth Sci Ctr Shreveport, Shreveport, LA 71105 USA. [Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Rizzieri, David A.] Duke Univ, Med Ctr, Durham, NC USA. [Schouten, Harry C.] Acad Ziekenhuis Maastricht, Maastricht, Netherlands. [Smith, Sonali M.] Univ Chicago Hosp, Chicago, IL 60637 USA. [Waller, Edmund K.] Emory Univ Hosp, Atlanta, GA 30322 USA. [Laport, Ginna G.] Stanford Hosp & Clin, Stanford, CA USA. RP Fenske, TS (reprint author), Med Coll Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA. EM tfenske@mcw.edu OI Hari, Parameswaran/0000-0002-8800-297X FU Otsuka American Pharmaceutical; Merck; Millennium Pharmaceuticals; sanofi-aventis; Seattle Genetics; Genentech FX Cesar O. Freytes, Otsuka American Pharmaceutical, Merck; Leona A. Holmberg, Millennium Pharmaceuticals, Merck, Otsuka American Pharmaceutical, sanofi-aventis, Seattle Genetics; Silvia Montoto, Genentech NR 29 TC 25 Z9 27 U1 1 U2 5 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD FEB 1 PY 2014 VL 32 IS 4 BP 273 EP + DI 10.1200/JCO.2013.49.2454 PG 11 WC Oncology SC Oncology GA AA4LH UT WOS:000331066600004 PM 24344210 ER PT J AU Williams, JLS Egede, LE AF Williams, Joni L. Strom Egede, Leonard E. TI Nontraditional Risk Factors as Mediators of Racial Differences in Diabetes Risk SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID DEPRESSION; ASSOCIATION; TYPE-2 C1 [Williams, Joni L. Strom; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Williams, Joni L. Strom; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston VA HSR&D COIN, Charleston, VA USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [K24DK093699, K24 DK093699, R01 DK098529, R01DK098529] NR 10 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 271 EP 272 DI 10.1007/s11606-013-2650-7 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500004 PM 24129857 ER PT J AU Kangovi, S Barg, FK Carter, T Levy, K Sellman, J Long, JA Grande, D AF Kangovi, Shreya Barg, Frances K. Carter, Tamala Levy, Kathryn Sellman, Jeffrey Long, Judith A. Grande, David TI Challenges Faced by Patients with Low Socioeconomic Status During the Post-Hospital Transition SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE post-hospital transition; disparities; goal-setting ID HEART-FAILURE; HEALTH-CARE; TASK-PERFORMANCE; FOLLOW-UP; OUTCOMES; RISK; REHOSPITALIZATION; READMISSIONS; EXPERIENCES; MOTIVATION AB Patients with low socioeconomic status (low-SES) are at risk for poor outcomes during the post-hospital transition. Few prior studies explore perceived reasons for poor outcomes from the perspectives of these high-risk patients. We explored low-SES patients' perceptions of hospitalization, discharge and post-hospital transition in order to generate hypotheses and identify common experiences during this transition. We conducted a qualitative study using in-depth semi-structured interviewing. We interviewed 65 patients who were: 1) uninsured, insured by Medicaid or dually eligible for Medicaid and Medicare; 2) residents of five low-income ZIP codes; 3) had capacity or a caregiver who could be interviewed as a proxy; and 4) hospitalized on the general medicine or cardiology services of two academically affiliated urban hospitals. Our interview guide investigated patients' perceptions of hospitalization, discharge and the post-hospital transition, and their performance of recommended post-hospital health behaviors related to: 1) experience of hospitalization and discharge; 2) external constraints on patients' ability to execute discharge instructions; 3) salience of health behaviors; and 4) self-efficacy to execute discharge instructions. We used a modified grounded theory approach to analysis. We identified six themes that low-SES patients shared in their narratives of hospitalization, discharge and post-hospital transition. These were: 1) powerlessness during hospitalization due to illness and socioeconomic factors; 2) misalignment of patient and care team goals; 3) lack of saliency of health behaviors due to competing issues; 4) socioeconomic constraints on patients' ability to perform recommended behaviors; 5) abandonment after discharge; and 6) loss of self-efficacy resulting from failure to perform recommended behaviors. Low-SES patients describe discharge goals that are confusing, unrealistic in the face of significant socioeconomic constraints, and in conflict with their own immediate goals. We hypothesize that this goal misalignment leads to a cycle of low achievement and loss of self-efficacy that may underlie poor post-hospital outcomes among low-SES patients. C1 [Kangovi, Shreya; Long, Judith A.] PhiladelphiaVet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Sellman, Jeffrey] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Levy, Kathryn; Long, Judith A.; Grande, David] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Long, Judith A.; Grande, David] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Barg, Frances K.; Carter, Tamala] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Kangovi, Shreya; Carter, Tamala] Univ Penn Hlth Syst, Penn Ctr Community Hlth Workers, Philadelphia, PA USA. RP Kangovi, S (reprint author), PhiladelphiaVet Affairs Med Ctr, 13th Floor Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kangovi@mail.med.upenn.edu OI Levy, Kathryn/0000-0003-1646-729X FU Leonard Davis Institute of Health Economics at the University of Pennsylvania FX This study was supported by the Leonard Davis Institute of Health Economics at the University of Pennsylvania. NR 37 TC 27 Z9 27 U1 2 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 283 EP 289 DI 10.1007/s11606-013-2571-5 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500011 PM 23918162 ER PT J AU Feingold, KR AF Feingold, Kenneth R. TI Capsule Commentary on Radin, Pitfalls in Hemoglobin A1c Measurement: When Results May Be Misleading SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID COMPLICATIONS C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Feingold, KR (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Kenneth.feingold@ucsf.edu NR 5 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2014 VL 29 IS 2 BP 363 EP 363 DI 10.1007/s11606-013-2632-9 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA AA2WS UT WOS:000330955500028 PM 24065382 ER PT J AU Krishna, V Andrews, H Varma, A Mintzer, J Kindy, MS Guest, J AF Krishna, Vibhor Andrews, Hampton Varma, Abhay Mintzer, Jacobo Kindy, Mark S. Guest, James TI Spinal Cord Injury: How Can We Improve the Classification and Quantification of Its Severity and Prognosis? SO JOURNAL OF NEUROTRAUMA LA English DT Review ID MOTOR-EVOKED-POTENTIALS; TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; CERVICAL SPONDYLOTIC MYELOPATHY; INTRATHECAL OXYGEN-TENSION; BLOOD-PRESSURE MANAGEMENT; PROTON MR SPECTROSCOPY; NEUROFILAMENT NF-H; ONE-YEAR EVOLUTION; INTERNATIONAL STANDARDS C1 [Krishna, Vibhor; Andrews, Hampton; Varma, Abhay; Mintzer, Jacobo; Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Mintzer, Jacobo; Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Guest, James] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA. [Guest, James] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA. RP Guest, J (reprint author), Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA. EM kindyms@musc.edu; jguest@med.miami.edu FU National Institutes of Health [ES016774]; VA Merit Review [RX000331]; NSF EPSCoR [EPS-0903795]; Institutional Development Award (IdeA, COBRE) from the National Institute of General Medical Sciences [P20GM103444]; clinical trials program of the Miami Project to Cure Paralysis FX We gratefully acknowledge the assistance of the Department of Neurosciences and the Veteran Affairs for the continued support of our research. Support was partially provided by the National Institutes of Health grant ES016774, VA Merit Review RX000331, NSF EPSCoR grant EPS-0903795 and Institutional Development Award (IdeA, COBRE) from the National Institute of General Medical Sciences grant P20GM103444 to Dr. Kindy. Dr. Guest received support from the clinical trials program of the Miami Project to Cure Paralysis. NR 144 TC 8 Z9 8 U1 0 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD FEB 1 PY 2014 VL 31 IS 3 BP 215 EP 227 PG 13 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA AA4RT UT WOS:000331084500001 PM 23895105 ER PT J AU Primack, BA Douglas, EL Land, SR Miller, E Fine, MJ AF Primack, Brian A. Douglas, Erika L. Land, Stephanie R. Miller, Elizabeth Fine, Michael J. TI Comparison of Media Literacy and Usual Education to Prevent Tobacco Use: A Cluster-Randomized Trial SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE adolescents; attitudes; media education; media literacy; normative beliefs; school-based; smoking; social influences; tobacco; youth ID LOW HEALTH LITERACY; ADOLESCENT SMOKING; CIGARETTE-SMOKING; VIEWING SMOKING; ASSOCIATION; MOVIES; INITIATION; EXPOSURE; CHILDREN; ALCOHOL AB BACKGROUNDMedia literacy programs have shown potential for reduction of adolescent tobacco use. We aimed to determine if an anti-smoking media literacy curriculum improves students' media literacy and affects factors related to adolescent smoking. METHODSWe recruited 1170 9th-grade students from 64 classrooms in 3 public urban high schools. Students were randomized by classroom to a media literacy curriculum versus a standard educational program. In an intent-to-treat analysis, we used multilevel modeling to determine if changes in study outcomes were associated with the curricular intervention, controlling for baseline student covariates and the clustering of students within classrooms. RESULTSAmong participants, mean age was 14.5 years and 51% were male, with no significant differences in baseline characteristics between groups. Smoking media literacy changed more among intervention participants compared with control participants (0.24 vs. 0.08, p < .001). Compared with controls, intervention students exhibited a greater reduction in the perceived prevalence of smoking (-14.0% vs. -4.6%, p < .001). Among those initially susceptible to smoking, intervention participants more commonly reverted to being nonsusceptible post-intervention (24% vs. 16%, p = .08). CONCLUSIONSA school-based media literacy curriculum is more effective than a standard educational program in teaching media literacy and improving perceptions of the true prevalence of smoking among adolescents. C1 [Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Douglas, Erika L.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15219 USA. [Land, Stephanie R.] NCI, NIH, Bethesda, MD 20892 USA. [Miller, Elizabeth] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15213 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, 230 McKee Pl Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu; douglasel@upmc.edu; stephanie.land@nih.gov; elizabeth.miller@chp.edu; finemj@upmc.edu FU Maurice Falk Foundation; Robert Wood Johnson Foundation; National Cancer Institute [K07-CA114315] FX B.A.P. was supported in part by a grant from the Maurice Falk Foundation, a Physician Faculty Scholar Award from the Robert Wood Johnson Foundation, and a career development award from the National Cancer Institute (K07-CA114315). NR 45 TC 5 Z9 5 U1 2 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD FEB PY 2014 VL 84 IS 2 BP 106 EP 115 DI 10.1111/josh.12130 PG 10 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA AA0KN UT WOS:000330784100005 PM 25099425 ER PT J AU Bhatia, S AF Bhatia, Sameer TI Lost in Translation? Error in Review Article in October JVIR SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Letter C1 Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Bhatia, S (reprint author), Birmingham VA Med Ctr, 700 South 19th St, Birmingham, AL 35233 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD FEB PY 2014 VL 25 IS 2 BP 325 EP 325 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA AA2KU UT WOS:000330924300023 PM 24461135 ER PT J AU Arthur, JM Hill, EG Alge, JL Lewis, EC Neely, BA Janech, MG Tumlin, JA Chawla, LS Shaw, AD AF Arthur, John M. Hill, Elizabeth G. Alge, Joseph L. Lewis, Evelyn C. Neely, Benjamin A. Janech, Michael G. Tumlin, James A. Chawla, Lakhmir S. Shaw, Andrew D. CA SAKInet Investigators TI Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery SO KIDNEY INTERNATIONAL LA English DT Article DE acute kidney injury; clinical nephrology; hemodialysis; outcomes; renal injury; statistics ID GELATINASE-ASSOCIATED LIPOCALIN; POOR OUTCOMES; RISK; AKI AB Biomarkers for acute kidney injury (AKI) have been used to predict the progression of AKI, but a systematic comparison of the prognostic ability of each biomarker alone or in combination has not been performed. In order to assess this, we measured the concentration of 32 candidate biomarkers in the urine of 95 patients with AKIN stage 1 after cardiac surgery. Urine markers were divided into eight groups based on the putative pathophysiological mechanism they reflect. We then compared the ability of the markers alone or in combination to predict the primary outcome of worsening AKI or death (23 patients) and the secondary outcome of AKIN stage 3 or death (13 patients). IL-18 was the best predictor of both outcomes (AUC of 0.74 and 0.89). L-FABP (AUC of 0.67 and 0.85), NGAL (AUC of 0.72 and 0.83), and KIM-1 (AUC of 0.73 and 0.81) were also good predictors. Correlation between most of the markers was generally related to their predictive ability, but KIM-1 had a relatively weak correlation with other markers. The combination of IL-18 and KIM-1 had a very good predictive value with an AUC of 0.93 to predict AKIN 3 or death. Thus, a combination of IL-18 and KIM-1 would result in improved identification of high-risk patients for enrollment in clinical trials. C1 [Arthur, John M.; Janech, Michael G.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA. [Arthur, John M.; Alge, Joseph L.; Lewis, Evelyn C.; Neely, Benjamin A.; Janech, Michael G.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Hill, Elizabeth G.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Tumlin, James A.] Univ Tennessee, Dept Med, Chattanooga, TN USA. [Chawla, Lakhmir S.] George Washington Univ, Dept Med, Washington, DC USA. [Chawla, Lakhmir S.] George Washington Univ, Dept Anesthesiol, Washington, DC USA. [Chawla, Lakhmir S.] George Washington Univ, Dept Crit Care Med, Washington, DC USA. [Shaw, Andrew D.] Durham VA Med Ctr, Dept Anesthesiol, Durham, NC USA. [Shaw, Andrew D.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA. RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Box 250623, Charleston, SC 29425 USA. EM arthurj@musc.edu OI Neely, Benjamin/0000-0001-6120-7695; Alge, Joseph/0000-0002-2491-1066; Janech, Michael/0000-0002-3202-4811 FU NIH [R01DK080234]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs FX This work was supported by an NIH grant number R01DK080234 and a VA Merit Award from the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. The contents do not necessarily represent the views of the Department of Veterans Affairs or the US Government. Additional members of the SAKInet consortium (www.sakinet.org): Medical University of South Carolina, Nithin Karakala, Juan Carlos Q Velez, Milos N Budisavljevic, Rick G Schnellmann; Vanderbilt University, Frederick T (Josh) Billings, Edward D Siew, and T Alp Ikizler. NR 24 TC 32 Z9 32 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2014 VL 85 IS 2 BP 431 EP 438 DI 10.1038/ki.2013.333 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AA5QV UT WOS:000331155600028 PM 24005224 ER PT J AU Baxter, P Chen, YT Xu, Y Swanson, RA AF Baxter, Paul Chen, Yanting Xu, Yun Swanson, Raymond A. TI Mitochondrial Dysfunction Induced by Nuclear Poly(ADP-Ribose) Polymerase-1: a Treatable Cause of Cell Death in Stroke SO TRANSLATIONAL STROKE RESEARCH LA English DT Review DE Ischemia; Mitochondrial depolarization; Mitochondrial permeability transition; Poly(ADP-ribose) polymerase-1; NAD(+); Apoptosis-inducing factor ID FOCAL CEREBRAL-ISCHEMIA; METHYL-D-ASPARTATE; HYPOGLYCEMIC NEURONAL DEATH; TRANSIENT FOREBRAIN ISCHEMIA; PERMEABILITY TRANSITION; GAMMA-HYDROXYBUTYRATE; ARTERY OCCLUSION; RAT-BRAIN; NITRIC-OXIDE; COGNITIVE IMPAIRMENT AB Many drugs targeting excitotoxic cell death have demonstrated robust neuroprotective effects in animal models of cerebral ischemia. However, these neuroprotective effects have almost universally required drug administration at relatively short time intervals after ischemia onset. This finding has translated to clinical trial results; interventions targeting excitotoxicity have had no demonstrable efficacy when initiated hours after ischemia onset, but beneficial effects have been reported with more rapid initiation. Consequently, there continues to be a need for interventions with efficacy at later time points after ischemia. Here, we focus on mitochondrial dysfunction as both a relatively late event in ischemic neuronal death and a recognized cause of delayed neuronal death. Activation of poly(ADP-ribose) polymerase-1 (PARP-1) is a primary cause of mitochondrial depolarization and subsequent mitochondria-triggered cell death in ischemia reperfusion. PARP-1 consumes cytosolic NAD(+), thereby blocking both glycolytic ATP production and delivery of glucose carbon to mitochondria for oxidative metabolism. However, ketone bodies such as pyruvate, beta- and gamma-hydroxybutyrate, and 1,4-butanediol can fuel mitochondrial metabolism in cells with depleted cytosolic NAD(+) as long as the mitochondria remain functional. Ketone bodies have repeatedly been shown to be highly effective in preventing cell death in animal models of ischemia, but a rigorous study of the time window of opportunity for this approach remains to be performed. C1 [Baxter, Paul; Chen, Yanting; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Baxter, Paul; Chen, Yanting; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA 94121 USA. [Chen, Yanting; Xu, Yun] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurol, Nanjing 210008, Jiangsu, Peoples R China. RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA. EM Raymond.swanson@ucsf.edu OI Swanson, Raymond/0000-0002-3664-5359 FU Chinese Research Scholarship Council; U.S. National Institutes of Health [NS041421]; U.S. Department of Veterans Affairs FX This work was supported by the Chinese Research Scholarship Council (Y.C.), the U.S. National Institutes of Health (grant no. NS041421, R.A.S.), and the U.S. Department of Veterans Affairs. NR 90 TC 17 Z9 17 U1 0 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD FEB PY 2014 VL 5 IS 1 BP 136 EP 144 DI 10.1007/s12975-013-0283-0 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA2TO UT WOS:000330947200013 PM 24323707 ER PT J AU Carreno, FR Frazer, A AF Carreno, Flavia Regina Frazer, Alan TI Activation of signaling pathways downstream of the brain-derived neurotrophic factor receptor, TrkB, in the rat brain by vagal nerve stimulation and antidepressant drugs SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Article DE Antidepressants; desipramine; sertraline; TrkB; vagal nerve stimulation ID TREATMENT-RESISTANT DEPRESSION; PHARMACOLOGICALLY DIVERSE ANTIDEPRESSANTS; CHRONIC MILD STRESS; NEURONAL PLASTICITY; FACTOR EXPRESSION; MAJOR DEPRESSION; CREB ACTIVATION; GENE-EXPRESSION; MESSENGER-RNA; MOUSE-BRAIN AB Vagal nerve stimulation (VNS) has been approved for treatment resistant depression (TRD) by the Food and Drug Administration (FDA) since 2005. However, the cellular and molecular targets responsible for its effects are still not characterized. Previously, chronic administration of VNS to rats was found to phosphorylate tyrosine 515 on TrkB, the neurotrophin receptor, whereas traditional antidepressants did not do this. In the present study, Western blot analysis was used to characterize activation due to phosphorylation in the hippocampus of down-stream pathways linked to specific key tyrosine residues on TrkB (namely Y816 and Y515) after either acute or chronic administration of VNS and traditional antidepressant drugs. Chronic administration of VNS caused phosphorylation of effectors linked to Y 515; namely Akt, ERK and p70S6 kinase, but this was not produced by either desipramine or sertraline. All the treatments, when given chronically, caused phosphorylation of the transcription factor, CREB. Acute administration of all the treatments also caused phosphorylation of PLC1 but this was not maintained with chronic treatment. Further research is required to determine what role, if any, activation of down-stream targets of Y515 plays in the behavioural effects of VNS. C1 [Carreno, Flavia Regina; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Frazer, Alan] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Carreno, FR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM carreno@uthscsa.edu FU NIMH [MH082933] FX This work was supported by NIMH grant MH082933 (A.F). The electrodes, VNS stimulators and dummy stimulators were gifts from Cyberonics Inc. NR 68 TC 8 Z9 9 U1 1 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD FEB PY 2014 VL 17 IS 2 BP 247 EP 258 DI 10.1017/S1461145713000977 PG 12 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 302HL UT WOS:000330594200007 PM 24103847 ER PT J AU Makam, AN Lanham, HJ Batchelor, K Moran, B Howell-Stampley, T Kirk, L Cherukuri, M Samal, L Santini, N Leykum, LK Halm, EA AF Makam, Anil N. Lanham, Holly J. Batchelor, Kim Moran, Brett Howell-Stampley, Temple Kirk, Lynne Cherukuri, Manjula Samal, Lipika Santini, Noel Leykum, Luci K. Halm, Ethan A. TI The good, the bad and the early adopters: providers' attitudes about a common, commercial EHR SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE LA English DT Article DE attitude of health personnel; attitude to computers; early adopter; electronic health record; physicians; primary care; primary health care ID ELECTRONIC HEALTH RECORDS; INFORMATION-TECHNOLOGY; AMBULATORY-CARE; USER ACCEPTANCE; MEDICAL-RECORDS; QUALITY; IMPACT; PHYSICIANS; BARRIERS; TRENDS AB Rationale, aims and objectivesTo describe primary care providers' (PCP) attitudes about the impact of a mature, commercial electronic health records (EHR) on clinical practice in settings with experience using the system and to evaluate whether a provider's propensity to adopt new technologies is associated with more favourable perceptions. MethodWe surveyed PCPs in 11 practices affiliated with three health systems in Texas. Most practices had greater than 5 years of experience with the Epic EHR. The effect of early adopter of technology status was evaluated using logistic regression. ResultsOne hundred forty-six PCPs responded (70%). Most thought the EHR had a positive impact on routine tasks, such as prescription refills (94%), whereas fewer agreed for complex tasks, such as delivery of guideline-concordant care for chronic illnesses (51%). Two-thirds (62%) thought it interfered with eye contact with patients, and 40% reported that it interfered with in-visit communication. Early adopters of technology reported greater positive effects of the EHR, even after adjusting for age, ranging from 2% to 15% higher on satisfaction ratings. ConclusionPCPs practicing in settings with considerable experience using a common commercial EHR identified many positive effects, as well as two key areas for improvement - patient centredness and intelligent decision support. Providers with a propensity to adopt new technologies have more favourable perceptions of the EHR. C1 [Makam, Anil N.; Batchelor, Kim; Moran, Brett; Howell-Stampley, Temple; Kirk, Lynne; Halm, Ethan A.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA. [Lanham, Holly J.; Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, San Antonio, TX 78229 USA. [Lanham, Holly J.; Leykum, Luci K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Cherukuri, Manjula] Univ N Texas, Hlth Sci Ctr, Dept Family & Community Med, Ft Worth, TX USA. [Samal, Lipika] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA. [Santini, Noel] Parkland Hlth & Hosp Syst, Community Med Div, Dallas, TX USA. RP Makam, AN (reprint author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM anil.makam@utsouthwestern.edu OI Makam, Anil/0000-0001-7072-9946 FU University of Texas; NRSA [T32HP19025-07-00] FX We would like to thank the primary care providers who participated in this study. This study was supported by a grant from the University of Texas Chancellors Fellow for Health Information Technology program (PI, Halm). Much of Dr. Makam's work on this project was completed while he was a Primary Care Research Fellow at the University of California San Francisco, funded by an NRSA training grant (T32HP19025-07-00). We have no conflicts of interest to disclose. The design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication were solely the discretion of the authors. Preliminary results of this study were presented at the Society of General Internal Medicine annual meeting in Orlando, Florida, in 2012. NR 21 TC 11 Z9 11 U1 1 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1356-1294 EI 1365-2753 J9 J EVAL CLIN PRACT JI J. Eval. Clin. Pract. PD FEB PY 2014 VL 20 IS 1 BP 36 EP 42 DI 10.1111/jep.12076 PG 7 WC Health Care Sciences & Services; Medical Informatics; Medicine, General & Internal SC Health Care Sciences & Services; Medical Informatics; General & Internal Medicine GA AA0QQ UT WOS:000330802100006 PM 23962319 ER PT J AU Hage, FG AF Hage, Fadi G. TI Left ventricular mechanical dyssynchrony by phase analysis as a prognostic indicator in heart failure SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID CARDIAC-RESYNCHRONIZATION THERAPY; BUNDLE-BRANCH BLOCK; ASSOCIATION; DYSFUNCTION; GUIDELINES; UPDATE; CRT C1 Univ Alabama Birmingham, Div Cardiovascular Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 23 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2014 VL 21 IS 1 BP 67 EP 70 DI 10.1007/s12350-013-9822-z PG 4 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AA0MI UT WOS:000330788800008 PM 24272972 ER PT J AU Hage, FG Aggarwal, H Patel, K Chen, J Jacobson, AF Heo, J Ahmed, A Iskandrian, AE AF Hage, Fadi G. Aggarwal, Himanshu Patel, Kanan Chen, Ji Jacobson, Arnold F. Heo, Jaekyeong Ahmed, Ali Iskandrian, Ami E. TI The relationship of left ventricular mechanical dyssynchrony and cardiac sympathetic denervation to potential sudden cardiac death events in systolic heart failure SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Dyssynchrony; heart failure; MIBG; phase analysis; sudden cardiac death ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; PHASE-ANALYSIS; NUCLEAR CARDIOLOGY; PROGNOSTIC VALUE; TASK-FORCE; RISK; COLLABORATION; GUIDELINES; DIAGNOSIS; SOCIETY AB Patients with heart failure (HF) are at increased risk for left ventricular (LV) dyssynchrony which is associated with sudden cardiac death (SCD). This study examined the association of LV mechanical dyssynchrony and cardiac sympathetic denervation with potential SCD events in symptomatic patients with HF and reduced ejection fraction (HFrEF). Of the 917 HFrEF patients in ADMIRE-HF, 92 experienced adjudicated potential SCD events during a 17 months median follow-up. Propensity scores were used to assemble a matched cohort of 85 pairs of patients with and without potential SCD events. ADMIRE-HF subjects had rest gated SPECT Tc-99m and I-123 MIBG imaging. Perfusion images were processed using phase analysis software to derive phase standard deviation (SD), an index of mechanical dyssynchrony. Of the 92 patients who experienced adjudicated potential SCD events 23 had SCD, 5 fatal myocardial infarction, 7 resuscitated cardiac arrest, 46 had appropriate ICD therapy, and 11 had sustained ventricular tachycardia. Patients who experienced potential SCD events had significantly wider phase SD than matched control patients (62.3 +/- A 2.4A(0) vs 55.5 +/- A 2.3A(0), P = .03) and were more likely to have a phase SD a parts per thousand yen 60A(0) (53 % vs 35 %, P = .03). Fewer patients with potential SCD events (6 % vs 15 % of the controls, P = .08) had an MIBG heart/mediastinum uptake-ratio a parts per thousand yen1.6. Among symptomatic HFrEF patients, LV mechanical dyssynchrony is independently associated with potential SCD events. Phase analysis may provide incremental prognostic information on top of current indicators of SCD risk in HFrEF. C1 [Hage, Fadi G.; Aggarwal, Himanshu; Patel, Kanan; Heo, Jaekyeong; Ahmed, Ali; Iskandrian, Ami E.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Hage, Fadi G.; Ahmed, Ali] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Chen, Ji] Emory Univ, Atlanta, GA 30322 USA. [Jacobson, Arnold F.] GE Healthcare, Princeton, NJ USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Zeigler Res Bldg 1024,703 19th St South, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU GE Healthcare FX This study was supported by an investigator initiated Grant by GE Healthcare. Dr Jacobson is an employee of GE Healthcare. NR 23 TC 10 Z9 10 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2014 VL 21 IS 1 BP 78 EP 85 DI 10.1007/s12350-013-9807-y PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA AA0MI UT WOS:000330788800010 PM 24170623 ER PT J AU Dzierzewski, JM Buman, MP Giacobbi, PR Roberts, BL Aiken-Morgan, AT Marsiske, M McCrae, CS AF Dzierzewski, Joseph M. Buman, Matthew P. Giacobbi, Peter R., Jr. Roberts, Beverly L. Aiken-Morgan, Adrienne T. Marsiske, Michael McCrae, Christina S. TI Exercise and sleep in community-dwelling older adults: evidence for a reciprocal relationship SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE daily associations; elderly; exercise; older adults; reciprocal relationships; sleep ID RANDOMIZED CONTROLLED-TRIAL; MODERATE-INTENSITY EXERCISE; PHYSICAL-ACTIVITY; QUALITY; MAINTENANCE AB Exercise behaviour and sleep are both important health indicators that demonstrate significant decreases with age, and remain modifiable well into later life. The current investigation examined both the chronic and acute relationships between exercise behaviour and self-reported sleep in older adults through a secondary analysis of a clinical trial of a lifestyle intervention. Seventy-nine community-dwelling, initially sedentary, older adults (mean age=63.58years, SD=8.66years) completed daily home-based assessments of exercise behaviour and sleep using daily diary methodology. Assessments were collected weekly and continued for 18 consecutive weeks. Multilevel models revealed a small positive chronic (between-person mean-level) association between exercise and wake time after sleep onset, and a small positive acute (within-person, day-to-day) association between exercise and general sleep quality rating. The within-person exercise and general sleep quality rating relationship was found to be reciprocal (i.e. sleep quality also predicted subsequent exercise behaviour). As such, it appears exercise and sleep are dynamically related in older adults. Efforts to intervene on either sleep or exercise in late-life would be wise to take the other into account. Light exposure, temperature regulation and mood may be potential mechanisms of action through which exercise can impact sleep in older adults. C1 [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Buman, Matthew P.] Arizona State Univ, Phoenix, AZ USA. [Giacobbi, Peter R., Jr.] W Virginia Univ, Morgantown, WV 26506 USA. [Roberts, Beverly L.; Marsiske, Michael; McCrae, Christina S.] Univ Florida, Gainesville, FL USA. [Aiken-Morgan, Adrienne T.] Duke Univ, Med Ctr, Durham, NC USA. RP Dzierzewski, JM (reprint author), Greater Los Angeles Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. EM Joseph.Dzierzewski@va.gov OI Marsiske, Michael/0000-0001-5973-2116; McCrae, Christina/0000-0003-4313-6867 FU National Institute on Aging [1R36AG029664-01]; University of Florida; Research Opportunity Fund in the College of Health and Human Performance at the University of Florida; Department of Veterans Affairs Advanced Geriatrics Fellowship Program, an Institutional Training Grant [T32-AG-020499]; University of Florida by the National Institute on Aging, and an Individual Training Grant [F31-AG-032802]; Public Health Service Training Grant [5-T32-HL-007034]; National Heart, Lung, and Blood Institute; Institutional Training Grant [T32-AG000029]; National Institute on Aging FX This work was supported by the National Institute on Aging (1R36AG029664-01, PI: A. T. A.-M.), University of Florida (Age Network research award, PI: C. S. M.), and a Research Opportunity Fund in the College of Health and Human Performance at the University of Florida. J. M. D. was supported by the Department of Veterans Affairs Advanced Geriatrics Fellowship Program, an Institutional Training Grant, T32-AG-020499, awarded to the University of Florida by the National Institute on Aging, and an Individual Training Grant, F31-AG-032802, awarded by the National Institute on Aging. M. P. B. was supported by Public Health Service Training Grant, 5-T32-HL-007034, from the National Heart, Lung, and Blood Institute. A. T. A.-M. was supported by an Institutional Training Grant, T32-AG000029, to Duke University by the National Institute on Aging. None of the authors have declared a conflict of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding sources, nor were funding sources responsible for the design, methods, subject recruitment, data collection, analysis or preparation of paper. NR 30 TC 17 Z9 17 U1 5 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD FEB PY 2014 VL 23 IS 1 BP 61 EP 68 DI 10.1111/jsr.12078 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA0QD UT WOS:000330800200008 PM 23980920 ER PT J AU Cooper, DC Ziegler, MG Milic, MS Ancoli-Israel, S Mills, PJ Loredo, JS Von Kanel, R Dimsdale, JE AF Cooper, Denise C. Ziegler, Michael G. Milic, Milos S. Ancoli-Israel, Sonia Mills, Paul J. Loredo, Jose S. Von Kaenel, Roland Dimsdale, Joel E. TI Endothelial function and sleep: associations of flow-mediated dilation with perceived sleep quality and rapid eye movement (REM) sleep SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE endothelial function; polysomnography; sleep; subjective sleep quality; vasodilation ID CARDIOVASCULAR-DISEASE; BRACHIAL-ARTERY; HEALTHY-MEN; APNEA; INFLAMMATION; DYSFUNCTION; STRESS; ATHEROSCLEROSIS; INTERLEUKIN-6; VASODILATION AB Endothelial function typically precedes clinical manifestations of cardiovascular disease and provides a potential mechanism for the associations observed between cardiovascular disease and sleep quality. This study examined how subjective and objective indicators of sleep quality relate to endothelial function, as measured by brachial artery flow-mediated dilation (FMD). In a clinical research centre, 100 non-shift working adults (mean age: 36years) completed FMD testing and the Pittsburgh Sleep Quality Index, along with a polysomnography assessment to obtain the following measures: slow wave sleep, percentage rapid eye movement (REM) sleep, REM sleep latency, total arousal index, total sleep time, wake after sleep onset, sleep efficiency and apnea-hypopnea index. Bivariate correlations and follow-up multiple regressions examined how FMD related to subjective (i.e. Pittsburgh Sleep Quality Index scores) and objective (i.e. polysomnography-derived) indicators of sleep quality. After FMD showed bivariate correlations with Pittsburgh Sleep Quality Index scores, percentage REM sleep and REM latency, further examination with separate regression models indicated that these associations remained significant after adjustments for sex, age, race, hypertension, body mass index, apnea-hypopnea index, smoking and income (Ps<0.05). Specifically, as FMD decreased, scores on the Pittsburgh Sleep Quality Index increased (indicating decreased subjective sleep quality) and percentage REM sleep decreased, while REM sleep latency increased (Ps<0.05). Poorer subjective sleep quality and adverse changes in REM sleep were associated with diminished vasodilation, which could link sleep disturbances to cardiovascular disease. C1 [Cooper, Denise C.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Ziegler, Michael G.; Milic, Milos S.; Loredo, Jose S.; Dimsdale, Joel E.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Ancoli-Israel, Sonia; Mills, Paul J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Von Kaenel, Roland] Univ Hosp Bern, Inselspital, Dept Gen Internal Med, Div Psychosomat Med, CH-3010 Bern, Switzerland. [Von Kaenel, Roland] Univ Bern, Bern, Switzerland. RP Cooper, DC (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM denise.cooper3@va.gov FU National Institutes of Health [HL36005, RR00827, AG08415, P60 MD00220] FX This study was supported by National Institutes of Health Grants HL36005, RR00827, AG08415 and P60 MD00220. NR 30 TC 7 Z9 7 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD FEB PY 2014 VL 23 IS 1 BP 84 EP 93 DI 10.1111/jsr.12083 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AA0QD UT WOS:000330800200011 PM 24033699 ER PT J AU Contreras, MA Alzate, O Singh, AK Singh, I AF Contreras, Miguel A. Alzate, Oscar Singh, Avtar K. Singh, Inderjit TI PPAR alpha Activation Induces N (epsilon)-Lys-Acetylation of Rat Liver Peroxisomal Multifunctional Enzyme Type 1 SO LIPIDS LA English DT Article DE Peroxisome proliferator-activated receptor alpha (PPAR alpha); Lysine-acetylation; Acetylation; Peroxisomes; Rat peroxisomal multifunctional enzyme type 1 (rpMFE-1); Peroxisome proliferation ID ACYL-COA OXIDASE; YEAST YARROWIA-LIPOLYTICA; MOUSE KIDNEY PEROXISOMES; BETA-OXIDATION ENZYMES; QUANTITATIVE PROTEOMICS; BIOGENESIS DISORDERS; LYSINE ACETYLATION; CRYSTAL-STRUCTURE; RECEPTOR-ALPHA; PROTEIN AB Peroxisomes are ubiquitous subcellular organelles that participate in metabolic and disease processes, with few of its proteins undergoing posttranslational modifications. As the role of lysine-acetylation has expanded into the cellular intermediary metabolism, we used a combination of differential centrifugation, organelle isolation by linear density gradient centrifugation, western blot analysis, and peptide fingerprinting and amino acid sequencing by mass spectrometry to investigate protein acetylation in control and ciprofibrate-treated rat liver peroxisomes. Organelle protein samples isolated by density gradient centrifugation from PPAR alpha-agonist treated rat liver screened with an anti-N (epsilon)-acetyl lysine antibody revealed a single protein band of 75 kDa. Immunoprecipitation with this antibody resulted in the precipitation of a protein from the protein pool of ciprofibrate-induced peroxisomes, but not from the protein pool of non-induced peroxisomes. Peptide mass fingerprinting analysis identified the protein as the peroxisomal multifunctional enzyme type 1. In addition, mass spectrometry-based amino acid sequencing resulted in the identification of unique peptides containing 4 acetylated-Lys residues (K-155, K-173, K-190, and K-583). This is the first report that demonstrates posttranslational acetylation of a peroxisomal enzyme in PPAR alpha-dependent proliferation of peroxisomes in rat liver. C1 [Contreras, Miguel A.; Singh, Avtar K.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA. [Alzate, Oscar] Univ N Carolina, Dept Cell & Dev Biol, Syst Prote Core Lab, Chapel Hill, NC 27599 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Dept Pathol, Charleston, SC 29401 USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, 171 Ashley Ave, Charleston, SC 29425 USA. EM miguel.contreras@nih.gov; oscar.alzate@ttuhsc.edu; singhi@musc.edu FU National Center for Research Resources [C06 RR018823, C06 RR015455]; National Institutes of Health [NS-22576, NS-34741, NS-37766, NS-64195] FX The authors greatly appreciate the technical assistance of Ms. Joyce Bryan and Ms. Desiree Vonkollmar, and the help of Dr. Osamu Morinaga for raising the polyclonal antibodies against very long chain acyl-CoA synthetase. They also thank Antonio Contreras for reading the manuscript. This work was supported by Grants from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR018823 and C06 RR015455] and from the National Institutes of Health [NS-22576, NS-34741, NS-37766, and NS-64195]. NR 49 TC 0 Z9 0 U1 1 U2 4 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0024-4201 EI 1558-9307 J9 LIPIDS JI Lipids PD FEB PY 2014 VL 49 IS 2 BP 119 EP 131 DI 10.1007/s11745-013-3843-x PG 13 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA 304BS UT WOS:000330721100001 PM 24092543 ER PT J AU Haris, M Singh, A Cai, KJ Kogan, F McGarvey, J DeBrosse, C Zsido, GA Witschey, WRT Koomalsingh, K Pilla, JJ Chirinos, JA Ferrari, VA Gorman, JH Hariharan, H Gorman, RC Reddy, R AF Haris, Mohammad Singh, Anup Cai, Kejia Kogan, Feliks McGarvey, Jeremy DeBrosse, Catherine Zsido, Gerald A. Witschey, Walter R. T. Koomalsingh, Kevin Pilla, James J. Chirinos, Julio A. Ferrari, Victor A. Gorman, Joseph H. Hariharan, Hari Gorman, Robert C. Reddy, Ravinder TI A technique for in vivo mapping of myocardial creatine kinase metabolism SO NATURE MEDICINE LA English DT Article ID CARDIOVASCULAR MAGNETIC-RESONANCE; ENERGY PHOSPHATE METABOLITES; FAILING HUMAN MYOCARDIUM; CONTRAST; VIABILITY; EXCHANGE; MRI; SPECTROSCOPY; INFARCTION; QUANTIFICATION AB ATP derived from the conversion of phosphocreatine to creatine by creatine kinase provides an essential chemical energy source that governs myocardial contraction. Here, we demonstrate that the exchange of amine protons from creatine with protons in bulk water can be exploited to image creatine through chemical exchange saturation transfer (CrEST) in myocardial tissue. We show that CrEST provides about two orders of magnitude higher sensitivity compared to H-1 magnetic resonance spectroscopy. Results of CrEST studies from ex vivo myocardial tissue strongly correlate with results from 1H and P-31 magnetic resonance spectroscopy and biochemical analysis. We demonstrate the feasibility of CrEST measurement in healthy and infarcted myocardium in animal models in vivo on a 3-T clinical scanner. As proof of principle, we show the conversion of phosphocreatine to creatine by spatiotemporal mapping of creatine changes in the exercised human calf muscle. We also discuss the potential utility of CrEST in studying myocardial disorders. C1 [Haris, Mohammad; Singh, Anup; Cai, Kejia; Kogan, Feliks; DeBrosse, Catherine; Witschey, Walter R. T.; Hariharan, Hari; Reddy, Ravinder] Univ Penn, Dept Radiol, Ctr Magnet Resonance & Opt Imaging, Philadelphia, PA 19104 USA. [McGarvey, Jeremy; Zsido, Gerald A.; Witschey, Walter R. T.; Koomalsingh, Kevin; Pilla, James J.; Gorman, Joseph H.; Gorman, Robert C.] Univ Penn, Dept Surg, Gorman Cardiovasc Res Grp, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Chirinos, Julio A.; Ferrari, Victor A.] Univ Penn, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA. RP Reddy, R (reprint author), Univ Penn, Dept Radiol, Ctr Magnet Resonance & Opt Imaging, Philadelphia, PA 19104 USA. EM krr@mail.med.upenn.edu OI Reddy, Ravinder/0000-0003-4580-2392; Hariharan, Hari/0000-0002-7032-6968 FU National Institutes of Health [P41 EB015893, P41 E5015893S1, R21DA032256-01]; Translational Biomedical Imaging Center of the Institute for Translational Medicine and Therapeutics of the University of Pennsylvania FX This work was supported by National Institutes of Health grants P41 EB015893, P41 E5015893S1 and R21DA032256-01 and a pilot grant from the Translational Biomedical Imaging Center of the Institute for Translational Medicine and Therapeutics of the University of Pennsylvania. The authors acknowledge W Liu and S. Pickup for technical assistance in using the 9.4-T NMR spectrometer, K. Nath for assistance with biochemical analysis and D. Reddy for help with regulatory protocol. NR 40 TC 30 Z9 31 U1 2 U2 20 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD FEB PY 2014 VL 20 IS 2 BP 209 EP 214 DI 10.1038/nm.3436 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA AA2HF UT WOS:000330915000023 PM 24412924 ER PT J AU Levin, MH Pistilli, M Daniel, E Gangaputra, SS Nussenblatt, RB Rosenbaum, JT Suhler, EB Thorne, JE Foster, CS Jabs, DA Levy-Clarke, GA Kempen, JH AF Levin, Marc H. Pistilli, Maxwell Daniel, Ebenezer Gangaputra, Sapna S. Nussenblatt, Robert B. Rosenbaum, James T. Suhler, Eric B. Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Levy-Clarke, Grace A. Kempen, John H. CA Systemic Immunosuppressive Therapy TI Incidence of Visual Improvement in Uveitis Cases with Visual Impairment Caused by Macular Edema SO OPHTHALMOLOGY LA English DT Article ID INTRAOCULAR INFLAMMATORY DISEASE; OPTICAL COHERENCE TOMOGRAPHY; OCULAR INFLAMMATION; EYE DISEASES; RISK; ACUITY; COMPLICATIONS; INTERMEDIATE; THERAPY; SMOKING AB Purpose: Among cases of visually significant uveitic macular edema (ME), to estimate the incidence of visual improvement and identify predictive factors. Design: Retrospective cohort study. Participants: Eyes with uveitis, seen at 5 academic ocular inflammation centers in the United States, for which ME was documented to be currently present and the principal cause of reduced visual acuity (<20/40). Methods: Data were obtained by standardized chart review. Main Outcome Measures: Decrease of >= 0.2 base 10 logarithm of visual acuity decimal fraction-equivalent; risk factors for such visual improvement. Results: We identified 1510 eyes (of 1077 patients) with visual impairment to a level <20/40 attributed to ME. Most patients were female (67%) and white (76%), and had bilateral uveitis (82%). The estimated 6-month incidence of >= 2 lines of visual acuity improvement in affected eyes was 52% (95% confidence interval [CI], 49%-55%). Vision reduced by ME was more likely to improve by 2 lines in eyes initially with poor visual acuity (<= 20/200; adjusted hazard ratio [HR] 1.5; 95% CI, 1.3-1.7), active uveitis (HR, 1.3; 95% CI, 1.1-1.5), and anterior uveitis as opposed to intermediate (HR, 1.2), posterior (HR, 1.3), or panuveitis (HR, 1.4; overall P 0.02). During follow-up, reductions in anterior chamber or vitreous cellular activity or in vitreous haze each led to significant improvements in visual outcome (P < 0.001 for each). Conversely, snowbanking (HR, 0.7; 95% CI, 0.4-0.99), posterior synechiae (HR, 0.8; 95% CI, 0.6-0.9), and hypotony (HR, 0.2; 95% CI, 0.06-0.5) each were associated with lower incidence of visual improvement with respect to eyes lacking each of these attributes at a given visit. Conclusions: These results suggest that many, but not all, patients with ME causing low vision in a tertiary care setting will enjoy meaningful visual recovery in response to treatment. Evidence of significant ocular damage from inflammation (posterior synechiae and hypotony) portends a lower incidence of visual recovery. Better control of anterior chamber or vitreous activity is associated with a greater incidence of visual improvement, supporting an aggressive anti-inflammatory treatment approach for ME cases with active inflammation. (C) 2014 by the American Academy of Ophthalmology. C1 [Levin, Marc H.; Pistilli, Maxwell; Daniel, Ebenezer; Kempen, John H.] Univ Penn, Perelman Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gangaputra, Sapna S.] Univ Wisconsin, Sch Med, Dept Ophthalmol, Fundus Photograph Reading Ctr, Madison, WI 53706 USA. [Nussenblatt, Robert B.; Levy-Clarke, Grace A.] NEI, Immunol Lab, Bethesda, MD 20892 USA. [Rosenbaum, James T.; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Foster, C. Stephen] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Preventat Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu OI Pistilli, Maxwell/0000-0002-4266-4150 FU National Eye Institute [EY014943]; Research to Prevent Blindness; Paul and Evanina Mackall Foundation; Veteran's Affairs Administration; intramural funds of the National Eye Institute FX Supported primarily by National Eye Institute Grant EY014943 (Dr. Kempen). Additional support was provided by Research to Prevent Blindness and the Paul and Evanina Mackall Foundation. During part of the conduct of this project, Dr. Levin was a Heed Ophthalmic Society Fellowship recipient, Dr. Kempenwas a Research to Prevent Blindness James S. Adams Special Scholar Award recipient, Dr. Thorne was a Research to Prevent Blindness Harrington Special Scholar Award recipient, and Drs. Jabs and Rosenbaumwere Research to Prevent Blindness Senior Scientific Investigator Award recipients. Dr. Suhler receives support from the Veteran's Affairs Administration. Dr. LevyClarke was previously supported by and Dr. Nussenblatt continues to be supported by intramural funds of the National Eye Institute. The funding organizations had no role in the design or conduct of this research. NR 31 TC 14 Z9 15 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD FEB PY 2014 VL 121 IS 2 BP 588 EP + DI 10.1016/j.ophtha.2013.09.023 PG 9 WC Ophthalmology SC Ophthalmology GA 302CO UT WOS:000330579200026 PM 24332536 ER PT J AU Hanson, JT Pierce, RG Dhaliwal, G AF Hanson, Joshua T. Pierce, Read G. Dhaliwal, Gurpreet TI The New Education Frontier: Clinical Teaching at Night SO ACADEMIC MEDICINE LA English DT Article ID REDESIGNING RESIDENCY EDUCATION; PATIENT-CARE; WORK HOURS; INTERNAL-MEDICINE; SUPERVISION; SLEEP; FLOAT; ASSOCIATION; PHYSICIANS; IMPACT AB Regulations that restrict resident work hours and call for increased resident supervision have increased attending physician presence in the hospital during the nighttime. The resulting increased interactions between attendings and trainees provide an important opportunity and obligation to enhance the quality of learning that takes place in the hospital between 6 pm and 8 am. Nighttime education should be transformed in a way that maintains clinical productivity for both attending and resident physicians, integrates high-quality teaching and curricula, and achieves a balance between patient safety and resident autonomy. Direct observation of trainees, instruction in communication, and modeling of cost-efficient medical practice may be more feasible during the night than during daytime hours. To realize the potential of this educational opportunity, training programs should develop skilled nighttime educators and establish metrics to define success. C1 [Hanson, Joshua T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Hanson, Joshua T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pierce, Read G.] Univ Colorado, Dept Med, Denver, CO USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hanson, JT (reprint author), 7703 Floyd Curl Dr MC 7982, San Antonio, TX 78229 USA. EM hansonj4@uthscsa.edu NR 33 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD FEB PY 2014 VL 89 IS 2 BP 215 EP 218 DI 10.1097/ACM.0000000000000096 PG 4 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 298EC UT WOS:000330305900012 PM 24362386 ER PT J AU Shunk, R Dulay, M Chou, CL Janson, S O'Brien, BC AF Shunk, Rebecca Dulay, Maya Chou, Calvin L. Janson, Susan O'Brien, Bridget C. TI Huddle-Coaching: A Dynamic Intervention for Trainees and Staff to Support Team-Based Care SO ACADEMIC MEDICINE LA English DT Article ID CENTERED MEDICAL HOME; GUIDE AB Many outpatient clinics where health professionals train will transition to a team-based medical home model over the next several years. Therefore, training programs need innovative approaches to prepare and incorporate trainees into team-based delivery systems. To address this need, educators at the San Francisco Veterans Affairs (VA) Medical Center included trainees in preclinic team huddles, or briefing meetings to facilitate care coordination, and developed an interprofessional huddle-coaching program for nurse practitioner students and internal medicine residents who function as primary providers for patient panels in VA outpatient primary care clinics. The program aimed to support trainees' partnerships with staff and full participation in the VA's Patient Aligned Care Teams. The huddle-coaching program focuses on structuring the huddle process via scheduling, checklists, and designated huddle coaches; building relationships among team members through team-building activities; and teaching core skills to support collaborative practice. A multifaceted evaluation of the program showed positive results. Participants rated training sessions and team-building activities favorably. In interviews, trainees valued their team members and identified improvements in efficiency and quality of patient care as a result of the team-based approach. Huddle checklists and scores on the Team Development Measure indicated progress in team processes and relationships as the year progressed. These findings suggest that the huddle-coaching program was a worthwhile investment in trainee development that also supported the clinic's larger mission to deliver team-based, patient-aligned care. As more training sites shift to team-based care, the huddle-coaching program offers a strategy for successfully incorporating trainees. C1 [Shunk, Rebecca; Dulay, Maya; Chou, Calvin L.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Shunk, Rebecca; Dulay, Maya; Chou, Calvin L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Janson, Susan] Univ Calif San Francisco, Sch Nursing, Dept Community Hlth Syst, San Francisco, CA 94143 USA. [Janson, Susan; O'Brien, Bridget C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [O'Brien, Bridget C.] Univ Calif San Francisco, Off Res & Dev Med Educ, San Francisco, CA 94143 USA. RP Shunk, R (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM rebecca.shunk@va.gov FU Centers of Excellence in Primary Care Education of the Office of Academic Affiliations, U.S. Department of Veterans Affairs Office of Academic Affiliations; San Francisco Veterans Affairs Medical Center; University of California, San Francisco (UCSF) FX The Centers of Excellence in Primary Care Education of the Office of Academic Affiliations, U.S. Department of Veterans Affairs Office of Academic Affiliations; San Francisco Veterans Affairs Medical Center; University of California, San Francisco (UCSF). NR 17 TC 10 Z9 10 U1 1 U2 22 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD FEB PY 2014 VL 89 IS 2 BP 244 EP 250 DI 10.1097/ACM.0000000000000104 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 298EC UT WOS:000330305900018 PM 24362383 ER PT J AU Lapham, GT Rubinsky, AD Heagerty, PJ Achtmeyer, C Williams, EC Hawkins, EJ Maynard, C Kivlahan, DR Au, D Bradley, KA AF Lapham, Gwen T. Rubinsky, Anna D. Heagerty, Patrick J. Achtmeyer, Carol Williams, Emily C. Hawkins, Eric J. Maynard, Charles Kivlahan, Daniel R. Au, David Bradley, Katharine A. TI Probability and Predictors of Patients Converting from Negative to Positive Screens for Alcohol Misuse SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Article DE Alcoholism and Addictive Behaviors; Screening; Decision Making ID PRIMARY-CARE; VETERANS-AFFAIRS; AUDIT-C; HEALTH-CARE; PREVENTIVE SERVICES; RISK DRINKING; USE DISORDERS; SCORES; TRAJECTORIES; CONSUMPTION AB BackgroundMedicare reimburses providers for annual alcohol screening. However, the benefit of rescreening patients a year after a negative screen for alcohol misuse is unknown. We hypothesized that some subgroups of patients who screen negative would have a very low probability of converting to a positive subsequent screen (e.g., <0.1%), calling into question the value of annual alcohol screening for some patient subgroups. MethodsThis retrospective cohort study estimated the probability of converting to a positive screen for alcohol misuse a year after a negative screen among outpatients from 30 Veterans Health Administration (VA) medical centers. Alcohol Use Disorders Identification TestConsumption (AUDIT-C) alcohol screening scores (range 0 to 12 points) from 2004 to 2008 were obtained from electronic health record data. Eligible patients screened negative on their initial screen (AUDIT-C scores 0 to 3 for men; 0 to 2 for women). The main outcome was a positive subsequent screen (AUDIT-C scores 4 men; 3 women). ResultsAmong 21,081 women and 323,913 men who screened negative on an initial screen, 5.4% and 6.0%, respectively, screened positive a year later. The adjusted probability of converting to a positive subsequent screen varied from 2.1 to 38.9% depending on age, gender, and initial negative screen score. Women, older patients, and those with initial AUDIT-C scores of 0 were least likely to a convert to a positive subsequent screen, while younger men with AUDIT-C scores of 3 were most likely to a convert to a positive subsequent screen. ConclusionsThe probability of a positive subsequent screen varied depending on age, gender, and initial negative screen score but exceeded 2% in all patient subgroups. Annual rescreening appears reasonable for all VA patients who had a negative screen the year prior. C1 [Lapham, Gwen T.; Rubinsky, Anna D.; Achtmeyer, Carol; Williams, Emily C.; Hawkins, Eric J.; Maynard, Charles; Kivlahan, Daniel R.; Au, David; Bradley, Katharine A.] Hlth Serv Res & Dev HSR&D Northwest Ctr Excellenc, Seattle, WA USA. [Lapham, Gwen T.; Rubinsky, Anna D.; Heagerty, Patrick J.; Williams, Emily C.; Maynard, Charles; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Lapham, Gwen T.; Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Heagerty, Patrick J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Achtmeyer, Carol; Hawkins, Eric J.; Bradley, Katharine A.] CESATE, Seattle, WA USA. [Achtmeyer, Carol; Au, David] Vet Affairs VA Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA. [Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Au, David; Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. RP Lapham, GT (reprint author), VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM gwendolyn.lap-ham@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU Department of Veterans Affairs, Veteran Health Administration, Health Services Research and Development Service; Veterans Affairs Substance Use Disorders Quality Enhancement Research Initiative [RRP 11-021] FX The study reported here was supported by the Department of Veterans Affairs, Veteran Health Administration, Health Services Research and Development Service. The manuscript was specifically produced with support from the Veterans Affairs Substance Use Disorders Quality Enhancement Research Initiative (RRP 11-021). Preliminary results of this study were presented at the 35th Annual Research Society on Alcoholism Scientific Meeting, June 2012 in San Francisco, CA. NR 51 TC 2 Z9 2 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD FEB PY 2014 VL 38 IS 2 BP 564 EP 571 DI 10.1111/acer.12260 PG 8 WC Substance Abuse SC Substance Abuse GA 297PC UT WOS:000330266400033 PM 24118025 ER PT J AU Kumar, V Tallaj, JA AF Kumar, V. Tallaj, J. A. TI To Transplant a Kidney With the Heart or Not-That Is the Real Question SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID MULTIORGAN; OUTCOMES AB This editorial addresses the indication for combined heart-kidney transplantation, challenging Schaffer et al's (page 384) recommendations of giving higher priority status exemptions to patients listed for multiple organs. C1 [Kumar, V.] Univ Alabama Birmingham, Div Nephrol Transplant Nephrol, Birmingham, AL USA. [Tallaj, J. A.] Univ Alabama Birmingham, Dept Med, Div Cardiol, Sect Adv Heart Failure Heart Transplantat, Birmingham, AL 35294 USA. [Tallaj, J. A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. RP Tallaj, JA (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiol, Sect Adv Heart Failure Heart Transplantat, Birmingham, AL 35294 USA. EM jtallaj@uab.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD FEB PY 2014 VL 14 IS 2 BP 253 EP 254 DI 10.1111/ajt.12523 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 297OT UT WOS:000330265500006 PM 24620374 ER PT J AU Djamali, A Kaufman, DB Ellis, TM Zhong, W Matas, A Samaniego, M AF Djamali, A. Kaufman, D. B. Ellis, T. M. Zhong, W. Matas, A. Samaniego, M. TI Diagnosis and Management of Antibody-Mediated Rejection: Current Status and Novel Approaches SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Review DE Antibody-mediated rejection; complement C4d; donor-specific antibodies; phenotype ID DONOR-SPECIFIC ANTIBODIES; RENAL-ALLOGRAFT REJECTION; KIDNEY-TRANSPLANT RECIPIENTS; HIGHLY SENSITIZED PATIENTS; POSITIVE CROSS-MATCH; SOLID-ORGAN TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; ACUTE HUMORAL REJECTION; HIGH-DOSE IVIG; HLA ANTIBODIES AB Advances in multimodal immunotherapy have significantly reduced acute rejection rates and substantially improved 1-year graft survival following renal transplantation. However, long-term (10-year) survival rates have stagnated over the past decade. Recent studies indicate that antibody-mediated rejection (ABMR) is among the most important barriers to improving long-term outcomes. Improved understanding of the roles of acute and chronic ABMR has evolved in recent years following major progress in the technical ability to detect and quantify recipient anti-HLA antibody production. Additionally, new knowledge of the immunobiology of B cells and plasma cells that pertains to allograft rejection and tolerance has emerged. Still, questions regarding the classification of ABMR, the precision of diagnostic approaches, and the efficacy of various strategies for managing affected patients abound. This review article provides an overview of current thinking and research surrounding the pathophysiology and diagnosis of ABMR, ABMR-related outcomes, ABMR prevention and treatment, as well as possible future directions in treatment. C1 [Djamali, A.] Univ Wisconsin, Dept Med, Div Nephrol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Djamali, A.; Kaufman, D. B.] Univ Wisconsin, Dept Surg, Div Transplantat, Sch Med & Publ Hlth, Madison, WI USA. [Ellis, T. M.; Zhong, W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. [Zhong, W.] William S Middleton Mem Vet Adm Med Ctr, Pathol Serv, Madison, WI USA. [Zhong, W.] William S Middleton Mem Vet Adm Med Ctr, Lab Serv, Madison, WI USA. [Matas, A.] Univ Minnesota, Dept Surg, Div Transplantat, Minneapolis, MN 55455 USA. [Samaniego, M.] Univ Michigan, Dept Med, Div Nephrol, Ann Arbor, MI 48109 USA. RP Djamali, A (reprint author), Univ Wisconsin, Dept Med, Div Nephrol, Sch Med & Publ Hlth, Madison, WI 53706 USA. EM axd@medicine.wisc.edu FU Bristol-Myers Squibb FX The authors would like to acknowledge CodonMedical (A Division of KnowledgePoint360 Group) for their assistance in conducting literature searches and coordinating the writing and editing of the manuscript, funded by Bristol-Myers Squibb. NR 149 TC 66 Z9 71 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD FEB PY 2014 VL 14 IS 2 BP 255 EP 271 DI 10.1111/ajt.12589 PG 17 WC Surgery; Transplantation SC Surgery; Transplantation GA 297OT UT WOS:000330265500007 PM 24401076 ER PT J AU Restrepo, MI Aliberti, S AF Restrepo, Marcos I. Aliberti, Stefano TI Healthcare-Associated Pneumonia: Where Do We Go Next? SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID MULTIDRUG-RESISTANT PATHOGENS; HOSPITALIZED-PATIENTS; COMMUNITY; INFECTIONS; ADULTS C1 [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, ALMD, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Aliberti, Stefano] Univ Milano Bicocca, UO Clin Pneumol, Monza, Italy. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst, ALMD, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014; Aliberti, Stefano/K-9115-2016 OI Aliberti, Stefano/0000-0002-0090-4531 FU NCATS NIH HHS [KL2 TR001118, UL1 TR001120]; NHLBI NIH HHS [K23 HL096054, K23HL096054] NR 10 TC 4 Z9 4 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2014 VL 58 IS 3 BP 340 EP 341 DI 10.1093/cid/cit738 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 300AD UT WOS:000330435900006 PM 24270052 ER PT J AU Biagtan, M Babler, B Kakumanu, S Mathur, SK AF Biagtan, Mark Babler, Bryan Kakumanu, Sujani Mathur, Sameer K. TI Effect Of Penicillin Allergy On Outpatient Antibiotic Prescriptions At VA Hospital SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 28-MAR 04, 2014 CL San Diego, CA SP Amer Acad Allergy Asthma & Immunol C1 [Biagtan, Mark; Kakumanu, Sujani; Mathur, Sameer K.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Biagtan, Mark; Babler, Bryan; Kakumanu, Sujani; Mathur, Sameer K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2014 VL 133 IS 2 SU S MA 918 BP AB266 EP AB266 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 297FO UT WOS:000330241301234 ER PT J AU He, WJ Harper, N Carrillo, A Andrews, C Rather, C Ramirez, D Jacobs, RL Ahuja, SK AF He, Weijing Harper, Nathan Carrillo, Andrew Andrews, Charles Rather, Cynthia Ramirez, Daniel Jacobs, Robert L. Ahuja, Sunil K. TI Atopic and Non-Atopic Individuals Manifest Partly Concordant Clinical and Leukocyte Responses Following Exposure To House Dust Mite In An Antigen Challenge Chamber (ACC) SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 28-MAR 04, 2014 CL San Diego, CA SP Amer Acad Allergy Asthma & Immunol C1 [He, Weijing; Harper, Nathan; Carrillo, Andrew; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [He, Weijing; Harper, Nathan; Carrillo, Andrew; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA. [Andrews, Charles; Rather, Cynthia; Ramirez, Daniel; Jacobs, Robert L.] Biogen Res Chamber, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2014 VL 133 IS 2 SU S MA 773 BP AB223 EP AB223 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 297FO UT WOS:000330241301089 ER PT J AU Jacobs, RL Rather, C Jimenez, F Martinez, H He, WJ Ramirez, D Andrews, C Ahuja, SK AF Jacobs, Robert L. Rather, Cynthia Jimenez, Fabio Martinez, Hernan He, Weijing Ramirez, Daniel Andrews, Charles Ahuja, Sunil K. TI Validation Of Biogenics Research Chamber For Elicitation Of Symptoms To Dust Mite Antigen (Der p1) SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 28-MAR 04, 2014 CL San Diego, CA SP Amer Acad Allergy Asthma & Immunol C1 [Jacobs, Robert L.; Rather, Cynthia; Ramirez, Daniel; Andrews, Charles] Biogen Res Chamber, San Antonio, TX USA. [Jimenez, Fabio; Martinez, Hernan; He, Weijing; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Jimenez, Fabio; Martinez, Hernan; He, Weijing; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2014 VL 133 IS 2 SU S MA 766 BP AB221 EP AB221 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 297FO UT WOS:000330241301082 ER PT J AU Lee, JXW Wojtczak, H Wachter, AM Lee, M Burns, L Chen, D Yusin, JS AF Lee, Joyce Xiang Wu Wojtczak, Henry Wachter, Allan M. Lee, Martin Burns, Lisa Chen, Diana Yusin, Joseph S. TI Understanding Asthma Medical Nonadherence In Adult and Pediatric Populations SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 28-MAR 04, 2014 CL San Diego, CA SP Amer Acad Allergy Asthma & Immunol C1 [Lee, Joyce Xiang Wu] VA Greater Los Angeles Hlth Care Syst, Allergy Immunol, Los Angeles, CA USA. [Wojtczak, Henry] Naval Med Ctr San Diego, San Diego, CA USA. [Wachter, Allan M.; Burns, Lisa; Chen, Diana] Fdn Asthma Res & Intervent, Phoenix, AZ USA. [Lee, Martin] UCLA Sch Publ Hlth, Los Angeles, CA USA. [Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2014 VL 133 IS 2 SU S MA 543 BP AB155 EP AB155 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 297FO UT WOS:000330241300540 ER PT J AU Parikh, N Yusin, JS AF Parikh, Neil Yusin, Joseph S. TI An Adult With Disseminated Herpes Zoster Infection Found To Have Rare Combined CD4, CD8 T-Cell and NK-Cell Deficiency SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 28-MAR 04, 2014 CL San Diego, CA SP Amer Acad Allergy Asthma & Immunol C1 [Parikh, Neil] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Yusin, Joseph S.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2014 VL 133 IS 2 SU S MA 335 BP AB97 EP AB97 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 297FO UT WOS:000330241300333 ER PT J AU Patel, B Karls, J Tompkins, S Nyland, D Clough, JA Ludwig, J Mathur, SK AF Patel, Bhavisha Karls, Joseph Tompkins, Sandra Nyland, Dawn Clough, Jo Ann Ludwig, Jane Mathur, Sameer K. TI Aspirin Allergy In a High Risk VA Population and Potential Benefit From Aspirin Desensitization SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 28-MAR 04, 2014 CL San Diego, CA SP Amer Acad Allergy Asthma & Immunol C1 [Patel, Bhavisha; Mathur, Sameer K.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Patel, Bhavisha; Karls, Joseph; Tompkins, Sandra; Nyland, Dawn; Clough, Jo Ann; Ludwig, Jane; Mathur, Sameer K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2014 VL 133 IS 2 SU S MA 915 BP AB265 EP AB265 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 297FO UT WOS:000330241301231 ER PT J AU Ramirez, D Jacobs, RL Rather, C Carrillo, A He, WJ Harper, N Andrews, C Ahuja, SK AF Ramirez, Daniel Jacobs, Robert L. Rather, Cynthia Carrillo, Andrew He, Weijing Harper, Nathan Andrews, Charles Ahuja, Sunil K. TI Baseline Predictors Of Symptom Severity Following Exposure To House Dust Mite In An Antigen Challenge Chamber (ACC) SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY FEB 28-MAR 04, 2014 CL San Diego, CA SP Amer Acad Allergy Asthma & Immunol C1 [Ramirez, Daniel; Jacobs, Robert L.; Rather, Cynthia; Andrews, Charles] Biogen Res Chamber, San Antonio, TX USA. [Carrillo, Andrew; He, Weijing; Harper, Nathan; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Carrillo, Andrew; He, Weijing; Harper, Nathan; Ahuja, Sunil K.] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2014 VL 133 IS 2 SU S MA 765 BP AB221 EP AB221 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 297FO UT WOS:000330241301081 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Patient-level improvements in pain and activities of daily living after total knee arthroplasty SO RHEUMATOLOGY LA English DT Article DE pain; activity limitation; activities of daily living; function; functional limitation; total knee replacement; arthroplasty; joint replacement; outcomes; patient-reported outcomes; primary ID QUALITY-OF-LIFE; SEVERE FUNCTIONAL LIMITATION; TOTAL HIP-ARTHROPLASTY; PREDICTORS; OUTCOMES; REPLACEMENT; EXPECTATIONS; PARTICIPATION; 5-YEARS; 2-YEARS AB Objective. To study patient-level improvements in pain and limitations of key activities of daily living (ADLs) after primary or revision total knee arthroplasty (TKA). Methods. We analysed prospectively collected data from the Mayo Clinic Total Joint Registry for improvements in index knee pain severity and limitations in three key ADLs (walking, climbing stairs and rising from a chair) from pre-operative to 2 and 5 years post-TKA. Results. The primary TKA cohort consisted of 7229 responders pre-operatively, 7139 at 2 years and 4234 at 5 years post-operatively. The revision TKA cohort consisted of 1206 responders pre-operatively, 1533 at 2 years and 881 at 5 years post-operatively. In the primary TKA cohort, important pain reduction to mild or no knee pain at 2 years was reported by 92% with moderate pre-operative pain and 93% with severe pre-operative pain; respective proportions were 91% and 91% at 5 years follow-up. For revision TKA, respective proportions were 71% and 66% at 2 years and 68% and 74% at 5 years. Three per cent with no/mild pre-operative overall limitation and 19% with moderate/severe pre-operative overall limitation had moderate/severe overall activity limitation 2 years post-operatively; at 5 years the respective proportions were 4% and 22%. Respective proportions for revision TKA were up to 3% and 32% at 2 years and 4% and 34% at 5 years. Conclusion. Our study provides comprehensive data for patient-level improvements in pain and key ADLs. These data can be used to inform patients pre-operatively of expected outcomes, based on pre-operative status, which may further help patients set realistic goals for improvements after TKA. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Department of Orthopaedic Surgery at the Mayo Clinic FX This study received research funding from the Department of Orthopaedic Surgery at the Mayo Clinic. NR 29 TC 7 Z9 7 U1 1 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD FEB PY 2014 VL 53 IS 2 BP 313 EP 320 DI 10.1093/rheumatology/ket325 PG 8 WC Rheumatology SC Rheumatology GA 299ZR UT WOS:000330434700017 PM 24162150 ER PT J AU Singh, JA Lewallen, DG AF Singh, Jasvinder A. Lewallen, David G. TI Underlying diagnosis predicts patient-reported outcomes after revision total knee arthroplasty SO RHEUMATOLOGY LA English DT Article DE total knee replacement; risk factor; arthroplasty; joint replacement; patient-reported outcomes; osteoarthritis; rheumatoid arthritis ID TOTAL HIP-ARTHROPLASTY; SEVERE FUNCTIONAL LIMITATION; PAIN; RESPONSIVENESS; TKA; REHABILITATION; FRACTURES; MORBIDITY; 5-YEARS; 2-YEARS AB Objective. To assess the association of underlying diagnosis with outcomes after revision total knee arthroplasty (TKA). Methods. For this cohort study we used prospectively collected data from the Mayo Clinic Total Joint Registry on all revision TKA patients from 1993 to 2005 with 2- or 5-year response to a validated knee questionnaire that assesses pain and function. We used logistic regression to assess the odds of moderate-severe activities of daily living (ADL) limitations and moderate-severe index knee pain 2 and 5 years after revision TKA. Odds ratios (ORs) and 95% CIs are presented. Results. The underlying diagnosis for the 2- and 5-year cohorts was loosening, wear or osteolysis in 73% and 75%; dislocation, bone or prosthesis fracture, instability or non-union in 17% and 15%; and failed prior arthroplasty with components removed or infection in 11% and 11%, respectively. In multivariable adjusted analyses that included preoperative status, compared with patients with loosening/wear/osteolysis, patients with dislocation/fracture/instability/non-union had an OR of 2.1 for moderate-severe ADL limitation (95% CI 1.3, 3.1, P < 0.001) and those with failed prior arthroplasty/infection had an OR of 1.1 (95% CI 0.6, 1.8, P = 0.4). At 5 years, differences were no longer significant. In multivariable adjusted analyses, compared with patients with loosening/wear/osteolysis, patients with dislocation/fracture/instability/non-union had an OR of 2.0 for moderate-severe pain (95% CI 1.3, 3.1, P < 0.01) at 2 years and an OR of 2.1 (95% CI 1.3, 3.8, P = 0.01) at 5 years. Failed prior arthroplasty/infection was not significantly different than the reference category. Conclusion. Underlying diagnosis is independently associated with ADL limitations and pain after revision TKA. This information can help patients have realistic expectations of outcomes. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Mayo Clinic Orthopaedic Surgery FX This material is the result of work supported by Mayo Clinic Orthopaedic Surgery research funds and the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, AL, USA. NR 29 TC 3 Z9 3 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD FEB PY 2014 VL 53 IS 2 BP 361 EP 366 DI 10.1093/rheumatology/ket357 PG 6 WC Rheumatology SC Rheumatology GA 299ZR UT WOS:000330434700023 PM 24196389 ER PT J AU Lourdault, K Wang, LC Vieira, A Matsunaga, J Melo, R Lewis, MS Haake, DA Gomes-Solecki, M AF Lourdault, Kristel Wang, Long-Chieh Vieira, Ana Matsunaga, James Melo, Rita Lewis, Michael S. Haake, David A. Gomes-Solecki, Maria TI Oral Immunization with Escherichia coli Expressing a Lipidated Form of LigA Protects Hamsters against Challenge with Leptospira interrogans Serovar Copenhageni SO INFECTION AND IMMUNITY LA English DT Article ID IMMUNOGLOBULIN-LIKE PROTEINS; BORRELIA-BURGDORFERI; LETHAL INFECTION; PATHOGENIC LEPTOSPIRA; OUTER-MEMBRANE; LYME-DISEASE; VACCINE; IMMUNITY; MODEL; SPIROCHETE AB Leptospirosis is a potentially fatal zoonosis transmitted by reservoir host animals that harbor leptospires in their renal tubules and shed the bacteria in their urine. Leptospira interrogans serovar Copenhageni transmitted from Rattus norvegicus to humans is the most prevalent cause of urban leptospirosis. We examined L. interrogans LigA, domains 7 to 13 (LigA7-13), as an oral vaccine delivered by Escherichia coli as a lipidated, membrane-associated protein. The efficacy of the vaccine was evaluated in a susceptible hamster model in terms of the humoral immune response and survival from leptospiral challenge. Four weeks of oral administration of live E. coli expressing LigA7-13 improved survival from intraperitoneal (i.p.) and intradermal (i.d.) challenge by L. interrogans serovar Copenhageni strain Fiocruz L1-130 in Golden Syrian hamsters. Immunization with E. coli expressing LigA7-13 resulted in a systemic antibody response, and a significant LigA7-13 IgG level after the first 2 weeks of immunization was completely predictive of survival 28 days after challenge. As in previous LigA vaccine studies, all immunized hamsters that survived infection had renal leptospiral colonization and histopathological changes. In summary, an oral LigA-based vaccine improved survival from leptospiral challenge by either the i.p. or i.d. route. C1 [Lourdault, Kristel; Wang, Long-Chieh; Matsunaga, James; Lewis, Michael S.; Haake, David A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lourdault, Kristel; Matsunaga, James; Haake, David A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Haake, David A.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Haake, David A.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. [Vieira, Ana; Melo, Rita; Gomes-Solecki, Maria] Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA. [Gomes-Solecki, Maria] Biopeptides Corp, Memphis, TN USA. RP Haake, DA (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM dhaake@ucla.edu FU National Institutes of Health [R01 AI034431, R43 AI096551]; Centers for Disease Control and Prevention [UO1 CK000107]; VA Merit Research Funds FX This work was supported by grants R01 AI034431 (to D.A.H.) and R43 AI096551 (to M.G.- S.) from the National Institutes of Health, grant UO1 CK000107 (to M.G.- S.) from the Centers for Disease Control and Prevention, and VA Merit Research Funds (to J.M.and D.A.H.). NR 44 TC 14 Z9 14 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD FEB PY 2014 VL 82 IS 2 BP 893 EP 902 DI 10.1128/IAI.01533-13 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 298XF UT WOS:000330357100040 PM 24478102 ER PT J AU McCauley, HL Silverman, J Broyles, LM Decker, MR Tancredi, D Zelazny, S Miller, E AF McCauley, Heather L. Silverman, Jay Broyles, Lauren M. Decker, Michele R. Tancredi, Daniel Zelazny, Sarah Miller, Elizabeth TI SUBSTANCE USE, INTIMATE PARTNER VIOLENCE AND SEXUAL ASSAULT AMONG ADOLESCENT AND YOUNG ADULT FEMALE FAMILY PLANNING CLIENTS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [McCauley, Heather L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Silverman, Jay; Tancredi, Daniel] Univ Calif San Diego, San Diego, CA 92103 USA. [Broyles, Lauren M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Decker, Michele R.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Zelazny, Sarah; Miller, Elizabeth] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. RI Miller, Elizabeth/E-7939-2012 NR 0 TC 1 Z9 1 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2014 VL 54 IS 2 SU S MA 13 BP S7 EP S8 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 298EV UT WOS:000330307800014 ER PT J AU Matos, JM Barshes, NR Mccoy, S Pisimisis, G Felkai, D Kougias, P Lin, PH Bechara, CF AF Matos, Jesus M. Barshes, Neal R. Mccoy, Sally Pisimisis, George Felkai, Deborah Kougias, Panos Lin, Peter H. Bechara, Carlos F. TI Validating common carotid stenosis by duplex ultrasound with carotid angiogram or computed tomography scan SO JOURNAL OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT Vascular Annual Meeting of the Society-for-Vascular-Surgery (SVS) CY MAY 29-JUN 01, 2013 CL San Francisco, CA SP Soc Vasc Surg ID RADIATION-THERAPY; NECK RADIATION AB Background: No consensus exists for duplex ultrasound criteria in the diagnosis of significant common carotid artery (CCA) stenosis. In general, peak systolic velocity (PSV) >150 cm/s with poststenotic turbulence indicates a stenosis >50%. The purpose of our study is to correlate CCA duplex velocities with angiographic findings of significant stenosis >60%. Methods: We reviewed the carotid duplex records from 2008 to 2011 looking for patients with isolated CCA stenosis and no ipsilateral internal or contralateral carotid artery disease who received either a carotid angiogram or a computed tomography scan. We identified 25 patients who had significant CCA disease >60%. We also selected 74 controls without known CCA stenosis. We performed receiver operating characteristics analysis to correlate PSV and end-diastolic velocity (EDV) with angiographic stenosis >60%. The degree of stenosis was determined by measuring the luminal stenosis in comparison to the proximal normal CCA diameter. Results: Most patients had a carotid angiogram (21/25), four only had a computed tomography angiography and four had both. Eighteen patients had history of neck radiation. The CCA PSV >= 250 cm/s had a sensitivity of 98.7% (81.5%-100%) and a specificity of 95.7% (92.0%-99.9%), CCA PSV >= 300 cm/s had a sensitivity of 90.9% (69.4%-98.4%) and a specificity of 98.7% (92.0%-99.9%). The CCA EDV >= 40 cm/s had a sensitivity of 95.5% (95% confidence interval of 75.1-99.8%) and specificity of 98.7% (92.0%-99.9%), EDV >= 60 cm/s had a sensitivity of 100% (75.1%-99.8%) and specificity of 87% (94.1-100%), and EDV >= 70 cm/s had a sensitivity of 86.4% (64.0%-96.4%) and specificity of 100% (94.1%-100%). The presence of both PSV <250 cm/s and EDV <60 cm/s had a 98.7% negative predictive value, and the presence of both PSV >= 250 cm/s and EDV >= 60 cm/s had 100% positive predictive value. Conclusions: Establishing CCA duplex criteria to screen patients with significant stenosis is crucial to identify those who will need further imaging modality or treatment. In our laboratory, CCA PSV >= 250 cm/s and EDV >= 60 cm/s are thresholds that can be used to identify significant (>60%) CCA stenosis with a high degree of accuracy. C1 [Matos, Jesus M.; Barshes, Neal R.; Pisimisis, George; Kougias, Panos; Lin, Peter H.; Bechara, Carlos F.] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Vasc & Endovasc Therapy, Houston, TX 77030 USA. [Barshes, Neal R.; Mccoy, Sally; Pisimisis, George; Felkai, Deborah; Kougias, Panos; Bechara, Carlos F.] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Bechara, CF (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcombe Blvd 112, Houston, TX 77030 USA. EM bechara@bcm.edu NR 19 TC 4 Z9 5 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD FEB PY 2014 VL 59 IS 2 BP 435 EP 439 DI 10.1016/j.jvs.2013.08.030 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 295QA UT WOS:000330129400024 PM 24080127 ER PT J AU Hazlett, EA Lamade, RV Graff, FS McClure, MM Kolaitis, JC Goldstein, KE Siever, LJ Godbold, JH Moshier, E AF Hazlett, Erin A. Lamade, Raina V. Graff, Fiona S. McClure, Margaret M. Kolaitis, Jeanine C. Goldstein, Kim E. Siever, Larry J. Godbold, James H. Moshier, Erin TI Visual-spatial working memory performance and temporal gray matter volume predict schizotypal personality disorder group membership SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizotypal; Prefrontal cortex; Temporal lobe volume; Neurocognition; Working memory; Dot Test; CVLT; PASAT; Diagnostic classification ID UNMEDICATED SCHIZOPHRENIA-PATIENTS; PREFRONTAL CORTEX; NEUROPSYCHOLOGICAL PERFORMANCE; MENTAL-DISORDERS; CONTINUED EVIDENCE; NEGATIVE SYMPTOMS; GYRUS VOLUME; SPECTRUM; MRI; DEFICITS AB Background: Prior work shows individuals with schizotypal personality disorder (SPD) evince temporal lobe volume abnormalities similar to schizophrenia but sparing of prefrontal cortex, which may mitigate psychosis and the severe neurocognitive impairments observed in schizophrenia. This study examined the extent to which frontal-temporal gray matter volume and neurocognitive performance predict: (1) SPD group membership in a demographically-balanced sample of 51 patients and 37 healthy controls; and (2) symptom severity in SPD. Methods: Dimensional gray-matter volume (left frontal-temporal regions (Brodmann area (BA) 10, 21, 22)) and neurocognitive performance on key memory tasks (California Verbal Learning Test (CVLT), Dot Test, Paced Auditory Serial Addition Test (PASAT)), all salient to schizophrenia-spectrum disorders were examined in a multi-variable model. Results: Middle temporal gyrus (BA21) volume and spatial-working memory (Dot Test) performance were significant predictors of SPD group membership likelihood, with poorer working-memory performance indicating increased probability of SPD membership. Combining across regional volumes or cognitive measures resulted in fair-to-good discrimination of group membership, but including neurocognitive and non-collinear regional volume measures together resulted in a receiver-operating-characteristic (ROC) curve with improved diagnostic discrimination. Larger BA10 volume in dorsolateral prefrontal cortex (DLPFC) significantly predicted less symptom severity in SPD. Conclusions: These findings suggest that temporal lobe volume and spatial-working memory performance are promising biological/phenotype markers for likelihood of SPD classification, while greater DLPFC volume may serve as a protective factor. Published by Elsevier B.V. C1 [Hazlett, Erin A.; Lamade, Raina V.; Graff, Fiona S.; McClure, Margaret M.; Kolaitis, Jeanine C.; Goldstein, Kim E.; Siever, Larry J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. [Siever, Larry J.] James J Peter Vet Affairs Med Ctr, Dept Outpatient Psychiat, Bronx, NY USA. [Hazlett, Erin A.; Lamade, Raina V.; Graff, Fiona S.; McClure, Margaret M.; Siever, Larry J.] James J Peter Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN 3, Bronx, NY USA. [Hazlett, Erin A.; Kolaitis, Jeanine C.] James J Peter Vet Affairs Med Ctr, Bronx, NY USA. [Godbold, James H.; Moshier, Erin] Icahn Sch Med Mt Sinai, Dept Biostat, New York, NY USA. RP Hazlett, EA (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN 3, 130 West Kingsbridge Rd,Rm 6A-45, Bronx, NY 10468 USA. EM erin.hazlett@mssm.edu FU VA MERIT grant [I01 CX000261]; Department of Veterans Affairs VISN3 Mental Illness Research, Education, and Clinical Center (MIRECC) at the James J. Peters VA Medical Center FX Support for this work came from a VA MERIT grant (I01 CX000261) to E.A.H. and the Department of Veterans Affairs VISN3 Mental Illness Research, Education, and Clinical Center (MIRECC) at the James J. Peters VA Medical Center. NR 80 TC 5 Z9 5 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2014 VL 152 IS 2-3 BP 350 EP 357 DI 10.1016/j.schres.2013.12.006 PG 8 WC Psychiatry SC Psychiatry GA 296MF UT WOS:000330188500005 PM 24398009 ER PT J AU Swerdlow, NR Light, GA Sprock, J Calkins, ME Green, MF Greenwood, TA Gur, RE Gur, RC Lazzeroni, LC Nuechterlein, KH Radant, AD Ray, A Seidman, LJ Siever, LJ Silverman, JM Stone, WS Sugar, CA Tsuang, DW Tsuang, MT Turetsky, BI Braff, DL AF Swerdlow, Neal R. Light, Gregory A. Sprock, Joyce Calkins, Monica E. Green, Michael F. Greenwood, Tiffany A. Gur, Raquel E. Gur, Ruben C. Lazzeroni, Laura C. Nuechterlein, Keith H. Radant, Allen D. Ray, Amrita Seidman, Larry J. Siever, Larry J. Silverman, Jeremy M. Stone, William S. Sugar, Catherine A. Tsuang, Debby W. Tsuang, Ming T. Turetsky, Bruce I. Braff, David L. TI Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS SO SCHIZOPHRENIA RESEARCH LA English DT Review DE Endophenotype; Genetics; Multi-site; Prepulse inhibition; Schizophrenia; Startle ID ACOUSTIC STARTLE RESPONSE; SENSORIMOTOR GATING DEFICITS; 1ST-EPISODE SCHIZOPHRENIA; ANTIPSYCHOTIC-NAIVE; JAPANESE PATIENTS; REFLEX; HABITUATION; MEDICATION; PSYCHOSIS; CONSORTIUM AB Background: Startle inhibition by weak prepulses (PPI) is studied to understand the biology of information processing in schizophrenia patients and healthy comparison subjects (HCS). The Consortium on the Genetics of Schizophrenia (COGS) identified associations between PPI and single nucleotide polymorphisms in schizophrenia probands and unaffected relatives, and linkage analyses extended evidence for the genetics of PPI deficits in schizophrenia in the COGS-1 family study. These findings are being extended in a 5-site "COGS-2" study of 1800 patients and 1200 unrelated HCS to facilitate genetic analyses. We describe a planned interim analysis of COGS-2 PPI data. Methods: Eyeblink startle was measured in carefully screened HCS and schizophrenia patients (n = 1402). Planned analyses of PPI (60 ms intervals) assessed effects of diagnosis, sex and test site, PPI-modifying effects of medications and smoking, and relationships between PPI and neurocognitive measures. Results: 884 subjects met strict inclusion criteria. ANOVA of PPI revealed significant effects of diagnosis (p = 0.0005) and sex (p < 0.002), and a significant diagnosis x test site interaction. HCS > schizophrenia PPI differences were greatest among patients not taking 2nd generation antipsychotics, and were independent of smoking status. Modest but significant relationships were detected between PPI and performance in specific neurocognitive measures. Discussion: The COGS-2multi-site study detects schizophrenia-related PPI deficits reported in single-site studies, including patterns related to diagnosis, prepulse interval, sex, medication and other neurocognitive measures. Site differences were detected and explored. The target COGS-2 schizophrenia "endophenotype" of reduced PPI should prove valuable for identifying and confirming schizophrenia risk genes in future analyses. (C) 2013 Elsevier B.V. All rights reserved. C1 [Swerdlow, Neal R.; Light, Gregory A.; Sprock, Joyce; Greenwood, Tiffany A.; Tsuang, Ming T.; Braff, David L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Calkins, Monica E.; Gur, Raquel E.; Gur, Ruben C.; Turetsky, Bruce I.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Radant, Allen D.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Radant, Allen D.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Green, Michael F.; Nuechterlein, Keith H.; Sugar, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lazzeroni, Laura C.; Ray, Amrita] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Lazzeroni, Laura C.; Ray, Amrita] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA. [Light, Gregory A.; Sprock, Joyce; Sugar, Catherine A.; Braff, David L.] VA San Diego Healthcare Syst, MIRECC, VISN 22, San Diego, CA USA. [Seidman, Larry J.; Stone, William S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Seidman, Larry J.; Stone, William S.] Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div, Boston, MA 02215 USA. [Siever, Larry J.; Silverman, Jeremy M.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry J.; Silverman, Jeremy M.] James J Peters VA Med Ctr, New York, NY USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Tsuang, Ming T.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA. [Tsuang, Ming T.] Harvard Inst Psychiat Epidemiol & Genet, Boston, MA USA. RP Swerdlow, NR (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM nswerdlow@ucsd.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Sprock, Joyce/0000-0003-0225-9422; Lazzeroni, Laura/0000-0002-1846-6920; Greenwood, Tiffany/0000-0002-6080-6503 FU National Institute of Mental Health [R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, K01-MH087889]; National Institutes of Health [HHSN268200782096C] FX This study was supported by grants R01-MH065571, R01-MH065588, R01-MH065562, R01-MH065707, R01-MH065554, R01-MH065578, R01-MH065558, R01 MH86135, and K01-MH087889 from the National Institute of Mental Health. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, Contract Number HHSN268200782096C. NR 69 TC 27 Z9 28 U1 1 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2014 VL 152 IS 2-3 BP 503 EP 512 DI 10.1016/j.schres.2013.12.004 PG 10 WC Psychiatry SC Psychiatry GA 296MF UT WOS:000330188500026 PM 24405980 ER PT J AU Breyer, BN Cohen, BE Bertenthal, D Rosen, RC Neylan, TC Seal, KH AF Breyer, Benjamin N. Cohen, Beth E. Bertenthal, Daniel Rosen, Raymond C. Neylan, Thomas C. Seal, Karen H. TI Lower Urinary Tract Dysfunction in Male Iraq and Afghanistan War Veterans: Association With Mental Health Disorders: A Population-based Cohort Study SO UROLOGY LA English DT Article ID QUALITY-OF-LIFE; CORTICOTROPIN-RELEASING-FACTOR; OVERACTIVE BLADDER; UNITED-STATES; BACH SURVEY; DEPRESSIVE SYMPTOMS; UROLOGICAL SYMPTOMS; PREVALENCE; WOMEN; INCONTINENCE AB OBJECTIVE To determine the prevalence and correlates of lower urinary tract symptoms (LUTS) among returned Iraq and Afghanistan veterans; in particular its association with mental health diagnoses and medication use. METHODS We performed a retrospective cohort study of Iraq and Afghanistan veterans who were new users of U. S. Department of Veterans Affairs health care. Mental health diagnoses were defined by International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) codes from medical records. LUTS was defined by ICD-9-CM code, use of prescription medication for LUTS, or procedure for LUTS. We determined the independent association of mental health diagnoses and LUTS after adjusting for sociodemographic and military service characteristics, comorbidities, and medications. RESULTS Of 519,189 veterans, 88% were men and the mean age was 31.8 years (standard deviation +/- 9.3). The overall prevalence of LUTS was 2.2% (11,237/519,189). Veterans with post-traumatic stress disorder (PTSD) were significantly more likely to have a LUTS diagnosis, prescription, or related procedure (3.5%) compared with veterans with no mental health diagnoses (1.3%) or a mental health diagnosis other than PTSD (3.1%, P < .001). In adjusted models, LUTS was significantly more common in veterans with PTSD with and without other mental health disorders vs those without mental health disorders (adjusted relative risk [ARR] - 2.04, 95% confidence interval [CI] 1.94-2.15) and in veterans prescribed opioids (ARR = 2.46, 95% CI = 2.36-2.56). CONCLUSION In this study of young returned veterans, mental health diagnoses and prescription for opioids were independently associated with increased risk of receiving a diagnosis, treatment, or procedure for LUTS. Provider awareness may improve the detection and treatment of LUTS, and improve patient care and quality of life. (C) 2014 Published by Elsevier Inc. C1 [Breyer, Benjamin N.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. New England Res Inst, Watertown, MA 02172 USA. RP Breyer, BN (reprint author), Univ Calif San Francisco, Dept Urol, 400 Parnassus Ave,A610, San Francisco, CA 94143 USA. EM bbreyer@urology.ucsf.edu FU National Institute for Health (NIH) [K12DK083021]; Mental Illness Research and Education Clinical Center (MIRECC) of the US Veterans Health Administration FX This research was supported, in part, by grants from the National Institute for Health (NIH) grant K12DK083021 (BNB), the Mental Illness Research and Education Clinical Center (MIRECC) of the US Veterans Health Administration (DB), the Department of Veterans Affairs (VA) Health Services Research and Development (HSR&D) Research Enhancement Award Program at the San Francisco VA Medical Center (KHS), and an NIH/NHLBI grant K23 HL 094765-01 (BEC). This manuscript is the result of work supported with resources and the use of facilities at the Veterans Administration Medical Center, San Francisco, California. NR 30 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD FEB PY 2014 VL 83 IS 2 BP 312 EP 319 DI 10.1016/j.urology.2013.08.047 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 296ZF UT WOS:000330223600018 PM 24149111 ER PT J AU Schopfer, DW Ku, IA Regan, M Whooley, MA AF Schopfer, David W. Ku, Ivy A. Regan, Mathilda Whooley, Mary A. TI Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study) SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE CORONARY SYNDROME; RISK STRATIFICATION; MYOCARDIAL-INFARCTION; PROGNOSTIC UTILITY; FAILURE; RECLASSIFICATION; INDIVIDUALS; PREDICTION; BIOMARKERS; SEVERITY AB Background Growth differentiation factor 15 (GDF-15) is a relatively new biomarker that predicts mortality in patients with chronic stable angina or acute coronary syndrome. However, the association of GDF-15 with cardiovascular (CV) events and the mechanisms of this association are not well understood. Methods We measured plasma GDF-15 and cardiac disease severity in 984 patients with stable ischemic heart disease who were recruited for the Heart and Soul Study between September 2000 and December 2002. Subsequent CV events (myocardial infarction, stroke, and CV death), hospitalization for heart failure, and all-cause mortality were determined by chart review during an average of 8.9-year follow-up. Results Each doubling in GDF-15 was associated with a 2.5-fold increased rate of CV events (hazard ratio [HR] 2.53, 95% CI 2.13-3.01, P < .001). This association persisted after extensive adjustment for covariates including comorbid conditions, measures of cardiac disease severity, cardiac function, inflammatory markers, and adipokines (HR 1.44, 95% CI 1.11-1.87, P < .01). Participants who had GDF-15 levels in the highest tertile had higher mortality compared with those in the lowest tertile (HR 2.73, 95% CI 1.80-4.15, P <= .001 adjusted for all covariates). Addition of GDF-15 to existing risk factors resulted in a 50% change in net reclassification of patients' risk for mortality. Conclusions Higher levels of GDF-15 are associated with major CV events in patients with stable ischemic heart disease. This suggests that GDF-15 is capturing an element of risk not explained by other known risk factors. C1 [Schopfer, David W.; Regan, Mathilda; Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ku, Ivy A.] Kaiser Permanente San Francisco, Dept Cardiol, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Schopfer, DW (reprint author), 4150 Clement St 111A1, San Francisco, CA 94121 USA. EM david.schopfer@ucsf.edu OI Schopfer, David/0000-0002-7244-9857 NR 31 TC 10 Z9 12 U1 1 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD FEB PY 2014 VL 167 IS 2 BP 186 EP + DI 10.1016/j.ahj.2013.09.013 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 290MD UT WOS:000329761200010 PM 24439979 ER PT J AU Hashim, T Elbaz, S Patel, K Morgan, CJ Fonarow, GC Fleg, JL McGwin, G Cutter, GR Allman, RM Prabhu, SD Zile, MR Bourge, RC Ahmed, A AF Hashim, Taimoor Elbaz, Shereen Patel, Kanan Morgan, Charity J. Fonarow, Gregg C. Fleg, Jerome L. McGwin, Gerald Cutter, Gary R. Allman, Richard M. Prabhu, Sumanth D. Zile, Michael R. Bourge, Robert C. Ahmed, Ali TI Digoxin and 30-day All-cause Hospital Admission in Older Patients with Chronic Diastolic Heart Failure SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Diastolic heart failure; Digoxin; 30-day all-cause hospital admission ID ANGINA-PECTORIS; MORTALITY; TRIAL; HYPERTROPHY; MORBIDITY; PROGRAM AB BACKGROUND: In the main Digitalis Investigation Group (DIG) trial, digoxin reduced the risk of 30-day all-cause hospitalization in older systolic heart failure patients. However, this effect has not been studied in older diastolic heart failure patients. METHODS: In the ancillary DIG trial, of the 988 patients with chronic heart failure and preserved (> 45%) ejection fraction, 631 were age >= 65 years (mean age 73 years, 45% women, 12% non-whites), of whom 311 received digoxin. RESULTS: All-cause hospitalization 30-day post randomization occurred in 4% of patients in the placebo group and 9% each among those in the digoxin group receiving 0.125 mg and >= 0.25 mg a day dosage (P = .026). Hazard ratios (HR) and 95% confidence intervals (CI) for digoxin use overall for 30-day, 3-month, and 12-month all-cause hospitalizations were 2.46 (1.25-4.83), 1.45 (0.96-2.20) and 1.14 (0.89-1.46), respectively. There was one 30-day death in the placebo group. Digoxin-associated HRs (95% CIs) for 30-day hospitalizations due to cardiovascular, heart failure, and unstable angina causes were 2.82 (1.18-6.69), 0.51 (0.09-2.79), and 6.21 (0.75-51.62), respectively. Digoxin had no significant association with 30-day all-cause hospitalization among younger patients (6% vs 7% for placebo; HR 0.80; 95% CI, 0.36-1.79). CONCLUSIONS: In older patients with chronic diastolic heart failure, digoxin increased the risk of 30-day all-cause hospital admission, but not during longer follow-up. Although chance finding due to small sample size is possible, these data suggest that unlike in systolic heart failure, digoxin may not reduce 30-day all-cause hospitalization in older diastolic heart failure patients. Published by Elsevier Inc. C1 [Hashim, Taimoor; Elbaz, Shereen; Patel, Kanan; Morgan, Charity J.; McGwin, Gerald; Cutter, Gary R.; Allman, Richard M.; Prabhu, Sumanth D.; Bourge, Robert C.; Ahmed, Ali] Univ Alabama Birmingham, Birmingham, AL USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Fleg, Jerome L.] NHLBI, Bethesda, MD 20892 USA. [Allman, Richard M.; Prabhu, Sumanth D.; Ahmed, Ali] Vet Affairs Med Ctr, Birmingham, AL USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Zile, Michael R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Ahmed, A (reprint author), UAB Comprehens Ctr Healthy Aging, 1720 2nd Ave South,CH19-219, Birmingham, AL 35294 USA. EM aahmed@uab.edu FU National Heart, Lung, and Blood Institute (NHLBI); Department of Veterans Affairs Cooperative Studies Program; National Institutes of Health from the NHLBI [R01-HL085561, R01-HL085561-S, R01-HL097047] FX The Digitalis Investigation Group (DIG) study was conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) and the Department of Veterans Affairs Cooperative Studies Program, in collaboration with the DIG Investigators. This article was prepared using a limited access dataset obtained from the NHLBI and does not necessarily reflect the opinions or views of the DIG Study or the NHLBI. Dr. Ahmed was in part supported by the National Institutes of Health through grants (R01-HL085561, R01-HL085561-S and R01-HL097047) from the NHLBI. NR 15 TC 9 Z9 12 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD FEB PY 2014 VL 127 IS 2 BP 132 EP 139 DI 10.1016/j.amjmed.2013.08.006 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 293PQ UT WOS:000329985800018 PM 24067296 ER PT J AU Han, JH Maslow, J Han, XY Xie, SX Tolomeo, P Santana, E Carson, L Lautenbach, E AF Han, Jennifer H. Maslow, Joel Han, Xiaoyan Xie, Sharon X. Tolomeo, Pam Santana, Evelyn Carson, Lesley Lautenbach, Ebbing TI Risk Factors for the Development of Gastrointestinal Colonization With Fluoroquinolone-Resistant Escherichia coli in Residents of Long-Term Care Facilities SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Escherichia coli; fluoroquinolones; resistance; long-term care; risk factors ID GRAM-NEGATIVE BACILLI; ANTIBIOTIC-RESISTANCE; ANTIMICROBIAL USE; NURSING-HOMES; MUTATIONS; INFECTIONS; EMERGENCE; IMPACT AB Background. The objective of this study was to assess risk factors for the development of fluoroquinolone (FQ)-resistant Escherichia coli gastrointestinal tract colonization in long-term care facility (LTCF) residents. Methods. A prospective cohort study was conducted from 2006 to 2008 at 3 LTCFs. Residents initially colonized with FQ-susceptible E. coli were followed by means of serial fecal sampling for new FQ-resistant E. coli colonization for up to 12 months or until discharge or death. A Cox proportional hazards regression model was developed to identify risk factors for new FQ-resistant E. coli colonization, with antibiotic and device exposures modeled as time-varying covariates. Results. Fifty-seven (47.5%) of 120 residents became newly colonized with FQ-resistant E. coli, with a median time to colonization of 57 days. Fecal incontinence (hazard ratio [HR], 1.78; 95% confidence interval [CI], 1.04-3.06; P = .04) was significantly associated with FQ-resistant E. coli acquisition. Receipt of amoxicillin-clavulanate (HR, 6.48; 95% CI, 1.43-29.4; P = .02) and the presence of a urinary catheter (HR, 3.81; 95% CI, 1.06-13.8; P = .04) during LTCF stay increased the risk of new FQ-resistant E. coli colonization. Conclusions. Acquisition of FQ-resistant E. coli was common, with nearly half of LTCF residents developing new FQ-resistant E. coli colonization. Further studies are needed on interventions to limit the emergence of FQ-resistant E. coli in LTCFs. C1 [Han, Jennifer H.; Lautenbach, Ebbing] Univ Penn, Perelman Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA. [Han, Jennifer H.; Han, Xiaoyan; Xie, Sharon X.; Tolomeo, Pam; Lautenbach, Ebbing] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Han, Jennifer H.; Han, Xiaoyan; Xie, Sharon X.; Tolomeo, Pam; Lautenbach, Ebbing] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Carson, Lesley] Univ Penn, Perelman Sch Med, Div Geriatr, Philadelphia, PA 19104 USA. [Santana, Evelyn] Philadelphia Vet Affairs Med Ctr, Sect Infect Dis, Philadelphia, PA USA. [Maslow, Joel] Morristown Mem Hosp, Div Infect Dis, Morristown, NJ USA. RP Han, JH (reprint author), Hosp Univ Penn, Div Infect Dis, Dept Med, 811 Blockely Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jennifer.han@uphs.upenn.edu FU National Institutes of Health [R01-AG023792, K24-AI080942]; Pennsylvania State Department of Health (Commonwealth Universal Research Enhancement Program grant); Centers for Disease Control and Prevention Epicenters Program [U54-CK000163] FX This work was supported by the National Institutes of Health (grants R01-AG023792 and K24-AI080942 to E. L.), the Pennsylvania State Department of Health (Commonwealth Universal Research Enhancement Program grant to E. L.), and the Centers for Disease Control and Prevention Epicenters Program (grant U54-CK000163 to E. L.). NR 24 TC 9 Z9 10 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2014 VL 209 IS 3 BP 420 EP 425 DI 10.1093/infdis/jit471 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 292SE UT WOS:000329921700016 PM 23986544 ER PT J AU Melis, M Pinna, A Okochi, S Masi, A Rosman, AS Neihaus, D Saunders, JK Newman, E Gouge, TH AF Melis, Marcovalerio Pinna, Antonio Okochi, Shunpei Masi, Antonio Rosman, Alan S. Neihaus, Dena Saunders, John K. Newman, Elliot Gouge, Thomas H. TI Validation of the Surgical Apgar Score in a Veteran Population Undergoing General Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID MORBIDITY AB BACKGROUND: The Surgical Apgar Score (SAS, a 10-point score calculated using limited intraoperative data) can correlate with postoperative morbidity and mortality after general surgery. We evaluated reliability of SAS in a veteran population. STUDY DESIGN: We prospectively collected demographics, medical history, type of surgery, and postoperative outcomes for any veteran undergoing general surgery at our institution (2006-2011). We categorized patients in 4 SAS groups and compared differences in morbidity and mortality. RESULTS: Our study population included 2,125 patients (SAS <= 4: n = 29; SAS 5 - 6: n = 227; SAS 7 - 8: n = 797; SAS 9 - 10: n = 1,072). Low-SAS patients were likely to have significant preoperative comorbidities and to undergo major surgery, and had increased postoperative morbidity and 30-day mortality. CONCLUSIONS: The SAS is easily calculated from 3 routinely available intraoperative measurements, correlates with fixed preoperative risk (acute conditions, pre-existing comorbidities, operative complexity), and effectively identifies veterans at high risk for postoperative complications. (J Am Coll Surg 2014; 218: 218-225. (C) 2014 by the American College of Surgeons) C1 [Melis, Marcovalerio; Pinna, Antonio; Okochi, Shunpei; Masi, Antonio; Neihaus, Dena; Saunders, John K.; Newman, Elliot; Gouge, Thomas H.] VAMC, New York Harbor Healthcare Syst, Dept Surg, Washington, DC USA. [Melis, Marcovalerio; Pinna, Antonio; Masi, Antonio; Saunders, John K.; Newman, Elliot; Gouge, Thomas H.] NYU, Sch Med, Dept Surg, New York, NY 10010 USA. [Pinna, Antonio] Univ Sassari, Clin Chirurg, Dept Gen Surg, I-07100 Sassari, Italy. [Rosman, Alan S.] Mt Sinai Sch Med, Gastroenterol Sect, New York, NY USA. [Rosman, Alan S.] Mt Sinai Sch Med, Program Med, New York, NY USA. [Rosman, Alan S.] James J Peters VAMC, New York, NY USA. RP Melis, M (reprint author), NYU, Sch Med, 423 East 23rd St,Rm 4153 N, New York, NY 10010 USA. EM marcovalerio.melis@nyumc.org OI Pinna, Antonio/0000-0002-2187-6744; Gouge, Thomas/0000-0001-8381-4146 NR 11 TC 5 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD FEB PY 2014 VL 218 IS 2 BP 218 EP 225 DI 10.1016/j.jamcollsurg.2013.10.021 PG 8 WC Surgery SC Surgery GA 290NB UT WOS:000329763900011 PM 24315891 ER PT J AU Mizukami, K Abrahamson, EE Mi, ZP Ishikawa, M Watanabe, K Kinoshita, S Asada, T Ikonomovic, MD AF Mizukami, Katsuyoshi Abrahamson, Eric E. Mi, Zhiping Ishikawa, Masanori Watanabe, Kazushi Kinoshita, Setsuo Asada, Takashi Ikonomovic, Milos D. TI Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: Association with neurofibrillary tangle pathology SO NEUROPATHOLOGY LA English DT Article DE Alzheimer; amyloid; Plic-1; tau; ubiquilin ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; UBIQUITIN; BRAINS; PROGRESSION; SUBUNITS; X-34 AB This post mortem immunohistochemical study examined the localization and distribution of ubiquilin-1 (UBL), a shuttle protein which interacts with ubiquitin and the proteasome, in the hippocampus from Alzheimer's disease (AD) dementia cases, and age-matched cases without dementia. In Braak stages 0-I-II cases, UBL immunoreactivity was detected in a dense fiber network in the neuropil, and in the cell cytoplasm and nucleoplasm of neurons in Cornu Ammonis (CA) fields and dentate gyrus granular neurons. In Braak stages III-IV and V-VI cases, UBL immunoreactivity was reduced in the neuropil and in the cytoplasm of the majority of CA1 neurons; some CA1 pyramidal neurons and the majority of CA2/3 pyramidal, CA4 multipolar, and dentate granular neurons had markedly increased UBL immunoreactivity in the nucleoplasm. Dual immunofluorescence analysis of UBL and antibody clone AT8 revealed co-localization most frequently in CA1 pyramidal neurons in Braak stage III-IV and V-VI cases. Further processing using the pan-amyloid marker X-34 revealed prominent UBL/X-34 dual labeling of extracellular NFT confined to the CA1/subiculum in Braak stage V-VI cases. Our results demonstrate that in AD hippocampus, early NFT changes are associated with neuronal up-regulation of UBL in nucleoplasm, or its translocation from the cytoplasm to the nucleus. The perseverance of UBL changes in CA2/3, CA4 and dentate gyrus, generally considered as more resistant to NFT pathology, but not in the CA1, may mark a compensatory, potentially protective response to increased tau phosphorylation in hippocampal neurons; the failure of such a response may contribute to neuronal degeneration in end-stage AD. C1 [Mizukami, Katsuyoshi] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tokyo 1120012, Japan. [Ishikawa, Masanori; Asada, Takashi] Univ Tsukuba, Inst Clin Med, Dept Psychiat, Tsukuba, Ibaraki 305, Japan. [Watanabe, Kazushi; Kinoshita, Setsuo] Proubase Technol Inc, Kawasaki, Kanagawa, Japan. [Abrahamson, Eric E.; Mi, Zhiping; Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Abrahamson, Eric E.; Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Mizukami, K (reprint author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Bunkyo Ku, 3-29-1 Otsuka, Tokyo 1120012, Japan. EM kmizukam@taiiku.tsukuba.ac.jp FU NIH [NIA AG05133, AG014449, AG025204]; Snee-Reinhardt Charitable Foundation; Japanese Ministry of Education, Culture, Sports, Science and Technology FX We are indebted to the support of the participants in the ADRC at the University of Pittsburgh. This study was supported by NIH grants NIA AG05133 (University of Pittsburgh ADRC), AG014449 and AG025204 (MDI), The Snee-Reinhardt Charitable Foundation (MDI), and by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (KM). Ms. Suganya Srinivasan, Ms. Lan Shao, Ms. Natsuko Kato and Ms. Megumi Mitani provided expert technical assistance. NR 28 TC 4 Z9 4 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0919-6544 EI 1440-1789 J9 NEUROPATHOLOGY JI Neuropathology PD FEB PY 2014 VL 34 IS 1 BP 11 EP 18 DI 10.1111/neup.12055 PG 8 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 291LB UT WOS:000329829100002 PM 23869942 ER PT J AU Back, SE Killeen, TK Teer, AP Hartwell, EE Federline, A Beylotte, F Cox, E AF Back, Sudie E. Killeen, Therese K. Teer, Andrew P. Hartwell, Emily E. Federline, Amanda Beylotte, Frank Cox, Elizabeth TI Substance use disorders and PTSD: An exploratory study of treatment preferences among military veterans. SO ADDICTIVE BEHAVIORS LA English DT Article DE Substance use disorders; PTSD; Post traumatic stress disorder; Prolonged exposure; Military ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; COMORBID ALCOHOL DEPENDENCE; COCAINE DEPENDENCE; EXPOSURE THERAPY; PSYCHOLOGICAL TREATMENTS; PROLONGED EXPOSURE; TREATMENT PROGRAMS; SYMPTOM INTERPLAY; SELF-MEDICATION AB Background: Substance use disorders (SUDs) and Post Traumatic Stress Disorder (PTSD) frequently co-occur among Veterans and are associated with poor treatment outcomes. Historically, treatments for SUDs and PTSD have been delivered sequentially and independently. More recently, however, integrated treatments have shown promise. This study investigated Veterans' perceptions of the interrelationship between SUDs and PTSD, as well as treatment preferences. Methods: Participants were 35 Veterans of recent military conflicts in Iraq and Afghanistan, and prior operations, who completed the Treatment Preferences Questionnaire as well as an in-depth interview. Results: The majority (94.3%) perceived a relationship between their SUD and PTSD symptoms. Veterans reported that PTSD symptom exacerbation was typically (85.3%) associated with an increase in substance use, and PTSD symptom improvement was typically (61.8%) followed by a decrease in substance use (p <.01). Approximately 66% preferred an integrated treatment approach. Conclusions: Although preliminary, the findings provide clinically-relevant information that can be used to enhance the development and provision of care for Veterans with SUDs and PTSD. Published by Elsevier Ltd. C1 [Back, Sudie E.; Killeen, Therese K.; Teer, Andrew P.; Hartwell, Emily E.; Federline, Amanda; Beylotte, Frank; Cox, Elizabeth] Med Univ S Carolina, Charleston, SC 29425 USA. [Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Back, SE (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 67 President St,POB 250861, Charleston, SC 29425 USA. EM backs@musc.edu FU NIDA [R01-DA030143] FX Funding for this study was supported by NIDA grant R01-DA030143 (PI: Back, SE). NIDA and NIH had no further role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication. NR 48 TC 11 Z9 11 U1 2 U2 22 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2014 VL 39 IS 2 SI SI BP 369 EP 373 DI 10.1016/j.addbeh.2013.09.017 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 286OU UT WOS:000329479400001 PM 24199930 ER PT J AU Chakravorty, S Grandner, MA Mavandadi, S Perlis, ML Sturgis, EB Oslin, DW AF Chakravorty, Subhajit Grandner, Michael A. Mavandadi, Shahrzad Perlis, Michael L. Sturgis, Elliott B. Oslin, David W. TI Suicidal ideation in Veterans misusing alcohol: Relationships with insomnia symptoms and sleep duration SO ADDICTIVE BEHAVIORS LA English DT Article DE Veterans; Suicidal ideation; Insomnia; Sleep duration; Alcohol ID GENERAL-POPULATION; PSYCHIATRIC-DISORDERS; COMPLETED SUICIDE; PRIMARY-CARE; BEHAVIOR; ADULTS; ASSOCIATION; DEPRESSION; DRINKING; INDIVIDUALS AB Objective: The aim of this investigation was to assess the relationships between suicidal ideation and insomnia symptoms in Veterans misusing alcohol. Method: Data were extracted in this retrospective chart review of Veterans referred from primary care for a behavioral health evaluation (N = 161) based on evidence of heavy drinking, drug use or another behavioral problem. Suicidal ideation (SI) was assessed using the Paykel questionnaire. Insomnia symptoms were assessed with standard diary questions in an interview format and pertained to sleep latency (SL), wake after sleep onset time (WASO), sleep quality (SQ), and habitual sleep duration (HSD). The relations between suicidal ideation and insomnia symptoms were assessed using ordinal regression analyses adjusted for socio-demographic, psychiatric and addiction-related variables. Results: Suicidal ideation was reported in 62 (39%) of the Veterans interviewed. In a multivariable model, only inadequate SQ was associated with suicidal ideation. Short sleepers were more likely to endorse suicidal ideation and have attempted suicide in the past year. In addition, older age, inadequate financial status, and the presence of a psychiatric disorder were also significantly associated with suicidal ideation in most of the adjusted models. Conclusion: Given their association with suicidal ideation, insomnia symptoms in Veterans misusing alcohol should prompt an assessment of underlying psychiatric and social factors. Published by Elsevier Ltd. C1 [Chakravorty, Subhajit; Mavandadi, Shahrzad; Sturgis, Elliott B.; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, MIRECC VISN 4, Philadelphia, PA 19104 USA. [Chakravorty, Subhajit; Grandner, Michael A.; Mavandadi, Shahrzad; Perlis, Michael L.; Oslin, David W.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Chakravorty, S (reprint author), Philadelphia Vet Affairs Med Ctr, MIRECC, 2nd Floor,Postal Code 116,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM SubhajitChakravorty@uphs.upenn.edu FU VISN-4 MIRECC of the Philadelphia Veterans Affairs Medical Center; Department of Veterans Affairs; National Institutes of Health [1K23HL110216-01, 1R21ES022931-01] FX The VISN-4 MIRECC of the Philadelphia Veterans Affairs Medical Center supported this study. The authors (SC, SM, DO) received salary support from the Department of Veterans Affairs. Dr. Grandner received a grant support from the National Institutes of Health ( 1K23HL110216-01, 1R21ES022931-01). NR 49 TC 11 Z9 11 U1 1 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2014 VL 39 IS 2 SI SI BP 399 EP 405 DI 10.1016/j.addbeh.2013.09.022 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 286OU UT WOS:000329479400006 PM 24169371 ER PT J AU Sartor, CE Kranzler, HR Gelernter, J AF Sartor, Carolyn E. Kranzler, Henry R. Gelernter, Joel TI Rate of progression from first use to dependence on cocaine or opioids: A cross-substance examination of associated demographic, psychiatric, and childhood risk factors SO ADDICTIVE BEHAVIORS LA English DT Article DE Cocaine dependence; Opioid dependence; Transition ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; DRUG-USE DISORDERS; UNITED-STATES; SEMISTRUCTURED ASSESSMENT; GENDER-DIFFERENCES; RAPID PROGRESSION; ALCOHOLISM SSADDA; CONDUCT DISORDER; HEROIN USERS AB Background: A number of demographic factors, psychiatric disorders, and childhood risk factors have been associated with cocaine dependence (CD) and opioid dependence (OD), but little is known about their relevance to the rate at which dependence develops. Identification of the subpopulations at elevated risk for rapid development of dependence and the risk factors that accelerate the course of dependence is an important public health goal. Methods: Data were derived from cocaine dependent (n = 6333) and opioid dependent (n = 3513) participants in a multi-site study of substance dependence. Mean age was approximately 40 and 40% of participants were women; 51.9% of cocaine dependent participants and 29.5% of opioid dependent participants self-identified as Black/African-American. The time from first use to dependence was calculated for each substance and a range of demographic, psychiatric, and childhood risk factors were entered into ordinal logistic regression models to predict the (categorical) transition time to CD and OD. Results: In both the cocaine and opioid models, conduct disorder and childhood physical abuse predicted rapid development of dependence and alcohol and nicotine dependence diagnoses were associated with slower progression to CD or OD. Blacks/African Americans were at greater risk than European Americans to progress rapidly to OD. Conclusions: Only a subset of factors known to be associated with CD and OD predicted the rate at which dependence developed. Nearly all were common to cocaine and opioids, suggesting that sources of influence on the timing of transitions to dependence are shared across the two substances. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Sartor, Carolyn E.; Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Kranzler, Henry R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Treatment Res Ctr, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA 19104 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. RP Sartor, CE (reprint author), Yale Univ, Sch Med, Dept Psychiat, VA Connecticut Healthcare Syst, 950 Campbell Ave,151D, West Haven, CT 06516 USA. EM carolyn.sartor@yale.edu FU National Institutes of Health (NIH) [AA017921, DA12849, DA12690, AA11330, AA13736]; VA CT; Philadelphia VA Mental Illness Research, Education, and Clinical Centers (MIRECCs) FX Funding for this study was provided by the National Institutes of Health (NIH) grants AA017921, DA12849, DA12690, AA11330, and AA13736 and the VA CT and Philadelphia VA Mental Illness Research, Education, and Clinical Centers (MIRECCs). The NIH, the VA CT, and the Philadelphia VA MIRECCs had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 45 TC 9 Z9 9 U1 2 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2014 VL 39 IS 2 SI SI BP 473 EP 479 DI 10.1016/j.addbeh.2013.10.021 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 286OU UT WOS:000329479400018 PM 24238782 ER PT J AU Baltzell, LS Billings, CJ AF Baltzell, Lucas S. Billings, Curtis J. TI Sensitivity of offset and onset cortical auditory evoked potentials to signals in noise SO CLINICAL NEUROPHYSIOLOGY LA English DT Article DE CAEP; Offset; Onset; Auditory; N1; N2; ERP; Evoked; Potential ID EVENT-RELATED POTENTIALS; BROAD-BAND NOISE; STIMULUS-INTENSITY; COMBINED TONE; BRAIN-STEM; RESPONSES; CORTEX; NEURONS; CAT; SPEECH AB Objective: The purpose of this study was to determine the effects of SNR and signal level on the offset response of the cortical auditory evoked potential (CAEP). Successful listening often depends on how well the auditory system can extract target signals from competing background noise. Both signal onsets and offsets are encoded neurally and contribute to successful listening in noise. Neural onset responses to signals in noise demonstrate a strong sensitivity to signal-to-noise ratio (SNR) rather than signal level; however, the sensitivity of neural offset responses to these cues is not known. Methods: We analyzed the offset response from two previously published datasets for which only the onset response was reported. For both datasets, CAEPs were recorded from young normal-hearing adults in response to a 1000-Hz tone. For the first dataset, tones were presented at seven different signal levels without background noise, while the second dataset varied both signal level and SNR. Results: Offset responses demonstrated sensitivity to absolute signal level in quiet, SNR, and to absolute signal level in noise. Conclusions: Offset sensitivity to signal level when presented in noise contrasts with previously published onset results. Significance: This sensitivity suggests a potential clinical measure of cortical encoding of signal level in noise. Published by Elsevier Ltd. on behalf of International Federation of Clinical Neurophysiology. C1 [Baltzell, Lucas S.; Billings, Curtis J.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Billings, Curtis J.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. RP Billings, CJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW S Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM Curtis.Billings2@va.gov FU Department of Veterans Affairs through the Rehabilitation Research and Development Service with Career Development and Center of Excellence Grants [C6971M]; National Institutes of Health [NIDCD:DC010914, T32-DC05361, R01-DC007705, P30-DC004661, F31-DC007296] FX We are grateful for helpful comments from Drs. Garnett McMillan, Erick Gallun, Melissa Papesh, and Tina Penman. This work is supported by the Department of Veterans Affairs through the Rehabilitation Research and Development Service with Career Development and Center of Excellence Grants (C6971M) and National Institutes of Health (NIDCD:DC010914). We are thankful to Kelly Tremblay and the Brain and Behavior Lab at the University of Washington where study design and collection of original data occurred with funding support from National Institutes of Health (T32-DC05361, R01-DC007705, P30-DC004661, and F31-DC007296). NR 37 TC 7 Z9 7 U1 1 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1388-2457 EI 1872-8952 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD FEB PY 2014 VL 125 IS 2 BP 370 EP 380 DI 10.1016/j.clinph.2013.08.003 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 289HO UT WOS:000329672800023 PM 24007688 ER PT J AU Griffin, WC Haun, HL Hazelbaker, CL Ramachandra, VS Becker, HC AF Griffin, William C., III Haun, Harold L. Hazelbaker, Callan L. Ramachandra, Vorani S. Becker, Howard C. TI Increased Extracellular Glutamate In the Nucleus Accumbens Promotes Excessive Ethanol Drinking in Ethanol Dependent Mice SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE ethanol; dependence; glutamate; drinking; microdialysis; mouse ID AMINO-ACID TRANSPORTERS; CENTRAL-NERVOUS-SYSTEM; ALCOHOL DEPENDENCE; C57BL/6J MICE; AGONIST LY379268; WITHDRAWAL; RATS; EXPOSURE; RECEPTOR; HISTORY AB Using a well-established model of ethanol dependence and relapse, this study examined adaptations in glutamatergic transmission in the nucleus accumbens (NAc) and their role in regulating voluntary ethanol drinking. Mice were first trained to drink ethanol in a free-choice, limited access (2 h/day) paradigm. One group (EtOH mice) received repeated weekly cycles of chronic intermittent ethanol (CIE) exposure with intervening weeks of test drinking sessions, whereas the remaining mice (CTL mice) were similarly treated but did not receive CIE treatment. Over repeated cycles of CIE exposure, EtOH mice exhibited significant escalation in drinking (up to B3.5 g/kg), whereas drinking remained relatively stable at baseline levels (2-2.5 g/kg) in CTL mice. Using in vivo microdialysis procedures, extracellular glutamate (GLU(EX)) levels in the NAc were increased approximately twofold in EtOH mice compared with CTL mice, and this difference was observed 7 days after final CIE exposure, indicating that this hyperglutamatergic state persisted beyond acute withdrawal. This finding prompted additional studies examining the effects of pharmacologically manipulating GLU(EX) in the NAc on ethanol drinking in the CIE model. The non-selective glutamate reuptake antagonist, threo-beta-benzyloxyaspartate (TBOA), was bilaterally microinjected into the NAc and found to dose-dependently increase drinking in nondependent (CTL) mice to levels attained by dependent (EtOH) mice. TBOA also further increased drinking in EtOH mice. In contrast, reducing glutamatergic transmission in the NAc via bilateral injections of the metabotropic glutamate receptor-2/3 agonist LY379268 reduced drinking in dependent (EtOH) mice to nondependent (CTL) levels, whereas having a more modest effect in decreasing ethanol consumption in CTL mice. Taken together, these data support an important role of glutamatergic transmission in the NAc in regulating ethanol drinking. Additionally, these results indicate that ethanol dependence produces adaptations that favor elevated glutamate activity in the NAc which, in turn, promote excessive levels of ethanol consumption associated with dependence. C1 [Griffin, William C., III; Haun, Harold L.; Hazelbaker, Callan L.; Ramachandra, Vorani S.; Becker, Howard C.] Med Univ S Carolina, Charleston Alcohol Res Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Becker, Howard C.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Becker, Howard C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Griffin, WC (reprint author), Med Univ S Carolina, Charleston Alcohol Res Ctr, Dept Psychiat & Behav Sci, MSC 861, Charleston, SC 29425 USA. EM griffinw@musc.edu FU NIH [P50 AA10716, F32 AA021321]; Department of Veterans Affairs Medical Research FX This work was supported by NIH grant P50 AA10716 (WCG and HCB), F32 AA021321 (VSR). Dr Becker's research program is funded by NIH and the Department of Veterans Affairs Medical Research. Dr Becker also has conducted contractual work and served as a consultant for Eli Lilly and Company, but those activities have no relationship to the present report. The authors declare no conflict of interest. NR 67 TC 31 Z9 31 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD FEB PY 2014 VL 39 IS 3 BP 707 EP 717 DI 10.1038/npp.2013.256 PG 11 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 291PZ UT WOS:000329842600019 PM 24067300 ER PT J AU Carpenter, MJ Saladin, ME LaRowe, SD McClure, EA Simonian, S Upadhyaya, HP Gray, KM AF Carpenter, Matthew J. Saladin, Michael E. LaRowe, Steven D. McClure, Erin A. Simonian, Susan Upadhyaya, Himanshu P. Gray, Kevin M. TI Craving, Cue Reactivity, and Stimulus Control Among Early-Stage Young Smokers: Effects of Smoking Intensity and Gender SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID ADOLESCENT CIGARETTE SMOKERS; NICOTINE DEPENDENCE; WITHDRAWAL SYMPTOMS; TOBACCO DEPENDENCE; COLLEGE-STUDENTS; LIGHT SMOKERS; RISK-FACTORS; CESSATION; QUESTIONNAIRE; TRAJECTORIES AB Smoking initiation usually begins in adolescence, but how and for whom nicotine dependence emerges during this period is unclear. The cue-reactivity paradigm is well suited to examine one marker of dependence: craving-related stimulus control, i.e., the ability of environmental cues to elicit craving to smoke. This study examined the effects of both level of smoking involvement (daily vs. occasional smoking) and gender on reactivity to both smoking and alcohol cues. Young (age range 1620; 42% female) daily (n 55) and occasional (n 52) smokers were exposed to each of three counterbalanced cues: (a) in vivo smoking (e.g., sight, smell, lighting of cigarette), (b) alcohol (e.g., opening, pouring, and smell of preferred beverage), and (c) neutral cue. Daily smokers exhibited higher levels of tonic (i.e., noncue-elicited) craving than did occasional smokers. Both groups showed significant increases in craving in response to cues (i.e., cue-elicited craving), with little evidence that cue-elicited craving differed between groups. Females were more cue reactive to both the alcohol and smoking cues than males, particularly for the positively reinforced aspects of smoking (i.e., hedonic craving). There were no gender group interaction effects in response to either the alcohol or the smoking cue. Findings show the presence of cue-elicited craving even among occasional smokers and are consistent with literature demonstrating heightened sensitivity to environmental cues among females. Cue-elicited craving may be one mechanism that contributes to the maintenance of smoking behavior and perhaps to the development of nicotine dependence within early stage smokers. C1 [Carpenter, Matthew J.; Saladin, Michael E.; LaRowe, Steven D.; McClure, Erin A.; Upadhyaya, Himanshu P.; Gray, Kevin M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Carpenter, Matthew J.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [LaRowe, Steven D.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. [Simonian, Susan] Coll Charleston, Dept Psychol, Charleston, SC 29401 USA. RP Carpenter, MJ (reprint author), Med Univ S Carolina, Dept Psychiat, Hollings Canc Ctr, Charleston, SC 29425 USA. EM carpente@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU NIDA [K23 DA020482, K12 DA000357] FX This work was supported by Career Development Awards from NIDA (K23 DA020482 to M.J.C.; K12 DA000357 to K.M.G). NR 55 TC 13 Z9 13 U1 4 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD FEB PY 2014 VL 16 IS 2 BP 208 EP 215 DI 10.1093/ntr/ntt147 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 284FZ UT WOS:000329302800010 PM 24042699 ER PT J AU Bischoff, D Zhu, JH Makhijani, N Yamaguchi, D AF Bischoff, David Zhu, Jian-hua Makhijani, Nalini Yamaguchi, Dean TI Induction of CXC Chemokines in Human Mesenchymal Stem Cells (hMSCs) by Stimulation with Secreted Frizzled-Related Proteins (sFRPs) through Non-Canonical Wnt Signaling SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-15, 2014 CL Houston, TX SP Amer Soc Bone & Mineral Res C1 [Bischoff, David; Zhu, Jian-hua; Makhijani, Nalini; Yamaguchi, Dean] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2014 VL 29 SU 1 MA MO0428 BP S483 EP S483 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK9ZS UT WOS:000356598702573 ER PT J AU Mcnabb, B Vittinghoff, E Schwartz, A Bauer, D Ensrud, K Barrett-Connor, E Eastell, R Black, D AF Mcnabb, Brian Vittinghoff, Eric Schwartz, Ann Bauer, Douglas Ensrud, Kristine Barrett-Connor, Elizabeth Eastell, Richard Black, Dennis TI Using Bone Turnover Markers to Predict Changes in BMD After Alendronate Therapy in Postmenopausal Women SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-15, 2014 CL Houston, TX SP Amer Soc Bone & Mineral Res C1 [Mcnabb, Brian] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Vittinghoff, Eric; Schwartz, Ann; Bauer, Douglas; Black, Dennis] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ensrud, Kristine] Univ Minnesota, Minneapolis, MN 55455 USA. [Ensrud, Kristine] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA. [Eastell, Richard] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2014 VL 29 SU 1 MA SU0283 BP S291 EP S291 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK9ZS UT WOS:000356598701589 ER PT J AU Parrish, R Rivoire, J Han, M Schafer, A Link, T Krug, R Kazakia, G AF Parrish, Robin Rivoire, Julien Han, Misung Schafer, Anne Link, Thomas Krug, Roland Kazakia, Galateia TI Multi-modality in vivo Imaging Identifies Marrow and Vasculature within Pathological Cortical Porosity SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-15, 2014 CL Houston, TX SP Amer Soc Bone & Mineral Res C1 [Parrish, Robin] Univ Calif Berkeley, Berkeley, CA USA. [Rivoire, Julien; Han, Misung; Krug, Roland] UC San Francisco, San Francisco, CA USA. [Schafer, Anne; Link, Thomas; Kazakia, Galateia] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schafer, Anne] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2014 VL 29 SU 1 MA FR0291 BP S96 EP S97 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK9ZS UT WOS:000356598700298 ER PT J AU Qin, WP Li, XD Cao, J Collier, L Peng, YZ Feng, J Li, JL Qin, YW Brown, T Ke, HZ Bauman, WA Cardozo, C AF Qin, Weiping Li, Xiaodong Cao, Jay Collier, Lauren Peng, Yuanzhen Feng, Jerry Li, Jiliang Qin, Yiwen Brown, Tom Ke, Hua Zhu (David) Bauman, William A. Cardozo, Christopher TI Mice with Sclerostin Gene Deficiency are Resistant to Bone Loss after Acute Spinal Cord Injury SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-15, 2014 CL Houston, TX SP Amer Soc Bone & Mineral Res C1 [Qin, Weiping; Collier, Lauren; Qin, Yiwen; Bauman, William A.; Cardozo, Christopher] James J Peters Va Med Ctr, Bronx, NY USA. [Li, Xiaodong; Brown, Tom; Ke, Hua Zhu (David)] Amgen Inc, Thousand Oaks, CA USA. [Cao, Jay] ARS, USDA, Lincoln, NE USA. [Peng, Yuanzhen] Mt Sinai Sch Med, New York, NY USA. [Feng, Jerry] Baylor Coll Dent, TX A&M, Dallas, TX 75246 USA. [Li, Jiliang] Indiana Univ Purdue Univ Indianapolis, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2014 VL 29 SU 1 MA MO0118 BP S385 EP S386 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK9ZS UT WOS:000356598702271 ER PT J AU Schafer, A Schwartz, A Black, D Wheeler, A Stewart, L Rogers, S Carter, J Posselt, A Shoback, D Li, XJ AF Schafer, Anne Schwartz, Ann Black, Dennis Wheeler, Amber Stewart, Lygia Rogers, Stanley Carter, Jonathan Posselt, Andrew Shoback, Dolores Li, Xiaojuan TI Changes in Bone Marrow Fat During Gastric Bypass Surgery-Induced Weight Loss SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-15, 2014 CL Houston, TX SP Amer Soc Bone & Mineral Res C1 [Schafer, Anne; Schwartz, Ann; Black, Dennis; Wheeler, Amber; Stewart, Lygia; Rogers, Stanley; Carter, Jonathan; Posselt, Andrew; Li, Xiaojuan] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schafer, Anne; Stewart, Lygia] San Francisco VA Med Ctr, San Francisco, CA USA. [Shoback, Dolores] VA Med Ctr, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2014 VL 29 SU 1 MA SU0106 BP S242 EP S242 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK9ZS UT WOS:000356598701418 ER PT J AU Schafer, A Sellmeyer, D Weaver, C Wheeler, A Stewart, L Rogers, S Carter, J Posselt, A Black, D Shoback, D AF Schafer, Anne Sellmeyer, Deborah Weaver, Connie Wheeler, Amber Stewart, Lygia Rogers, Stanley Carter, Jonathan Posselt, Andrew Black, Dennis Shoback, Dolores TI Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery, Despite Optimization of Vitamin D Status SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-15, 2014 CL Houston, TX SP Amer Soc Bone & Mineral Res C1 [Schafer, Anne; Wheeler, Amber; Stewart, Lygia; Rogers, Stanley; Carter, Jonathan; Posselt, Andrew; Black, Dennis] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schafer, Anne; Stewart, Lygia] San Francisco VA Med Ctr, San Francisco, CA USA. [Sellmeyer, Deborah] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA. [Weaver, Connie] Purdue Univ, W Lafayette, IN 47907 USA. [Shoback, Dolores] VA Med Ctr, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2014 VL 29 SU 1 MA 1077 BP S26 EP S26 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK9ZS UT WOS:000356598700078 ER PT J AU Wang, LP Roth, TM Nguyen, TA Zhou, P Zhang, JS Nakamura, M Huang, EJ Farese, RV Nissenson, R AF Wang, Liping Roth, Theresa M. Nguyen, Thi A. Zhou, Ping Zhang, Jiasheng Nakamura, Mary Huang, Eric J. Farese, Robert V., Jr. Nissenson, Robert TI Loss of Progranulin Increases Bone Mass in Adult Mice in a Gender Dependent Manner. SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Bone-and-Mineral-Research CY SEP 12-15, 2014 CL Houston, TX SP Amer Soc Bone & Mineral Res C1 [Wang, Liping; Nissenson, Robert] VA Med Ctr, San Francisco, CA USA. [Roth, Theresa M.] VA Med Ctr, Endocrine Unit, San Francisco, CA USA. [Nguyen, Thi A.; Zhou, Ping; Farese, Robert V., Jr.] Gladstone Inst Cardiovasc Dis, San Francisco, CA USA. [Zhang, Jiasheng; Huang, Eric J.] Univ Calif, Pathol, Berkeley, CA USA. [Nakamura, Mary; Nissenson, Robert] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Nakamura, Mary] San Francisco VA Med Ctr, San Francisco, CA USA. [Huang, Eric J.] VA Med Ctr, Pathol Serv, Portland, OR USA. [Farese, Robert V., Jr.] Univ Calif, Med & Biochem & Biophys, Berkeley, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD FEB PY 2014 VL 29 SU 1 MA FR0462 BP S123 EP S124 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK9ZS UT WOS:000356598701065 ER PT J AU Porteous, NB Bizra, E Cothron, A Yeh, CK AF Porteous, Nuala B. Bizra, Eamon Cothron, Annaliese Yeh, Chih-Ko TI A Survey of Infection Control Teaching in US Dental Schools SO JOURNAL OF DENTAL EDUCATION LA English DT Article DE infection control; dental schools; dental education; clinic management; clinical education; infection control teaching; infection control compliance in dental schools; bloodborne pathogen ID PERCUTANEOUS INJURIES; STUDENTS; PREVENTION; DENTISTRY; EDUCATION AB This study was conducted to determine the content of infection control (IC) curricula, the extent of IC monitoring and compliance, and the number of bloodborne pathogen (BBP) exposures/year in U.S. dental schools. A questionnaire was emailed to persons responsible for predoctoral IC programs. The response rate was 60 percent. Most schools did not have an independent course and used classroom lectures and clinic demonstrations to teach IC. Schools with an IC committee were more likely to use online learning (p<0.05), utilize multiple teaching methods (p<0.05), issue written warnings for IC violations (p<0.0001), and use multiple disciplinary actions (p<0.005) than schools without an IC committee. Schools with an IC coordinator were less likely to issue grade reductions for IC violations than schools with no IC coordinator (p<0.05). Thirty-eight percent reported >= 16 BBP exposures/year, and 18 percent reported <5. There was significant correlation between BBP exposure incidents and large class size (p<0.005). Respondents were satisfied with their IC curriculum and perceived that dental students had a high level of IC compliance and satisfaction, along with staff IC promotion and compliance. The findings suggest that schools without an IC committee should consider its benefits. Further investigation of schools with high numbers of BBP exposures is recommended. C1 [Porteous, Nuala B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, Sch Dent, San Antonio, TX 78229 USA. [Bizra, Eamon; Cothron, Annaliese; Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Sch Dent, San Antonio, TX 78229 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr San Antonio, San Antonio, TX USA. RP Porteous, NB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, Sch Dent, MC 7914,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM porteous@uthscsa.edu FU NIDCR NIH HHS [R01 DE021084, R21 DE015381] NR 32 TC 1 Z9 2 U1 1 U2 6 PU AMER DENTAL EDUCATION ASSOC-ADEA PI WASHINGTON PA 655 K STREET NW, SUITE 800, WASHINGTON, DC 20001 USA SN 0022-0337 EI 1930-7837 J9 J DENT EDUC JI J. Dent. Educ. PD FEB PY 2014 VL 78 IS 2 BP 187 EP 194 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA AY0HW UT WOS:000347278900003 PM 24489026 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Timing of endoscopy in gastrointestinal bleeding SO UNITED EUROPEAN GASTROENTEROLOGY JOURNAL LA English DT Editorial Material DE Decision analysis; gastrointestinal bleeding; gastrointestinal endoscopy; threshold analysis ID HIGH-RISK PATIENTS; VARICEAL HEMORRHAGE; PEPTIC-ULCER; MANAGEMENT; MORTALITY; OXYGEN AB Background: In gastrointestinal bleeding, a physician often has to make a decision between two possible choices. Endoscopic management of the bleeding could be initiated immediately, or it could be delayed until the patient has become haemodynamically stable or the conditions for a successful endoscopy have otherwise improved. Objective: The present article serves to present such situations and highlights their characteristic features. Methods: The choice between immediate and delayed endoscopy is analysed in terms of a decision tree, comparing the expected results of the two management alternatives. The decision tree is applied to three different clinical scenarios associated with gastrointestinal bleeding, where performing endoscopy later rather than sooner represents the preferred management option. Results: The work up of chronic iron-deficient anaemia in patients with serious cardiac problems should be deferred until resolution of their reduced cardiovascular status. It is also recommended that, even in acute bleeding, endoscopy is deferred until the patient has become haemodynamically stable. Lastly, for nonemergency treatment of oesophageal varices bleeding, a long rather than short interval between consecutive banding sessions appears more beneficial. Conclusions: The results illustrate how to use threshold analysis as a simple bedside tool to solve seemingly complex decisions associated with management of gastrointestinal bleeding. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 19 TC 1 Z9 1 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 2050-6406 EI 2050-6414 J9 UNITED EUR GASTROENT JI United European Gastroenterol. J. PD FEB PY 2014 VL 2 IS 1 BP 5 EP 9 DI 10.1177/2050640613518773 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AY7ZG UT WOS:000347773700001 PM 24918002 ER PT J AU Klein, L Hsia, H AF Klein, Liviu Hsia, Henry TI Sudden Cardiac Death in Heart Failure SO CARDIOLOGY CLINICS LA English DT Article DE Heart failure; Implantable cardiac defibrillators; Ischemic heart disease; Nonischemic cardiomyopathy; Sudden death; Ventricular tachycardia ID LEFT-VENTRICULAR DYSFUNCTION; ACUTE MYOCARDIAL-INFARCTION; IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SIGNAL-AVERAGED ELECTROCARDIOGRAM; RANDOMIZED INTERVENTION TRIAL; ANTIARRHYTHMIC-DRUG THERAPY; T-WAVE ALTERNANS; EJECTION FRACTION; UNEXPECTED DEATH; RATE-VARIABILITY AB Sudden cardiac deaths account for 350,000 to 380,000 deaths in the United States annually. Implantable cardioverter-defibrillators have improved sudden death outcomes in patients with heart failure, but only a minority of patients with defibrillators receives appropriate therapy for ventricular arrhythmias. The risk prediction for sudden death and selection of patients for defibrillators is based largely on left ventricular ejection fraction and heart failure symptoms because there are no other risk stratification tools that can determine the individual patients who will derive the greatest benefit. There are several other pharmacologic strategies designed to prevent sudden death in patients with heart failure. C1 [Klein, Liviu] Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA. [Hsia, Henry] Univ Calif San Francisco, Div Cardiol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Hsia, H (reprint author), Univ Calif San Francisco, Div Cardiol, San Francisco Vet Affairs Med Ctr, Bldg 203,111C-6,Room 2A-52A,4150 Clement St, San Francisco, CA 94121 USA. EM henry.hsia@ucsf.edu FU St. Jude Medical; Medtronic, Inc FX Liviu Klein is a consultant for Boston Scientific, and Zoll Medical; and has received research grants from St. Jude Medical. Henri Hsia is a consultant for Vytron US, Inc; is on the Advisory Board for Biosense Webster, Medtronic, Inc; and has received research support from Medtronic, Inc. NR 71 TC 1 Z9 1 U1 3 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8651 EI 1558-2264 J9 CARDIOL CLIN JI Cardiol. Clin. PD FEB PY 2014 VL 32 IS 1 BP 135 EP + DI 10.1016/j.ccl.2013.09.008 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 281GD UT WOS:000329087100012 PM 24286584 ER PT J AU Millard, SP Lutz, F Li, G Galasko, DR Farlowg, MR Quinn, JF Kaye, JA Leverenz, JB Tsuang, D Yu, CE Peskind, ER Bekris, LM AF Millard, Steven P. Lutz, Franziska Li, Ge Galasko, Douglas R. Farlowg, Martin R. Quinn, Joseph F. Kaye, Jeffrey A. Leverenz, James B. Tsuang, Debby Yu, Chang-En Peskind, Elaine R. Bekris, Lynn M. TI Association of cerebrospinal fluid A beta(42) with A2M gene in cognitively normal subjects SO NEUROBIOLOGY OF AGING LA English DT Article DE Alzheimer's disease; Cerebrospinal fluid; A beta(42); alpha-2-Macroglobulin; A2M; APOE ID ARGYROPHILIC GRAIN DISEASE; BETA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; AMYLOID FORMATION; GAMMA-SECRETASE; ALPHA-2-MACROGLOBULIN GENE; CLINICAL-DIAGNOSIS; PLASMA BIOMARKERS; CANDIDATE GENES AB Low cerebrospinal fluid (CSF) A beta(42) levels correlate with increased brain Ab deposition in Alzheimer's disease (AD), which suggests a disruption in the degradation and clearance of Ab from the brain. In addition, APOE epsilon 4 carriers have lower CSF A beta(42) levels than non-carriers. The hypothesis of this investigation was that CSF A beta(42) levels would correlate with regulatory region variation in genes that are biologically associated with degradation or clearance of Ab from the brain. CSF A beta(42) levels were tested for associations with Ab degradation and clearance genes and APOE epsilon 4. Twenty-four SNPs located within the 5' and 3' regions of 12 genes were analyzed. The study sample consisted of 99 AD patients and 168 cognitively normal control subjects. CSF A beta(42) levels were associated with APOE epsilon 4 status in controls but not in AD patients; A2M regulatory region SNPs were also associated with CSF A beta(42) levels in controls but not in AD patients, even after adjusting for APOE epsilon 4. These results suggest that genetic variation within the A2M gene influences CSF A beta(42) levels. (C) 2014 Elsevier Inc. All rights reserved. C1 [Millard, Steven P.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Northwest Network VISN Mental Illness Res Educ &, Seattle, WA 98108 USA. [Lutz, Franziska; Tsuang, Debby; Yu, Chang-En; Bekris, Lynn M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Lutz, Franziska; Yu, Chang-En; Bekris, Lynn M.] Univ Washington, Dept Med, Seattle, WA USA. [Li, Ge; Leverenz, James B.; Tsuang, Debby; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Galasko, Douglas R.] VA Med Ctr San Diego, San Diego, CA USA. [Farlowg, Martin R.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA. [Quinn, Joseph F.; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.; Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Northwest Network VISN Parkinsons Dis Res Educ &, Seattle, WA 98108 USA. RP Millard, SP (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116 MIRECC, Seattle, WA 98108 USA. EM SteveMillard@comcast.net RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU US Department of Veterans Affairs Office of Research and Development Biomedical Laboratory Research Program [1101BX000531]; National Institute of Health [NS48595, NS065070, NS062684, AG06781, AG10845, AG05136, AG05133, AG028383, AG008017, AG027224, AG10124, AG030653, K99 AG034214/5 R00 AG034214] FX This material is based on work supported in part by the US Department of Veterans Affairs Office of Research and Development Biomedical Laboratory Research Program (Merit Review 1101BX000531). It is also supported by National Institute of Health grants NS48595, NS065070, NS062684, AG06781, AG10845, AG05136, AG05133, AG028383, AG008017, AG027224, AG10124, AG030653, and K99 AG034214/5 R00 AG034214. NR 66 TC 2 Z9 2 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD FEB PY 2014 VL 35 IS 2 BP 357 EP 364 DI 10.1016/j.neurobiolaging.2013.07.027 PG 8 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 275DD UT WOS:000328655600010 PM 24011543 ER PT J AU Stewart, T Sui, YT Gonzalez-Cuyar, LF Wong, DTW Akin, DM Tumas, V Aasly, J Ashmore, E Aro, P Ginghina, C Korff, A Zabetian, CP Leverenz, JB Shi, M Zhang, J AF Stewart, Tessandra Sui, Yu-Ting Gonzalez-Cuyar, Luis F. Wong, David T. W. Akin, David M. Tumas, Vitor Aasly, Jan Ashmore, Emily Aro, Patrick Ginghina, Carmen Korff, Ane Zabetian, Cyrus P. Leverenz, James B. Shi, Min Zhang, Jing TI Cheek cell-derived alpha-synuclein and DJ-1 do not differentiate Parkinson's disease from control SO NEUROBIOLOGY OF AGING LA English DT Article DE Parkinson's disease; Neurodegeneration; Movement disorder; alpha-Synuclein; DJ-1; Saliva; Biomarker AB Recently, alpha-synuclein (alpha-syn) and DJ-1, 2 proteins critically involved in Parkinson's disease (PD), have been shown to be present in saliva, suggesting their potential utility as biomarkers of PD. However, the origin and influence of demographic characteristics (e.g., age or sex) on these proteins are unknown. We identified cheek epithelium, which forms the majority of the cellular component of saliva and is readily accessible clinically, as 1 of several potential sources of salivary alpha-syn and DJ-1. However, no PD-related trend in the cellular component was present. In the supernatant collected from 198 healthy subjects, no correlation was seen between salivary DJ-1 or alpha-syn with age. When male and female subjects were analyzed separately, a weak age-dependent increase in DJ-1 level was present in male subjects, along with slightly increased alpha-syn in female subjects. These results, albeit largely negative, provide critical information for understanding the salivary gland pathology and saliva as a PD biomarker source, and must be considered in future investigations of salivary changes in PD. (C) 2014 Elsevier Inc. All rights reserved. C1 [Stewart, Tessandra; Sui, Yu-Ting; Gonzalez-Cuyar, Luis F.; Aro, Patrick; Ginghina, Carmen; Korff, Ane; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Wong, David T. W.; Akin, David M.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Zabetian, Cyrus P.; Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA. [Ashmore, Emily; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Shi, Min] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [Shi, Min] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Tumas, Vitor] Univ Sao Paulo, Ribeirao Preto Sch Med, Dept Neurosci & Behav, Sao Paulo, Brazil. [Aasly, Jan] St Olavs Univ Hosp, Dept Neurol, Trondheim, Norway. RP Zhang, J (reprint author), Univ Washington, Sch Med, Harborview Med Ctr, Div Neuropathol, Box 359635,325 9th Ave, Seattle, WA 98104 USA. EM zhangj@u.washington.edu RI Shi, Min/G-6165-2012; Tumas, Vitor/C-9949-2014 OI Shi, Min/0000-0002-6901-2558; FU Michael J. Fox Foundation; National Institutes of Health [AG033398, ES004696, 5897, ES007033, 6364, ES016873, ES019277, 02S1, NS057567, NS062684, 6221, NS065070, NS082137, T32ES015459]; National Institute of Neurological Disorders and Stroke [U24 NS072026]; National Institute on Aging [P30 AG19610]; Arizona Department of Health Services [211002]; Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001] FX We thank all subjects for the generous donation of their time and the samples used in this study. We also appreciate the staff of the autopsy service affiliated with the University of Washington for their efforts in contributing cheek and submandibular gland samples. The research is supported by generous funds from the Michael J. Fox Foundation and from the National Institutes of Health (AG033398, ES004696 (subaward 5897), ES007033 (subaward 6364), ES016873, ES019277 (subaward 02S1), NS057567, NS062684 (subaward 6221), NS065070, NS082137, and T32ES015459). We are grateful to the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona for providing human submandibular gland tissue. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901, and 1001 to the Arizona Parkinson's Disease Consortium), The KS Ervik Donation, Norway, and the Michael J. Fox Foundation for Parkinson's Research. NR 5 TC 6 Z9 7 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD FEB PY 2014 VL 35 IS 2 BP 418 EP 420 DI 10.1016/j.neurobiolaging.2013.08.008 PG 3 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 275DD UT WOS:000328655600017 PM 24041968 ER PT J AU Tranah, GJ Yokoyama, JS Katzman, SM Nalls, MA Newman, AB Harris, TB Cesari, M Manini, TM Schork, NJ Cummings, SR Liu, Y Yaffe, K AF Tranah, Gregory J. Yokoyama, Jennifer S. Katzman, Shana M. Nalls, Michael A. Newman, Anne B. Harris, Tamara B. Cesari, Matteo Manini, Todd M. Schork, Nicholas J. Cummings, Steven R. Liu, Yongmei Yaffe, Kristine CA Hlth Aging and Body Composition TI Mitochondrial DNA sequence associations with dementia and amyloid-beta in elderly African Americans SO NEUROBIOLOGY OF AGING LA English DT Article DE Dementia; Mitochondria; mtDNA; Amyloid-beta; Oxidative stress ID ALPHA-KETOGLUTARATE DEHYDROGENASE; ACTIVITY ENERGY-EXPENDITURE; MILD COGNITIVE IMPAIRMENT; AMINO-ACID SUBSTITUTIONS; INDUCED OXIDATIVE STRESS; GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; CALORIE RESTRICTION; BODY-COMPOSITION; POINT MUTATIONS AB Mitochondrial dysfunction occurs early in the course of several neurodegenerative diseases, and is potentially related to increased oxidative damage and amyloid-beta (A beta) formation in Alzheimer's disease. The goals of this study were to assess mtDNA sequence associations with dementia risk, 10-year cognitive change, and markers of oxidative stress and A beta among 1089 African-Americans in the population-based Health, Aging, and Body Composition Study. Participants were free of dementia at baseline, and incidence was determined in 187 (18%) cases over 10 to 12 follow-up years. Haplogroup L1 participants were at increased risk for developing dementia (odds ratio = 1.88, 95% confidence interval = 1.23-2.88, p = 0.004), lower plasma A beta 42 levels (p = 0.03), and greater 10-year decline on the Digit Symbol Substitution Test (p = 0.04) when compared with common haplogroup L3. The p.V193I, ND2 substitution was associated with significantly higher A beta 42 levels (p = 0.0012), and this association was present in haplogroup L3 (p = 0.018) but not L1 (p = 0.90) participants. All associations were independent of potential confounders, including APOE epsilon 4 status and nuclear genetic ancestry. Identification of mtDNA sequence variation associated with dementia risk and cognitive decline may contribute to the development of new treatment targets and diagnostic tests that identify responders to interventions targeting mitochondria. (C) 2014 Published by Elsevier Inc. C1 [Tranah, Gregory J.; Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst San Francisco, San Francisco, CA USA. [Yokoyama, Jennifer S.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA. [Katzman, Shana M.] Buck Inst Res Aging, Novato, CA USA. [Nalls, Michael A.] NIA, Neurogenet Lab, Intramural Res Program, Bethesda, MD 20892 USA. [Newman, Anne B.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Cesari, Matteo] Ctr Hospitalier Univ Toulouse, INSERM UMR 1027, Gerontopole, Toulouse, France. [Manini, Todd M.] Univ Florida, Dept Aging & Geriatr Res, Gainesville, FL USA. [Schork, Nicholas J.] Scripps Translat Sci Inst, La Jolla, CA USA. [Liu, Yongmei] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Tranah, GJ (reprint author), UCSF, San Francisco Coordinating Ctr, Res Inst, Calif Pacific Med Ctr, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM gtranah@sfcc-cpmc.edu RI Cesari, Matteo/A-4649-2008; Newman, Anne/C-6408-2013 OI Cesari, Matteo/0000-0002-0348-3664; Newman, Anne/0000-0002-0106-1150 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050, R03-AG032498, 1R01AG032098-01A1]; NINR grant [R01-NR012459, Z01AG000951]; Intramural Research Program of the NIH, National Institute on Aging; National Institutes of Health [HHSN268200782096C] FX This research was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grants R01-AG028050 and R03-AG032498, NINR grant R01-NR012459; and Z01AG000951. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to Johns Hopkins University, contract number HHSN268200782096C. Data analyses for this study used the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov). NR 120 TC 7 Z9 7 U1 0 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD FEB PY 2014 VL 35 IS 2 AR 442.e1 DI 10.1016/j.neurobiolaging.2013.05.023 PG 8 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 275DD UT WOS:000328655600020 PM 24140124 ER PT J AU Meier, RH Heckman, JT AF Meier, Robert H., III Heckman, Jeffrey T. TI Principles of Contemporary Amputation Rehabilitation in the United States, 2013 SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Amputation; Rehabilitation; Veterans Health Administration; Follow-up care AB Providing rehabilitation services for the person with an amputation has become more difficult in today's health care environment. Amputation rehabilitation calls for specialized, multidisciplinary rehabilitation training. In examining the principles of amputation rehabilitation, one must understand the lessons learned from the Veterans Affairs Amputation System of Care and return to the founding principles of rehabilitation medicine. Persons with amputations must be reevaluated in a tight program of follow-up care. C1 [Meier, Robert H., III] Amputee Serv Amer, Denver, CO USA. [Heckman, Jeffrey T.] Univ Washington, Seattle Div, VA Puget Sound Hlth Care Syst,RAC, Dept Rehabil Med, Seattle, WA 98108 USA. RP Meier, RH (reprint author), Amputee Serv Amer, Denver, CO USA. EM skipdoc3@gmail.com NR 7 TC 1 Z9 1 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 EI 1558-1381 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD FEB PY 2014 VL 25 IS 1 BP 29 EP + DI 10.1016/j.pmr.2013.09.004 PG 7 WC Rehabilitation SC Rehabilitation GA 278UV UT WOS:000328916300005 PM 24287237 ER PT J AU Liu, XH Kang, H Shahnazari, M Kim, H Wang, LP Larm, O Adolfsson, L Nissenson, R Halloran, B AF Liu, Xuhui Kang, Heejae Shahnazari, Mohammad Kim, Hubert Wang, Liping Larm, Olla Adolfsson, Lars Nissenson, Robert Halloran, Bernard TI A Novel Mouse Model of Trauma Induced Heterotopic Ossification SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE heterotopic ossification; trauma; bone morphogenetic protein; mouse model; MicroCT ID BONE-FORMATION; BRAIN-INJURY; RISK-FACTORS; PROGRESSIVA; PREVALENCE; CELLS AB Severe soft tissue trauma is associated with heterotopic ossification (HO), the abnormal deposition of bone at extra-skeletal sites. The pathophysiology of the development of trauma-induced HO remains largely unknown due in part to the lack of appropriate animal models. In this study, we sought to develop a new trauma-induced HO mouse model using muscle impact injury combined with low dose BMP-2. BMP-2 at doses ranging from 0 to 2 mu g was injected into quadriceps muscles of adult male C57/BL6 mice. Animals then received a one-time quadriceps impaction injury to mimic the trauma associated with severe injuries. HO was monitored using in vivo microCT scanning at 1, 2, 4, and 8 weeks after treatment. After trauma, the expression of BMP-2, -4, BMP receptor 1, SOX9 and RUNX2 were increased in muscle. Although little or no HO was observed in mice receiving 1 mu g BMP-2, combining this dose with muscle trauma produced an abundance of HO. At higher doses of BMP-2, trauma did not augment mineral deposition. These results suggest that BMP-2 signaling can sensitize muscle to trauma-induced HO. They also provide the basis for a new model to study the pathogenesis of trauma-induced HO. (c) 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:183-188, 2014. C1 [Liu, Xuhui; Kang, Heejae; Shahnazari, Mohammad; Kim, Hubert; Wang, Liping; Nissenson, Robert; Halloran, Bernard] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94404 USA. [Liu, Xuhui; Kim, Hubert] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA. [Shahnazari, Mohammad; Wang, Liping; Nissenson, Robert; Halloran, Bernard] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Larm, Olla; Adolfsson, Lars] Karolinska Inst, ExThera AB, SE-17177 Stockholm, Sweden. RP Halloran, B (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, 4150 Clement St, San Francisco, CA 94404 USA. EM bernard.halloran@ucsf.edu FU Department of Defense [W81XWH-11-2-0189]; Veterans Affairs Merit review program; Northern California Institute for Research and Education FX Grant sponsor: Department of Defense; Grant number: W81XWH-11-2-0189; Grant sponsor: Veterans Affairs Merit review program; Grant sponsor: Northern California Institute for Research and Education. NR 30 TC 9 Z9 9 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD FEB PY 2014 VL 32 IS 2 BP 183 EP 188 DI 10.1002/jor.22500 PG 6 WC Orthopedics SC Orthopedics GA 270JQ UT WOS:000328315100002 PM 24136593 ER PT J AU Onur, TS Wu, RB Chu, S Chang, WH Kim, HT Dang, ABC AF Onur, Tarik S. Wu, Ruobin Chu, Stacey Chang, Wenhan Kim, Hubert T. Dang, Alexis B. C. TI Joint Instability and Cartilage Compression in a Mouse Model of Posttraumatic Osteoarthritis SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE posttraumatic osteoarthritis; anterior cruciate ligament; compression; cartilage; mouse model ID ANTERIOR CRUCIATE LIGAMENT; SUBCHONDRAL BONE CHANGES; SINGLE-IMPACT LOAD; ARTICULAR-CARTILAGE; KNEE OSTEOARTHRITIS; ACL INJURY; DEGENERATION; ARTHRITIS; TIBIAE; MATRIX AB Joint instability and cartilage trauma have been previously studied and identified as key mediators in the development of posttraumatic osteoarthritis (PTOA). The purpose of this study was to use an in vivo model to compare the effect of joint instability, caused by the rupture of the anterior cruciate ligament (ACL), versus cartilage compression. In this study, mice were subjected to cyclical axial loads of twelve Newtons (N) for 240 cycles or until the ACL ruptured. One and eight weeks after this procedure, knees were sectioned coronally and evaluated for osteoarthritis by histology. Using a scoring scale established by [Pritzker K, Gay S, Jimenez S, et al. (2006): Osteoarthritis Cartilage 14:13-29], the articular cartilage across each surface was scored and combined to produce a total degeneration score. The ACL-ruptured group had a significantly greater total degeneration score than either control or compression treated joints at 1 and 8 weeks. Additionally, only sections from ACL-ruptured knees consistently showed synovitis after 1 week and osteophyte formation after 8 weeks. Thus, it appears using that ACL rupture consistently creates a severe osteoarthritis phenotype, while axial cartilage compression alone does not appear to be an appropriate method of inducing PTOA in vivo. (c) 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:318-323, 2014. C1 [Onur, Tarik S.; Wu, Ruobin; Chu, Stacey; Kim, Hubert T.; Dang, Alexis B. C.] San Francisco VA Med Ctr, Dept Orthopaed Surg, San Francisco, CA USA. [Chang, Wenhan] San Francisco VA Med Ctr, Dept Endocrinol, San Francisco, CA USA. [Chang, Wenhan] Univ Calif San Francisco, Dept Endocrinol, San Francisco, CA 94143 USA. [Kim, Hubert T.; Dang, Alexis B. C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. RP Onur, TS (reprint author), San Francisco VA Med Ctr, Dept Orthopaed Surg, San Francisco, CA USA. EM t.s.onur17@gmail.com FU UCSF Department of Orthopaedic Surgery; Northern California Institute of Research and Education FX Grant sponsor: UCSF Department of Orthopaedic Surgery; Grant sponsor: Northern California Institute of Research and Education. NR 35 TC 16 Z9 16 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD FEB PY 2014 VL 32 IS 2 BP 318 EP 323 DI 10.1002/jor.22509 PG 6 WC Orthopedics SC Orthopedics GA 270JQ UT WOS:000328315100021 PM 24167068 ER PT J AU Stallons, LJ Whitaker, RM Schnellmann, RG AF Stallons, L. Jay Whitaker, Ryan M. Schnellmann, Rick G. TI Suppressed mitochondrial biogenesis in folic acid-induced acute kidney injury and early fibrosis SO TOXICOLOGY LETTERS LA English DT Article DE Acute kidney injury; Mitochondrial biogenesis; Fibrosis; Folic acid ID ACUTE-RENAL-FAILURE; PERITUBULAR CAPILLARY LOSS; ENDOTHELIAL GROWTH-FACTOR; TUBULAR CELLS; PROGRESSION; DISEASE; PGC-1-ALPHA; EXPRESSION; RECOVERY; MICE AB Acute kidney injury (AKI) is a disease with mitochondrial dysfunction and a newly established risk factor for the development of chronic kidney disease (CKD) and fibrosis. We examined mitochondrial homeostasis in the folic acid (FA)-induced AKI model that develops early fibrosis over a rapid time course. Mice given a single dose of FA had elevated serum creatinine (3-fold) and urine glucose (2.2-fold) 1 and 2d after injection that resolved by 4d. In contrast, peroxisome proliferator gamma coactivator 1 alpha(PGC-1 alpha) and mitochondrial transcription factor A (TFAM), critical transcriptional regulators of mitochondrial biogenesis (MB), were down-regulated similar to 80% 1d after FA injection and remained depressed through 14d. Multiple electron transport chain and ATP synthesis genes were also down-regulated from 1 to 14d after FA, including NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 (NDUF beta 8), ATP synthase subunit beta (ATPS-beta), and cytochrome C oxidase subunit I (COXI). Mitochondrial DNA copy number was reduced similar to 50% from 2 to 14d after FA injection. Protein levels of early fibrosis markers alpha-smooth muscle actin and transforming growth factor beta 1 were elevated at 6 and 14d after FA. Picrosirius red staining and collagen 1A2 (COL1A2) IHC revealed staining for mature collagen deposition at 14d. We propose that mitochondrial dysfunction induced by AKI is a persistent cellular injury that promotes progression to fibrosis and CKD, and that this model can be used to test mitochondrial therapeutics that limit progression to fibrosis and CKD. Published by Elsevier Ireland Ltd. C1 [Stallons, L. Jay; Whitaker, Ryan M.; Schnellmann, Rick G.] Med Univ S Carolina, Ctr Cell Death Injury & Regenerat, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Ctr Cell Death Injury & Regenerat, Dept Drug Discovery & Biomed Sci, 280 Calhoun St, Charleston, SC 29425 USA. EM stallons@musc.edu; whitakr@musc.edu; schnell@musc.edu FU National Institutes of Health [R01 GM084147, T32 HL007260, F32DK098053, F30DK096964, UL1 RR029882]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs [BX000851]; SC COBRE in Oxidants, Redox Balance and Stress Signaling [P20 GM103542]; South Carolina Clinical and Translational Research (SCTR) Institute; Medical University of South Carolina CTSA FX This study was supported by the National Institutes of Health [R01 GM084147 to R.G.S., T32 HL007260 and F32DK098053 to L.J.S., and F30DK096964 to R.M.W.], and by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs [BX000851]. This publication was supported, in part, by the SC COBRE in Oxidants, Redox Balance and Stress Signaling [P20 GM103542], and the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina CTSA, and funded by the National Institutes of Health [UL1 RR029882]. NR 40 TC 16 Z9 16 U1 1 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-4274 EI 1879-3169 J9 TOXICOL LETT JI Toxicol. Lett. PD JAN 30 PY 2014 VL 224 IS 3 BP 326 EP 332 DI 10.1016/j.toxlet.2013.11.014 PG 7 WC Toxicology SC Toxicology GA 281OW UT WOS:000329111900003 PM 24275386 ER PT J AU Zhang, MJ Wang, SP Mao, LL Leak, RK Shi, YJ Zhang, WT Hu, XM Sun, BL Cao, GD Gao, YQ Xu, Y Chen, J Zhang, F AF Zhang, Meijuan Wang, Suping Mao, Leilei Leak, Rehana K. Shi, Yejie Zhang, Wenting Hu, Xiaoming Sun, Baoliang Cao, Guodong Gao, Yanqin Xu, Yun Chen, Jun Zhang, Feng TI Omega-3 Fatty Acids Protect the Brain against Ischemic Injury by Activating Nrf2 and Upregulating Heme Oxygenase 1 SO JOURNAL OF NEUROSCIENCE LA English DT Article ID POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC ACID; CEREBRAL-ISCHEMIA; IN-VIVO; OXIDATIVE STRESS; EICOSAPENTAENOIC ACID; LIPID-PEROXIDATION; NEURONAL SURVIVAL; FISH CONSUMPTION; TRANSGENIC MICE AB Ischemic stroke is a debilitating clinical disorder that affects millions of people, yet lacks effective neuroprotective treatments. Fish oil is known to exert beneficial effects against cerebral ischemia. However, the underlying protective mechanisms are not fully understood. The present study tests the hypothesis that omega-3 polyunsaturated fatty acids (n-3 PUFAs) attenuate ischemic neuronal injury by activating nuclear factor E2-related factor 2 (Nrf2) and upregulating heme oxygenase-1 (HO-1) in both in vitro and in vivo models. We observed that pretreatment of rat primary neurons with docosahexaenoic acid (DHA) significantly reduced neuronal death following oxygen-glucose deprivation. This protection was associated with increased Nrf2 activation and HO-1 upregulation. Inhibition of HO-1 activity with tin protoporphyrin IX attenuated the protective effects of DHA. Further studies showed that 4-hydroxy-2E-hexenal (4-HHE), an end-product of peroxidation of n-3 PUFAs, was a more potent Nrf2 inducer than 4-hydroxy-2E-nonenal derived from n-6 PUFAs. In an in vivo setting, transgenic mice overexpressing fatty acid metabolism-1, an enzyme that converts n-6 PUFAs to n-3 PUFAs, were remarkably resistant to focal cerebral ischemia compared with their wild-type littermates. Regular mice fed with a fish oil-enhanced diet also demonstrated significant resistance to ischemia compared with mice fed with a regular diet. As expected, the protection was associated with HO-1 upregulation, Nrf2 activation, and 4-HHE generation. Together, our data demonstrate that n-3 PUFAs are highly effective in protecting the brain, and that the protective mechanisms involve Nrf2 activation and HO-1 upregulation by 4-HHE. Further investigation of n-3 PUFA neuroprotective mechanisms may accelerate the development of stroke therapies. C1 [Zhang, Meijuan; Mao, Leilei; Zhang, Wenting; Hu, Xiaoming; Gao, Yanqin; Chen, Jun; Zhang, Feng] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Zhang, Meijuan; Mao, Leilei; Zhang, Wenting; Hu, Xiaoming; Gao, Yanqin; Chen, Jun; Zhang, Feng] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Zhang, Meijuan; Wang, Suping; Mao, Leilei; Shi, Yejie; Hu, Xiaoming; Cao, Guodong; Chen, Jun; Zhang, Feng] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Zhang, Meijuan; Wang, Suping; Mao, Leilei; Shi, Yejie; Hu, Xiaoming; Cao, Guodong; Chen, Jun; Zhang, Feng] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Zhang, Meijuan; Xu, Yun] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurol, Nanjing 210008, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Sun, Baoliang; Zhang, Feng] Shandong Univ, Affiliated Hosp, Taishan Med Coll, Dept Neurol, Tai An 271000, Shandong, Peoples R China. [Sun, Baoliang; Zhang, Feng] Shandong Univ, Affiliated Hosp, Taishan Med Coll, Key Lab Cerebral Microcirculat, Tai An 271000, Shandong, Peoples R China. [Hu, Xiaoming; Cao, Guodong; Chen, Jun; Zhang, Feng] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res,Educ & Clin Ctr, Pittsburgh, PA 15240 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, S-507 Biomed Sci Tower, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu; zhanfx2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417; Zhang, Meijuan/0000-0002-5375-5349 FU National Institutes of Health/National Institute of Neurological Disorders and Stroke [NS36736, NS43802, NS45048]; American Heart Association [10SDG2560122]; Natural Science Foundation of China [81228008, 81271276, 81271275, 81070947, 81020108021, 81171149, 81371306]; Doctoral Fund of Ministry of Education of China [20120071110042]; Natural Science Foundation of Shandong [Y2007C014] FX This work was supported by grants from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NS36736, NS43802, and NS45048 to J.C.), the American Heart Association (10SDG2560122 to F.Z.), the Natural Science Foundation of China (81228008 to J.C.; 81271276 to F.Z.; 81271275 and 81070947 to B. S.; 81020108021, 81171149, and 81371306 to Y.G.), the Doctoral Fund of Ministry of Education of China (20120071110042 to J.C.), and the Natural Science Foundation of Shandong (Y2007C014 to B.S.). We thank Dr. Richard M. LoPachin (Albert Einstein College of Medicine) for calculating the electrophilicity indexes of 4-HNE and 4-HHE. We also thank Carol Culver for editorial assistance and Pat Strickler for secretarial support. NR 76 TC 40 Z9 42 U1 3 U2 19 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JAN 29 PY 2014 VL 34 IS 5 BP 1903 EP 1915 DI 10.1523/JNEUROSCI.4043-13.2014 PG 13 WC Neurosciences SC Neurosciences & Neurology GA AB0AU UT WOS:000331455000030 PM 24478369 ER PT J AU Xu, GG McMahan, CA Walter, CA AF Xu, Guogang McMahan, C. Alex Walter, Christi A. TI Early-Life Exposure to Benzo[a]pyrene Increases Mutant Frequency in Spermatogenic Cells in Adulthood SO PLOS ONE LA English DT Article ID NUCLEOTIDE EXCISION-REPAIR; LUNG-CANCER RISK; MALE GERM-CELLS; DNA-ADDUCTS; CHILDRENS HEALTH; SPONTANEOUS MUTATION; PHAGOCYTIC FUNCTION; SECONDHAND SMOKE; GENE-EXPRESSION; TRANSGENIC MICE AB Children are vulnerable to environmental mutagens, and the developing germline could also be affected. However, little is known about whether exposure to environmental mutagens in childhood will result in increased germline mutations in subsequent adult life. In the present study, male transgenic lacI mice at different ages (7, 25 and 60 days old) were treated with a known environmental mutagen (benzo[a]pyrene, B[a]P) at different doses (0, 50, 200 or 300 mg/kg body weight). Mutant frequency was then determined in a meiotic cell type (pachytene spermatocyte), a post-meiotic cell type (round spermatid) and epididymal spermatozoa after at least one cycle of spermatogenesis. Our results show that 1) mice treated with B[a]P at 7 or 25 days old, both being pre-adult ages, had significantly increased mutant frequencies in all spermatogenic cell types tested when they were 60 days old; 2) spermatogenic cells from mice treated before puberty were more susceptible to B[a]P-associated mutagenesis compared to adult mice; and 3) unexpectedly, epididymal spermatozoa had the highest mutant frequency among the spermatogenic cell types tested. These data show that pre-adult exposure to B[a]P increases the male germline mutant frequency in young adulthood. The data demonstrate that exposure to environmental genotoxins at different life phases (e.g., pre-adult and adult) can have differential effects on reproductive health. C1 [Xu, Guogang; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Sci, San Antonio, TX 78229 USA. [Walter, Christi A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU [AG021163] FX Funding was provided by AG021163, http://www.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 69 TC 4 Z9 4 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 29 PY 2014 VL 9 IS 1 AR e87439 DI 10.1371/journal.pone.0087439 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 301ZC UT WOS:000330570000145 PM 24489914 ER PT J AU Heredia, A Davis, C Amin, MN Le, NM Wainberg, MA Oliveira, M Deeks, SG Wang, LX Redfield, RR AF Heredia, Alonso Davis, Charles Amin, Mohammed N. Le, Nhut M. Wainberg, Mark A. Oliveira, Maureen Deeks, Steven G. Wang, Lai-Xi Redfield, Robert R. TI Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1 SO AIDS LA English DT Article DE antiretroviral therapy; cytosine analogs; drug resistance; emtricitabine; HIV-1; M184V mutation; nucleoside analog reverse transcriptase inhibitors; resource-limited setting ID RESOURCE-LIMITED SETTINGS; REVERSE-TRANSCRIPTASE INHIBITORS; DRUG-RESISTANCE; RIBONUCLEOTIDE REDUCTASE; ANTIRETROVIRAL TREATMENT; SYNERGISTIC INHIBITION; VIROLOGICAL FAILURE; PROCESSIVITY DEFECT; LEUKEMIA-CELLS; DNA-SYNTHESIS AB Objective:The M184V mutation in the HIV-1 reverse transcriptase gene is frequent (>50%) in patients, both in resource-rich and resource-limited countries, conferring high-level resistance (>100-fold) to the cytosine analog reverse transcriptase inhibitors lamivudine and emtricitabine. The reverse transcriptase enzyme of M184V HIV-1 mutants has reduced processivity, resulting in reduced viral replication, particularly at low deoxynucleotide (dNTP) levels. We hypothesized that lowering intracellular dNTPs with resveratrol, a dietary supplement, could interfere with replication of M184V HIV-1 mutants.Design and methods:Evaluation of the activity of resveratrol on infection of primary peripheral blood lymphocytes by wild-type and M184V mutant HIV-1. We assayed both molecular clones and primary isolates of HIV-1, containing M184V alone and in combination with other reverse transcriptase mutations. Viral infection was quantified by p24 ELISA and by quantitative real-time PCR analysis. Cell viability was measured by colorimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assays.Results:In virus-infectivity assays, resveratrol did not inhibit replication of wild-type NL4-3 (resveratrol EC50>10mol/l), but it inhibited NL4-3 184V mutant (resveratrol EC50=5.8mol/l). These results were confirmed by real-time PCR analysis of early and late products of reverse transcription. Resveratrol inhibited molecular clones and primary isolates carrying M184V, alone or in combination with other reverse transcriptase mutations (resveratrol EC50 values ranging from 2.5 to 7.7mol/l).Conclusions:Resveratrol inhibits HIV-1 strains carrying the M184V mutation in reverse transcriptase. We propose resveratrol as a potential adjuvant in HIV-1 therapy, particularly in resource-limited settings, to help control emtricitabine-resistant M184V HIV-1mutants. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Heredia, Alonso; Davis, Charles; Amin, Mohammed N.; Le, Nhut M.; Wang, Lai-Xi; Redfield, Robert R.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. [Wainberg, Mark A.; Oliveira, Maureen] McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada. [Deeks, Steven G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Deeks, Steven G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Heredia, A (reprint author), Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA. EM aheredia@ihv.umaryland.edu FU Institute of Human Virology; NIAID [K24AI069994]; UCSF/Gladstone Institute of Virology & Immunology CFAR [P30 AI027763]; UCSF Clinical and Translational Research Institute Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24 AI067039] FX This work was supported in part by research funds from the Institute of Human Virology. HIV-1 primary isolates were from patients in the SCOPE cohort, which was supported by the NIAID (K24AI069994), the UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763), the UCSF Clinical and Translational Research Institute Clinical Research Center (UL1 RR024131), the Center for AIDS Prevention Studies (P30 MH62246), and the CFAR Network of Integrated Systems (R24 AI067039). NR 44 TC 6 Z9 6 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JAN 28 PY 2014 VL 28 IS 3 BP 317 EP 323 DI 10.1097/QAD.0000000000000168 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AB1OA UT WOS:000331560500004 PM 24326355 ER PT J AU Yukl, SA Sinclair, E Somsouk, M Hunt, PW Epling, L Killian, M Girling, V Li, PL Havlir, DV Deeks, SG Wong, JK Hatano, H AF Yukl, Steven A. Sinclair, Elizabeth Somsouk, Ma Hunt, Peter W. Epling, Lorrie Killian, Maudi Girling, Valerie Li, Peilin Havlir, Diane V. Deeks, Steven G. Wong, Joseph K. Hatano, Hiroyu TI A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4 R T cells, including myeloid cells SO AIDS LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; LYMPHOID-TISSUE; GASTROINTESTINAL-TRACT; INTESTINAL-MUCOSA; VIRAL PERSISTENCE; POSITIVE PATIENTS; INFECTION; MACROPHAGES; GUT AB We compared different techniques for measuring gut HIV reservoirs and assessed for HIV in non-CD4(+) T cells. HIV DNA levels were similar when measured from rectal biopsies and isolated rectal cells, while HIV RNA tended to be higher in rectal cells. HIV DNA levels in total rectal cells were greater than those predicted from levels in sorted CD4(+) T cells, suggesting a reservoir in non-CD4(+) T cells, and HIV DNA was detected in sorted myeloid cells (7/7 subjects). C1 [Yukl, Steven A.; Li, Peilin; Wong, Joseph K.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sinclair, Elizabeth; Somsouk, Ma; Hunt, Peter W.; Epling, Lorrie; Killian, Maudi; Girling, Valerie; Havlir, Diane V.; Deeks, Steven G.; Wong, Joseph K.; Hatano, Hiroyu] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Yukl, SA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111W3, San Francisco, CA 94121 USA. EM steven.yukl@ucsf.edu FU U.S. Department of Veterans Affairs [1 IK2 CX000520-01, I01 BX000192]; Delaney AIDS Research Enterprise (DARE) [U19AI096109]; UCSF-Gladstone Center for AIDS Research (CFAR) [P30-AI027763]; National Cancer Institute [K23 CA157929]; National Institute of Allergy and Infectious Diseases at the National Institutes of Health [R56AI091573, K24 AI069994] FX the U.S. Department of Veterans Affairs [1 IK2 CX000520-01 (to S.Y.), I01 BX000192 (to J.W.)]; the Delaney AIDS Research Enterprise (DARE) [U19AI096109]; the UCSF-Gladstone Center for AIDS Research (CFAR) [P30-AI027763]; the National Cancer Institute [K23 CA157929 (to M.S.)]; and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health [R56AI091573 [J.W., S.Y., A.S., D.H.] and K24 AI069994 (to S.D.)]. NR 24 TC 16 Z9 16 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JAN 28 PY 2014 VL 28 IS 3 BP 439 EP 442 DI 10.1097/QAD.0000000000000166 PG 4 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AB1OA UT WOS:000331560500017 PM 24322272 ER PT J AU Poulin, C Shiner, B Thompson, P Vepstas, L Young-Xu, Y Goertzel, B Watts, B Flashman, L McAllister, T AF Poulin, Chris Shiner, Brian Thompson, Paul Vepstas, Linas Young-Xu, Yinong Goertzel, Benjamin Watts, Bradley Flashman, Laura McAllister, Thomas TI Predicting the Risk of Suicide by Analyzing the Text of Clinical Notes SO PLOS ONE LA English DT Article ID HEALTH SYSTEM; UNITED-STATES; PRIMARY-CARE; DEPRESSION; VETERANS; THOUGHTS; COMORBIDITY; IDEATION; ALTITUDE; OUTCOMES AB We developed linguistics-driven prediction models to estimate the risk of suicide. These models were generated from unstructured clinical notes taken from a national sample of U. S. Veterans Administration (VA) medical records. We created three matched cohorts: veterans who committed suicide, veterans who used mental health services and did not commit suicide, and veterans who did not use mental health services and did not commit suicide during the observation period (n = 70 in each group). From the clinical notes, we generated datasets of single keywords and multi-word phrases, and constructed prediction models using a machine-learning algorithm based on a genetic programming framework. The resulting inference accuracy was consistently 65% or more. Our data therefore suggests that computerized text analytics can be applied to unstructured medical records to estimate the risk of suicide. The resulting system could allow clinicians to potentially screen seemingly healthy patients at the primary care level, and to continuously evaluate the suicide risk among psychiatric patients. C1 [Poulin, Chris; Thompson, Paul; Flashman, Laura; McAllister, Thomas] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA. [Poulin, Chris; Thompson, Paul; Flashman, Laura; McAllister, Thomas] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Poulin, Chris; Thompson, Paul; Vepstas, Linas] Durkheim Project, Portsmouth, NH USA. [Shiner, Brian; Young-Xu, Yinong; Watts, Bradley] US Dept Vet Affairs, White River Junct VA Med Ctr, White River Jct, VT USA. [Goertzel, Benjamin] Novamente LLC, Rockville, MD USA. RP Poulin, C (reprint author), Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA. EM chris@durkheimproject.org FU Defense Advanced Research Projects Agency (DARPA); Space Warfare Systems Center Pacific [N66001-11-4006]; Intelligence Advanced Research Projects Activity (IARPA) via the Department of Interior National Business Center [N10PC20221] FX This material is based upon work supported by the Defense Advanced Research Projects Agency (DARPA), and Space Warfare Systems Center Pacific under Contract N66001-11-4006. Also supported by, the Intelligence Advanced Research Projects Activity (IARPA) via the Department of Interior National Business Center contract number N10PC20221. The opinions, findings and conclusions or recommendations expressed in this material are those of the authors(s) and do not necessarily reflect the views of the Defense Advanced Research Projects Agency (DARPA) and the Space Naval Warfare Systems Center Pacific, or IARPA, DOI/NBC, or the U. S. Government. The funders had no role in study design, data collection and analysis, or preparation of the manuscript. NR 36 TC 17 Z9 17 U1 4 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 28 PY 2014 VL 9 IS 1 AR e85733 DI 10.1371/journal.pone.0085733 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 301CJ UT WOS:000330510000018 PM 24489669 ER PT J AU Wu, A Good, C Downs, JR Fine, MJ Pugh, MJV Anzueto, A Mortensen, EM AF Wu, Albert Good, Chester Downs, John R. Fine, Michael J. Pugh, Mary Jo V. Anzueto, Antonio Mortensen, Eric M. TI The Association of Cardioprotective Medications with Pneumonia-Related Outcomes SO PLOS ONE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-DISTRESS-SYNDROME; ACUTE CORONARY SYNDROMES; HEART-DISEASE; INFECTION; COMPLICATION; POLYMORPHISM; MORTALITY; ACCURACY; RECEPTOR AB Introduction: Little research has examined whether cardiovascular medications, other than statins, are associated with improved outcomes after pneumonia. Our aim was to examine the association between the use of beta-blockers, statins, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) with pneumonia-related outcomes. Materials and Methods: We conducted a retrospective population-based study on male patients >= 65 years of age hospitalized with pneumonia and who did not have pre-existing cardiac disease. Our primary analyses were multilevel regression models that examined the association between cardiovascular medication classes and either mortality or cardiovascular events. Results: Our cohort included 21,985 patients: 22% died within 90 days of admission, and 22% had a cardiac event within 90 days. The cardiovascular medications studied that were associated with decreased 90-day mortality included: statins (OR 0.70, 95% CI 0.63-0.77), ACE inhibitors (OR 0.82, 95% CI 0.74-0.91), and ARBs (OR 0.58, 95% CI 0.44-0.77). However, none of the medications were significantly associated with decreased cardiovascular events. Discussion: While statins, ACE inhibitors, and ARBs, were associated with decreased mortality, there was no significant association with decreased CV events. These results indicate that this decreased mortality is unlikely due to their potential cardioprotective effects. C1 [Wu, Albert; Downs, John R.; Pugh, Mary Jo V.; Anzueto, Antonio] South Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX USA. [Wu, Albert; Downs, John R.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, San Antonio, TX 78229 USA. [Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA. [Good, Chester; Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Good, Chester; Fine, Michael J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Med Serv, Dallas, TX 75216 USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. RP Mortensen, EM (reprint author), VA North Texas Hlth Care Syst, Med Serv, Dallas, TX 75216 USA. EM Eric.Mortensen@UTSouthwestern.edu OI Pugh, Mary Jo/0000-0003-4196-7763; Mortensen, Eric/0000-0002-3880-5563 FU National Institute of Nursing Research [R01NR010828] FX This work was supported by grant number (R01NR010828) from the National Institute of Nursing Research. This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 5 Z9 5 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 28 PY 2014 VL 9 IS 1 AR e85797 DI 10.1371/journal.pone.0085797 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 301CJ UT WOS:000330510000019 PM 24489672 ER PT J AU Kaz, AM Grady, WM AF Kaz, Andrew M. Grady, William M. TI Epigenetic biomarkers in esophageal cancer SO CANCER LETTERS LA English DT Review DE DNA methylation; Biomarker; Barrett's esophagus; Esophageal adenocarcinoma; Esophageal squamous cell carcinoma ID SQUAMOUS-CELL CARCINOMA; CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENES; BARRETTS-ESOPHAGUS; PROMOTER HYPERMETHYLATION; NEOPLASTIC PROGRESSION; EARLY EVENT; PREDICTS PROGRESSION; POOR-PROGNOSIS; E-CADHERIN AB The aberrant DNA methylation of tumor suppressor genes is well documented in esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC) as well as in Barrett's esophagus (BE), a pre-malignant condition that is associated with chronic acid reflux. BE is a well-recognized risk factor for the development of EAC, and consequently the standard of care is for individuals with BE to be placed in endoscopic surveillance programs aimed at detecting early histologic changes that associate with an increased risk of developing EAC. Yet because the absolute risk of EAC in individuals with BE is minimal, a clinical need in the management of BE is the identification of additional risk markers that will indicate individuals who are at a significant absolute risk of EAC so that they may be subjected to more intensive surveillance. The best currently available risk marker is the degree of dysplasia in endoscopic biopsies from the esophagus; however, this marker is suboptimal for a variety of reasons. To date, there are no molecular biomarkers that have been translated to widespread clinical practice. The search for biomarkers, including hypermethylated genes, for either the diagnosis of BE, EAC, or ESCC or for risk stratification for the development of EAC in those with BE is currently an area of active research. In this review, we summarize the status of identified candidate epigenetic biomarkers for BE, EAC, and ESCC. Most of these aberrantly methylated genes have been described in the context of early detection or diagnostic markers; others might prove useful for estimating prognosis or predicting response to treatment. Finally, special attention will be paid to some of the challenges that must be overcome in order to develop clinically useful esophageal cancer biomarkers. Published by Elsevier Ireland Ltd. C1 [Kaz, Andrew M.; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. RP Kaz, AM (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave North,D4-100, Seattle, WA 98109 USA. EM akaz@fhcrc.org; wgrady@fhcrc.org FU NIH [5KO8DK080630-05, 5U01CA152756-02, 1U54CA163060, 5U01CA 152756, 5U54CA143682]; Burroughs Wellcome Fund FX This work was supported by the NIH (5KO8DK080630-05, 5U01CA152756-02) to AMK; and NIH (1U54CA163060, 5U01CA 152756, 5U54CA143682) and Burroughs Wellcome Fund to WMG. We regret that we were not able to discuss all the outstanding research being done in this area, but space restraints prevented us from being able to cite all the relevant studies related to epigenetic alterations and esophageal cancer. NR 80 TC 24 Z9 25 U1 2 U2 21 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3835 EI 1872-7980 J9 CANCER LETT JI Cancer Lett. PD JAN 28 PY 2014 VL 342 IS 2 SI SI BP 193 EP 199 DI 10.1016/j.canlet.2012.02.036 PG 7 WC Oncology SC Oncology GA 278ZJ UT WOS:000328928100005 PM 22406828 ER PT J AU Reese, PP Bloom, RD Shults, J Thomasson, A Mussell, A Rosas, SE Johansen, KL Abt, P Levine, M Caplan, A Feldman, HI Karlawish, J AF Reese, Peter P. Bloom, Roy D. Shults, Justine Thomasson, Arwin Mussell, Adam Rosas, Sylvia E. Johansen, Kirsten L. Abt, Peter Levine, Matthew Caplan, Arthur Feldman, Harold I. Karlawish, Jason TI Functional Status and Survival After Kidney Transplantation SO TRANSPLANTATION LA English DT Article DE Older age; Functional status; Kidney transplant; Survival ID DIALYSIS PATIENTS; RENAL-TRANSPLANTATION; HEMODIALYSIS-PATIENTS; PHYSICAL FUNCTION; OLDER-ADULTS; CANDIDATES; MORTALITY; ASSOCIATION; INFLAMMATION; POPULATION AB Background Older patients constitute a growing proportion of U.S. kidney transplant recipients and often have a high burden of comorbidities. A summary measure of health such as functional status might enable transplant professionals to better evaluate and counsel these patients about their prognosis after transplant. Methods We linked United Network for Organ Sharing registry data about posttransplantation survival with pretransplantation functional status data (physical function [PF] scale of the Medical Outcomes Study Short Form-36) among individuals undergoing kidney transplant from June 1, 2000 to May 31, 2006. We examined the relationship between survival and functional status with multivariable Cox regression, adjusted for age. Using logistic regression models for 3-year survival, we also estimated the reduction in deaths in the hypothetical scenario that recipients with poor functional status in this cohort experienced modest improvements in function. Results The cohort comprised 10,875 kidney transplant recipients with a mean age of 50 years; 14% were 65. Differences in 3-year mortality between highest and lowest PF groups ranged from 3% among recipients <35 years to 14% among recipients 65 years. In multivariable Cox regression, worse PF was associated with higher mortality (hazard ratio, 1.66 for lowest vs. highest PF quartiles; P<0.001). Interactions between PF and age were nonsignificant. We estimated that 11% fewer deaths would occur if kidney transplant recipients with the lowest functional status experienced modest improvements in function. Conclusions Across a wide age range, functional status was an independent predictor of posttransplantation survival. Functional status assessment may be a useful tool with which to counsel patients about posttransplantation outcomes. C1 [Reese, Peter P.; Bloom, Roy D.; Mussell, Adam; Rosas, Sylvia E.; Feldman, Harold I.] Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA. [Reese, Peter P.; Feldman, Harold I.; Karlawish, Jason] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Reese, Peter P.; Feldman, Harold I.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Reese, Peter P.; Karlawish, Jason] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Shults, Justine; Thomasson, Arwin] Univ Penn, Dept Biostat, Philadelphia, PA 19104 USA. [Rosas, Sylvia E.] Philadelphia Veteran Affairs Med Ctr, Philadelphia, PA USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Abt, Peter; Levine, Matthew] Univ Penn, Perelman Sch Med, Dept Surg, Philadelphia, PA 19104 USA. [Caplan, Arthur] NYU, Div Med Eth, New York, NY USA. [Karlawish, Jason] Univ Penn, Perelman Sch Med, Div Geriatr, Philadelphia, PA 19104 USA. RP Reese, PP (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 917 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM peter.reese@uphs.upenn.edu RI Levine, Matthew/O-4809-2015 OI Levine, Matthew/0000-0003-4525-5827 FU Society of Specialty Professors; American Society of Nephrology; John A. Hartford Foundation; Atlantic Philanthropies; [R01-DK090388-01A1] FX P.P.R. was supported by R01-DK090388-01A1 and by a grant from the Society of Specialty Professors, the American Society of Nephrology, the John A. Hartford Foundation, and the Atlantic Philanthropies. NR 39 TC 7 Z9 7 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD JAN 27 PY 2014 VL 97 IS 2 BP 189 EP 195 DI 10.1097/TP.0b013e3182a89338 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA AH0VE UT WOS:000335837900017 PM 24113514 ER PT J AU Johnson, CS Frei, CR Metersky, ML Anzueto, AR Mortensen, EM AF Johnson, Christopher S. Frei, Christopher R. Metersky, Mark L. Anzueto, Antonio R. Mortensen, Eric M. TI Non-invasive mechanical ventilation and mortality in elderly immunocompromised patients hospitalized with pneumonia: a retrospective cohort study SO BMC PULMONARY MEDICINE LA English DT Article DE Mechanical ventilation; Mortality; Immunocompromised; Pneumonia ID ACUTE RESPIRATORY-FAILURE; COMMUNITY-ACQUIRED PNEUMONIA; IMMUNOSUPPRESSED PATIENTS; OUTCOMES; TRIAL AB Background: Mortality after pneumonia in immunocompromised patients is higher than for immunocompetent patients. The use of non-invasive mechanical ventilation for patients with severe pneumonia may provide beneficial outcomes while circumventing potential complications associated with invasive mechanical ventilation. The aim of our study was to determine if the use of non-invasive mechanical ventilation in elderly immunocompromised patients with pneumonia is associated with higher all-cause mortality. Methods: In this retrospective cohort study, data were obtained from the Department of Veterans Affairs administrative databases. We included veterans age >= 65 years who were immunocompromised and hospitalized due to pneumonia. Multilevel logistic regression analysis was used to determine the relationship between the use of invasive versus non-invasive mechanical ventilation and 30-day and 90-day mortality. Results: Of 1,946 patients in our cohort, 717 received non-invasive mechanical ventilation and 1,229 received invasive mechanical ventilation. There was no significant association between all-cause 30-day mortality and non-invasive versus invasive mechanical ventilation in our adjusted model (odds ratio (OR) 0.85, 95% confidence interval (CI) 0.66-1.10). However, those patients who received non-invasive mechanical ventilation had decreased 90-day mortality (OR 0.66, 95% CI 0.52-0.84). Additionally, receipt of guideline-concordant antibiotics in our immunocompromised cohort was significantly associated with decreased odds of 30-day mortality (OR 0.31, 95% CI 0.24-0.39) and 90-day mortality (OR 0.41, 95% CI 0.31-0.53). Conclusions: Our findings suggest that physicians should consider the use of non-invasive mechanical ventilation, when appropriate, for elderly immunocompromised patients hospitalized with pneumonia. C1 [Johnson, Christopher S.; Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Johnson, Christopher S.; Mortensen, Eric M.] Dallas VA Med Ctr, VA North Texas Hlth Care Syst, Dallas, TX 75216 USA. [Frei, Christopher R.; Anzueto, Antonio R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Frei, Christopher R.; Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Frei, Christopher R.] Univ Texas Austin, Austin, TX 78712 USA. [Metersky, Mark L.] Univ Connecticut, Sch Med, Farmington, CT 06030 USA. RP Mortensen, EM (reprint author), Univ Texas SW Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM eric.mortensen@utsouthwestern.edu OI Mortensen, Eric/0000-0002-3880-5563 FU National Institute of Nursing Research [R01NR010828] FX The project described was supported by Grant Number R01NR010828 from the National Institute of Nursing Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research or the National Institutes of Health. This material is the result of work supported with resources and the use of facilities at the VA North Texas Health Care System. Funding agencies had no role in conducting the study, or role in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 23 TC 2 Z9 3 U1 2 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2466 J9 BMC PULM MED JI BMC Pulm. Med. PD JAN 27 PY 2014 VL 14 AR 7 DI 10.1186/1471-2466-14-7 PG 10 WC Respiratory System SC Respiratory System GA AB1QT UT WOS:000331569100003 PM 24468062 ER PT J AU Mathalon, DH Ahn, KH Perry, EB Cho, HS Roach, BJ Blais, RK Bhakta, S Ranganathan, M Ford, JM D'Souza, DC AF Mathalon, Daniel H. Ahn, Kyung-Heup Perry, Edward B. Cho, Hyun-Sang Roach, Brian J. Blais, Rebecca K. Bhakta, Savita Ranganathan, Mohini Ford, Judith M. D'Souza, Deepak Cyril TI Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans SO FRONTIERS IN PSYCHIATRY LA English DT Article DE schizophrenia; nicotine; ketamine; N-methyl-D-aspartatereceptor; nicotinic acetylcholine receptor; event-related potential; mismatch negativity; P300 AB Background: N-methyl-d-aspartate (NMDA) receptor hypofunction has been implicated in the pathophysiology of schizophrenia and its associated neurocognitive impairments. The high rate of cigarette smoking in schizophrenia raises questions about how nicotine modulates putative NMDA receptor hypofunction in the illness. Accordingly, we examined the modulatory effects of brain nicotinic acetylcholine receptor (nAChR) stimulation on NMDA receptor hypofunction by examining the interactive effects of nicotine, a nAChR agonist, and ketamine, a non-competitive NMDA receptor antagonist, on behavioral and neurophysiological measures in healthy human volunteers. Methods: From an initial sample of 17 subjects (age range 1855 years), 8 subjects successfully completed 4 test sessions, each separated by at least 3 days, during which they received ketamine or placebo and two injections of nicotine or placebo in a double-blind, counterbalanced manner. Schizophrenia-like effects Positive and Negative Syndrome Scale, perceptual alterations Clinician Administered Dissociative Symptoms Scale, subjective effects Visual Analog Scale and auditory event-related brain potentials (mismatch negativity, MMN; P300) were assessed during each test session. Results: Consistent with existing studies, ketamine induced transient schizophrenia-like behavioral effects. P300 was reduced and delayed by ketamine regardless of whether it was elicited by a target (P3b) or novel (P3a) stimulus, while nicotine only reduced the amplitude of P3a. Nicotine did not rescue P300 from the effects of ketamine; the interactions of ketamine and nicotine were not significant. While nicotine significantly reduced MMN amplitude, ketamine did not. Conclusion: Nicotine failed to modulate ketamine-induced neurophysiological and behavioral effects in this preliminary study. Interestingly, ketamine reduced P3b amplitude and nicotine reduced P3a amplitude, suggesting independent roles of NMDA receptor and nAChR in the generation of P3b and P3a, respectively. C1 [Mathalon, Daniel H.; Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Mathalon, Daniel H.; Roach, Brian J.; Ford, Judith M.] San Francisco VA Med Ctr, Mental Hlth Serv 116D, 4150 Clement St, San Francisco, CA USA. [Ahn, Kyung-Heup; Perry, Edward B.; Cho, Hyun-Sang; Blais, Rebecca K.; Bhakta, Savita; Ranganathan, Mohini; D'Souza, Deepak Cyril] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Ahn, Kyung-Heup; Perry, Edward B.; D'Souza, Deepak Cyril] VA Connecticut Healthcare Syst, Schizophrenia Biol Res Ctr 116A, West Haven, CT USA. [Ahn, Kyung-Heup; Perry, Edward B.; D'Souza, Deepak Cyril] Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, New Haven, CT 06519 USA. [Cho, Hyun-Sang] Yonsei Univ, Coll Med, Dept Psychiat, Seoul, South Korea. RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv 116D, 4150 Clement St, San Francisco, CA USA. EM daniel.mathalon@ucsf.edu FU Department of Veterans Affairs Schizophrenia Biological Research Center; NARSAD FX The authors also thank Angelina Genovese, R.N.C., M.B.A.; Elizabeth O'Donnell, R.N.; Brenda Breault, R.N., B.S.N.; Sonah Yoo, R.Ph.; Robert Sturwold, R.Ph.; and Willie Ford of the Neurobiological Studies Unit at the VA Connecticut Healthcare System, West Haven Campus for their central contributions to the success of this project. The authors also acknowledge the contributions of John Krystal, MD for his role in providing the impetus in conducting the study. The Department of Veterans Affairs Schizophrenia Biological Research Center and a NARSAD Young Investigator Award to Hyun-Sang Cho supported this study. NR 141 TC 11 Z9 11 U1 0 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-0640 J9 FRONT PSYCHIATRY JI Front. Psychiatry PD JAN 24 PY 2014 VL 4 AR 3 DI 10.3389/fpsyt.2014.00003 PG 16 WC Psychiatry SC Psychiatry GA V46QJ UT WOS:000209898400002 PM 24478731 ER PT J AU Goswami, ND Tsalik, EL Naggie, S Miller, WC Horton, JR Pfeiffer, CD Hicks, CB AF Goswami, Neela D. Tsalik, Ephraim L. Naggie, Susanna Miller, William C. Horton, John R. Pfeiffer, Christopher D. Hicks, Charles B. TI A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design SO TRIALS LA English DT Article DE Industry; Pharmaceutical; Bias; Randomization; Methodology; Trial ID CONFLICTS-OF-INTEREST; PHARMACEUTICAL-INDUSTRY; BIOMEDICAL-RESEARCH; CLINICALTRIALS.GOV; IMPACT; ONCOLOGY; QUALITY AB Background: The proportion of clinical research sponsored by industry will likely continue to expand as federal funds for academic research decreases, particularly in the fields of HIV/AIDS and hepatitis C (HCV). While HIV and HCV continue to burden the US population, insufficient data exists as to how industry sponsorship affects clinical trials involving these infectious diseases. Debate exists about whether pharmaceutical companies undertake more market-driven research practices to promote therapeutics, or instead conduct more rigorous trials than their non-industry counterparts because of increased resources and scrutiny. The ClinicalTrials. gov registry, which allows investigators to fulfill a federal mandate for public trial registration, provides an opportunity for critical evaluation of study designs for industry-sponsored trials, independent of publication status. As part of a large public policy effort, the Clinical Trials Transformation Initiative (CTTI) recently transformed the ClinicalTrials. gov registry into a searchable dataset to facilitate research on clinical trials themselves. Methods: We conducted a cross-sectional analysis of 477 HIV and HCV drug treatment trials, registered with ClinicalTrials. gov from 1 October 2007 to 27 September 2010, to study the relationship of study sponsorship with randomized study design. The likelihood of using randomization given industry (versus non-industry) sponsorship was reported with prevalence ratios (PR). PRs were estimated using crude and stratified tabular analysis and Poisson regression adjusting for presence of a data monitoring committee, enrollment size, study phase, number of study sites, inclusion of foreign study sites, exclusion of persons older than age 65, and disease condition. Results: The crude PR was 1.17 (95% CI 0.94, 1.45). Adjusted Poisson models produced a PR of 1.13 (95% CI 0.82, 1.56). There was a trend toward mild effect measure modification by study phase, but this was not statistically significant. In stratified tabular analysis the adjusted PR was 1.14 (95% CI 0.78, 1.68) among phase 2/3 trials and 1.06 (95% CI 0.50, 2.22) among phase 4 trials. Conclusions: No significant relationship was found between industry sponsorship and use of randomization in trial design in this cross-sectional study. Prospective studies evaluating other aspects of trial design may shed further light on the relationship between industry sponsorship and appropriate trial methodology. C1 [Goswami, Neela D.] Emory Univ, Sch Med, Rollins Sch Publ Hlth, Dept Endocrinol,Dept Med, Atlanta, GA 30322 USA. [Tsalik, Ephraim L.; Naggie, Susanna; Hicks, Charles B.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Naggie, Susanna] Duke Clin Res Inst, Durham, NC USA. [Miller, William C.] Univ N Carolina, Gillings Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Horton, John R.] GlaxoSmithKline Hlth Care, Parsippany, NJ USA. [Pfeiffer, Christopher D.] Portland VA Med Ctr, Dept Hosp & Specialty Med, Portland, OR USA. [Pfeiffer, Christopher D.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Tsalik, Ephraim L.] Durham VAMC, Res Serv, Durham, NC 27710 USA. RP Goswami, ND (reprint author), Emory Univ, Sch Med, Rollins Sch Publ Hlth, Dept Endocrinol,Dept Med, Atlanta, GA 30322 USA. EM neela.goswami@emory.edu RI Miller, William/H-4800-2014 OI Miller, William/0000-0002-1934-7827 FU FDA; Clinical Science Research and Development Service of the Veterans Health Administration Office of Research and Development [1IK2CX000530] FX This work was supported by a grant from the FDA awarded to Duke University. The study sponsor had no role in the design or performance of this study, or in the writing of the manuscript. We would like to thank Karen Chiswell, Sara Calvert, and Asba Tasneem for facilitating our use of data in the ClinicalTrials.gov registry.; Ephraim Tsalik was supported by Award Number 1IK2CX000530 from the Clinical Science Research and Development Service of the Veterans Health Administration Office of Research and Development. NR 29 TC 3 Z9 3 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD JAN 22 PY 2014 VL 15 AR 31 DI 10.1186/1745-6215-15-31 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AD7SH UT WOS:000333465600001 PM 24450313 ER PT J AU Roussos, P Haroutunian, V AF Roussos, Panos Haroutunian, Vahram TI Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities SO FRONTIERS IN CELLULAR NEUROSCIENCE LA English DT Review DE systems biology; polygenic; node of Ranvier; disconnectivity; GWAS ID FAMILY-BASED ASSOCIATION; CHINESE HAN POPULATION; ANTERIOR CINGULATE CORTEX; MESSENGER-RNA; STRUCTURAL CONNECTIVITY; JAPANESE POPULATION; CONVERGENT EVIDENCE; EXPRESSION ANALYSIS; PREFRONTAL CORTEX; BIPOLAR DISORDER AB Given that the genetic risk for schizophrenia is highly polygenic and the effect sizes, even for rare or de novo events, are modest at best, it has been suggested that multiple biological pathways are likely to be involved in the etiopathogenesis of the disease. Most efforts in understanding the cellular basis of schizophrenia have followed a "neuroncentric" approach, focusing on alterations in neurotransmitter systems and synapse cytoarchitecture. However, multiple lines of evidence coming from genetics and systems biology approaches suggest that apart from neurons, oligodendrocytes and potentially other glia are affected from schizophrenia risk loci. Neurobiological abnormalities linked with genetic association signal could identify abnormalities that are more likely to be primary, versus environmentally induced changes or downstream events. Here, we summarize genetic data that support the involvement of oligodendrocytes in schizophrenia, providing additional evidence for a causal role with the disease. Given the undeniable evidence of both neuronal and glial abnormalities in schizophrenia, we propose a neuro-glial model that invokes abnormalities at the node of Ranvier as a functional unit in the etiopathogenesis of the disease. C1 [Roussos, Panos; Haroutunian, Vahram] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY USA. [Roussos, Panos; Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos; Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Inst Multiscale Biol, New York, NY 10029 USA. [Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. RP Roussos, P (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM panagiotis.roussos@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU NIH [MH066392, MH064673]; Veterans Administration MIRECC FX We thank Dr, Georgios Voloudakis for figures. We apologize for not citing some of papers due to space limitation. Work in the authors' laboratory has been supported by NIH grants MH066392 and MH064673 and Veterans Administration MIRECC. NR 79 TC 29 Z9 29 U1 1 U2 16 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5102 J9 FRONT CELL NEUROSCI JI Front. Cell. Neurosci. PD JAN 21 PY 2014 VL 8 AR 5 DI 10.3389/fncel.2014.00005 PG 7 WC Neurosciences SC Neurosciences & Neurology GA AA4FN UT WOS:000331051100001 PM 24478629 ER PT J AU Volgin, DV Lu, JW Stettner, GM Mann, GL Ross, RJ Morrison, AR Kubin, L AF Volgin, Denys V. Lu, Jackie W. Stettner, Georg M. Mann, Graziella L. Ross, Richard J. Morrison, Adrian R. Kubin, Leszek TI Time- and Behavioral State-Dependent Changes in Posterior Hypothalamic GABA(A) Receptors Contribute to the Regulation of Sleep SO PLOS ONE LA English DT Article ID SUBUNIT MESSENGER-RNAS; EYE-MOVEMENT SLEEP; ADULT-RAT BRAIN; OREXIN NEURONS; SUPRACHIASMATIC NUCLEUS; LATERAL HYPOTHALAMUS; PROTEIN-KINASE; BETA-SUBUNITS; PREOPTIC AREA; REM-SLEEP AB Sleep-wake behavior is regulated by a circadian rhythm, homeostatically and by additional mechanisms that determine the timing of slow-wave sleep and rapid eye movement sleep (REMS) episodes. The posterior hypothalamus coordinates the neural and humoral signals with the rest-activity cycle. It contains wake-active neurons, and is a site where stimulation of inhibitory GABA(A) receptors promotes sleep, whereas their antagonism enhances wakefulness. We explored whether GABAergic mechanisms present in the posterior hypothalamus contribute to the homeostatic and other aspects of sleepwake regulation. Using micropunches of tissue extracted from either the perifornical (PF) or dorsomedial (DM) regions of the posterior hypothalamus of rats, we determined that mRNA levels for selected subunits of GABA(A) receptors (beta(1), beta(3) and epsilon) were higher at the end of the active period or following sleep deprivation, when the need for sleep is high, than after several hours of sleep, when sleep need is partially fulfilled. Such a pattern was present in the PF region only, and was consistent with changes in beta(1) subunit and GABA synthesizing enzyme (GAD) protein levels. In contrast, in the DM region, the levels of GABA(A) receptor subunit mRNAs and proteins (alpha(1), alpha(2), beta 1) and GAD varied with circadian time, but were not responsive to sleep deprivation. Separate experiments with sleep-wake monitoring and local perfusion of the PF region with the GABA(A) receptor antagonist bicuculline revealed that the antagonist had a weaker sleep-reducing effect when sleep need was enhanced by sleep deprivation and that the increased amount of REMS characteristic of the late sleep period was dependent on endogenous GABAergic inhibition. These results support the concept that a varying magnitude of GABAergic inhibition exerted within the PF region contributes to the homeostatic regulation of sleep and shapes its temporal pattern, whereas GABAergic mechanisms in the DM region contribute to circadian regulation. C1 [Volgin, Denys V.; Lu, Jackie W.; Stettner, Georg M.; Mann, Graziella L.; Ross, Richard J.; Morrison, Adrian R.; Kubin, Leszek] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA. [Ross, Richard J.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Ross, Richard J.] Philadelphia Vet Affairs Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. RP Kubin, L (reprint author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA. EM lkubin@vet.upenn.edu FU United States National Institutes of Health [HL-071097]; Deutsche Forschungsgemeinschaft [Ste1899/1-1] FX Support was provided by United States National Institutes of Health grant HL-071097 and Deutsche Forschungsgemeinschaft fellowship DFG Ste1899/1-1 to GMS. Neither the funders nor the Department of Veterans Affairs had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 108 TC 5 Z9 5 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 21 PY 2014 VL 9 IS 1 AR e86545 DI 10.1371/journal.pone.0086545 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 297GT UT WOS:000330244500258 PM 24466145 ER PT J AU Ismahil, MA Hamid, T Bansal, SS Patel, B Kingery, JR Prabhu, SD AF Ismahil, Mohamed Ameen Hamid, Tariq Bansal, Shyam S. Patel, Bindiya Kingery, Justin R. Prabhu, Sumanth D. TI Remodeling of the Mononuclear Phagocyte Network Underlies Chronic Inflammation and Disease Progression in Heart Failure SO CIRCULATION RESEARCH LA English DT Article DE dendritic cells; heart failure; inflammation; monocytes; spleen ID PLASMACYTOID DENDRITIC CELLS; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; ADOPTIVE TRANSFER; STEADY-STATE; KAPPA-B; MONOCYTE; SUBSETS; INFARCTION; SPLEEN; EXPRESSION AB Rationale: The role of mononuclear phagocytes in chronic heart failure (HF) is unknown. Objective: Our aim was to delineate monocyte, macrophage, and dendritic cell trafficking in HF and define the contribution of the spleen to cardiac remodeling. Methods and Results: We evaluated C57Bl/6 mice with chronic HF 8 weeks after coronary ligation. As compared with sham-operated controls, HF mice exhibited: (1) increased proinflammatory CD11b(+)F4/80(+)CD206(-) macrophages and CD11b(+)F4/80(+)Gr-1(hi) monocytes in the heart and peripheral blood, respectively, and reduced CD11b(+)F4/80(+)Gr-1(hi) monocytes in the spleen; (2) significantly increased CD11c(+)B220(-) classical dendritic cells and CD11c(+/low)B220(+) plasmacytoid dendritic cells in both the heart and spleen, and increased classic dendritic cells and plasmacytoid dendritic cells in peripheral blood and bone marrow, respectively; (3) increased CD4(+) helper and CD8(+) cytotoxic T-cells in the spleen; and (4) profound splenic remodeling with abundant white pulp follicles, markedly increased size of the marginal zone and germinal centers, and increased expression of alarmins. Splenectomy in mice with established HF reversed pathological cardiac remodeling and inflammation. Splenocytes adoptively transferred from mice with HF, but not from sham-operated mice, homed to the heart and induced long-term left ventricular dilatation, dysfunction, and fibrosis in naive recipients. Recipient mice also exhibited monocyte activation and splenic remodeling similar to HF mice. Conclusions: Activation of mononuclear phagocytes is central to the progression of cardiac remodeling in HF, and heightened antigen processing in the spleen plays a critical role in this process. Splenocytes (presumably splenic monocytes and dendritic cells) promote immune-mediated injurious responses in the failing heart and retain this memory on adoptive transfer. C1 [Ismahil, Mohamed Ameen; Hamid, Tariq; Bansal, Shyam S.; Patel, Bindiya; Prabhu, Sumanth D.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA. [Ismahil, Mohamed Ameen; Hamid, Tariq; Bansal, Shyam S.; Patel, Bindiya; Prabhu, Sumanth D.] Birmingham VAMC, Birmingham, AL USA. [Kingery, Justin R.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. RP Prabhu, SD (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, 311 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA. EM sprabhu@uab.edu FU VA Merit Award; National Institutes of Health grants [HL-78825, HL-99014]; American Heart Association SDG award [0835456 N] FX This work was supported by a VA Merit Award (to S.D.P.), National Institutes of Health grants HL-78825 and HL-99014 (to S.D.P.), and an American Heart Association SDG award 0835456 N (to T.H.). NR 47 TC 55 Z9 59 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7330 EI 1524-4571 J9 CIRC RES JI Circ.Res. PD JAN 17 PY 2014 VL 114 IS 2 BP 266 EP 282 DI 10.1161/CIRCRESAHA.113.301720 PG 17 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA AG7GU UT WOS:000335587100014 PM 24186967 ER PT J AU Ong, QR Chan, ES Lim, ML Cole, GM Wong, BS AF Ong, Qi-Rui Chan, Elizabeth S. Lim, Mei-Li Cole, Gregory M. Wong, Boon-Seng TI Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice SO SCIENTIFIC REPORTS LA English DT Article ID CEREBRAL GLUCOSE-METABOLISM; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; SYNAPTIC PLASTICITY; APOE EPSILON-4; MOUSE MODEL; SIGNALING PATHWAY; TRANSPORT PROTEIN; TRANSGENIC MICE AB Human ApoE4 accelerates memory decline in ageing and in Alzheimer's disease. Although intranasal insulin can improve cognition, this has little effect in ApoE4 subjects. To understand this ApoE genotype-dependent effect, we examined brain insulin signaling in huApoE3 and huApoE4 targeted replacement (TR) mice. At 32 weeks, lower insulin receptor substrate 1 (IRS1) at S636/639 and Akt phosphorylation at T308 were detected in fasting huApoE4 TR mice as compared to fasting huApoE3 TR mice. These changes in fasting huApoE4 TR mice were linked to lower brain glucose content and have no effect on plasma glucose level. However, at 72 weeks of age, these early changes were accompanied by reduction in IRS2 expression, IRS1 phosphorylation at Y608, Akt phosphorylation at S473, and MAPK (p38 and p44/42) activation in the fasting huApoE4 TR mice. The lower brain glucose was significantly associated with higher brain insulin in the aged huApoE4 TR mice. These results show that ApoE4 reduces brain insulin signaling and glucose level leading to higher insulin content. C1 [Ong, Qi-Rui; Chan, Elizabeth S.; Lim, Mei-Li; Wong, Boon-Seng] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore. [Cole, Gregory M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Cole, Gregory M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Cole, Gregory M.] Vet Affairs Med Ctr, Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res & Clin Ctr, North Hills, CA USA. RP Ong, QR (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore. EM bswong@nus.edu.sg RI Wong, Boon-Seng/G-2759-2012 OI Wong, Boon-Seng/0000-0002-7118-8077 FU National Medical Research Council [NMRC/1148/2008]; Biomedical Research Council [BMRC/05/1/21/19/401]; Singapore Ministry of Education FX This work was supported by grants to B.S.W. from the National Medical Research Council (NMRC/1148/2008) and the Biomedical Research Council (BMRC/05/1/21/19/401). Q.R.O. and E.S.C. were supported by graduate scholarships from Singapore Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 71 TC 5 Z9 5 U1 0 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD JAN 17 PY 2014 VL 4 AR 3754 DI 10.1038/srep03754 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 291SH UT WOS:000329849100020 PM 24435134 ER PT J AU Shaik, JSB Miller, TM Graham, SH Manole, MD Poloyac, SM AF Shaik, Jafar Sadik B. Miller, Tricia M. Graham, Steven H. Manole, Mioara D. Poloyac, Samuel M. TI Rapid and simultaneous quantitation of prostanoids by UPLC-MS/MS in rat brain SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES LA English DT Article DE Arachidonic acid; Cyclooxygenase; Eicosanoids; Ischemic stroke; Prostanoids; UPLC-MS/MS ID PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; FOCAL CEREBRAL-ISCHEMIA; SOLID-PHASE EXTRACTION; PGE(2) EP2 RECEPTOR; ARACHIDONIC-ACID; CARDIOVASCULAR ACTIONS; HUMAN PLASMA; PROSTAGLANDINS; PROSTACYCLIN AB The metabolites of arachidonic acid (AA) produced from the cyclooxygenase (COX) pathway, collectively termed as prostanoids, and from the CYP 450 pathway, eicosanoids, have been implicated in various neuro-degenerative and neuroinflammatory diseases. This study developed a quantitative UPLC-MS/MS method to simultaneously measure 11 prostanoids including prostaglandins and cyclopentenone metabolites in the rat brain cortical tissue. Linear calibration curves ranging from 0.104 to 33.3 ng/ml were validated. The inter-day and intra-day variance for all metabolites was less than 15%. The extraction recovery efficiency and matrix (deionized water) effects measured at 12.5 ng/ml (750 pg on column) ranged from 88 to 100% and 3 to 14%, respectively, with CV% values below 20%. Additionally, applying the processing and extraction conditions of this method to our previous CYP450 eicosanoids method resulted in overall improvement in extraction recovery and reduction in matrix effects at low (0.417 ng/ml) and high (8.33 ng/ml) concentrations. In rat brain cortical tissue samples, concentrations of prostanoids ranged from 10.2 to 937 pmol/g wet tissue and concentration of eicosanoids ranged from 2.23 to 793 pmol/g wet tissue. These data demonstrate that the successive measurement of prostanoids and eicosanoids from a single extracted sample of rat brain tissue can be achieved with a UPLC-MS/MS system and that this method is necessary for evaluation of these metabolites to delineate their role in various neuroinflammatory and cerebrovascular disorders. (C) 2013 Elsevier BM. All rights reserved. C1 [Shaik, Jafar Sadik B.; Miller, Tricia M.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. [Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Manole, Mioara D.] Childrens Hosp Pittsburgh, Div Pediat Emergency Med, Dept Pediat, Pittsburgh, PA 15261 USA. [Manole, Mioara D.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15261 USA. RP Poloyac, SM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, 807 Salk Hall, Pittsburgh, PA 15261 USA. EM poloyac@pitt.edu RI SHAIK, JAFAR SADIK/A-9638-2010 OI SHAIK, JAFAR SADIK/0000-0001-5776-3138 FU AHA [10BGIA3580040]; NIH [R01HD075760]; [R01NS37459]; [S10RR023461] FX This work was funded by R01NS37459 (SHG), AHA 10BGIA3580040 (MDM), NIH R01HD075760 (MDM), S10RR023461 (SMP). NR 46 TC 6 Z9 6 U1 0 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-0232 EI 1873-376X J9 J CHROMATOGR B JI J. Chromatogr. B PD JAN 15 PY 2014 VL 945 BP 207 EP 216 DI 10.1016/j.jchromb.2013.11.041 PG 10 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 295WS UT WOS:000330147700029 PM 24355215 ER PT J AU Carstens, JL Shahi, P Van Tsang, S Smith, B Creighton, CJ Zhang, YQ Seamans, A Seethammagari, M Vedula, I Levitt, JM Ittmann, MM Rowley, DR Spencer, DM AF Carstens, Julienne L. Shahi, Payam Van Tsang, Susan Smith, Billie Creighton, Chad J. Zhang, Yiqun Seamans, Amber Seethammagari, Mamatha Vedula, Indira Levitt, Jonathan M. Ittmann, Michael M. Rowley, David R. Spencer, David M. TI FGFR1-WNT-TGF-beta Signaling in Prostate Cancer Mouse Models Recapitulates Human Reactive Stroma SO CANCER RESEARCH LA English DT Article ID LARGE GENE LISTS; IN-VITRO; WNT/BETA-CATENIN; PRIMITIVE STREAK; GROWTH-FACTORS; ACTIVATION; CELLS; WNT; TUMORIGENESIS; EXPRESSION AB The reactive stroma surrounding tumor lesions performs critical roles ranging from supporting tumor cell proliferation to inducing tumorigenesis and metastasis. Therefore, it is critical to understand the cellular components and signaling control mechanisms that underlie the etiology of reactive stroma. Previous studies have individually implicated fibroblast growth factor receptor 1 (FGFR1) and canonical WNT/beta-catenin signaling in prostate cancer progression and the initiation and maintenance of a reactive stroma; however, both pathways are frequently found to be coactivated in cancer tissue. Using autochthonous transgenic mouse models for inducible FGFR1 (JOCK1) and prostate-specific and ubiquitously expressed inducible beta-catenin (Pro-Cat and Ubi-Cat, respectively) and bigenic crosses between these lines (Pro-Cat x JOCK1 and Ubi-Cat x JOCK1), we describe WNT-induced synergistic acceleration of FGFR1-driven adenocarcinoma, associated with a pronounced fibroblastic reactive stroma activation surrounding prostatic intraepithelial neoplasia (mPIN) lesions found both in in situ and reconstitution assays. Both mouse and human reactive stroma exhibited increased transforming growth factor-beta (TGF-beta) signaling adjacent to pathologic lesions likely contributing to invasion. Furthermore, elevated stromal TGF-beta signaling was associated with higher Gleason scores in archived human biopsies, mirroring murine patterns. Our findings establish the importance of the FGFR1-WNT-TGF-beta signaling axes as driving forces behind reactive stroma in aggressive prostate adenocarcinomas, deepening their relevance as therapeutic targets. C1 [Carstens, Julienne L.; Shahi, Payam; Seethammagari, Mamatha; Vedula, Indira; Levitt, Jonathan M.; Rowley, David R.; Spencer, David M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Van Tsang, Susan; Ittmann, Michael M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Carstens, Julienne L.; Smith, Billie; Creighton, Chad J.; Zhang, Yiqun; Seamans, Amber; Ittmann, Michael M.; Rowley, David R.; Spencer, David M.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Ittmann, Michael M.] Dept Vet Affairs Med Ctr, Houston, TX USA. RP Spencer, DM (reprint author), Baylor Coll Med, 1 Baylor Plaza,MS245, Houston, TX 77030 USA. EM drowley@bcm.edu; dspencer@bcm.edu OI Carstens, Julienne/0000-0001-9914-0430 FU mouse models for human cancer consortium (MMHCC) [U01-CA84296, NIH R01 CA58093]; NIH [AI036211, CA125123, RR024574]; National Cancer Institute P30 Cancer Center [P30 CA125123] FX This work was financially supported by the mouse models for human cancer consortium (MMHCC) grant U01-CA84296, NIH R01 CA58093; the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (AI036211, CA125123, and RR024574); and the National Cancer Institute P30 Cancer Center support grant (P30 CA125123) for support of the Human Tissue Acquisition and Pathology and Genetically Engineered Mouse Cores. NR 47 TC 12 Z9 12 U1 0 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD JAN 15 PY 2014 VL 74 IS 2 BP 609 EP 620 DI 10.1158/0008-5472.CAN-13-1093 PG 12 WC Oncology SC Oncology GA 294HB UT WOS:000330034200020 PM 24305876 ER PT J AU James, AE Gellad, WF Primack, BA AF James, A. Everette, III Gellad, Walid F. Primack, Brian A. TI Implications of New Insurance Coverage for Access to Care, Cost-Sharing, and Reimbursement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [James, A. Everette, III] Univ Pittsburgh, Sch Hlth Sci, Hlth Policy Inst, Pittsburgh, PA 15261 USA. [James, A. Everette, III] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA. [Primack, Brian A.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15261 USA. RP James, AE (reprint author), Univ Pittsburgh, Hlth Policy Inst, 3550 Terrace St,S306 Scaife Hall, Pittsburgh, PA 15261 USA. EM aejames@pitt.edu NR 8 TC 5 Z9 5 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 15 PY 2014 VL 311 IS 3 BP 241 EP 242 DI 10.1001/jama.2013.283150 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 287TZ UT WOS:000329566400012 PM 24337312 ER PT J AU Ostroff, R Mehan, MR Williams, S Brody, E Pass, H Rom, W Siegfried, J Muley, T Franklin, W Merrick, D van Bokhoven, A Wolf, H Feser, W Baron, AE Miller, Y AF Ostroff, Rachel Mehan, Michael R. Williams, Stephen Brody, Edward Pass, Harvey Rom, William Siegfried, Jill Muley, Thomas Franklin, Wilbur Merrick, Dan van Bokhoven, Adrie Wolf, Holly Feser, William Baron, Anna E. Miller, York TI Distinctive squamous cell carcinoma protein signatures. SO CLINICAL CANCER RESEARCH LA English DT Meeting Abstract CT 3rd AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer CY JAN 06-09, 2014 CL San Diego, CA SP Amer Assoc Canc Res, IASLC C1 [Ostroff, Rachel; Mehan, Michael R.; Williams, Stephen; Brody, Edward] SomaLogic, Boulder, CO USA. [Pass, Harvey; Rom, William] NYU, Langone Med & Canc Ctr, New York, NY USA. [Siegfried, Jill] Univ Minnesota, Minneapolis, MN USA. [Muley, Thomas] Univ Heidelberg Hosp, Heidelberg, Germany. [Franklin, Wilbur; van Bokhoven, Adrie; Wolf, Holly; Feser, William; Baron, Anna E.] Univ Colorado, Ctr Canc, Denver, CO USA. [Merrick, Dan; Miller, York] Univ Colorado, Ctr Canc, Denver, CO 80202 USA. [Merrick, Dan; Miller, York] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JAN 15 PY 2014 VL 20 SU 2 MA PR04 DI 10.1158/1078-0432.14AACRIASLC-PR04 PG 1 WC Oncology SC Oncology GA CR5LV UT WOS:000361385000070 ER PT J AU Barocas, JA Brennan, MB Hull, SJ Stokes, S Fangman, JJ Westergaard, RP AF Barocas, Joshua A. Brennan, Meghan B. Hull, Shawnika J. Stokes, Scott Fangman, John J. Westergaard, Ryan P. TI Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study SO HARM REDUCTION JOURNAL LA English DT Article DE Hepatitis C; Screening; Injection drug use; Stigma; Health care access ID VIRUS-INFECTION; UNITED-STATES; USERS; CARE; PERCEPTIONS; ANTIBODY; BEHAVIOR; IMPACT AB Background: People who inject drugs (PWID) are at high risk of contracting and transmitting and hepatitis C virus (HCV). While accurate screening tests and effective treatment are increasingly available, prior research indicates that many PWID are unaware of their HCV status. Methods: We examined characteristics associated with HCV screening among 553 PWID utilizing a free, multi-site syringe exchange program (SEP) in 7 cities throughout Wisconsin. All participants completed an 88-item, computerized survey assessing past experiences with HCV testing, HCV transmission risk behaviors, and drug use patterns. A subset of 362 clients responded to a series of open-ended questions eliciting their perceptions of barriers and facilitators to screening for HCV. Transcripts of these responses were analyzed qualitatively using thematic analysis. Results: Most respondents (88%) reported receiving a HCV test in the past, and most of these (74%) were tested during the preceding 12 months. Despite the availability of free HCV screening at the SEP, fewer than 20% of respondents had ever received a test at a syringe exchange site. Clients were more likely to receive HCV screening in the past year if they had a primary care provider, higher educational attainment, lived in a large metropolitan area, and a prior history of opioid overdose. Themes identified through qualitative analysis suggested important roles of access to medical care and prevention services, and nonjudgmental providers. Conclusions: Our results suggest that drug-injecting individuals who reside in non-urban settings, who have poor access to primary care, or who have less education may encounter significant barriers to routine HCV screening. Expanded access to primary health care and prevention services, especially in non-urban areas, could address an unmet need for individuals at high risk for HCV. C1 [Barocas, Joshua A.; Brennan, Meghan B.; Westergaard, Ryan P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. [Brennan, Meghan B.] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Brennan, Meghan B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Hull, Shawnika J.] Univ Wisconsin, Sch Journalism & Mass Commun, Madison, WI 53706 USA. [Stokes, Scott; Fangman, John J.] AIDS Resource Ctr Wisconsin, Milwaukee, WI 53208 USA. [Fangman, John J.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Westergaard, Ryan P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA. RP Barocas, JA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, 1685 Highland Ave,UWMFCB 5th Floor, Madison, WI 53705 USA. EM jbarocas@medicine.wisc.edu FU NCATS NIH HHS [UL1TR000427, UL1 TR000427]; NIDA NIH HHS [K23 DA032306, K23DA032306] NR 31 TC 14 Z9 14 U1 0 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1477-7517 J9 HARM REDUCT J JI Harm Reduct. J. PD JAN 14 PY 2014 VL 11 AR 1 DI 10.1186/1477-7517-11-1 PG 8 WC Substance Abuse SC Substance Abuse GA 295JZ UT WOS:000330113700001 PM 24422784 ER PT J AU Borrero, S Zite, N Potter, JE Trussell, J AF Borrero, Sonya Zite, Nikki Potter, Joseph E. Trussell, James TI Medicaid Policy on Sterilization - Anachronistic or Still Relevant? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID FORM C1 [Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. [Borrero, Sonya] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Zite, Nikki] Univ Tennessee, Grad Sch Med, Dept Obstet & Gynecol, Knoxville, TN USA. [Potter, Joseph E.] Univ Texas Austin, Populat Res Ctr, Austin, TX 78712 USA. [Trussell, James] Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA. [Trussell, James] Hull York Med Sch, Kingston Upon Hull, N Humberside, England. RP Borrero, S (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. OI Potter, Joseph/0000-0002-8960-813X FU NICHD NIH HHS [P2C HD047879, R24 HD042849] NR 4 TC 11 Z9 11 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 9 PY 2014 VL 370 IS 2 BP 102 EP 104 DI 10.1056/NEJMp1313325 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AH4TA UT WOS:000336119800004 PM 24401047 ER PT J AU Gettings, J O'Neill, B Chokshi, DA Colbert, JA Gill, P Lebovic, G Lexchin, J Persaud, N AF Gettings, Jennifer O'Neill, Braden Chokshi, Dave A. Colbert, James A. Gill, Peter Lebovic, Gerald Lexchin, Joel Persaud, Navindra TI Differences in the Volume of Pharmaceutical Advertisements between Print General Medical Journals SO PLOS ONE LA English DT Article ID REFERENCES; QUALITY; YES AB Background: Pharmaceutical advertisements have been argued to provide revenue that medical journals require but they are intended to alter prescribing behaviour and they are known to include low quality information. We determined whether a difference exists in the current level of pharmaceutical advertising in print general medical journals, and we estimated the revenue generated from print pharmaceutical advertising. Methods: Six print general medical journals in Canada, the United States, and the United Kingdom were sampled between 2007 and 2012. The number of advertisements and other journal content in selected issues of the Canadian Medical Association Journal (CMAJ), Canadian Family Physician (CFP), Journal of the American Medical Association (JAMA), New England Journal of Medicine (NEJM), British Medical Journal (BMJ), and Lancet were determined. Revenue gained from pharmaceutical advertising was estimated using each journal's 2013 advertising price list. Findings: The two Canadian journals sampled (CMAJ, CFP) contained five times more advertisements than the two American journals (JAMA, NEJM), and two British journals (BMJ, Lancet) (p<0.0001). The estimated annual revenue from pharmaceutical advertisements ranged from 0.025 pound million (for Lancet) to 3.8 pound million (for JAMA). The cost savings due to revenue from pharmaceutical advertising to each individual subscriber ranged from 0.02 pound (for Lancet) to 3.56 pound (for CFP) per issue. Conclusion: The volume of pharmaceutical advertisements differs between general medical journals, with the two Canadian journals sampled containing the most advertisements. International and temporal variations suggest that there is an opportunity for all general medical journals to reduce the number of pharmaceutical advertisements, explore other sources of revenue, and increase transparency regarding sources of revenue. C1 [Gettings, Jennifer; Persaud, Navindra] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada. [O'Neill, Braden; Gill, Peter] Univ Oxford, Dept Primary Care Hlth Sci, Oxford, England. [O'Neill, Braden] Univ Calgary, Fac Med, Calgary, AB, Canada. [Chokshi, Dave A.] US Dept Vet Affairs, Washington, DC USA. [Colbert, James A.] Brigham & Womens Hosp, Div Med Commun, Boston, MA 02115 USA. [Colbert, James A.] Newton Wellesley Hosp, Dept Med, Boston, MA USA. [Gill, Peter] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada. [Lebovic, Gerald] St Michaels Hosp, Appl Hlth Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada. [Lebovic, Gerald] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Lexchin, Joel] York Univ, Sch Hlth Policy & Management, Toronto, ON M3J 2R7, Canada. [Lexchin, Joel] Univ Hlth Network, Emergency Dept, Toronto, ON, Canada. [Lexchin, Joel; Persaud, Navindra] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada. [Persaud, Navindra] St Michaels Hosp, Dept Family & Community Med, Toronto, ON M5B 1W8, Canada. RP Persaud, N (reprint author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada. EM nav.persaud@utoronto.ca OI Chokshi, Dave/0000-0001-7467-4591 NR 20 TC 1 Z9 1 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 8 PY 2014 VL 9 IS 1 AR e84790 DI 10.1371/journal.pone.0084790 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 291WL UT WOS:000329862500169 PM 24416286 ER PT J AU Sargoy, A Sun, XP Barnes, S Brecha, NC AF Sargoy, Allison Sun, Xiaoping Barnes, Steven Brecha, Nicholas C. TI Differential Calcium Signaling Mediated by Voltage-Gated Calcium Channels in Rat Retinal Ganglion Cells and Their Unmyelinated Axons SO PLOS ONE LA English DT Article ID DISPLACED AMACRINE CELLS; BIPOLAR CELLS; MOUSE RETINA; OPTIC-NERVE; BETA-SUBUNITS; IN-VIVO; CURRENTS; NEURONS; MIBEFRADIL; EXPRESSION AB Aberrant calcium regulation has been implicated as a causative factor in the degeneration of retinal ganglion cells (RGCs) in numerous injury models of optic neuropathy. Since calcium has dual roles in maintaining homeostasis and triggering apoptotic pathways in healthy and injured cells, respectively, investigation of voltage-gated Ca channel (VGCC) regulation as a potential strategy to reduce the loss of RGCs is warranted. The accessibility and structure of the retina provide advantages for the investigation of the mechanisms of calcium signalling in both the somata of ganglion cells as well as their unmyelinated axons. The goal of the present study was to determine the distribution of VGCC subtypes in the cell bodies and axons of ganglion cells in the normal retina and to define their contribution to calcium signals in these cellular compartments. We report L-type Ca channel alpha 1C and alpha 1D subunit immunoreactivity in rat RGC somata and axons. The N-type Ca channel alpha 1B subunit was in RGC somata and axons, while the P/Q-type Ca channel alpha 1A subunit was only in the RGC somata. We patch clamped isolated ganglion cells and biophysically identified T-type Ca channels. Calcium imaging studies of RGCs in wholemounted retinas showed that selective Ca channel antagonists reduced depolarization-evoked calcium signals mediated by L-, N-, P/Q- and T-type Ca channels in the cell bodies but only by L-type Ca channels in the axons. This differential contribution of VGCC subtypes to calcium signals in RGC somata and their axons may provide insight into the development of target-specific strategies to spare the loss of RGCs and their axons following injury. C1 [Sargoy, Allison; Sun, Xiaoping; Barnes, Steven; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Sargoy, Allison; Sun, Xiaoping; Barnes, Steven; Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. [Barnes, Steven; Brecha, Nicholas C.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Barnes, Steven] Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS, Canada. [Barnes, Steven] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada. RP Barnes, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. EM sbarnes@dal.ca FU NIH [EY04067]; VA Merit Review; CIHR; NSHRF Regional Partnership Program; NSERC; U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine & Advanced Technology Research Center (TATRC) at Fort Detrick, MD [W81XWH-10-2-0077] FX Support for these studies came from NIH EY04067 (NCB), a VA Merit Review (NCB), a CIHR and NSHRF Regional Partnership Program grant (SB), and NSERC (SB). Part of this work was made possible by a contract agreement awarded to NCB and administered by the U.S. Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC) at Fort Detrick, MD under Contract Number: W81XWH-10-2-0077. NCB is a VA Senior Career Research Scientist. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 65 TC 9 Z9 9 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 8 PY 2014 VL 9 IS 1 AR e84507 DI 10.1371/journal.pone.0084507 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 291WL UT WOS:000329862500133 PM 24416240 ER PT J AU Sproul, AA Jacob, S Pre, D Kim, SH Nestor, MW Navarro-Sobrino, M Santa-Maria, I Zimmer, M Aubry, S Steele, JW Kahler, DJ Dranovsky, A Arancio, O Crary, JF Gandy, S Noggle, SA AF Sproul, Andrew A. Jacob, Samson Pre, Deborah Kim, Soong Ho Nestor, Michael W. Navarro-Sobrino, Miriam Santa-Maria, Ismael Zimmer, Matthew Aubry, Soline Steele, John W. Kahler, David J. Dranovsky, Alex Arancio, Ottavio Crary, John F. Gandy, Sam Noggle, Scott A. TI Characterization and Molecular Profiling of PSEN1 Familial Alzheimer's Disease iPSC-Derived Neural Progenitors SO PLOS ONE LA English DT Article ID PLURIPOTENT STEM-CELLS; 21ST-CENTURY BRAIN BANKING; NEURONAL GENE-EXPRESSION; COLUMBIA-UNIVERSITY; ADULT NEUROGENESIS; TRANSGENIC MICE; HUMAN ES; A-BETA; PRESENILIN-1; ACTIVATION AB Presenilin 1 (PSEN1) encodes the catalytic subunit of gamma-secretase, and PSEN1 mutations are the most common cause of early onset familial Alzheimer's disease (FAD). In order to elucidate pathways downstream of PSEN1, we characterized neural progenitor cells (NPCs) derived from FAD mutant PSEN1 subjects. Thus, we generated induced pluripotent stem cells (iPSCs) from affected and unaffected individuals from two families carrying PSEN1 mutations. PSEN1 mutant fibroblasts, and NPCs produced greater ratios of A beta 42 to A beta 40 relative to their control counterparts, with the elevated ratio even more apparent in PSEN1 NPCs than in fibroblasts. Molecular profiling identified 14 genes differentially-regulated in PSEN1 NPCs relative to control NPCs. Five of these targets showed differential expression in late onset AD/Intermediate AD pathology brains. Therefore, in our PSEN1 iPSC model, we have reconstituted an essential feature in the molecular pathogenesis of FAD, increased generation of A beta 42/40, and have characterized novel expression changes. C1 [Sproul, Andrew A.; Jacob, Samson; Nestor, Michael W.; Zimmer, Matthew; Kahler, David J.; Noggle, Scott A.] New York Stem Cell Fdn, New York, NY 10023 USA. [Pre, Deborah; Santa-Maria, Ismael; Aubry, Soline; Arancio, Ottavio; Crary, John F.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA. [Pre, Deborah; Santa-Maria, Ismael; Aubry, Soline; Arancio, Ottavio; Crary, John F.] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. [Kim, Soong Ho; Steele, John W.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY USA. [Kim, Soong Ho; Steele, John W.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. [Kim, Soong Ho; Steele, John W.; Gandy, Sam] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY USA. [Navarro-Sobrino, Miriam; Dranovsky, Alex] Columbia Univ, Dept Psychiat, New York, NY USA. [Gandy, Sam] James J Peters Vet Adm Med Ctr, Bronx, NY USA. RP Sproul, AA (reprint author), New York Stem Cell Fdn, New York, NY 10023 USA. EM asproul@nsycf.org; snoggle@nyscf.org OI Sproul, Andrew/0000-0001-6972-1592 FU Charles Evans Foundation; Alzheimer's Drug Discovery Foundation; NY Community Trust; National Institutes of Health (NIH) [R21AG042965, 1U01AG046170-01, NS049442, R01MH091844]; Cure Alzheimer's Fund; BrightFocus Foundation; Taub Institute; Aging Brain at Columbia University [P50AG08702, RO1AG037212, P01AG07232] FX This work is generously supported by grants to Scott Noggle by Charles Evans Foundation, Alzheimer's Drug Discovery Foundation, and NY Community Trust. Scott Noggle and Sam Gandy are jointly supported by National Institutes of Health (NIH) grants R21AG042965 and 1U01AG046170-01, and the Cure Alzheimer's Fund. Ottavio Arancio is supported by NIH grant NS049442. Alex Dranovsky is supported by NIH grant R01MH091844. Soong Ho Kim is supported by the BrightFocus Foundation. The authors express their sincerest gratitude to the patients and staff of the Taub Institute for Research on Alzheimer's Disease & the Aging Brain at Columbia University (P50AG08702, RO1AG037212, P01AG07232). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 29 Z9 32 U1 4 U2 16 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 8 PY 2014 VL 9 IS 1 AR e84547 DI 10.1371/journal.pone.0084547 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 291WL UT WOS:000329862500135 PM 24416243 ER PT J AU Walsh, ME Shi, Y Van Remmen, H AF Walsh, Michael E. Shi, Yun Van Remmen, Holly TI The effects of dietary restriction on oxidative stress in rodents SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Review DE Dietary restriction; Calorie restriction; Oxidative stress; Reactive oxygen species; Antioxidant enzymes; Oxidative damage; Aging ID TERM CALORIE RESTRICTION; OXYGEN SPECIES PRODUCTION; SKELETAL-MUSCLE MITOCHONDRIA; RAT-LIVER MITOCHONDRIA; SUPEROXIDE DISMUTASE/CATALASE MIMETICS; AMYOTROPHIC-LATERAL-SCLEROSIS; HYDROGEN-PEROXIDE PRODUCTION; GLUTATHIONE REDOX STATE; DIFFERENT BRAIN-REGIONS; AGE-RELATED INCREASE AB Oxidative stress is observed during aging and in numerous age-related diseases. Dietary restriction (DR) is a regimen that protects against disease and extends life span in multiple species. However, it is unknown how DR mediates its protective effects. One prominent and consistent effect of DR in a number of systems is the ability to reduce oxidative stress and damage. The purpose of this review is to comprehensively examine the hypothesis that dietary restriction reduces oxidative stress in rodents by decreasing reactive oxygen species (ROS) production and increasing antioxidant enzyme activity, leading to an overall reduction of oxidative damage to macromolecules. The literature reveals that the effects of DR on oxidative stress are complex and likely influenced by a variety of factors, including sex, species, tissue examined, types of ROS and antioxidant enzymes examined, and duration of DR. Here we present a comprehensive review of the existing literature on the effect of DR on mitochondrial ROS generation, antioxidant enzymes, and oxidative damage. In a majority of studies, dietary restriction had little effect on mitochondrial ROS production or antioxidant activity. On the other hand, DR decreased oxidative damage in the majority of cases. Although the effects of DR on endogenous antioxidants are mixed, we find that glutathione levels are the most likely antioxidant to be increased by dietary restriction, which supports the emerging redox-stress hypothesis of aging. Published by Elsevier Inc. C1 [Walsh, Michael E.; Shi, Yun; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Shi, Yun; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Van Remmen, Holly] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu FU NIA Training Grant on the Biology of Aging [T32AG021890]; National Institutes of Health - National Institute on Aging Grant [P01AG20591] FX This work was supported by an NIA Training Grant on the Biology of Aging (M.E.W., T32AG021890) and a National - Institutes of Health National Institute on Aging Grant (H.V.R., P01AG20591). NR 229 TC 19 Z9 19 U1 1 U2 24 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JAN 8 PY 2014 VL 66 SI SI BP 88 EP 99 DI 10.1016/j.freeradbiomed.2013.05.037 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 287SQ UT WOS:000329562900011 PM 23743291 ER PT J AU Martin, SS Blaha, MJ Blankstein, R Agatston, A Rivera, JJ Virani, SS Ouyang, P Jones, SR Blumenthal, RS Budoff, MJ Nasir, K AF Martin, Seth S. Blaha, Michael J. Blankstein, Ron Agatston, Arthur Rivera, Juan J. Virani, Salim S. Ouyang, Pamela Jones, Steven R. Blumenthal, Roger S. Budoff, Matthew J. Nasir, Khurram TI Dyslipidemia, Coronary Artery Calcium, and Incident Atherosclerotic Cardiovascular Disease Implications for Statin Therapy From the Multi-Ethnic Study of Atherosclerosis SO CIRCULATION LA English DT Article DE atherosclerosis; cardiovascular diseases; cholesterol; computed tomography ID C-REACTIVE PROTEIN; RISK; GUIDELINES; CHOLESTEROL; EVENTS; TRIALS; SCORE; MESA; RECOMMENDATIONS; INDIVIDUALS AB Background-Worldwide clinical practice guidelines for dyslipidemia emphasize allocating statin therapy to those at the highest absolute atherosclerotic cardiovascular disease (CVD) risk. Methods and Results-We examined 5534 Multi-Ethnic Study of Atherosclerosis (MESA) participants who were not on baseline medications for dyslipidemia. Participants were classified by baseline coronary artery calcium (CAC) score (>0, >= 100) and the common clinical scheme of counting lipid abnormalities (LA), including low-density lipoprotein cholesterol >= 3.36 mmol/L (130 mg/dL), high-density lipoprotein cholesterol <1.03 mmol/L (40 mg/dL) for men or <1.29 mmol/L (50 mg/dL) for women, and triglycerides >= 1.69 mmol/L (150 mg/dL). Our main outcome measure was incident CVD (myocardial infarction, angina resulting in revascularization, resuscitated cardiac arrest, stroke, cardiovascular death). Over a median follow-up of 7.6 years, more than half of events (55%) occurred in the 21% of participants with CAC >= 100. Conversely, 65% of events occurred in participants with 0 or 1 LA. In those with CAC >= 100, CVD rates ranged from 22.7 to 29.5 per 1000 person-years across LA categories. In contrast, with CAC=0, CVD rates ranged from 2.7 to 5.9 per 1000 person-years across LA categories. Individuals with 0 LA and CAC >= 100 had a higher event rate compared with individuals with 3 LA but CAC=0 (22.7 versus 5.9 per 1000 person-years). Similar results were obtained when we classified LA using data set quartiles of total cholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or low-density lipoprotein particle concentration and guideline categories of low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol. Conclusions-CAC may have the potential to help match statin therapy to absolute CVD risk. Across the spectrum of dyslipidemia, event rates similar to secondary prevention populations were observed for patients with CAC >= 100. C1 [Martin, Seth S.; Blaha, Michael J.; Ouyang, Pamela; Jones, Steven R.; Blumenthal, Roger S.; Nasir, Khurram] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA. [Blankstein, Ron] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Noninvas Cardiovasc Imaging Program, Boston, MA 02115 USA. [Blankstein, Ron] Brigham & Womens Hosp, Boston, MA 02115 USA. [Agatston, Arthur] Univ Miami, South Beach Prevent Cardiol Ctr, Miami, FL USA. [Rivera, Juan J.] Columbia Univ, Div Cardiol, Mt Sinai Med Ctr, Miami Beach, FL USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Budoff, Matthew J.] Harbor Univ Calif Los Angeles Med Ctr, Div Cardiol, Los Angeles, CA USA. [Nasir, Khurram] Baptist Hlth Med Grp, Ctr Prevent & Wellness Res, Miami, FL USA. [Nasir, Khurram] Baptist Hlth South Florida, Baptist Cardiovasc Inst, Miami, FL USA. [Nasir, Khurram] Florida Int Univ, Robert Stempel Coll Publ Hlth, Dept Epidemiol, Miami, FL 33199 USA. [Nasir, Khurram] Herbert Wertheim Coll Med, Dept Med, Miami, FL USA. RP Nasir, K (reprint author), Baptist Hlth South Florida, Ctr Wellness & Prevent, 1691 Michigan Ave,Suite 500, Miami Beach, FL 33139 USA. EM khurramn@baptisthealth.net OI Virani, Salim/0000-0001-9541-6954 FU Pollin Cardiovascular Prevention Fellowship; Marie-Josee and Henry R. Kravis endowed fellowship; National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169] FX Dr Martin is supported by the Pollin Cardiovascular Prevention Fellowship, as well as the Marie-Josee and Henry R. Kravis endowed fellowship. MESA, which supplied the data for this analysis, was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute. A group of individual investigators proposed and undertook the present study, for which we did not have any specific funding. National Heart, Lung, and Blood Institute-sponsored MESA committees reviewed and approved the proposal, abstract, and manuscript from the present study. Drs Martin and Nasir had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NR 24 TC 55 Z9 58 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD JAN 7 PY 2014 VL 129 IS 1 BP 77 EP + DI 10.1161/CIRCULATIONAHA.113.003625 PG 16 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AI2YY UT WOS:000336726300013 PM 24141324 ER PT J AU Hawkins, MS Hough, LJ Berger, MA Mor, MK Steenkiste, AR Gao, SS Stone, RA Burkitt, KH Marcus, BH Ciccolo, JT Kriska, AM Klinvex, DT Sevick, MA AF Hawkins, Marquis S. Hough, Linda J. Berger, Marie A. Mor, Maria K. Steenkiste, Ann R. Gao, Shasha Stone, Roslyn A. Burkitt, Kelly H. Marcus, Bess H. Ciccolo, Joseph T. Kriska, Andrea M. Klinvex, Deborah T. Sevick, Mary A. TI Recruitment of veterans from primary care into a physical activity randomized controlled trial: the experience of the VA-STRIDE study SO TRIALS LA English DT Article DE Veterans; Primary care; Physical activity; Overweight; Randomized controlled trial AB Background: Much of the existing literature on physical activity (PA) interventions involves physically inactive individuals recruited from community settings rather than clinical practice settings. Recruitment of patients into interventions in clinical practice settings is difficult due to limited time available in the clinic, identification of appropriate personnel to efficiently conduct the process, and time-consuming methods of recruitment. The purpose of this report is to describe the approach used to identify and recruit veterans from the Veterans Affairs (VA) Pittsburgh Healthcare System Primary Care Clinic into a randomized controlled PA study. Methods: A sampling frame of veterans was developed using the VA electronic medical record. During regularly scheduled clinic appointments, primary care providers (PCPs) screened identified patients for safety to engage in moderate-intensity PA and willingness to discuss the study with research staff members. Research staff determined eligibility with a subsequent telephone screening call and scheduled a research study appointment, at which time signed informed consent and baseline measurements were obtained. Results: Of the 3,482 veterans in the sampling frame who were scheduled for a primary care appointment during the study period, 1,990 (57.2%) were seen in the clinic and screened by the PCP; moderate-intensity PA was deemed safe for 1,293 (37.1%), 871 (25.0%) agreed to be contacted for further screening, 334 (9.6%) were eligible for the study, and 232 (6.7%) enrolled. Conclusions: Using a semiautomated screening approach that combined an electronically-derived sampling frame with paper and pencil prescreening by PCPs and research staff, VA-STRIDE was able to recruit 1 in 15 veterans in the sampling frame. Using this approach, a high proportion of potentially eligible veterans were screened by their PCPs. C1 [Hawkins, Marquis S.] Univ Massachusetts, Amherst Sch Publ Hlth & Hlth Sci, Div Biostat & Epidemiol, Amherst, MA 01003 USA. [Hough, Linda J.; Berger, Marie A.; Mor, Maria K.; Steenkiste, Ann R.; Gao, Shasha; Stone, Roslyn A.; Burkitt, Kelly H.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Mor, Maria K.; Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA. [Marcus, Bess H.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Ciccolo, Joseph T.] Columbia Univ Teachers Coll, Dept Biobehav Sci, New York, NY 10027 USA. [Kriska, Andrea M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Klinvex, Deborah T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15260 USA. [Sevick, Mary A.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA. RP Hawkins, MS (reprint author), Univ Massachusetts, Amherst Sch Publ Hlth & Hlth Sci, Div Biostat & Epidemiol, Amherst, MA 01003 USA. EM mshawkins@schoolph.umass.edu OI Kriska, Andrea/0000-0002-3522-0869 FU Veterans' Administration Health Services Research and Development Service [IIR 07-154] FX This work was supported by the Veterans' Administration Health Services Research and Development Service under award IIR 07-154, and by resources and the use of facilities at the VA Pittsburgh Healthcare System. The authors are grateful for the contributions of Erika Hoffman, MD (Medical Director), and the PCPs and clinic staff from VAPHS UD for screening potential participants; the assistance of Kathleen Sward, PhD, and Robert M Powell, MS, for participant recruitment, PA counseling, and assessments; and Deborah Wetzler, BA, and D Scott Obrosky, MS, for data management and programming. NR 14 TC 2 Z9 2 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD JAN 7 PY 2014 VL 15 AR 11 DI 10.1186/1745-6215-15-11 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA AD7QY UT WOS:000333461000001 PM 24398076 ER PT J AU Jones, SS Rudin, RS Perry, T Shekelle, PG AF Jones, Spencer S. Rudin, Robert S. Perry, Tanja Shekelle, Paul G. TI Health Information Technology: An Updated Systematic Review With a Focus on Meaningful Use SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID CLINICAL DECISION-SUPPORT; PROVIDER ORDER ENTRY; MEDICATION ERRORS; PATIENT OUTCOMES; CARE; MANAGEMENT; EFFICIENCY; IMPROVE; QUALITY; RECORDS AB Background: Incentives offered by the U.S. government have spurred marked increases in use of health information technology (IT). Purpose: To update previous reviews and examine recent evidence that relates health IT functionalities prescribed in meaningful use regulations to key aspects of health care. Data Sources: English-language articles in PubMed from January 2010 to August 2013. Study Selection: 236 studies, including pre-post and time-series designs and clinical trials that related the use of health IT to quality, safety, or efficiency. Data Extraction: Two independent reviewers extracted data on functionality, study outcomes, and context. Data Synthesis: Fifty-seven percent of the 236 studies evaluated clinical decision support and computerized provider order entry, whereas other meaningful use functionalities were rarely evaluated. Fifty-six percent of studies reported uniformly positive results, and an additional 21% reported mixed-positive effects. Reporting of context and implementation details was poor, and 61% of studies did not report any contextual details beyond basic information. Limitation: Potential for publication bias, and evaluated health IT systems and outcomes were heterogeneous and incompletely described. Conclusion: Strong evidence supports the use of clinical decision support and computerized provider order entry. However, insufficient reporting of implementation and context of use makes it impossible to determine why some health IT implementations are successful and others are not. The most important improvement that can be made in health IT evaluations is increased reporting of the effects of implementation and context. C1 RAND Corp, Santa Monica, CA USA. Soutern Calif Evidence Based Practice Ctr, Santa Monica, CA USA. Harvard Univ, Sch Med, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Vanguard Hlth Syst, Nashville, TN USA. RP Jones, SS (reprint author), RAND Hlth, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90401 USA. EM spencer.jones@vanguardhealth.com FU Office of the National Coordinator FX Office of the National Coordinator. NR 38 TC 78 Z9 79 U1 1 U2 27 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 7 PY 2014 VL 160 IS 1 BP 48 EP + DI 10.7326/M13-1531 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 297IS UT WOS:000330249700006 PM 24573664 ER PT J AU Ivanova, MI Sievers, SA Guenther, EL Johnson, LM Winkler, DD Galaleldeen, A Sawaya, MR Hart, PJ Eisenberg, DS AF Ivanova, Magdalena I. Sievers, Stuart A. Guenther, Elizabeth L. Johnson, Lisa M. Winkler, Duane D. Galaleldeen, Ahmad Sawaya, Michael R. Hart, P. John Eisenberg, David S. TI Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE protein aggregation; peptide structure; amyotrophic lateral sclerosis ID AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; COPPER-BINDING-SITE; WILD-TYPE; TRANSGENIC MICE; MOLECULAR-BASIS; MUTATION; INCLUSIONS; INSIGHTS AB ALS is a terminal disease of motor neurons that is characterized by accumulation of proteinaceous deposits in affected cells. Pathological deposition of mutated Cu/Zn superoxide dismutase (SOD1) accounts for similar to 20% of the familial ALS (fALS) cases. However, understanding the molecular link between mutation and disease has been difficult, given that more than 140 different SOD1 mutants have been observed in fALS patients. In addition, the molecular origin of sporadic ALS (sALS) is unclear. By dissecting the amino acid sequence of SOD1, we identified four short segments with a high propensity for amyloid fibril formation. We find that fALS mutations in these segments do not reduce their propensity to form fibrils. The atomic structures of two fibril-forming segments from the C terminus, (DSVISLS107)-D-101 and (147)GVIGIAQ(153), reveal tightly packed beta-sheets with steric zipper interfaces characteristic of the amyloid state. Based on these structures, we conclude that both C-terminal segments are likely to form aggregates if available for interaction. Proline substitutions in (DSVISLS107)-D-101 and (147)GVIGIAQ(153) impaired nucleation and fibril growth of full-length protein, confirming that these segments participate in aggregate formation. Our hypothesis is that improper protein maturation and incompletely folded states that render these aggregation-prone segments available for interaction offer a common molecular pathway for sALS and fALS. C1 [Ivanova, Magdalena I.; Sievers, Stuart A.; Guenther, Elizabeth L.; Johnson, Lisa M.; Sawaya, Michael R.; Eisenberg, David S.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA. [Ivanova, Magdalena I.; Sievers, Stuart A.; Guenther, Elizabeth L.; Johnson, Lisa M.; Sawaya, Michael R.; Eisenberg, David S.] Univ Calif Los Angeles, UCLA DOE Inst Genom & Prote, Los Angeles, CA 90095 USA. [Ivanova, Magdalena I.; Sievers, Stuart A.; Guenther, Elizabeth L.; Johnson, Lisa M.; Sawaya, Michael R.; Eisenberg, David S.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA. [Ivanova, Magdalena I.] Univ Michigan, Dept Neurol, Sch Med, Ann Arbor, MI 48109 USA. [Sievers, Stuart A.] CALTECH, Div Biol, Pasadena, CA 91125 USA. [Winkler, Duane D.; Galaleldeen, Ahmad; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Winkler, Duane D.] Univ Texas Dallas, Dept Mol & Cell Biol, Richardson, TX 75080 USA. [Galaleldeen, Ahmad] St Marys Univ, Dept Biol Sci, San Antonio, TX 78228 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Eisenberg, DS (reprint author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA. EM david@mbi.ucla.edu FU Howard Hughes Medical Institute [P01 NS049134]; National Institutes of Health [AG029430]; NIH; Department of Energy; Department of Veterans Affairs [1I01BX000506]; Judith and Jean Pape Adams Charitable Foundation; NIH [R01 NS39112] FX We thank Dr. L. Goldschmidt, Dr. M. Chattopadhyay, Dr. R. Nelson, Dr. B. Chan, and Prof. J. S. Valentine for discussions; Dr. I. Kourinov, Dr. J. Schuermann, Dr. K. Rajashankar, Dr. N. Sukumar, and Dr. S. Banerjee at Advanced Photon Source beamline 24-ID-E and European Synchrotron Radiation Facility beamline ID13 for help with X-ray data collection; Howard Hughes Medical Institute, P01 NS049134, National Institutes of Health AG029430, NIH P01, and Department of Energy for support to the D.E. laboratory; and Department of Veterans Affairs 1I01BX000506, the Judith and Jean Pape Adams Charitable Foundation, and NIH R01 NS39112 for support to the P.J.H. laboratory. NR 27 TC 25 Z9 26 U1 1 U2 11 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JAN 7 PY 2014 VL 111 IS 1 BP 197 EP 201 DI 10.1073/pnas.1320786110 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 284VY UT WOS:000329350700062 PM 24344300 ER PT J AU Bowers, E Scamurra, RW Asrani, A Beniguel, L MaWhinney, S Keays, KM Thurn, JR Janoff, EN AF Bowers, Elisabeth Scamurra, Ronald W. Asrani, Anil Beniguel, Lydie MaWhinney, Samantha Keays, Kathryne M. Thurn, Joseph R. Janoff, Edward N. TI Decreased Mutation Frequencies among Immunoglobulin G Variable Region Genes during Viremic HIV-1 Infection SO PLOS ONE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; INDUCED CYTIDINE DEAMINASE; B-CELLS; SOMATIC HYPERMUTATION; CAPSULAR POLYSACCHARIDE; PNEUMOCOCCAL VACCINE; ANTIBODY-RESPONSE; LYMPHOID-TISSUE; DNA-REPAIR; IN-VIVO AB Background/Objective: HIV-1 infection is complicated by high rates of opportunistic infections against which specific antibodies contribute to immune defense. Antibody function depends on somatic hypermutation (SHM) of variable regions of immunoglobulin heavy chain genes (V-H-D-J). We characterized the frequency of SHM in expressed IgG mRNA immunoglobulin transcripts from control and HIV-1-infected patients. Design: We compared utilization of genes in the most prominent V-H family (V(H)3) and mutation frequencies and patterns of cDNA from V(H)3-IgG genes from 10 seronegative control subjects and 21 patients with HIV-1 infection (6 without and 15 patients with detectable plasma viremia). Methods: Unique IgG V(H)3 family cDNA sequences (n = 1,565) were PCR amplified, cloned, and sequenced from blood. Sequences were analyzed using online (Vbase) and in-house immunoglobulin alignment resources. Results: Mutation frequencies in the antigen-binding hypervariable complementarity determining regions (CDR1/2) of IgG class-switched B cells were lower among viremic HIV-1-infected patients vs. controls for nucleotides (CDR1/2: 10+/-5% vs. 13.5+/-6%, p = 0.03) and amino acids (CDR: 20%+/-10 vs. 25%+/-12, p = 0.02) and in structural framework regions. Mutation patterns were similar among groups. The most common V(H)3 gene, V(H)3-23, was utilized less frequently among viremic HIV-1-infected patients (p = 0.03), and overall, mutation frequencies were decreased in nearly all V(H)3 genes compared with controls. Conclusions: B cells from HIV-1-infected patients show decreased mutation frequencies, especially in antigen-binding V(H)3 CDR genes, and selective defects in gene utilization. Similar mutation patterns suggest defects in the quantity, but not quality, of mutator activity. Lower levels of SHM in IgG class-switched B cells from HIV-1-infected patients may contribute to the increased risk of opportunistic infections and impaired humoral responses to preventative vaccines. C1 [Bowers, Elisabeth; MaWhinney, Samantha; Keays, Kathryne M.; Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. [Bowers, Elisabeth; Keays, Kathryne M.; Janoff, Edward N.] Univ Colorado Denver, Div Infect Dis, Aurora, CO USA. [Bowers, Elisabeth; Janoff, Edward N.] Univ Colorado Denver, Dept Microbiol, Aurora, CO USA. [MaWhinney, Samantha] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. [Bowers, Elisabeth; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Scamurra, Ronald W.; Asrani, Anil; Thurn, Joseph R.] Univ Minnesota, Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Beniguel, Lydie] Univ St Etienne, Fac Med, GIMAP EA 3064, Saint Etienne, France. RP Janoff, EN (reprint author), Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado MAVRC, Aurora, CO 80045 USA. EM Edward.Janoff@ucdenver.edu FU Veterans Affairs Research Service; University of Colorado Denver Mucosal and Vaccine Research Program Colorado (MAVRC); Colorado Center for AIDS Research Grant [P30 AI054907]; University of Colorado Cancer Center [P30CA046934]; Conseil Regional Rhone-Alpes; National Institutes of Health (NIH) [F32DE005703-01, RO1A10495752-01] FX This work has been supported by the Veterans Affairs Research Service and the University of Colorado Denver Mucosal and Vaccine Research Program Colorado (MAVRC) (ENJ) and facilitated by the infrastructure and resources provided by the Colorado Center for AIDS Research Grant (P30 AI054907), the University of Colorado Cancer Center Core Sequencing Facility (P30CA046934), a grant from "Conseil Regional Rhone-Alpes'' (Recontres Regionales de la Recherche) (LB) and National Institutes of Health (NIH) grants F32DE005703-01 and RO1A10495752-01 (RWS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 7 Z9 7 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 7 PY 2014 VL 9 IS 1 AR e81913 DI 10.1371/journal.pone.0081913 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 286JC UT WOS:000329463500002 PM 24409278 ER PT J AU Mor, MK Sevick, MA Shields, AM Green, JA Palevsky, PM Arnold, RM Fine, MJ Weisbord, SD AF Mor, Maria K. Sevick, Mary Ann Shields, Anne Marie Green, Jamie A. Palevsky, Paul M. Arnold, Robert M. Fine, Michael J. Weisbord, Steven D. TI Sexual Function, Activity, and Satisfaction among Women Receiving Maintenance Hemodialysis SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID QUALITY-OF-LIFE; STAGE RENAL-DISEASE; SYMPTOM MANAGEMENT STRATEGIES; ERECTILE DYSFUNCTION; SILDENAFIL TREATMENT; PERITONEAL-DIALYSIS; FUNCTION INDEX; DEPRESSION; PAIN; PREVALENCE AB Background and objectivesPast studies that demonstrated that sexual dysfunction is common among women receiving chronic hemodialysis did not distinguish sexual dysfunction/difficulty from sexual inactivity. This study sought to differentiate these in order to elucidate the prevalence of true sexual dysfunction in this population.Design, setting, participants, & measurementsAs part of a clinical trial of symptom management strategies in patients receiving chronic hemodialysis, female sexual function was prospectively assessed monthly for 6 months and quarterly thereafter using the Female Sexual Function Index, to which questions were added differentiating sexual dysfunction/difficulty from sexual inactivity. Beginning in month 7, patients were asked three questions about sexual activity, difficulty, and satisfaction monthly.ResultsOf the women enrolled in the clinical trial,125 participants completed 1721 assessments between 2009 and 2011. Scores on 574 of 643 (89%) quarterly Female Sexual Function Index assessments were consistent with sexual dysfunction, due largely to sexual inactivity, which was reported on 525 (82%) quarterly assessments. When reported (n=1663), the most frequently described reasons for sexual inactivity were lack of interest in sex (n=715; 43%) and lack of a partner (n=647; 39%), but rarely sexual difficulty (n=36; 2%). When reported (n=1582), women were moderately to very satisfied with their sexual life on 1020 (64%) assessments and on 513 of 671 (76%) assessments in which lack of interest was cited as a reason for sexual inactivity. Women indicated an interest in learning about the causes of and treatment for sexual dysfunction on just 5% of all assessments.ConclusionsAlthough many women receiving chronic hemodialysis are sexually inactive, few describe sexual difficulty. Most, including those with a lack of interest in sex, are satisfied with their sexual life and few wish to learn about treatment options. These findings suggest that true sexual dysfunction is uncommon in this population and that treatment opportunities are rare. C1 [Mor, Maria K.; Shields, Anne Marie; Fine, Michael J.; Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Green, Jamie A.] Geisinger Med Ctr, Dept Nephrol, Danville, PA 17822 USA. [Palevsky, Paul M.; Weisbord, Steven D.] Vet Affairs Pittsburgh Healthcare Syst, Med Serv Line, Renal Sect, Pittsburgh, PA 15240 USA. [Palevsky, Paul M.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Arnold, Robert M.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Arnold, Robert M.] Univ Pittsburgh, Sch Med, Div Palliat Care, Pittsburgh, PA USA. RP Weisbord, SD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Med Serv Line, Renal Sect, 7E Room 120,111F-U, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu FU Department of Veterans Affairs Health Services Research and Development Merit Review award [IIR 07-190] FX This work was supported by a Department of Veterans Affairs Health Services Research and Development Merit Review award (IIR 07-190). NR 31 TC 10 Z9 10 U1 1 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JAN 7 PY 2014 VL 9 IS 1 BP 128 EP 134 DI 10.2215/CJN.05470513 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 285AL UT WOS:000329364700018 PM 24357510 ER PT J AU Gross, R Bellamy, SL Chapman, J Han, XY O'Duor, J Strom, BL Houts, PS Palmer, SC Coyne, JC AF Gross, Robert Bellamy, Scarlett L. Chapman, Jennifer Han, Xiaoyan O'Duor, Jacqueline Strom, Brian L. Houts, Peter S. Palmer, Steven C. Coyne, James C. TI The Effects of a Problem Solving-Based Intervention on Depressive Symptoms and HIV Medication Adherence Are Independent SO PLOS ONE LA English DT Article ID ANTIRETROVIRAL THERAPY; ANTIDEPRESSANT TREATMENT; CANCER-PATIENTS; DISORDERS; RISK; METAANALYSIS; HIV/AIDS; PROJECT; ANXIETY; TRIAL AB Depression and depressive symptoms predict poor adherence to medical therapy, but the association is complex, nonspecific, and difficult to interpret. Understanding this association may help to identify the mechanism explaining the results of interventions that improve both medical therapy adherence and depressive symptoms as well as determine the importance of targeting depression in adherence interventions. We previously demonstrated that Managed Problem Solving (MAPS) focused on HIV medication adherence improved adherence and viral load in patients initiating a new antiretroviral regimen. Here, we assessed whether MAPS improved depressive symptoms and in turn, whether changes in depressive symptoms mediated changes in adherence and treatment outcomes. We compared MAPS to usual care with respect to presence of depressive symptoms during the trial using logistic regression. We then assessed whether MAPS' effect on depressive symptoms mediated the relationship between MAPS and adherence and virologic outcomes using linear and logistic regression, respectively. Mediation was defined by the disappearance of the mathematical association between MAPS and the outcomes when the proposed mediator was included in regression models. Although MAPS participants had a lower rate of depressive symptoms (OR = 0.45, 95% confidence interval 0.21-0.93), there was no evidence of mediation of the effects of MAPS on adherence and virological outcome by improvements in depression. Thus, interventions for medication adherence may not need to address depressive symptoms in order to impact both adherence and depression; this remains to be confirmed, however, in other data. C1 [Gross, Robert; Bellamy, Scarlett L.; Chapman, Jennifer; Han, Xiaoyan; O'Duor, Jacqueline; Strom, Brian L.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gross, Robert; Bellamy, Scarlett L.; Chapman, Jennifer; Han, Xiaoyan; O'Duor, Jacqueline; Strom, Brian L.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Gross, Robert; Strom, Brian L.] Univ Penn, Perelman Sch Med, Ctr Pharmacoepidemiol Res & Training, Philadelphia, PA 19104 USA. [Gross, Robert] Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Gross, Robert] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Houts, Peter S.] Penn State Univ, Coll Med, Hershey, PA USA. [Palmer, Steven C.; Coyne, James C.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Coyne, James C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Hlth Psychol Sect, Groningen, Netherlands. RP Gross, R (reprint author), Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. EM grossr@mail.med.upenn.edu FU National Institute Of Mental Health [R01 MH080701, R01 MH067498]; National Center for Research Resources [UL1 RR024134]; National Institute of Allergy and Infectious Diseases; Penn Center for AIDS Research [P30 AI045008]; Philadelphia Veterans Affairs Medical Center; Bristol-Myers Squibb; Abbott Laboratories FX Research reported in this publication was supported by the National Institute Of Mental Health under Award Numbers R01 MH080701 and R01 MH067498, by the National Center for Research Resources under Award Number UL1 RR024134, by the National Institute of Allergy and Infectious Diseases via core services and support from the Penn Center for AIDS Research under Award Number P30 AI045008 and career support (RG) from the Philadelphia Veterans Affairs Medical Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. During the course of this study, Dr. Gross received research support via contracts with Bristol-Myers Squibb and Abbott Laboratories for work related to HIV and its treatment, but not for work on this study. Dr. Strom was supported in part by contracts with and received payment for consulting with numerous pharmaceutical companies, none of which was related to HIV or this study. NR 26 TC 4 Z9 4 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 6 PY 2014 VL 9 IS 1 AR e84952 DI 10.1371/journal.pone.0084952 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 286IW UT WOS:000329462700058 PM 24400124 ER PT J AU Lei, NY Jabaji, Z Wang, JF Joshi, VS Brinkley, GJ Khalil, H Wang, FC Jaroszewicz, A Pellegrini, M Li, LH Lewis, M Stelzner, M Dunn, JCY Martin, MG AF Lei, Nan Ye Jabaji, Ziyad Wang, Jiafang Joshi, Vaidehi S. Brinkley, Garrett J. Khalil, Hassan Wang, Fengchao Jaroszewicz, Artur Pellegrini, Matteo Li, Linheng Lewis, Michael Stelzner, Matthias Dunn, James C. Y. Martin, G. Martin TI Intestinal Subepithelial Myofibroblasts Support the Growth of Intestinal Epithelial Stem Cells SO PLOS ONE LA English DT Article ID IN-VITRO; WNT/BETA-CATENIN; SELF-RENEWAL; NICHE; LGR5; CRYPT; DIFFERENTIATION; TRANSPLANTATION; RECEPTORS; PITFALLS AB Intestinal epithelial stem cells (ISCs) are the focus of recent intense study. Current in vitro models rely on supplementation with the Wnt agonist R-spondin1 to support robust growth, ISC self-renewal, and differentiation. Intestinal subepithelial myofibroblasts (ISEMFs) are important supportive cells within the ISC niche. We hypothesized that co-culture with ISEMF enhances the growth of ISCs in vitro and allows for their successful in vivo implantation and engraftment. ISC-containing small intestinal crypts, FACS-sorted single ISCs, and ISEMFs were procured from C57BL/6 mice. Crypts and single ISCs were grown in vitro into enteroids, in the presence or absence of ISEMFs. ISEMFs enhanced the growth of intestinal epithelium in vitro in a proximity-dependent fashion, with co-cultures giving rise to larger enteroids than monocultures. Co-culture of ISCs with supportive ISEMFs relinquished the requirement of exogenous R-spondin1 to sustain long-term growth and differentiation of ISCs. Mono-and co-cultures were implanted subcutaneously in syngeneic mice. Co-culture with ISEMFs proved necessary for successful in vivo engraftment and proliferation of enteroids; implants without ISEMFs did not survive. ISEMF whole transcriptome sequencing and qPCR demonstrated high expression of specific R-spondins, well-described Wnt agonists that supports ISC growth. Specific non-supportive ISEMF populations had reduced expression of R-spondins. The addition of ISEMFs in intestinal epithelial culture therefore recapitulates a critical element of the intestinal stem cell niche and allows for its experimental interrogation and biodesign-driven manipulation. C1 [Lei, Nan Ye; Joshi, Vaidehi S.; Dunn, James C. Y.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA. [Lei, Nan Ye; Jabaji, Ziyad; Khalil, Hassan; Stelzner, Matthias; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Wang, Jiafang; Brinkley, Garrett J.; Martin, G. Martin] Univ Calif Los Angeles, Mattel Childrens Hosp, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA 90095 USA. [Wang, Jiafang; Brinkley, Garrett J.; Martin, G. Martin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wang, Fengchao; Li, Linheng] Stowers Inst Med Res, Kansas City, MO USA. [Jaroszewicz, Artur; Pellegrini, Matteo] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA USA. [Li, Linheng] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66103 USA. [Li, Linheng] Univ Kansas, Med Ctr, Lab Med, Kansas City, KS 66103 USA. [Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Stelzner, Matthias] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Martin, MG (reprint author), Univ Calif Los Angeles, Mattel Childrens Hosp, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA 90095 USA. EM mmartin@mednet.ucla.edu OI Khalil, Hassan/0000-0002-3835-1290 FU National Institute of Diabetes and Digestive and Kidney Diseases U01 Intestinal Stem Cell Consortium [DK085535-01, DK085535-02S2, DK083762, DK083319]; California Institute for Regenerative Medicine [RT2-01985] FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases U01 Intestinal Stem Cell Consortium (DK085535-01 and DK085535-02S2), DK083762, DK083319 and the California Institute for Regenerative Medicine (RT2-01985). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 18 Z9 20 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 6 PY 2014 VL 9 IS 1 AR e84651 DI 10.1371/journal.pone.0084651 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 286IW UT WOS:000329462700040 PM 24400106 ER PT J AU Bhatt, SP Cole, AG Wells, JM Nath, H Watts, JR Cockcroft, JR Dransfield, MT AF Bhatt, Surya P. Cole, Adam G. Wells, James Michael Nath, Hrudaya Watts, Jubal R. Cockcroft, John R. Dransfield, Mark T. TI Determinants of arterial stiffness in COPD SO BMC PULMONARY MEDICINE LA English DT Article DE COPD; Arterial stiffness; Arterial calcification; Cardiovascular ID OBSTRUCTIVE PULMONARY-DISEASE; CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK; ALL-CAUSE; MORTALITY; EMPHYSEMA; PREDICTION; ATHEROSCLEROSIS; CALCIFICATION; IMPROVEMENT AB Background: Cardiovascular morbidity and mortality is high in patients with chronic obstructive pulmonary disease (COPD) and arterial stiffness is a potentially modifiable risk factor with added predictive value beyond that obtained from traditional risk factors. Arterial stiffness has been the target of pharmacologic and exercise interventions in patients with COPD, but the effects appear limited to those patients with more significant elevations in arterial stiffness. We aimed to identify predictors of increased arterial stiffness in a cohort with moderate to severe COPD. Methods: Aortic pulse wave velocity (aPWV) was measured in subjects with moderate to severe COPD enrolled in a multicenter randomized controlled trial. Subjects were categorized into quartiles based on aPWV values and factors affecting high arterial stiffness were assessed. Multivariate models were created to identify independent predictors of high aPWV, and cardiovascular disease (CVD). Results: 153 patients were included. Mean age was 63.2 (SD 8.2) years and mean FEV1 was 55.4 (SD 15.2) % predicted. Compared to the quartile with the lowest aPWV, subjects in the highest quartile were older, had higher systolic blood pressure (SBP), were more likely to be current smokers, and had greater burden of thoracic aortic calcification. On multivariate analyses, age (adjusted OR 1.14, 95% CI 1.05 to 1.25, p = 0.003) and SBP (adjusted OR 1.06, 95% CI 1.02 to 1.09, p = 0.001) were independent predictors of elevated aPWV. Body mass index, therapy with cholesterol lowering medications and coronary calcification were independent predictors of CVD. Conclusions: Elevated arterial stiffness in patients with COPD can be predicted using age, blood pressure and thoracic aortic calcification. This will help identify subjects for enrollment in clinical trials using aPWV for assessing the impact of COPD therapies on CV outcomes. C1 [Bhatt, Surya P.; Cole, Adam G.; Wells, James Michael; Dransfield, Mark T.] Univ Alabama Birmingham, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Nath, Hrudaya; Watts, Jubal R.] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA. [Cockcroft, John R.] Univ Wales Hosp, Dept Cardiol, Wales Heart Res Inst, Cardiff CF4 4XW, S Glam, Wales. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Bhatt, SP (reprint author), Univ Alabama Birmingham, Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. EM spbhatt@uab.edu OI Watts, Jubal/0000-0002-9006-1637 FU GlaxoSmithKline, Respiratory and Immuno-Inflammation Medicines Development Center, Research Triangle Park, NC, USA FX GlaxoSmithKline, Respiratory and Immuno-Inflammation Medicines Development Center, Research Triangle Park, NC, USA NR 32 TC 9 Z9 9 U1 2 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2466 J9 BMC PULM MED JI BMC Pulm. Med. PD JAN 4 PY 2014 VL 14 AR 1 DI 10.1186/1471-2466-14-1 PG 7 WC Respiratory System SC Respiratory System GA AB1QE UT WOS:000331567400001 PM 24387157 ER PT J AU McKenney, ML Schultz, KA Boyd, JH Byrd, JP Alloosh, M Teague, SD Arce-Esquivel, AA Fain, JN Laughlin, MH Sacks, HS Sturek, M AF McKenney, Mikaela L. Schultz, Kyle A. Boyd, Jack H. Byrd, James P. Alloosh, Mouhamad Teague, Shawn D. Arce-Esquivel, Arturo A. Fain, John N. Laughlin, M. Harold Sacks, Harold S. Sturek, Michael TI Epicardial adipose excision slows the progression of porcine coronary atherosclerosis SO JOURNAL OF CARDIOTHORACIC SURGERY LA English DT Article DE Atherosclerosis; Computed tomography; Surgery; Intravascular ultrasound ID METABOLIC SYNDROME; PERICARDIAL FAT; ARTERY-DISEASE; NONCONTRAST CT; T-CADHERIN; TISSUE; SWINE; EXPRESSION; RECEPTORS; EXERCISE AB Background: In humans there is a positive association between epicardial adipose tissue (EAT) volume and coronary atherosclerosis (CAD) burden. We tested the hypothesis that EAT contributes locally to CAD in a pig model. Methods: Ossabaw miniature swine (n = 9) were fed an atherogenic diet for 6 months to produce CAD. A 15 mm length by 3-5 mm width coronary EAT (cEAT) resection was performed over the middle segment of the left anterior descending artery (LAD) 15 mm distal to the left main bifurcation. Pigs recovered for 3 months on atherogenic diet. Intravascular ultrasound (IVUS) was performed in the LAD to quantify atheroma immediately after adipectomy and was repeated after recovery before sacrifice. Coronary wall biopsies were stained immunohistochemically for atherosclerosis markers and cytokines and cEAT was assayed for atherosclerosis-related genes by RT-PCR. Total EAT volume was measured by non-contrast CT before each IVUS. Results: Circumferential plaque length increased (p < 0.05) in the proximal and distal LAD segments from baseline until sacrifice whereas plaque length in the middle LAD segment underneath the adipectomy site did not increase. T-cadherin, scavenger receptor A and adiponectin were reduced in the intramural middle LAD. Relative to control pigs without CAD, 11 beta-hydroxysteroid dehydrogenase (11 beta HSD-1), CCL19, CCL21, prostaglandin D2 synthase, gp91phox [NADPH oxidase], VEGF, VEGFGR1, and angiotensinogen mRNAs were up-regulated in cEAT. EAT volume increased over 3 months. Conclusion: In pigs used as their own controls, resection of cEAT decreased the progression of CAD, suggesting that cEAT may exacerbate coronary atherosclerosis. C1 [McKenney, Mikaela L.; Schultz, Kyle A.; Byrd, James P.; Alloosh, Mouhamad; Sturek, Michael] Indiana Univ Sch Med, Dept Cellular, Indianapolis, IN 46202 USA. [McKenney, Mikaela L.; Schultz, Kyle A.; Byrd, James P.; Alloosh, Mouhamad; Sturek, Michael] Indiana Univ Sch Med, Dept Integrat Physiol, Indianapolis, IN 46202 USA. [Boyd, Jack H.] Indiana Univ Sch Med, Dept Cardiothorac Surg, Indianapolis, IN 46202 USA. [Teague, Shawn D.] Indiana Univ Sch Med, Dept Biol, Indianapolis, IN 46202 USA. [Arce-Esquivel, Arturo A.; Laughlin, M. Harold] Univ Missouri, Dept Biomed Sci, Columbia, MO 65211 USA. [Fain, John N.] Univ Tennessee, Dept Mol Sci, Hlth Sci Ctr, Memphis, TN 38163 USA. [Sacks, Harold S.] VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. [Sacks, Harold S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Sturek, M (reprint author), Indiana Univ Sch Med, Dept Cellular, 635 Barnhill Dr,Room 385, Indianapolis, IN 46202 USA. EM msturek@iu.edu FU NIH [HL062552, P01 HL052490]; Cardiometabolic Disease Research Foundation, Los Angeles, CA; NIH/NCATS CTSI [TL1 TR000162] FX NIH HL062552 (MS, MLM, KAS, JPB, MA), P01 HL052490 (MHL), Cardiometabolic Disease Research Foundation, Los Angeles, CA (HS, MS), and NIH/NCATS CTSI TL1 TR000162 (MLM). NR 31 TC 26 Z9 27 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1749-8090 J9 J CARDIOTHORAC SURG JI J. Cardiothorac. Surg. PD JAN 3 PY 2014 VL 9 AR 2 DI 10.1186/1749-8090-9-2 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AB6GS UT WOS:000331886200002 PM 24387639 ER PT J AU Taylor, BK Fu, W Kuphal, KE Stiller, CO Winter, MK Chen, W Corder, GF Urban, JH McCarson, KE Marvizon, JC AF Taylor, B. K. Fu, W. Kuphal, K. E. Stiller, C. -O Winter, M. K. Chen, W. Corder, G. F. Urban, J. H. McCarson, K. E. Marvizon, J. C. TI INFLAMMATION ENHANCES Y1 RECEPTOR SIGNALING, NEUROPEPTIDE Y-MEDIATED INHIBITION OF HYPERALGESIA, AND SUBSTANCE P RELEASE FROM PRIMARY AFFERENT NEURONS SO NEUROSCIENCE LA English DT Article DE pain; G-protein; neurokinin-1 receptor; calcitonin gene-related peptide; isolectin B4; capsaicin ID RAT SPINAL-CORD; METHYL-D-ASPARTATE; DORSAL-HORN NEURONS; CENTRAL-NERVOUS-SYSTEM; IN-VIVO RELEASE; NEUROKININ-1 RECEPTOR; GABA(B) RECEPTORS; MESSENGER-RNA; SUBARACHNOID SPACE; TONIC INHIBITION AB Neuropeptide Y (NPY) is present in the superficial laminae of the dorsal horn and inhibits spinal nociceptive processing, but the mechanisms underlying its anti-hyperalgesic actions are unclear. We hypothesized that NPY acts at neuropeptide Y1 receptors in the dorsal horn to decrease nociception by inhibiting substance P (SP) release, and that these effects are enhanced by inflammation. To evaluate SP release, we used microdialysis and neurokinin 1 receptor (NK1R) internalization in rat. NPY decreased capsaicin-evoked SP-like immunoreactivity in the microdialysate of the dorsal horn. NPY also decreased non-noxious stimulus (paw brush)-evoked NK1R internalization (as well as mechanical hyperalgesia and mechanical and cold allodynia) after intraplantar injection of carrageenan. Similarly, in rat spinal cord slices with dorsal root attached, [Leu(31), Pro(34)]-NPY inhibited dorsal root stimulus-evoked NK1R internalization. In rat dorsal root ganglion neurons, Y1 receptors colocalized extensively with calcitonin gene-related peptide (CGRP). In dorsal horn neurons, Y1 receptors were extensively expressed and this may have masked the detection of terminal co-localization with CGRP or SP. To determine whether the pain inhibitory actions of Y1 receptors are enhanced by inflammation, we administered [Leu(31), Pro(34)]-NPY after intraplantar injection of complete Freund's adjuvant (CFA) in rat. We found that [Leu(31), Pro(34)]-NPY reduced paw clamp-induced NK1R internalization in CFA rats but not uninjured controls. To determine the contribution of increased Y1 receptor-G protein coupling, we measured [S-35]GTP gamma S binding simulated by [Leu(31), Pro(34)]-NPY in mouse dorsal horn. CFA inflammation increased the affinity of Y1 receptor G-protein coupling. We conclude that Y1 receptors contribute to the anti-hyperalgesic effects of NPY by mediating the inhibition of SP release, and that Y1 receptor signaling in the dorsal horn is enhanced during inflammatory nociception. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Taylor, B. K.; Fu, W.; Corder, G. F.] Univ Kentucky, Med Ctr, Sch Med, Dept Physiol, Lexington, KY 40536 USA. [Kuphal, K. E.] Univ Missouri, Div Pharmacol, Kansas City, MO 64110 USA. [Stiller, C. -O] Karolinska Inst, Karolinska Hosp, Dept Med, Div Clin Pharmacol, S-10401 Stockholm, Sweden. [Winter, M. K.; McCarson, K. E.] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA. [Chen, W.; Marvizon, J. C.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chen, W.; Marvizon, J. C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Urban, J. H.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Physiol & Biophys, N Chicago, IL USA. RP Taylor, BK (reprint author), Univ Kentucky, Med Ctr, Dept Physiol, 800 Rose St, Lexington, KY 40536 USA. EM brad.taylor@uky.edu OI Stiller, Carl-Olav/0000-0003-0684-635X FU NIH [R01NS45954, K02DA19656]; NICHD [HD02528] FX Supported by NIH R01NS45954 to B.K.T. and J.C.M. and K02DA19656 to B.K.T. and NICHD HD02528 to K.E.M. NR 78 TC 7 Z9 9 U1 1 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD JAN 3 PY 2014 VL 256 BP 178 EP 194 DI 10.1016/j.neuroscience.2013.10.054 PG 17 WC Neurosciences SC Neurosciences & Neurology GA 300SY UT WOS:000330485500018 PM 24184981 ER PT J AU Dong, QH Sharma, S Liu, H Chen, L Gu, BX Sun, XN Wang, GY AF Dong, Qinghua Sharma, Sherven Liu, Hai Chen, Long Gu, Benxing Sun, Xiaonan Wang, Guanyu TI HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression SO TOXICOLOGY LETTERS LA English DT Article DE Acquired radioresistance; HDIs; Bmi-1; Esophageal carcinoma; DNA repair ID HISTONE DEACETYLASE INHIBITOR; DNA-DAMAGE; TUMOR-CELLS; REPAIR; TRICHOSTATIN; ENHANCEMENT; RADIOSENSITIZATION; RADIORESISTANCE; THIOREDOXIN; P21(WAF1) AB Tumors treated with fractionated doses of ionizing radiation (IR) often acquire radioresistance. Although histone deacetylase inhibitors (HDIs) have been demonstrated to sensitize intrinsic radioresistant cancer cell lines to IR, little is known on the impact of HDIs on the effects of IR in acquired radioresistant cancer cells. This study evaluates the mechanisms by which HDIs sensitize acquired radioresistant esophageal squamous cell carcinoma cells to IR. The HDIs trichostatin A and sodium butyrate were tested for their ability to sensitize acquired radioresistant KYSE-150R and radiosensitive KYSE-150 parental cells to IR. Although the HDIs induced similar levels of cytotoxicity in the KYSE-150 and the KYSE-150R cells, HDIs increased the: (i) radiosensitivity, (ii) IR-induced ROS generation, and (iii) IR-induced G2/M arrest and apoptosis of KYSE-150R cells compared with those of KYSE-150 cells. These changes were accompanied by increased p21 expression and decreased mitochondrial membrane potential. When combined with IR, HDIs inhibited Bmi-1 expression in KYSE-150R cells and their ability to repair DNA damage. The results demonstrate the potential utility of HDIs in augmenting the efficacy of fractionated radiotherapy. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Dong, Qinghua; Chen, Long] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Biomed Res Ctr, Hangzhou 310016, Zhejiang, Peoples R China. [Dong, Qinghua] China Natl Minist Educ, Key Lab Canc Prevent & Intervent, Hangzhou, Zhejiang, Peoples R China. [Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Sharma, Sherven] US Dept Vet Affairs, Los Angeles, CA USA. [Liu, Hai; Gu, Benxing; Sun, Xiaonan] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Radiotherapy, Hangzhou 310016, Zhejiang, Peoples R China. [Wang, Guanyu] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gen Surg, Hangzhou 310016, Zhejiang, Peoples R China. RP Wang, GY (reprint author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gen Surg, Hangzhou 310016, Zhejiang, Peoples R China. EM wangguanyu@zju.edu.cn FU National Natural Science Foundation of China [81272493]; Science Technology Department of Zhejiang Province [2012R10047, 2012C33116]; Scientific Research Foundation for Returned Scholars by Ministry of Education of China; Zhejiang Educational Committee [Y201224108] FX This work was supported by the National Natural Science Foundation of China (No. 81272493), the Science Technology Department of Zhejiang Province (No. 2012R10047 and No. 2012C33116), Scientific Research Foundation for Returned Scholars by Ministry of Education of China and the Zhejiang Educational Committee (No. Y201224108). NR 36 TC 9 Z9 13 U1 2 U2 15 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0378-4274 EI 1879-3169 J9 TOXICOL LETT JI Toxicol. Lett. PD JAN 3 PY 2014 VL 224 IS 1 BP 121 EP 129 DI 10.1016/j.toxlet.2013.10.014 PG 9 WC Toxicology SC Toxicology GA 264OE UT WOS:000327887100016 PM 24459703 ER PT J AU Jiang, DF Aguiar, RCT AF Jiang, Daifeng Aguiar, Ricardo C. T. TI MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-beta 1/SMAD5 signaling module SO BLOOD LA English DT Article ID GROWTH-FACTOR-BETA; CELL LYMPHOMA; TGF-BETA; PHOSPHODIESTERASE 4B; EXPRESSION; CANCER; SMAD; TRANSCRIPTION; RECEPTORS; COMPLEXES AB MicroRNA-155 (miR-155) plays pleiotropic roles in the biology of normal and malignant B lymphocytes, including the modulation of the transforming growth factor beta (TGF-beta) pathway via the targeting of SMAD5. However, the extent of the miR-155-mediated disruption of the TGF-beta 1/SMAD5 axis remains to be elucidated. To address this issue, we used the miR-155 knockout (KO) mouse and diffuse large B-cell lymphoma (DLBCL) cell lines ectopically expressing miR-155. In the DLBCL models, expression of miR-155 blocked TGF-beta 1-mediated activation of the retinoblastoma protein (RB), decreasing the abundance of the inhibitory pRB-E2F1 complex and limiting G0/G1 arrest. Genetic knockdown of SMAD5, p15, or p21 recapitulated these effects, establishing a circuitry whereby the targeting of SMAD5 by miR-155 blunts the TGF-beta 1-induced transcription of p15 and p21, thus sustaining RB phosphorylation and inactivity. Next, we demonstrated that SMAD5 levels are elevated in mature B lymphocytes from the miR-155 KO mice, which display a heightened sensitivity to TGF-beta 1 characterized by suppression of RB phosphorylation and more pronounced G0/G1 cell cycle arrest. Our findings suggest that a miR-155-mediated perturbation of the RB/E2F axis may play a role in DLBCL pathogenesis, and contribute to the reduced number of germinal center B cells and impaired T cell-dependent antibody response found in the miR-155 KO mice. C1 [Jiang, Daifeng; Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hematol & Med Oncol, San Antonio, TX 78229 USA. [Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA. [Aguiar, Ricardo C. T.] Audie Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Aguiar, RCT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM aguiarr@uthscsa.edu FU National Institutes of Health National Cancer Institute [R01-CA138747]; Young Investigator Award from the Voelcker Fund; National Institutes of Health National Cancer Institute Cancer Center [P30 CA054174] FX This work was supported by a grant from the National Institutes of Health National Cancer Institute (R01-CA138747) (R.C.T.A), a Young Investigator Award from the Voelcker Fund (R.C.T.A), and a National Institutes of Health National Cancer Institute Cancer Center Support Grant (P30 CA054174). NR 27 TC 15 Z9 15 U1 0 U2 7 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD JAN 2 PY 2014 VL 123 IS 1 BP 86 EP 93 DI 10.1182/blood-2013-07-515254 PG 8 WC Hematology SC Hematology GA 290GJ UT WOS:000329742300018 PM 24136167 ER PT J AU Panos, SE Del Re, AC Thames, AD Arentsen, TJ Patel, SM Castellon, SA Singer, EJ Hinkin, CH AF Panos, Stella E. Del Re, A. C. Thames, April D. Arentsen, Timothy J. Patel, Sapna M. Castellon, Steven A. Singer, Elyse J. Hinkin, Charles H. TI The impact of neurobehavioral features on medication adherence in HIV: Evidence from longitudinal models SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; AIDS; antiretroviral therapy; adherence; neurobehavioral; psychosocial ID ANTIRETROVIRAL THERAPY; SELF-EFFICACY; PROTEASE INHIBITORS; INFECTED ADULTS; CLINICAL-TRIALS; DRUG-USERS; PREDICTORS; APATHY; INDIVIDUALS; DYSFUNCTION AB Effective antiretroviral therapy has led to substantial improvements in health-related outcomes among individuals with HIV. Despite advances in HIV pharmacotherapy, suboptimal medication adherence remains a significant barrier to successful treatment. Although several factors have been associated with medication adherence in the extant literature, study assessing the effects of some of the neurobehavioral features specific to HIV has been limited. Moreover, although there is a growing body of literature measuring medication adherence in HIV prospectively, few employ advanced statistical methodologies suited to handle advanced models with multiple predictors that would strengthen our understanding of medication adherence trajectories in HIV. This study sought to integrate traditionally assessed predictors of medication adherence with neurobehavioral features of HIV in a longitudinal study of medication adherence to combined antiretroviral therapy (cART). The current study used multilevel modeling to examine a wide arrangement of categories of factors - demographic, medication related, psychosocial, and neurobehavioral - on medication adherence. The sample consisted of 235 HIV+ individuals whose medication adherence was monitored over the course of six months using electronic monitoring devices. After controlling for the effects of demographic, medication, and psychosocial factors, neurobehavioral features added predictive validity to the model. In the final model, simultaneously controlling for the effects of each of the predictors within all the categories, age, self-efficacy, executive functioning, apathy, and frequency of stimulant use emerged as unique individual predictors of average medication adherence across the 6-month study. Self-efficacy and irritability predicted changes in medication adherence over time. Adherence behavior is multidetermined. Adequate assessment of these factors, combined with timely intervention, appears to be warranted in order to boost adherence rates. C1 [Panos, Stella E.; Thames, April D.; Arentsen, Timothy J.; Patel, Sapna M.; Castellon, Steven A.; Hinkin, Charles H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Panos, Stella E.; Thames, April D.; Arentsen, Timothy J.; Patel, Sapna M.; Castellon, Steven A.; Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, Dept Psychol, Los Angeles, CA USA. [Del Re, A. C.] Stanford Univ, Sch Med, Dept Hlth Serv, Stanford, CA 94305 USA. [Del Re, A. C.] VA Palo Alto Healthcare Syst, Dept Psychol, Palo Alto, CA USA. [Singer, Elyse J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. RP Panos, SE (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. EM spanos@mednet.ucla.edu RI Thames, April/K-1964-2014; Del Re, A. C./N-2616-2014 OI Thames, April/0000-0001-8414-7189; Del Re, Aaron/0000-0002-9571-7623 FU NIDA NIH HHS [R01 DA13799, R01 DA013799]; NIMH NIH HHS [K23MH095661, T32 MH19535, K23 MH095661, U24 MH100929, T32 MH019535] NR 39 TC 8 Z9 8 U1 1 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD JAN 2 PY 2014 VL 26 IS 1 BP 79 EP 86 DI 10.1080/09540121.2013.802275 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 276DK UT WOS:000328728100010 PM 23756102 ER PT J AU Momplaisir, F Mounzer, K Long, JA AF Momplaisir, Florence Mounzer, Karam Long, Judith A. TI Preventive cancer screening practices in HIV-positive patients SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE cancer screening; HIV; primary care; model of care; preventive care ID UNITED-STATES; INFECTED WOMEN; OLDER; HEALTH; AIDS; AGE AB As patients with HIV age, they are at risk of developing non-AIDS defining malignancies. We performed a questionnaire study to evaluate colorectal and breast cancer screening among HIV-positive and HIV-negative patients seeking care from either an integrated (HIV/primary care), nonintegrated (specialized HIV), or general internal medicine clinic between August 2010 and July 2011. We performed a logistic regression to determine the odds of cancer screening. A total of 813 surveys were collected, and 762 were included in the analysis. As much as 401 were from HIV-positive patients. Patients with HIV were less likely to be current with their colorectal cancer screening (CRCS) (54.4% versus 65.0%, p=0.009); mammography rates were 24.3% versus 62.3% if done during the past year (p<0.001), and 42.0% versus 86.7% if done during the past 5 years (p<0.001). In adjusted models, the odds of colorectal cancer screening in HIV-positive patients compared to negative controls was not statistically significant (OR 0.8; 95% CI 0.5-1.3); however, HIV-positive women remained significantly less likely to be current with breast cancer screening (BCS) whether their mammogram was completed within 1 year (OR 0.1, 95% CI 0.1-0.2) or within 5 years (OR 0.1, 95% CI 0.0-0.2). Integrated care was not associated with improved screening; however, having frequent visits to a primary care physician (PCP) increased the likelihood of getting screened. BCS was lower in HIV-positive compared to HIV-negative women. Frequent visits to a PCPs improved cancer screening. C1 [Momplaisir, Florence] Temple Univ Hosp & Med Sch, Div Infect Dis, Philadelphia, PA 19140 USA. [Mounzer, Karam; Long, Judith A.] Univ Penn, Perelman Sch Med, Div Internal Med, Philadelphia, PA 19104 USA. [Mounzer, Karam] Jonathan Lax Ctr, Philadelphia FIGHT, Philadelphia, PA USA. [Long, Judith A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Momplaisir, F (reprint author), Temple Univ Hosp & Med Sch, Div Infect Dis, Philadelphia, PA 19140 USA. EM Florence.Momplaisir@tuhs.temple.edu NR 16 TC 4 Z9 4 U1 0 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PD JAN 2 PY 2014 VL 26 IS 1 BP 87 EP 94 DI 10.1080/09540121.2013.802276 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 276DK UT WOS:000328728100011 PM 23742681 ER PT J AU Anderson, TS Good, CB Gellad, WF AF Anderson, Timothy S. Good, Chester B. Gellad, Walid F. TI Macitentan and Pulmonary Arterial Hypertension SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter AB To the Editor: Pulido et al. (Aug. 29 issue)(1) report the results of the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN), an Actelion Pharmaceuticals-funded study of macitentan to treat pulmonary arterial hypertension. Although the article provides potentially good news for patients, the authors note that Actelion Pharmaceuticals conducted all the statistical analyses and hired a professional medical writer to assist. The acknowledgments thank these persons, thus meeting the standards of the International Committee of Medical Journal Editors.(2) However, the blurred line between hired writing assistance and ghostwriting is unsettling. Disclosure is only ... C1 [Anderson, Timothy S.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. [Good, Chester B.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Anderson, TS (reprint author), Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. EM andersont@upmc.edu NR 4 TC 0 Z9 0 U1 0 U2 6 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 2 PY 2014 VL 370 IS 1 BP 81 EP 81 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 284XA UT WOS:000329354100018 PM 24382072 ER PT J AU Baxi, SM Greenblatt, RM Bacchetti, P Scherzer, R Minkoff, H Huang, Y Anastos, K Cohen, M Gange, SJ Young, M Shlipak, MG Gandhi, M AF Baxi, Sanjiv M. Greenblatt, Ruth M. Bacchetti, Peter Scherzer, Rebecca Minkoff, Howard Huang, Yong Anastos, Kathryn Cohen, Mardge Gange, Stephen J. Young, Mary Shlipak, Michael G. Gandhi, Monica TI Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women SO AIDS LA English DT Article DE areas under the concentration-time curve; cystatin C; diverse populations; exposure; glomerular filtration rate; HIV-infected women; pharmacokinetics; tenofovir ID IMMUNODEFICIENCY-VIRUS-INFECTION; CO-FORMULATED ELVITEGRAVIR; CHRONIC KIDNEY-DISEASE; SERUM CYSTATIN-C; DISOPROXIL FUMARATE; PREEXPOSURE PROPHYLAXIS; ATAZANAVIR-RITONAVIR; INITIAL TREATMENT; INTERIM GUIDANCE; ESTIMATING GFR AB Objective:Tenofovir is used commonly in HIV treatment and prevention settings, but factors that correlate with tenofovir exposure in real-world settings are unknown.Design:Intensive pharmacokinetic studies of tenofovir in a large, diverse cohort of HIV-infected women over 24h at steady state were performed and factors that influenced exposure [assessed by areas under the concentration-time curves (AUCs)] identified.Methods:HIV-infected women (n=101) on tenofovir-based therapy underwent intensive 24-h pharmacokinetic sampling. Data on race/ethnicity, age, exogenous steroid use, menstrual cycle phase, concomitant medications, recreational drugs and/or tobacco, hepatic and renal function, weight, and BMI were collected. Multivariable models using forward stepwise selection identified factors associated with effects on AUC. Glomerular filtration rates (GFRs) prior to starting tenofovir were estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation using both creatinine and cystatin-C measures.Results:The median (range) of tenofovir AUCs was 3350 (1031-13911) ngxh/ml. Higher AUCs were associated with concomitant ritonavir use (1.33-fold increase, P=0.002), increasing age (1.21-fold increase per decade, P=0.0007), and decreasing BMI (1.04-fold increase per 10% decrease in BMI). When GFR was calculated using cystatin-C measures, mild renal insufficiency prior to tenofovir initiation was associated with higher subsequent exposure (1.35-fold increase when pre-tenofovir GFR <70ml/min, P=0.0075).Conclusion:Concomitant ritonavir use, increasing age, decreasing BMI, and lower GFR prior to tenofovir initiation as estimated by cystatin C were all associated with elevated tenofovir exposure in a diverse cohort of HIV-infected women. Clinicians treating HIV-infected women should be aware of common clinical conditions that affect tenofovir exposure when prescribing this medication. C1 [Baxi, Sanjiv M.; Greenblatt, Ruth M.; Scherzer, Rebecca; Shlipak, Michael G.; Gandhi, Monica] Univ Calif San Francisco, Dept Med, San Francisco, CA 94122 USA. [Greenblatt, Ruth M.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94122 USA. [Greenblatt, Ruth M.; Bacchetti, Peter] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94122 USA. [Minkoff, Howard] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Huang, Yong] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94122 USA. [Anastos, Kathryn] Albert Einstein Univ, Dept Med, Bronx, NY USA. [Cohen, Mardge] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge] Rush Univ, Chicago, IL 60612 USA. [Gange, Stephen J.] Johns Hopkins Univ, Dept Med, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. RP Gandhi, M (reprint author), Univ Calif San Francisco, Div HIV AIDS, 405 Irving St,2nd Floor, San Francisco, CA 94122 USA. EM monica.gandhi@ucsf.edu OI Gange, Stephen/0000-0001-7842-512X FU National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) [K23 A1067065, RO1 AI098472]; National Center for Research Resources (NCRR)/NIH via the UCSF-CTSI [UL1 RR024131]; NIAID [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders FX This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) (K23 A1067065 and RO1 AI098472 to M. G.). Additional funding is also provided by the National Center for Research Resources (NCRR)/NIH via the UCSF-CTSI (UL1 RR024131). Data in this study were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC, Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by NIAID (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. NR 49 TC 29 Z9 29 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JAN 2 PY 2014 VL 28 IS 1 BP 59 EP 66 DI 10.1097/QAD.0000000000000033 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 277KQ UT WOS:000328818400007 PM 24275255 ER PT J AU Thase, ME Swartz, HA Frank, E Miklowitz, DJ Gabbard, GO Goldberg, JF AF Thase, Michael E. Swartz, Holly A. Frank, Ellen Miklowitz, David J. Gabbard, Glen O. Goldberg, Joseph F. BA Gabbard, GO BF Gabbard, GO TI Psychotherapy of Mood Disorders SO GABBARD'S TREATMENTS OF PSYCHIATRIC DISORDERS, 5TH EDITION LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; FAMILY-FOCUSED TREATMENT; SOCIAL RHYTHM THERAPY; COLLABORATIVE RESEARCH-PROGRAM; PEDIATRIC-BIPOLAR-DISORDER; MAJOR DEPRESSIVE DISORDER; MENTAL-HEALTH TREATMENT; EXPRESSED EMOTION; PSYCHOSOCIAL TREATMENT C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Swartz, Holly A.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Frank, Ellen] Univ Penn, Psychiat, Philadelphia, PA 19104 USA. [Frank, Ellen] Univ Penn, Dept Psychol, Clin Program, Psychol, Philadelphia, PA 19104 USA. [Miklowitz, David J.] UCLA Semel Inst Neurosci & Human Behav, Psychiat, Los Angeles, CA USA. [Miklowitz, David J.] UCLA Semel Inst Neurosci & Human Behav, Child & Adolescent Mood Disorders Program, Los Angeles, CA USA. [Gabbard, Glen O.] SUNY Upstate Med Univ, Psychiat, Syracuse, NY 13210 USA. [Gabbard, Glen O.] Baylor Coll Med, Psychiat, Houston, TX 77030 USA. [Gabbard, Glen O.] Gabbard Ctr, Houston, TX USA. [Goldberg, Joseph F.] Icahn Sch Med Mt Sinai, Psychiat, New York, NY 10029 USA. [Goldberg, Joseph F.] Silver Hill Hosp, Affect Disorders Res Program, New Canaan, CT USA. RP Thase, ME (reprint author), Univ Penn, Perelman Sch Med, Psychiat, Philadelphia, PA 19104 USA. NR 83 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209 USA BN 978-1-58562-442-3 PY 2014 BP 221 EP 248 PG 28 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA BD9FX UT WOS:000364632600016 ER PT J AU George, MS Taylor, JJ Short, EB Snipes, J Pelic, C Fryml, LD AF George, Mark S. Taylor, Joseph J. Short, E. Baron Snipes, Jonathan Pelic, Christopher Fryml, Leah D. BA Gabbard, GO BF Gabbard, GO TI Brain Stimulation Treatments for Mood Disorders SO GABBARD'S TREATMENTS OF PSYCHIATRIC DISORDERS, 5TH EDITION LA English DT Article; Book Chapter ID TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE-STIMULATION; TREATMENT-RESISTANT DEPRESSION; OBSESSIVE-COMPULSIVE DISORDER; LEFT PREFRONTAL RTMS; HUMAN MOTOR CORTEX; ADMINISTERED SEIZURE THERAPY; INTENSITY FOCUSED ULTRASOUND; RANDOMIZED CONTROLLED-TRIAL; SHAM-CONTROLLED TRIAL C1 [George, Mark S.] Med Univ S Carolina, Layton McCurdy Endowed Chair, Psychiat Radiol & Neurosci, Charleston, SC 29403 USA. [George, Mark S.] Med Univ S Carolina, BSL, Charleston, SC USA. [George, Mark S.] RH Johnson VA Med Ctr, Charleston, SC USA. [Taylor, Joseph J.; Short, E. Baron; Snipes, Jonathan; Fryml, Leah D.] Med Univ S Carolina, Charleston, SC 29425 USA. [Pelic, Christopher] Med Univ S Carolina, Coll Med, Student Career Planning, Charleston, SC 29425 USA. [Pelic, Christopher] Med Univ S Carolina, South Carolina Alpha Chapter, Charleston, SC 29425 USA. [Pelic, Christopher] Med Univ S Carolina, Neurol Psychiat Combined Program, Charleston, SC 29425 USA. [Pelic, Christopher] Med Univ S Carolina, Ralph H Johnson VA Hosp, Charleston, SC 29425 USA. RP George, MS (reprint author), Med Univ S Carolina, Layton McCurdy Endowed Chair, Psychiat Radiol & Neurosci, Charleston, SC 29403 USA. NR 160 TC 1 Z9 1 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209 USA BN 978-1-58562-442-3 PY 2014 BP 303 EP 337 PG 35 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA BD9FX UT WOS:000364632600019 ER PT J AU Stein, MB Yang, CT Campbell-Sills, L AF Stein, Murray B. Yang, Calvin T. Campbell-Sills, Laura BA Gabbard, GO BF Gabbard, GO TI Panic Disorder SO GABBARD'S TREATMENTS OF PSYCHIATRIC DISORDERS, 5TH EDITION LA English DT Article; Book Chapter ID COGNITIVE-BEHAVIORAL THERAPY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ANXIETY DISORDERS; EXTENDED-RELEASE; ALPRAZOLAM DISCONTINUATION; PROGNOSTIC INDEXES; RANDOMIZED-TRIAL; STANDARD CBT; FOLLOW-UP C1 [Stein, Murray B.] Univ Calif San Diego, Psychiat & Family & Prevent Med, San Diego, CA 92103 USA. [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA USA. [Yang, Calvin T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Yang, Calvin T.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Campbell-Sills, Laura] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. RP Stein, MB (reprint author), Univ Calif San Diego, Psychiat & Family & Prevent Med, San Diego, CA 92103 USA. NR 44 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209 USA BN 978-1-58562-442-3 PY 2014 BP 343 EP 355 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA BD9FX UT WOS:000364632600021 ER PT B AU Fisher, MB Soegaard, N Steinberg, DR Mauck, RL AF Fisher, Matthew B. Soeegaard, Nicole Steinberg, David R. Mauck, Robert L. GP ASME TI TRAJECTORY-BASED TISSUE ENGINEERING FOR CARTILAGE REPAIR: CORRELATION BETWEEN MATURATION RATE AND INTEGRATION CAPACITY SO PROCEEDINGS OF THE ASME SUMMER BIOENGINEERING CONFERENCE - 2013, PT A LA English DT Proceedings Paper CT 15th American-Society-Mechanical-Engineering Summer Bioengineering Conference (SBC2013) CY JUN 26-29, 2013 CL Sunriver, OR SP Amer Soc Mech Engn, Bioengineer Div C1 [Fisher, Matthew B.; Soeegaard, Nicole; Steinberg, David R.; Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Steinberg, David R.; Mauck, Robert L.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Fisher, MB (reprint author), Univ Penn, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 978-0-7918-5560-7 PY 2014 AR V01AT17A022 PG 2 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA BD2YH UT WOS:000359389200225 ER PT B AU Fisher, MB Soegaard, N Esterhai, JL Mauck, RL AF Fisher, Matthew B. Soeegaard, Nicole Esterhai, John L. Mauck, Robert L. GP ASME TI ENGINEERING MENISCUS FORM AND FUNCTION VIA MULTI-LAYER CELL-SEEDED NANOFIBROUS SCAFFOLDS WITH CIRCUMFERENTIALLY ALIGNED FIBERS SO PROCEEDINGS OF THE ASME SUMMER BIOENGINEERING CONFERENCE - 2013, PT B LA English DT Proceedings Paper CT 15th American-Society-Mechanical-Engineering Summer Bioengineering Conference (SBC2013) CY JUN 26-29, 2013 CL Sunriver, OR SP Amer Soc Mech Engn, Bioengineer Div C1 [Fisher, Matthew B.; Soeegaard, Nicole; Esterhai, John L.; Mauck, Robert L.] Univ Penn, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Esterhai, John L.; Mauck, Robert L.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Fisher, MB (reprint author), Univ Penn, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 978-0-7918-5561-4 PY 2014 AR V01BT39A012 PG 2 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA BD2YI UT WOS:000359389300107 ER PT B AU Woodruff, SC Arnkoff, DB Glass, CR Hindman, RK AF Woodruff, Scott C. Arnkoff, Diane B. Glass, Carol R. Hindman, Robert K. BE Ie, A Ngnoumen, CT Langer, EJ TI Mindfulness and Anxiety SO WILEY BLACKWELL HANDBOOK OF MINDFULNESS, VOLS I AND II LA English DT Article; Book Chapter ID OBSESSIVE-COMPULSIVE DISORDER; STRESS REDUCTION PROGRAM; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; 3-YEAR FOLLOW-UP; COGNITIVE THERAPY; COMMITMENT THERAPY; CANCER OUTPATIENTS; BEHAVIOR-THERAPY; PANIC DISORDER C1 [Glass, Carol R.] Catholic Univ Amer, Psychol, Washington, DC 20064 USA. [Glass, Carol R.] Catholic Univ Amer, Undergrad Program, Washington, DC 20064 USA. [Glass, Carol R.] Amer Psychol Assoc, Washington, DC USA. [Glass, Carol R.] Soc Explorat Psychotherapy Integrat, Board Directors, Los Angeles, CA USA. [Hindman, Robert K.] Beck Inst Cognit Behav Therapy, Bala Cynwyd, PA USA. RP Woodruff, SC (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 129 TC 0 Z9 0 U1 1 U2 3 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND BN 978-1-118-29490-1; 978-1-118-29487-1 PY 2014 BP 732 EP 754 D2 10.1002/9781118294895 PG 23 WC Psychology, Clinical SC Psychology GA BC7HY UT WOS:000354891500042 ER PT B AU Martindale, RG McClave, SA Warren, M Desai, S AF Martindale, Robert G. McClave, Stephen A. Warren, Malissa Desai, Svetang BE Schiffrin, EJ Marteau, P Brassart, D TI Influence of the Intestinal Microbiota on the Critically Ill Patient SO INTESTINAL MICROBIOTA IN HEALTH AND DISEASE: MODERN CONCEPTS LA English DT Article; Book Chapter ID CLOSTRIDIUM-DIFFICILE DISEASE; VENTILATOR-ASSOCIATED PNEUMONIA; PLACEBO-CONTROLLED TRIAL; SEVERE ACUTE-PANCREATITIS; MULTIPLE ORGAN FAILURE; INTENSIVE-CARE-UNIT; GUT MICROBIOTA; DOUBLE-BLIND; SACCHAROMYCES-BOULARDII; PSEUDOMONAS-AERUGINOSA C1 [Martindale, Robert G.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. [McClave, Stephen A.] Univ Louisville, Louisville, KY 40202 USA. [Warren, Malissa] Portland VA Med Ctr, Portland, OR 97207 USA. [Desai, Svetang] Duke Univ, Gastroenterol Sect, Duke Clin 2G 2H, Durham, NC 27710 USA. RP Martindale, RG (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L223A, Portland, OR 97239 USA. EM martindr@ohsu.edu; Stephen.mcclave@louisville.edu; Malissa.warren@va.gov; Svetang@gmail.com NR 56 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4822-2677-5; 978-1-4822-2676-8 PY 2014 BP 293 EP 306 PG 14 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA BC8FY UT WOS:000355632100014 ER PT J AU Schapira, MM Walker, CM Miller, T Fletcher, KE Ganschow, PS Jacobs, EA Imbert, D O'Connell, M Neuner, JM AF Schapira, Marilyn M. Walker, Cindy M. Miller, Tamara Fletcher, Kathlyn E. Ganschow, Pamela S. Jacobs, Elizabeth A. Imbert, Diana O'Connell, Maria Neuner, Joan M. TI Development and Validation of the Numeracy Understanding in Medicine Instrument Short Form SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID ITEM RESPONSE THEORY; FUNCTIONAL HEALTH LITERACY; RISK PERCEPTION; COMMUNICATION; INFORMATION; SCALE; CARE; COMPREHENSION; FRAMEWORK; ADULTS AB Health numeracy can be defined as the ability to understand and use numeric information and quantitative concepts in the context of health. The authors previously reported the development of the Numeracy Understanding in Medicine Instrument (NUMi), a 20-item test developed using item response theory. The authors now report the development and validation of a short form of the NUMi. Item statistics were used to identify a subset of 8 items representing a range of difficulty and content areas. Internal reliability was evaluated with Cronbach's alpha. Divergent and convergent validity was assessed by comparing scores of the S-NUMI with existing measures of education, print and numeric health literacy, mathematic achievement, cognitive reasoning, and the original NUMi. The 8-item scale had adequate reliability (alpha = .72) and was strongly correlated to the 20-item NUMi (alpha = .92). S-NUMi scores were strongly correlated with the Lipkus Expanded Health Numeracy Scale (alpha = .62), the Wide Range of Achievement Test-Mathematics (alpha = .72), and the Wonderlic Cognitive Ability Test (alpha = .76). Moderate correlation was found with education level (alpha = .58) and print literacy as measured by the Test of Functional Health Literacy in Adults (alpha = .49). Results show that the short form of the NUMi is a reliable and valid measure of health numeracy feasible for use in clinical and research settings. C1 [Schapira, Marilyn M.; Imbert, Diana] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res Program, Philadelphia, PA USA. [Walker, Cindy M.; Miller, Tamara] Univ Wisconsin, Dept Educ Psychol, Milwaukee, WI 53201 USA. [Fletcher, Kathlyn E.; Neuner, Joan M.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Fletcher, Kathlyn E.] Zablocki VA Med Ctr, Milwaukee, WI USA. [Ganschow, Pamela S.; O'Connell, Maria] Rush Univ, Sch Med, Dept Med, Chicago, IL 60612 USA. [Jacobs, Elizabeth A.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA. RP Schapira, MM (reprint author), Univ Penn, Perelman Sch Med, Dept Med, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM mschap@upenn.edu FU National Cancer Institute of the National Institutes of Health [NC1R01CA115954]; American Cancer Society [121158-RSG-11-104-01-CPPB] FX This work was supported by grants from the National Cancer Institute of the National Institutes of Health NC1R01CA115954 and the American Cancer Society 121158-RSG-11-104-01-CPPB. NR 46 TC 4 Z9 4 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1081-0730 EI 1087-0415 J9 J HEALTH COMMUN JI J. Health Commun. PY 2014 VL 19 SU 2 SI SI BP 240 EP 253 DI 10.1080/10810730.2014.933916 PG 14 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA CE5OI UT WOS:000351884600021 PM 25315596 ER PT J AU Giordano, S Darley-Usmar, V Zhang, JH AF Giordano, Samantha Darley-Usmar, Victor Zhang, Jianhua TI Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease SO REDOX BIOLOGY LA English DT Article DE Parkinson's disease; Protein aggregation; Neurons; Mitochondrial dysfunction; Reactive oxygen species; Anti-oxidants; Autophagy; Toxins; Clinical trials; Animal models; Redox signaling ID EARLY PARKINSON-DISEASE; INCREASED OXIDATIVE DAMAGE; HUMAN SUBSTANTIA-NIGRA; ALPHA-SYNUCLEIN; DOPAMINERGIC-NEURONS; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; NITRIC-OXIDE; DOUBLE-BLIND; ENZYME-ACTIVITIES AB Oxidative stress including DNA damage, increased lipid and protein oxidation, are important features of aging and neurodegeneration suggesting that endogenous antioxidant protective pathways are inadequate or overwhelmed. Importantly, oxidative protein damage contributes to age-dependent accumulation of dysfunctional mitochondria or protein aggregates. In addition, environmental toxins such as rotenone and paraquat, which are risk factors for the pathogenesis of neurodegenerative diseases, also promote protein oxidation. The obvious approach of supplementing the primary antioxidant systems designed to suppress the initiation of oxidative stress has been tested in animal models and positive results were obtained. However, these findings have not been effectively translated to treating human patients, and clinical trials for antioxidant therapies using radical scavenging molecules such as alpha-tocopherol, ascorbate and coenzyme Q have met with limited success, highlighting several limitations to this approach. These could include: (1) radical scavenging antioxidants cannot reverse established damage to proteins and organelles; (2) radical scavenging antioxidants are oxidant specific, and can only be effective if the specific mechanism for neurodegeneration involves the reactive species to which they are targeted and (3) since reactive species play an important role in physiological signaling, suppression of endogenous oxidants maybe deleterious. Therefore, alternative approaches that can circumvent these limitations are needed. While not previously considered an antioxidant system we propose that the autophagy-lysosomal activities, may serve this essential function in neurodegenerative diseases by removing damaged or dysfunctional proteins and organelles. (C) 2014 The Authors. Published by Elsevier B.V. All rights reserved C1 [Giordano, Samantha; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA. [Giordano, Samantha; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35233 USA. EM zhanja@uab.edu OI Zhang, Jianhua/0000-0002-2128-9574 FU VA merit award; [NIHR01-NS064090] FX This work was supported by NIHR01-NS064090 and a VA merit award (to JZ). NR 133 TC 70 Z9 75 U1 13 U2 52 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PY 2014 VL 2 BP 82 EP 90 DI 10.1016/j.redox.2013.12.013 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CD0MY UT WOS:000350769600012 PM 24494187 ER PT S AU Rohrer, B Kunchithapautham, K Genewsky, A Strauss, O AF Rohrer, Barbel Kunchithapautham, Kannan Genewsky, Andreas Strauss, Olaf BE Ash, JD Grimm, C Hollyfield, JG Anderson, RE LaVail, MM Rickman, CB TI Prolonged Src Kinase Activation, a Mechanism to Turn Transient, Sublytic Complement Activation into a Sustained Pathological Condition in Retinal Pigment Epithelium Cells SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 15th International Symposium on Retinal Degeneration (RD) CY JUL 16-21, 2012 CL GERMANY DE Complement activation; Vascular endothelial growth factor; Voltage-dependent calcium channel; Calcium imaging; Patch clamp analysis ID MACULAR DEGENERATION; VEGF; SECRETION; CA2+ AB Age-related macular degeneration (AMD) is a slowly progressing multifactorial disease involving genetic abnormalities and environmental insults. Genetic studies have demonstrated that polymorphisms in different complement proteins increase the risk for developing AMD. Previously, we have shown that in retinal pigment epithelium (RPE) monolayers, exposure to oxidative stress reduced complement inhibition on the cell surface, with the resulting increase in complement activation leading to vascular endothelial growth factor (VEGF) release and VEGF-receptor-2-mediated disruption of the monolayer barrier function. Complement activation was found to be sublytic and transient and require the assembly of the membrane attack complex (MAC). Here, we asked how this transient, sublytic complement activation could trigger long-term pathological changes in RPE cells. The initial activation of the L-type voltage-gated calcium channels was followed by calcium influx and activation of several kinases. While Erk/Ras activation was found to be transient, Src kinase phosphorylation was sustained. We have shown previously that Src kinase controls VEGF release from RPE cells by altering the activity of the L-type channel. We propose that the prolonged Src kinase activation, and its resulting effects on membrane depolarization and calcium influx, leads to sustained VEGF secretion. In addition, the previously shown effect of the autocrine positive feedback loop in RPE cells, involving VEGF-induced VEGF production and secretion via VEGFR-2 receptors, will augment and prolong the effects of sublytic complement activation. In summary, identification of the links between oxidative stress, chronic, low-grade activation of the complement system, and elevated VEGF expression and secretion might offer opportunities to selectively inhibit pathological VEGF release only. C1 [Rohrer, Barbel; Kunchithapautham, Kannan] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA. [Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. [Genewsky, Andreas; Strauss, Olaf] Klinikum Univ Regensburg, Dept Expt Ophthalmol, Regensburg, Germany. [Strauss, Olaf] Charite, Dept Ophthalmol, D-13353 Berlin, Germany. RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI614, Charleston, SC 29425 USA. EM rohrer@musc.edu; kunchit@musc.edu; andreas_genewsky@mpipsykl.mpg.de; olaf.strauss@charite.de FU NEI NIH HHS [R01 EY019320, R01EY019320] NR 20 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-1-4614-3209-8; 978-1-4614-3208-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2014 VL 801 BP 221 EP 227 DI 10.1007/978-1-4614-3209-8_29 PG 7 WC Biology; Medicine, Research & Experimental; Ophthalmology SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine; Ophthalmology GA BC1TP UT WOS:000350418200030 PM 24664702 ER PT S AU Woodell, A Rohrer, B AF Woodell, Alex Rohrer, Baerbel BE Ash, JD Grimm, C Hollyfield, JG Anderson, RE LaVail, MM Rickman, CB TI A Mechanistic Review of Cigarette Smoke and Age-Related Macular Degeneration SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 15th International Symposium on Retinal Degeneration (RD) CY JUL 16-21, 2012 CL GERMANY DE Cigarette smoke; Age-related macular degeneration; Oxidative stress; Antioxidant; Complement; Angiogenesis ID CAUSES OXIDATIVE DAMAGE; COMPLEMENT FACTOR-H; LIPID-PEROXIDATION; HUMAN RETINA; MOUSE MODEL; VITAMIN-C; PLASMA; ANGIOGENESIS; ASSOCIATIONS; PATHOGENESIS AB Age-related macular degeneration (AMD), a complex disease stemming from both genetic abnormalities and environmental insults, is the most common form of visual impairment in elderly individuals of the Western world. Many potential etiologies are linked to AMD, but smoking is the leading environmental insult associated with this maculopathy. Smoke-induced damage is mediated in part through direct oxidation, depletion of antioxidants, complement activation, and vascular transmutations. Clinically, these mechanisms manifest themselves as keystones of atrophic AMD: retinal pigment epithelium degeneration, formation of extracellular deposits such as drusen, and thickening of Bruch's membrane. Furthermore, smoking induces angiogenesis and choroidal neovascularization, advancing the course of the disease to late-stage AMD. Further exploration of the biological processes affected by cigarette smoke exposure will provide greater insight into the pathogenesis of AMD. C1 [Woodell, Alex; Rohrer, Baerbel] Med Univ S Carolina, Div Res, Dept Neurosci, Charleston, SC 29425 USA. [Rohrer, Baerbel] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA. [Rohrer, Baerbel] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Rohrer, B (reprint author), Med Univ S Carolina, Div Res, Dept Neurosci, 167 Ashley Ave,SEI 614, Charleston, SC 29425 USA. EM woodell@musc.edu; rohrer@musc.edu FU National Institutes of Health (NIH) [R01EY019320]; Department of Veterans Affairs [I01 RX000444]; Foundation Fighting Blindness; Research to Prevent Blindness (RPB), Inc., New York, NY FX The authors thank Christine Curcio for critical discussions. This review was supported in part by the National Institutes of Health (NIH) (R01EY019320), Department of Veterans Affairs (I01 RX000444), Foundation Fighting Blindness, and an unrestricted grant to MUSC from Research to Prevent Blindness (RPB), Inc., New York, NY. The authors have no financial conflicts of interest. NR 38 TC 12 Z9 13 U1 1 U2 3 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-1-4614-3209-8; 978-1-4614-3208-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2014 VL 801 BP 301 EP 307 DI 10.1007/978-1-4614-3209-8_38 PG 7 WC Biology; Medicine, Research & Experimental; Ophthalmology SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine; Ophthalmology GA BC1TP UT WOS:000350418200039 PM 24664711 ER PT S AU Schnabolk, G Tomlinson, S Rohrer, B AF Schnabolk, Gloriane Tomlinson, Stephen Rohrer, Baerbel BE Ash, JD Grimm, C Hollyfield, JG Anderson, RE LaVail, MM Rickman, CB TI The Complement Regulatory Protein CD59: Insights into Attenuation of Choroidal Neovascularization SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 15th International Symposium on Retinal Degeneration (RD) CY JUL 16-21, 2012 CL GERMANY DE AMD; CD59; Complement; Choroidal neovascularization (CNV); Membrane attack complex (MAC) ID MACULAR DEGENERATION; MOUSE MODEL; INHIBITOR; ACTIVATION; DRUSEN; INJURY AB Complement activation is associated with age-related macular degeneration (AMD), with the retinal pigment epithelium (RPE) being one of the main target tissues. In AMD, disease severity is correlated with the formation of the membrane attack complex (MAC), the terminal step in the complement cascade, as well as diminished RPE expression of CD59, a membrane-bound regulatory protein of MAC formation. This has prompted the search for therapeutic strategies based on MAC inhibition, and soluble forms of CD59 (sCD59) have been investigated in mouse laser-induced choroidal neovascularization, a model for "wet" AMD. Unlike membrane-bound CD59, sCD59 provides relatively poor cell protection from complement, and different strategies to increase sCD59 activity at the cell membrane level have been investigated. These include increasing the circulatory half-life of sCD59 by the addition of an Fc moiety; increasing the half-life of sCD59 in target tissues by modifying CD59 with a (non-specific) membrane-targeting domain; and by locally overexpressing sCD59 via adenoviral vectors. Finally, a different strategy currently under investigation employs complement receptor (CR) 2-mediated targeting of CD59 exclusively to membranes under complement attack. CR2 recognizes long-lasting membrane-bound breakdown activation fragments of complement C3. CR2-CD59 may have greater therapeutic potential than other complement inhibitory approaches, since it can be administered either systemically or locally, it will bind specifically to membranes containing activated complement activation fragments, and dosing can be regulated. Hence, this strategy might offer opportunities for site-specific inhibition of complement in diseases with restricted sites of inflammation such as AMD. C1 [Tomlinson, Stephen; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC 29401 USA. [Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol, Charleston, SC 29425 USA. [Tomlinson, Stephen] Med Univ S Carolina, Dept Immunol, Charleston, SC 29425 USA. [Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA. [Rohrer, Baerbel] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Rohrer, B (reprint author), Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC 29401 USA. EM faith@musc.edu; faith@musc.edu; rohrer@musc.edu FU National Institutes of Health (NIH) [R01EY019320]; Department of Veterans Affairs [I01 RX000444]; Foundation Fighting Blindness; Research to Prevent Blindness (RPB), Inc., New York, NY FX This review was supported in part by the National Institutes of Health (NIH) (R01EY019320), Department of Veterans Affairs (I01 RX000444), Foundation Fighting Blindness, and an unrestricted grant to MUSC from Research to Prevent Blindness (RPB), Inc., New York, NY. The authors have no financial conflicts of interest. NR 21 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-1-4614-3209-8; 978-1-4614-3208-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2014 VL 801 BP 435 EP 440 DI 10.1007/978-1-4614-3209-8_55 PG 6 WC Biology; Medicine, Research & Experimental; Ophthalmology SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine; Ophthalmology GA BC1TP UT WOS:000350418200056 PM 24664728 ER PT S AU Pardue, MT Ciavatta, VT Hetling, JR AF Pardue, Machelle T. Ciavatta, Vincent T. Hetling, John R. BE Ash, JD Grimm, C Hollyfield, JG Anderson, RE LaVail, MM Rickman, CB TI Neuroprotective Effects of Low Level Electrical Stimulation Therapy on Retinal Degeneration SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT 15th International Symposium on Retinal Degeneration (RD) CY JUL 16-21, 2012 CL GERMANY DE Retinal degeneration; Electrical stimulation; Subretinal; Transcorneal; Neuroprotection; Photoreceptors; Retinal ganglion cells ID MULLER CELLS; RETINITIS-PIGMENTOSA; RATS; PHOTORECEPTORS; INDUCTION; PROMOTES; SURVIVAL AB Low-level electrical stimulation applied to the eye has been shown to have neuroprotective effects on photoreceptors and retinal ganglion cells. In this review, we compare the effects of Subretinal Electrical Stimulation (SES), Transcorneal Electrical Stimulation (TES), and Whole Eye Stimulation (WES) on preserving retinal structure and function, and visual acuity, in retinal degeneration. Similarities and differences in stimulus parameters, targeted cells and growth factor expression will be discussed with emphasis on studies that have translated laboratory findings into clinical trials. C1 [Pardue, Machelle T.; Ciavatta, Vincent T.] Emory Univ, Sch Med, Ophthalmol, Atlanta, GA 30322 USA. [Pardue, Machelle T.; Ciavatta, Vincent T.] US Dept Vet Affairs, Rehab R&D Ctr Excellence, Decatur, GA USA. [Pardue, Machelle T.] Atlanta VA Med Ctr, Res Serv 151Oph, Decatur, GA 30033 USA. [Hetling, John R.] Univ Illinois, Bioengn, Chicago, IL USA. RP Pardue, MT (reprint author), Emory Univ, Sch Med, Ophthalmol, Atlanta, GA 30322 USA. EM mpardue@emory.edu; vciavat@emory.edu; JHetli1@uic.edu NR 29 TC 3 Z9 3 U1 0 U2 4 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-1-4614-3209-8; 978-1-4614-3208-1 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2014 VL 801 BP 845 EP 851 DI 10.1007/978-1-4614-3209-8_106 PG 7 WC Biology; Medicine, Research & Experimental; Ophthalmology SC Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine; Ophthalmology GA BC1TP UT WOS:000350418200107 PM 24664779 ER PT J AU Lampert, EJ Choudhury, KR Hostage, CA Rathakrishnan, B Weiner, M Petrella, JR Doraiswamy, PM AF Lampert, Erika J. Choudhury, Kingshuk Roy Hostage, Christopher A. Rathakrishnan, Bharath Weiner, Michael Petrella, Jeffrey R. Doraiswamy, P. Murali CA Alzheimers Dis Neuroimaging Initia TI Brain atrophy rates in first degree relatives at risk for Alzheimer's SO NEUROIMAGE-CLINICAL LA English DT Article DE Hippocampus; Amygdala; Entorhinal cortex; Memory; Dementia; Family history ID HUMAN CEREBRAL-CORTEX; MATERNAL HISTORY; APOLIPOPROTEIN-E; FAMILY-HISTORY; DISEASE; MRI; THICKNESS AB A positive family history (FH) raises the risk for late-onset Alzheimer's disease though, other than the known risk conferred by apolipoprotein epsilon 4 (ApoE4), much of the genetic variance remains unexplained. We examined the effect of family history on longitudinal regional brain atrophy rates in 184 subjects (42% FH+, mean age 79.9) with mild cognitive impairment (MCI) enrolled in a national biomarker study. An automated image analysis method was applied to T1-weightedMR images to measure atrophy rates for 20 cortical and subcortical regions. Mixed-effects linear regression models incorporating repeated-measures to control for within-subject variation over multiple time points tested the effect of FH over a follow-up of up to 48 months. Most of the 20 regions showed significant atrophy over time. Adjusting for age and gender, subjects with a positive FH had greater atrophy of the amygdala (p < 0.01), entorhinal cortex (p < 0.01), hippocampus (p < 0.053) and cortical gray matter (p < 0.009). However, when E4 genotype was added as a covariate, none of the FH+ effects remained significant. Analyses by ApoE genotype showed that the effect of FH on amygdala atrophy rates was numerically greater in epsilon 3 homozygotes than in E4 carriers, but this difference was not significant. FH+ subjects had numerically greater 4-year cognitive decline and conversion rates than FH- subjects but the difference was not statistically significant after adjusting for ApoE and other variables. We conclude that a positive family history of AD may influence cortical and temporal lobe atrophy in subjects with mild cognitive impairment, but it does not have a significant additional effect beyond the known effect of the E4 genotype. (C) 2014 The Authors. Published by Elsevier Inc. C1 [Lampert, Erika J.; Rathakrishnan, Bharath; Doraiswamy, P. Murali] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. [Choudhury, Kingshuk Roy; Hostage, Christopher A.; Petrella, Jeffrey R.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA. [Doraiswamy, P. Murali] Duke Univ, Med Ctr, Inst Brain Sci, Durham, NC 27710 USA. [Weiner, Michael] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Weiner, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. [Weiner, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. RP Lampert, EJ (reprint author), Duke Univ, DUMC 3018 South Hosp, Durham, NC 27710 USA. EM ejlampert@gmail.com; kingshuk.roy.choudhury@duke.edu; cah1289@gmail.com; bg.rathakrishnan@gmail.com; Michael.weiner@ucsf.edu; jeffrey.petrella@duke.edu; murali.doraiswamy@duke.edu FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Canadian Institutes of Health Research; Northern California Institute for Research and Education; ADNI; Wrenn Clinical Research Scholar award FX Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc., Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & > Development LLC; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.; PMD and JRP have received research grants and/or advisory fees from several government agencies, advocacy groups and pharmaceutical/imaging companies. PMD received a grant from ADNI to support data collection for this study and he owns stock in Sonexa, Maxwell, Adverse Events and Clarimedix, whose products are not discussed here. EJL was supported by the Wrenn Clinical Research Scholar award. NR 21 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2014 VL 6 BP 340 EP 346 DI 10.1016/j.nicl.2014.08.024 PG 7 WC Neuroimaging SC Neurosciences & Neurology GA CB5LL UT WOS:000349668500039 PM 25379448 ER PT J AU Rissling, AJ Miyakoshi, M Sugar, CA Braff, DL Makeig, S Light, GA AF Rissling, Anthony J. Miyakoshi, Makoto Sugar, Catherine A. Braff, David L. Makeig, Scott Light, Gregory A. TI Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia SO NEUROIMAGE-CLINICAL LA English DT Article DE Schizophrenia; Mismatch negativity; Attention; EEG; Independent component analysis ID INDEPENDENT COMPONENT ANALYSIS; EVENT-RELATED POTENTIALS; INFERIOR FRONTAL GYRUS; DURATION MISMATCH NEGATIVITY; ANTERIOR CINGULATE CORTEX; SKILLS ASSESSMENT UPSA; WORKING-MEMORY; EEG DATA; 1ST-EPISODE SCHIZOPHRENIA; RESPONSE-INHIBITION AB Although sensory processing abnormalities contribute to widespread cognitive and psychosocial impairments in schizophrenia (SZ) patients, scalp-channel measures of averaged event-related potentials (ERPs) mix contributions from distinct cortical source-area generators, diluting the functional relevance of channel-based ERP measures. SZ patients (n = 42) and non-psychiatric comparison subjects (n = 47) participated in a passive auditory duration oddball paradigm, eliciting a triphasic (Deviant-Standard) tone ERP difference complex, here termed the auditory deviance response (ADR), comprised of a mid-frontal mismatch negativity (MMN), P3a positivity, and re-orienting negativity (RON) peak sequence. To identify its cortical sources and to assess possible relationships between their response contributions and clinical SZ measures, we applied independent component analysis to the continuous 68-channel EEG data and clustered the resulting independent components (ICs) across subjects on spectral, ERP, and topographic similarities. Six IC clusters centered in right superior temporal, right inferior frontal, ventral mid-cingulate, anterior cingulate, medial orbitofrontal, and dorsal mid-cingulate cortex each made triphasic response contributions. Although correlations between measures of SZ clinical, cognitive, and psychosocial functioning and standard (Fz) scalp-channel ADR peak measures were weak or absent, for at least four IC clusters one or more significant correlations emerged. In particular, differences in MMN peak amplitude in the right superior temporal IC cluster accounted for 48% of the variance in SZ-subject performance on tasks necessary for real-world functioning and medial orbitofrontal cluster P3a amplitude accounted for 40%/54% of SZ-subject variance in positive/negative symptoms. Thus, source-resolved auditory deviance response measures including MMN may be highly sensitive to SZ clinical, cognitive, and functional characteristics. Published by Elsevier Inc. C1 [Rissling, Anthony J.; Braff, David L.; Light, Gregory A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Miyakoshi, Makoto; Makeig, Scott] Univ Calif San Diego, Inst Neural Computat, Swartz Ctr Computat Neurosci, La Jolla, CA 92093 USA. [Miyakoshi, Makoto] Japan Soc Promot Sci, Tokyo, Japan. [Braff, David L.; Light, Gregory A.] VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, Los Angeles, CA USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA. [Sugar, Catherine A.] Greater Los Angeles VA Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 22, Los Angeles, CA USA. RP Light, GA (reprint author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM glight@ucsd.edu FU National Alliance for Research on Schizophrenia and Depression/Brain and Behavior Research Foundation; Sydney R. Baer, Jr. Foundation; Department of Veteran Affairs (VISN 22 Mental Illness Research, Education, and Clinical Center); VeteransMedical Research Foundation; National Institute ofMental Health [MH079777, MH042228, MH065571, MH094151, MH093453, MH094320, UL1TR000100, MH081944]; Japan Society for the Promotion of Science (JSPS); Office of Naval Research; Swartz Foundation (Old Field, NY) FX This work was supported by the National Alliance for Research on Schizophrenia and Depression/Brain and Behavior Research Foundation, Sydney R. Baer, Jr. Foundation, the Department of Veteran Affairs (VISN 22 Mental Illness Research, Education, and Clinical Center), The VeteransMedical Research Foundation, The National Institute ofMental Health (MH079777, MH042228, MH065571, MH094151, MH093453, MH094320, UL1TR000100, MH081944), The Japan Society for the Promotion of Science (JSPS), The Office of Naval Research, and by a gift from The Swartz Foundation (Old Field, NY). The authors wish to thank Joyce Sprock, Marlena Pela, Richard Sharp, Stacy Langton, Arnaud Delorme, and Drs. Jared Young and Ricki-Lee Malaguti for their assistance, and (SM) Valerie Shafer, Peter Ullsperger, and Risto Naatanen for encouragement. NR 116 TC 13 Z9 13 U1 6 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2014 VL 6 BP 424 EP 437 DI 10.1016/j.nicl.2014.09.006 PG 14 WC Neuroimaging SC Neurosciences & Neurology GA CB5LL UT WOS:000349668500047 PM 25379456 ER PT J AU Horan, WP Iacoboni, M Cross, KA Korb, A Lee, J Nori, P Quintana, J Wynn, JK Green, MF AF Horan, William P. Iacoboni, Marco Cross, Katy A. Korb, Alex Lee, Junghee Nori, Poorang Quintana, Javier Wynn, Jonathan K. Green, Michael F. TI Self-reported empathy and neural activity during action imitation and observation in schizophrenia SO NEUROIMAGE-CLINICAL LA English DT Article DE Imitation; Observation; Simulation; Schizophrenia; Mirror neuron system; Empathy ID PSYCHIATRIC RATING-SCALE; MIRROR-NEURON; SOCIAL COGNITION; FACIAL EXPRESSIONS; MOTOR CORTEX; MECHANISMS; EMOTIONS; SYSTEM; DYSFUNCTION; BRAIN AB Introduction: Although social cognitive impairments are key determinants of functional outcome in schizophrenia their neural bases are poorly understood. This study investigated neural activity during imitation and observation of finger movements and facial expressions in schizophrenia, and their correlates with self-reported empathy. Methods: 23 schizophrenia outpatients and 23 healthy controls were studied with functional magnetic resonance imaging (fMRI) while they imitated, executed, or simply observed finger movements and facial emotional expressions. Between-group activation differences, as well as relationships between activation and self-reported empathy, were evaluated. Results: Both patients and controls similarly activated neural systems previously associated with these tasks. We found no significant between-group differences in task-related activations. There were, however, between-group differences in the correlation between self-reported empathy and right inferior frontal (pars opercularis) activity during observation of facial emotional expressions. As in previous studies, controls demonstrated a positive association between brain activity and empathy scores. In contrast, the pattern in the patient group reflected a negative association between brain activity and empathy. Conclusions: Although patients with schizophrenia demonstrated largely normal patterns of neural activation across the finger movement and facial expression tasks, they reported decreased self perceived empathy and failed to show the typical relationship between neural activity and self-reported empathy seen in controls. These findings suggest that patients show a disjunction between automatic neural responses to low level social cues and higher level, integrative social cognitive processes involved in self-perceived empathy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. C1 [Horan, William P.; Lee, Junghee; Nori, Poorang; Quintana, Javier; Wynn, Jonathan K.; Green, Michael F.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Horan, William P.; Iacoboni, Marco; Cross, Katy A.; Korb, Alex; Lee, Junghee; Nori, Poorang; Quintana, Javier; Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Horan, WP (reprint author), Univ Calif Los Angeles, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU Abbott Laboratories; Amgen; Cypress; Lundbeck; Teva; Otsuka; Sunovion FX Dr. Green reports having received consulting fees from Abbott Laboratories, Amgen, Cypress, Lundbeck, and Teva. He has received speaking fees from Otsuka and Sunovion. The rest of the authors report no biomedical financial interests or potential conflicts of interest. NR 65 TC 7 Z9 8 U1 3 U2 19 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2014 VL 5 BP 100 EP 108 DI 10.1016/j.nicl.2014.06.006 PG 9 WC Neuroimaging SC Neurosciences & Neurology GA CB5LF UT WOS:000349667800013 PM 25009771 ER PT J AU Mueller, SG Bateman, LM Laxer, KD AF Mueller, Susanne G. Bateman, Lisa M. Laxer, Kenneth D. TI Evidence for brainstem network disruption in temporal lobe epilepsy and sudden unexplained death in epilepsy SO NEUROIMAGE-CLINICAL LA English DT Article DE Deformation based morphometry; TLEgraph analysis; autonomic control; SUDEP ID SOLITARY TRACT NUCLEI; UNEXPECTED DEATH; CARDIOVASCULAR-RESPONSES; PERIAQUEDUCTAL GRAY; CUNEIFORM NUCLEUS; MESIAL SCLEROSIS; RAT; HYPOVENTILATION; MICROINJECTION; ABNORMALITIES AB The symptoms witnessed in unexplained death in epilepsy (SUDEP) suggest a breakdown of central autonomic control. Since the brainstem plays a crucial role in autonomic control, the objectives of this study were 1. To investigate if temporal lobe epilepsy (TLE) is associated with brainstem atrophy and to characterize it using graph Analysis 2. To compare the findings with those in two probable TLESUDEP. T1 images were obtained from 17 controls, 30 TLE (16 with mesial-temporal-sclerosis (TLE-MTS) and 14 without (TLE-no)) and from 2 patients who died of SUDEP. The brainstem was extracted, warped onto a brainstem atlas and Jacobian determinants maps (JDM) calculated. SPM8 was used to compare the JDMs at the group level, z-score maps were calculated for single subject analysis. Brainstem regions encompassing autonomic structures were identified based on macroscopic landmarks and mean z-scores from 5x5x5 voxel cubes extracted to calculate a new measure called atrophy-similarity index (ASI) for graph analysis. TLE-MTS had volume loss in the dorsal mesencephalon. The SUDEP cases had severe and more extensive volume loss in the same region. Nodal degrees and participation coefficients were decreased and local efficiency increased in SUDEP compared to controls. TLE is associated with volume loss in brainstem regions involved in autonomic control. Structural damage in these regions might increase the risk for a fatal dysregulation during situations with increased demand such as following severe seizures. (C) 2014 The Authors. Published by Elsevier Inc. C1 [Mueller, Susanne G.] VAMC, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Bateman, Lisa M.] Columbia Univ, Dept Neurol, New York, NY USA. [Laxer, Kenneth D.] Calif Pacific Med Ctr, Sutter Pacific Epilepsy Program, San Francisco, CA USA. RP Mueller, SG (reprint author), US Dept Vet Affairs, Med Ctr, Ctr Imaging Neurodegenerat Dis, Clement St 4150, San Francisco, CA 94121 USA. EM susanne.mueller@ucsf.edu FU NIH [RO1-NS31966] FX This work was supported by the NIH grant RO1-NS31966 to K.D.L. None of the authors has a conflict of interest to declare with regards to the findings reported in this manuscript. NR 37 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2014 VL 5 BP 208 EP 216 DI 10.1016/j.nicl.2014.06.010 PG 9 WC Neuroimaging SC Neurosciences & Neurology GA CB5LF UT WOS:000349667800024 PM 25068110 ER PT J AU Damaraju, E Allen, EA Belger, A Ford, JM McEwen, S Mathalon, DH Mueller, BA Pearlson, GD Potkin, SG Preda, A Turner, JA Vaidya, JG van Erp, TG Calhoun, VD AF Damaraju, E. Allen, E. A. Belger, A. Ford, J. M. McEwen, S. Mathalon, D. H. Mueller, B. A. Pearlson, G. D. Potkin, S. G. Preda, A. Turner, J. A. Vaidya, J. G. van Erp, T. G. Calhoun, V. D. TI Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia SO NEUROIMAGE-CLINICAL LA English DT Article ID EYE-MOVEMENT SLEEP; RESTING-STATE; BRAIN ACTIVITY; GRAPHICAL LASSO; NETWORK; FLUCTUATIONS; CONNECTOMICS; FMRI; DYSFUNCTION; REGRESSION AB Schizophrenia is a psychotic disorder characterized by functional dysconnectivity or abnormal integration between distant brain regions. Recent functional imaging studies have implicated large-scale thalamo-cortical connectivity as being disrupted in patients. However, observed connectivity differences in schizophrenia have been inconsistent between studies, with reports of hyperconnectivity and hypoconnectivity between the same brain regions. Using resting state eyes-closed functional imaging and independent component analysis on a multi-site data that included 151 schizophrenia patients and 163 age- and gender matched healthy controls, we decomposed the functional brain data into 100 components and identified 47 as functionally relevant intrinsic connectivity networks. We subsequently evaluated group differences in functional network connectivity, both in a static sense, computed as the pairwise Pearson correlations between the full network time courses (5.4 minutes in length), and a dynamic sense, computed using sliding windows (44 s in length) and k-means clustering to characterize five discrete functional connectivity states. Static connectivity analysis revealed that compared to healthy controls, patients show significantly stronger connectivity, i.e., hyperconnectivity, between the thalamus and sensory networks (auditory, motor and visual), as well as reduced connectivity (hypoconnectivity) between sensory networks from all modalities. Dynamic analysis suggests that (1), on average, schizophrenia patients spend much less time than healthy controls in states typified by strong, large-scale connectivity, and (2), that abnormal connectivity patterns are more pronounced during these connectivity states. In particular, states exhibiting cortical-subcortical antagonism (anti-correlations) and strong positive connectivity between sensory networks are those that show the group differences of thalamic hyperconnectivity and sensory hypoconnectivity. Group differences are weak or absent during other connectivity states. Dynamic analysis also revealed hypoconnectivity between the putamen and sensory networks during the same states of thalamic hyperconnectivity; notably, this finding cannot be observed in the static connectivity analysis. Finally, in post-hoc analyses we observed that the relationships between sub-cortical low frequency power and connectivity with sensory networks is altered in patients, suggesting different functional interactions between sub-cortical nuclei and sensorimotor cortex during specific connectivity states. While important differences between patients with schizophrenia and healthy controls have been identified, one should interpret the results with caution given the history of medication in patients. Taken together, our results support and expand current knowledge regarding dysconnectivity in schizophrenia, and strongly advocate the use of dynamic analyses to better account for and understand functional connectivity differences. (C) 2014 The Authors. Published by Elsevier Inc. C1 [Damaraju, E.; Allen, E. A.; Calhoun, V. D.] Mind Res Network, Albuquerque, NM USA. [Allen, E. A.] Univ Bergen, KG Jebsen Ctr Res Neuropsychiat Disorders, Bergen, Norway. [Belger, A.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Ford, J. M.; Mathalon, D. H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Ford, J. M.; Mathalon, D. H.] San Francisco VA Med Ctr, San Francisco, CA USA. [McEwen, S.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA USA. [Mueller, B. A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Pearlson, G. D.] Yale Univ, Sch Med, New Haven, CT USA. [Potkin, S. G.; Preda, A.; van Erp, T. G.] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA. [Turner, J. A.] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [Vaidya, J. G.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA. [Calhoun, V. D.] Univ New Mexico, Dept ECE, Albuquerque, NM 87131 USA. RP Damaraju, E (reprint author), 1101 Yale Blvd NE, Albuquerque, NM 87106 USA. EM edamaraju@mrn.org RI Preda, Adrian /K-8889-2013 OI Preda, Adrian /0000-0003-3373-2438; Potkin, Steven/0000-0003-1028-1013; Belger, Aysenil/0000-0003-2687-1966 FU NCRR NIH HHS [U24 RR021992]; NICHD NIH HHS [U54 HD079124]; NIGMS NIH HHS [P20 GM103472]; NIMH NIH HHS [K01 MH099431] NR 54 TC 72 Z9 74 U1 2 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2014 VL 5 BP 298 EP 308 DI 10.1016/j.nicl.2014.07.003 PG 11 WC Neuroimaging SC Neurosciences & Neurology GA CB5LF UT WOS:000349667800033 PM 25161896 ER PT J AU Adluru, N Destiche, DJ Lu, SYF Doran, ST Birdsill, AC Melah, KE Okonkwo, OC Alexander, AL Dowling, NM Johnson, SC Sager, MA Bendlin, BB AF Adluru, Nagesh Destiche, Daniel J. Lu, Sharon Yuan-Fu Doran, Samuel T. Birdsill, Alex C. Melah, Kelsey E. Okonkwo, Ozioma C. Alexander, Andrew L. Dowling, N. Maritza Johnson, Sterling C. Sager, Mark A. Bendlin, Barbara B. TI White matter microstructure in late middle-age: Effects of apolipoprotein E4 and parental family history of Alzheimer's disease SO NEUROIMAGE-CLINICAL LA English DT Article DE Alzheimer's disease; family history; APOE4; diffusion tensor imaging; MRI; risk factors; age sex ID MILD-COGNITIVE-IMPAIRMENT; DIFFUSION TENSOR TRACTOGRAPHY; APOE EPSILON-4 ALLELE; POSITRON-EMISSION-TOMOGRAPHY; CORPUS-CALLOSUM ATROPHY; VOXEL-BASED MORPHOMETRY; DETECTS AXONAL INJURY; IN-VIVO; GRAY-MATTER; RHESUS-MONKEY AB Introduction: Little is still known about the effects of risk factors for Alzheimer's disease (AD) on white matter microstructure in cognitively healthy adults. The purpose of this cross-sectional study was to assess the effect of two well-known risk factors for AD, parental family history and APOE4 genotype. Methods: This study included 343 participants from the Wisconsin Registry for Alzheimer's Prevention, who underwent diffusion tensor imaging (DTI). A region of interest analysis was performed on fractional anisotropy maps, in addition to mean, radial, and axial diffusivity maps, aligned to a common template space using a diffeomorphic, tensor-based registration method. The analysis focused on brain regions known to be affected in AD including the corpus callosum, superior longitudinal fasciculus, fornix, cingulum, and uncinate fasciculus. Analyses assessed the impact of APOE4, parental family history of AD, age, and sex on white matter microstructure in late middle-aged participants (aged 47-76 years). Results: Both APOE4 and parental family history were associated with microstructural white matter differences. Participants with parental family history of AD had higher FA in the genu of the corpus callosum and the superior longitudinal fasciculus. We observed an interaction between family history and APOE4, where participants who were family history positive but APOE4 negative had lower axial diffusivity in the uncinate fasciculus, and participants who were both family history positive and APOE4 positive had higher axial diffusivity in this region. We also observed an interaction between APOE4 and age, whereby older participants (>= 65 years of age) who were APOE4 carriers, had higher MD in the superior longitudinal fasciculus and in the portion of the cingulum bundle running adjacent to the cingulate cortex, compared to non-carriers. Older participants who were APOE4 carriers also showed higher radial diffusivity in the genu compared to non-carriers. Across all participants, age had an effect on FA, MD, and axial and radial diffusivities. Sex differences were observed in FA and radial diffusivity. Conclusion: APOE4 genotype, parental family history of AD, age, and sex are all associated with microstructural white matter differences in late middle-aged adults. In participants at risk for AD, alterations in diffusion characteristics-both expected and unexpected-may represent cellular changes occurring at the earliest disease stages, but further work is needed. Higher mean, radial, and axial diffusivities were observed in participants who are more likely to be experiencing later stage preclinical pathology, including participants who were both older and carried APOE4, or who were positive for both APOE4 and parental family history of AD. (C) 2014 The Authors. Published by Elsevier Inc. C1 [Adluru, Nagesh; Destiche, Daniel J.; Lu, Sharon Yuan-Fu; Doran, Samuel T.; Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA. [Birdsill, Alex C.; Melah, Kelsey E.; Okonkwo, Ozioma C.; Dowling, N. Maritza; Johnson, Sterling C.; Sager, Mark A.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Dept Med, Madison, WI 53792 USA. [Alexander, Andrew L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI 53705 USA. [Alexander, Andrew L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Psychiat, Madison, WI 53719 USA. [Dowling, N. Maritza] Dept Biostat & Med Informat, Madison, WI 53792 USA. [Johnson, Sterling C.; Sager, Mark A.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Johnson, Sterling C.; Sager, Mark A.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53719 USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, J5-1 Mezzanine,600 Highland Ave, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU Alzheimer's Association [NIRG-09-132626]; National Institute on Aging [R01 AG037639, R01 AG027161]; ADRC [P50 AG033514, R01 AG021155]; University of Wisconsin Institute for Clinical and Translational Research; National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award [1UL1RR025011]; program of the National Center for Research Resources, United States National Institutes of Health; Veteran's Administration [I01CX000165]; Waisman Center Core grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [P30 HD003352-45] FX This project was supported by the Alzheimer's Association, NIRG-09-132626, the National Institute on Aging (R01 AG037639 [BBB], R01 AG027161 [MAS], ADRC P50 AG033514 [SA], R01 AG021155 [SCJ], the University of Wisconsin Institute for Clinical and Translational Research, funded through a National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award, 1UL1RR025011, a program of the National Center for Research Resources, United States National Institutes of Health), by the Veteran's Administration [I01CX000165], and by the Waisman Center Core grant P30 HD003352-45 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The project was also facilitated by the facilities and resources at the Geriatric Research, Education and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison, WI (GRECC MS # 2013-08). The authors gratefully acknowledge Nancy Davenport-Sis, Amy Hawley, Sandra Harding, Caitlin Cleary, Jennifer Bond, Jennifer Oh, and Chuck Illingworth, and the support of researchers and staff at the Waisman Center, University of Wisconsin-Madison, for their assistance in recruitment, data collection, and data analysis. Above all, we wish to thank our dedicated volunteers for their participation in this research. NR 162 TC 13 Z9 13 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2014 VL 4 BP 730 EP 742 DI 10.1016/j.nicl.2014.04.008 PG 13 WC Neuroimaging SC Neurosciences & Neurology GA CB5LD UT WOS:000349667600080 PM 24936424 ER PT S AU Fox, PT Lancaster, JL Laird, AR Eickhoff, SB AF Fox, Peter T. Lancaster, Jack L. Laird, Angela R. Eickhoff, Simon B. BE Hyman, SE TI Meta-Analysis in Human Neuroimaging: Computational Modeling of Large-Scale Databases SO ANNUAL REVIEW OF NEUROSCIENCE, VOL 37 SE Annual Review of Neuroscience LA English DT Review; Book Chapter DE human brain mapping; activation likelihood estimation; ALE; magnetic resonance imaging; MRI; fMRI ID POSITRON-EMISSION-TOMOGRAPHY; LIKELIHOOD ESTIMATION METAANALYSIS; ACTIVATION-BASED PARCELLATION; FUNCTIONAL IMAGING DATA; HUMAN VISUAL-CORTEX; HUMAN-BRAIN; ALE METAANALYSIS; WORKING-MEMORY; HUMAN AMYGDALA; PET IMAGES AB Spatial normalization-applying standardized coordinates as anatomical addresses within a reference space-was introduced to human neuroimaging research nearly 30 years ago. Over these three decades, an impressive series of methodological advances have adopted, extended, and popularized this standard. Collectively, this work has generated a methodologically coherent literature of unprecedented rigor, size, and scope. Large-scale online databases have compiled these observations and their associated meta-data, stimulating the development ofmeta-analytic methods to exploit this expanding corpus. Coordinate-based meta-analytic methods have emerged and evolved in rigor and utility. Early methods computed cross-study consensus, in a manner roughly comparable to traditional (nonimaging) meta-analysis. Recent advances now compute coactivation-based connectivity, connectivity-based functional parcellation, and complex network models powered from data sets representing tens of thousands of subjects. Meta-analyses of human neuroimaging data in large-scale databases now stand at the forefront of computational neurobiology. C1 [Fox, Peter T.; Lancaster, Jack L.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.; Lancaster, Jack L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China. [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. [Eickhoff, Simon B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, D-40225 Dusseldorf, Germany. RP Fox, PT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. EM Fox@uthscsa.edu; jlancaster@uthscsa.edu; angie.laird@fiu.edu; simon.b.eickhoff@gmail.com RI Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU NCRR NIH HHS [RR024387]; NIAAA NIH HHS [R01 AA019691, AA019691]; NIBIB NIH HHS [EB015314, R01 EB015314]; NIMH NIH HHS [MH084812, MH74457, R01 MH074457, R01 MH084812]; NINDS NIH HHS [NS062254, R21 NS062254] NR 108 TC 32 Z9 34 U1 2 U2 7 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0147-006X BN 978-0-8243-2437-7 J9 ANNU REV NEUROSCI JI Annu. Rev. Neurosci. PY 2014 VL 37 BP 409 EP 434 DI 10.1146/annurev-neuro-062012-170320 PG 26 WC Neurosciences SC Neurosciences & Neurology GA BB9LX UT WOS:000348454500021 PM 25032500 ER PT J AU Ford, JH Wise, M Krahn, D Oliver, KA Hall, C Sayer, N AF Ford, James H., II Wise, Meg Krahn, Dean Oliver, Karen Anderson Hall, Carmen Sayer, Nina TI Family Care Map: Sustaining family-centered care in Polytrauma Rehabilitation Centers SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE affective commitment to change; barriers; Family Care Map; family-centered care; information; participation; polytrauma; program implementation; strategies; sustainability; traumatic brain injury; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; QUALITY IMPROVEMENT; HEALTH; SUSTAINABILITY; VETERANS; FRAMEWORK; SYSTEM; PAIN; IMPLEMENTATION AB The study assessed sustainability of the Family Care Map, a family-centered approach to providing care for Veterans with polytrauma-related injuries, in four Department of Veterans Affairs Polytrauma Rehabilitation Centers. We applied a mixed-methods approach. Staff surveys used standardized measures of sustainability, commitment to change, information, and participation during implementation. Qualitative inquiry assessed Family Care Map implementation and facilitators and barriers to sustainability. Staff sustainability perceptions had a significant positive correlation with affective commitment to change, participation, and information received about the change process. Family Care Map integration into standard practices and use of its concepts with patients and families related to staff perceptions about sustainability. The degree of use and integration of the Family Care Map in traumatic brain injury/polytrauma care varied among the Polytrauma Rehabilitation Centers. Some successful sustainability strategies included integration into daily workflow and organizational culture. Examples of sustainability barriers included staff awareness and use and outdated information. Some practices, such as measuring and documenting the use of the Family Care Map in treatment plans, may not routinely occur. The focus on family-centered care will require further evaluation of organization-, staff-, and innovation-level attributes that influence sustainability of changes designed to improve family-centered care. C1 [Ford, James H., II] Univ Wisconsin, Ctr Hlth Syst Res & Anal, Madison, WI 53726 USA. [Wise, Meg] Univ Wisconsin, Sonderegger Res Ctr, Madison, WI 53726 USA. [Krahn, Dean; Oliver, Karen Anderson] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Krahn, Dean] Univ Wisconsin, Dept Psychiat, Madison, WI 53726 USA. [Hall, Carmen] Metropolitan State Univ, St Paul, MN USA. [Sayer, Nina] Vet Affairs Med Ctr, Minneapolis Dept, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Sayer, Nina] Vet Affairs Med Ctr, Minneapolis Dept, Polytrauma & Blast Related Injuries Qual Enhancem, Minneapolis, MN USA. RP Ford, JH (reprint author), Univ Wisconsin, Ctr Hlth Syst Res & Anal, 610 Walnut St, Madison, WI 53726 USA. EM jhfordii@wisc.edu RI Sayer, Nina/E-3249-2016 OI /0000-0003-3045-2414 FU VA Polytrauma and Blast-Related Injuries (PT/BRI) Quality Enhancement and Research Initiative (QUERI) Locally Initiated Project [QLP 56-002]; National Institute of Drug Abuse [5 R01 DA020832] FX Funding/Support: This material was based on work supported by the VA Polytrauma and Blast-Related Injuries (PT/BRI) Quality Enhancement and Research Initiative (QUERI) Locally Initiated Project (grant QLP 56-002). Dr. Ford's work was also supported in part by the National Institute of Drug Abuse (grant 5 R01 DA020832). NR 40 TC 3 Z9 3 U1 2 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2014 VL 51 IS 8 BP 1311 EP 1324 DI 10.1682/JRRD.2014.03.0066 PG 14 WC Rehabilitation SC Rehabilitation GA CA2ZZ UT WOS:000348776400013 PM 25671632 ER PT S AU Simon, JH AF Simon, Jack H. BE Goodin, DS TI MRI outcomes in the diagnosis and disease course of multiple sclerosis SO MULTIPLE SCLEROSIS AND RELATED DISORDERS SE Handbook of Clinical Neurology LA English DT Article; Book Chapter ID APPEARING WHITE-MATTER; QUANTITATIVE MAGNETIZATION-TRANSFER; CLINICALLY ISOLATED SYNDROMES; RELAPSING-REMITTING MS; SECONDARY PROGRESSIVE MS; PLACEBO-CONTROLLED TRIAL; BLOOD-BRAIN-BARRIER; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; INTRAMUSCULAR INTERFERON BETA-1A; RESONANCE-IMAGING FINDINGS C1 [Simon, Jack H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Simon, Jack H.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Simon, JH (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Jack.Simon3@va.gov NR 200 TC 9 Z9 9 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0072-9752 BN 978-0-444-63309-5; 978-0-444-52001-2 J9 HAND CLINIC PY 2014 VL 122 BP 405 EP 425 PG 21 WC Clinical Neurology SC Neurosciences & Neurology GA BB8LN UT WOS:000346798400020 PM 24507528 ER PT J AU Tapp, A Wood, A Kilzieh, N Sylvers, P Rasmussen, DD Raskind, M AF Tapp, A. Wood, A. Kilzieh, N. Sylvers, P. Rasmussen, D. D. Raskind, M. TI OLANZAPINE, CORRECTION OF MELATONIN SUPPRESSION, AND METABOLIC INDICES SO EUROPEAN PSYCHIATRY LA English DT Meeting Abstract C1 [Tapp, A.; Wood, A.; Kilzieh, N.; Sylvers, P.] VA Puget Sound Hlth Care Syst, Mental Hlth Res, Tacoma, WA USA. [Rasmussen, D. D.] VA Puget Sound Hlth Care Syst, Res, Seattle, WA USA. [Raskind, M.] VA Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 EI 1778-3585 J9 EUR PSYCHIAT JI Eur. Psychiat. PY 2014 VL 29 SU 1 MA EPA-0982 PG 1 WC Psychiatry SC Psychiatry GA AY0IO UT WOS:000347280700753 ER PT J AU Huang, LW Xiao, A Choi, SY Kan, QN Zhou, WB Chacon-Heszele, MF Ryu, YK McKenna, S Zuo, XF Kuruvilla, R Lipschutz, JH AF Huang, Liwei Xiao, An Choi, Soo Young Kan, Quane Zhou, Weibin Chacon-Heszele, Maria F. Ryu, Yun Kyoung McKenna, Sarah Zuo, Xiaofeng Kuruvilla, Rejji Lipschutz, Joshua H. TI Wnt5a Is Necessary for Normal Kidney Development in Zebrafish and Mice SO NEPHRON EXPERIMENTAL NEPHROLOGY LA English DT Article DE Wnt5a; Kidney development; Pronephros; Mesonephros; Metanephros ID PLANAR CELL POLARITY; ROBINOW-SYNDROME; RENAL DEVELOPMENT; PATHWAY; DISEASE; CILIA AB Background: Wnt5a is important for the development of various organs and postnatal cellular function. Little is known, however, about the role of Wnt5a in kidney development, although WNT5A mutations were identified in patients with Robinow syndrome, a genetic disease which includes developmental defects in kidneys. Our goal in this study was to determine the role of Wnt5a in kidney development. Methods: Whole-mount in situ hybridization was used to establish the expression pattern of Wnt5a during kidney development. Zebrafish with wnt5a knockdown and Wnt5a global knockout mice were used to identify kidney phenotypes. Results: In zebrafish, wnt5a knockdown resulted in glomerular cyst formation and dilated renal tubules. In mice, Wnt5a global knockout resulted in pleiotropic, but severe, kidney phenotypes, including agenesis, fused kidney, hydronephrosis and duplex kidney/ureter. Conclusions: Our data demonstrated the important role of Wnt5a in kidney development. Disrupted Wnt5a resulted in kidney cysts in zebrafish and pleiotropic abnormal kidney development in mice. (C) 2014 S. Karger AG, Basel C1 [Huang, Liwei; Xiao, An; Kan, Quane] Eastern Virginia Med Sch, Dept Med, Norfolk, VA 23501 USA. [Ryu, Yun Kyoung; Kuruvilla, Rejji] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA. [Zhou, Weibin] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA. [Choi, Soo Young; Zuo, Xiaofeng; Lipschutz, Joshua H.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC USA. [Chacon-Heszele, Maria F.; McKenna, Sarah] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. RP Lipschutz, JH (reprint author), Med Univ S Carolina, Clinical Sci Bldg 829,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM lipschut@musc.edu OI Kuruvilla, Rejji/0000-0002-2851-675X FU Veteran Affair Merit Award; NIH [DK069909, DK047757, DK093625]; University of Pennsylvania Translational Medicine Institute (Pilot Grant); Satellite Healthcare FX This study was funded by Veteran Affair Merit Award to J.H.L, NIH (DK069909 and DK047757) to J.H.L, DK093625 to L.H, Satellite Healthcare (Norman S. Coplon Extramural Research Grant) to J.H.L, and University of Pennsylvania Translational Medicine Institute (Pilot Grant) to J.H.L. NR 23 TC 6 Z9 7 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2129 J9 NEPHRON EXP NEPHROL JI Nephron Exp. Nephrol PY 2014 VL 128 IS 1-2 BP 80 EP 88 DI 10.1159/000368411 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA AZ3KD UT WOS:000348125100009 PM 25412793 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID NOMINAL GROUP TECHNIQUE; QUALITY-OF-LIFE; GENERAL-PRACTICE; RHEUMATOID-ARTHRITIS; UNITED-STATES; CARE; HEALTH; MANAGEMENT; HYPERURICEMIA; PREVALENCE AB Introduction: The aim of this study was to examine the impact of gout on quality of life (QOL) and study differences by gender and race. Methods: Ten race-and sex-stratified nominal groups were conducted, oversampling for African-Americans and women with gout. Patients presented, discussed, combined and rank-ordered their concerns. Results: A total of 62 patients with mean age 65.1 years, 60% men, 64% African-American, participated in 10 nominal groups: African-American men (n = 23; 3 groups); African-American women (n = 18; 3 groups); Caucasian men (n = 15; 3 groups); and Caucasian women (n = 6; 1 group). The most frequently cited high-ranked concerns among the ten nominal groups were: (1) effect of gout flare on daily activities (n = 10 groups); (2) work disability (n = 8 groups); (3) severe pain (n = 8 groups); (4) joint swelling and tenderness (n = 6 groups); (5) food restrictions (n = 6 groups); (6) medication related issues (n = 6 groups); (7) dependency on family and others (n = 5 groups); (8) emotional Impact (n = 5 groups); (9) interference with sexual function (n = 4 groups); (10) difficulty with shoes (n = 4 groups); and (11) sleep disruption (n = 4 groups). Compared with men, women ranked the following concerns high more often: problems with shoes (n = 4 versus n = 0 groups); dependency (n = 3 versus n = 2 groups); and joint/limb deformity (n = 2 versus n = 0 group). Compared with Caucasians, African-Americans ranked the following concerns high more often: dietary restrictions (n = 6 versus n = 0 groups); severe pain (n = 6 versus n = 2 groups); gout bringing the day to a "halt" (n = 2 versus n = 0 group); effect on emotional health (n = 4 versus n = 1 groups); and the need for canes/crutches during flares (n = 2 versus n = 0 group). Conclusions: Gout has a significant impact on a patient's QOL. Important differences in the impact of gout by gender and race were noted. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Sch Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. EM Jasvinder.md@gmail.com FU Division of Rheumatology at the University of Alabama at Birmingham; Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute (PCORI) [CE-1304-6631] FX I am thankful to Bridgett Alday, Ana Oliviera and Aseem Bharat for contacting patients and providing support for conducting the nominal groups and Mary Elkins for the administrative oversight. I thank Dr Bruce Lambert for his insightful comments on this paper. I thank several colleagues and patients who provided informal input into drafting the question for the nominal groups. This material is the result of work supported by a grant from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. JAS is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, and research contract CE-1304-6631 from Patient Centered Outcomes Research Institute (PCORI). NR 52 TC 10 Z9 12 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2014 VL 16 IS 3 AR R132 DI 10.1186/ar4589 PG 15 WC Rheumatology SC Rheumatology GA AX7EC UT WOS:000347078700027 PM 24961941 ER PT J AU Xu, J Patel, Z Kottyan, L Gatti, RA McCurdy, DK Kaufman, KM Harley, JB AF Xu, Jiadi Patel, Zubin Kottyan, Leah Gatti, Richard A. McCurdy, Deborah K. Kaufman, Kenneth M. Harley, John B. TI DNA repair in lupus SO ARTHRITIS RESEARCH & THERAPY LA English DT Meeting Abstract CT Conference on Lupus - New Targets, New Approaches CY SEP 18-20, 2014 CL Quebec, CANADA C1 [Xu, Jiadi; Patel, Zubin; Kottyan, Leah] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA. [Gatti, Richard A.; McCurdy, Deborah K.] Univ Calif Los Angeles, Los Angeles, CA USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. EM john.harley@cchmc.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2014 VL 16 SU 1 MA A7 PG 1 WC Rheumatology SC Rheumatology GA AX9IK UT WOS:000347216600008 ER PT J AU Pope, C Davis, BH Hays, MM North-Lee, B AF Pope, Charlene Davis, Boyd H. Hays, Mary M. North-Lee, Bertha TI Task at hand habitus: The search for teamwork in the discourse of nurse to nurse shift handoff communication SO INTERNATIONAL JOURNAL OF QUALITATIVE METHODS LA English DT Meeting Abstract C1 [Pope, Charlene; North-Lee, Bertha] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Pope, Charlene] Med Univ S Carolina, Coll Nursing, Charleston, SC USA. [Davis, Boyd H.] Univ N Carolina, Charlotte, NC 28223 USA. [Hays, Mary M.] Univ Alabama, Huntsville, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU UNIV ALBERTA, INT INST QUALITATIVE METHODOLOGY PI EDMONTON PA 5-217, EDMONTON CLINIC HEALTH ACAD, 11405 87 AVENUE, EDMONTON, AB T6G 1C9, CANADA SN 1609-4069 J9 INT J QUAL METH JI Int. J. Qual. Meth. PY 2014 VL 13 BP 458 EP 458 PG 1 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA AX1KD UT WOS:000346705100033 ER PT J AU Azarbal, B Arbit, B Ramaraj, R Kittleson, M Young, A Czer, L Rafiei, M Currier, J Makkar, R Kobashigawa, J AF Azarbal, Babak Arbit, Boris Ramaraj, Radhakrishnan Kittleson, Michelle Young, Amelia Czer, Lawrence Rafiei, Matthew Currier, Jesse Makkar, Raj Kobashigawa, Jon TI Clinical and Angiographic Outcomes with Everolimus Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy SO JOURNAL OF INTERVENTIONAL CARDIOLOGY LA English DT Article ID PERCUTANEOUS CORONARY INTERVENTION; BARE-METAL STENTS; SINGLE-CENTER EXPERIENCE; ASSOCIATION TASK-FORCE; INTRAVASCULAR ULTRASOUND; ARTERY-DISEASE; INTERNATIONAL SOCIETY; TRANSPLANT VASCULOPATHY; PRACTICE GUIDELINES; AMERICAN-COLLEGE AB Objectives: This study aimed to examine clinical efficacy, safety, and intermediate clinical outcomes with everolimus-eluting stents (EESs) in patients with transplant coronary artery disease (TCAD). Background: TCAD is a major cause of mortality in patients following orthotopic heart transplantation (OHT). Systemic everolimus in OHT patients has been shown to reduce TCAD. The safety and efficacy of an EES, the Xience V, have not been evaluated in this population. Methods: Patients post-OHT with hemodynamically significant CAD who underwent percutaneous coronary intervention (PCI) with EES were included. Participants were maintained on dual antiplatelet therapy for 1-year post-PCI. We examined procedural success, in-hospital and 1-year mortality, stent thrombosis, angiographic restenosis, and myocardial infarction rates. All patients had follow-up angiography 1-year after PCI. Target vessel revascularization (TVR), target lesion revascularization (TLR), in-segment restenosis, target vessel failure (TVF), and lumen late loss were noted. Results: PCI was performed in 34 de novo lesions in 21 patients, and 40 EES were placed. Procedural success rate was 100%. Average stent was 16.5 +/- 5.1mm long and 3.0 +/- 0.6mm in diameter. All patients had angiographic follow-up (409 +/- 201 days). There was no stent thrombosis, deaths, or myocardial infarctions during follow-up. Two patients had focal in-stent restenosis. TLR rate was 5.9% (2/34), and TVR rate was 11.1% (3/27). Quantitative coronary angiography (QCA) showed stenosis diameter to be 19.98 +/- 17.57%. Conclusions: Use of an EES is associated with a low incidence of TVR and TLR in patients with TCAD. Further studies are needed to determine whether PCI with EES changes long-term outcomes. C1 [Azarbal, Babak; Arbit, Boris; Ramaraj, Radhakrishnan; Kittleson, Michelle; Young, Amelia; Czer, Lawrence; Rafiei, Matthew; Makkar, Raj; Kobashigawa, Jon] Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA. [Currier, Jesse] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Arbit, B (reprint author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. EM boris.arbit@cshs.org NR 33 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0896-4327 EI 1540-8183 J9 J INTERV CARDIOL JI J. Interv. Cardiol. PD JAN PY 2014 VL 27 IS 1 BP 73 EP 79 DI 10.1111/joic.12071 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AX1HE UT WOS:000346697600010 PM 24118198 ER PT J AU Serper, M Forde, KA Kaplan, DE AF Serper, Marina Forde, Kimberly A. Kaplan, David E. TI Serologic Testing Rates among US Veterans with Hepatitis B SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Serper, Marina; Forde, Kimberly A.; Kaplan, David E.] Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 68 BP 230A EP 231A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483801002 ER PT J AU Portelius, E Dean, RA Andreasson, U Mattsson, N Westerlund, A Olsson, M Demattos, RB Racke, MM Zetterberg, H May, PC Blennow, K AF Portelius, Erik Dean, Robert A. Andreasson, Ulf Mattsson, Niklas Westerlund, Anni Olsson, Maria Demattos, Ronald Bradley Racke, Margaret M. Zetterberg, Henrik May, Patrick C. Blennow, Kaj TI beta-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces A beta 5-X peptides through alternative amyloid precursor protein cleavage SO ALZHEIMERS RESEARCH & THERAPY LA English DT Article ID GAMMA-SECRETASE INHIBITION; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; ISOFORM PATTERN; QUANTIFICATION; DEPOSITION; CSF AB Introduction: The beta-secretase enzyme, beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), cleaves amyloid precursor protein (APP) in the first step in beta-amyloid (A beta) peptide production. Thus, BACE1 is a key target for candidate disease-modifying treatment of Alzheimer's disease. In a previous exploratory A beta biomarker study, we found that BACE1 inhibitor treatment resulted in decreased levels of A beta 1-34 together with increased A beta 5-40, suggesting that these A beta species may be novel pharmacodynamic biomarkers in clinical trials. We have now examined whether the same holds true in humans. Methods: In an investigator-blind, placebo-controlled and randomized study, healthy subjects (n = 18) were randomly assigned to receive a single dose of 30 mg of LY2811376 (n = 6), 90 mg of LY2811376 (n = 6), or placebo (n = 6). We used hybrid immunoaffinity-mass spectrometry (HI-MS) and enzyme-linked immunosorbent assays to monitor a variety of A beta peptides. Results: Here, we demonstrate dose-dependent changes in cerebrospinal fluid (CSF) A beta 1-34, A beta 5-40 and A beta 5-X after treatment with the BACE1-inhibitor LY2811376. A beta 5-40 and A beta 5-X increased dose-dependently, as reflected by two independent methods, while A beta 1-34 dose-dependently decreased. Conclusion: Using HI-MS for the first time in a study where subjects have been treated with a BACE inhibitor, we confirm that CSF A beta 1-34 may be useful in clinical trials on BACE1 inhibitors to monitor target engagement. Since it is less hydrophobic than longer A beta species, it is less susceptible to preanalytical confounding factors and may thus be a more stable marker. By independent measurement techniques, we also show that BACE1 inhibition in humans is associated with APP-processing into N-terminally truncated A beta peptides via a BACE1-independent pathway. C1 [Portelius, Erik; Andreasson, Ulf; Mattsson, Niklas; Westerlund, Anni; Olsson, Maria; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Clin Neurochem Lab,Inst Neurosci & Phys, S-43180 Molndal, Sweden. [Dean, Robert A.; Demattos, Ronald Bradley; Racke, Margaret M.; May, Patrick C.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Mattsson, Niklas] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Zetterberg, Henrik] UCL Inst Neurol, London WC1N 3BG, England. RP Portelius, E (reprint author), Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Clin Neurochem Lab,Inst Neurosci & Phys, S-43180 Molndal, Sweden. EM erik.portelius@neuro.gu.se FU Lundbeck Foundation; Swedish Research Council; Swedish State Support for Clinical Research; Stiftelsen Psykiatriska Forskningsfonden; Wolfson Foundation; Stiftelsen Gamla Tjanarinnor; Magn. Bergvalls Stiftelse; Gun och Bertil Stohnes Stiftelse; Uppsala Universitets Medicinska Fakultet stiftelse for psykiatrisk och neurologisk forskning; Swedish Brain Fund; Alzheimer Foundation, Sweden; Dementia Association, Sweden; Eli Lilly FX The study was supported by the Lundbeck Foundation, the Swedish Research Council, Swedish State Support for Clinical Research, Stiftelsen Psykiatriska Forskningsfonden, the Wolfson Foundation, Stiftelsen Gamla Tjanarinnor, Magn. Bergvalls Stiftelse, Gun och Bertil Stohnes Stiftelse, Uppsala Universitets Medicinska Fakultet stiftelse for psykiatrisk och neurologisk forskning, the Swedish Brain Fund, the Alzheimer Foundation, Sweden, the Dementia Association, Sweden, and Eli Lilly and Company. NR 28 TC 8 Z9 8 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-9193 J9 ALZHEIMERS RES THER JI Alzheimers Res. Ther. PY 2014 VL 6 IS 9 AR 75 DI 10.1186/s13195-014-0075-0 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AW6CS UT WOS:000346357700006 PM 25404952 ER PT J AU Williams, AR Williams, DD Williams, PD AF Williams, Arthur R. Williams, David D. Williams, Phoebe D. BE Ortuno, F Rojas, I TI The Development and Application of an Oncology Therapy-Related Symptom Checklist for Adults (TRSC) and Children (TRSC-C) SO PROCEEDINGS IWBBIO 2014: INTERNATIONAL WORK-CONFERENCE ON BIOINFORMATICS AND BIOMEDICAL ENGINEERING, VOLS 1 AND 2 LA English DT Proceedings Paper CT 2nd International Work-Conference on Bioinformatics and Biomedical Engineering (IWBBIO) CY APR 07-09, 2014 CL Granada, SPAIN SP Univ Granada, IEEE Computat Intelligence Soc, Spanish Chapter, BioMed Central, e Health Business Dev BULL Espana S A ID CANCER AB Background: Studies found that treatment symptoms of concern to oncology/hematology patients were greatly under-documented in medical records: on average 11.0 symptoms by patient report versus 1.5 in medical records. Studies now indicate that a solution to this problem and improved patient outcomes is use of a quick, clinic-friendly, easy to use symptom checklist just before medical consultations with patients. Purposes: Describe the oncology Therapy-Related Symptom Checklists for Adults (TRSC) and Children (TRSC-C). The TRSC has 25 items/symptoms and the TRSC-C 30 items/symptoms, and these items capture up to 90% of symptoms mentioned by patients. Measurement properties and applications with outpatients are presented. Informatics applications are indicated. Methods: The TRSC was developed for adults (N=282) then modified for children (N=385). Statistical analyses have been done using correlational, epidemiologic, and qualitative methods. Extensive validation of measurement properties has been completed. Integration of the checklists into electronic/computer systems is proceeding. Findings: Completed research has found high levels of patient/clinician satisfaction, no increase in clinic costs, and strong correlations of TRSC/TRSC-C scores with the number of patient symptoms documented/managed, functional status, and quality of life. A recently published sequential cohort trial with adult outpatients at a Mayo Clinic community cancer center found TRSC use produced a 7.2% higher patient quality of life, 116% more symptoms documented/managed, and higher functional status. Other TRSC/TRSC-C study findings are presented in papers in this special session. Conclusion: A symptom checklist (TRSC/TRSC-C) can facilitate monitoring, management of symptoms, and informatics applications helpful to patients and clinicians. Implications: Gathering information about symptom occurrence and severity can optimize cancer care. TRSC studies suggest that electronic applications are a next step. C1 [Williams, Arthur R.] US Dept Vet Affairs, CINDRR, Washington, DC 20420 USA. RP Williams, AR (reprint author), US Dept Vet Affairs, CINDRR, Washington, DC 20420 USA. EM arthur.williams1@va.gov; ddwilliams@cmh.edu; pwilliam@kumc.edu NR 10 TC 1 Z9 1 U1 0 U2 1 PU COPICENTRO GRANADA S L PI GRANADA PA AV ANDALUCIA, 38, GRANADA, GRANADA 18014, SPAIN BN 978-84-15814-84-9 PY 2014 BP 298 EP 307 PG 10 WC Engineering, Biomedical; Medical Informatics SC Engineering; Medical Informatics GA BB8CY UT WOS:000346381500034 ER PT J AU Alemi, F Hesham, H Williams, AR Williams, PD Donley, B Kheirbek, RE AF Alemi, F. Hesham, H. Williams, A. R. Williams, P. D. Donley, B. Kheirbek, R. E. BE Ortuno, F Rojas, I TI Computers that Show Recognition of Patients' Symptoms SO PROCEEDINGS IWBBIO 2014: INTERNATIONAL WORK-CONFERENCE ON BIOINFORMATICS AND BIOMEDICAL ENGINEERING, VOLS 1 AND 2 LA English DT Proceedings Paper CT 2nd International Work-Conference on Bioinformatics and Biomedical Engineering (IWBBIO) CY APR 07-09, 2014 CL Granada, SPAIN SP Univ Granada, IEEE Computat Intelligence Soc, Spanish Chapter, BioMed Central, e Health Business Dev BULL Espana S A DE Symptoms' recognition; Feedback loop; Symptom management; Man machine interaction; Therapy-Related Symptom Checklist; Cancer ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE AB The goal of automated symptom management has often been narrowly defined as collection and reporting of data. Yet, an automated system can do more. These systems can mimic human reassurance for patients that their symptoms have been recognized. Patient engagement has long been recognized as central in symptom management. An electronic system was built to collect the Treatment Related Symptom Checklist (TRSC) and to reassure patients. In this paper we discuss the design of the system and procedures taken to show recognition of patients' symptoms. The literature on clinician-patient interactions was reviewed selectively. Methods used by clinicians to promote patient engagement during medical history were identified. Similar methods were incorporated into the symptom management system in order to facilitate understanding by the patient. These included (a) conversational data collection as opposed to survey style or standardized questionnaires, (b) short response phrases indicating understanding of the reported symptom, (c) use of open ended questions to reduce asking long lists of symptoms, (d) leading questions that ask for confirmation of expected symptoms, (e) review of symptoms at designated stages, and (d) alerting patients when computer has informed the clinician about patient-reported symptoms. We are in the process of pilot testing the system among oncology patients in one hospital. Examination of existing informatics knowledge eases integration of well established paper-based tools into automated systems. C1 [Alemi, F.; Hesham, H.] Dist Columbia Vet Adm Med Ctr, Washington, DC 20544 USA. [Williams, A. R.] Univ S Florida, US Dept Vet Affairs, Tampa, FL USA. [Williams, P. D.] Univ Kansas, Med Ctr, Sch Nursing, Kansas City, KS USA. [Donley, B.] Quaso LLC, Montross, VA USA. [Kheirbek, R. E.] Med Ctr, Washington, DC USA. RP Alemi, F (reprint author), Dist Columbia Vet Adm Med Ctr, Washington, DC 20544 USA. EM farrokh.alemi@va.gov; hosai.hesham@va.gov; arthur.williams1@va.gov; pwilliam@kumc.edu; blaine.donley@quaso.com; raya.kheirbek@va.gov NR 18 TC 0 Z9 0 U1 0 U2 0 PU COPICENTRO GRANADA S L PI GRANADA PA AV ANDALUCIA, 38, GRANADA, GRANADA 18014, SPAIN BN 978-84-15814-84-9 PY 2014 BP 321 EP 329 PG 9 WC Engineering, Biomedical; Medical Informatics SC Engineering; Medical Informatics GA BB8CY UT WOS:000346381500037 ER PT J AU Fleehart, S Fan, VS Nguyen, HQ Lee, J Kohen, R Herting, JR Matute-Bello, G Adams, SG Pagalilauan, G Borson, S AF Fleehart, Sara Fan, Vincent S. Nguyen, Huong Q. Lee, Jungeun Kohen, Ruth Herting, Jerald R. Matute-Bello, Gustavo Adams, Sandra G. Pagalilauan, Genevieve Borson, Soo TI Prevalence and correlates of suicide ideation in patients with COPD: a mixed methods study SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE depression; qualitative; PHQ-9; suicide; pulmonary disease; chronic obstructive ID OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; HOSPITAL READMISSION; DEPRESSIVE SYMPTOMS; PRIMARY-CARE; RISK-FACTORS; SHORT-FORM; ANXIETY; MORTALITY; EXACERBATIONS AB Purpose: The purpose of this study was to examine the prevalence and correlates of suicidal ideation (SI) in patients with stable moderate to very severe chronic obstructive pulmonary disease (COPD). Patients and methods: We conducted an exploratory mixed methods analysis of data from participants in a longitudinal observational study of depression in COPD. We measured depression with the Patient Health Questionnaire-9 (PHQ-9), which includes an item on SI. We compared participants with and without SI in relation to sociodemographics, symptoms, anxiety, and healthcare resource use with independent t-tests and chi-square tests. Content analysis was performed on qualitative data gathered during a structured SI safety assessment. Results: Of 202 participants, 121 (60%) had depressive symptoms (PHQ >= 6); 51 (25%) had a PHQ-9 >= 10, indicating a high likelihood of current major depression; and 22 (11%) reported SI. Compared to the 99 depressed participants without SI, those with SI were more likely to be female (59% vs 27%, P=0.004); had worse dyspnea (P=0.009), depression (P<0.001), and anxiety (P=0.003); and were also more likely to have received treatment for depression and/or anxiety (82% vs 40%, P<0.001) and more hospitalizations for COPD exacerbations (P=0.03) but had similar levels of airflow obstruction and functioning than participants without SI. Themes from the qualitative analysis among those with SI included current or prior adverse life situations, untreated or partially treated complex depression, loss of a key relationship, experience of illness and disability, and poor communication with providers. Conclusion: Our findings suggest that current SI is common in COPD, may occur disproportionately in women, can persist despite mental health treatment, and has complex relationships with both health and life events. Adequate management of SI in COPD may therefore require tailored, comprehensive treatment approaches that integrate medical and mental health objectives. C1 [Fleehart, Sara; Lee, Jungeun] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Fan, Vincent S.; Matute-Bello, Gustavo] VAPuget Sound Hlth Care Ctr, Seattle, WA USA. [Fan, Vincent S.; Kohen, Ruth; Matute-Bello, Gustavo; Pagalilauan, Genevieve; Borson, Soo] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Nguyen, Huong Q.] Kaiser Permanente So Calif, Res & Evaluat, Pasadena, CA 91101 USA. [Herting, Jerald R.] Univ Washington, Dept Sociol, Seattle, WA 98195 USA. [Adams, Sandra G.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. [Adams, Sandra G.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Borson, S (reprint author), Univ Washington, Sch Med, Box 356560,1959 NE Pacific St, Seattle, WA 98195 USA. EM soob@uw.edu FU Department of Veterans Affairs [5R01HL093146, UL1RR025014.] FX We would like to express our heartfelt gratitude to all the study participants. This work was supported in part by: 5R01HL093146 and UL1RR025014. Dr Fan has funding through the Department of Veterans Affairs. NR 33 TC 2 Z9 2 U1 1 U2 7 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2014 VL 9 BP 1321 EP 1329 DI 10.2147/COPD.S65507 PG 9 WC Respiratory System SC Respiratory System GA AW2LZ UT WOS:000346120800001 ER PT S AU Houser, CR AF Houser, Carolyn R. BE Scharfman, HE Buckmaster, PS TI Do Structural Changes in GABA Neurons Give Rise to the Epileptic State? SO ISSUES IN CLINICAL EPILEPTOLOGY: A VIEW FROM THE BENCH SE Advances in Experimental Medicine and Biology LA English DT Article; Proceedings Paper CT Workshop on Issues in Clinical Epileptology - A View from the Bench held in honor of Phil CY MAY 03-05, 2013 CL Watsonville, CA DE Inhibition; Plasticity; Seizures; Sprouting; Somatostatin; Parvalbumin ID TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; PILOCARPINE-INDUCED SEIZURES; HILAR SOMATOSTATIN INTERNEURONS; DECARBOXYLASE MESSENGER-RNA; GAMMA-AMINOBUTYRIC-ACID; BASKET CELL HYPOTHESIS; DENTATE GRANULE CELLS; GLUTAMATE-DECARBOXYLASE; NEUROPEPTIDE-Y AB Identifying the role of GABA neurons in the development of an epileptic state has been particularly difficult in acquired epilepsy, in part because of the multiple changes that occur in such conditions. Although once questioned, there is now considerable evidence for loss of GABA neurons in multiple brain regions in models of acquired epilepsy. This loss can affect several cell types, including both somatostatin-and parvalbumin-expressing interneurons, and the cell type that is most severely affected can vary among brain regions and models. Because of the diversity of GABA neurons in the hippocampus and cerebral cortex, resulting functional deficits are unlikely to be compensated fully by remaining GABA neurons of other subtypes. The fundamental importance of GABA neuron loss in epilepsy is supported by findings in genetic mouse models in which GABA neurons appear to be decreased relatively selectively, and increased seizure susceptibility and spontaneous seizures develop. Alterations in remaining GABA neurons also occur in acquired epilepsy. These include alterations in inputs or receptors that could impair function, as well as morphological reorganization of GABAergic axons and their synaptic connections. Such axonal sprouting could be compensatory if normal circuits are reestablished, but the creation of aberrant circuitry could contribute to an epileptic condition. The functional effects of GABA neuron alterations thus may include not only reductions in GABAergic inhibition but also excessive neuronal synchrony and, potentially, depolarizing GABAergic influences. The combination of GABA neuron loss and alterations in remaining GABA neurons provides likely, though still unproven, substrates for the epileptic state. C1 [Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Houser, Carolyn R.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Houser, Carolyn R.] Vet Adm Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. RP Houser, CR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM houser@mednet.ucla.edu FU National Institutes of Health [NS075245]; Veterans Affairs Medical Research Funds FX This work was supported by National Institutes of Health Grant NS075245 and Veterans Affairs Medical Research Funds. I gratefully acknowledge the members of my laboratory, past and present, for their superb work and strong dedication to our studies of GABA neurons and epilepsy. NR 54 TC 17 Z9 17 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS SN 0065-2598 BN 978-94-017-8914-1; 978-94-017-8913-4 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2014 VL 813 BP 151 EP 160 DI 10.1007/978-94-017-8914-1_12 PG 10 WC Medicine, Research & Experimental; Clinical Neurology; Neurosciences SC Research & Experimental Medicine; Neurosciences & Neurology GA BB7UO UT WOS:000346021700014 PM 25012374 ER PT J AU Sher, L AF Sher, Leo TI MEN'S MENTAL HEALTH AND SUICIDE SO PSYCHIATRIA DANUBINA LA English DT Letter C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 4 TC 1 Z9 1 U1 0 U2 3 PU MEDICINSKA NAKLADA PI ZAGREB PA VLASKA 69, HR-10000 ZAGREB, CROATIA SN 0353-5053 J9 PSYCHIAT DANUB JI Psychiatr. Danub. PY 2014 VL 26 IS 3 BP 298 EP 298 PG 1 WC Psychiatry SC Psychiatry GA AW2WL UT WOS:000346147300018 PM 25191782 ER PT J AU Menon, S Smith, MW Sittig, DF Petersen, NJ Hysong, SJ Espadas, D Modi, V Singh, H AF Menon, Shailaja Smith, Michael W. Sittig, Dean F. Petersen, Nancy J. Hysong, Sylvia J. Espadas, Donna Modi, Varsha Singh, Hardeep TI How context affects electronic health record-based test result follow-up: a mixed-methods evaluation SO BMJ OPEN LA English DT Article ID PATIENT SAFETY; PRIMARY-CARE; MEDICAL-RECORD; INFORMATION; MANAGEMENT; SYSTEM; IMPLEMENTATION; INTERVENTIONS; NOTIFICATION; FREQUENCY AB Objectives: Electronic health record (EHR)-based alerts can facilitate transmission of test results to healthcare providers, helping ensure timely and appropriate follow-up. However, failure to follow-up on abnormal test results (missed test results) persists in EHR-enabled healthcare settings. We aimed to identify contextual factors associated with facility-level variation in missed test results within the Veterans Affairs (VA) health system. Design, setting and participants: Based on a previous survey, we categorised VA facilities according to primary care providers' (PCPs') perceptions of low (n=20) versus high (n=20) risk of missed test results. We interviewed facility representatives to collect data on several contextual factors derived from a sociotechnical conceptual model of safe and effective EHR use. We compared these factors between facilities categorised as low and high perceived risk, adjusting for structural characteristics. Results: Facilities with low perceived risk were significantly more likely to use specific strategies to prevent alerts from being lost to follow-up (p=0.0114). Qualitative analysis identified three high-risk scenarios for missed test results: alerts on tests ordered by trainees, alerts 'handed off' to another covering clinician (surrogate clinician), and alerts on patients not assigned in the EHR to a PCP. Test result management policies and procedures to address these high-risk situations varied considerably across facilities. Conclusions: Our study identified several scenarios that pose a higher risk for missed test results in EHR-based healthcare systems. In addition to implementing provider-level strategies to prevent missed test results, healthcare organisations should consider implementing monitoring systems to track missed test results. C1 [Menon, Shailaja; Smith, Michael W.; Petersen, Nancy J.; Hysong, Sylvia J.; Espadas, Donna; Modi, Varsha; Singh, Hardeep] Baylor Coll Med, Dept Med, Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Menon, Shailaja; Smith, Michael W.; Petersen, Nancy J.; Hysong, Sylvia J.; Espadas, Donna; Modi, Varsha; Singh, Hardeep] Sect Hlth Serv Res, Houston, TX USA. [Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. RP Singh, H (reprint author), Baylor Coll Med, Dept Med, Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. EM hardeeps@bcm.edu RI Hysong, Sylvia/B-8420-2008 OI Hysong, Sylvia/0000-0002-9063-5207 FU VA National Center of Patient Safety; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413]; AHRQ; VA HSR&D Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX This work was supported by the VA National Center of Patient Safety and partially supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and the Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413). SM is supported by AHRQ training fellowship in Patient Safety and Quality and partially supported with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX. NR 42 TC 7 Z9 7 U1 1 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2014 VL 4 IS 11 AR e005985 DI 10.1136/bmjopen-2014-005985 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AU7EA UT WOS:000345762300036 PM 25387758 ER PT J AU Ross, JS Russo, SB Chavis, GC Cowart, LA AF Ross, Jessica S. Russo, Sarah B. Chavis, Georgia C. Cowart, Lauren A. TI Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview SO CLINICAL LIPIDOLOGY LA English DT Review DE free fatty acids; lipotoxicity; obesity; sphingolipid; Type 2 diabetes mellitus ID NECROSIS-FACTOR-ALPHA; FREE FATTY-ACIDS; INDUCED INSULIN-RESISTANCE; ACTIVATED RECEPTOR-ALPHA; LOW-DENSITY-LIPOPROTEIN; PANCREATIC BETA-CELLS; ISCHEMIC/REPERFUSED RAT-HEART; ENDOPLASMIC-RETICULUM STRESS; INDUCED CARDIAC-HYPERTROPHY; CORONARY-ARTERY-DISEASE AB Climbing obesity rates have contributed to worldwide increases in obesity-associated diseases, including the metabolic syndrome and Type 2 diabetes mellitus (T2DM). Sphingolipids, an important class of structural and signaling lipids, have emerged as key players in the development and pathogenesis of insulin resistance and T2DM. More specifically, sphingolipids have been demonstrated to play integral roles in lipotoxicity and other aspects of pathogenesis in T2DM, although the cellular mechanisms by which this occurs and by which sphingolipid metabolism is dysregulated in T2DM remain under investigation. This review summarizes current knowledge of sphingolipid metabolism and signaling in key organs and tissues affected by T2DM, including the pancreas, adipose tissue, skeletal muscle, cardiovascular system and liver, and highlights areas that ripe for future investigation. C1 [Ross, Jessica S.; Russo, Sarah B.; Chavis, Georgia C.; Cowart, Lauren A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Cowart, Lauren A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Cowart, LA (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM cowartl@musc.edu FU NIH [1RO1HL117233, 5P30 GM103339-03]; Veteran's Affairs Merit Award [210 IBX000200-04A2, T32 HL007260-38] FX This work was supported in part by NIH Grants 1RO1HL117233 and 5P30 GM103339-03, Veteran's Affairs Merit Award 210 IBX000200-04A2, all to LA Cowart, and T32 HL007260-38, to SB Russo. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 188 TC 0 Z9 0 U1 2 U2 7 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1758-4299 EI 1758-4302 J9 CLIN LIPIDOL JI Clin. Lipidol. PY 2014 VL 9 IS 5 BP 553 EP 569 DI 10.2217/CLP.14.37 PG 17 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AU5LB UT WOS:000345647300009 ER PT J AU Ahmad, M Dar, NJ Bhat, ZS Hussain, A Shah, A Liu, H Graham, SH AF Ahmad, Muzamil Dar, Nawab J. Bhat, Zubair S. Hussain, Aehtesham Shah, Ayatullah Liu, Hao Graham, Steven H. TI Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS LA English DT Article DE Cerebral ischemia; cyclooxygenase-2; cytokines and chemokines; inflammation; microglia; middle cerebral artery occlusion; prostaglandin ID FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; INTERCELLULAR-ADHESION MOLECULE-1; BLOOD-BRAIN-BARRIER; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; TRANSIENT FOREBRAIN ISCHEMIA; ANEURYSMAL SUBARACHNOID HEMORRHAGE; NEUTROPHIL INHIBITORY FACTOR AB Ischemic stroke is caused when blood flow to the brain is hampered, leading to instant deficiency of nutrients and oxygen required for normal brain functioning. Reperfusion can alleviate damage from stroke if performed immediately after the onset of ischemia however the efficacy of reperfusion is tempered by secondary injury mechanisms. This multifarious sequence of events leads to the commencement of deleterious cycles of inflammation, oxidant stress and apoptosis that finally culminate in delayed death of neuronal cells even when the brain is effectively reperfused. Wealth of data from clinical as well as experimental studies points to a prominent role of inflammation in secondary injury. In this review we will discuss, in detail, the cellular and molecular mediators of inflammation and their possible therapeutic targets in both experimental and clinical forms of stroke. C1 [Ahmad, Muzamil; Dar, Nawab J.; Bhat, Zubair S.; Hussain, Aehtesham; Shah, Ayatullah] Indian Inst Integrat Med, CSIR, Neuropharmacol Lab, Srinagar 190005, Jammu & Kashmir, India. [Ahmad, Muzamil; Dar, Nawab J.; Bhat, Zubair S.; Hussain, Aehtesham; Shah, Ayatullah] Indian Inst Integrat Med, CSIR, Acad Sci & Innovat Res, Jammu 180001, Jammu & Kashmir, India. [Liu, Hao; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr Syst, Pittsburgh, PA 15261 USA. [Liu, Hao; Graham, Steven H.] Univ Pittsburgh, Sch Med Pittsburgh, Dept Neurol, Pittsburgh, PA USA. RP Ahmad, M (reprint author), Indian Inst Integrat Med, CSIR, Neuropharmacol Lab, Srinagar 190005, Jammu & Kashmir, India. EM mahmad@iiim.res.in OI Bhat, Zubair Shanib/0000-0003-2497-0581 FU Department of Biotechnology [MLP6009]; NIH [R01 NS37459-10]; Department of Veteran's Affairs FX Dr. Ahmad's work is partly supported by Ramalingaswamy Fellowship of Department of Biotechnology to MA and financial assistance (MLP6009) as well as logistic support from Council for Scientific and Industrial Research. Dr. Graham's work was partially supported by NIH (R01 NS37459-10) and Department of Veteran's Affairs RDD merit review program. Contents do not represent any governmental views of India or United States. NR 362 TC 21 Z9 23 U1 3 U2 10 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1871-5273 EI 1996-3181 J9 CNS NEUROL DISORD-DR JI CNS Neurol. Disord.-Drug Targets PY 2014 VL 13 IS 8 BP 1378 EP 1396 PG 19 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA AU6BE UT WOS:000345686300010 PM 25345517 ER PT J AU Liu, P Liu, XL Liou, AKF Xing, J Jing, Z Ji, XM Liu, XR Zhao, HP Yan, F Chen, J Cao, GD Luo, YM AF Liu, Ping Liu, Xiaolei Liou, Anthony Kian-Fong Xing, Juan Jing, Zheng Ji, Xunming Liu, Xiangrong Zhao, Haiping Yan, Feng Chen, Jun Cao, Guodong Luo, Yumin TI The Neuroprotective Mechanism of Erythropoietin-TAT Fusion Protein Against Neurodegeneration from Ischemic Brain Injury SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS LA English DT Article DE Cerebral ischemia; erythropoietin; neurodegeneration; neuroprotection; reperfusion ID RECOMBINANT-HUMAN-ERYTHROPOIETIN; CEREBRAL-ARTERY OCCLUSION; KIDNEY INJURY; MODULATION; ACTIVATION; PATHWAYS; NEURONS; MYOCARDIUM; PROTECTION; INFARCTION AB Aims: To compare the neuroprotection of erythropoietin (EPO) and EPO fusion protein containing transduction domain derived from HIV TAT (EPO-TAT) against ischemic brain injury, inclusive of the side effect, and explore the mechanism underlying the role of EPO-TAT in a transient focal cerebral ischemia model in rats. Methods: Transient focal ischemia was induced by middle cerebral artery occlusion (MCAO) in rats. Rats were treated, respectively, with following regimens: saline, 1000 U/kg EPO, 5000 U/kg EPO, 1000 U/kg EPO-TAT, 1000 U/kg EPOTAT + 5 mu l of 10 mM LY294002 (or/plus 5 mu l of 5 mM PD98059). Neurological deficit scores, infarct volume, and hematologic side effect were assessed at 72 hours after MCAO. Apoptotic cells were determined with TUNEL staining. The expression and localization of phosphorylated AKT (pAKT) and phosphorylated ERK (pERK) were detected with Western blot, immunohistochemistry, and immunofluorescence, respectively. Results: 1000 U/kg EPO-TAT exhibited a comparable neuroprotection to 5000 U/kg EPO, as evidenced by a comparable attenuation in neurological deficit, infarct volume, and number of apoptotic cells in the rat ischemic cortex after MCAO. The pAKT and pERK levels were significantly elevated solely in neurons of rodents receiving EPO or EPO-TAT treatments, suggesting the concurrent activation of these two pathways. Specific inhibition of either AKT or ERK pathway partially abolished EPO-TAT protection, but exhibited no influence on the activation status of its counterpart, suggesting no cross-modulation between these two protective pathways. Conclusion: Our study indicates that EPO-TAT at 1000 U/kg displays neuroprotection with no detectable side effects. The mechanism for neuroprotection may be attributable to the simultaneous activation of the AKT and ERK pathways, which preserve neuronal cell viability and attenuate behavioral deficits. C1 [Liu, Ping; Liu, Xiaolei; Ji, Xunming; Liu, Xiangrong; Zhao, Haiping; Yan, Feng; Luo, Yumin] Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing 100053, Peoples R China. [Liu, Xiaolei] Taiyuan Peoples Hosp, Dept Neurol, Taiyuan 030032, Shanxi, Peoples R China. [Liou, Anthony Kian-Fong; Xing, Juan; Jing, Zheng; Chen, Jun; Cao, Guodong] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Chen, Jun; Cao, Guodong] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Luo, YM (reprint author), Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Key Lab Neurodegenerat Dis,Minist Educ, 45 Changchun St, Beijing 100053, Peoples R China. EM caog@upmc.edu; yumin111@ccmu.edu.cn FU Chinese Natural Science Foundation [30670725, 81071058, 81471340]; National Institutes of Health [NS079345, NS053473]; Department of Veterans Affairs Merit Review [101RX000199] FX This project was supported by Chinese Natural Science Foundation grants 30670725, 81071058 and 81471340 (to Y. Luo); National Institutes of Health grant NS079345 and NS053473 (to G. Cao); and Department of Veterans Affairs Merit Review grant 101RX000199 (to G. Cao). NR 37 TC 1 Z9 3 U1 0 U2 3 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1871-5273 EI 1996-3181 J9 CNS NEUROL DISORD-DR JI CNS Neurol. Disord.-Drug Targets PY 2014 VL 13 IS 8 BP 1465 EP 1474 PG 10 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA AU6BE UT WOS:000345686300018 PM 25106625 ER PT J AU Dismuke, CE Hernandez-Tejada, MA Egede, LE AF Dismuke, Clara E. Hernandez-Tejada, Melba A. Egede, Leonard E. TI RELATIONSHIP OF SERIOUS PSYCHOLOGICAL DISTRESS TO QUALITY OF LIFE IN ADULTS WITH DIABETES SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE serious psychological distress; quality of life; diabetes; SF-12 ID FACTOR SURVEILLANCE SYSTEM; MAJOR DEPRESSIVE DISORDER; US ADULTS; UNITED-STATES; RISK-FACTORS; PREVALENCE; VALIDITY; SCALES AB Objective: To examine the association between serious psychological distress (SPD) and the Physical and Mental Health components of Quality of Life (QOL) while controlling for depression in a national sample of adults with diabetes. Methods: SPD was assessed in 1,659 adults with diabetes who participated in the 2007 Medical Care Expenditure Survey (MEPS). SPD was measured by the 6-item Kessler scale. Depression was assessed with the PHQ-2 screen. Quality of life was measured with the physical (PCS) and mental (MCS) components of the SF-12. We used multiple linear regression to assess the relationship between SPD and quality of life while controlling for relevant covariates and depression screen results to assess the independent effect of SPD on QOL above and beyond the effect of depression. Results: Among US adults with diabetes, 9% had SPD and 15.4% screened positive for depression. Among those with SPD, 85.8% had depression and among those with depression, 50.5% had SPD. In the adjusted model for socio-demographic factors and comorbidities, SPD was significantly associated with lower PCS scores (-5.51 95% CI -7.55; -3.45) and MCS scores (-18.99 95% CI -20.81; -17.18). In the adjusted model that also controlled for depression, SPD was still significantly associated with lower PCS scores (-3.03 95% CI -5.63; -0.43) and MCS scores (-9.46 95% CI -11.67; -7.24). Conclusions: Among U.S. adults, SPD is associated with significantly diminished QOL above and beyond the effects of depression. Targeted interventions to mitigate the adverse effects of SPD are needed, independent of programs to address depression. C1 [Dismuke, Clara E.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Dismuke, Clara E.; Hernandez-Tejada, Melba A.; Egede, Leonard E.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute for Diabetes, Digestive and Kidney Diseases [K24 DK093699] FX Dr. Egede is supported by grant #K24 DK093699 funded by the National Institute for Diabetes, Digestive and Kidney Diseases. The manuscript represents the views of the authors and not those of the VA or NIH. Dr. Leonard E. Egede is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 29 TC 2 Z9 2 U1 1 U2 5 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 EI 1541-3527 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2014 VL 48 IS 2 BP 135 EP 146 DI 10.2190/PM.48.2.f PG 12 WC Psychiatry SC Psychiatry GA AU5XU UT WOS:000345677700006 PM 25377154 ER PT J AU Cifu, DX Hoke, KW Wetzel, PA Wares, JR Gitchel, G Carne, W AF Cifu, David X. Hoke, Kathy W. Wetzel, Paul A. Wares, Joanna R. Gitchel, George Carne, William TI Effects of hyperbaric oxygen on eye tracking abnormalities in males after mild traumatic brain injury SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE blast injury; blinded; concussion; eye tracking; hyperbaric oxygen; postconcussive syndrome; randomized; saccades; sham controlled; traumatic brain injury ID POST-CONCUSSION SYNDROME; POSTTRAUMATIC-STRESS-DISORDER; NEURAL STEM-CELLS; POSTCONCUSSION SYMPTOMS; THERAPY; RATS; PERSISTENT; MOVEMENTS; MILITARY; RECOVERY AB The effects of hyperbaric oxygen (HBO2) on eye movement abnormalities in 60 military servicemembers with at least one mild traumatic brain injury (mTBI) from combat were examined in a single-center, randomized, double-blind, sham-controlled, prospective study at the Naval Medicine Operational Training Center. During the 10 wk of the study, each subject was delivered a series of 40, once a day, hyperbaric chamber compressions at a pressure of 2.0 atmospheres absolute (ATA). At each session, subjects breathed one of three preassigned oxygen fractions (10.5%, 75%, or 100%) for 1 h, resulting in an oxygen exposure equivalent to breathing either surface air, 100% oxygen at 1.5 ATA, or 100% oxygen at 2.0 ATA, respectively. Using a standardized, validated, computerized eye tracking protocol, fixation, saccades, and smooth pursuit eye movements were measured just prior to intervention and immediately postintervention. Between-and within-groups testing of pre-and postintervention means revealed no significant differences on eye movement abnormalities and no significant main effect for HBO2 at either 1.5 ATA or 2.0 ATA equivalent compared with the sham-control. This study demonstrated that neither 1.5 nor 2.0 ATA equivalent HBO2 had an effect on postconcussive eye movement abnormalities after mTBI when compared with a sham-control. C1 [Cifu, David X.; Carne, William] Virginia Commonwealth Univ, Dept PM&R, Richmond, VA 23298 USA. [Cifu, David X.] US Dept Vet Affairs, Phys Med & Rehabil Program Off, Richmond, VA USA. [Hoke, Kathy W.; Wares, Joanna R.] Univ Richmond, Dept Math & Comp Sci, Richmond, VA 23173 USA. [Wetzel, Paul A.; Gitchel, George] Virginia Commonwealth Univ, Dept Biomed Engn, Richmond, VA 23298 USA. RP Carne, W (reprint author), Virginia Commonwealth Univ, Dept PM&R, 1223 East Marshall St, Richmond, VA 23298 USA. EM lasile@aol.com FU Air Force Medical Support Agency Medical Modernization Directorate; 711th Human Performance Wing; U.S. Navy Bureau of Medicine and Surgery; U.S. Army Medical Materiel Development Activity; Defense Advanced Research Projects Agency [N66001-09-2-206]; Defense and Veterans Brain Injury Center; U.S. Army Medical Research Acquisition Activity [W81XWH-08-2-0178]; DoD; VA Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095] FX This material was based on work funded by the Air Force Medical Support Agency Medical Modernization Directorate and the 711th Human Performance Wing for the primary study, the U.S. Navy Bureau of Medicine and Surgery for contract funding temporary duty requirements, and the U.S. Army Medical Materiel Development Activity for end of study contract funding. Dr. Cifu's efforts were supported, in part, through a Defense Advanced Research Projects Agency grant (N66001-09-2-206) and a contract from the U.S. Army Medical Materiel Development Activity. Dr. Carne's efforts were supported, in part, through contracts from the U.S. Army Medical Materiel Development Activity and the Defense and Veterans Brain Injury Center. This work was funded primarily by the U.S. Army Medical Research Acquisition Activity (award W81XWH-08-2-0178) with support from the Defense and Veterans Brain Injury Center. Following completion of the study, additional support came from the DoD and VA Chronic Effects of Neurotrauma Consortium (grant W81XWH-13-2-0095). NR 31 TC 4 Z9 4 U1 1 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2014 VL 51 IS 7 BP 1047 EP 1055 DI 10.1682/JRRD.2014.01.0013 PG 9 WC Rehabilitation SC Rehabilitation GA AU8JB UT WOS:000345841300004 PM 25436771 ER PT J AU Kang, HJ Dang, ABC Joshi, SK Halloran, B Nissenson, R Zhang, X Li, JA Kim, HT Liu, XH AF Kang, Heejae Dang, Alexis B. C. Joshi, Sunil K. Halloran, Bernard Nissenson, Robert Zhang, Xia Li, Jianan Kim, Hubert T. Liu, Xuhui TI Novel mouse model of spinal cord injury-induced heterotopic ossification SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE bone morphogenetic protein-2; heterotopic ossification; injury; microcomputed tomography; mouse model; muscle; rehabilitation; spinal cord injury; trauma; Veterans ID TRAUMATIC BRAIN-INJURY; RISK-FACTORS; PREVALENCE; SYSTEM; BONE AB Heterotopic ossification (HO) develops in about 20% to 30% of patients with spinal cord injury (SCI) and significantly impairs their rehabilitation. There is no effective prevention or treatment for this condition at this time. Our current understanding of its etiology and pathophysiology is limited partially due to the lack of clinically relevant animal models. In this study, we report a novel mouse model of SCI-induced HO by administering a subthreshold dose of bone morphogenetic protein (BMP)-2 to muscles in mice after SCI. Microcomputed tomography scanning showed that an intramuscular injection of 0.25 micrograms of BMP-2 causes significant HO in mice with SCI but not in control (sham surgery) mice. Our analysis of gene expression showed significantly increased BMP signaling in quadriceps following SCI, suggesting that BMP signaling may play a role in SCI-induced HO. Administering 0.25 micrograms of BMP-2 to the front arms of the mice with SCI also results in the development of significant HO but not in control mice. This suggests that SCI causes a systematic osteogenic effect, which is not limited to paralyzed limbs. This novel mouse model will serve as a powerful tool in exploring the molecular mechanisms of SCI-induced HO, which may lead to novel treatment for this disease. C1 [Kang, Heejae; Dang, Alexis B. C.; Joshi, Sunil K.; Halloran, Bernard; Nissenson, Robert; Kim, Hubert T.; Liu, Xuhui] San Francisco Dept Vet Affairs Med Ctr, San Francisco, CA USA. [Dang, Alexis B. C.; Joshi, Sunil K.; Kim, Hubert T.; Liu, Xuhui] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. [Halloran, Bernard; Nissenson, Robert] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Zhang, Xia; Li, Jianan] Nanjing Med Univ, Affiliate Hosp 1, Dept Rehabil Med, Nanjing, Jiangsu, Peoples R China. RP Liu, XH (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Bldg 2,Room 639, San Francisco, CA 94121 USA. EM Liux@orthosurg.ucsf.edu FU Department of Defense [W81XWH-11-2-0189]; Department of Veterans Affairs (VA) Rehabilitation Research and Development Merit Review [RX000195]; Northern California Institute for Research and Education FX This material was based on work supported by the Department of Defense (grant W81XWH-11-2-0189), Department of Veterans Affairs (VA) Rehabilitation Research and Development Merit Review (grant RX000195), and the Northern California Institute for Research and Education. We thank Drs. Olla Larm and Lars Adolfsson (ExThera AB; Stockholm, Sweden) for their kind gift of heparin-chitosan hydrogel. NR 20 TC 2 Z9 3 U1 1 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2014 VL 51 IS 7 BP 1109 EP 1117 DI 10.1682/JRRD.2014.01.0019 PG 9 WC Rehabilitation SC Rehabilitation GA AU8JB UT WOS:000345841300010 PM 25436890 ER PT J AU Sharma, A Garg, A Borer, JS Krishnamoorthy, P Garg, J Lavie, CJ Arbab-Zadeh, A Mukherjee, D Ahmad, H Lichstein, E AF Sharma, Abhishek Garg, Akash Borer, Jeffrey S. Krishnamoorthy, Parasuram Garg, Jalaj Lavie, Carl J. Arbab-Zadeh, Armin Mukherjee, Debabrata Ahmad, Hasan Lichstein, Edgar TI Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome SO CARDIOLOGY LA English DT Article DE Acute coronary syndrome; Factor Xa; Coagulation pathway ID ELEVATION MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; UNFRACTIONATED HEPARIN; ANTIPLATELET THERAPY; CONTROLLED-TRIAL; IN-VIVO; UNSTABLE ANGINA; POOLED ANALYSIS; ARTERY-DISEASE; DOUBLE-BLIND AB Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS. (C) 2014 S. Karger AG, Basel C1 [Sharma, Abhishek] Suny Downstate Med Ctr, Div Cardiovasc Med, New York, NY USA. [Borer, Jeffrey S.] Suny Downstate Med Ctr, Howard Gilman Inst Heart Valve Dis, New York, NY USA. [Borer, Jeffrey S.] Suny Downstate Med Ctr, Schiavone Inst Cardiovasc Translat Res, New York, NY USA. [Garg, Akash] Mt Sinai Sch Med, James J Peters VA Med Ctr, Dept Med, New York, NY USA. [Lichstein, Edgar] Maimonides Hosp, Dept Med, New York, NY USA. [Krishnamoorthy, Parasuram] Mt Sinai Englewood Hosp & Med Ctr Englewood, Dept Internal Med, Englewood, CO USA. [Garg, Jalaj] New York Med Coll, Dept Internal Med, Westchester Med Ctr, Valhalla, NY 10595 USA. [Ahmad, Hasan] New York Med Coll, Westchester Med Ctr, Div Cardiol, Valhalla, NY 10595 USA. [Lavie, Carl J.] Univ Queensland, Sch Med, John Ochsner Heart & Vasc Inst, Dept Cardiovasc Dis,Ochsner Clin Sch, New Orleans, LA USA. [Lavie, Carl J.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Dept Prevent Med, Baton Rouge, LA USA. [Arbab-Zadeh, Armin] Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA. [Mukherjee, Debabrata] Texas Tech Univ, Div Cardiol, Lubbock, TX 79409 USA. RP Sharma, A (reprint author), 240 78th St Apt 2R, Brooklyn, NY 11209 USA. EM abhisheksharma4mamc@gmail.com RI Lavie, Carl/A-6014-2011 OI Krishnamoorthy, Parasuram/0000-0002-4560-7346 NR 51 TC 0 Z9 0 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2014 VL 129 IS 4 BP 224 EP 232 DI 10.1159/000368747 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AU2KL UT WOS:000345447000005 PM 25402219 ER PT J AU Jiang, FG Deng, Y Yeh, CK Sun, YY AF Jiang, Fuguang Deng, Ying Yeh, Chih-Ko Sun, Yuyu TI Quaternized chitosans bind onto preexisting biofilms and eradicate pre-attached microorganisms SO JOURNAL OF MATERIALS CHEMISTRY B LA English DT Article ID CATHETER-RELATED INFECTIONS; GRAM-NEGATIVE BACTERIA; LACTIC-ACID BACTERIA; TRIMETHYL CHITOSAN; NOSOCOMIAL INFECTIONS; ANTIMICROBIAL ACTIVITY; UNITED-STATES; DERIVATIVES; RESISTANCE; MEMBRANE AB Quaternized chitosans, N,N,N-trimethylchitosan (TMC), with different degrees of quaternization were synthesized by reacting methyl iodide with chitosan. The reaction was confirmed by FT-IR and H-1-NMR characterization. Antimicrobial assay showed that the prepared TMC had potent biocidal effects against planktonic Gram-positive bacteria Staphylococcus epidermidis, Gram-negative bacteria Escherichia coli, and yeast Candida albicans. Bacterial and fungal biofilms were formed on poly(methyl methacrylate) (PMMA) films and then treated with TMC aqueous solution. Zeta potential measurement suggested that TMC bonded onto the preexisting biofilms. Biofilm-binding kinetics was evaluated in UV studies using phenyl group-labeled TMC as a model compound, which revealed that quaternized chitosans bonded onto the preexisting biofilms rapidly. Colony-forming unit (CFU) determination and SEM, confocal laser scanning microscopy (CLSM) and fluorescence microscopy studies demonstrated that the bonded TMC had powerful biocidal activities to eradicate the pre-attached bacterial and fungal cells in the preexisting biofilms. The biocompatibility of the TMC samples with rat skin fibroblast cells was evaluated in the MTT assay. C1 [Jiang, Fuguang; Sun, Yuyu] Univ Massachusetts Lowell, Dept Chem, Lowell, MA 01854 USA. [Deng, Ying] Univ S Dakota, Biomed Engn Program, Sioux Falls, SD 57107 USA. [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div,South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Sun, YY (reprint author), Univ Massachusetts Lowell, Dept Chem, Lowell, MA 01854 USA. EM ying.deng@usd.edu; yeh@uthscsa.edu; yuyu_sun@uml.edu FU NIDCR, NIH [R01 DE021084]; VA Merit Review [1I01BX001103-01A1] FX This study was supported by NIDCR, NIH (R01 DE021084) and VA Merit Review (1I01BX001103-01A1). NR 50 TC 4 Z9 4 U1 0 U2 10 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2050-750X EI 2050-7518 J9 J MATER CHEM B JI J. Mat. Chem. B PY 2014 VL 2 IS 48 BP 8518 EP 8527 DI 10.1039/c4tb01131g PG 10 WC Materials Science, Biomaterials SC Materials Science GA AU3QT UT WOS:000345529400008 PM 25984341 ER PT B AU Johansen, KL Painter, P AF Johansen, Kirsten L. Painter, Patricia BE ByhamGray, LD Burrowes, JD Chertow, GM TI Physical Activity and Exercise SO NUTRITION IN KIDNEY DISEASE, 2ND EDITION SE Nutrition and Health Series LA English DT Article; Book Chapter DE Physical activity; Exercise; Chronic kidney disease; Reconditioning; Walking; End-stage renal disease; Dialysis ID STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; AMERICAN-HEART-ASSOCIATION; QUALITY-OF-LIFE; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; AMBULATORY PATIENTS; OLDER-ADULTS; PERITONEAL-DIALYSIS; TRANSPLANT PATIENTS C1 [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA. [Painter, Patricia] Univ Utah, Coll Hlth, Dept Phys Therapy, Salt Lake City, UT 84108 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu; trish.painter@hsc.utah.edu NR 75 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-62703-685-6; 978-1-62703-684-9 J9 NUTR HEALTH SER JI Nutr. Health Ser. PY 2014 BP 271 EP 287 DI 10.1007/978-1-62703-685-6_16 D2 10.1007/978-1-62703-685-6 PG 17 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA BB6QG UT WOS:000344931000019 ER PT J AU Weinstein, L Perez-Rodriguez, MM Siever, L AF Weinstein, Lissa Mercedes Perez-Rodriguez, M. Siever, Larry TI Personality Disorders, Attachment and Psychodynamic Psychotherapy SO PSYCHOPATHOLOGY LA English DT Article DE Personality disorders; Attachment patterns; Psychodynamic psychotherapy; Interpersonal functioning ID MENTALIZATION-BASED TREATMENT; INTRANASAL OXYTOCIN; INSECURE ATTACHMENT; BORDERLINE TRAITS; SOCIAL ATTACHMENT; MATERNAL BRAIN; NEUROBIOLOGY; ADULTS; STRESS; SCHIZOPHRENIA AB While attachment has been a fruitful and critical concept in understanding enduring individual templates for interpersonal relationships, it does not have a well-understood relationship to personality disorders, where impairment of interpersonal functioning is paramount. Despite the recognition that attachment disturbances do not simply reflect nonoptimal caretaking environments, the relationship of underlying temperamental factors to these environmental insults has not been fully explored. In this paper we provide an alternate model for the role of neurobiological temperamental factors, including brain circuitry and neuropeptide modulation, in mediating social cognition and the internalization and maintenance of attachment patterns. The implications of these altered attachment patterns on personality disorders and their neurobiological and environmental roots for psychoanalytically based treatment models designed to ameliorate difficulties in interpersonal functioning through the medium of increased access to mature forms of mentalization is discussed. (C) 2014 S. Karger AG, Basel C1 [Weinstein, Lissa] CUNY City Coll, Doctoral Program Clin Psychol, New York, NY 10031 USA. [Weinstein, Lissa] CUNY, Grad Ctr, New York, NY USA. [Mercedes Perez-Rodriguez, M.; Siever, Larry] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Mercedes Perez-Rodriguez, M.; Siever, Larry] Mental Hlth Patient Care Ctr, Bronx, NY USA. [Mercedes Perez-Rodriguez, M.; Siever, Larry] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Mercedes Perez-Rodriguez, M.] Autonomous Univ Madrid, Fdn Jimenez Diaz Hosp, CIBERSAM, E-28049 Madrid, Spain. RP Weinstein, L (reprint author), CUNY City Coll, 160 Convent Ave, New York, NY 10031 USA. EM lissa_weinstein@hotmail.com RI Perez Rodriguez, Maria/B-9410-2013 OI Perez Rodriguez, Maria/0000-0001-5137-1993 NR 110 TC 1 Z9 1 U1 3 U2 15 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0254-4962 EI 1423-033X J9 PSYCHOPATHOLOGY JI Psychopathology PY 2014 VL 47 IS 6 BP 425 EP 436 DI 10.1159/000366135 PG 12 WC Psychiatry SC Psychiatry GA AU5QJ UT WOS:000345661400010 PM 25376756 ER PT J AU Shechter, A St-Onge, MP Kuna, ST Zammit, G RoyChoudhury, A Newman, AB Millman, RP Reboussin, DM Wadden, TA Jakicic, JM Pi-Sunyer, FX Wing, RR Foster, GD AF Shechter, Ari St-Onge, Marie-Pierre Kuna, Samuel T. Zammit, Gary RoyChoudhury, Arindam Newman, Anne B. Millman, Richard P. Reboussin, David M. Wadden, Thomas A. Jakicic, John M. Pi-Sunyer, F. Xavier Wing, Rena R. Foster, Gary D. CA Look Ahead Res Grp TI Sleep Architecture Following a Weight Loss Intervention in Overweight and Obese Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Relationship to Apnea-Hypopnea Index SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE sleep architecture; obstructive sleep apnea; obesity; type 2 diabetes ID RANDOMIZED CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; SLOW-WAVE SLEEP; CARDIOVASCULAR RISK-FACTORS; AIRWAY PRESSURE THERAPY; EYE-MOVEMENT SLEEP; LOW ENERGY DIET; DAYTIME SLEEPINESS; BARIATRIC SURGERY; DURATION AB Study Objectives: To determine if weight loss and/or changes in apnea-hypopnea index (AHI) improve sleep architecture in overweight/obese adults with type 2 diabetes (T2D) and obstructive sleep apnea (OSA). Methods: This was a randomized controlled trial including 264 overweight/obese adults with T2D and OSA. Participants were randomized to an intensive lifestyle intervention (ILI) or a diabetes and support education (DSE) control group. Measures included anthropometry, AHI, and sleep at baseline and year-1, year-2, and year-4 follow-ups. Results: Changes in sleep duration (total sleep time [TST]), continuity [wake after sleep onset (WASO)], and architecture stage 1, stage 2, slow wave sleep, and REM sleep) from baseline to year 1, 2, and 4 did not differ between ILI and DSE. Repeated-measure mixed-model analyses including data from baseline through year-4 for all participants demonstrated a significant positive association between AHI and stage 1 sleep (p < 0.001), and a significant negative association between AHI and stage 2 (p = 0.01) and REM sleep (p < 0.001), whereas changes in body weight had no relation to any sleep stages or TST. WASO had a significant positive association with change in body weight (p = 0.009). Conclusions: Compared to control, the ILI did not induce significant changes in sleep across the 4-year follow-up. In participants overall, reduced AHI in overweight/obese adults with T2D and OSA was associated with decreased stage 1, and increased stage 2 and REM sleep. These sleep architecture changes are more strongly related to reductions in AHI than body weight, whereas WASO may be more influenced by weight than AHI. C1 [Shechter, Ari; St-Onge, Marie-Pierre; RoyChoudhury, Arindam; Pi-Sunyer, F. Xavier] Columbia Univ, New York, NY 10032 USA. [Kuna, Samuel T.; Wadden, Thomas A.] Univ Penn, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Zammit, Gary] Clinilabs, New York, NY USA. [Newman, Anne B.; Jakicic, John M.] Univ Pittsburgh, Pittsburgh, PA USA. [Millman, Richard P.; Wing, Rena R.] Brown Univ, Providence, RI 02912 USA. [Reboussin, David M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Foster, Gary D.] Temple Univ, Philadelphia, PA 19122 USA. RP Shechter, A (reprint author), Columbia Univ, New York Obes Res Ctr, 622 West 168th St, New York, NY 10032 USA. EM as4180@columbia.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU National Institutes of Health NHLBI grant [HL070301]; NIDDK [DK60426, DK56992, DK057135, DK007559]; Philips Respironics; Abbott; Actelion; Ancile; Apnex; Arena; Aventis; Cephalon Inc; CHDI; Elan; Epis; Evotec; Forest; Galderma; Glaxo Smith Kline; H. Lundbeck A/S; King; Merck and Co.; National Institute of Health (NIH); Neurim; Neurocrine Biosciences; Neurogen; Organon; Orphan Medical; Otsuka; Pfizer; Predix; Respironics; Sanofi-Aventis; Sanofi-Synthelabo; Schering-Plough; Sepracor; Shire; Samaxon; Takeda Pharmaceuticals North America; Targacept; Thymon; Transcept; UCB Pharma; Vanda; Wyeth-Ayerst Research; King Pharmaceuticals; McNeil; Vela Pharmaceuticals; Novo Nordisk; NutriSystem; BodyMedia, Inc.; JennyCraig; Coca Cola Company; Orexigen FX This was not an industry supported study. The study was supported by the National Institutes of Health NHLBI grant HL070301 and NIDDK grants DK60426, DK56992, DK057135, and DK007559. Dr. Kuna has received research support from Philips Respironics. Dr. Zammit is a consultant for Actelion, Alexza, Arena, Aventis, Biovail, Boehringer-Ingelheim, Cephalon, Elan, Eli Lilly, Evotec, Forest, Glaxo Smith Kline, Jazz, King Pharmaceuticals, Ligand, McNeil, Merck, Neurocrine Biosciences, Organon, Phizer, Renovis, Sanofi-Aventis, Select Comfort, Sepracor, Shire, Somnus, Takeda Pharmaceuticals, Vela, Wyeth-Ayerst Research; provides expert testimony for Acorda; has grants or grants pending from Abbott, Actelion, Ancile, Apnex, Arena, Aventis, Cephalon Inc, CHDI, Elan, Epis, Evotec, Forest, Galderma, Glaxo Smith Kline, H. Lundbeck A/S, King, Merck and Co., National Institute of Health (NIH), Neurim, Neurocrine Biosciences, Neurogen, Organon, Orphan Medical, Otsuka, Pfizer, Predix, Respironics, Sanofi-Aventis, Sanofi-Synthelabo, Schering-Plough, Sepracor, Shire, Samaxon, Takeda Pharmaceuticals North America, Targacept, Thymon, Transcept, UCB Pharma, Predix, Vanda, Wyeth-Ayerst Research. And has received payment for lectures from Neurocrine Biosciences, King Pharmaceuticals, McNeil, Sanofi-Aventis, Sanofi-Synthelabo, Sepracor, Takeda Pharmaceuticals, Vela Pharmaceuticals, Wyeth-Ayerst Research. Dr. Wadden serves on advisory boards for Orexigen Therapeutics and Novo Nordisk and has received grant support from Novo Nordisk and NutriSystem. Dr. Jakicic is a member of Free & Clear Scientific Advisory Board, has received grants or has grants pending from BodyMedia, Inc., and receives payment for lectures by JennyCraig. Dr. Foster serves on the Scientific Advisory Board of Con Agra Foods, Nutrisystem, Amylin, GI Dynamics, and United Health Group. He has received grants from Coca Cola Company and Orexigen. The other authors have indicated no financial conflicts of interest. NR 42 TC 2 Z9 2 U1 0 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2014 VL 10 IS 11 BP 1205 EP 1211 DI 10.5664/jcsm.4202 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AT8XT UT WOS:000345213100007 PM 25325608 ER PT J AU Chidi, AP Rogal, SS Bryce, CL Fine, MJ Good, CB Myaskovsky, L Rustgi, VK Tsung, A Smith, KJ AF Chidi, Alexis P. Rogal, Shari S. Bryce, Cindy L. Fine, Michael J. Good, Chester B. Myaskovsky, Larissa Rustgi, Vinod K. Tsung, Allan Smith, Kenneth J. TI Cost-Effectiveness of Novel Hepatitis C Drug Regimens Among Treatment-Experienced US Veterans SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Chidi, Alexis P.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Chidi, Alexis P.; Fine, Michael J.; Good, Chester B.; Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Rogal, Shari S.; Rustgi, Vinod K.] Univ Pittsburgh, Div GI Hepatol & Nutr, Pittsburgh, PA USA. [Bryce, Cindy L.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Bryce, Cindy L.; Fine, Michael J.; Myaskovsky, Larissa; Smith, Kenneth J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Good, Chester B.] Dept Vet Affairs, Pittsburgh, PA USA. [Rustgi, Vinod K.; Tsung, Allan] Univ Pittsburgh, Starzl Transplant Inst, Pittsburgh, PA USA. [Tsung, Allan] Univ Pittsburgh, Div Hepatobiliary & Pancreat Surg, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 75 BP 234A EP 234A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483801009 ER PT J AU Saxena, V Flemming, JA Shen, H Terrault, N Monto, A Rongey, C AF Saxena, Varun Flemming, Jennifer A. Shen, Hui Terrault, Norah Monto, Alexander Rongey, Catherine TI Facility and patient level predictors of endoscopic variceal screening within the largest integrated healthcare system in the United States SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Saxena, Varun; Shen, Hui; Terrault, Norah; Monto, Alexander; Rongey, Catherine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shen, Hui; Monto, Alexander; Rongey, Catherine] San Francisco VA Med Ctr, San Francisco, CA USA. [Flemming, Jennifer A.] Queens Univ, Kingston, ON K7L 3N6, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 95 BP 246A EP 246A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483801029 ER PT J AU Rahman, K Thorn, N Kumar, P Nusrat, A Parkos, CA Anania, FA AF Rahman, Khalidur Thorn, Natalie Kumar, Pradeep Nusrat, Asma Parkos, Charles A. Anania, Frank A. TI Compromised intestinal epithelial barrier function is a major contributor in the progression of diet induced non-alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) and is driven primarily by innate immune activation SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Rahman, Khalidur; Thorn, Natalie; Kumar, Pradeep; Anania, Frank A.] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA USA. [Rahman, Khalidur; Anania, Frank A.] Atlanta VA Med Ctr, US Dept Vet Affairs, Decatur, GA USA. [Nusrat, Asma; Parkos, Charles A.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 97 BP 247A EP 247A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483801031 ER PT J AU Berry, K Taylor, J Liou, IW Ioannou, GN AF Berry, Kristin Taylor, Justin Liou, Iris W. Ioannou, George N. TI Portal vein thrombosis is not associated with increased mortality in cirrhotic patients SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Berry, Kristin; Liou, Iris W.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Taylor, Justin; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 386 BP 391A EP 392A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483801318 ER PT J AU Basu, P Shah, NJ Lee, D Aloysius, M Gress, FG AF Basu, Patrick Shah, Niraj J. Lee, David Aloysius, M. Gress, Frank G. TI Novel colonoscopy preparation of organic coconut water with Miralax and Dulcolax in split doses for decompensated cirrhotics. A randomized double blinded open labelled clinical pilot single centered observational study. COSMIC Study SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Basu, Patrick; Gress, Frank G.] Columbia Univ, Sch Phys & Surg, New York, NY USA. [Basu, Patrick; Lee, David; Aloysius, M.] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 652 BP 516A EP 516A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483802148 ER PT J AU Basu, P Shah, NJ Aloysius, M AF Basu, Patrick Shah, Niraj J. Aloysius, M. TI Berberine with Alfa Lipoic Acid (ALA) in Non Alcoholic Steato-hepatitis (NASH). A randomized double blinded placebo control trial. A Clinical pilot - The BANISH Trial SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Basu, Patrick] Columbia Univ Sch Phys & Surg, New York, NY USA. [Basu, Patrick; Aloysius, M.] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 877 BP 624A EP 624A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483802373 ER PT J AU Backus, LI Belperio, PS Shahoumian, TA Mole, LA AF Backus, Lisa I. Belperio, Pamela S. Shahoumian, Troy A. Mole, Larry A. TI Early Assessment of Hepatitis C Virologic Response of US Veterans Receiving Sofosbuvir-based Therapy SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Backus, Lisa I.; Belperio, Pamela S.; Shahoumian, Troy A.; Mole, Larry A.] Vet Affairs Palo Alto Hlth Care Syst, Off Publ Hlth Populat Hlth, Palo Alto, CA USA. [Backus, Lisa I.] VA Palo Alto Healthcare Syst, Dept Med, Palo Alto, CA USA. [Belperio, Pamela S.] VA Greater Los Angeles, Dept Pharm, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 953 BP 659A EP 659A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803002 ER PT J AU Jimmerson, LC Burton, JR Baouchi, F Truesdale, AE Price, A Ray, M Bushman, L Hammond, K Langness, J Tise, S Everson, GT Kiser, J AF Jimmerson, Leah C. Burton, James R. Baouchi, Fafa Truesdale, Aimee E. Price, Angie Ray, Michelle Bushman, Lane Hammond, Kyle Langness, Jacob Tise, Sarah Everson, Gregory T. Kiser, Jennifer TI Effects of Ribavirin on Red Blood Cell Concentrations of Endogenous Purines in Patients with Hepatitis C Virus Undergoing Ribavirin-Based Treatment SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Jimmerson, Leah C.; Ray, Michelle; Bushman, Lane; Hammond, Kyle; Kiser, Jennifer] Univ Colorado, Aurora, CO USA. [Burton, James R.; Langness, Jacob; Tise, Sarah; Everson, Gregory T.] Univ Colorado Hosp, Aurora, CO USA. [Baouchi, Fafa; Truesdale, Aimee E.] Denver Hlth, Digest & Liver Hlth, Denver, CO USA. [Price, Angie] Denver VA Hosp, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 991 BP 681A EP 682A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803040 ER PT J AU Basu, P Shah, NJ Aloysius, M AF Basu, Patrick Shah, Niraj J. Aloysius, M. TI Simeprevir and Sofosbuvir with modified doses of Ribavirin (RBV) therapy on Telaprevir experienced Co infected (with HIV) cirrhotics with chronic hepatitis C (CHC) A randomized open label clinical pilot study: STOP C SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Basu, Patrick] Columbia Univ, Sch Phys & Surg, New York, NY USA. [Basu, Patrick; Aloysius, M.] Kings Cty Hosp, Med Ctr, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 993 BP 682A EP 683A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803042 ER PT J AU Wedd, JP Ashcraft, B Babson, K Boyd, N Costelow, M Pepe, A Tong, Y Rosen, HR Redington, J AF Wedd, Joel P. Ashcraft, Becky Babson, Kristin Boyd, Nancy Costelow, Marsha Pepe, Anthony Tong, Yvette Rosen, Hugo R. Redington, John TI Treating Advanced Hepatitis C Virus with New Direct Acting Antiviral Medications, a VA Experience SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Wedd, Joel P.; Rosen, Hugo R.] Univ Colorado Denver, Aurora, CO USA. [Ashcraft, Becky; Babson, Kristin; Boyd, Nancy; Costelow, Marsha; Pepe, Anthony; Tong, Yvette; Redington, John] Denver VAMC, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1025 BP 699A EP 699A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803074 ER PT J AU Basu, P Shah, NJ Aloysius, M Brown, RS AF Basu, Patrick Shah, Niraj J. Aloysius, M. Brown, Robert S. TI Interferon ineligible naive chronic hepatitis C genotype I subjects treated with Simeprevir and Sofosbuvir in special population (psychiatric). An open label prospective clinical pilot study; INSPIRE C study SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Basu, Patrick; Brown, Robert S.] Columbia Univ, Sch Phys & Surg, New York, NY USA. [Basu, Patrick; Aloysius, M.] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1043 BP 708A EP 708A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803092 ER PT J AU Xu, J Chi, F Punj, V Lee, WNP French, SW Tsukamoto, H AF Xu, Jun Chi, Feng Punj, Vasu Lee, W. N. Paul French, Samuel W. Tsukamoto, Hidekazu TI Notch1 reprograms mitochondria metabolism for hepatic macrophage M1 activation in ASH through upregulation of pyruvate dehydrogenase (PDH) activity and mtDNA transcription SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Xu, Jun; Chi, Feng; Punj, Vasu; Tsukamoto, Hidekazu] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Lee, W. N. Paul; French, Samuel W.] Harbor UCLA Med Ctr, Torrance, CA USA. [Tsukamoto, Hidekazu] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1116 BP 742A EP 742A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803165 ER PT J AU Platt, HL Citti, CC Minguez, B Chen, TY Ventura-Cots, M Hernandez, MD Jalali, Z Badshah, MB Yin, M Aytaman, A Nelson, M Rockstroh, JK Goetz, MB Schwartz, M Dieterich, D Aberg, J Hoshida, Y Brau, N AF Platt, Heather L. Citti, Caitlin C. Minguez, Beatriz Chen, Ting-Yi Ventura-Cots, Meritxell Hernandez, Maria D. Jalali, Ziba Badshah, Maaz B. Yin, Michael Aytaman, Ayse Nelson, Mark Rockstroh, Juergen K. Goetz, Matthew B. Schwartz, Myron Dieterich, Douglas Aberg, Judith Hoshida, Yujin Braeu, Norbert TI Liver Transplantation for HIV-Infected Patients with Hepatocellular Carcinoma (HCC) SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Platt, Heather L.; Yin, Michael] Columbia Univ, Med Ctr, Div Infect Dis, New York, NY USA. [Citti, Caitlin C.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Minguez, Beatriz; Ventura-Cots, Meritxell] Hosp Univ Vall dHebron, Barcelona, Spain. [Chen, Ting-Yi] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Hernandez, Maria D.] Univ Miami, Miami, FL USA. [Jalali, Ziba] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Jalali, Ziba] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Badshah, Maaz B.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Aytaman, Ayse] VA New York Harbor HCS, Brooklyn, NY USA. [Aytaman, Ayse] SUNY Downstate Hlth Sci Ctr, Brooklyn, NY USA. [Nelson, Mark] Chelsea & Westminster Hosp, London, England. [Rockstroh, Juergen K.] Univ Klinikum Bonn, Bonn, Germany. [Goetz, Matthew B.] VA Greater Los Angeles HCS, Los Angeles, CA USA. [Schwartz, Myron] Icahn Sch Med Mt Sinai, Div Hepatobiliary Surg, New York, NY 10029 USA. [Dieterich, Douglas; Aberg, Judith; Hoshida, Yujin; Braeu, Norbert] Icahn Sch Med Mt Sinai, Div Infect Dis & Liver Dis, New York, NY 10029 USA. [Braeu, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1320 BP 834A EP 834A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803368 ER PT J AU Chen, TY Merchante, N Citti, CC Platt, HL Badshah, MB Ventura-Cots, M Merino, E Kikuchi, L Jain, MK Rodriguez-Arrondo, F Minguez, B Yin, M Aytaman, A Tural, C Schwartz, M Dieterich, D Aberg, J Pineda, J Marrero, JA Sherman, M Hoshida, Y Brau, N AF Chen, Ting-Yi Merchante, Nicolas Citti, Caitlin C. Platt, Heather L. Badshah, Maaz B. Ventura-Cots, Meritxell Merino, Esperanza Kikuchi, Luciana Jain, Mamta K. Rodriguez-Arrondo, Francisco Minguez, Beatriz Yin, Michael Aytaman, Ayse Tural, Cristina Schwartz, Myron Dieterich, Douglas Aberg, Judith Pineda, Juan Marrero, Jorge A. Sherman, Morris Hoshida, Yujin Braeu, Norbert TI Predicting Survival of HIV-Infected Patients with Liver Cancer - the SHILCA Score and Staging Model SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Chen, Ting-Yi; Jain, Mamta K.; Marrero, Jorge A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Merchante, Nicolas; Pineda, Juan] Hosp Univ Valme, Seville, Spain. [Citti, Caitlin C.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Platt, Heather L.; Yin, Michael] Columbia Univ, Med Ctr, Div Infect Dis, New York, NY USA. [Badshah, Maaz B.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Ventura-Cots, Meritxell; Minguez, Beatriz] Hosp Univ Vall dHebron, Barcelona, Spain. [Merino, Esperanza] Hosp Gen Univ Alicante, Alicante, Spain. [Kikuchi, Luciana] Univ Sao Paulo, Sao Paulo, Brazil. [Aytaman, Ayse] VA New York Harbor HCS, Brooklyn, NY USA. [Tural, Cristina] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain. [Schwartz, Myron] Icahn Sch Med Mt Sinai, Div Hepatobiliary Surg, New York, NY 10029 USA. [Dieterich, Douglas; Hoshida, Yujin; Braeu, Norbert] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA. [Rodriguez-Arrondo, Francisco] Hosp Univ Donostia, San Sebastian, Spain. [Dieterich, Douglas; Aberg, Judith] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA. [Sherman, Morris] Toronto Gen Hosp, Toronto, ON, Canada. [Sherman, Morris] Univ Toronto, Toronto, ON, Canada. [Braeu, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1322 BP 835A EP 835A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803370 ER PT J AU Jou, JH Beste, LA Yang, Y Chang, MF Muir, AJ AF Jou, Janice H. Beste, Lauren A. Yang, Yin Chang, Michael F. Muir, Andrew J. TI Specialty Care is Associated with Early Diagnosis of Hepatitis C-related Hepatocellular Carcinoma in US Veterans SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Jou, Janice H.; Chang, Michael F.] Portland VA Med Ctr, Portland, OR USA. [Beste, Lauren A.; Yang, Yin] Puget Sound VA Med Ctr, Seattle, WA USA. [Muir, Andrew J.] Duke Univ, Med Ctr, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1330 BP 839A EP 839A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803378 ER PT J AU Citti, CC Platt, HL Badshah, MB Chen, TY Kikuchi, L Ventura-Cots, M Chaudhary, N Marcus, S Yin, M Aytaman, A Aberg, J Schwartz, M Dieterich, D Hoshida, Y Brau, N AF Citti, Caitlin C. Platt, Heather L. Badshah, Maaz B. Chen, Ting-Yi Kikuchi, Luciana Ventura-Cots, Meritxell Chaudhary, Noami Marcus, Sonja Yin, Michael Aytaman, Ayse Aberg, Judith Schwartz, Myron Dieterich, Douglas Hoshida, Yujin Braeu, Norbert TI HIV Viral Load Independently Predicts Survival in HIV-Infected Patients With Hepatocellular Carcinoma (HCC) SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Citti, Caitlin C.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Platt, Heather L.; Yin, Michael] Columbia Univ Med Ctr, Div Infect Dis, New York, NY USA. [Badshah, Maaz B.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Chen, Ting-Yi] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Kikuchi, Luciana] Univ Sao Paulo, Sao Paulo, Brazil. [Ventura-Cots, Meritxell] Hosp Univ Vall dHebron, Barcelona, Spain. [Chaudhary, Noami] NYU Med Ctr, New York, NY USA. [Marcus, Sonja; Braeu, Norbert] James J Peters VA Med Ctr, Bronx, NY USA. [Aytaman, Ayse] VA New York Harbor HCS, Brooklyn, NY USA. [Aytaman, Ayse] SUNY Downstate Hlth Sci Ctr, Brooklyn, NY USA. [Aberg, Judith; Dieterich, Douglas; Hoshida, Yujin; Braeu, Norbert] Icahn Sch Med Mt Sinai, Div Infect Dis & Liver Dis, New York, NY 10029 USA. [Schwartz, Myron] Icahn Sch Med Mt Sinai, Div Hepatobiliary Surg, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1391 BP 867A EP 868A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803438 ER PT J AU Li, YH Kaplan, DE AF Li, Yonghai Kaplan, David E. TI In vitro validation of human glypican-3 specific chimeric antigen receptors for hepatocellular carcinoma SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Li, Yonghai; Kaplan, David E.] Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1397 BP 870A EP 870A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483803444 ER PT J AU Beste, LA Green, P Ioannou, GN AF Beste, Lauren A. Green, Pamela Ioannou, George N. TI Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in a real world HIV/HCV co-infected cohort SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Internal Med, Seattle, WA USA. [Beste, Lauren A.; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Ioannou, George N.] VA Puget Sound Hlth Care Syst, Gastroenterol, Seattle, WA USA. [Green, Pamela] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1525 BP 932A EP 933A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483804088 ER PT J AU Beste, LA Pichler, R Germani, M Chang, MF Young, B AF Beste, Lauren A. Pichler, Raimund Germani, Maureen Chang, Michael F. Young, Bessie TI Telehepatology improves provider satisfaction and specialty care integration among rural Veterans Affairs Primary Care Providers SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Internal Med, Seattle, WA USA. [Beste, Lauren A.; Pichler, Raimund; Young, Bessie] Univ Washington, Seattle, WA 98195 USA. [Pichler, Raimund; Young, Bessie] VA Puget Sound Hlth Care Syst, Nephrol, Seattle, WA USA. [Germani, Maureen] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Chang, Michael F.] Portland VA Med Ctr, Portland, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1578 BP 958A EP 958A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483804141 ER PT J AU Zickmund, SL Chapko, MK Hanusa, BH Youk, AO Switzer, GE Sevick, MA Obrosky, DS Bayliss, NK Zook, CL Arnold, RA AF Zickmund, Susan L. Chapko, Michael K. Hanusa, Barbara H. Youk, Ada O. Switzer, Galen E. Sevick, Mary Ann Obrosky, David S. Bayliss, Nichole K. Zook, Carolyn L. Arnold, Robert A. TI Predictors of Attendance at the Gastroenterology Clinic to Discuss Treatment for Hepatitis C SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Zickmund, Susan L.; Youk, Ada O.; Switzer, Galen E.; Arnold, Robert A.] Univ Pittsburgh, Pittsburgh, PA USA. [Zickmund, Susan L.; Hanusa, Barbara H.; Youk, Ada O.; Switzer, Galen E.; Obrosky, David S.] VA Pittsburgh Healthcare Syst, Res, Pittsburgh, PA USA. [Chapko, Michael K.] VA Puget Sound Healthcare Syst, Res, Seattle, WA USA. [Bayliss, Nichole K.] Chatham Univ, Pittsburgh, PA USA. [Sevick, Mary Ann] NYU, New York, NY USA. [Zook, Carolyn L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1580 BP 959A EP 959A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483804143 ER PT J AU Zickmund, SL Chapko, MK Hanusa, BH Youk, AO Switzer, GE Sevick, MA Bayliss, NK Zook, CL Obrosky, DS Arnold, RA AF Zickmund, Susan L. Chapko, Michael K. Hanusa, Barbara H. Youk, Ada O. Switzer, Galen E. Sevick, Mary Ann Bayliss, Nichole K. Zook, Carolyn L. Obrosky, David S. Arnold, Robert A. TI Barriers to Initiating Treatment for Hepatitis C: Results of a Veteran Population SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Zickmund, Susan L.; Youk, Ada O.; Switzer, Galen E.; Arnold, Robert A.] Univ Pittsburgh, Pittsburgh, PA USA. [Zickmund, Susan L.; Hanusa, Barbara H.; Youk, Ada O.; Switzer, Galen E.; Obrosky, David S.] VA Pittsburgh Healthcare Syst, Res, Pittsburgh, PA USA. [Chapko, Michael K.] VA Puget Sound Healthcare Syst, Res, Seattle, WA USA. [Sevick, Mary Ann] NYU, New York, NY USA. [Bayliss, Nichole K.] Chatham Univ, Pittsburgh, PA USA. [Zook, Carolyn L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1586 BP 961A EP 962A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483804149 ER PT J AU Backus, LI Belperio, PS Loomis, TP Mole, LA AF Backus, Lisa I. Belperio, Pamela S. Loomis, Timothy P. Mole, Larry A. TI Hepatitis B Screening and Prevalence among High-Risk Populations within the Department of Veterans Affairs SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Backus, Lisa I.; Belperio, Pamela S.; Loomis, Timothy P.; Mole, Larry A.] Off Publ Hlth Populat Hlth, Dept Vet Affairs, Palo Alto, CA USA. [Backus, Lisa I.] Vet Affairs Palo Alto Healthcare Syst, Dept Med, Palo Alto, CA USA. [Belperio, Pamela S.] Vet Affairs Greater Los Angeles, Dept Pharm, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1611 BP 973A EP 973A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483804174 ER PT J AU Kushner, T Kaplan, DE AF Kushner, Tatyana Kaplan, David E. TI Delta Hepatitis Within the Veterans Affairs Medical System SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kushner, Tatyana; Kaplan, David E.] Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1612 BP 974A EP 974A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483804175 ER PT J AU Harwood, NM Golden-Mason, L Rosen, HR Mengshol, JA AF Harwood, Noah M. Golden-Mason, Lucy Rosen, Hugo R. Mengshol, John A. TI Full Length and Subgenomic HCV Infection, Endosomal TLR Stimulation, and Differentiation Increase Macrophage Immunoregulatory Galectin-9 SO HEPATOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases CY NOV 07-11, 2014 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Harwood, Noah M.; Golden-Mason, Lucy; Rosen, Hugo R.; Mengshol, John A.] Univ Colorado SOM, Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PY 2014 VL 60 SU 1 SI SI MA 1820 BP 1073A EP 1074A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA AS8EW UT WOS:000344483804382 ER PT J AU Shore, P Goranson, A Ward, MF Lu, MW AF Shore, Peter Goranson, Anders Ward, Mark F. Lu, Mary W. TI MEETING VETERANS WHERE THEY'RE @: A VA HOME-BASED TELEMENTAL HEALTH (HBTMH) PILOT PROGRAM SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE telemedicine; telehealth; videoconference; behavioral medicine; veterans AB Objectives: The first Home-Based Telemental pilot program (HBTMH) in the Department of Veterans Affairs addresses the significant challenge of access to mental health treatment for rural veterans. Though the feasibility of telemental healthcare in clinic-based settings has been well documented, the feasibility of telemental health via webcam and computer in a patient's home or other non-clinic settings is unknown. Methods: The HBTMH program, established in December 2009 at the Portland VA Medical Center, delivers a wide range of mental health services into the homes and other non-clinic settings of rural veterans via webcam, secure and encrypted software and veteran-owned personal computers. The program adhered to a Standard Operating Procedure (SOP) Manual, evaluated patients with the Assessment for Suitability for Home Based Telemental Health (ASH-25), utilized a Patient Support Person (PSP), and incorporated a peer technical consultant to provide assistance to veterans. The authors describe satisfaction and safety survey results from the initial 40 veterans enrolled. Results: Survey results support the feasibility and safety of using webcams, secure/encrypted software and veteran-owned personal computers for the delivery of mental health services into the home. Veterans report high levels of satisfaction and perceived safety with home-based telemental health. Results also suggest fewer no-show appointments in home-based telemental health compared to clinic-based telemental health. Conclusions: The authors discuss the strength and limitations of the program as well as potential areas of future research. C1 [Shore, Peter; Goranson, Anders; Ward, Mark F.; Lu, Mary W.] Portland VA Med Ctr, Portland, OR 97239 USA. [Shore, Peter; Goranson, Anders; Lu, Mary W.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Shore, P (reprint author), Portland VA Med Ctr, Dept Vet Affairs, 3710 SW US Vet Hosp Rd P3TELH, Portland, OR 97239 USA. EM shore@ohsu.edu FU Pacific Northwest Mental Illness Research and Education and Clinical Center (MIRECC) FX This work was partially supported by the Pacific Northwest Mental Illness Research and Education and Clinical Center (MIRECC). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 8 TC 4 Z9 4 U1 0 U2 3 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 EI 1541-3527 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2014 VL 48 IS 1 BP 5 EP 17 DI 10.2190/PM.48.1.b PG 13 WC Psychiatry SC Psychiatry GA AT3IZ UT WOS:000344830100002 PM 25354923 ER PT J AU Hernandez-Tejada, MA Zoller, JS Ruggiero, KJ Kazley, AS Acierno, R AF Hernandez-Tejada, Melba A. Zoller, James S. Ruggiero, Kenneth J. Kazley, Abby Swanson Acierno, Ron TI EARLY TREATMENT WITHDRAWAL FROM EVIDENCE-BASED PSYCHOTHERAPY FOR PTSD: TELEMEDICINE AND IN-PERSON PARAMETERS SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE attrition; telemedicine; psychotherapy; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE THERAPY; COGNITIVE-BEHAVIORAL THERAPY; EYE-MOVEMENT DESENSITIZATION; PROCESSING THERAPY; PSYCHOLOGICAL TREATMENTS; CONTROLLED-TRIAL; ASSAULT VICTIMS; RAPE VICTIMS; VETERANS AB Objective: To determine differences in reported barriers to treatment completion associated with telemedicine vs. in-person delivery of evidence-based treatment for PTSD in combat veterans. Method: The present study was derived from two ongoing randomized controlled trials (RCTs) comparing in-person vs. telemedicine delivery of exposure therapy for PTSD. A one-time telephone assessment of participants who dropped out from the treatment phase of these two studies was conducted, with measures focusing on reported reasons for dropout, and perceived comfort and efficacy of the treatment modality. Dichotomous data were analyzed via chi-square and logistic regression; continuous data via ANOVA. Results: Forty-seven of 69 total dropouts participated. There was no difference in rate of dropout between modalities. A greater proportion of participants receiving in-person exposure therapy reported difficulties with logistical aspects of care (e.g., parking), whereas a greater proportion of participants receiving telemedicine therapy reported difficulty tolerating certain stressful aspects of treatment; however, those receiving telemedicine delivered treatment completed more sessions before dropping out. Participants in both conditions reported that they liked and were confident in their therapist Conclusions: Dropout reasons varied according to type of treatment delivery. Recommendations for future research are given in terms of modification of treatment protocol according to delivery modality. C1 [Hernandez-Tejada, Melba A.; Zoller, James S.; Ruggiero, Kenneth J.; Kazley, Abby Swanson; Acierno, Ron] Med Univ S Carolina, Johns Isl, SC 29455 USA. [Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Hernandez-Tejada, MA (reprint author), Med Univ S Carolina, 2505 Watercrest Lane, Johns Isl, SC 29455 USA. EM hernanma@musc.edu FU Veterans Affairs Health Services Research and Development [NCT01102764]; Department of Defense [PT073980] FX This work was supported by a grant from Veterans Affairs Health Services Research and Development awarded to R. Acierno (NCT01102764) and a grant from the Department of Defense (PT073980). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, Department of Defense, or the United States government. There are no conflicts of interest to disclose. NR 56 TC 5 Z9 5 U1 1 U2 6 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 EI 1541-3527 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2014 VL 48 IS 1 BP 33 EP 55 DI 10.2190/PM.48.1.d PG 23 WC Psychiatry SC Psychiatry GA AT3IZ UT WOS:000344830100004 PM 25354925 ER PT J AU Davidson, TM Yuen, EK Felton, JW McCauley, J Gros, KS Ruggiero, KJ AF Davidson, Tatiana M. Yuen, Erica K. Felton, Julia W. McCauley, Jenna Gros, Kirstin Stauffacher Ruggiero, Kenneth J. TI FEASIBILITY ASSESSMENT OF A BRIEF, WEB-BASED BEHAVIORAL ACTIVATION INTERVENTION FOR ADOLESCENTS WITH DEPRESSED MOOD SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE behavioral activation; adolescents; depression; web-based intervention ID LONG-TERM OUTCOMES; DISORDER; TRIAL; ONSET AB Objective: Adolescent depression is a major public health concern. Efficacious interventions exist, but are underutilized. Novel approaches to improving access are therefore a top priority. Web-based approaches offer a viable treatment delivery solution; this approach may reach adolescents who might not otherwise receive formal treatment. Behavioral activation (BA) approaches have had success in treatment of depressive symptoms in youth. The purpose of this article is to: (1) describe the development process of a web-based, behavioral activation intervention for adolescents; (2) summarize the preliminary feasibility data; and (3) discuss the benefits and challenges associated with development and evaluation of adolescent self-help resources. Methods: The current study is part of a larger NIMH funded study focusing on the development and evaluation of Bounce Back Now (BBN), an evidence-informed, web resource for disaster-affected adolescents and their families. This study is specifically on the development of the BA component of the mood module of BBN, which was evaluated more extensively than other components. We present data from a formal usability evaluation conducted with 24 adolescents, and preliminary usage data collected from 2,000 disaster affected adolescents recruited from the tornado-affected coordinates in Alabama and Joplin, MO. Results: Preliminary data supported the feasibility of this approach: qualitative data with the clinic-based sample revealed favorable reactions to the intervention, and preliminary data from the large ongoing randomized controlled trial have indicated moderate levels of access. Conclusions: Brief, web-based approaches may offer a promising alternative to address access barriers for adolescents with depressed mood. C1 [Davidson, Tatiana M.; McCauley, Jenna; Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Yuen, Erica K.] Univ Tampa, Tampa, FL USA. [Felton, Julia W.] Univ Maryland, College Pk, MD 20742 USA. [Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Davidson, TM (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, 67 President St IOP 2 South,MSC 861, Charleston, SC 29425 USA. EM davidst@musc.edu FU NIMH [R01 MH081056, R01 MH081056-03S2] FX This research is supported by NIMH Grant R01 MH081056 (PI: Ruggiero). Dr. Davidson is supported by NIMH Diversity Supplement Grant (R01 MH081056-03S2). Views expressed in this article do not necessarily reflect those of the VA or of the funding agencies acknowledged. NR 30 TC 3 Z9 3 U1 0 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0091-2174 EI 1541-3527 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2014 VL 48 IS 1 BP 69 EP 82 DI 10.2190/PM.48.1.f PG 14 WC Psychiatry SC Psychiatry GA AT3IZ UT WOS:000344830100006 PM 25354927 ER PT J AU Thomas, FP Goetz, LL Dixon, T Ho, C Holmes, SA Sandford, P Smith, S Ottomanelli, L AF Thomas, Florian P. Goetz, Lance L. Dixon, Thomas Ho, Chester Holmes, Sally Ann Sandford, Paul Smith, Sheila Ottomanelli, Lisa TI OPTIMIZING MEDICAL CARE TO FACILITATE AND SUSTAIN EMPLOYMENT AFTER SPINAL CORD INJURY SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material ID TRAUMATIC BRAIN-INJURY; SUPPORTED EMPLOYMENT; PRESSURE ULCERS; CHRONIC PAIN; NEUROGENIC BOWEL; RISK-FACTORS; VETERANS; WORK; RETURN; MANAGEMENT C1 [Thomas, Florian P.] St Louis Univ, Dept Neurol & Psychiat, St Louis, MO 63103 USA. [Goetz, Lance L.] Hunter Holmes McGuire Dept Vet Affairs VA Med Ctr, Spinal Cord Injury Ctr, Richmond, VA USA. [Goetz, Lance L.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA. [Dixon, Thomas] Louis Stokes Cleveland VA Med Ctr, Psychol Serv, Cleveland, OH USA. [Ho, Chester] Univ Calgary, Dept Clin Neurosci, Div Phys Med & Rehabil, Calgary, AB, Canada. [Holmes, Sally Ann] VA Med Ctr, Spinal Cord Injury Ctr, Houston, TX USA. [Holmes, Sally Ann] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Sandford, Paul] Clement J Zablocki VA Med Ctr, Milwaukee, WI USA. [Sandford, Paul] Med Coll Wisconsin, Dept Phys Med & Rehabil, Milwaukee, WI 53226 USA. [Smith, Sheila] Louis Stokes VA Med Ctr, Spinal Cord Injury Ctr, Cleveland, OH USA. [Ottomanelli, Lisa] James A Haley Vet Affairs Hosp, Ctr Innovat Disabil & Rehabil Res, Tampa, FL USA. [Ottomanelli, Lisa] Univ S Florida, Dept Rehabil & Mental Hlth Counseling, Tampa, FL USA. RP Thomas, FP (reprint author), St Louis Univ, Dept Neurol & Psychiat, St Louis, MO 63103 USA. EM thomasfp@slu.edu NR 69 TC 1 Z9 1 U1 2 U2 5 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2014 VL 51 IS 6 BP XI EP XXI DI 10.1682/JRRD.2014.05.0119 PG 11 WC Rehabilitation SC Rehabilitation GA AT0OT UT WOS:000344635900003 PM 25479192 ER PT J AU Littman, AJ Boyko, EJ Thompson, ML Haselkorn, JK Sangeorzan, BJ Arterburn, DE AF Littman, Alyson J. Boyko, Edward J. Thompson, Mary Lou Haselkorn, Jodie K. Sangeorzan, Bruce J. Arterburn, David E. TI Physical activity barriers and enablers in older Veterans with lower-limb amputation SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE activity scale; amputee intervention; barriers; exercise; facilitators; lower-limb amputation; partial foot amputation; physical activity; trauma-related amputation; Veterans ID PATIENT-REPORTED OUTCOMES; INFORMATION-SYSTEM PROMIS; QUALITY-OF-LIFE; LOWER-EXTREMITY AMPUTEES; UNITED-STATES; ENERGY-EXPENDITURE; RECREATIONAL ACTIVITIES; ACTIVITY QUESTIONNAIRE; SEDENTARY BEHAVIOR; HEALTH-PROMOTION AB Little is known about the types of physical activities that older individuals with lower-limb loss perform, correlates of regular physical activity (PA), and barriers and facilitators to PA. We conducted an exploratory study in 158 older Veterans from the Pacific Northwest with a partial foot (35%), below-knee (39%), and above-knee (26%) amputation. Ninety-eight percent of survey respondents were male, on average 65 yr of age and 15 yr postamputation; 36% of amputations were trauma-related. The most commonly reported physical activities were walking/wheeling (65%), muscle strengthening (42%), exercise prescribed by a physical or occupational therapist (32%), and gardening (31%). Forty-three percent were classified as physically active based on weekly moderate-and vigorous-intensity PA. History of vigorous preamputation PA was positively associated with being active, while low wealth and watching 5 h/d or more of television/videos were inversely associated. While pain-and resource-related barriers to PA were most frequently reported, only knowledge-related and interest/motivation-related barriers were inversely associated with being active. Family support and financial assistance to join a gym were the most commonly reported factors that would facilitate PA. To increase PA in the older amputee population, interventions should address motivational issues, knowledge gaps, and television watching; reduce financial barriers to exercising; and consider involving family members. C1 [Littman, Alyson J.; Boyko, Edward J.; Thompson, Mary Lou] Seattle Epidemiol Res & Informat Ctr, Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. [Littman, Alyson J.; Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Thompson, Mary Lou] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Haselkorn, Jodie K.] VA Puget Sound Hlth Care Syst, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. [Haselkorn, Jodie K.] Univ Washington, Dept Rehabil, Seattle, WA 98195 USA. [Sangeorzan, Bruce J.] VA Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA USA. [Sangeorzan, Bruce J.] Univ Washington, Med Ctr, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Sangeorzan, Bruce J.] Univ Washington, Harborview Med Ctr, Dept Orthopaed & Sports Med, Seattle, WA 98104 USA. [Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA. RP Littman, AJ (reprint author), Seattle Epidemiol Res & Informat Ctr, VA Affairs Puget Sound Med Ctr, 1100 Olive Way,Metropolitan Pk West,Suite 1400, Seattle, WA 98101 USA. EM alyson.littman@va.gov OI Boyko, Edward/0000-0002-3695-192X FU VA Office of Research and Development Cooperative Studies Program; Seattle Epidemiologic Research and Information Center of the VA; VA Rehabilitation Research and Development Career Development Award [6982] FX This material was based on work supported in part by the VA Office of Research and Development Cooperative Studies Program. The Seattle Epidemiologic Research and Information Center of the VA provided support for this research. Dr. Littman's time was also supported by a VA Rehabilitation Research and Development Career Development Award (#6982). NR 53 TC 3 Z9 3 U1 2 U2 8 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2014 VL 51 IS 6 BP 895 EP 906 DI 10.1682/JRRD.2013.06.0152 PG 12 WC Rehabilitation SC Rehabilitation GA AT0OT UT WOS:000344635900008 PM 25356624 ER PT J AU Mahajan, HP Spaeth, DM Dicianno, BE Brown, K Cooper, RA AF Mahajan, Harshal P. Spaeth, Donald M. Dicianno, Brad E. Brown, Karl Cooper, Rory A. TI Preliminary evaluation of a variable compliance joystick for people with multiple sclerosis SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE fatigue; joystick; MS; multiple sclerosis; outcome measures; tremor filter; variable compliance joystick; virtual reality; wheelchair; wheelchair driving ID WHEELCHAIR DRIVING PERFORMANCE; TRAUMATIC BRAIN-INJURY; ASSISTIVE TECHNOLOGY; POWERED WHEELCHAIR; TREMOR; INDIVIDUALS; SIMULATOR; MOBILITY; FATIGUE; DISABILITIES AB Upper-limb fatigue is a common problem that may restrict people with multiple sclerosis (MS) from using their electric powered wheelchair effectively and for a long period of time. The objective of this research is to evaluate whether participants with MS can drive better with a variable compliance joystick (VCJ) and customizable algorithms than with a conventional wheelchair joystick. Eleven participants were randomly assigned to one of two groups. The groups used the VCJ in either compliant or noncompliant isometric mode and a standard algorithm, personally fitted algorithm, or personally fitted algorithm with fatigue adaptation running in the background in order to complete virtual wheelchair driving tasks. Participants with MS showed better driving performance metrics while using the customized algorithms than while using the standard algorithm with the VCJ. Fatigue adaptation algorithms are especially beneficial in improving overall task performance while using the VCJ in isometric mode. The VCJ, along with the personally fitted algorithms and fatigue adaptation algorithms, has the potential to be an effective input interface for wheelchairs. C1 [Mahajan, Harshal P.; Spaeth, Donald M.; Dicianno, Brad E.; Brown, Karl; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Dept Vet Affairs VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. [Mahajan, Harshal P.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu FU Department of Veteran Affairs (VA) Research and Development Office [B3287R] FX This material was based on work supported by the Department of Veteran Affairs (VA) Research and Development Office (grant B3287R) and with the resources and facilities of HERL, VA Pittsburgh Healthcare System. NR 46 TC 3 Z9 3 U1 4 U2 6 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2014 VL 51 IS 6 BP 951 EP 961 DI 10.1682/JRRD.2013.01.0023 PG 11 WC Rehabilitation SC Rehabilitation GA AT0OT UT WOS:000344635900012 PM 25356558 ER PT J AU Levine, BS Rodriguez, M Felsenfeld, AJ AF Levine, Barton S. Rodriguez, Mariano Felsenfeld, Arnold J. TI Serum calcium and bone: effect of PTH, phosphate, vitamin D and uremia SO NEFROLOGIA LA English DT Review DE Bone; Calcium; Parathyroid hormone; Phosphate; Uremia; Vitamin D ID CHRONIC KIDNEY-DISEASE; PARATHYROID-HORMONE; D INTOXICATION; RENAL-FAILURE; HEMODIALYSIS-PATIENTS; SKELETAL RESISTANCE; DIETARY PHOSPHORUS; CALCEMIC RESPONSE; SECONDARY HYPERPARATHYROIDISM; D DEFICIENCY AB Hyperparathyroidism develops in chronic kidney disease (CKD). A decreased calcemic response to parathyroid hormone (PTH) contributes to the development of hyperparathyroidism and is presumed due to reduced calcium efflux from bone. Contributing factors to the decreased calcemic response to PTH in CKD include: 1) hyperphosphatemia; 2) decreased serum calcitriol; 3) downregulation of the PTH1 receptor; 4) large, truncated amino-terminal PTH fragments acting at the carboxy-PTH receptor; and 5) uremic toxins. Also, prolonged high dose calcitriol administration may decrease the exchangeable pool of bone calcium independent of PTH. The goal of the review is to provide a better understanding of how the above cited factors affect calcium efflux from bone in CKD. In conclusion, much remains to be learned about the role of bone in the regulation of serum calcium. C1 [Levine, Barton S.; Felsenfeld, Arnold J.] Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Levine, Barton S.; Felsenfeld, Arnold J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rodriguez, Mariano] Hosp Univ Reina Sofia, IMIBIC, Dept Nephrol, Red Ren, Cordoba, Spain. RP Felsenfeld, AJ (reprint author), Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. EM Arnold.Felsenfeld@va.gov FU Instituto Carlos III [FIS 07/0287, FIS 07/0315, 010/1311]; Consejeria de Salud [JA 0127/2008]; UE [FP7-241544]; Consejeria de Innovacion, Ciencia y Empresa of Junta de Andalucia [CTS-5205, CTS-170] FX M.R. has received grant support from the Instituto Carlos III (FIS 07/0287, FIS 07/0315, 010/1311), Consejeria de Salud (JA 0127/2008), a UE Grant from Framework Programme 7 Syskid (FP7-241544), and Consejeria de Innovacion, Ciencia y Empresa (CTS-5205 and CTS-170) of Junta de Andalucia. NR 88 TC 3 Z9 3 U1 3 U2 8 PU SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ PI MADRID PA HOSPITAL RAMON Y CAJAL CTR DE COLMENAR, KM 9,100, 28034 MADRID, SPAIN SN 0211-6995 EI 1989-2284 J9 NEFROLOGIA JI Nefrologia PY 2014 VL 34 IS 5 BP 658 EP 669 DI 10.3265/Nefrologia.pre2014.Jun.12379 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA AS1FR UT WOS:000344025900017 PM 25259820 ER PT S AU Allum, WH Bonavina, L Cassivi, SD Cuesta, MA Dong, ZM Felix, VN Figueredo, E Gatenby, PAC Haverkamp, L Ibraev, MA Krasna, MJ Lambert, R Langer, R Lewis, MPN Nason, KS Parry, K Preston, SR Ruurda, JP Schaheen, LW Tatum, RP Turkin, IN van der Horst, S van der Peet, DL van der Sluis, PC van Hillegersberg, R Wormald, JCR Wu, PC AF Allum, William H. Bonavina, Luigi Cassivi, Stephen D. Cuesta, Miguel A. Dong, Zhao Ming Nilton Felix, Valter Figueredo, Edgar Gatenby, Piers A. C. Haverkamp, Leonie Ibraev, Maksat A. Krasna, Mark J. Lambert, Rene Langer, Rupert Lewis, Michael P. N. Nason, Katie S. Parry, Kevin Preston, Shaun R. Ruurda, Jelle P. Schaheen, Lara W. Tatum, Roger P. Turkin, Igor N. van der Horst, Sylvia van der Peet, Donald L. van der Sluis, Peter C. van Hillegersberg, Richard Wormald, Justin C. R. Wu, Peter C. BE Giuli, R Umar, A TI Surgical treatments for esophageal cancers SO 12TH OESO WORLD CONFERENCE: CANCERS OF THE ESOPHAGUS SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 12th OESO World Conference - Cancers of the Esophagus CY AUG, 2013 CL UNESCO, Paris, FRANCE SP World Hlth Org, Int Agcy Res Canc, Natl Canc Inst HO UNESCO DE esophageal resection; Nissen fundoplication; esophagogastrostomy; esophagectomy; chemoradiotherapy; OESO ID QUALITY-OF-LIFE; CIRCUMFERENTIAL RESECTION MARGIN; RANDOMIZED CONTROLLED-TRIAL; SQUAMOUS-CELL CARCINOMA; CHYLOTHORAX COMPLICATING ESOPHAGECTOMY; LONG-TERM SURVIVAL; EXTENDED TRANSTHORACIC RESECTION; MINIMALLY INVASIVE ESOPHAGECTOMY; LAPAROSCOPIC ANTIREFLUX SURGERY; BARRETTS-ESOPHAGUS AB The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the role of the nurse in preparation of esophageal resection ( ER); the management of patients who develop high-grade dysplasia after having undergone Nissen fundoplication; the trajectory of care for the patient with esophageal cancer; the influence of the site of tumor in the choice of treatment; the best location for esophagogastrostomy; management of chylous leak after esophagectomy; the optimal approach to manage thoracic esophageal leak after esophagectomy; the choice for operational approach in surgery of cardioesophageal crossing; the advantages of robot esophagectomy; the place of open esophagectomy; the advantages of esophagectomy compared to definitive chemoradiotherapy; the pathologist report in the resected specimen; the best way to manage patients with unsuspected positive microscopic margin after ER; enhanced recovery after surgery for ER: expedited care protocols;and long-term quality of life in patients following esophagectomy. C1 [Allum, William H.; Gatenby, Piers A. C.] UCL, Div Surg & Intervent Sci, London, England. [Bonavina, Luigi] Univ Milan, Sch Med, Div Gen Surg, Dept Biomed Sci Hlth, Milan, Italy. [Cassivi, Stephen D.] Mayo Clin, Dept Surg, Rochester, MN USA. [Cuesta, Miguel A.; van der Peet, Donald L.] Vrije Univ Amsterdam Med Ctr, Dept Surg, Amsterdam, Netherlands. [Dong, Zhao Ming] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Nilton Felix, Valter] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil. [Figueredo, Edgar; Tatum, Roger P.; Wu, Peter C.] VA Puget Sound, Dept Surg, Seattle, WA USA. [Figueredo, Edgar; Tatum, Roger P.; Wu, Peter C.] Univ Washington, Seattle, WA 98195 USA. [Gatenby, Piers A. C.; Preston, Shaun R.] Royal Surrey Cty Hosp, Guildford, Surrey, England. [Gatenby, Piers A. C.] Royal Marsden Hosp, Acad Dept Surg, London SW3 6JJ, England. [Haverkamp, Leonie; Parry, Kevin; Ruurda, Jelle P.; van der Horst, Sylvia; van der Sluis, Peter C.; van Hillegersberg, Richard] Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands. [Ibraev, Maksat A.; Turkin, Igor N.] RAMS, NN Blokhin Russian Canc Res Ctr, Moscow, Russia. [Krasna, Mark J.] Jersey Shore Univ, Med Ctr, Dept Oncol, Neptune, NJ USA. [Lambert, Rene] Int Agcy Res Canc, WHO, Screening Grp, F-69372 Lyon, France. [Langer, Rupert] Univ Bern, Inst Pathol, Bern, Switzerland. [Lewis, Michael P. N.; Wormald, Justin C. R.] Dept Gen Surg, Norfolk, VA USA. [Lewis, Michael P. N.; Wormald, Justin C. R.] Norwich Univ Hosp, Norwich, Norfolk, England. [Nason, Katie S.; Schaheen, Lara W.] Univ Pittsburgh, Dept Cardiothorac Surg, Pittsburgh, PA USA. RP Allum, WH (reprint author), UCL, Div Surg & Intervent Sci, London, England. EM annals@nyas.org RI Gatenby, Piers/C-1696-2008 OI Gatenby, Piers/0000-0002-1361-9940; Wormald, Justin/0000-0001-6197-4093; Bonavina, Luigi/0000-0002-4880-1670 FU NCI NIH HHS [K07 CA151613]; World Health Organization [001] NR 124 TC 6 Z9 6 U1 0 U2 3 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2014 VL 1325 BP 242 EP 268 DI 10.1111/nyas.12533 PG 27 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA BB5DU UT WOS:000343712700022 PM 25266029 ER PT J AU Al Hazzouri, AZ Yaffe, K AF Al Hazzouri, Adina Zeki Yaffe, Kristine TI Arterial Stiffness and Cognitive Function in the Elderly SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Aging; arterial stiffness; cognitive decline; dementia; epidemiology ID PULSE-WAVE VELOCITY; HEART-RATE-VARIABILITY; ALL-CAUSE MORTALITY; BLOOD-PRESSURE; OLDER-ADULTS; ESSENTIAL-HYPERTENSION; CARDIOVASCULAR EVENTS; INDEPENDENT PREDICTOR; AORTIC STIFFNESS; CALCIUM SCORE AB Cognitive decline and dementia are a major cause of disability and mortality among older adults. Cross-sectional evidence from observational studies suggests that greater arterial stiffness is associated with worse cognitive performance. These associations have been observed on measures of global cognition and across multiple domains of cognition. Epidemiologic evidence on the association between arterial stiffness and rate of cognitive decline has been less definitive, and very few studies have investigated the risk of developing dementia. This review summarizes the current research on arterial stiffness and cognition, issues around measurement, and the effect that potential intervention might have on the course of cognitive aging. The evidence on pharmacological and non-pharmacological (exercise, nutrition, etc.) interventions in older adults with arterial stiffness is promising. Yet there are no studies or trials that directly evaluate how interventions of arterial stiffness reduce or prevent cognitive impairment and risk of developing dementia. More research is needed to elucidate the causal link between arterial stiffness and cognitive decline and dementia, and to identify whether potential interventions to prevent or reduce arterial stiffness may benefit cognitive health of the elderly. C1 [Al Hazzouri, Adina Zeki] Univ Miami, Dept Publ Hlth Sci, Div Epidemiol & Populat Hlth, Miami, FL 33136 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Al Hazzouri, AZ (reprint author), Univ Miami, Dept Publ Hlth Sci, Div Epidemiol & Populat Hlth, 1120 NW 14th St,9th Floor, Miami, FL 33136 USA. EM axz122@miami.edu FU NIH, National Institute on Aging [K01AG047273]; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [KL2TR000143] FX Dr. Zeki Al Hazzouri was supported by a grant from the NIH, National Institute on Aging (K01AG047273) and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number KL2TR000143. NR 65 TC 8 Z9 8 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 42 SU 4 BP S503 EP S514 DI 10.3233/JAD-141563 PG 12 WC Neurosciences SC Neurosciences & Neurology GA AR9KQ UT WOS:000343893000019 ER PT S AU Gorelick, DA Zangen, A George, MS AF Gorelick, David A. Zangen, Abraham George, Mark S. BE Uhl, GR TI Transcranial magnetic stimulation in the treatment of substance addiction SO ADDICTION REVIEWS SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE addiction; substance use disorder; TMS; transcranial magnetic stimulation; treatment ID DORSOLATERAL PREFRONTAL CORTEX; COCAINE-DEPENDENT PATIENTS; TREATMENT-RESISTANT DEPRESSION; SHAM-CONTROLLED TRIALS; HF-RTMS SESSION; BRAIN-STIMULATION; MAJOR DEPRESSION; CORTICAL EXCITABILITY; DOPAMINE RELEASE; MOTOR CORTEX AB Transcranial magnetic stimulation (TMS) is a noninvasive method of brain stimulation used to treat a variety of neuropsychiatric disorders, but is still in the early stages of study as addiction treatment. We identified 19 human studies using repetitive TMS (rTMS) to manipulate drug craving or use, which exposed a total of 316 adults to active rTMS. Nine studies involved tobacco, six alcohol, three cocaine, and one methamphetamine. The majority of studies targeted high-frequency (5-20 Hz; expected to stimulate neuronal activity) rTMS pulses to the dorsolateral prefrontal cortex. Only five studies were controlled clinical trials: two of four nicotine trials found decreased cigarette smoking; the cocaine trial found decreased cocaine use. Many aspects of optimal treatment remain unknown, including rTMS parameters, duration of treatment, relationship to cue-induced craving, and concomitant treatment. The mechanisms of rTMS potential therapeutic action in treating addictions are poorly understood, but may involve increased dopamine and glutamate function in corticomesolimbic brain circuits and modulation of neural activity in brain circuits that mediate cognitive processes relevant to addiction, such as response inhibition, selective attention, and reactivity to drug-associated cues. rTMS treatment of addiction must be considered experimental at this time, but appears to have a promising future. C1 [Gorelick, David A.] NIDA, Chem & Drug Metab Sect, Intramural Res Program, NIH, Baltimore, MD USA. [Gorelick, David A.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. [Zangen, Abraham] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel. [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Gorelick, DA (reprint author), Univ Maryland, Maryland Psychiat Res Ctr, Tawes Bldg,POB 21247, Baltimore, MD 21228 USA. EM dgorelick@mprc.umaryland.edu FU Intramural NIH HHS [Z99 DA999999] NR 107 TC 26 Z9 27 U1 4 U2 16 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2014 VL 1327 BP 79 EP 93 DI 10.1111/nyas.12479 D2 10.1111/nyas.12571 PG 15 WC Substance Abuse SC Substance Abuse GA BB5KA UT WOS:000343916500006 PM 25069523 ER PT J AU Lin, YS Boninger, M Worobey, L Farrokhi, S Koontz, A AF Lin, Yen-Sheng Boninger, Michael Worobey, Lynn Farrokhi, Shawn Koontz, Alicia TI Effects of Repetitive Shoulder Activity on the Subacromial Space in Manual Wheelchair Users SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID SPINAL-CORD-INJURY; PAIN INDEX WUSPI; ADULT OMNI SCALE; IMPINGEMENT SYNDROME; ROTATOR CUFF; GLENOHUMERAL KINEMATICS; PERCEIVED EXERTION; EXTERNAL ROTATION; ELECTROMYOGRAPHIC ANALYSIS; SCAPULAR KINEMATICS AB This study investigated (1) the effect of repetitive weight-relief raises (WR) and shoulder external rotation (ER) on the acromiohumeral distance (AHD) among manual wheelchair users (MWUs) and (2) the relationship between shoulder pain, subject characteristics, and AHD changes. Twenty-three MWUs underwent ultrasound imaging of the nondominant shoulder in an unloaded baseline position and while holding a WR position before and after the WR/ER tasks. Paired t-tests and Spearman correlational analysis were used to assess differences in the AHD before and after each task and the relationships between pain, subject characteristics, and the AHD measures. A significant reduction in the subacromial space (P < 0.01) occurred when subjects performed a WR position compared to baseline. Individuals with increased years of disability had greater AHD percentage narrowing after WR (P = 0.008). Increased shoulder pain was associated with AHD percentage narrowing after ER (P <= 0.007). The results support clinical practice guidelines that recommend MWUs limit WR to preserve shoulder function. The isolated repetitive shoulder activity did not contribute to the changes of subacromial space in MWUs. The ultrasonographic measurement of the AHD may be a target for identifying future interventions that prevent pain. C1 [Lin, Yen-Sheng; Boninger, Michael; Worobey, Lynn; Farrokhi, Shawn; Koontz, Alicia] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Lin, Yen-Sheng; Boninger, Michael; Koontz, Alicia] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Boninger, Michael; Farrokhi, Shawn; Koontz, Alicia] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA. [Boninger, Michael; Worobey, Lynn] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. [Farrokhi, Shawn] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA 15260 USA. RP Koontz, A (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu OI Worobey, Lynn/0000-0001-8795-6061; Boninger, Michael/0000-0001-6966-919X FU Department of Veterans Affairs Rehabilitation Research and Development Service [B6789C]; Paralyzed Veterans of America; US Department of Education [H133N110011] FX This material is based upon work supported by the Department of Veterans Affairs Rehabilitation Research and Development Service (Grant no. B6789C), the Paralyzed Veterans of America, and US Department of Education (Grant no. H133N110011). This material is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, VA Pittsburgh Healthcare System. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. An extended abstract was presented in student scientific paper winner session of 2012 Rehabilitation Engineering and Assistive Technology Society in North America annual conference. NR 50 TC 0 Z9 0 U1 6 U2 11 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2014 AR 583951 DI 10.1155/2014/583951 PG 9 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA AQ6RI UT WOS:000342941100001 ER PT J AU Leutwyler, H Hubbard, E Jeste, D Miller, B Vinogradov, S AF Leutwyler, H. Hubbard, E. Jeste, D. Miller, B. Vinogradov, S. TI Association between schizophrenia symptoms and neurocognition on mobility in older adults with schizophrenia SO AGING & MENTAL HEALTH LA English DT Article DE schizophrenia and paranoid disorders; functional status; cognitive functioning ID CONSENSUS COGNITIVE BATTERY; MEDICAL COMORBIDITY; PHYSICAL-ACTIVITY; MENTAL-ILLNESS; CARDIOVASCULAR RISK; PROCESSING SPEED; EXCESS MORTALITY; HEALTH; GAIT; CARE AB Objectives: Older persons with schizophrenia develop problems associated with aging, such as poor mobility, at more rapid rates than people without serious mental illness. Decrements in mobility contribute to poor health outcomes. Impaired neurocognitive function and psychiatric symptoms are central aspects of schizophrenia. The purpose of this study was to determine the association between neurocognitive impairment and schizophrenia symptoms to mobility in older adults with schizophrenia. Methods: A cross-sectional study with 46 older adults with schizophrenia. Participants were assessed on neurocognitive function (MATRICS Consensus Cognitive Battery), psychiatric symptoms (Positive and Negative Syndrome Scale or PANSS), and mobility (Timed Get Up and Go or TGUG test). Pearson's bivariate correlations (two-tailed) and a simultaneous regression model were used. Results: Lower severity of negative symptoms and faster speed of processing tests were associated with faster TGUG time in bivariate correlations and multivariate regression analyses (p<.05). Conclusion: Our data suggest that lower negative symptoms and faster speed of processing positively impact mobility in older patients with schizophrenia. Mobility interventions for this population need to target neurocognitive impairment and schizophrenia symptoms for optimal results. C1 [Leutwyler, H.; Hubbard, E.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94107 USA. [Jeste, D.] Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, San Diego, CA 92103 USA. [Miller, B.] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA USA. [Vinogradov, S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Vinogradov, S.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Leutwyler, H (reprint author), Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94107 USA. EM heather.leutwyler@nursing.ucsf.edu FU UCSF Academic Senate; National Center for Advancing Translational Sciences, National Institutes of Health through UCSF-CTSI [KL2TR000143]; National Institute of Nursing Research [P30-NR011934-0] FX This work was supported by the UCSF Academic Senate [Individual Investigator Grant]; National Center for Advancing Translational Sciences, National Institutes of Health through UCSF-CTSI [grant number KL2TR000143]; and the National Institute of Nursing Research [grant number P30-NR011934-0] to H. Leutwyler. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. NR 51 TC 0 Z9 0 U1 4 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 EI 1364-6915 J9 AGING MENT HEALTH JI Aging Ment. Health PY 2014 VL 18 IS 8 BP 1006 EP 1012 DI 10.1080/13607863.2014.903467 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AP7XP UT WOS:000342291900008 PM 24697281 ER PT J AU Kalapatapu, RK Neylan, TC Regan, MC Cohen, BE AF Kalapatapu, Raj K. Neylan, Thomas C. Regan, Mathilda C. Cohen, Beth E. TI ASSOCIATION OF ALCOHOL USE BIOMARKERS AND COGNITIVE PERFORMANCE IN VETERANS WITH PROBLEMATIC ALCOHOL USE AND POSTTRAUMATIC STRESS DISORDER: DATA FROM THE MIND YOUR HEART STUDY SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article DE Alcohol use biomarkers; cognitive performance; problematic alcohol use; posttraumatic stress disorder ID SUBSTANCE-ABUSE TREATMENT; PSYCHOMETRIC PROPERTIES; TREATMENT ENTRY; PTSD CHECKLIST; NORMATIVE DATA; IMPAIRMENT; DEPRESSION; DRINKING; MEMORY; RELIABILITY AB The authors conducted a study of alcohol use biomarkers and cognitive performance among 85 veterans with problematic alcohol use and posttraumatic stress disorder (PTSD). All analyses were adjusted for demographics, depression, anxiety, and PTSD symptoms. Elevated levels of aspartate aminotransferase were associated with worse performance on the Trail Making Test Part A and Hopkins Verbal Learning Test. Two other biomarkers were not associated with any neurocognitive measures. Indirect alcohol use biomarkers (e.g., aspartate aminotransferase) may have a specific role in identifying veterans with problematic alcohol use and PTSD who show a change in psychomotor speed and immediate verbal memory performance. C1 [Kalapatapu, Raj K.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kalapatapu, Raj K.; Neylan, Thomas C.; Regan, Mathilda C.; Cohen, Beth E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Neylan, Thomas C.; Cohen, Beth E.] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Kalapatapu, RK (reprint author), San Francisco VA Med Ctr, Dept Psychiat, Opioid Replacement Treatment Clin, 4150 Clement St,Mailstop 116F,Bldg 1, San Francisco, CA 94121 USA. EM kalapatapu.raj.k@gmail.com FU NHLBI NIH HHS [K23HL094765, K23 HL094765]; NIDA NIH HHS [K23 DA034883, K23DA034883]; NIMH NIH HHS [5R01MH073978-04, R01 MH073978, R34 MH077667] NR 53 TC 1 Z9 1 U1 3 U2 14 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1055-0887 EI 1545-0848 J9 J ADDICT DIS JI J. Addict. Dis. PY 2014 VL 33 IS 2 BP 67 EP 76 DI 10.1080/10550887.2014.909701 PG 10 WC Substance Abuse SC Substance Abuse GA AP7XU UT WOS:000342292500001 PM 24717141 ER PT J AU Broyles, LM Binswanger, IA Jenkins, JA Finnell, DS Faseru, B Cavaiola, A Pugatch, M Gordon, AJ AF Broyles, Lauren M. Binswanger, Ingrid A. Jenkins, Jennifer A. Finnell, Deborah S. Faseru, Babalola Cavaiola, Alan Pugatch, Marianne Gordon, Adam J. TI Confronting Inadvertent Stigma and Pejorative Language in Addiction Scholarship: A Recognition and Response SO SUBSTANCE ABUSE LA English DT Editorial Material DE Criminal justice; language; mental disorders; publishing; social stigma; substance-related disorders AB Appropriate use of language in the field of addiction is important. Inappropriate use of language can negatively impact the way society perceives substance use and the people who are affected by it. Language frames what the public thinks about substance use and recovery, and it can also affect how individuals think about themselves and their own ability to change. But most importantly, language intentionally and unintentionally propagates stigma: the mark of dishonor, disgrace, and difference that depersonalizes people, depriving them of individual or personal qualities and personal identity. Stigma is harmful, distressing, and marginalizing to the individuals, groups, and populations who bear it. For these reasons, the Editorial Team of Substance Abuse seeks to formally operationalize respect for personhood in our mission, our public relations, and our instructions to authors. We ask authors, reviewers, and readers to carefully and intentionally consider the language used to describe alcohol and other drug use and disorders, the individuals affected by these conditions, and their related behaviors, comorbidities, treatment, and recovery in our publication. Specifically, we make an appeal for the use of language that (1) respects the worth and dignity of all persons ("people-first language"); (2) focuses on the medical nature of substance use disorders and treatment; (3) promotes the recovery process; and (4) avoids perpetuating negative stereotypes and biases through the use of slang and idioms. In this paper, we provide a brief overview of each of the above principles, along with examples, as well as some of the nuances and tensions that inherently arise as we give greater attention to the issue of how we talk and write about substance use and addiction. C1 [Broyles, Lauren M.; Jenkins, Jennifer A.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. [Broyles, Lauren M.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15240 USA. [Broyles, Lauren M.; Gordon, Adam J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Binswanger, Ingrid A.] Univ Colorado, Div Gen Internal Med, Sch Med, Aurora, CO USA. [Binswanger, Ingrid A.] Univ Colorado, Div Subst Dependence, Sch Med, Aurora, CO USA. [Binswanger, Ingrid A.] Denver Hlth Med Ctr, Community Hlth Serv, Denver, CO USA. [Finnell, Deborah S.] Johns Hopkins Univ, Sch Nursing, Acute & Chron Care Dept, Baltimore, MD USA. [Faseru, Babalola] Univ Kansas, Med Ctr, Dept Prevent Med & Publ Hlth, Kansas City, KS 66103 USA. [Faseru, Babalola] Univ Kansas, Med Ctr, Dept Family Med, Kansas City, KS 66103 USA. [Faseru, Babalola] Bur Hlth Promot, Kansas Dept Hlth & Environm, Topeka, KS USA. [Cavaiola, Alan] Monmouth Univ, West Long Branch, NJ USA. [Pugatch, Marianne] Boston Childrens Hosp, Adolescent Subst Abuse Program, Boston, MA USA. [Pugatch, Marianne] Boston Childrens Hosp, Ctr Subst Abuse Res, Boston, MA USA. [Pugatch, Marianne] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Pugatch, Marianne] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, CHERP, Univ Dr C 151C, Pittsburgh, PA 15240 USA. EM Lauren.Broyles@va.gov RI Faseru, Babalola/N-6514-2014 OI Faseru, Babalola/0000-0003-3805-1850; Binswanger, Ingrid/0000-0001-8862-8078 FU NIAAA NIH HHS [T32 AA007567] NR 24 TC 21 Z9 21 U1 1 U2 15 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2014 VL 35 IS 3 BP 217 EP 221 DI 10.1080/08897077.2014.930372 PG 5 WC Substance Abuse SC Substance Abuse GA AP7VA UT WOS:000342284200001 PM 24911031 ER PT J AU Gordon, AJ Galanter, M Khalsa, JH AF Gordon, Adam J. Galanter, Marc Khalsa, Jag H. TI Addressing Addiction Across Borders: An International Perspective on Policies, Scholarship, and Collaboration SO SUBSTANCE ABUSE LA English DT Editorial Material ID SUBSTANCE-ABUSE PREVENTION; SECONDARY-SCHOOL; STUDENTS; KHAT C1 [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Galanter, Marc] NYU, Sch Med, Div Alcoholism & Drug Abuse, New York, NY USA. [Khalsa, Jag H.] NIDA, Med Consequences Branch, Div Pharmacotherapies & Med Consequences Drug Abu, NIH, Bethesda, MD 20892 USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C,Bldg 30, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 18 TC 1 Z9 1 U1 1 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2014 VL 35 IS 3 BP 290 EP 291 DI 10.1080/08897077.2014.929906 PG 2 WC Substance Abuse SC Substance Abuse GA AP7VA UT WOS:000342284200012 PM 24892635 ER PT J AU Horner, MD VanKirk, KK Dismuke, CE Turner, TH Muzzy, W AF Horner, Michael David VanKirk, Kathryn K. Dismuke, Clara E. Turner, Travis H. Muzzy, Wendy TI Inadequate Effort on Neuropsychological Evaluation is Associated With Increased Healthcare Utilization SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Health care utilization; Neuropsychological assessment; Clinical neuropsychology; Health outcomes; Effort ID EXAGGERATION; VETERANS; SAMPLE; RATES AB Patients who exert inadequate effort on neuropsychological examination might not receive accurate diagnoses and recommendations, and might not cooperate fully with other aspects of healthcare. This study examined whether inadequate effort is associated with increased healthcare utilization. Of 355 patients seen for routine, clinical neuropsychological examination at a VA Medical Center, 283 (79.7%) showed adequate effort and 72 (20.3%) showed inadequate effort, as determined at time of evaluation using the Word Memory Test and/or Test of Memory Malingering. Utilization data included number of Emergency Department (ED) visits and inpatient hospitalizations in the year following evaluation. Patients who had shown inadequate effort on examination had more Emergency Department visits, more inpatient hospitalizations, and more days of inpatient hospitalization in the year after evaluation, compared to patients who had exerted adequate effort. This finding was not attributable to group differences in age or medical/psychiatric comorbidities. Thus, patients who exerted inadequate effort showed greater healthcare utilization in the year following evaluation. Such patients might use more resources since diagnostic evaluations are inconclusive. Inadequate effort on examination might also serve as a "marker" for more general failure to cooperate fully in one's healthcare, possibly resulting in greater utilization. C1 [Horner, Michael David; VanKirk, Kathryn K.; Turner, Travis H.] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [Horner, Michael David; VanKirk, Kathryn K.; Turner, Travis H.; Muzzy, Wendy] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Dismuke, Clara E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29401 USA. [Dismuke, Clara E.] Med Univ S Carolina, Dept Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Turner, Travis H.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Muzzy, Wendy] Charleston Res Inst, Charleston, SC USA. RP Horner, MD (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM hornermd@musc.edu FU American Academy of Clinical Neuropsychology Foundation FX This work was supported by a grant from the American Academy of Clinical Neuropsychology Foundation to Dr. VanKirk. NR 14 TC 5 Z9 5 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2014 VL 28 IS 5 BP 703 EP 713 DI 10.1080/13854046.2014.925143 PG 11 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA AP4MM UT WOS:000342051100001 PM 24931877 ER PT J AU Cottingham, ME Victor, TL Boone, KB Ziegler, EA Zeller, M AF Cottingham, Maria Easter Victor, Tara L. Boone, Kyle B. Ziegler, Elizabeth A. Zeller, Michelle TI Apparent Effect of Type of Compensation Seeking (Disability Versus Litigation) on Performance Validity Test Scores may be due to Other Factors SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Compensation; Performance validity; Neuropsychology; Disability; mTBI ID SOCIAL-SECURITY DISABILITY; TRAUMATIC BRAIN-INJURY; WORD RECOGNITION TEST; MILD HEAD TRAUMA; SUSPECT EFFORT; RESPONSE BIAS; SYMPTOM EXAGGERATION; CONSULTATIVE EXAM; CROSS-VALIDATION; BASE RATES AB Neuropsychologists use performance validity tests (PVTs; Larrabee, 2012) to ensure that results of testing are reflective of the test taker's true neurocognitive ability, and their use is recommended in all compensation-seeking settings. However, whether the type of compensation context (e.g., personal injury litigation versus disability seeking) impacts the nature and extent of neurocognitive symptom feigning has not been adequately investigated. PVT performance was compared in an archival data set of noncredible individuals in either a personal injury litigation (n = 163) or a disability-seeking context (n = 201). Individuals were deemed noncredible based on meeting Slick, Sherman, and Iverson's (1999) criteria including failure on at least two PVTs and a lack of congruency between their low cognitive scores and normal function in activities of daily living (ADLs). In general, disability seekers tended to perform in a less sophisticated manner than did litigants (i.e., they failed more indicators and did so more extensively). Upon further investigation, these differences were in part accounted for by type of diagnoses feigned; those seeking compensation for mental health diagnoses were more likely to feign or exaggerate a wide variety of cognitive deficits, whereas those with claimed medical diagnoses (i.e., traumatic brain injury) were more targeted in their attempts to feign and/or exaggerate neurocognitive compromise. C1 [Cottingham, Maria Easter] Olive View UCLA Med Ctr, Dept Psychiat, Sylmar, CA 91342 USA. [Victor, Tara L.] Calif State Univ, Dept Psychol, Carson, CA USA. [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA USA. [Ziegler, Elizabeth A.] Spokane Vet Adm Med Ctr, Dept Mental Behav Hlth, Spokane, WA USA. [Zeller, Michelle] Greater Los Angeles Vet Healthcare Syst, Dept Psychol, Los Angeles, CA USA. RP Cottingham, ME (reprint author), TBI Clin, 11050 Mt Belvedere Blvd,Bldg 25, Ft Drum, NY 13601 USA. EM mecottingham@gmail.com NR 51 TC 6 Z9 6 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2014 VL 28 IS 6 BP 1030 EP 1047 DI 10.1080/13854046.2014.951397 PG 18 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA AP4MR UT WOS:000342051600010 PM 25157537 ER PT S AU Loftis, JM Janowsky, A AF Loftis, Jennifer M. Janowsky, Aaron BE Cui, C Shurtleff, D Harris, RA TI Neuroimmune Basis of Methamphetamine Toxicity SO NEUROIMMUNE SIGNALING IN DRUG ACTIONS AND ADDICTIONS SE International Review of Neurobiology LA English DT Review; Book Chapter ID BLOOD-BRAIN-BARRIER; HEPATITIS-C VIRUS; NF-KAPPA-B; SUBSTANCE USE DISORDERS; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TIGHT JUNCTION PROTEINS; MATURE DENDRITIC CELLS; DOPAMINE NERVE-ENDINGS; INDUCED NEUROTOXICITY AB Although it is not known which antigen-specific immune responses (or if antigen-specific immune responses) are relevant or required for methamphetamine's neurotoxic effects, it is apparent that methamphetamine exposure is associated with significant effects on adaptive and innate immunity. Alterations in lymphocyte activity and number, changes in cytokine signaling, impairments in phagocytic functions, and glial activation and gliosis have all been reported. These drug-induced changes in immune response, particularly within the CNS, are now thought to play a critical role in the addiction process for methamphetamine dependence as well as for other substance use disorders. In Section 2, methamphetamine's effects on glial cell (e.g., microglia and astrocytes) activity and inflammatory signaling cascades are summarized, including how alterations in immune cell function can induce the neurotoxic and addictive effects of methamphetamine. Section 2 also describes neurotransmitter involvement in the modulation of methamphetamine's inflammatory effects. Section 3 discusses the very recent use of pharmacological and genetic animal models which have helped elucidate the behavioral effects of methamphetamine's neurotoxic effects and the role of the immune system. Section 4 is focused on the effects of methamphetamine on blood brain barrier integrity and associated immune consequences. Clinical considerations such as the combined effects of methamphetamine and HIV and/or HCV on brain structure and function are included in Section 4. Finally, in Section 5, immune-based treatment strategies are reviewed, with a focus on vaccine development, neuroimmune therapies, and other anti-inflammatory approaches. C1 [Loftis, Jennifer M.; Janowsky, Aaron] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Loftis, Jennifer M.; Janowsky, Aaron] Oregon Hlth & Sci Univ, Dept Psychiat, Sch Med, Portland, OR 97201 USA. [Loftis, Jennifer M.; Janowsky, Aaron] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97201 USA. [Janowsky, Aaron] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. EM loftisj@ohsu.edu FU BLRD VA [I01 BX002061]; NIDA NIH HHS [DA018165, P50 DA018165] NR 153 TC 18 Z9 18 U1 6 U2 12 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 BN 978-0-12-801284-0 J9 INT REV NEUROBIOL JI Int. Rev. Neurobiol. PY 2014 VL 118 BP 165 EP 197 DI 10.1016/B978-0-12-801284-0.00007-5 PG 33 WC Neurosciences SC Neurosciences & Neurology GA BB2IQ UT WOS:000341798700007 PM 25175865 ER PT J AU Wahl, KR Margolis, A Lintner, K Hartkopf, K Martin, B AF Wahl, Kimberly R. Margolis, Amanda Lintner, Kimberly Hartkopf, Katherine Martin, Beth TI Impact and Application of Material Learned in a Pharmacy Residency Teaching Certificate Program SO AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION LA English DT Article DE teaching certificate program; pharmacy; residency training ID EXPERIENCES AB Objective. To describe the impact and application of material learned in a pharmacy resident teaching certificate program on the career experiences of alumni 1 to 11 years after completion of the program. Design. A teaching certificate program was established in 2001 that brought together residents from various training programs throughout Wisconsin to discuss essential educational skills in a dynamic learning environment. The purpose of the program was to teach participants the fundamental skills to continue to develop as a pharmacy educator throughout their career. Assessment. An electronic survey instrument was sent to alumni of the program. Greater than 70% of respondents agreed that the teaching certificate program reinforced their desire to teach in practice and that the program helped qualify them for their current or previous practice position. Alumni in academic positions more strongly agreed that the program changed their career interest to include academia and qualified them for their position in academia. Conclusions. A teaching certificate program can reinforce or stimulate interest among pharmacy residents in pursuing an academic career and prepare them for this role. Completion of the program led to a high level of confidence among the majority of alumni in their ability to precept students and residents and influenced some alumni involved in the hiring of pharmacists. C1 [Wahl, Kimberly R.; Margolis, Amanda; Martin, Beth] Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA. [Wahl, Kimberly R.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Lintner, Kimberly] Meriter Hosp, Madison, WI USA. [Hartkopf, Katherine] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. RP Martin, B (reprint author), Univ Wisconsin, Sch Pharm, 1022 Rennebohm Hall,777 Highland Ave, Madison, WI 53705 USA. EM bamartin@pharmacy.wisc.edu NR 12 TC 4 Z9 4 U1 1 U2 3 PU AMER ASSOC COLL PHARMACY PI ALEXANDRIA PA 1426 PRINCE STREET, ALEXANDRIA, VA 22314-2815 USA SN 0002-9459 EI 1553-6467 J9 AM J PHARM EDUC JI Am. J. Pharm. Educ. PY 2014 VL 78 IS 6 AR 123 PG 8 WC Education, Scientific Disciplines; Pharmacology & Pharmacy SC Education & Educational Research; Pharmacology & Pharmacy GA AO5WT UT WOS:000341417800012 PM 25147395 ER PT J AU Hula, WD Fergadiotis, G Doyle, PJ AF Hula, William D. Fergadiotis, Gerasimos Doyle, Patrick J. TI A core outcome set for aphasia treatment research: Obstacles, risks, and benefits SO APHASIOLOGY LA English DT Editorial Material ID MEASUREMENT INVARIANCE; TRIALS; MATTER C1 [Hula, William D.; Doyle, Patrick J.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Hula, William D.; Doyle, Patrick J.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Fergadiotis, Gerasimos] Portland State Univ, Dept Speech & Hearing Sci, Portland, OR 97207 USA. RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Univ Dr Div 132SP U, Pittsburgh, PA 15240 USA. EM william.hula@va.gov NR 14 TC 3 Z9 3 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0268-7038 EI 1464-5041 J9 APHASIOLOGY JI Aphasiology PY 2014 VL 28 IS 11 BP 1396 EP 1399 DI 10.1080/02687038.2014.930264 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA AO7CE UT WOS:000341508800008 ER PT J AU Edwards, M Balldin, VH Hall, J O'Bryant, S AF Edwards, Melissa Balldin, Valerie Hobson Hall, James O'Bryant, Sid TI Combining Select Neuropsychological Assessment with Blood-Based Biomarkers to Detect Mild Alzheimer's Disease: A Molecular Neuropsychology Approach SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; biomarkers; molecular; neuropsychology ID CLOCK-DRAWING TEST; NATIONAL INSTITUTE; DEMENTIA; GUIDELINES; DIAGNOSIS; MARKERS AB Background: Current work has sought to establish a rapid and cost effective means of screening for Alzheimer's disease (AD) with the most recent findings showing utility of integrating blood-based biomarkers with cognitive measures. Objective: The current project sought to create a combined biomarker-cognitive profile to detect mild AD. Methods: Data was analyzed from 266 participants (129 AD cases [Early AD n = 93; Very Early AD n = 36]; 137 controls) enrolled in the Texas Alzheimer's Research and Care Consortium (TARCC). Non-fasting serum samples were collected from each participant and assayed via a multi-plex biomarker assay platform using electrochemiluminescence. Logistic Regression was utilized to detect early AD using two serum biomarkers (TNF alpha and IL7), demographic information (age), and one neuropsychological measure (Clock 4-point) as predictor variable. Disease severity was determined via Clinical Dementia Rating (CDR) scale global scores. Results: In the total sample (all levels of CDR scores), the combination of biomarkers, cognitive test score, and demographics yielded the obtained sensitivity (SN) of 0.94, specificity (SP) of 0.90, and an overall accuracy of 0.92. When examining early AD cases (i.e.m CDR = 0.5-1), the biomarker-cognitive profile yielded SN of 0.94, SP of 0.85, and an overall accuracy of 0.91. When restricted to very early AD cases (i.e., CDR = 0.5), the biomarker-cognitive profile yielded SN of 0.97 and SP of 0.72, with an overall accuracy of 0.91. Conclusions: The combination of demographics, two biomarkers, and one cognitive test created a biomarker-cognitive profile that was highly accurate in detecting the presence of AD, even in the very early stages. C1 [Edwards, Melissa] Univ N Texas, Dept Psychol, Denton, TX 76203 USA. [Balldin, Valerie Hobson] South Texas Vet Hlth Care Syst, Dept Psychol, San Antonio, TX USA. [Hall, James] Univ N Texas, Hlth Sci Ctr, Dept Psychiat, Ft Worth, TX 76107 USA. [Hall, James; O'Bryant, Sid] Univ N Texas, Hlth Sci Ctr, Inst Aging & Alzheimers Dis Res, Ft Worth, TX 76107 USA. [O'Bryant, Sid] Univ N Texas, Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX 76107 USA. RP O'Bryant, S (reprint author), Univ N Texas, Hlth Sci Ctr, Dept Internal Med, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA. EM Sid.O'Bryant@unthsc.edu OI O'Bryant, Sid/0000-0003-0582-5266 FU National Institute on Aging (NIA) [R01AG039389, P30AG12300]; Texas Council on Alzheimer's Disease and Related Disorders FX Research reported in this publication was supported by the National Institute on Aging (NIA) under Award Numbers R01AG039389 and P30AG12300. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was also made possible by a grant from the Texas Council on Alzheimer's Disease and Related Disorders to the Texas Alzheimer's Research & Care Consortium (TARCC)*. NR 28 TC 1 Z9 1 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 42 IS 2 BP 635 EP 640 DI 10.3233/JAD-140852 PG 6 WC Neurosciences SC Neurosciences & Neurology GA AO7ZP UT WOS:000341572000025 PM 24916542 ER PT J AU Talbot, LS Neylan, TC Metzler, TJ Cohen, BE AF Talbot, Lisa S. Neylan, Thomas C. Metzler, Thomas J. Cohen, Beth E. TI The Mediating Effect of Sleep Quality on the Relationship between PTSD and Physical Activity SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE posttraumatic stress disorder; sleep quality; physical activity ID POSTTRAUMATIC-STRESS-DISORDER; CORONARY-HEART-DISEASE; NATIONALLY REPRESENTATIVE SAMPLE; METABOLIC SYNDROME; HEALTH BEHAVIORS; GENERAL-POPULATION; VIETNAM VETERANS; WEIGHT-GAIN; RISK; ASSOCIATION AB Study Objectives: Physical inactivity is linked to health outcomes such as obesity, diabetes, and psychiatric disorders. Sleep disturbance has been linked to the same adverse outcomes. We examine the influence of sleep on physical activity as a novel approach to understand these relationships. Specifically, our objective was to determine whether low sleep quality predicts low physical activity in posttraumatic stress disorder (PTSD), a disorder associated with sleep disturbance, physical inactivity, and poor health outcomes. Methods: We used data from the Mind Your Heart Study, a prospective cohort study of 736 outpatients recruited from two Department of Veterans Affairs (VA) medical centers. We assessed PTSD with the Clinician Administered PTSD Scale, sleep quality using an item from the Pittsburgh Sleep Quality Index, and physical activity by self-report at baseline and again one year later. Hierarchical multiple regression models and structural equation modeling were used to examine the relationships among PTSD, sleep, and physical activity. Results: Sleep quality but not PTSD status was prospectively associated with lower physical activity in a model adjusting for age, sex, apnea probability, depression, body mass index, and baseline physical activity (beta = 0.129, SE = 0.072, p < 0.01). Structural equation modeling indicated that the results were consistent with sleep quality statistically mediating the relationship between PTSD status at baseline and physical activity one year later. Conclusions: Worse sleep quality predicts lower physical activity in PTSD, providing possible evidence for a behavioral pathway from disturbed sleep to poor physical health outcomes. C1 [Talbot, Lisa S.; Neylan, Thomas C.; Metzler, Thomas J.; Cohen, Beth E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Talbot, Lisa S.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Talbot, LS (reprint author), San Francisco VA Med Ctr 116H, 4150 Clement St, San Francisco, CA 94121 USA. EM lisa.talbot@gmail.com FU National Heart, Lung, and Blood Institute [K23 HL 094765]; Irene Perstein Foundation; Mental Illness Research and Education Clinical Center of the US Veterans Health Administration FX This was not an industry supported study. This research was supported by grants from the National Heart, Lung, and Blood Institute (BEC: K23 HL 094765), the Irene Perstein Foundation, and the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration. The authors have indicated no financial conflicts of interest. NR 50 TC 9 Z9 9 U1 1 U2 8 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2014 VL 10 IS 7 BP 795 EP 801 DI 10.5664/jcsm.3878 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AO2GN UT WOS:000341136100014 PM 25024659 ER PT S AU Mallipattu, SK He, JC AF Mallipattu, Sandeep K. He, John C. BE Liu, ZH He, JC TI Podocyte Injury in HIV-Associated Nephropathy SO PODOCYTOPATHY SE Contributions to Nephrology LA English DT Article; Book Chapter ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; HIV-1-ASSOCIATED NEPHROPATHY; TRANSGENIC MICE; EXPRESSION; KIDNEY; APOL1; INFECTION; GENES; SUSCEPTIBILITY; EPITHELIUM AB Prior to the widespread use of antiretroviral therapy, HIV-associated nephropathy (HIVAN) was the leading cause of end-stage renal disease among individuals of African descent. HIVAN, a rapidly progressing glomerulopathy, is characterized by collapsing focal segmental glomerulosclerosis, podocyte hypertrophy, and proliferation of epithelial cells overlying the Bowman's space. Although the origin of these proliferating cells is debatable, a large body of evidence suggests that podocyte dysfunction occurs in HIVAN. In the last decade, several groups have demonstrated that the podocyte serves as a reservoir for the virus and podocyte dysfunction is a direct result of specific viral protein expression. The viral protein, nef, directly activates several signaling pathways, resulting in podocyte dedifferentiation and proliferation. Today, with the widespread use of antiretroviral therapy, classical HIVAN is rare. Nonetheless, as patients with chronically infected HIV live longer, many still succumb to chronic kidney disease due to coexisting illnesses such as diabetes and hypertension. However, it remains unclear whether this viral reservoir serves a medium for development of non-HIVAN-related kidney diseases such as diabetic nephropathy. We also provide some insights into potential areas of research in characterizing podocyte biology in this changing spectrum of HIV-related kidney disease. (C) 2014 S. Karger AG, Basel C1 [Mallipattu, Sandeep K.] SUNY Stony Brook, Div Nephrol, Dept Med, Sch Med, Stony Brook, NY 11794 USA. [He, John C.] Icahn Sch Med Mt Sinai, Div Nephrol, Dept Med, New York, NY 10029 USA. [He, John C.] James J Peters VA Med Ctr, Renal Sect, New York, NY USA. RP He, JC (reprint author), Icahn Sch Med Mt Sinai, Dept Med Nephrol, One Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM cijiang.he@mssm.edu RI Mallipattu , Sandeep/M-7009-2014 NR 30 TC 0 Z9 0 U1 1 U2 3 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 978-3-318-02651-1; 978-3-318-02650-4 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 2014 VL 183 BP 181 EP 190 DI 10.1159/000360113 PG 10 WC Cell Biology; Urology & Nephrology SC Cell Biology; Urology & Nephrology GA BB1TT UT WOS:000341359900015 ER PT S AU Sharma, S Mallipattu, SK Zhong, YF He, JC AF Sharma, Shuchita Mallipattu, Sandeep K. Zhong, Yifei He, John C. BE Liu, ZH He, JC TI Retinoic Acid: A Potential Pharmacologic Approach in the Treatment of Podocytopathy SO PODOCYTOPATHY SE Contributions to Nephrology LA English DT Article; Book Chapter ID HIV-ASSOCIATED NEPHROPATHY; GLOMERULAR-DISEASE; EXPRESSION; GLOMERULONEPHRITIS; DIFFERENTIATION; RECEPTORS; PODOCYTES; CELLS; MODEL; RATS AB In the setting of injury, podocytes can undergo dedifferentiation and proliferation, apoptosis, or cell detachment, resulting in proteinuria. Significant injury resulting in a loss of podocytes contributes to progressive kidney disease. Consequently, therapies that prevent podocyte injury and promote their regeneration will have a major clinical impact on glomerular disease. All-trans-retinoic acid (RA), which is a derivative of vitamin A, has many cellular functions including induction of cell differentiation, regulation of apoptosis, and inhibition of inflammation and proliferation. In addition to its established role in the treatment of variety of cancers, RA has been demonstrated to provide protection in various experimental models of kidney diseases with podocyte injury. RA produces its beneficial effects in the kidney due to its anti-inflammatory and antiproliferative effects. Also, RA helps maintain the normal morphology and preserves the differentiation markers of the podocytes. RA produces its effects in the podocytes via retinoic acid receptor-a (RAR-alpha). Treatment with RAR-a agonist, Am580, has a similar efficacy as RA in a mouse model of HIVAN. However, due to its systemic toxicity, clinical studies evaluating the use of RA have been challenging. Therefore, novel RAR-alpha agonist such as BD4 has been synthesized, which has a similar efficacy as RA and Am580, with lower toxicity. (C) 2014 S. Karger AG, Basel C1 [Sharma, Shuchita; He, John C.] Icahn Sch Med Mt Sinai, Div Nephrol, Dept Med, New York, NY 10029 USA. [Mallipattu, Sandeep K.] SUNY Stony Brook, Div Nephrol, Dept Med, Sch Med, Stony Brook, NY USA. [He, John C.] James J Peters VA Med Ctr, Div Renal, New York, NY USA. [Zhong, Yifei] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Nephrol, Shanghai, Peoples R China. RP He, JC (reprint author), Icahn Sch Med Mt Sinai, Dept Med Nephrol, One Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM cijiang.he@mssm.edu RI Mallipattu , Sandeep/M-7009-2014 NR 26 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 978-3-318-02651-1; 978-3-318-02650-4 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 2014 VL 183 BP 191 EP 198 DI 10.1159/000360114 PG 8 WC Cell Biology; Urology & Nephrology SC Cell Biology; Urology & Nephrology GA BB1TT UT WOS:000341359900016 ER PT B AU Koenig, CJ Robinson, JD AF Koenig, Christopher J. Robinson, Jeffrey D. BE Whaley, BB TI CONVERSATION ANALYSIS Understanding the Structure of Health Talk SO RESEARCH METHODS IN HEALTH COMMUNICATION: PRINCIPLES AND APPLICATION LA English DT Article; Book Chapter ID PHYSICIANS OPENING QUESTIONS; TREATMENT RECOMMENDATIONS; MEDICAL INTERACTIONS; PATIENT INTERACTION; PARENT RESISTANCE; PRIMARY-CARE; COMMUNICATION; ANTIBIOTICS; VISITS; FORMULATIONS C1 [Koenig, Christopher J.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Koenig, Christopher J.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Robinson, Jeffrey D.] Univ Dayton, Dayton, OH 45469 USA. RP Koenig, CJ (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. OI Koenig, Christopher J./0000-0003-0884-4120 NR 74 TC 1 Z9 1 U1 0 U2 1 PU ROUTLEDGE PI ABINGDON PA 2 PARK SQ, MILTON PARK, ABINGDON OX14 4RN, OXFORD, ENGLAND BN 978-0-415-53186-3; 978-0-203-11529-9; 978-0-415-53185-6 PY 2014 BP 119 EP 140 PG 22 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA BB1TI UT WOS:000341356000008 ER PT B AU Kanauchi, O Larauche, M Tache, Y AF Kanauchi, Osamu Larauche, Muriel Tache, Yvette BE Watson, RR Preedy, VR Zibadi, S TI Development of Functional Foods (Enzyme-Treated Rice Fiber) from Rice By-products SO WHEAT AND RICE IN DISEASE PREVENTION AND HEALTH: BENEFITS, RISKS AND MECHANISMS OF WHOLE GRAINS IN HEALTH PROMOTION LA English DT Article; Book Chapter ID IRRITABLE-BOWEL-SYNDROME; GERMINATED BARLEY FOODSTUFF; DEXTRAN SULFATE SODIUM; MUCOSAL IMMUNE-SYSTEM; FECAL MICROFLORA; AMELIORATES INFLAMMATION; WHEAT BRAN; DISEASE; COLITIS; MODULATION C1 [Kanauchi, Osamu] Kirin Holdings Co Ltd, Strateg Res & Dev Dept, Chuo Ku, Tokyo, Japan. [Kanauchi, Osamu] Shiga Univ Med Sci, Otzu, Japan. [Larauche, Muriel; Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Larauche, Muriel; Tache, Yvette] Univ Calif Los Angeles, Div Digest Dis, Oppenheimer Family Ctr Neurobiol Stress, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Kanauchi, O (reprint author), Kirin Holdings Co Ltd, Strateg Res & Dev Dept, Chuo Ku, Tokyo, Japan. OI Larauche, Muriel/0000-0003-3320-3675 NR 79 TC 1 Z9 1 U1 0 U2 3 PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND BN 978-0-12-404604-7; 978-0-12-401716-0 PY 2014 BP 521 EP 532 DI 10.1016/B978-0-12-401716-0.00040-4 PG 12 WC Public, Environmental & Occupational Health; Nutrition & Dietetics SC Public, Environmental & Occupational Health; Nutrition & Dietetics GA BB1MZ UT WOS:000341214700041 ER PT J AU Jackevicius, CA Wong, J Aroustamian, I Gee, M Mody, FV AF Jackevicius, Cynthia A. Wong, Joyce Aroustamian, Irina Gee, Manyee Mody, Freny Vaghaiwalla TI Rates and predictors of ACE inhibitor discontinuation subsequent to elevated serum creatinine: a retrospective cohort study SO BMJ OPEN LA English DT Article ID CONVERTING ENZYME-INHIBITOR; HIGH BLOOD-PRESSURE; RENAL-INSUFFICIENCY; HEART-FAILURE; THERAPY; KIDNEY; DISEASE; CARE AB Objectives: ACE inhibitors (ACEI) are underutilised despite cardiovascular benefits, in part due to concerns of known transient elevations in serum creatinine (SCr) after initiation. Our objectives were to evaluate rates and predictors of ACEI discontinuation after SCr elevation post-ACEI initiation since limited data are available that examine this issue. Setting: Primary and tertiary Veterans healthcare system in Los Angeles, California, USA Participants: 3039 outpatients initiating an ACEI with a SCr measured within 6 months prior to and approximately 3 months after initiating an ACEI. Patients were divided into three groups (SCr <1.5, 1.5-2 and >2). Primary and secondary outcome measures: Rates and factors associated with ACEI discontinuation subsequent to SCr elevation after ACEI initiation and for patients with baseline SCr >2 mg/dL, the change in SCr associated with chronic use. Predictors were identified using multivariate logistic regression modelling. Results: At 3 months follow-up, for those with an increase in SCr, the mean increase post-ACEI initiation was 26%, ranging from -0.01 mg/dL to 0.42 mg/dL varying according to a level of baseline renal function. ACEI discontinuation was higher in patients with elevated baseline SCr (19/165, 11.5%) compared with those with SCr <1.5 (135/2497, 5.4%), and those with SCr 1.5-2.0 (28/377, 7.4%). Male patients, and those with heart failure were less likely to discontinue ACEI after an elevation of SCr post-ACEI initiation, while those taking non-steroidal anti-inflammatory drugs, diuretics and beta-blockers were more likely to discontinue ACEI. Conclusions: SCr increases <30% on average within 3 months of ACEI initiation, with subsequent discontinuation rates varying by baseline SCr. Elevation in SCr was not associated with ACEI discontinuation rates. In patients with SCr >2 mg/dL at baseline, despite an acute increase in SCr after ACEI initiation, chronic ACEI use was associated with a decrease in SCr in most patients. C1 [Jackevicius, Cynthia A.; Wong, Joyce; Aroustamian, Irina] Western Univ Hlth Sci, Dept Pharm Practice & Adm, Pomona, CA USA. [Jackevicius, Cynthia A.; Gee, Manyee; Mody, Freny Vaghaiwalla] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med & Pharm, Los Angeles, CA 90073 USA. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Hlth Network, Dept Pharm, Toronto, ON, Canada. [Mody, Freny Vaghaiwalla] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA. RP Mody, FV (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med & Pharm, Los Angeles, CA 90073 USA. EM freny.mody@va.gov NR 21 TC 2 Z9 2 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2014 VL 4 IS 8 AR e005181 DI 10.1136/bmjopen-2014-005181 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA AN7KT UT WOS:000340779400021 PM 25232564 ER PT J AU Gong, B Levine, S Barnum, SR Pasinetti, GM AF Gong, Bing Levine, Samara Barnum, Scott R. Pasinetti, Giulio M. TI Role of Complement Systems in IVIG Mediated Attenuation of Cognitive Deterioration in Alzheimer's Disease SO CURRENT ALZHEIMER RESEARCH LA English DT Article DE Alzheimer's disease; cognitive function; complement component; immunotherapy; IVIG; synaptic plasticity ID CENTRAL-NERVOUS-SYSTEM; HUMAN INTRAVENOUS IMMUNOGLOBULIN; ANAPHYLATOXIN C5A NEUROPROTECTS; LONG-TERM POTENTIATION; MOUSE MODEL; SYNAPTIC PLASTICITY; GENE-EXPRESSION; AMYLOID-BETA; NEURODEGENERATIVE DISORDERS; HIPPOCAMPAL-NEURONS AB Human intravenous immunoglobulin (IVIG) has been indicated as a potential therapy for autoimmune neurological disorders, as well as in many neurodegenerative diseases, with various underlying therapeutic mechanisms such as regulation of T-cell trafficking, cytokines, Fc receptor blocking, and interruption of complement activation cascade. In Alzheimer's disease (AD), IVIG presents naturally occurring antibodies against amyloid-beta (A beta) aggregation, thus IVIG immunotherapy may increase the clearance of A beta and protect brain function. Recently, we and others reported that besides A beta clearance, IVIG specifically regulates the levels of complement-derived anaphylatoxins, such as C5a and C3, which play an important role in the regulation of AMPA and NMDA receptor expression in the brain and further upregulate the AMPA-PKA-CREB signaling pathway and synaptic function in AD mouse models. Since down-regulation of complement components has been linked with deficits of cognitive function in age-related dementia following the decline of innate immunity during aging, the IVIG immunotherapy could be an attractive novel AD therapeutic through its local regulation of C3, C5a component levels in brain. C1 [Gong, Bing; Levine, Samara; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Ctr Excellence Novel Approaches Neurotherapeut, Dept Neurol, New York, NY 10029 USA. [Barnum, Scott R.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Veterans Administration FX The studies described here were supported in part from a grant from the Veterans Administration and by discretionary funding to G.M.P. NR 82 TC 3 Z9 3 U1 0 U2 1 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1567-2050 EI 1875-5828 J9 CURR ALZHEIMER RES JI Curr. Alzheimer Res. PY 2014 VL 11 IS 7 BP 637 EP 644 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AN9LG UT WOS:000340927500003 PM 25115545 ER PT J AU Daskalakis, NP Yehuda, R AF Daskalakis, Nikolaos P. Yehuda, Rachel TI Principles for developing animal models of military PTSD SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Article DE Animal; posttraumatic stress disorder; military; combat; biomarkers ID POSTTRAUMATIC-STRESS-DISORDER; SOCIAL DEFEAT STRESS; TRAUMATIC STRESS; AGGRESSION; EXPOSURE; BRAIN; FEAR; HIPPOCAMPUS; RESILIENCE; BIOMARKERS AB The extent to which animal studies can be relevant to military posttraumatic stress disorder (PTSD) continues to be a matter of discussion. Some features of the clinical syndrome are more easily modeled than others. In the animal literature, a great deal of attention is focused on modeling the characteristics of military exposures and their impact on measurable behaviors and biological parameters. There are many issues to consider regarding the ecological validity of predator, social defeat or immobilization stress to combat-related experience. In contrast, less attention has been paid to individual variation following these exposures. Such variation is critical to understand how individual differences in the response to military trauma exposure may result to PTSD or resilience. It is important to consider potential differences in biological findings when comparing extremely exposed to non-exposed animals, versus those that result from examining individual differences. Animal models of military PTSD are also critical in advancing efforts in clinical treatment. In an ideal translational approach to study deployment related outcomes, information from humans and animals, blood and brain, should be carefully considered in tandem, possibly even computed simultaneously, to identify molecules, pathways and networks that are likely to be the key drivers of military PTSD symptoms. With the use novel biological methodologies (e. g., optogenetics) in the animal models, critical genes and pathways can be tuned up or down (rather than over-expressed or ablated completely) in discrete brain regions. Such techniques together with pre-and post-deployment human imaging will accelerate the identification of novel pharmacological and non-pharmacological intervention strategies. C1 [Daskalakis, Nikolaos P.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Daskalakis, Nikolaos P.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY USA. RP Daskalakis, NP (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM Nikolaos.Daskalakis@mssm.edu RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 NR 50 TC 8 Z9 9 U1 2 U2 9 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2014 VL 5 AR 23825 DI 10.3402/ejpt.v5.23825 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AO2HI UT WOS:000341139000001 ER PT J AU Ivanov, I Yehuda, R AF Ivanov, Iliyan Yehuda, Rachel TI Optimizing fitness for duty and post-combat clinical services for military personnel and combat veterans with ADHD-a systematic review of the current literature SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Review DE ADHD; military; PTSD ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT-HYPERACTIVITY DISORDER; POSTTRAUMATIC-STRESS-DISORDER; PREFRONTAL CORTEX; PSYCHIATRIC-DISORDERS; ADULT ADHD; FOLLOW-UP; CHILDREN; ABNORMALITIES; ADOLESCENTS AB Background: Attention deficit hyper activity disorder (ADHD) is a developmental disorder, most often diagnosed in childhood, and characterized by hyperactivity and inattention that negatively impacts one's ability to function and fulfill social and personal obligations. Individuals with past history of ADHD may enlist in the military under certain conditions, however the full impact of military training and deployment of later in life ADHD symptoms is unclear. It is of particular interest how military experience may affect ADHD in remission and if such individuals might be at elevated risk for relapse of ADHD symptoms. Method: We performed a systematic review f the available literature including the Department of Defense (DOD) guidelines for both eligibility to enlist and fitness for deployment based on reported history and current symptomatology of ADHD. Results: The after care for veterans with ADHD relapse is inconsistent and presents with number of challenges. We evaluate the DOD policies regarding the implications of ADHD for fitness for military service and post-combat mental health. Conclusion: The full extend of the interaction between pre-existing ADHD and post-combat PTSD are not fully understood. The development of comprehensive and clear algorithms for diagnosing and treating ADHD in the military before and after deployment will have a strong positive impact on the quality of care delivered to soldiers and veterans. C1 [Ivanov, Iliyan] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Yehuda, Rachel] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA. RP Ivanov, I (reprint author), Mt Sinai Med Ctr, Dept Psychiat, One Gustave L,Levy Pl,Box 1230, New York, NY 10029 USA. EM iliyan.ivanov@mssm.edu NR 52 TC 3 Z9 3 U1 2 U2 5 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2014 VL 5 AR 23894 DI 10.3402/ejpt.v5.23894 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AO2HN UT WOS:000341139600001 ER PT J AU Lehrner, A Yehuda, R AF Lehrner, Amy Yehuda, Rachel TI PTSD IN THE MILITARY: PREVALENCE, PATHOPHYSIOLOGY, TREATMENT Biomarkers of PTSD: military applications and considerations SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Article DE Posttraumatic stress disorder; biomarkers; clinical utility; ethics; translation ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE-BEHAVIORAL THERAPY; PREDICTS TREATMENT RESPONSE; LATENT CLASS ANALYSIS; EXTREME STRESS; ANTERIOR CINGULATE; DISSOCIATIVE-SUBTYPE; ALZHEIMERS-DISEASE; MAJOR DEPRESSION AB Background: Although there are no established biomarkers for posttraumatic stress disorder (PTSD) as yet, biological investigations of PTSD have made progress identifying the pathophysiology of PTSD. Given the biological and clinical complexity of PTSD, it is increasingly unlikely that a single biomarker of disease will be identified. Rather, investigations will more likely identify different biomarkers that indicate the presence of clinically significant PTSD symptoms, associate with risk for PTSD following trauma exposure, and predict or identify recovery. While there has been much interest in PTSD biomarkers, there has been less discussion of their potential clinical applications, and of the social, legal, and ethical implications of such biomarkers. Objective: This article will discuss possible applications of PTSD biomarkers, including the social, legal, and ethical implications of such biomarkers, with an emphasis on military applications. Method: Literature on applications of PTSD biomarkers and on potential ethical and legal implications will be reviewed. Results: Biologically informed research findings hold promise for prevention, assessment, treatment planning, and the development of prophylactic and treatment interventions. As with any biological indicator of disorder, there are potentially positive and negative clinical, social, legal, and ethical consequences of using such biomarkers. Conclusions: Potential clinical applications of PTSD biomarkers hold promise for clinicians, patients, and employers. The search for biomarkers of PTSD should occur in tandem with an interdisciplinary discussion regarding the potential implications of applying biological findings in clinical and employment settings. C1 [Lehrner, Amy; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. RP Lehrner, A (reprint author), James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM amy.lehrner@va.gov NR 74 TC 10 Z9 10 U1 3 U2 13 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2014 VL 5 AR 23797 DI 10.3402/ejpt.v5.23797 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AO2HF UT WOS:000341138600001 ER PT J AU Neylan, TC Schadt, EE Yehuda, R AF Neylan, Thomas C. Schadt, Eric E. Yehuda, Rachel TI Biomarkers for combat-related PTSD: focus on molecular networks from high-dimensional data SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Article DE PTSD; genomics; gene expression; proteomics; Computational Biology; risk factors ID POSTTRAUMATIC-STRESS-DISORDER; PLURIPOTENT STEM-CELLS; GENE-EXPRESSION; ALZHEIMERS-DISEASE; SCHIZOPHRENIA; SUSCEPTIBILITY; OBESITY; SYSTEMS; MOUSE; LOCI AB Posttraumatic stress disorder (PTSD) and other deployment-related outcomes originate from a complex interplay between constellations of changes in DNA, environmental traumatic exposures, and other biological risk factors. These factors affect not only individual genes or bio-molecules but also the entire biological networks that in turn increase or decrease the risk of illness or affect illness severity. This review focuses on recent developments in the field of systems biology which use multidimensional data to discover biological networks affected by combat exposure and post-deployment disease states. By integrating large-scale, high-dimensional molecular, physiological, clinical, and behavioral data, the molecular networks that directly respond to perturbations that can lead to PTSD can be identified and causally associated with PTSD, providing a path to identify key drivers. Reprogrammed neural progenitor cells from fibroblasts from PTSD patients could be established as an in vitro assay for high throughput screening of approved drugs to determine which drugs reverse the abnormal expression of the pathogenic biomarkers or neuronal properties. C1 [Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Neylan, Thomas C.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Schadt, Eric E.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. [Yehuda, Rachel] Mt Sinai Sch Med, Dept Psychiat & Neurobiol, New York, NY USA. RP Neylan, TC (reprint author), VAMC 116P,4150 Clement St, San Francisco, CA 94121 USA. EM Thomas.Neylan@ucsf.edu NR 63 TC 5 Z9 5 U1 0 U2 8 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2014 VL 5 AR 23938 DI 10.3402/ejpt.v5.23938 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AO4PW UT WOS:000341323900001 ER PT J AU Yehuda, R Vermetten, E McFarlane, AC Lehrner, A AF Yehuda, Rachel Vermetten, Eric McFarlane, Alexander C. Lehrner, Amy TI PTSD in the military: special considerations for understanding prevalence, pathophysiology and treatment following deployment SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Editorial Material DE posttraumatic stress disorder; combat; military; deployment; prevalence; treatment; biomarkers ID PERSONNEL; IRAQ AB Given the unique context of warzone engagement, which may include chronic threat, multiple and lengthy deployments, and loss, there is a need to understand whether and to what extent knowledge about PTSD derived from studies of civilian trauma exposure is generalizeable to the military. This special issue on PTSD in the military addresses a range of issues and debates related to mental health in military personnel and combat veterans. This article provides an overview of the issues covered in selected contributions that have been assembled for a special volume to consider issues unique to the military. Several leading scholars and military experts have contributed papers regarding: 1) prevalence rates of PTSD and other post-deployment mental health problems in different NATO countries, 2) the search for biomarkers of PTSD and the potential applications of such findings, and 3) prevention and intervention approaches for service members and veterans. The volume includes studies that highlight the divergence in prevalence rates of PTSD and other post-deployment mental health problems across nations and that discuss potential causes and implications. Included studies also provide an overview of research conducted in military or Veteran's Affairs settings, and overarching reviews of military-wide approaches to research, promotion of resilience, and mental health interventions in the Unites States and across NATO and allied ISAF partners. C1 [Yehuda, Rachel; Lehrner, Amy] James J Peters Vet Affairs Med Ctr, New York, NY USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Vermetten, Eric] Leiden Univ Med Ctr, Dept Psychiat, Leiden, Netherlands. [Vermetten, Eric] Arq Psychotrauma Expert Grp, Diemen, Netherlands. [Vermetten, Eric] Mil Mental Hlth Res, Dept Def, Utrecht, Netherlands. [McFarlane, Alexander C.] Univ Adelaide, Ctr Traumat Stress Studies, Adelaide, SA, Australia. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@va.gov NR 20 TC 3 Z9 3 U1 1 U2 12 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2014 VL 5 AR 25322 DI 10.3402/ejpt.v5.25322 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AO2HS UT WOS:000341140400001 ER PT J AU Imel, ZE Barco, JS Brown, HJ Baucom, BR Baer, JS Kircher, JC Atkins, DC AF Imel, Zac E. Barco, Jacqueline S. Brown, Halley J. Baucom, Brian R. Baer, John S. Kircher, John C. Atkins, David C. TI The Association of Therapist Empathy and Synchrony in Vocally Encoded Arousal SO JOURNAL OF COUNSELING PSYCHOLOGY LA English DT Article DE empathy; synchrony; speech signal processing ID INTERPERSONAL COMPLEMENTARITY; FUNDAMENTAL-FREQUENCY; SOCIAL-INTERACTION; PSYCHOTHERAPY; MODELS; EXPRESSION; CONFLICT; PATTERNS; LANGUAGE; EMOTION AB Empathy is a critical ingredient in motivational interviewing (MI) and in psychotherapy generally. It is typically defined as the ability to experience and understand the feelings of another. Basic science indicates that empathy is related to the development of synchrony in dyads. However, in clinical research, empathy has proved difficult to operationalize and measure, and has mostly relied on the felt sense of observers, clients, or therapists. We extracted estimates of therapist and standardized patient (SP) vocally encoded arousal (mean fundamental frequency; mean f(0)) in 89 MI sessions with high and low empathy ratings from independent observers. We hypothesized (a) therapist and SP mean f0 would be correlated and (b) the correlation of therapist and SP mean f(0) would be greater in sessions with high empathy as compared with low. On the basis of a multivariate mixed model, the correlation between therapist and SP mean f(0) was large (r = .71) and close to 0 in randomly assigned therapist-SP dyads (r = -.08). The association was higher in sessions with high empathy ratings (r = .80) than in sessions with low ratings (r = .36). There was strong evidence for vocal synchrony in clinical dyads as well as for the association of synchrony with empathy ratings, illustrating the relevance of basic psychological processes to clinical interactions. These findings provide initial evidence for an objective and nonobtrusive method for assessing therapist performance. Novel indicators of therapist empathy may have implications for the study of MI process as well as the training of therapists generally. C1 [Imel, Zac E.; Barco, Jacqueline S.; Brown, Halley J.; Kircher, John C.] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA. [Baucom, Brian R.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA. [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Baer, John S.] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA USA. [Atkins, David C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Imel, ZE (reprint author), Univ Utah, Dept Educ Psychol, Counseling Psychol Program, 1705 Campus Ctr Dr,Room 327, Salt Lake City, UT 84112 USA. EM zac.imel@utah.edu OI imel, zachary/0000-0001-9645-7184; Atkins, David/0000-0002-5781-9880 FU NIAAA NIH HHS [R01 AA018673]; NIDA NIH HHS [R01 DA016360, R34 DA034860] NR 53 TC 14 Z9 14 U1 1 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-0167 EI 1939-2168 J9 J COUNS PSYCHOL JI J. Couns. Psychol. PD JAN PY 2014 VL 61 IS 1 BP 146 EP 153 DI 10.1037/a0034943 PG 8 WC Psychology, Educational; Psychology, Applied SC Psychology GA AO2SF UT WOS:000341175100013 PM 24274679 ER PT J AU Wei, LN Sweeney, AJ Sheng, LY Fang, Y Kindy, MS Xi, TF Gao, BZ AF Wei, Lina Sweeney, Andrew J. Sheng, Liyuan Fang, Yu Kindy, Mark S. Xi, Tingfei Gao, Bruce Z. TI Single-neuron axonal pathfinding under geometric guidance: low-dose-methylmercury developmental neurotoxicity test SO LAB ON A CHIP LA English DT Article ID WHITE-MATTER; IN-VITRO; GROWTH; EXPOSURE; MECHANISMS; OUTGROWTH; CULTURE; BINDING; PIONEER; AUTISM AB Because the nervous system is most vulnerable to toxicants during development, there is a crucial need for a highly sensitive developmental-neurotoxicity-test model to detect potential toxicants at low doses. We developed a lab-on-chip wherein single-neuron axonal pathfinding under geometric guidance was created using soft lithography and laser cell-micropatterning techniques. After coating the surface with L1, an axon-specific member of the Ig family of cell adhesion molecules (CAMs), and optimizing microunit geometric parameters, we introduced low-dose methylmercury, a well-known, environmentally significant neurotoxicant, in the shared medium. Its developmental neurotoxicity was evaluated using a novel axonal pathfinding assay including axonal turning and branching rates at turning points in this model. Compared to the conventional neurite-outgrowth assay, this model's detection threshold for low-dose methylmercury was 10-fold more sensitive at comparable exposure durations. These preliminary results support study of developmental effects of known and potential neurotoxicants on axon pathfinding. This novel assay model would be useful to study neuronal disease mechanisms at the single-cell level. To our knowledge, the potential of methylmercury chloride to cause acute in vitro developmental neurotoxicity (DNT) at such a low dosage has not been reported. This is the first DNT test model with high reproducibility to use single-neuron axonal pathfinding under precise geometric guidance. C1 [Wei, Lina; Xi, Tingfei] Peking Univ, Acad Adv Interdisciplinary Studies, Ctr Biomed Mat & Tissue Engn, Beijing 100871, Peoples R China. [Sweeney, Andrew J.; Kindy, Mark S.; Gao, Bruce Z.] Clemson Univ, Dept Bioengn, Biophoton Lab, Clemson, SC 29634 USA. [Sheng, Liyuan; Xi, Tingfei] Peking Univ, Shenzhen Inst, Key Lab Human Tissue Regenerat & Repair, Shenzhen 518057, Peoples R China. [Fang, Yu] Natl Inst Food & Drug Control, Inst Med Devices Control, Div Standardizat & Sci Res, Beijing 100050, Peoples R China. [Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29466 USA. [Kindy, Mark S.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29466 USA. [Kindy, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA. RP Xi, TF (reprint author), Peking Univ, Acad Adv Interdisciplinary Studies, Ctr Biomed Mat & Tissue Engn, Beijing 100871, Peoples R China. EM xitingfei@pku.edu.cn; zgao@clemson.edu RI Sheng, Liyuan/E-2741-2012 OI Sheng, Liyuan/0000-0002-2642-7622 FU National Natural Science Foundation of China [31070847, 31370956]; Strategic New Industry Development Special Foundation of Shenzhen [JCYJ20130402172114948]; Guangdong Provincial Department of Science and Technology, China [2011B050400011]; NIH COBRE grant from NIGMS [NIH P20GM103444] FX The authors would like to thank Dr. Ken Webb for insightful discussion of application of L1. This work was supported by the National Natural Science Foundation of China (no. 31070847, 31370956), Strategic New Industry Development Special Foundation of Shenzhen (no. JCYJ20130402172114948), Guangdong Provincial Department of Science and Technology, China (2011B050400011), and NIH COBRE grant from NIGMS (NIH P20GM103444). NR 33 TC 2 Z9 2 U1 4 U2 19 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 EI 1473-0189 J9 LAB CHIP JI Lab Chip PY 2014 VL 14 IS 18 BP 3564 EP 3571 DI 10.1039/c4lc00723a PG 8 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA AN3GQ UT WOS:000340474300017 PM 25041816 ER PT J AU Portelius, E Soininen, H Andreasson, U Zetterberg, H Persson, R Karlsson, G Blennow, K Herukka, SK Mattsson, N AF Portelius, Erik Soininen, Hilkka Andreasson, Ulf Zetterberg, Henrik Persson, Rita Karlsson, Goesta Blennow, Kaj Herukka, Sanna-Kaisa Mattsson, Niklas TI Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid SO NEURODEGENERATIVE DISEASES LA English DT Article DE Down's syndrome; Alzheimer's disease; Orexin-A; Amyloid-beta; YKL-40; Tau ID AMYLOID-BETA-PEPTIDE; DISEASE; PROTEIN; DEMENTIA; OREXIN; TAU; INFLAMMATION; DEPOSITION; BRAIN; CDNA AB Background: Individuals with Down's syndrome (DS) develop early Alzheimer's disease (AD) with beta-amyloid (A beta) plaque pathology. The extra amyloid precursor protein (APP) gene copy in DS is believed to result in a 50% increase in A beta production, but it is unclear how this relates to the development of other AD hallmarks, including axonal degeneration and microglia cell activation, and to other neurological problems in DS, including disturbed sleep regulation. Objective: To evaluate if cerebrospinal fluid (CSF) biomarkers for cerebral annyloidosis, axonal degeneration, microglial activation and sleep regulation were altered in young and old patients with DS, and if these biomarkers were related to altered A beta and APP metabolism, reflected by CSF levels of different A beta and APP peptides. Methods: CSF from DS patients (n = 12) and healthy controls (n = 20) were analyzed for A beta peptides (A beta 1-42, A beta X-38/40/42), secreted APP species (sAPP alpha/beta), biomarkers for AD-like axonal degeneration [total tau (T-tau), phosphorylated tau], microglial activation (YKL-40, CC chemokine ligand 2) and orexin-A, which is a peptide involved in sleep regulation. We compared biomarker levels between groups and tested for relations between biomarkers, disease stage and age. Results: Several of the markers were specifically increased in DS, including ABX-40, sAPP alpha and sAPP beta. Orexin-A was significantly decreased in DS and correlated with A beta and sAPP. Orexin-A decreased with age in DS, while T-tau and YKL-40 increased with age. Conclusion: Down's patients have increased APP and A beta production and increased microglial activation with age. The orexin-A metabolism is disturbed in DS and may be linked to APP and A beta production. Bionnarker studies of DS may contribute to our understanding of the annyloidogenic and neurodegenerative process in AD. (C) 2014 S. Karger AG, Basel C1 [Portelius, Erik; Andreasson, Ulf; Zetterberg, Henrik; Persson, Rita; Karlsson, Goesta; Blennow, Kaj; Mattsson, Niklas] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden. [Soininen, Hilkka; Herukka, Sanna-Kaisa] Univ Eastern Finland, Dept Neurol, Kuopio, Finland. [Soininen, Hilkka; Herukka, Sanna-Kaisa] Kuopio Univ Hosp, SF-70210 Kuopio, Finland. [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London, England. [Mattsson, Niklas] Univ Calif San Francisco, Ctr Imaging Neurodegenerat Dis, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Mattsson, Niklas] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Portelius, E (reprint author), Sahlgrenska Univ Hosp Molndal, Dept Psychiat & Neurochem, SE-43180 Molndal, Sweden. EM erik.portelius@neuro.gu.se FU Swedish Research Council [14002, K2010-63P-21562-01-4, K2011-61X-20401-05-6]; Knut and Alice Wallenberg Foundation; Stiftelsen Gamla Tjanarinnor; Magn. Bergvalls Stiftelse; Gun och Bertil Stohnes Stiftelse; Swedish Brain Fund; Alzheimer Foundation, Sweden; Dementia Association, Sweden; Wenner-Gren foundation; JPND Project BIOMARKAPD; Goteborgs Lakaresallskap; Svenska Lakaresallskapet; Sahlgrenska Universitetssjukhuset; Carl-Bertil Laurells fond; Klinisk Biokemi i Norden FX This study was supported by the Swedish Research Council (project No. 14002, K2010-63P-21562-01-4, K2011-61X-20401-05-6), the Knut and Alice Wallenberg Foundation, Stiftelsen Gamla Tjanarinnor, Magn. Bergvalls Stiftelse, Gun och Bertil Stohnes Stiftelse, the Swedish Brain Fund, the Alzheimer Foundation, Sweden, the Dementia Association, Sweden, the Wenner-Gren foundation, the JPND Project BIOMARKAPD, Goteborgs Lakaresallskap, Svenska Lakaresallskapet, Sahlgrenska Universitetssjukhuset, Carl-Bertil Laurells fond and Klinisk Biokemi i Norden. NR 47 TC 9 Z9 10 U1 1 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2854 EI 1660-2862 J9 NEURODEGENER DIS JI Neurodegener. Dis. PY 2014 VL 14 IS 2 BP 98 EP 106 DI 10.1159/000358800 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA AN7WV UT WOS:000340812600005 PM 24992945 ER PT S AU Carrithers, MD AF Carrithers, Michael D. BE Tselis, AC Booss, J TI Innate immune viral recognition: relevance to CNS infections SO NEUROVIROLOGY SE Handbook of Clinical Neurology LA English DT Article; Book Chapter ID WEST-NILE-VIRUS; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; RIG-I; ADAPTIVE IMMUNITY; SIGNAL-TRANSDUCTION; MULTIPLE-SCLEROSIS; STRANDED-RNA; HEPATITIS-C; MACROPHAGES C1 [Carrithers, Michael D.] William S Middleton Mem Vet Adm Med Ctr, Neurol Serv, Madison, WI USA. [Carrithers, Michael D.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA. RP Carrithers, MD (reprint author), Univ Wisconsin, Dept Neurol, 1300 Univ Ave,Room 2679, Madison, WI 53706 USA. EM carrithers@neurology.wisc.edu NR 62 TC 3 Z9 3 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0072-9752 BN 978-0-444-53488-0; 978-0-702-04539-4 J9 HAND CLINIC PY 2014 VL 123 BP 215 EP 223 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA BB1EM UT WOS:000341048300011 PM 25015487 ER PT J AU Mattocks, KM Frayne, S Phibbs, CS Yano, EM Zephyrin, L Shryock, H Haskell, S Katon, J Sullivan, JC Weinreb, L Ulbricht, C Bastian, LA AF Mattocks, Kristin M. Frayne, Susan Phibbs, Ciaran S. Yano, Elizabeth M. Zephyrin, Laurie Shryock, Holly Haskell, Sally Katon, Jodie Sullivan, J. Cherry Weinreb, Linda Ulbricht, Christine Bastian, Lori A. TI Five-year Trends in Women Veterans' Use of VA Maternity Benefits, 2008-2012 SO WOMENS HEALTH ISSUES LA English DT Article ID HEALTH-CARE; MENTAL-HEALTH; RISK-FACTORS; MEDICAID; COVERAGE; FEMALE; AFGHANISTAN; PREVALENCE; PREGNANCY; MILITARY AB Background: An increasing number of young women veterans are returning from war and military service and are seeking reproductive health care from the Veterans Health Administration (VHA). Many of these women seek maternity benefits from the VHA, and yet little is known regarding the number of women veterans utilizing VHA maternity benefits nor the characteristics of pregnant veterans using these benefits. In May 2010, VHA maternity benefits were expanded to include 7 days of infant care, which may serve to entice more women to use VHA maternity benefits. Understanding the changing trends in women veterans seeking maternity benefits will help the VHA to improve the quality of reproductive care over time. Objective: The goal of this study was to examine the trends in delivery claims among women veterans receiving VHA maternity benefits over a 5-year period and the characteristics of pregnant veterans utilizing VHA benefits. Design: We undertook a retrospective, national cohort study of pregnant veterans enrolled in VHA care with inpatient deliveries between fiscal years (FY) 2008 and 2012. Participants: We included pregnant veterans using VHA maternity benefits for delivery. Main Measures: Measures included annualized numbers and rates of inpatient deliveries and delivery-related costs, as well as cesarean section rates as a quality indicator. Key Results: During the 5-year study period, there was a significant increase in the number of deliveries to women veterans using VHA maternity benefits. The overall delivery rate increased by 44% over the study period from 12.4 to 17.8 deliveries per 1,000 women veterans. A majority of women using VHA maternity benefits were age 30 or older and had a service-connected disability. From FY 2008 to 2012, the VHA paid more than $46 million in delivery claims to community providers for deliveries to women veterans ($4,993/veteran). Conclusions: Over a 5-year period, the volume of women veterans using VHA maternity benefits increased by 44%. Given this sizeable increase, the VHA must increase its capacity to care for pregnant veterans and ensure care coordination systems are in place to address the needs of pregnant veterans with service-connected disabilities. Published by Elsevier Inc. on behalf of the Jacobs Institute of Women's Health. C1 [Mattocks, Kristin M.] VA Cent Western Massachusetts, Res & Dev, Leeds, MA USA. [Mattocks, Kristin M.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Frayne, Susan] VA Palo Alto Hlth Care Syst, VA HSR&D Ctr Excellence, Ctr Hlth Care Evaluat, Palo Alto, CA USA. [Frayne, Susan] Stanford Univ, Div Gen Med Disciplines, Palo Alto, CA 94304 USA. [Frayne, Susan] Stanford Univ, Ctr Primary Care & Outcomes Res, Palo Alto, CA 94304 USA. [Phibbs, Ciaran S.] VA Palo Alto Hlth Care Syst, VA Palo Alto Hlth Care Syst Ctr Hlth Care Evaluat, Hlth Econ Resource Ctr, Palo Alto, CA USA. [Phibbs, Ciaran S.] Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Dept Pediat, Stanford, CA 94305 USA. [Yano, Elizabeth M.] VA Greater Angeles HSR&D Ctr Excellence Study Hea, Sepulveda, CA USA. [Yano, Elizabeth M.] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Zephyrin, Laurie] Dept Vet Affairs, Off Patient Care Serv, Womens Hlth Serv, New York, NY USA. [Shryock, Holly] VHA Chief Business Off, Purchased Care Program Oversight & Informat, Denver, CO USA. [Haskell, Sally] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Katon, Jodie] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Katon, Jodie] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Sullivan, J. Cherry] VA Cent Western Massachusetts Healthcare Syst, Leeds, MA USA. [Weinreb, Linda] Univ Massachusetts, Sch Med, Dept Family Med & Community Hlth, Worcester, MA USA. [Ulbricht, Christine] Univ Massachusetts, Sch Med, Worcester, MA USA. [Bastian, Lori A.] VA Connecticut, Newington, CT USA. [Bastian, Lori A.] Univ Connecticut, Div Gen Internal Med, Farmington, CT USA. RP Mattocks, KM (reprint author), VA Cent Western Massachusetts Hlth Care Syst VACW, Leeds, MA 01642 USA. EM Kristin.Mattocks@va.gov NR 34 TC 10 Z9 10 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JAN-FEB PY 2014 VL 24 IS 1 BP E37 EP E42 DI 10.1016/j.whi.2013.10.002 PG 6 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA AO1YW UT WOS:000341112500007 PM 24439945 ER PT J AU Lovejoy, TI Heckman, TG AF Lovejoy, Travis I. Heckman, Timothy G. TI Depression Moderates Treatment Efficacy of an HIV Secondary-Prevention Intervention for HIV-Positive Late Middle-Age and Older Adults SO BEHAVIORAL MEDICINE LA English DT Article DE depression; HIV/AIDS; moderator; motivational interviewing; sexual risk behavior ID RISKY SEXUAL-BEHAVIOR; STRESS SCALES DASS; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-TRIALS; BECK DEPRESSION; PRIMARY-CARE; MEN; INFECTION; STATES; HIV/AIDS AB An estimated one-third of HIV-positive older adults continues to engage in sexual behaviors that risk HIV transmission or the acquisition of other sexually transmitted infections. A recently completed pilot randomized controlled trial of telephone-administered motivational interviewing (Tele-MI) targeting sexual risk behavior in 100 HIV-positive late middle-age and older adults found that a four-session Tele-MI intervention reduced episodes of noncondom- protected anal and vaginal intercourse. This secondary analysis examined the moderating effect of baseline depressive symptoms on intervention efficacy. When compared to one session of Tele-MI or standard of care, four sessions of Tele-MI produced greater reductions in sexual risk behavior in participants with subsyndromal depression at baseline but was no more efficacious than the other two conditions for participants with no or elevated baseline depressive symptoms. Large-scale studies that further elucidate the role of depression in sexual risk reduction interventions for HIV-positive persons are needed. C1 [Lovejoy, Travis I.] Portland VA Med Ctr, Portland, OR 97239 USA. [Lovejoy, Travis I.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Heckman, Timothy G.] Univ Georgia, Coll Publ Hlth, Athens, GA 30602 USA. RP Lovejoy, TI (reprint author), Portland VA Med Ctr, R&D 66,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM travis.lovejoy@va.gov NR 40 TC 4 Z9 4 U1 4 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0896-4289 EI 1940-4026 J9 BEHAV MED JI Behav. Med. PY 2014 VL 40 IS 3 SI SI BP 124 EP 133 DI 10.1080/08964289.2014.893982 PG 10 WC Behavioral Sciences; Psychiatry SC Behavioral Sciences; Psychiatry GA AN2YL UT WOS:000340451900006 PM 25090365 ER PT J AU Tsai, CY Hogaboom, NS Boninger, ML Koontz, AM AF Tsai, Chung-Ying Hogaboom, Nathan S. Boninger, Michael L. Koontz, Alicia M. TI The Relationship between Independent Transfer Skills and Upper Limb Kinetics in Wheelchair Users SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID SPINAL-CORD-INJURY; SITTING PIVOT TRANSFERS; UPPER EXTREMITY PAIN; LOW-LEVEL PARAPLEGIA; SHOULDER PAIN; JOINT KINEMATICS; INDIVIDUALS; PATIENT; SYSTEM; ELBOW AB Transfers are one of the most physically demanding wheelchair activities. The purpose of this study was to determine if using proper transfer skills as measured by the Transfer Assessment Instrument (TAI) is associated with reduced loading on the upper extremities. Twenty-three wheelchair users performed transfers to a level-height bench while a series of forces plates, load cells, and a motion capture system recorded the biomechanics of their natural transferring techniques. Their transfer skills were simultaneously evaluated by two study clinicians using the TAI. Logistic regression and multiple linear regression models were used to determine the relationships between TAI scores and the kinetic variables on both arms across all joints. The results showed that the TAI measured transfer skills were closely associated with the magnitude and timing of joint moments (P < .02, model R-2 values ranged from 0.27 to 0.79). Proper completion of the skills which targeted the trailing arm was associated with lower average resultant moments and rates of rise of resultant moments at the trailing shoulder and/or elbow. Some skills involving the leading side had the effect of increasing the magnitude or rate loading on the leading side. Knowledge of the kinetic outcomes associated with each skill may help users to achieve the best load-relieving effects for their upper extremities. C1 [Tsai, Chung-Ying; Hogaboom, Nathan S.; Boninger, Michael L.; Koontz, Alicia M.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Tsai, Chung-Ying; Hogaboom, Nathan S.; Boninger, Michael L.; Koontz, Alicia M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. [Boninger, Michael L.; Koontz, Alicia M.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA. [Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA. RP Koontz, AM (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu OI Hogaboom, Nathan/0000-0002-0601-5751; Boninger, Michael/0000-0001-6966-919X FU Department of Veterans Affairs [B7149I] FX This material is based upon work supported by the Department of Veterans Affairs (B7149I). NR 57 TC 2 Z9 2 U1 1 U2 3 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2014 AR 984526 DI 10.1155/2014/984526 PG 12 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA AN2DV UT WOS:000340394900001 ER PT J AU Slatore, CG Feemster, LC Au, DH Engelberg, RA Curtis, JR Uman, J Reinke, LF AF Slatore, Christopher G. Feemster, Laura Cecere Au, David H. Engelberg, Ruth A. Curtis, J. Randall Uman, Jane Reinke, Lynn F. TI Which Patient and Clinician Characteristics Are Associated With High-Quality Communication Among Veterans With Chronic Obstructive Pulmonary Disease? SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID OF-LIFE CARE; HEALTH-CARE; PATIENTS PERCEPTIONS; COPD; SATISFACTION; PHYSICIANS; OUTCOMES; RECOMMENDATIONS; QUESTIONNAIRE; MANAGEMENT AB The authors evaluated associations of patient and clinician characteristics with high-quality communication among patients with chronic obstructive pulmonary disease. Using a cross-sectional analysis from patients with chronic obstructive pulmonary disease enrolled in a clinical trial, the authors evaluated the association of patient and clinician characteristics with patient-reported communication quality. The authors measured these associations using general estimating equations and adjusted odds ratios for best imagined communication quality. Most patient and clinician characteristics, including age, race I ethnicity, mental health attributes, and clinician specialty, were not associated with communication quality. Patient-reported clinician expertise (OR= 2.10, 95% CI [1.52, 2.88], p < .001) was associated with increased communication quality, while the patient not being married was associated with decreased quality (OR= 0.52, 95% CI [0.27, 0.99], p =.047). Only one modifiable characteristic, patient-reported clinician expertise, was associated with best imagined communication quality. This characteristic may be important to include as a potential intermediate outcome in future communication intervention studies. Predictors and outcomes of communication quality are not uniform across patient populations and settings. To maximize the effectiveness of communication interventions, it is important to have a thorough understanding of which patient, clinician, and system factors are associated with communication quality. C1 [Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR 97239 USA. [Slatore, Christopher G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR 97239 USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Feemster, Laura Cecere; Au, David H.; Uman, Jane; Reinke, Lynn F.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Feemster, Laura Cecere; Au, David H.; Engelberg, Ruth A.; Curtis, J. Randall] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA. [Reinke, Lynn F.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. RP Slatore, CG (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM christopher.slatore@va.gov OI Slatore, Christopher/0000-0003-0958-8122 NR 46 TC 0 Z9 0 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 CHESTNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1081-0730 EI 1087-0415 J9 J HEALTH COMMUN JI J. Health Commun. PY 2014 VL 19 IS 8 BP 907 EP 921 DI 10.1080/10810730.2013.864732 PG 15 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA AN3PO UT WOS:000340500600004 PM 24558957 ER PT S AU Faverio, P Restrepo, MI AF Faverio, Paola Restrepo, Marcos I. BE Chalmers, JD Pletz, MW Aliberti, S Welte, T TI Non-antibiotic therapies for CAP SO COMMUNITY-ACQUIRED PNEUMONIA SE European Respiratory Monograph LA English DT Article; Book Chapter ID COMMUNITY-ACQUIRED PNEUMONIA; CONVERTING-ENZYME-INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; FACTOR PATHWAY INHIBITOR; PSEUDOMONAS-AERUGINOSA PNEUMONIA; PLACEBO-CONTROLLED TRIAL; NITRIC-OXIDE INHALATION; II RECEPTOR BLOCKERS; INTENSIVE-CARE-UNIT; LUNG FLUID BALANCE AB Several novel non-antibiotic therapies have been used in patients with pneumonia. Among many alternatives, anti-inflammatory and immunomodulatory agents such as corticosteroids, statins, nonsteroid anti-inflammatory medications, immunoglobulins and anticoagulants have been tested. Other agents, such as angiotensin-converting enzyme inhibitors and mucolytics, showed a potential beneficial effect on airways protection mechanisms and secretion clearance. The therapeutic effect of nonpharmacological strategies (i.e. chest physiotherapy) has also been considered. However, other than use of corticosteroids in certain populations, there is still a need for further research before these medications are recommended for clinical use. This chapter discusses the evidence regarding novel non-antibiotic therapies and the association with clinical outcomes in patients with pneumonia. C1 [Faverio, Paola] Univ Milano Bicocca, Dept Hlth Sci, Clin Pneumol, AO San Gerardo, Monza, Italy. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst ALMD, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu NR 92 TC 1 Z9 1 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOCIETY PI SHEFFIELD PA 442 GLOSSOP ROAD, SHEFFIELD, S10 2PX, ENGLAND SN 2075-6674 BN 978-1-84984-049-1; 978-1-84984-048-4 J9 EUR RESPIR MONOGR PY 2014 IS 63 BP 219 EP 233 DI 10.1183/1025448x.10004513 D2 10.1183/1025448x.erm6314 PG 15 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA BA9YL UT WOS:000339965900018 ER PT J AU Hirsch, J Chalkley, RJ Bentley, T Burlingame, AL Frank, JA AF Hirsch, Jan Chalkley, Robert J. Bentley, Trevor Burlingame, Alma L. Frank, James A. TI Double impact of cigarette smoke and mechanical ventilation on the alveolar epithelial type II cell SO CRITICAL CARE LA English DT Article ID ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; QUADRUPOLE COLLISION CELL; FLIGHT MASS-SPECTROMETER; RISK-FACTORS; BRONCHOALVEOLAR LAVAGE; COMPREHENSIVE ANALYSIS; MEMBRANE-PROTEINS; OXIDATIVE STRESS; TIDAL VOLUMES AB Introduction: Ventilator-induced lung injury (VILI) impacts clinical outcomes in acute respiratory distress syndrome (ARDS), which is characterized by neutrophil-mediated inflammation and loss of alveolar barrier function. Recent epidemiological studies suggest that smoking may be a risk factor for the development of ARDS. Because alveolar type II cells are central to maintaining the alveolar epithelial barrier during oxidative stress, mediated in part by neutrophilic inflammation and mechanical ventilation, we hypothesized that exposure to cigarette smoke and mechanical strain have interactive effects leading to the activation of and damage to alveolar type II cells. Methods: To determine if cigarette smoke increases susceptibility to VILI in vivo, a clinically relevant rat model was established. Rats were exposed to three research cigarettes per day for two weeks. After this period, some rats were mechanically ventilated for 4 hours. Bronchoalveolar lavage (BAL) and differential cell count was done and alveolar type II cells were isolated. Proteomic analysis was performed on the isolated alveolar type II cells to discover alterations in cellular pathways at the protein level that might contribute to injury. Effects on levels of proteins in pathways associated with innate immunity, oxidative stress and apoptosis were evaluated in alveolar type II cell lysates by enzyme-linked immunosorbent assay. Statistical comparisons were performed by t-tests, and the results were corrected for multiple comparisons using the false discovery rate. Results: Tobacco smoke exposure increased airspace neutrophil influx in response to mechanical ventilation. The combined exposure to cigarette smoke and mechanical ventilation significantly increased BAL neutrophil count and protein content. Neutrophils were significantly higher after smoke exposure and ventilation than after ventilation alone. DNA fragments were significantly elevated in alveolar type II cells. Smoke exposure did not significantly alter other protein-level markers of cell activation, including Toll-like receptor 4; caspases 3, 8 and 9; and heat shock protein 70. Conclusions: Cigarette smoke exposure may impact ventilator-associated alveolar epithelial injury by augmenting neutrophil influx. We found that cigarette smoke had less effect on other pathways previously associated with VILI, including innate immunity, oxidative stress and apoptosis. C1 [Hirsch, Jan; Chalkley, Robert J.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Hirsch, Jan; Chalkley, Robert J.] San Francisco VA Med Ctr, Anesthesia Serv, San Francisco, CA 94121 USA. [Bentley, Trevor; Burlingame, Alma L.; Frank, James A.] Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spectrometry Facil, San Francisco, CA 94158 USA. [Bentley, Trevor; Burlingame, Alma L.; Frank, James A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Bentley, Trevor; Burlingame, Alma L.; Frank, James A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Bentley, Trevor; Burlingame, Alma L.; Frank, James A.] San Francisco VA Med Ctr, Med Serv, Div Pulm, San Francisco, CA 94121 USA. RP Hirsch, J (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. EM jan.hirsch@ucsf.edu FU National Institutes of Health [8P41GM103481, HL088440]; intramural Research Evaluation and Allocation Committee grant from the University of California, San Francisco; Department of Anesthesia and Perioperative Care at the University of California, San Francisco; Northern California Institute for Research and Education FX This study was supported in part by grants from the National Institutes of Health (8P41GM103481 to ALB and HL088440 to JAF), an intramural Research Evaluation and Allocation Committee grant from the University of California, San Francisco (to JH), and startup funds from the Department of Anesthesia and Perioperative Care at the University of California, San Francisco, and the Northern California Institute for Research and Education (to JH). No private funding was used. This national and university grant funding provided resources for the design, collection, analysis and interpretation of data as well as salary support. The writing of the manuscript and the decision to submit it for publication were carried out by the authors without the participation or influence of, or restrictions by, any of the funding sources. NR 54 TC 5 Z9 5 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X EI 1364-8535 J9 CRIT CARE JI Crit. Care PY 2014 VL 18 IS 2 AR R50 DI 10.1186/cc13795 PG 12 WC Critical Care Medicine SC General & Internal Medicine GA AM1SA UT WOS:000339627400068 PM 24666941 ER PT J AU Leavitt, VM Cirnigliaro, C Cohen, A Farag, A Brooks, M Wecht, JM Wylie, GR Chiaravalloti, ND DeLuca, J Sumowski, JF AF Leavitt, V. M. Cirnigliaro, C. Cohen, A. Farag, A. Brooks, M. Wecht, J. M. Wylie, G. R. Chiaravalloti, N. D. DeLuca, J. Sumowski, J. F. TI Aerobic exercise increases hippocampal volume and improves memory in multiple sclerosis: Preliminary findings SO NEUROCASE LA English DT Article DE Multiple sclerosis; Aerobic; Memory; Functional connectivity; Hippocampus AB Multiple sclerosis leads to prominent hippocampal atrophy, which is linked to memory deficits. Indeed, 50% of multiple sclerosis patients suffer memory impairment, with negative consequences for quality of life. There are currently no effective memory treatments for multiple sclerosis either pharmacological or behavioral. Aerobic exercise improves memory and promotes hippocampal neurogenesis in nonhuman animals. Here, we investigate the benefits of aerobic exercise in memory-impaired multiple sclerosis patients. Pilot data were collected from two ambulatory, memory-impaired multiple sclerosis participants randomized to non-aerobic (stretching) and aerobic (stationary cycling) conditions. The following baseline/follow-up measurements were taken: high-resolution MRI (neuroanatomical volumes), fMRI (functional connectivity), and memory assessment. Intervention was 30-minute sessions 3 times per week for 3 months. Aerobic exercise resulted in 16.5% increase in hippocampal volume and 53.7% increase in memory, as well as increased hippocampal resting-state functional connectivity. Improvements were specific, with no comparable changes in overall cerebral gray matter (+2.4%), non-hippocampal deep gray matter structures (thalamus, caudate: -4.0%), or in non-memory cognitive functioning (executive functions, processing speed, working memory: changes ranged from -11% to +4%). Non-aerobic exercise resulted in relatively no change in hippocampal volume (2.8%) or memory (0.0%), and no changes in hippocampal functional connectivity. This is the first evidence for aerobic exercise to increase hippocampal volume and connectivity and improve memory in multiple sclerosis. Aerobic exercise represents a cost-effective, widely available, natural, and self-administered treatment with no adverse side effects that may be the first effective memory treatment for multiple sclerosis patients. C1 [Leavitt, V. M.; Cohen, A.; Wylie, G. R.; Chiaravalloti, N. D.; DeLuca, J.; Sumowski, J. F.] Kessler Fdn, Res Ctr, W Orange, NJ 07052 USA. [Leavitt, V. M.; Wylie, G. R.; Chiaravalloti, N. D.; DeLuca, J.; Sumowski, J. F.] Rutgers New Jersey Med Sch, Newark, NJ USA. [Cirnigliaro, C.; Farag, A.; Brooks, M.; Wecht, J. M.] James J Peters VA Med Ctr, Bronx, NY USA. [Cirnigliaro, C.] Kessler Inst Rehabil, W Orange, NJ USA. RP Leavitt, VM (reprint author), Kessler Fdn, Res Ctr, Neuropsychol & Neurosci Lab, 300 Execut Dr,Suite 70, W Orange, NJ 07052 USA. EM vleavitt@kesslerfoundation.org NR 7 TC 21 Z9 21 U1 3 U2 23 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-4794 EI 1465-3656 J9 NEUROCASE JI Neurocase PY 2014 VL 20 IS 6 BP 695 EP 697 DI 10.1080/13554794.2013.841951 PG 3 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA AN0IW UT WOS:000340269000010 PM 24090098 ER PT J AU Liwanpo, L Ro, C Haq, S Hershman, JM AF Liwanpo, Llanyee Ro, Cynthia Haq, Salman Hershman, Jerome M. TI Sunitinib Does Not Block Thyroid Peroxidase in Patients SO THYROID LA English DT Letter ID HYPOTHYROIDISM C1 [Liwanpo, Llanyee] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Endocrinol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Liwanpo, L (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Endocrinol, Los Angeles, CA 90073 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PY 2014 VL 24 IS 8 BP 1325 EP 1326 DI 10.1089/thy.2014.0006 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AM9JM UT WOS:000340197700017 PM 24521256 ER PT S AU Dorsey, R Graham, G Glied, S Meyers, D Clancy, C Koh, H AF Dorsey, Rashida Graham, Garth Glied, Sherry Meyers, David Clancy, Carolyn Koh, Howard BE Fielding, JE TI Implementing Health Reform: Improved Data Collection and the Monitoring of Health Disparities SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 35 SE Annual Review of Public Health LA English DT Review; Book Chapter DE data standards; Affordable Care Act; demographic data; population-based surveys ID LIMITED ENGLISH PROFICIENCY; PRIMARY LANGUAGE; UNITED-STATES; GENDER-DIFFERENCES; INTELLECTUAL DISABILITIES; MEASUREMENT ISSUES; SEX DIFFERENTIALS; DATA STANDARDS; PUBLIC-HEALTH; MEDICAL-CARE AB The relative lack of standards for collecting data on population subgroups has not only limited our understanding of health disparities, but also impaired our ability to develop policies to eliminate them. This article provides background about past challenges to collecting data by race/ethnicity, primary language, sex, and disability status. It then discusses how passage of the Affordable Care Act has provided new opportunities to improve data-collection standards for the demographic variables of interest and, as such, a better understanding of the characteristics of populations served by the U. S. Department of Health and Human Services (HHS). The new standards have been formally adopted by the Secretary of HHS for application in all HHS-sponsored population health surveys involving self-reporting. The new data-collection standards will not only promote the uniform collection and utilization of demographic data, but also help the country shape future programs and policies to advance public health and to reduce disparities. C1 [Dorsey, Rashida] US Dept HHS, Off Minor Hlth, Rockville, MD 20852 USA. [Graham, Garth] Univ Florida, Dept Med, Gainesville, FL 32611 USA. [Glied, Sherry] NYU, Robert F Wagner Grad Sch Publ Serv, New York, NY 10012 USA. [Meyers, David] US Dept HHS, Agcy Healthcare Res & Qual, Rockville, MD 20850 USA. [Clancy, Carolyn] US Dept Vet Affairs, Off Qual Safety & Value, Washington, DC 20420 USA. [Koh, Howard] US Dept HHS, Off Assistant Secretary Hlth, Washington, DC 20201 USA. RP Dorsey, R (reprint author), US Dept HHS, Off Minor Hlth, Rockville, MD 20852 USA. EM Rashida.Dorsey@hhs.gov; Garth.Graham@medicine.ufl.edu; sherry.glied@nyu.edu; David.Meyers@ahrq.hhs.gov; Carolyn.Clancy@va.gov; Howard.Koh@hhs.gov NR 101 TC 3 Z9 3 U1 3 U2 13 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2735-4 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2014 VL 35 BP 123 EP 138 DI 10.1146/annurev-publhealth-032013-182423 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BA4SB UT WOS:000336207500009 PM 24365094 ER PT J AU Edwards, J Vess, J Reger, G Cernich, A AF Edwards, Joe Vess, James Reger, Greg Cernich, Alison TI The Use of Virtual Reality in the Military's Assessment of Service Members With Traumatic Brain Injury: Recent Developments and Emerging Opportunities SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE assessment; ecological validity; military psychology; traumatic brain injury; virtual reality ID COMPUTERIZED NEUROPSYCHOLOGICAL ASSESSMENT; ECOLOGICAL VALIDITY; EXECUTIVE DYSFUNCTION; COGNITIVE IMPAIRMENTS; DRIVING ASSESSMENT; CLINICAL NEUROPSYCHOLOGY; TASK-PERFORMANCE; REHABILITATION; ENVIRONMENT; SIMULATOR AB Traumatic brain injury (TBI) is a common event in the current extended conflicts by American service members, with estimates that as many as 300,000 have sustained combat-related concussions during Operation Iraqi Freedom and Operation Enduring Freedom. The limited ecological validity of traditional neuropsychological assessment measures presents a challenge to effective postconcussion evaluation of service members in relation to fitness-for-duty decisions or rehabilitation needs. Virtual reality (VR) technology offers a promising opportunity to advance the field of functional assessment for TBI. This article reviews the current professional literature on VR applications for TBI assessment, with special emphasis on those that are particularly relevant to U.S. service members. VR affords several advantages for clinical use. These include assessment of complex sets of cognitive and behavioral functions rather than the isolated components assessed by traditional measures; more precise control over the standardized presentation of task stimuli and the recording of response data; and enhanced ecological validity that can lead to more useful assessment data in the applied contexts faced by the U.S. military. C1 [Edwards, Joe] TBI Clin, Dept Behav Hlth, Ft Wainwright, AK USA. [Vess, James; Reger, Greg] Natl Ctr Telehlth & Technol, Emerging Technol Program, Tacoma, WA 98431 USA. [Cernich, Alison] US Dept Vet Affairs, Mental Hlth Serv, Silver Spring, MD USA. [Cernich, Alison] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Cernich, Alison] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. [Cernich, Alison] Def Ctr Excellence Psychol Hlth, Silver Spring, MD USA. [Cernich, Alison] TBI, Silver Spring, MD USA. RP Vess, J (reprint author), Natl Ctr Telehlth & Technol, Emerging Technol Program, 9933 West Hayes St, Tacoma, WA 98431 USA. EM james.d.vess3.civ@mail.mil NR 106 TC 4 Z9 5 U1 1 U2 16 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0908-4282 EI 1532-4826 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PY 2014 VL 21 IS 3 BP 220 EP 230 DI 10.1080/09084282.2013.796554 PG 11 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA AM9VN UT WOS:000340229200006 PM 25084846 ER PT J AU Boyd, JE Adler, EP Otilingam, PG Peters, T AF Boyd, Jennifer E. Adler, Emerald P. Otilingam, Poomi G. Peters, Townley TI Internalized Stigma of Mental Illness (ISMI) Scale: A multinational review SO COMPREHENSIVE PSYCHIATRY LA English DT Article ID QUALITY-OF-LIFE; SCHIZOPHRENIA SPECTRUM DISORDERS; 14 EUROPEAN COUNTRIES; SELF-STIGMA; BIPOLAR DISORDER; PERCEIVED DISCRIMINATION; PSYCHOMETRIC PROPERTIES; TREATMENT SEEKING; SUBSTANCE-ABUSE; GAMIAN-EUROPE AB The Internalized Stigma of Mental Illness (ISMI) scale is a 29-item questionnaire measuring self-stigma among persons with psychiatric disorders. It was developed with substantial consumer input and has been widely used, but its psychometric qualities have not been comprehensively evaluated across multiple versions. Here we review the 55 known versions, and provide the 47 available versions, including: Arabic, Armenian, Bengali, Bulgarian, Chinese (Mainland, Taiwan, Hong Kong), Croatian, Dutch, English (USA, South Africa), Estonian, Farsi, Finnish, French, German, Greek, Hebrew, Hindi, Japanese, Khmer, Korean, Lithuanian, Lugandan, Maltese, Polish, Portuguese (Portugal, Brazil), Romanian, Russian, Samoan, Slovenian, Spanish (Spain), Swahili, Swedish, Tongan, Turkish, Urdu, and Yoruba, and qualitative English and Swahili versions, as well as versions for depression, schizophrenia, substance abuse, eating disorders, epilepsy, inflammatory bowel disease, leprosy, smoking, parents and caregivers of people with mental illness, and ethnicity. The various versions show reliability and validity across a wide range of languages, cultures, and writing systems. The most commonly reported findings of studies using the ISMI are that internalized stigma correlates with higher depression, lower self esteem, and higher symptom severity. Initial studies of ways to reduce internalized stigma are promising and warrant further investigation. Published by Elsevier Inc. C1 [Boyd, Jennifer E.; Otilingam, Poomi G.; Peters, Townley] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. [Boyd, Jennifer E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Adler, Emerald P.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr Post Traumat Stress Disorder, Menlo Pk, CA 94025 USA. [Peters, Townley] Alliant Int Univ, Calif Sch Profess Psychol, Clin Psychol, San Francisco, CA 94133 USA. RP Boyd, JE (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. EM jennifer.boyd@ucsf.edu NR 85 TC 43 Z9 43 U1 10 U2 52 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0010-440X EI 1532-8384 J9 COMPR PSYCHIAT JI Compr. Psychiat. PD JAN PY 2014 VL 55 IS 1 BP 221 EP 231 DI 10.1016/j.comppsych.2013.06.005 PG 11 WC Psychiatry SC Psychiatry GA AM5VO UT WOS:000339929300027 PM 24060237 ER PT J AU Joshi, A Barsuglia, JP Mather, MJ Jimenez, EE Shapira, J Mendez, MF AF Joshi, Aditi Barsuglia, Joseph P. Mather, Michelle J. Jimenez, Elvira E. Shapira, Jill Mendez, Mario F. TI Evaluation of Emotional Blunting in Behavioral Variant Frontotemporal Dementia Compared to Alzheimer's Disease SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Scale for Emotional Blunting; Dementia; Caregiver ID QUALITY-OF-LIFE; DIAGNOSTIC-CRITERIA; CAREGIVER BURDEN; RATING-SCALES; CONSENSUS AB Background: Emotional blunting is a major clinical feature of behavioral variant frontotemporal dementia (bvFTD). Assessing the change in emotional blunting may facilitate the differential diagnosis of this disorder and can quantify a major source of distress for the patients' caregivers and families. Methods: We evaluated investigator ratings on the Scale for Emotional Blunting (SEB) for 13 patients with bvFTD versus 18 patients with early-onset Alzheimer's disease (AD). The caregivers also performed SEB ratings for both the patients' premorbid behavior (before dementia onset) and the patients' behavior on clinical presentation (after dementia onset). Results: Before the onset of dementia, the caregivers reported normal SEB scores for both dementia groups. After the onset of dementia, both caregivers and investigators reported greater SEB scores for the bvFTD patients compared to the AD patients. The patients were rated to be much more emotionally blunted by the bvFTD caregivers than by the investigators. A change of >= 15 in the caregiver SEB ratings suggests bvFTD. The change in caregiver SEB ratings was positively correlated with bifrontal hypometabolism on FDG-PET scans. Conclusions: Changes in the caregiver assessment of emotional blunting with dementia onset can distinguish patients with bvFTD from those with AD, and they may better reflect the impact of emotional blunting than similar assessments made by clinicians/investigators. (C) 2014 S. Karger AG, Basel C1 [Mather, Michelle J.; Jimenez, Elvira E.; Shapira, Jill; Mendez, Mario F.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Joshi, Aditi; Barsuglia, Joseph P.; Mather, Michelle J.; Jimenez, Elvira E.; Shapira, Jill; Mendez, Mario F.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Mendez, MF (reprint author), VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@ucla.edu OI Barsuglia, Joseph/0000-0001-7337-9486 FU NIA [R01AG034499-04]; VA GRECC Advanced Fellowship FX This study was supported by NIA Grant No. R01AG034499-04 and the VA GRECC Advanced Fellowship in Geriatrics Award (J.B.). We acknowledge Dr. Natalie Wolcott for neuropsychological evaluations. NR 35 TC 4 Z9 4 U1 2 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 EI 1421-9824 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2014 VL 38 IS 1-2 BP 79 EP 88 DI 10.1159/000357838 PG 10 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA AM5JN UT WOS:000339893700009 PM 24603498 ER PT S AU Kreklywich, CN Smith, PP Jones, CB Cornea, A Orloff, SL Streblow, DN AF Kreklywich, Craig N. Smith, Patricia P. Jones, Carmen Baca Cornea, Anda Orloff, Susan L. Streblow, Daniel N. BE Yurochko, AD Miller, WE TI Fluorescence-Based Laser Capture Microscopy Technology Facilitates Identification of Critical In Vivo Cytomegalovirus Transcriptional Programs SO HUMAN CYTOMEGALOVIRUSES: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Laser capture microscopy; Cytomegalovirus; Green fluorescence protein; Microarray analysis ID TRANSPLANT VASCULAR SCLEROSIS; CHRONIC REJECTION; GENE-EXPRESSION; ALLOGRAFT RECIPIENTS; HEART-TRANSPLANTS; INFECTION; LATENCY; ATHEROSCLEROSIS; DISEASE; GENOME AB Cytomegalovirus gene expression in highly permissive, cultured fibroblasts occurs in three kinetic classes known as immediate early, early, and late. Infection of these cells results in a predictable transcriptional program leading to high levels of virus production. Infection of other, so-called, nonpermissive cell types results in a transcriptional program that either fails to produce virus particles or production is substantially reduced compared to fibroblasts. We have found that CMV gene expression profiles in tissues from infected hosts differ greatly from those observed in infected tissue culture cells. The number of viral genes expressed in tissues is much more limited, and the number of highly active genes does not correlate with viral DNA load. Additionally, viral gene expression in vivo is tissue selective with no two tissues expressing the exact same viral gene profile. Thus, in vivo CMV gene expression appears to be governed by mechanisms that are still uncharacterized. Cytomegalovirus remains in a persistent phase for the lifetime of the host. During this phase only a limited number of host cells are infected, and it is very difficult to detect CMV gene expression in whole tissues without sub-fractionating infected vs. uninfected cells. Herein, we describe the development of a fluorescence-based laser capture microscopy technique coupled with small sample size microarray analysis to determine the viral gene expression in 50-100 infected cells isolated from frozen RCMV-infected tissue sections. C1 [Kreklywich, Craig N.; Smith, Patricia P.; Jones, Carmen Baca; Orloff, Susan L.; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Mol Microbiol & Immunol, Beaverton, OR USA. [Kreklywich, Craig N.; Orloff, Susan L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. [Cornea, Anda] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR USA. [Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA. RP Kreklywich, CN (reprint author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Dept Mol Microbiol & Immunol, Beaverton, OR USA. FU NCRR NIH HHS [P51 RR000163, S10 RR027503]; NHLBI NIH HHS [R01 HL083194, HL-66238-01, HL-083194, R01 HL066238] NR 24 TC 1 Z9 1 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-62703-788-4; 978-1-62703-787-7 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2014 VL 1119 BP 217 EP 237 DI 10.1007/978-1-62703-788-4_13 D2 10.1007/978-1-62703-788-4 PG 21 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Virology SC Biochemistry & Molecular Biology; Virology GA BA8RJ UT WOS:000338506900014 PM 24639226 ER PT J AU Wylie, KP Rojas, DC Ross, RG Hunter, SK Maharajh, K Cornier, MA Tregellas, JR AF Wylie, Korey P. Rojas, Donald C. Ross, Randal G. Hunter, Sharon K. Maharajh, Keeran Cornier, Marc-Andre Tregellas, Jason R. TI Reduced brain resting-state network specificity in infants compared with adults SO NEUROPSYCHIATRIC DISEASE AND TREATMENT LA English DT Article DE functional connectivity magnetic resonance imaging; networks; development; infancy; resting-state; connectivity AB Purpose: Infant resting-state networks do not exhibit the same connectivity patterns as those of young children and adults. Current theories of brain development emphasize developmental progression in regional and network specialization. We compared infant and adult functional connectivity, predicting that infants would exhibit less regional specificity and greater internetwork communication compared with adults. Patients and methods: Functional magnetic resonance imaging at rest was acquired in 12 healthy, term infants and 17 adults. Resting-state networks were extracted, using independent components analysis, and the resulting components were then compared between the adult and infant groups. Results: Adults exhibited stronger connectivity in the posterior cingulate cortex node of the default mode network, but infants had higher connectivity in medial prefrontal cortex/anterior cingulate cortex than adults. Adult connectivity was typically higher than infant connectivity within structures previously associated with the various networks, whereas infant connectivity was frequently higher outside of these structures. Internetwork communication was significantly higher in infants than in adults. Conclusion: We interpret these findings as consistent with evidence suggesting that resting-state network development is associated with increasing spatial specificity, possibly reflecting the corresponding functional specialization of regions and their interconnections through experience. C1 [Wylie, Korey P.; Rojas, Donald C.; Ross, Randal G.; Hunter, Sharon K.; Maharajh, Keeran; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. [Cornier, Marc-Andre] Univ Colorado, Dept Med, Div Endocrinol Diabet & Metab, Aurora, CO USA. [Tregellas, Jason R.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tregellas, JR (reprint author), Univ Colorado, Dept Psychiat, Box F456,Anschutz Med Campus,13001 E 17th Ave, Aurora, CO 80045 USA. EM jason.tregellas@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616 FU National Institutes of Health [R01 MH082820, R01 MH081920, R01 DK089095, P50 MH086383]; Brain Research Foundation; Blowitz-Ridgeway Foundation FX Support for this research came from National Institutes of Health grants R01 MH082820, R01 MH081920, R01 DK089095, and P50 MH086383; the Brain Research Foundation; and the Blowitz-Ridgeway Foundation. The financial sponsors had no role in the design, data collection analysis, data interpretation, or writing of the manuscript or decision to submit the manuscript for publication. NR 2 TC 9 Z9 9 U1 1 U2 8 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2021 J9 NEUROPSYCH DIS TREAT JI Neuropsychiatr. Dis. Treat. PY 2014 VL 10 BP 1349 EP 1359 DI 10.2147/NDT.S63773 PG 11 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA AM5TX UT WOS:000339924600001 PM 25092980 ER PT J AU Warren, M Martindale, R AF Warren, Malissa Martindale, Robert BE Faber, P Siervo, M TI Enteral and parenteral feeding protocols SO NUTRITION IN CRITICAL CARE LA English DT Article; Book Chapter ID INTENSIVE-CARE-UNIT; CONTROLLED-TRIAL; ENERGY DEFICIT; NUTRITION; IMPLEMENTATION; MULTICENTER; DELIVERY; THERAPY; IMPACT C1 [Warren, Malissa] Portland VA Med Ctr, Portland, OR 97239 USA. [Martindale, Robert] Oregon Hlth & Sci Univ, Div Gen Surg, Portland, OR 97201 USA. RP Warren, M (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND BN 978-1-107-66901-7 PY 2014 BP 43 EP 51 D2 10.1017/CBO9781139342452 PG 9 WC Critical Care Medicine; Nutrition & Dietetics SC General & Internal Medicine; Nutrition & Dietetics GA BA9KT UT WOS:000339513400006 ER PT S AU Wheeler, JB Ikonomidis, JS Jones, JA AF Wheeler, Jason B. Ikonomidis, John S. Jones, Jeffrey A. BE Halper, J TI Connective Tissue Disorders and Cardiovascular Complications: The Indomitable Role of Transforming Growth Factor-Beta Signaling SO PROGRESS IN HERITABLE SOFT CONNECTIVE TISSUE DISEASES SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Shprintzen-Goldberg syndrome hereditary hemorrhagic telangiectasia (HHT); Marfan syndrome (MFS); Loeys-Dietz syndrome (LDS); Primary pulmonary hypertension; Fibrodysplasia ossificans progressiva (FOP); Familial thoracic aortic aneurysm and dissection syndrome (FTAAD); Smad; TGF-beta receptor; Curacao diagnostic criteria ID HEREDITARY HEMORRHAGIC TELANGIECTASIA; SHPRINTZEN-GOLDBERG-SYNDROME; THORACIC AORTIC-ANEURYSMS; LATENT TGF-BETA; PULMONARY ARTERIOVENOUS-MALFORMATIONS; ARTERIAL-TORTUOSITY-SYNDROME; SMOOTH-MUSCLE-CELLS; MARFAN-SYNDROME; EXTRACELLULAR-MATRIX; BINDING-PROTEIN AB Marfan Syndrome (MFS) and Loeys-Dietz Syndrome (LDS) represent heritable connective tissue disorders that cosegregate with a similar pattern of cardiovascular defects (thoracic aortic aneurysm, mitral valve prolapse/regurgitation, and aortic root dilatation with regurgitation). This pattern of cardiovascular defects appears to be expressed along a spectrum of severity in many heritable connective tissue disorders and raises suspicion of a relationship between the normal development of connective tissues and the cardiovascular system. Given the evidence of increased transforming growth factor-beta (TGF-beta) signaling in MFS and LDS, this signaling pathway may represent the common link in this relationship. To further explore this hypothetical link, this chapter will review the TGF-beta signaling pathway, heritable connective tissue syndromes related to TGF-beta receptor (TGFBR) mutations, and discuss the pathogenic contribution of TGF-beta to these syndromes with a primary focus on the cardiovascular system. C1 [Wheeler, Jason B.; Ikonomidis, John S.; Jones, Jeffrey A.] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Jones, Jeffrey A.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Jones, JA (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,114 Doughty St,Suite 326, Charleston, SC 29425 USA. EM jonesja@musc.edu FU BLRD VA [I01 BX000904]; NHLBI NIH HHS [T32 HL007260, R01 HL102121]; NIA NIH HHS [R01 AG036954] NR 158 TC 8 Z9 8 U1 0 U2 6 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0065-2598 BN 978-94-007-7893-1; 978-94-007-7892-4 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2014 VL 802 BP 107 EP 127 DI 10.1007/978-94-007-7893-1_8 D2 10.1007/978-94-007-7893-1 PG 21 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA BA9GG UT WOS:000339357300008 PM 24443024 ER PT S AU Feldman, HH Haas, M Gandy, S Schoepp, DD Cross, AJ Mayeux, R Sperling, RA Fillit, H van de Hoef, DL Dougal, S Nye, JS AF Feldman, Howard H. Haas, Magali Gandy, Sam Schoepp, Darryle D. Cross, Alan J. Mayeux, Richard Sperling, Reisa A. Fillit, Howard van de Hoef, Diana L. Dougal, Sonya Nye, Jeffrey S. CA One Mind Res New York Acad Sci GP Annals New York Acad Sci TI Alzheimer's disease research and development: a call for a new research roadmap SO ANNALS REPORTS SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE Alzheimer's disease; dementia; research and development; therapy; treatment; economics; epidemiology ID DEMENTIA; BIOMARKERS; CASCADE; HEALTH; BRAIN; IVIG AB Epidemiological projections of the prevalence ofAlzheimer's disease (AD) and related dementias, the rapidly expanding population over the age of 65, and the enormous societal consequence on health, economics, and community foretell of a looming global public health crisis. Currently available treatments for AD are symptomatic, with modest effect sizes and limited impact on longer term disease outcomes. There have been no newly approved pharmaceutical treatments in the last decade, despite enormous efforts to develop disease-modifying treatments directed at Alzheimer's-associated pathology. An unprecedented collaborative effort of government, regulators, industry, academia, and the community at-large is needed to address this crisis and to develop an actionable plan for rapid progress toward successfully developing effective treatments. Here, we map out a course of action in four key priority areas, including (1) addressing the fundamental mechanisms of disease, with the goal of developing a core set of research tools, a framework for data sharing, and creation of accessible validated and replicated disease models; (2) developing translational research that emphasizes rapid progress in disease model development and better translation from preclinical to clinical stages, deploying leading technologies to more accurately develop predictive models; (3) preventing AD through the development of robust methods and resources to advance trials and creating fundamental resources such as continuous adaptive trials, registries, data repositories, and instrument development; and (4) innovating public/private partnerships and global collaborations, with mechanisms to incentivize collaborations and investments, develop larger precompetitive spaces, and more rapid data sharing. C1 [Feldman, Howard H.] Univ British Columbia, Fac Med, Div Neurol, Vancouver, BC, Canada. [Haas, Magali] One Mind Res, Seattle, WA USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Gandy, Sam] James J Peters VA Med Ctr, New York, NY USA. [Schoepp, Darryle D.] Merck & Co Inc, N Wales, PA USA. [Cross, Alan J.] AstraZeneca Pharmaceut LP, Wilmington, DE USA. [Mayeux, Richard] Columbia Univ, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY 10027 USA. [Sperling, Reisa A.] Harvard Univ, Sch Med, Dept Neurol, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA. [Fillit, Howard] Alzheimers Drug Discovery Fdn, New York, NY USA. [van de Hoef, Diana L.] New York Acad Sci, New York, NY USA. [Dougal, Sonya] NYU, Langone Med Ctr, Steven & Alexandra Cohen Vet Ctr, New York, NY USA. [Nye, Jeffrey S.] Johnson & Johnson Innovat, Janssen R&D LLC, Titusville, NJ USA. RP Feldman, HH (reprint author), S151 Univ British Columbia Hosp, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada. EM howard.feldman@ubc.ca RI Cross, Alan/L-5456-2016 OI Cross, Alan/0000-0002-2992-2258; Feldman, Howard/0000-0002-9258-4538 FU One Mind for Research; New York Academy of Sciences FX The authors gratefully acknowledge the contributions of the medical writing agency Percolation Communications LLC, who produced the first draft of this paper. They were funded by One Mind for Research and the New York Academy of Sciences to integrate all the historical notes, minutes, and interviews from the workshops conducted in 2011-12, sponsored by One Mind for Research. The subsequent drafts were advanced to final form by the lead and co-authors. The authors also acknowledge in-kind support from PricewaterhouseCoopers. NR 24 TC 9 Z9 10 U1 6 U2 19 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2014 VL 1313 BP 1 EP 16 DI 10.1111/nyas.12424 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BA8GQ UT WOS:000338100700001 PM 24754377 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID NOMINAL GROUP TECHNIQUE; SERUM URATE; GENERAL-PRACTICE; MEDICATION USE; CARE; MANAGEMENT; PATIENT; HEALTH; SEX; HYPERURICEMIA AB Introduction: Limited literature exists for qualitative studies of medication adherence in gout, especially in African-Americans. The aim of this study was to examine the facilitators and barriers to adherence to urate-lowering therapy (ULT) in African-Americans with gout. Methods: In this study, nine nominal groups lasting 1 to 1.5 hours each were conducted in African-Americans with gout, six with low ULT and three with high ULT adherence (medication possession ratios of <0.80 or >= 0.80, respectively). Patients presented, discussed, combined and rank ordered their concerns. A qualitative analysis was performed. Results: This study included 43 patients with mean age 63.9 years (standard deviation, 9.9), 67% men, who participated in nine nominal groups (seven in men, two in women): African-American men (n = 30); African-American women (n = 13). The main facilitators to ULT adherence (three groups) were the recognition of the need to take ULT regularly to prevent gout flares, prevent pain from becoming chronic/severe and to have less dietary restriction; the lack of side effects from ULT; trust in physicians; and avoiding the need to seek emergent/urgent care for flares. Patients achieved high ULT adherence by organizing their pills using the pillbox and the incorporation of ULT intake into their routine to prevent forgetting. The main barriers to optimal ULT adherence were (six groups): doubts about effectiveness of ULT, concerns about cost and side effects, concomitant medications, forgetfulness, refilling the prescriptions on time, pill size and difficulty in swallowing, competing priorities, patient preference for alternative medicines (that is, cherry juice) and frequent travel. Conclusions: Identification of facilitators and barriers to high ULT adherence in African-Americans with gout in this study lays the foundation for designing interventions to improve ULT adherence in racial minorities. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 805B,510 20th St S, Birmingham, AL 35233 USA. EM Jasvinder.md@gmail.com FU resources and use of facilities at the Birmingham VA Medical Center, Birmingham, AL, USA; Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute (PCORI) [CE-1304-6631] FX I thank Dr. Isabel Scarinci for her comments on this manuscript, Bridgett Alday for contacting patients and providing support for conducting the nominal groups, Ana Oliviera and Aseem Bharat for help conducting the nominal groups and Mary Elkins for the administrative oversight. I thank the patients and several colleagues who provided informal input into drafting the question for the nominal groups. This material is the result of work supported by a grant from the Division of Rheumatology at the University of Alabama at Birmingham. JAS is supported by the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, AL, USA. JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, and National Cancer Institute (NCI) U10 CA149950 and research contract CE-1304-6631 from Patient Centered Outcomes Research Institute (PCORI). NR 41 TC 10 Z9 10 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2014 VL 16 IS 2 AR R82 DI 10.1186/ar4524 PG 13 WC Rheumatology SC Rheumatology GA AL2YZ UT WOS:000338993100035 PM 24678765 ER PT B AU Lieb, JG AF Lieb, John G., II BE Adler, DG TI The Structure and Function of the Modern Colonoscope SO CORE CONCEPTS IN COLONOSCOPY LA English DT Article; Book Chapter ID HISTORY C1 [Lieb, John G., II] Univ Penn, Philadelphia, PA 19104 USA. [Lieb, John G., II] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Lieb, JG (reprint author), Univ Penn, Philadelphia, PA 19104 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-614-8 PY 2014 BP 1 EP 11 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BA5ZM UT WOS:000337068200001 ER PT J AU So-Armah, KA Chang, J Alcorn, C Lo Re, V Baker, JV Tracy, R Butt, AA Agan, BK Rimland, D Gibert, CL Goetz, MB Oursler, KK Rodriguez-Barradas, MC Kuller, LH Brown, ST Stein, JH Skanderson, M Justice, AC Freiberg, MS AF So-Armah, Kaku A. Chang, Joyce Alcorn, Charles Lo Re, Vincent Baker, Jason V. Tracy, Russell Butt, Adeel A. Agan, Brian K. Rimland, David Gibert, Cynthia L. Goetz, Matthew B. Oursler, Krisann K. Rodriguez-Barradas, Maria C. Kuller, Lewis H. Brown, Sheldon T. Stein, James H. Skanderson, Melissa Justice, Amy C. Freiberg, Matthew S. TI HIV Infection, Antiretroviral Therapy Initiation and Longitudinal Changes in Biomarkers of Organ Function SO CURRENT HIV RESEARCH LA English DT Article DE Clinical biomarkers; chronic diseases of aging; HIV infection; lipids ID IMMUNODEFICIENCY-VIRUS-INFECTION; DISEASE PROGRESSION; SERUM-LIPIDS; COHORT; VETERANS; RISK; COMORBIDITIES; INDIVIDUALS; COINFECTION; PREVALENCE AB Background: HIV is associated with end-organ diseases of aging via unclear mechanisms. Longitudinally assessing how HIV infection and ART initiation affect biomarkers of end organ function/disease could clarify these mechanisms. We investigated longitudinal changes in clinical biomarkers following 1) HIV infection and 2) ART initiation with evidence of viral suppression. Methods: Cohort: Veterans Aging Cohort Study Virtual Cohort (VACS VC). VACS VC is a longitudinal cohort of HIV infected (HIV+) and race-ethnicity, sex, age, and clinical site-matched uninfected Veterans enrolled in the same calendar year. Inclusion criteria: a negative and successively positive (>six months) HIV antibody test. We used Wilcoxon signed-rank tests to analyze 1) the effect of HIV infection on lipids, renal, hepatic and hematologic/cardiovascular biomarkers and 2) whether ART initiation with HIV-1 RNA<500 cpm reverts any changes back to pre-HIV levels Results: 422 Veterans had at least 1 biomarker measurement available prior to HIV infection and prior to ART initiation. 297 had at least 1 biomarker measurement available prior to HIV infection and after ART initiation with evidence of viral suppression. Mean age prior to HIV infection was 43 years. HIV infection was associated with reduction in total cholesterol, HDL cholesterol, LDL cholesterol, serum albumin, ALT, platelet count, hemoglobin and elevation of FIB-4 score and triglycerides. These changes occurred without significant changes in BMI. ART initiation (with HIV-1 RNA<500cpm) did not reverse alteration in triglycerides, LDL cholesterol, hemoglobin, or FIB-4 to pre-HIV infection levels. Conclusions: HIV infection is associated with longitudinal changes in serum levels of several biomarkers of end-organ function/disease and mortality. Multiple biomarkers (triglycerides, LDL cholesterol, hemoglobin, and FIB-4) remain altered from levels prior to HIV infection levels even following inititiation of ART and evidence of viral suppression. These results give insights into underlying mechanisms of increased risk for aging-related chronic diseases in the context of HIV infection. C1 [So-Armah, Kaku A.; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Chang, Joyce; Butt, Adeel A.; Freiberg, Matthew S.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Chang, Joyce; Alcorn, Charles] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Lo Re, Vincent] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Lo Re, Vincent] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Baker, Jason V.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Baker, Jason V.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Tracy, Russell] Univ Vermont, Dept Biochem, Burlington, VT 05405 USA. [Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Butt, Adeel A.] Sheikh Khalifa Med City, Dept Med, Abu Dhabi, U Arab Emirates. [Agan, Brian K.] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA. [Rimland, David] Emory Univ, Sch Med, Dept Med, Div Infect Dis,VA Med Ctr, Atlanta, GA USA. [Gibert, Cynthia L.] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Sch Med, Washington, DC USA. [Goetz, Matthew B.] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Oursler, Krisann K.] Baltimore Vet Affairs Med Ctr, Baltimore, MD USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kuller, Lewis H.; Freiberg, Matthew S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA. [Stein, James H.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Skanderson, Melissa; Justice, Amy C.] VA Connecticut Healthcare Syst, New Haven, CT USA. RP Freiberg, MS (reprint author), 230 McKee Pl, Pittsburgh, PA 15213 USA. EM freibergms@upmc.edu RI Lo Re, Vincent/N-7817-2015 OI Agan, Brian/0000-0002-5114-1669; Goetz, Matthew/0000-0003-4542-992X FU National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH) [HL095136-04]; National Institute on Alcohol Abuse and Alcoholism at the NIH [AA013566-10, AA020790, AA020794] FX This work was supported by grant HL095136-04 from the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH) and grants AA013566-10, AA020790, and AA020794 from the National Institute on Alcohol Abuse and Alcoholism at the NIH. NR 31 TC 7 Z9 7 U1 3 U2 7 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1570-162X EI 1873-4251 J9 CURR HIV RES JI Curr. HIV Res. PY 2014 VL 12 IS 1 BP 50 EP 59 PG 10 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA AL5MN UT WOS:000339178000006 PM 25034208 ER PT J AU Kim, S Saad, M Tsuang, DW Wijsman, EM AF Kim, Sulgi Saad, Mohamad Tsuang, Debby W. Wijsman, Ellen M. TI Visualization of Haplotype Sharing Patterns in Pedigree Samples SO HUMAN HEREDITY LA English DT Article DE IBD; Linkage analysis; Gene mapping; Sampling subjects; Sequencing; Sequence ID LINKAGE ANALYSIS; GENETIC-LINKAGE; COMPLEX DISEASE; RARE VARIANTS; SCHIZOPHRENIA; TRAITS; MAPS; ERA AB Objectives: A particular approach to the visualization of descent of founder DNA copies in a pedigree has been suggested, which helps to understand haplotype sharing patterns among subjects of interest. However, the approach does not provide the information in an ideal format to show haplotype sharing patterns. Therefore, we aimed to find an efficient way to visualize such sharing patterns and to demonstrate that our tool provides useful information for finding an informative subset of subjects for a sequence study. Methods: The visualization package, SharedHap, computes and visualizes a novel metric, the SharedHap proportion, which quantifies haplotype sharing among a set of subjects of interest. We applied SharedHap to simulated and real pedigree datasets to illustrate the approach. Results: SharedHap successfully represents haplotype sharing patterns that contribute to linkage signals in both simulated and real datasets. Using the visualizations we were also able to find ideal sets of subjects for sequencing studies. Conclusions: Our novel metric that can be computed using the SharedHap package provides useful information about haplotype sharing pat-terns among subjects of interest. The visualization of the SharedHap proportion provides useful information in pedigree studies, allowing for a better selection of candidate subjects for use in further sequencing studies. (C) 2014 S. Karger AG, Basel C1 [Kim, Sulgi; Saad, Mohamad; Wijsman, Ellen M.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA. [Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Wijsman, Ellen M.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Wijsman, Ellen M.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA. [Tsuang, Debby W.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. RP Wijsman, EM (reprint author), Univ Washington, Dept Med, Div Med Genet, Box 359460, Seattle, WA 98195 USA. EM wijsman@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU US Department of Veterans Affairs, Office of Research Development, Biomedical Laboratory Research; NIH [R01MH065558, P50AG005136]; VISN-20 MIRECC FX This work was supported by a US Department of Veterans Affairs, Office of Research Development, Biomedical Laboratory Research merit review; VISN-20 MIRECC, and NIH grants No. R01MH065558 and P50AG005136. The funding agencies did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 0 Z9 0 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5652 EI 1423-0062 J9 HUM HERED JI Hum. Hered. PY 2014 VL 78 IS 1 BP 1 EP 8 DI 10.1159/000358171 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA AL7OA UT WOS:000339322500001 PM 24969160 ER PT J AU Lee, GJ Lu, PH Mather, MJ Shapira, J Jimenez, E Leow, AD Thompson, PM Mendez, MF AF Lee, Grace J. Lu, Po H. Mather, Michelle J. Shapira, Jill Jimenez, Elvira Leow, Alex D. Thompson, Paul M. Mendez, Mario F. TI Neuroanatomical Correlates of Emotional Blunting in Behavioral Variant Frontotemporal Dementia and Early-Onset Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; early onset; emotional blunting; frontotemporal dementia; magnetic resonance imaging ID TENSOR-BASED MORPHOMETRY; DIAGNOSTIC-CRITERIA; LOBAR DEGENERATION; SOCIAL-BEHAVIOR; DYSFUNCTION; DISORDERS; EMPATHY; COGNITION; SYMPTOMS; PATTERNS AB Background: Emotional blunting is a characteristic feature of behavioral variant frontotemporal dementia (bvFTD) and can help discriminate between patients with bvFTD and other forms of younger-onset dementia. Objective: We compared the presence of emotional blunting symptoms in patients with bvFTD and early-onset Alzheimer's disease (AD), and investigated the neuroanatomical associations between emotional blunting and regional brain volume. Methods: Twenty-five individuals with bvFTD (n = 11) and early-onset AD (n = 14) underwent magnetic resonance imaging (MRI) and were rated on symptoms of emotional blunting using the Scale for Emotional Blunting (SEB). The two groups were compared on SEB ratings and MRI-derived brain volume using tensor-based morphometry. Voxel-wise linear regression was performed to determine neuroanatomical correlates of SEB scores. Results: The bvFTD group had significantly higher SEB scores compared to the AD group. On MRI, bvFTD patients had smaller bilateral frontal lobe volume compared to AD patients, while AD patients had smaller bilateral temporal and left parietal volume than bvFTD patients. In bvFTD, SEB ratings were strongly correlated with right anterior temporal volume, while the association between SEB and the right orbitofrontal cortex was non-significant. Conclusions: Symptoms of emotional blunting were more prevalent in bvFTD than early-onset AD patients. These symptoms were particularly associated with right-sided atrophy, with significant involvement of the right anterior temporal region. Based on these findings, the SEB appears to measure symptoms of emotional blunting that are localized to the right anterior temporal lobe. C1 [Lee, Grace J.] Loma Linda Univ, Sch Behav Hlth, Dept Psychol, Loma Linda, CA 92350 USA. [Lu, Po H.; Mather, Michelle J.; Shapira, Jill; Jimenez, Elvira; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mather, Michelle J.; Shapira, Jill; Jimenez, Elvira; Mendez, Mario F.] Greater Los Angeles VA Healthcare Syst, West Los Angeles, CA USA. [Leow, Alex D.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Leow, Alex D.] Univ Illinois, Dept Bioengn, Chicago, IL USA. [Thompson, Paul M.] Keck Sch Med USC, Inst Neuroimaging & Informat, Lab NeuroImaging, Los Angeles, CA USA. RP Lee, GJ (reprint author), 11130 Anderson St,Cent Bldg, Loma Linda, CA 92350 USA. EM gracelee@llu.edu RI Leow, Alex/K-3236-2014 OI Leow, Alex/0000-0002-5660-8651 FU NIH from the National Institute of Aging (NIA) [K23-AG028727, R01-AG034499]; Alzheimer's Disease Research Center [P50 AG-16570]; California Alzheimer's Disease Centers; Department of Veterans Affairs FX This work was supported by NIH grants K23-AG028727 and R01-AG034499 from the National Institute of Aging (NIA), the Alzheimer's Disease Research Center grant P50 AG-16570, California Alzheimer's Disease Centers, and the Department of Veterans Affairs. NR 34 TC 7 Z9 7 U1 0 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 41 IS 3 BP 793 EP 800 DI 10.3233/JAD-132219 PG 8 WC Neurosciences SC Neurosciences & Neurology GA AL7QG UT WOS:000339329100016 PM 24685626 ER PT J AU Costantini, A Pompili, M Innamorati, M Zezza, MC Di Carlo, A Sher, L Girardi, P AF Costantini, Anna Pompili, Maurizio Innamorati, Marco Zezza, Maria Cristina Di Carlo, Alessandra Sher, Leo Girardi, Paolo TI Psychiatric Pathology and Suicide Risk in Patients with Cancer SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Article DE psychoncology; cancer; psychiatry; suicide ID TERMINALLY-ILL; PSYCHOLOGICAL DISTRESS; DEPRESSION; PREVALENCE; REGISTER; SCALE AB The aims of the study were to assess sociodemographic and clinical factors associated with suicidal ideation in patients with cancer who required a psycho-oncological support. Among 504 participants, there were 136 (23 men and 113 women) cancer patients who completed psychological assessment when admitted to the Psycho-oncology Outpatient Clinic between 2006 and 2011. Suicidal ideation was assessed by Item 9 of the Brief Symptom Inventory, Hopelessness was assessed by the hopelessness subscale of the Mini-Mental Adjustment to Cancer Scale, and Depression was assessed by the depression subscale of the Hospital and Anxiety Depression Scale. Around 30% of this sample reported affective symptoms and around 20% reported suicidal ideation and hopelessness. Patients who reported suicidal ideation were more hopeless (18.8 +/- 6.7vs. 15.7 +/- 5.2; t(134) = 2.54; p < 0.05) and reported more depression (11.8 +/- 4.8vs. 6.8 +/- 4.1; t(134) = 5.30; p < 0.001). It is evident that cancer can result in a strong psychological distress in the patient. It is important, therefore, that cancer patients receive a proper assistance and psychological support and that both the possible presence of depression and suicidal ideation are constantly monitored. C1 [Costantini, Anna; Zezza, Maria Cristina; Di Carlo, Alessandra] Univ Roma La Sapienza, Psychooncol Unit, St Andrea Hosp, I-00189 Rome, Italy. [Pompili, Maurizio; Innamorati, Marco; Girardi, Paolo] Univ Roma La Sapienza, Dept Neurosci Mental Hlth & Sensory Funct, Suicide Prevent Ctr, St Andrea Hosp, I-00189 Rome, Italy. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. RP Pompili, M (reprint author), Univ Roma La Sapienza, Dept Neurosci Mental Hlth & Sensory Funct, Suicide Prevent Ctr, St Andrea Hosp, Via Grottarossa 1035, I-00189 Rome, Italy. EM maurizio.pompili@uniroma1.it OI Pompili, Maurizio/0000-0003-1886-4977 NR 33 TC 3 Z9 3 U1 0 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0734-7332 EI 1540-7586 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PY 2014 VL 32 IS 4 BP 383 EP 395 DI 10.1080/07347332.2014.917136 PG 13 WC Psychology, Social SC Psychology GA AL4KD UT WOS:000339100900001 PM 24797891 ER PT J AU Woodard, LD Landrum, CR Amspoker, AB Ramsey, D Naik, AD AF Woodard, LeChauncy D. Landrum, Cassie R. Amspoker, Amber B. Ramsey, David Naik, Aanand D. TI Interaction between functional health literacy, patient activation, and glycemic control SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE health literacy; diabetes mellitus; self-care; veterans ID DIABETES SELF-MANAGEMENT; SCREENING QUESTIONS; IDENTIFY PATIENTS; OLDER PATIENTS; MELLITUS; OUTCOMES; CARE; COMMUNICATION; ASSOCIATION; VALIDATION AB Background: Functional health literacy (FHL) and patient activation can impact diabetes control through enhanced diabetes self-management. Less is known about the combined effect of these characteristics on diabetes outcomes. Using brief, validated measures, we examined the interaction between FHL and patient activation in predicting glycosylated hemoglobin (HbA(1c)) control among a cohort of multimorbid diabetic patients. Methods: We administered a survey via mail to 387 diabetic patients with coexisting hypertension and ischemic heart disease who received outpatient care at one regional VA medical center between November 2010 and December 2010. We identified patients with the study conditions using the International Classification of Diseases-Ninth Revision-Clinical Modification (ICD-9-CM) diagnoses codes and Current Procedure Terminology (CPT) -procedures codes. Surveys were returned by 195 (50.4%) patients. We determined patient activation levels based on participant responses to the 13-item Patient Activation Measure and FHL levels using the single-item screening question, "How confident are you filling out medical forms by yourself?" We reviewed patient medical records to assess glycemic control. We used multiple logistic regression to examine whether activation and FHL were individually or jointly related to HbA(1c) control. Results: Neither patient activation nor FHL was independently related to glycemic control in the unadjusted main effects model; however, the interaction between the two was significantly associated with glycemic control (odds ratio 1.05 [95% confidence interval 1.01-1.09], P=0.02). Controlling for age, illness burden, and number of primary care visits, the combined effect of these measures on glycemic control remained significant (odds ratio 1.05 [95% confidence interval 1.01-1.09], P=0.02). Conclusion: The interaction between FHL and patient activation is associated with HbA1c control beyond the independent effects of these parameters alone. A personalized approach to diabetes management incorporating these characteristics may increase patient-centered care and improve outcomes for patients with diabetes. C1 Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Vet Affairs Hlth Serv Res & Dev, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Woodard, LD (reprint author), MEDVAMC 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM lwoodard@bcm.edu FU Veterans Affairs Health Services Research and Development (VA HSRD) [PPO 09-316]; Houston VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety [CIN13-413] FX This work was supported by a Veterans Affairs Health Services Research and Development (VA HSR&D) pilot grant PPO 09-316 (LDW) and the Houston VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety (CIN13-413). The authors are grateful to Sylvia Hysong for assistance with development of the survey, and to Tracy Urech and Omolola Adepoju, all of the Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety for assistance with manuscript review. NR 35 TC 4 Z9 4 U1 2 U2 9 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2014 VL 8 BP 1019 EP 1024 DI 10.2147/PPA.S63954 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA AL8LX UT WOS:000339391500001 PM 25092966 ER PT J AU Breyer, BN Cohen, BE Bertenthal, D Rosen, RC Neylan, TC Seal, KH AF Breyer, Benjamin N. Cohen, Beth E. Bertenthal, Daniel Rosen, Raymond C. Neylan, Thomas C. Seal, Karen H. TI Sexual Dysfunction in Male Iraq and Afghanistan War Veterans: Association with Posttraumatic Stress Disorder and Other Combat-Related Mental Health Disorders: A Population-Based Cohort Study SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Combat; Posttraumatic Stress Disorder; Sexual Dysfunction; Military Service ID RISK; PTSD; CARE; DIAGNOSES; PREVALENCE; OPERATION; SYMPTOMS; SERVICES AB Introduction Mental health disorders are prevalent in the United States, Iraq, and Afghanistan war veterans. Mental illness, including posttraumatic stress disorder (PTSD) with or without psychiatric medications, can increase the risk for male sexual dysfunction, threatening quality of life. Aims We sought to determine the prevalence and correlates of sexual dysfunction among male Iraq and Afghanistan veterans. Methods We performed a retrospective cohort study of 405,275 male Iraq and Afghanistan veterans who were new users of U.S. Department of Veterans Affairs healthcare from October 7, 2001 to September 30, 2009 and had 2-year follow-up. Main Outcome Measures We determined the independent association of mental health diagnoses and sexual dysfunction after adjusting for sociodemographic and military service characteristics, comorbidities, and medications. Results Veterans with PTSD were more likely to have a sexual dysfunction diagnosis, be prescribed medications for sexual dysfunction, or both (10.6%), compared with veterans having a mental diagnosis other than PTSD (7.2%), or no mental health diagnosis (2.3%). In a fully adjusted model, PTSD increased the risk of sexual dysfunction by more than threefold (adjusted risk ratio = 3.61, 95% CI = 3.48-3.75). Veterans with mental health disorders, particularly PTSD, were at the highest risk of sexual dysfunction when prescribed psychiatric medications (adjusted risk ratio = 4.59, 95% CI = 4.41-4.77). Conclusions Among U.S. combat veterans, mental health disorders, particularly PTSD, increased the risk of sexual dysfunction independent of the use of psychiatric medications. C1 [Breyer, Benjamin N.; Rosen, Raymond C.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Cohen, Beth E.; Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Cohen, Beth E.; Neylan, Thomas C.; Seal, Karen H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Cohen, Beth E.; Bertenthal, Daniel; Neylan, Thomas C.; Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Rosen, Raymond C.] New England Res Inst, Watertown, MA 02172 USA. RP Breyer, BN (reprint author), Univ Calif San Francisco, Dept Urol, 400 Parnassus Ave,A610, San Francisco, CA 94143 USA. EM bbreyer@urology.ucsf.edu FU NIDDK NIH HHS [K12 DK083021] NR 36 TC 8 Z9 8 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD JAN PY 2014 VL 11 IS 1 BP 75 EP 83 DI 10.1111/jsm.12201 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA AE9ML UT WOS:000334331800009 PM 23679562 ER PT J AU Ojeda, M Ding, D AF Ojeda, Manoela Ding, Dan TI Temporal Parameters Estimation for Wheelchair Propulsion Using Wearable Sensors SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID SPINAL-CORD-INJURY; CARPAL-TUNNEL-SYNDROME; UPPER EXTREMITY PAIN; SHOULDER PAIN; LONG-TERM; ACTIVITY MONITOR; USERS; BIOMECHANICS; PARAPLEGIA; VALIDATION AB Due to lower limb paralysis, individuals with spinal cord injury (SCI) rely on their upper limbs for mobility. The prevalence of upper extremity pain and injury is high among this population. We evaluated the performance of three triaxis accelerometers placed on the upper arm, wrist, and under the wheelchair, to estimate temporal parameters of wheelchair propulsion. Twenty-six participants with SCI were asked to push their wheelchair equipped with a SMART(Wheel). The estimated stroke number was compared with the criterion from video observations and the estimated push frequency was compared with the criterion from the SMARTWheel. Mean absolute errors (MAE) and mean absolute percentage of error (MAPE) were calculated. Intraclass correlation coefficients and Bland-Altman plots were used to assess the agreement. Results showed reasonable accuracies especially using the accelerometer placed on the upper arm where the MAPE was 8.0% for stroke number and 12.9% for push frequency. The ICC was 0.994 for stroke number and 0.916 for push frequency. The wrist and seat accelerometer showed lower accuracy with a MAPE for the stroke number of 10.8% and 13.4% and ICC of 0.990 and 0.984, respectively. Results suggested that accelerometers could be an option for monitoring temporal parameters of wheelchair propulsion. C1 [Ojeda, Manoela; Ding, Dan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA. RP Ojeda, M (reprint author), VA Pittsburgh Healthcare Syst, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM manola.ojeda@gmail.com FU National Institute of Disability and Rehabilitation Research's Rehabilitation Engineering Research Center on Spinal Cord Injury [H133E070024]; Human Engineering Research Laboratories, VA Pittsburgh Healthcare System FX The authors gratefully acknowledge that this research was supported by the National Institute of Disability and Rehabilitation Research's Rehabilitation Engineering Research Center on Spinal Cord Injury (no. H133E070024). The work was also supported by the Human Engineering Research Laboratories, VA Pittsburgh Healthcare System. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. They also would like to acknowledge the contributions of Jui-Te Lin, Vijeta Parvatikar, and Annmarie Kelleher. NR 37 TC 1 Z9 1 U1 2 U2 3 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2014 AR 645284 DI 10.1155/2014/645284 PG 10 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA AL1ET UT WOS:000338869300001 ER PT J AU Jackevicius, CA Le, J Nazer, L Hess, K Wang, J Law, AV AF Jackevicius, Cynthia A. Le, Jennifer Nazer, Lama Hess, Karl Wang, Jeffrey Law, Anandi V. TI A Formal Mentorship Program for Faculty Development SO AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION LA English DT Article DE mentorship; mentor; protege; pharmacy; faculty ID MENTORING MATTER; METAANALYSIS; MENTEES AB Objective. To describe the development, implementation, and evaluation of a formal mentorship program at a college of pharmacy. Methods. After extensive review of the mentorship literature within the health sciences, a formal mentorship program was developed between 2006 and 2008 to support and facilitate faculty development. The voluntary program was implemented after mentors received training, and mentors and proteges were matched and received an orientation. Evaluation consisted of conducting annual surveys and focus groups with mentors and proteges. Results. Fifty-one mentor-protege pairs were formed from 2009 to 2012. A large majority of the mentors (82.8%-96.9%) were satisfied with the mentorship program and its procedures. The majority of the proteges (>= 70%) were satisfied with the mentorship program, mentor-protege relationship, and program logistics. Both mentors and proteges reported that the proteges most needed guidance on time management, prioritization, and work-life balance. While there were no significant improvements in the proteges' number of grant submissions, retention rates, or success in promotion/tenure, the total number of peer-reviewed publications by junior faculty members was significantly higher after program implementation (mean of 7 per year vs 21 per year, p=0.03) in the college's pharmacy practice and administration department. Conclusions. A formal mentorship program was successful as measured by self-reported assessments of mentors and proteges. C1 [Jackevicius, Cynthia A.; Le, Jennifer; Nazer, Lama; Hess, Karl; Wang, Jeffrey; Law, Anandi V.] Western Univ Hlth Sci, Pomona, CA USA. [Jackevicius, Cynthia A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Univ Hlth Network, Inst Clin Evaluat Sci, Toronto, ON, Canada. [Le, Jennifer] Univ Calif San Diego, La Jolla, CA 92093 USA. [Le, Jennifer] Long Beach Mem Med Ctr, Long Beach, CA USA. [Le, Jennifer] Miller Childrens Hosp, Long Beach, CA USA. [Nazer, Lama] King Hussein Canc Ctr, Amman, Jordan. RP Jackevicius, CA (reprint author), FCSHP Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu NR 17 TC 4 Z9 4 U1 1 U2 6 PU AMER ASSOC COLL PHARMACY PI ALEXANDRIA PA 1426 PRINCE STREET, ALEXANDRIA, VA 22314-2815 USA SN 0002-9459 EI 1553-6467 J9 AM J PHARM EDUC JI Am. J. Pharm. Educ. PY 2014 VL 78 IS 5 AR 100 PG 7 WC Education, Scientific Disciplines; Pharmacology & Pharmacy SC Education & Educational Research; Pharmacology & Pharmacy GA AK4XW UT WOS:000338428800011 PM 24954940 ER PT J AU Wortzel, HS Arciniegas, DB AF Wortzel, Hal S. Arciniegas, David B. TI The DSM-5 approach to the evaluation of traumatic brain injury and its neuropsychiatric sequelae SO NEUROREHABILITATION LA English DT Article DE Traumatic brain injury; cognition disorders; DSM-5 ID MONTREAL COGNITIVE ASSESSMENT; MINI-MENTAL-STATE; MILD HEAD-INJURY; COMPUTED-TOMOGRAPHY; POSTCONCUSSIONAL DISORDER; INTRACRANIAL INJURY; UNIFIED DEFINITION; IV CRITERIA; MANAGEMENT; RECOVERY AB INTRODUCTION: The advent of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is accompanied by substantial changes in the approach taken in this manual to traumatic brain injury (TBI) and its neuropsychiatric sequelae. OBJECTIVE: This article reviews the issues pertaining to the treatment of TBI in the DSM-5, and changes relative to the outgoing DSM-IV-TR. The primary context for discussion of TBI in the DSM-5 is the section on Neurocognitive Disorders, where a basic framework is provided for the retrospective diagnosis of TBI and characterization of the clinical presentation as a Mild or Major Neurocognitive Disorder. The distinctions between these conditions rest not on the initial severity of TBI but instead on the severity of posttraumatic cognitive impairments and their effects on everyday function. The text succinctly reviews the epidemiology, phenomenology, and natural history of TBI and highlights the need to consider the differential diagnosis for persistent postconcussive symptoms. CONCLUSION: The approach taken to the diagnosis of TBI and its neuropsychiatric consequences in the DSM-5 is improved substantially over that of the DSM-IV-TR, and it is likely to improve the evaluations of persons with TBI by mental health professionals. However, challenges borne of this approach are likely to be revealed as it is implemented in everyday practice and will guide the development of this section of DSM-5.1. C1 [Wortzel, Hal S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Wortzel, Hal S.] Univ Colorado, Sch Med, Dept Psychiat, Div Forens Psychiat, Aurora, CO USA. [Wortzel, Hal S.; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Psychiat, Neuropsychiat Serv, Aurora, CO USA. [Wortzel, Hal S.; Arciniegas, David B.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Beth K & Stuart C Yudofsky Div Neuropsychiat, Houston, TX 77030 USA. [Arciniegas, David B.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA. RP Wortzel, HS (reprint author), Denver Vet Hosp, VISN 19 MIRECC,1055 Clermont St, Denver, CO 80220 USA. EM hal.wortzel@ucdenver.edu FU Veterans Health Administration's VISN-19 MIRECC; National Institute on Disability and Rehabilitation Research (NIDRR) [H133A120020, H133A130047] FX Support for this work was provided by the Veterans Health Administration's VISN-19 MIRECC (HSW) and National Institute on Disability and Rehabilitation Research (NIDRR) grants H133A120020 and H133A130047 (DBA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs or NIDRR. NR 60 TC 4 Z9 4 U1 1 U2 13 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 EI 1878-6448 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2014 VL 34 IS 4 BP 613 EP 623 DI 10.3233/NRE-141086 PG 11 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AK5CY UT WOS:000338443100003 PM 24820171 ER PT J AU Maier, MM He, H Schafer, SD Ward, TT Zaman, A AF Maier, Marissa M. He, Haiou Schafer, Sean D. Ward, Thomas T. Zaman, Atif TI Hepatitis C treatment eligibility among HIV-hepatitis C virus coinfected patients in Oregon: a population-based sample SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE coinfection; eligibility; hepatitis C; HIV; treatment ID HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-2A PLUS RIBAVIRIN; INJECTION-DRUG USERS; INFECTED PATIENTS; LIVER-DISEASE; PEGINTERFERON; TELAPREVIR; IMPACT; CARE; MORTALITY AB Approximately 287,000 individuals in the USA are coinfected with HIV and hepatitis C. Recently, new hepatitis C regimens have become available, increasing rates of sustained virologic response in the monoinfected, with studies evaluating their success in the coinfected under way. Previous investigators estimated eligibility for hepatitis C therapy among the coinfected patients, but all had significant methodological limitations. Our study is the first to use a multi-year, statewide, population-based sample to estimate treatment eligibility, and the first to estimate eligibility in the setting of an interferon-free regimen. In a population-based sample of 161 patients infected with HIV and hepatitis C living in Oregon during 2007-2010, 21% were eligible for hepatitis C therapy. Despite the anticipation surrounding an interferon-sparing regimen, eligibility assuming an interferon-free regimen increased only to 26%, largely due to multiple simultaneous contraindications. Obesity was described for the first time as being associated with decreased eligibility (OR: 0.11). Active alcohol abuse was the most common contraindication (24%); uncontrolled mental health (22%), recent injection drug use (21%), poor antiretroviral adherence (22%), and infection (21%) were also common excluding conditions. When active drug or alcohol abuse was excluded as contraindications to therapy, the eligibility rate was 34%, a 62% increase. Assuming an interferon-free regimen and the exclusion of active drug or alcohol abuse as contraindications to therapy, the eligibility rate increased to 42%. Despite the availability of direct-acting anti-viral regimens, eligibility rates in HIV-hepatitis C virus (HCV) coinfection are modest. Many factors precluding hepatitis C therapy are reversible, and targeted interventions could result in increased eligibility. C1 [Maier, Marissa M.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [He, Haiou] Oregon Hlth Author, Program Design & Evaluat Serv, Portland, OR USA. [Schafer, Sean D.] Oregon Hlth Author, HIV STD TB Program, Portland, OR USA. [Ward, Thomas T.] Portland VA Med Ctr, Infect Dis Sect, Portland, OR USA. [Zaman, Atif] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA. RP Maier, MM (reprint author), Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. EM maierma@ohsu.edu NR 30 TC 5 Z9 5 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2014 VL 26 IS 9 BP 1178 EP 1185 DI 10.1080/09540121.2014.892563 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA AJ8NO UT WOS:000337962500017 PM 24601687 ER PT J AU Zackowski, KM Cameron, M Wagner, JM AF Zackowski, Kathleen M. Cameron, Michelle Wagner, Joanne M. TI 2nd International Symposium on Gait and Balance in Multiple Sclerosis: interventions for gait and balance in MS SO DISABILITY AND REHABILITATION LA English DT Article DE Physical therapy; rehabilitation; walking ID FUNCTIONAL ELECTRICAL-STIMULATION; RANDOMIZED CONTROLLED-TRIAL; DEFICIT HYPERACTIVITY DISORDER; DWELLING OLDER-PEOPLE; SPINAL-CORD-INJURY; PARKINSONS-DISEASE; DOUBLE-BLIND; LOCOMOTOR ADAPTATIONS; MANAGEMENT PROGRAM; ACCIDENTAL FALLS AB Purpose: To provide a review of the 2nd International Symposium on Gait and Balance in Multiple Sclerosis (MS), emphasizing interventions in gait and balance for people with MS. Method: Review of current research on interventions used with people having MS and with people having other disorders that may provide novel insights into improving gait and balance and preventing falls in people with MS (pwMS). Results: Nine speakers provided evidence-based recommendations for interventions aimed at improving gait and balance dysfunction. Speaker recommendations covered the following areas: balance rehabilitation, self-management, medications, functional electrical stimulation, robotics, sensory augmentation, gait training with error feedback and fall prevention. Conclusions: The causes of gait and balance dysfunction in pwMS are multifactorial and therefore may benefit from a wide range of interventions. The symposium provides avenues for exchange of evidence and clinical experience that is critical in furthering physical rehabilitation including gait and balance dysfunction in MS. C1 [Zackowski, Kathleen M.] Johns Hopkins Univ, Kennedy Krieger Inst, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21205 USA. [Cameron, Michelle] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Cameron, Michelle] Portland VA Med Ctr, Portland, OR 97201 USA. [Wagner, Joanne M.] St Louis Univ, Dept Phys Therapy & Athlet Training, Doisy Coll Hlth Sci, St Louis, MO 63103 USA. RP Zackowski, KM (reprint author), Johns Hopkins Univ, Kennedy Krieger Inst, Sch Med, 707 N Broadway,G-05, Baltimore, MD 21205 USA. EM zackowski@kennedykrieger.org FU Acorda Therapeutics; Sun Pharmaceuticals; Biogen Idec. FX Kathleen Zackowski has research grant support from the Acorda Therapeutics, Biogen Idec., and Sun Pharmaceuticals. Michelle Cameron has received honorarium and travel for speaking and consultation from Acorda Therapeutics. Joanne Wagner has received honorarium for speaking from Acorda Therapeutics. The 2nd International Symposium on Gait and Balance was in-part supported by Acorda Therapeutics through an educational grant. Additional expenses were covered by registration and exhibit fees. NR 59 TC 0 Z9 0 U1 1 U2 9 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0963-8288 EI 1464-5165 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2014 VL 36 IS 13 BP 1128 EP 1132 DI 10.3109/09638288.2013.833306 PG 5 WC Rehabilitation SC Rehabilitation GA AJ5VJ UT WOS:000337757600011 PM 24041009 ER PT J AU Wang, J Varghese, M Ono, K Yamada, M Levine, S Tzavaras, N Gong, B Hurst, WJ Blitzer, RD Pasinetti, GM AF Wang, Jun Varghese, Merina Ono, Kenjiro Yamada, Masahito Levine, Samara Tzavaras, Nikos Gong, Bing Hurst, William J. Blitzer, Robert D. Pasinetti, Giulio Maria TI Cocoa Extracts Reduce Oligomerization of Amyloid-beta: Implications for Cognitive Improvement in Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyloid; diet therapy; oligomerization; polyphenols; synapses ID FLAVANOL-RICH COCOA; TETRAHYDROXYSTILBENE GLUCOSIDE; ANTIOXIDANT CAPACITY; SYNAPTIC PLASTICITY; MEMORY; PERFORMANCE; CHOCOLATE; PRODUCTS; PROCYANIDIN; POLYPHENOLS AB Background: Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder, characterized by pathological aggregates of amyloid peptide-beta (A beta) and tau protein. Currently available therapies mediate AD symptoms without modifying disease progression. Polyphenol-rich diets are reported to reduce the risk for AD. Objective: In the present study, we investigated the AD disease-modifying effects of cocoa, a rich source of flavanols, which are a class of polyphenols. We hypothesized that cocoa extracts interfere with amyloid-beta oligomerization to prevent synaptic deficits. Methods: We tested the effects of three different cocoa extracts, viz. Natural, Dutched, and Lavado extracts, on A beta(42) and A beta(40) oligomerization, using photo-induced cross-linking of unmodified proteins technique. To assess the effects of cocoa extracts on synaptic function, we measured long term potentiation in mouse brain hippocampal slices exposed to oligomeric A beta. Results: Our results indicate that cocoa extracts are effective in preventing the oligomerization of A beta, with Lavado extract being most effective. Lavado extract, but not Dutched extract, was effective in restoring the long term potentiation response reduced by oligomeric A beta. Conclusion: Our findings indicate that cocoa extracts have multiple disease-modifying properties in AD and present a promising route of therapeutic and/or preventative initiatives. C1 [Wang, Jun; Varghese, Merina; Levine, Samara; Gong, Bing; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Tzavaras, Nikos; Blitzer, Robert D.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. [Wang, Jun; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Ono, Kenjiro; Yamada, Masahito] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol & Aging, Kanazawa, Ishikawa, Japan. [Hurst, William J.] Hershey Co, Hershey Ctr Hlth & Nutr, Hershey, PA USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu NR 37 TC 11 Z9 13 U1 6 U2 23 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 41 IS 2 BP 643 EP 650 DI 10.3233/JAD-132231 PG 8 WC Neurosciences SC Neurosciences & Neurology GA AJ7YN UT WOS:000337918000027 PM 24957018 ER PT J AU Vaudreuil, NJ Ledoux, WR Roush, GC Whittaker, EC Sangeorzan, BJ AF Vaudreuil, Nicholas J. Ledoux, William R. Roush, Grant C. Whittaker, Eric C. Sangeorzan, Bruce J. TI Comparison of Transfer Sites for Flexor Digitorum Longus in a Cadaveric Adult Acquired Flatfoot Model SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE posterior tibial tendon dysfunction; flexor digitorum longus transfer; PTTD; FDL; gait simulation ID POSTERIOR TIBIAL-TENDON; CALCANEAL OSTEOTOMY; GAIT SIMULATOR; DYSFUNCTION; HINDFOOT; FOOT; KINEMATICS; DEFORMITY; PRESSURE; ARCH AB Posterior tibialis tendon (PTT) dysfunction (PTTD) is associated with adult acquired flatfoot deformity. PTTD is commonly treated with a flexor digitorum longus (FDL) tendon transfer (FDLTT) to the navicular (NAV), medial cuneiform (CUN), or distal residuum of the degraded PTT (rPTT). We assessed the kinetic and kinematic outcomes of these three attachment sites using cadaveric gait simulation. Three transfer locations (NAV, CUN, rPTT) were tested on seven prepared flatfoot models using a robotic gait simulator (RGS). The FDLTT procedures were simulated by pulling on the PTT with biomechanically realistic FDL forces (rPTT) or by pulling on the transected FDL tendon after fixation to the navicular or medial cuneiform (NAV and CUN, respectively). Plantar pressure and foot bone motion were quantified. Peak plantar pressure significantly decreased from the flatfoot condition at the first metatarsal (NAV) and hallux (CUN). No difference was found in the medial-lateral center of pressure. Kinematic findings showed minimal differences between flatfoot and FDLTT specimens. The three locations demonstrated only minimal differences from the flatfoot condition, with the NAV and CUN procedures resulting in decreased medial pressures. Functionally, all three surgical procedures performed similarly. Published 2013 by Wiley Periodicals, Inc. on behalf of the Orthopaedic Research Society. C1 [Vaudreuil, Nicholas J.; Ledoux, William R.; Roush, Grant C.; Whittaker, Eric C.; Sangeorzan, Bruce J.] VA Puget Sound, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA 98108 USA. [Vaudreuil, Nicholas J.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Ledoux, William R.; Roush, Grant C.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.; Sangeorzan, Bruce J.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU Department of Veterans Affairs Rehabilitation Research and Development Service [A4843C]; University of Washington Medical Student Research Training Program FX Grant sponsor: Department of Veterans Affairs Rehabilitation Research and Development Service; Grant number: A4843C; Grant sponsor: University of Washington Medical Student Research Training Program. NR 30 TC 1 Z9 1 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD JAN PY 2014 VL 32 IS 1 BP 102 EP 109 DI 10.1002/jor.22488 PG 8 WC Orthopedics SC Orthopedics GA AK0EW UT WOS:000338086700014 PM 24115238 ER PT J AU Joshi, SK Kim, HT Feeley, BT Liu, XH AF Joshi, Sunil K. Kim, Hubert T. Feeley, Brian T. Liu, Xuhui TI Differential Ubiquitin-Proteasome and Autophagy Signaling Following Rotator Cuff Tears and Suprascapular Nerve Injury SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE rotator cuff tear; denervation; muscle atrophy; ubiquitin-proteasome; autophagy ID SKELETAL-MUSCLE ATROPHY; DENERVATION ATROPHY; FATTY INFILTRATION; PROTEIN-SYNTHESIS; RAT MODEL; DEGRADATION; REPAIR; IDENTIFICATION; SUPRASPINATUS; ACTIVATION AB Previous studies have evaluated role of Akt/mTOR signaling in rotator cuff muscle atrophy and determined that there was differential in signaling following tendon transection (TT) and suprascapular nerve (SSN) denervation (DN), suggesting that atrophy following TT and DN was modulated by different protein degradation pathways. In this study, two muscle proteolytic systems that have been shown to be potent regulators of muscle atrophy in other injury models, the ubiquitin-proteasome pathway and autophagy, were evaluated following TT and DN. In addition to examining protein degradation, this study assessed protein synthesis rate following these two surgical models to understand how the balance between protein degradation and synthesis results in atrophy following rotator cuff injury. In contrast to the traditional theory that protein synthesis is decreased during muscle atrophy, this study suggests that protein synthesis is up-regulated in rotator cuff muscle atrophy following both surgical models. While the ubiquitin-proteasome pathway was a major contributor to the atrophy seen following DN, autophagy was a major contributor following TT. The findings of this study suggest that protein degradation is the primary factor contributing to atrophy following rotator cuff injury. However, different proteolytic pathways are activated if SSN injury is involved. (C) 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. C1 [Joshi, Sunil K.; Kim, Hubert T.; Feeley, Brian T.; Liu, Xuhui] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94153 USA. [Joshi, Sunil K.; Kim, Hubert T.; Feeley, Brian T.; Liu, Xuhui] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94158 USA. RP Liu, XH (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, 4150 Clement St, San Francisco, CA 94153 USA. EM Liux@orthosurg.ucsf.edu FU Veterans Affairs RR & D Merit Review Grant [RX000195]; NIH/NIAMS RO3 [AR060871-02]; Orthopaedic Research and Education Foundation FX Grant sponsor: Veterans Affairs RR & D Merit Review Grant; Grant number: RX000195; Grant sponsor: NIH/NIAMS RO3; Grant number: AR060871-02; Grant sponsor: Orthopaedic Research and Education Foundation. NR 43 TC 9 Z9 9 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD JAN PY 2014 VL 32 IS 1 BP 138 EP 144 DI 10.1002/jor.22482 PG 7 WC Orthopedics SC Orthopedics GA AK0EW UT WOS:000338086700019 PM 24018537 ER PT S AU Fusar-Poli, P Carpenter, WT Woods, SW McGlashan, TH AF Fusar-Poli, P. Carpenter, W. T. Woods, S. W. McGlashan, T. H. BE Cannon, TD Widiger, T TI Attenuated Psychosis Syndrome: Ready for DSM-5.1? SO ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 10 SE Annual Review of Clinical Psychology LA English DT Article; Book Chapter DE psychosis; schizophrenia; prodromal; high risk; prevention; attenuated psychosis syndrome ID ULTRA-HIGH-RISK; RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; MAGNETIC-RESONANCE SPECTROSCOPY; 1ST EPISODE PSYCHOSIS; BASIC SYMPTOMS BSABS; CLINICAL HIGH-RISK; AT-RISK; 1ST-EPISODE PSYCHOSIS; COMPREHENSIVE ASSESSMENT AB Prodromal features of the schizophrenia syndrome have been described for a century, and work in the past two decades has produced a substantial literature based on these features to identify individuals at increased risk for developing a psychotic disorder. Sometimes conceptualized as a "risk state" and sometimes as early manifestations of a "disorder," the work has been conducted with several related but different constructs. Early in the preparation of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) public comment was sought on the proposal to create a new disorder termed attenuated psychosis syndrome (APS), and a range of issues emerged that generated interesting and important controversies. In this review, these criticisms are fully discussed, the APS concept is explicated; data relating to reliability, validity, and treatment are updated; the heterogeneity of APS is considered; and alternative views of the construct are presented with an emphasis on developmental pattern with timing for primary and secondary prevention and early treatment. Areas of future research are identified, and a potential roadmap for inclusion in DSM-5.1 is traced. C1 [Fusar-Poli, P.] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London SE5 8AF, England. [Fusar-Poli, P.] South London & Maudsley SLaM NHS Fdn Trust, OASIS Prodromal Team, London SE5 8AF, England. [Carpenter, W. T.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Baltimore, MD 21228 USA. [Carpenter, W. T.] US Dept Vet Affairs, VISN Mental Illness Res & Clin Ctr 5, Baltimore, MD 21201 USA. [Woods, S. W.; McGlashan, T. H.] Yale Univ, Sch Med, Dept Psychiat, Connecticut Mental Hlth Ctr, New Haven, CT 06519 USA. RP Fusar-Poli, P (reprint author), Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London SE5 8AF, England. EM p.fusar@libero.it FU NIMH NIH HHS [U01 MH082022] NR 134 TC 36 Z9 38 U1 5 U2 20 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1548-5943 BN 978-0-8243-3910-4 J9 ANNU REV CLIN PSYCHO JI Annu. Rev. Clin. Psychol. PY 2014 VL 10 BP 155 EP 192 DI 10.1146/annurev-clinpsy-032813-153645 PG 38 WC Psychology, Clinical; Psychology SC Psychology GA BA4XX UT WOS:000336428200008 PM 24471375 ER PT S AU Tomer, Y AF Tomer, Yaron BE Abbas, AK Galli, SJ Howley, PM TI Mechanisms of Autoimmune Thyroid Diseases: From Genetics to Epigenetics SO ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 SE Annual Review of Pathology-Mechanisms of Disease LA English DT Review; Book Chapter DE autoimmunity; thyroid; Graves disease; Hashimoto's thyroiditis ID SINGLE-NUCLEOTIDE POLYMORPHISM; LYMPHOID TYROSINE PHOSPHATASE; GRAVES-DISEASE; RHEUMATOID-ARTHRITIS; ASSOCIATION ANALYSIS; INHIBITORY FUNCTION; WHICKHAM SURVEY; UNITED-STATES; DANISH TWINS; T-CELLS AB Recent advances in our understanding of genetic-epigenetic interactions have unraveled new mechanisms underlying the etiology of complex autoimmune diseases. Autoimmune thyroid diseases (AITDs) are highly prevalent, affecting 1% to 5% of the population. The major AITDs include Graves disease (GD) and Hashimoto's thyroiditis (HT); although these diseases contrast clinically, their pathogenesis involves shared immunogenetic mechanisms. Genetic data point to the involvement of both shared and unique genes. Among the shared susceptibility genes, HLA-DR beta 1-Arg74 (human leukocyte antigen DR containing an arginine at position beta 74) confers the strongest risk. Recent genome-wide analyses have revealed new putative candidate genes. Epigenetic modulation is emerging as a major mechanism by which environmental factors interact with AITD susceptibility genes. Dissecting the genetic-epigenetic interactions underlying the pathogenesis of AITD is essential to uncover new therapeutic targets. C1 [Tomer, Yaron] Mt Sinai Med Ctr, Dept Med, Div Endocrinol, New York, NY 10029 USA. [Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Dept Med, Div Endocrinol, New York, NY 10029 USA. EM yaron.tomer@mssm.edu FU NIDDK NIH HHS [DK067555, DK073681, DK61659, R01 DK061659, R01 DK067555, R01 DK073681] NR 63 TC 32 Z9 32 U1 2 U2 17 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1553-4006 BN 978-0-8243-4309-5 J9 ANNU REV PATHOL-MECH JI Annu. Rev. Pathol.-Mech Dis. PY 2014 VL 9 BP 147 EP 156 DI 10.1146/annurev-pathol-012513-104713 PG 10 WC Pathology SC Pathology GA BA4OG UT WOS:000336055900007 PM 24460189 ER PT J AU Wang, JM Tao, J Chen, DD Cai, JJ Irani, K Wang, QD Yuan, H Chen, AF AF Wang, Jie-Mei Tao, Jun Chen, Dan-Dan Cai, Jing-Jing Irani, Kaikobad Wang, Qinde Yuan, Hong Chen, Alex F. TI MicroRNA miR-27b Rescues Bone Marrow-Derived Angiogenic Cell Function and Accelerates Wound Healing in Type 2 Diabetes Mellitus SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE microRNAs; diabetes mellitus; type 2; wound healing ID ENDOTHELIAL PROGENITOR CELLS; VIVO REENDOTHELIALIZATION CAPACITY; OXIDATIVE STRESS; HIGH GLUCOSE; IN-VIVO; PROTEIN THROMBOSPONDIN-1; MYOCARDIAL-INFARCTION; UP-REGULATION; MICE; EXPRESSION AB Objective-Vascular precursor cells with angiogenic potentials are important for tissue repair, which is impaired in diabetes mellitus. MicroRNAs are recently discovered key regulators of gene expression, but their role in vascular precursor cell-mediated angiogenesis in diabetes mellitus is unknown. We tested the hypothesis that the microRNA miR-27b rescues impaired bone marrow-derived angiogenic cell (BMAC) function in vitro and in vivo in type 2 diabetic mice. Approach and Results-BMACs from adult male type 2 diabetic db/db and from normal littermate db/+ mice were used. miR-27b expression was decreased in db/db BMACs. miR-27b mimic improved db/db BMAC function, including proliferation, adhesion, tube formation, and delayed apoptosis, but it did not affect migration. Elevated thrombospondin-1 (TSP-1) protein in db/db BMACs was suppressed on miR-27b mimic transfection. Inhibition of miR-27b in db/+ BMACs reduced angiogenesis, which was reversed by TSP-1 small interfering RNA (siRNA). miR-27b suppressed the pro-oxidant protein p66(shc) and mitochondrial oxidative stress, contributing to its protection of BMAC function. miR-27b also suppressed semaphorin 6A to improve BMAC function in diabetes mellitus. Luciferase binding assay suggested that miR-27b directly targeted TSP-1, TSP-2, p66(shc), and semaphorin 6A. miR-27b improved topical cell therapy of diabetic BMACs on diabetic skin wound closure, with a concomitant augmentation of wound perfusion and capillary formation. Normal BMAC therapy with miR-27b inhibition demonstrated reduced efficacy in wound closure, perfusion, and capillary formation. Local miR-27b delivery partly improved wound healing in diabetic mice. Conclusions-miR-27b rescues impaired BMAC angiogenesis via TSP-1 suppression, semaphorin 6A expression, and p66shc-dependent mitochondrial oxidative stress and improves BMAC therapy in wound healing in type 2 diabetic mice. C1 [Wang, Jie-Mei; Chen, Dan-Dan; Wang, Qinde; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Vasc Surg Res, Pittsburgh, PA USA. [Wang, Jie-Mei; Tao, Jun] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hypertens & Vasc Dis, Guangzhou 510275, Guangdong, Peoples R China. [Wang, Jie-Mei; Chen, Dan-Dan; Cai, Jing-Jing; Wang, Qinde; Yuan, Hong; Chen, Alex F.] Cent S Univ, Dept Cardiol, Changsha 410013, Hunan, Peoples R China. [Wang, Jie-Mei; Chen, Dan-Dan; Cai, Jing-Jing; Wang, Qinde; Yuan, Hong; Chen, Alex F.] Cent S Univ, Xiangya Hosp 3, Ctr Clin Pharmacol, Changsha 410013, Hunan, Peoples R China. [Irani, Kaikobad] Univ Iowa, Dept Internal Med, Div Cardiovasc Med, Carver Coll Med, Iowa City, IA 52242 USA. RP Chen, AF (reprint author), Cent S Univ, Xiangya Hosp 3, 138 Tong Zi Bo Rd, Changsha 410013, Hunan, Peoples R China. EM afychen@yahoo.com RI WANG, JIEMEI/G-9805-2017 OI WANG, JIEMEI/0000-0002-8723-4410; Irani, Kaikobad/0000-0001-9194-7387 FU National Institutes of Health (NIH)/National Institute of General Medical Sciences [R01 GM077352]; Department of Veterans Affairs [I01RX000244, 1I01RX000652]; American Diabetes Association [7-11-BS-23]; National Science Foundation of China [81130004]; NIH [1R21CA158650]; China Overseas Scholarship [20070320]; American Heart Association [0920110G, 13SDG16930098] FX This work was supported, in part, by the National Institutes of Health (NIH)/National Institute of General Medical Sciences R01 GM077352 (to A. F. Chen), Department of Veterans Affairs Rehabilitation Research and Development Merit Awards I01RX000244 and 1I01RX000652 (to A. F. Chen), American Diabetes Association Research Award 7-11-BS-23 (to A. F. Chen), the National Science Foundation of China Key Research Project 81130004 (to A. F. Chen), and NIH 1R21CA158650 (to Q. D. Wang). Dr Jie-Mei Wang was the awardee of China Overseas Scholarship 20070320, American Heart Association Postdoctoral Fellowship 0920110G, and American Heart Association Scientist Development Grant 13SDG16930098. NR 61 TC 24 Z9 27 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 EI 1524-4636 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD JAN PY 2014 VL 34 IS 1 BP 99 EP + DI 10.1161/ATVBAHA.113.302104 PG 30 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA AJ5NO UT WOS:000337731100015 PM 24177325 ER PT J AU Park, M Vittinghoff, E Ganz, P Peralta, CA Whooley, M Shlipak, MG AF Park, Meyeon Vittinghoff, Eric Ganz, Peter Peralta, Carmen A. Whooley, Mary Shlipak, Michael G. TI Role of Soluble Endothelial Cell-Selective Adhesion Molecule Biomarker in Albuminuria and Kidney Function Changes in Patients With Coronary Artery Disease The Heart and Soul Study SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE albuminuria; atherosclerosis; kidney diseases ID CARDIOVASCULAR-DISEASE; RENAL-DISEASE; DYSFUNCTION; RISK; OUTCOMES; ATHEROSCLEROSIS; ASSOCIATIONS; POPULATION; MORTALITY; EVENTS AB Objective-Endothelial dysfunction is a possible mechanism to explain the association between atherosclerosis and kidney disease. This study evaluated circulating soluble endothelial cell-selective adhesion molecule (sESAM), a marker of endothelial dysfunction, as a risk factor for kidney function decline and albuminuria. Approach and Results-In the Heart and Soul Study, we measured sESAM from baseline serum samples and defined elevated levels of sESAM by the highest quartile (quartile 4 [Q4]: >65.4 ng/mL). We evaluated the associations of high sESAM with baseline estimated glomerular filtration rate (eGFR) and ratio of urine albumin to creatinine (ACR), and with longitudinal changes in eGFR and ACR. Among 990 participants with sESAM measurements, median sESAM was 54.5 ng/mL (interquartile range, 45.3-65.8). After multivariable adjustment, elevated levels of sESAM were strongly and independently associated with baseline reduced eGFR <60 mL/min per 1.73 m(2) (odds ratio [OR], 11.44; P<0.0001) and ACR >= 30 mg/g (OR, 5.23; P<0.0001). Associations of sESAM (Q4 versus quartile 1 [Q1]) with change in ACR (beta=54.47; P<0.0001) were also significant after full adjustment. The association with change in eGFR (1.56%; P=0.0049) was not statistically significant after application of the Bonferroni correction for multiple markers. In unadjusted models, sESAM was associated with rapid kidney function loss, defined as 3% annual eGFR decline (OR, 2.28; P=0.0003), although this was attenuated by adjustment (OR, 2.11; P=0.0095). Conclusions-sESAM is associated with albuminuria and reduced kidney function in both cross-sectional and longitudinal analyses. These findings implicate endothelial dysfunction as a potential contributor to the elevated kidney disease risk in persons with cardiovascular disease. C1 [Park, Meyeon; Peralta, Carmen A.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Vittinghoff, Eric; Whooley, Mary; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Ganz, Peter; Whooley, Mary; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Ganz, Peter] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA. [Whooley, Mary; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Park, M (reprint author), 521 Parnassus Ave,C443,Box 0532, San Francisco, CA 94143 USA. EM meyeon.park@ucsf.edu FU Meyeon Park's NIH/NIDDK [F32DK093231]; American Heart Association [11POST7230046]; NIH/NIDDK [1K23DK082793]; NIH [R01 DK080662, 1 P50 DA036109]; Department of Veteran Affairs (Epidemiology Merit Review Program), Washington, DC; National Heart, Lung, and Blood Institute, Bethesda, MD [R01 HL-079235]; Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), Princeton, NJ; American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program), New York, NY; Ischemia Research and Education Foundation, South San Francisco, CA; [R01 AG034853-04]; [5R01AG027002-06]; [5R01DK087961-02] FX This work was supported by Meyeon Park's NIH/NIDDK F32DK093231 and American Heart Association 11POST7230046 (to M. Park). M. S. is supported by R01 AG034853-04, 5R01AG027002-06, and 5R01DK087961-02. C. P. is funded by NIH/NIDDK 1K23DK082793. P. G. is funded by NIH R01 DK080662 and NIH 1 P50 DA036109. The Heart and Soul Study was funded by the Department of Veteran Affairs (Epidemiology Merit Review Program), Washington, DC; grant R01 HL-079235 from the National Heart, Lung, and Blood Institute, Bethesda, MD; the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program), Princeton, NJ; the American Federation for Aging Research (Paul Beeson Faculty Scholars in Aging Research Program), New York, NY; and the Ischemia Research and Education Foundation, South San Francisco, CA. NR 28 TC 7 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 EI 1524-4636 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD JAN PY 2014 VL 34 IS 1 BP 231 EP 236 DI 10.1161/ATVBAHA.113.301806 PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA AJ5NO UT WOS:000337731100031 PM 24177327 ER PT J AU Schulz, R Rosen, J Klinger, J Musa, D Castle, NG Kane, AL Lustig, A AF Schulz, Richard Rosen, Jules Klinger, Julie Musa, Donald Castle, Nicholas G. Kane, April L. Lustig, Amy TI Effects of a Psychosocial Intervention on Caregivers of Recently Placed Nursing Home Residents: A Randomized Controlled Trial SO CLINICAL GERONTOLOGIST LA English DT Article DE caregiving; complicated grief; long-term care ID QUALITY-OF-LIFE; COMPLICATED GRIEF; ADVANCED DEMENTIA; COOPERATIVE COMMUNICATION; DEPRESSIVE SYMPTOMS; FAMILY INVOLVEMENT; ALZHEIMERS-DISEASE; STAFF PERCEPTIONS; CARE; TRANSITION AB Many caregivers continue to provide care and support to their care recipients after institutional placement. A two-group randomized controlled trial was carried out to test the efficacy of a psychosocial intervention for informal caregivers whose care recipients resided in a long-term care facility. The intervention was delivered during the 6-month period following baseline assessment. Follow-up assessments were carried out at 6, 12, and 18 months. Primary outcomes were caregiver depression, anxiety, burden, and complicated grief. Significant time effects were found for all three primary outcomes showing that caregiver depression, anxiety, and burden improved over time. No treatment effects were found for these outcomes. However, complicated grief was significantly lower for caregivers in the treatment condition. C1 [Schulz, Richard; Rosen, Jules; Klinger, Julie; Musa, Donald; Castle, Nicholas G.; Kane, April L.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Lustig, Amy] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Schulz, R (reprint author), Univ Pittsburgh, Dept Psychiat, 3343 Forbes Ave, Pittsburgh, PA 15260 USA. EM schulz@pitt.edu FU National Institute of Nursing Research [NR009573] FX This work was supported by a grant from the National Institute of Nursing Research (NR009573). NR 44 TC 4 Z9 4 U1 8 U2 23 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0731-7115 EI 1545-2301 J9 CLIN GERONTOLOGIST JI Clin. Gerontol. PY 2014 VL 37 IS 4 BP 347 EP 367 DI 10.1080/07317115.2014.907594 PG 21 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AJ4YN UT WOS:000337686200002 PM 25071302 ER PT J AU Teng, E Yamasaki, TR Tran, M Hsiao, JJ Sultzer, DL Mendez, MF AF Teng, Edmond Yamasaki, Tritia R. Tran, Michelle Hsiao, Julia J. Sultzer, David L. Mendez, Mario F. TI Cerebrospinal Fluid Biomarkers in Clinical Subtypes of Early-Onset Alzheimer's Disease SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Early-onset Alzheimer's disease; Logopenic progressive aphasia; Posterior cortical atrophy; Cerebrospinal fluid; Biological markers; Amyloid; Tau ID POSTERIOR CORTICAL ATROPHY; PRIMARY PROGRESSIVE APHASIA; CSF BIOMARKERS; TAU; DIAGNOSIS; PRESENTATIONS; THREONINE-181; PATHOLOGY; VARIANTS; DEMENTIA AB Background/Aims: Accurate diagnosis of sporadic early-onset Alzheimer's disease (EOAD) can be challenging, and cerebrospinal fluid (CSF) biomarkers may assist in this process. We compared CSF indices between three EOAD subtypes: amnestic, logopenic progressive aphasia (LPA), and posterior cortical atrophy (PCA). Methods: We identified 21 amnestic EOAD, 20 LPA, and 12 PCA patients with CSF data, which included amyloid beta(1-42) (A beta 42), total tau (t-tau), phospho-tau(181) (p-tau), and A beta 42/t-tau index (ATI) levels. Results: A beta 42 and ATI levels were similar across groups, but t-tau and p-tau levels were significantly lower in PCA patients. Conclusions: The A beta 42 and ATI data confirm the commonality of the A beta pathology in EOAD. The lower tau indices in PCA patients may reflect differences in the distribution of neurofibrillary tangles or rates of neurodegeneration. (C) 2013 S. Karger AG, Basel C1 [Teng, Edmond; Yamasaki, Tritia R.; Tran, Michelle; Hsiao, Julia J.; Sultzer, David L.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA. [Teng, Edmond; Hsiao, Julia J.; Sultzer, David L.; Mendez, Mario F.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Teng, E (reprint author), West Los Angeles VA Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu FU National Institute on Aging [R01 AG034499, K08 AG34628]; NIA; AFAR; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; VA Merit Review FX The authors would like to thank Po-Heng Tsai, Elvira Jimenez, and Michelle Mather for their assistance with data management. This work was supported by the National Institute on Aging [R01 AG034499 (to M.F.M.) and K08 AG34628 (to E.T.; jointly sponsored by the NIA, AFAR, the John A. Hartford Foundation, the Atlantic Philanthropies, the Starr Foundation, and an anonymous donor)], and a VA Merit Review (to M.F.M.). NR 41 TC 8 Z9 8 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 EI 1421-9824 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2014 VL 37 IS 5-6 BP 307 EP 314 DI 10.1159/000355555 PG 8 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA AJ6IL UT WOS:000337795500006 PM 24401901 ER PT S AU Tsao, S Gajawelli, N Hwang, DH Kriger, S Law, M Chui, H Weiner, M Lepore, N AF Tsao, Sinchai Gajawelli, Niharika Hwang, Darryl Hwa Kriger, Stephen Law, Meng Chui, Helena Weiner, Michael Lepore, Natasha BE Law, MY Cook, TS TI Mapping of ApoE4 Related White Matter Damage using Diffusion MRI SO MEDICAL IMAGING 2014: PACS AND IMAGING INFORMATICS: NEXT GENERATION AND INNOVATIONS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - PACS and Imaging Informatics - Next Generation and Innovations CY FEB 18-20, 2014 CL San Diego, CA SP SPIE, Modus Med Devices Inc, XIFIN Inc, Ventana Med Syst Inc, Intrace Med DE DTI; Diffusion MRI; MRI; Alzheimer's Disease; Dementia; ApoE; Neuroimaging AB ApoliopoproteinE epsilon 4 (ApoE-epsilon 4) polymorphism is the most well known genetic risk factor for developing Alzheimers Disease. The exact mechanism through which ApoE epsilon 4 increases AD risk is not fully known, but may be related to decreased clearance and increased oligomerization of A beta. By making measurements of white matter integrity via diffusion MR and correlating the metrics in a voxel-based statistical analysis with ApoE-epsilon 4 genotype (whilst controlling for vascular risk factor, gender, cognitive status and age) we are able to identify changes in white matter associated with carrying an ApoE epsilon 4 allele. We found potentially significant regions (P-uncorrected < 0.05) near the hippocampus and the posterior cingulum that were independent of voxels that correlated with age or clinical dementia rating (CDR) status suggesting that ApoE may affect cognitive decline via a pathway in dependent of normal aging and acute insults that can be measured by CDR and Framingham Coronary Risk Score (FCRS). C1 [Tsao, Sinchai] Univ Washington, Seattle, WA 98195 USA. [Gajawelli, Niharika; Hwang, Darryl Hwa; Law, Meng; Chui, Helena; Lepore, Natasha] Univ South Calif, Los Angeles, CA 90089 USA. [Gajawelli, Niharika; Lepore, Natasha] Childrens Hosp Los Angeles, Los Angeles, CA USA. [Kriger, Stephen; Weiner, Michael] San Francisco VA Med Ctr, Ctr Nerodegenerat Dis, San Francisco, CA USA. RP Tsao, S (reprint author), Univ Washington, Seattle, WA 98195 USA. EM mail@SinchaiTsao.com; lepore@usc.edu FU National Institute of Biomedical Imaging and Bioengineering [5R21EB013456-02]; [5P01AG012435-18] FX This work hasbeen supported by USC ADRC's National Institutes of Aging Program Grant 5P01AG012435-18 as well as National Institute of Biomedical Imaging and Bioengineering grant 5R21EB013456-02 NR 1 TC 3 Z9 3 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9832-8 J9 PROC SPIE PY 2014 VL 9039 AR UNSP 90390H DI 10.1117/12.2043925 PG 5 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BA7IY UT WOS:000337584000014 PM 25076830 ER PT J AU Wood, GC Boucher, AB Johnson, JL Wisniewski, JN Magnotti, LJ Croce, MA Swanson, JM Boucher, BA Fabian, TC AF Wood, G. Christopher Boucher, Andrew B. Johnson, Jessica L. Wisniewski, Jennifer N. Magnotti, Louis J. Croce, Martin A. Swanson, Joseph M. Boucher, Bradley A. Fabian, Timothy C. TI Effectiveness of Pseudoephedrine as Adjunctive Therapy for Neurogenic Shock After Acute Spinal Cord Injury: A Case Series SO PHARMACOTHERAPY LA English DT Article DE pseudoephedrine; vasopressor; neurogenic shock; spinal cord injury; bradycardia; hypotension ID SYMPTOMATIC BRADYCARDIA; MANAGEMENT; AMINOPHYLLINE; COMPLICATIONS; ASYSTOLE; TETRAPLEGIA AB STUDY OBJECTIVE To evaluate the effectiveness of pseudoephedrine as adjunctive therapy for neurogenic shock in patients with acute spinal cord injury (SCI). DESIGN Case series. SETTING Academic medical center. PATIENTS Thirty-eight patients admitted to the trauma intensive care unit between September 2005 and October 2012 with an acute SCI and who received more than 1 day of pseudoephedrine for one or more of the following: treatment of bradycardia (heart rate < 50 beats/min), treatment of hypotension (systolic blood pressure < 90 mm Hg), or were receiving intravenous vasopressor support. MEASUREMENTS AND MAIN RESULTS The effect of adjunctive pseudoephedrine (PSE) was categorized as a success if vasopressors were discontinued after the initiation of PSE or improvement in the number of episodes of bradycardia was noted after the initiation of PSE as evidenced by decreased use of atropine. The effect of pseudoephedrine was categorized as a failure if it did not meet one of the criteria for success. The effect of pseudoephedrine was categorized as inconclusive if there were confounding factors such as vasopressors being restarted for another indication after initial discontinuation. Pseudoephedrine was successful in 31/38 (82%) patients, failed in 2/38 (5%) patients, and had inconclusive results in 5/38 (13%) patients. The mean +/- SD time to successful weaning of intravenous vasopressors was 7 +/- 7 days. Daily maximum pseudoephedrine doses ranged from 60-720 mg. Mean +/- SD duration of pseudoephedrine therapy was 32 +/- 23 days (range 2-135 days), with 64.5% of surviving patients discharged while receiving pseudoephedrine. CONCLUSION These data suggest that pseudoephedrine is an effective adjunctive therapy in facilitating the discontinuation of intravenous vasopressors and/or atropine in patients with acute SCI with neurogenic shock, although patients will typically require long durations of therapy. C1 [Wood, G. Christopher; Swanson, Joseph M.; Boucher, Bradley A.] Univ Tennessee, Dept Clin Pharm, Coll Pharm, Hlth Sci Ctr, Memphis, TN 38163 USA. [Boucher, Andrew B.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Memphis, TN 38163 USA. [Johnson, Jessica L.] MedStar Union Mem Hosp, Dept Pharm, Baltimore, MD USA. [Wisniewski, Jennifer N.] Ralph H Johnson Vet Affairs Med Ctr, Serv Pharm, Charleston, SC USA. [Magnotti, Louis J.; Croce, Martin A.; Fabian, Timothy C.] Univ Tennessee, Dept Surg, Coll Med, Hlth Sci Ctr, Memphis, TN 38163 USA. RP Wood, GC (reprint author), Univ Tennessee, Dept Clin Pharm, Coll Pharm, Hlth Sci Ctr, 881 Madison Ave, Memphis, TN 38163 USA. EM cwood@uthsc.edu NR 23 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JAN PY 2014 VL 34 IS 1 BP 89 EP 93 DI 10.1002/phar.1335 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AJ2UJ UT WOS:000337518800012 PM 23918202 ER PT J AU Jensen, KP Stein, MB Kranzler, HR Yang, BZ Farrer, LA Gelernter, J AF Jensen, K. P. Stein, M. B. Kranzler, H. R. Yang, B. Z. Farrer, L. A. Gelernter, J. TI The alpha-endomannosidase gene (MANEA) is associated with panic disorder and social anxiety disorder SO TRANSLATIONAL PSYCHIATRY LA English DT Article DE anxiety; behavior; cocaine; gene expression; mannosidosis; mannosidase ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; NATIONAL-COMORBIDITY-SURVEY; WHOLE GENOME ASSOCIATION; DSM-IV; SEMISTRUCTURED ASSESSMENT; PSYCHIATRIC-DISORDERS; ALCOHOLISM SSADDA; DRUG-DEPENDENCE; MANNOSIDOSIS; IDENTIFICATION AB Unbiased genome-wide approaches can provide novel insights into the biological pathways that are important for human behavior and psychiatric disorder risk. The association of alpha-endomannosidase gene (MANEA) variants and cocaine-induced paranoia (CIP) was initially described in a study that used a whole-genome approach. Behavioral effects have been reported for other mannosidase genes, but MANEA function in humans and the clinical potential of the previous findings remain unclear. We hypothesized that MANEA would be associated with psychiatric phenotypes unrelated to cocaine use. We used a multi-stage association study approach starting with four psychiatric disorders to show an association between a MANEA single-nucleotide polymorphism (SNP; rs1133503) and anxiety disorders. In the first study of 2073 European American (EA) and 2459 African American subjects mostly with comorbid drug or alcohol dependence, we observed an association in EAs of rs1133503 with panic disorder (PD) (191 PD cases, odds ratio (OR) = 1.7 (95% confidence interval (CI): 1.22-2.41), P = 0.002). We replicated this finding in an independent sample of 142 PD cases (OR = 1.53 (95% CI: 1.00-2.31), P = 0.043) and extended it in an independent sample of 131 generalized social anxiety disorder cases (OR = 2.15 (95% CI: 1.27-3.64), P = 0.004). MANEA alleles and genotypes were also associated with gene expression differences in whole blood cells. Using publically available data, we observed a consistent effect on expression in brain tissue. We conclude that pathways involving a-endomannosidase warrant further investigation in relation to anxiety disorders. C1 [Jensen, K. P.; Yang, B. Z.; Gelernter, J.] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, New Haven, CT USA. [Jensen, K. P.; Yang, B. Z.; Gelernter, J.] VA CT Healthcare Ctr, West Haven, CT USA. [Stein, M. B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Stein, M. B.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Kranzler, H. R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, H. R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA. [Farrer, L. A.] Boston Univ, Sch Med & Publ Hlth, Dept Med, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Med & Publ Hlth, Dept Neurol, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Med & Publ Hlth, Dept Ophthalmol, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Med & Publ Hlth, Dept Genet & Genom, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Med & Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Med & Publ Hlth, Dept Biostat, Boston, MA 02215 USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. RP Gelernter, J (reprint author), Yale Univ, Sch Med, Div Human Genet Psychiat, Dept Psychiat,VA CT Healthcare Ctr 116A2, 950 Campbell Ave, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu FU National Institutes of Health [N01-HG-65403, RC2 DA028909 DA12849, DA12690, DA18432, AA017535, AA11330, DA24758, MH64122, T32 MH014276, MH057858, MH058915, MH070022, MH057835, MH072952]; VA MERIT award FX Data from the CALM study were provided by the respective PIs: Michelle Craske PhD (UCLA), Peter Roy-Byrne MD (U Washington) and Greer Sullivan MD, MSPH (University of Arkansas for Medical Sciences). Genotyping services for some parts of the study were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University (contract number N01-HG-65403). This work was supported in part by NIH grants, RC2 DA028909 DA12849, DA12690, DA18432, AA017535, AA11330, DA24758, MH64122, T32 MH014276, MH057858, MH058915, MH070022, MH057835, MH64122, MH072952 and a VA MERIT award. NR 36 TC 3 Z9 3 U1 5 U2 9 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2158-3188 J9 TRANSL PSYCHIAT JI Transl. Psychiatr. PD JAN PY 2014 VL 4 AR e353 DI 10.1038/tp.2013.122 PG 6 WC Psychiatry SC Psychiatry GA AJ2RL UT WOS:000337507500015 PM 24473444 ER PT J AU Keller, SC Momplaisir, F Lo Re, V Newcomb, C Liu, Q Ratcliffe, SJ Long, JA AF Keller, Sara C. Momplaisir, Florence Lo Re, Vincent Newcomb, Craig Liu, Qing Ratcliffe, Sarah J. Long, Judith A. TI Colorectal cancer incidence and screening in US Medicaid patients with and without HIV infection SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; colorectal cancer; non-AIDS defining malignancies; Medicaid; colorectal cancer screening ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; CARE; DIAGNOSIS; POPULATION; SERVICES; ADULTS; OLDER; RISK; AIDS AB Non-AIDS defining malignancies, particularly colorectal cancer (CRC), may be more prevalent among persons living with HIV (PLWH). Further, PLWH may be less likely to receive CRC screening (CRCS). We studied the epidemiology of CRC and CRCS patterns in PLWH and HIV-uninfected persons in a large US Medicaid population. We performed a matched cohort study examining CRC incidence in 2006 and CRCS between 1999 and 2007. Study participants were continuously enrolled in the Medicaid programs of California, Florida, New York, Ohio, and Pennsylvania. All PLWH enrollees were matched to five randomly sampled HIV-uninfected enrollees on 5-year age group, gender, and state. Adjusted odds ratios (AORs) for incident CRC (adjusted for comorbidity index) and the presence of CRCS (adjusted for comorbidity index and years in the data-set) among PLWH compared to HIV-uninfected enrollees were calculated. PLWH were not more likely to be diagnosed with CRC after adjusting for comorbidity index (unadjusted OR: 1.73, 95% confidence interval [CI]: 1.37-2.19; AOR 1.29; 95% CI: 0.98-1.70). While CRCS rates were low overall, PLWH were more likely to have received CRCS in unadjusted analyses (35.8% vs. 33.7%; OR 1.10, 95% CI: 1.07-1.13). This relationship was reversed after adjusting for comorbidity index and years in the data-set (AOR: 0.80, 95% CI: 0.77-0.83). Limitations of the study include a focus on the Medicaid population, an inability to detect fecal occult blood tests (FOBT), and having half of patients between 50 and 55 years of age. In conclusion, PLWH were not more likely to be diagnosed with CRC, but in adjusted analyses, were less likely to have received CRCS. As we showed a low rate of CRCS overall in this Medicaid population, researchers, clinicians, and policy-makers should improve access to and uptake of CRCS among all Medicaid patients, and particularly among PLWH. C1 [Keller, Sara C.; Lo Re, Vincent] Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Momplaisir, Florence] Temple Univ, Sch Med, Div Infect Dis, Villanova, PA USA. [Newcomb, Craig; Liu, Qing; Ratcliffe, Sarah J.] Univ Penn, Perelman Sch Med, Dept Biostat & Clin Epidemiol, Philadelphia, PA 19104 USA. [Long, Judith A.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Keller, SC (reprint author), Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. EM skeller9@jhmi.edu RI Lo Re, Vincent/N-7817-2015 OI Ratcliffe, Sarah/0000-0002-6644-8284 FU NCATS NIH HHS [UL1 TR000003]; NCI NIH HHS [KM1 CA156715]; NCRR NIH HHS [UL1 RR024134]; NIAID NIH HHS [P30 AI045008] NR 32 TC 3 Z9 3 U1 2 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2014 VL 26 IS 6 BP 716 EP 722 DI 10.1080/09540121.2013.855700 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA AI9BJ UT WOS:000337221100007 PM 24188387 ER PT J AU Ojikutu, B Holman, J Kunches, L Landers, S Perlmutter, D Ward, M Fant, G Hirschhorn, L AF Ojikutu, Bisola Holman, Jeremy Kunches, Laureen Landers, Stewart Perlmutter, Dianne Ward, Melina Fant, Gregory Hirschhorn, Lisa TI Interdisciplinary HIV care in a changing healthcare environment in the USA SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; AIDS; interdisciplinary care; multidisciplinary care; medical home AB HIV remains a complex disease that requires comprehensive, coordinated care to ensure optimal outcomes. In the USA, interdisciplinary models of care have developed over time to optimize treatment outcomes. These models may be increasingly important in an era of healthcare reform in the USA. A qualitative study of nine clinical sites funded by the Ryan White HIV/AIDS Program (RWHAP), the federally funded "safety net" program for uninsured and underinsured people living with HIV, was undertaken to identify components of successful models of interdisciplinary HIV care. Findings suggest that these include: (1) patient-centered, one-stop-shop approaches with integrated or co-located services; (2) diverse teams of clinical and nonclinical providers; (3) a site culture that promotes a stigma reducing environment for clients; (4) the availability of a comprehensive array of medical, behavioral health, and psychosocial services; (5) effective communication strategies, including electronic health records (EHRs); and (6) a focus on quality. The importance of RWHAP funding in sustaining these programs is highlighted. C1 [Ojikutu, Bisola; Holman, Jeremy; Kunches, Laureen; Landers, Stewart; Perlmutter, Dianne; Ward, Melina; Hirschhorn, Lisa] John Snow Inc, Boston, MA 02210 USA. [Ojikutu, Bisola; Hirschhorn, Lisa] Harvard Univ, Sch Med, Boston, MA USA. [Fant, Gregory] Vet Hlth Adm, US Dept Vet Affairs, Washington, DC USA. RP Ojikutu, B (reprint author), John Snow Inc, Boston, MA 02210 USA. EM bojikutu@jsi.com FU PHS HHS [HHSH250200646026I] NR 10 TC 4 Z9 4 U1 1 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2014 VL 26 IS 6 BP 731 EP 735 DI 10.1080/09540121.2013.855299 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA AI9BJ UT WOS:000337221100009 PM 24191727 ER PT J AU Striebel, JM Kalapatapu, RK AF Striebel, Joan M. Kalapatapu, Raj K. TI THE ANTI-SUICIDAL POTENTIAL OF BUPRENORPHINE: A CASE REPORT SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE LA English DT Article DE buprenorphine; suicidality; pain; depression ID STRESS; DEPRESSION; DYNORPHIN; PAIN; RISK AB The very strong relationship between suicide, depressive disorders, and substance use disorders is well recognized. Certain pain syndromes are significantly associated with suicide, irrespective of co-occurring medical or psychiatric diagnosis. Chronic pain, depression, substance use disorders, and suicide appear to involve overlapping neural pathways and brain regions that function in the processing of emotional and physical pain, as well as maintaining reward and anti-reward circuitry. In this article, we employ a clinical case to illustrate how various stressors disrupted the balance between pain and opioid-facilitated analgesia. This disruption resulted in excessive use of short-acting opioids to treat pain with ensuing allostatic overload and culmination in chronic suicidal ideation with a suicide attempt. Sublingual buprenorphine was selected to treat the opioid use disorder. We propose that the unique pharmacodynamics of this drug served to stabilize dysregulated neural circuits, neurotransmitters, and neuropeptides, allowing the mitigation of pain, assuaging opioid cravings, easing depression, and resolving suicidal ideation. To our knowledge, this is the first case report to describe the possible anti-suicidal effect of sublingual buprenorphine. C1 [Striebel, Joan M.; Kalapatapu, Raj K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Striebel, Joan M.; Kalapatapu, Raj K.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Striebel, JM (reprint author), San Francisco VA Med Ctr, Dept Psychiat, Opioid Replacement Treatment Clin, 4150 Clement St,Mailstop 116F,Bldg 1, San Francisco, CA 94121 USA. EM joan.striebel@gmail.com FU ACGME-accredited Fellowship in Addiction Psychiatry at the University of California, San Francisco; [K23DA034883] FX Dr. Striebel is currently funded by the ACGME-accredited Fellowship in Addiction Psychiatry at the University of California, San Francisco. Dr. Kalapatapu is currently funded by K23DA034883. NR 16 TC 3 Z9 3 U1 1 U2 1 PU BAYWOOD PUBL CO INC PI AMITYVILLE PA 26 AUSTIN AVE, PO BOX 337, AMITYVILLE, NY 11701 USA SN 0091-2174 EI 1541-3527 J9 INT J PSYCHIAT MED JI Int. J. Psychiatr. Med. PY 2014 VL 47 IS 2 BP 169 EP 174 DI 10.2190/PM.47.2.g PG 6 WC Psychiatry SC Psychiatry GA AI8MP UT WOS:000337171200001 PM 25084802 ER PT J AU Matejkowski, J Fairfax-Columbo, J Cullen, SW Marcus, SC Solomon, PL AF Matejkowski, Jason Fairfax-Columbo, Jaymes Cullen, Sara W. Marcus, Steven C. Solomon, Phyllis L. TI Exploring the potential of stricter gun restrictions for people with serious mental illness to reduce homicide in the United States SO JOURNAL OF FORENSIC PSYCHIATRY & PSYCHOLOGY LA English DT Article DE gun violence; serious mental illness; multiple-victim homicide ID VIOLENCE; RISK AB This study explores the potential that current efforts to limit access to firearms for individuals with serious mental illness (SMI) have for reducing overall rates of murder by firearm in the United States. Official arrest, court and health records provided data on personal and offense characteristics of 95 individuals with SMI and 423 without, all of whom had been convicted of murder in the State of Indiana between 1990 and 2002. Bivariate analyses examined differences between the two groups and logistic regression models examined the relationship between SMI and offense characteristics. Compared to those without, a relatively small proportion of convicted murderers had a diagnosis indicating SMI. The presence of SMI was associated with reduced likelihood of targeting a stranger and was not associated with having multiple-victims or firearm use. Focusing on access to firearms exclusively by individuals with SMI will have little impact on multiple-victim or firearm-related homicides. C1 [Matejkowski, Jason] Univ Kansas, Sch Social Welf, Lawrence, KS 66045 USA. [Fairfax-Columbo, Jaymes] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA. [Cullen, Sara W.; Solomon, Phyllis L.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Matejkowski, J (reprint author), Univ Kansas, Sch Social Welf, Lawrence, KS 66045 USA. EM jmate@ku.edu NR 20 TC 3 Z9 3 U1 3 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1478-9949 EI 1478-9957 J9 J FORENSIC PSYCHI PS JI J. Forensic Psychiatry Psychol. PY 2014 VL 25 IS 3 BP 362 EP 369 DI 10.1080/14789949.2014.909868 PG 8 WC Criminology & Penology; Psychiatry SC Criminology & Penology; Psychiatry GA AI9JD UT WOS:000337248000007 ER PT J AU Jenkins, JA Gordon, AJ AF Jenkins, Jennifer A. Gordon, Adam J. TI Advancing the Peer Review Process: A Multifaceted Approach to Improving Quality SO SUBSTANCE ABUSE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; MASKING AUTHOR IDENTITY; BLIND C1 [Jenkins, Jennifer A.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C,Bldg 30, Pittsburgh, PA 15240 USA. EM adam.gordon@va.gov NR 13 TC 0 Z9 0 U1 2 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2014 VL 35 IS 2 BP 105 EP 107 DI 10.1080/08897077.2014.898978 PG 3 WC Substance Abuse SC Substance Abuse GA AI9HY UT WOS:000337244900001 PM 24580113 ER PT J AU Gordon, AJ Broyles, LM AF Gordon, Adam J. Broyles, Lauren M. TI A Physician-Centered Approach to Addiction Identification and Treatment Misses the Opportunity for Interdisciplinary Solutions SO SUBSTANCE ABUSE LA English DT Editorial Material C1 [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C,Bldg 30, Pittsburgh, PA 15240 USA. EM adam.gordon@va.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2014 VL 35 IS 2 BP 108 EP 109 DI 10.1080/08897077.2014.898976 PG 2 WC Substance Abuse SC Substance Abuse GA AI9HY UT WOS:000337244900002 PM 24580098 ER PT J AU Dulin, PL Gonzalez, VM Campbell, K AF Dulin, Patrick L. Gonzalez, Vivian M. Campbell, Kendra TI Results of a Pilot Test of a Self-Administered Smartphone-Based Treatment System for Alcohol Use Disorders: Usability and Early Outcomes SO SUBSTANCE ABUSE LA English DT Article DE Alcohol intervention; M-health; self-administered; smartphone; usability ID PERSONALIZED-FEEDBACK INTERVENTIONS; RANDOMIZED CONTROLLED-TRIAL; PROBLEM DRINKERS; DSM-IV; DRINKING; FEASIBILITY; DEPENDENCE; DIAGNOSIS; BARRIERS; STUDENTS AB .Background: This paper provides results from a pilot study focused on assessing early-stage effectiveness and usability of a smartphone-based intervention system that provides a stand-alone, self-administered intervention option, the Location-Based Monitoring and Intervention for Alcohol Use Disorders (LBMI-A). The LBMI-A provided numerous features for intervening with ongoing drinking, craving, connection with supportive others, managing life problems, high-risk location alerting, and activity scheduling. Methods: Twenty-eight participants, ranging in age from 22 to 45, who met criteria for an alcohol use disorder used an LBMI-A-enabled smartphone for 6 weeks. Results: Participants indicated the LBMI-A intervention modules were helpful in highlighting alcohol use patterns. Tools related to managing alcohol craving, monitoring consumption, and identifying triggers to drink were rated by participants as particularly helpful. Participants also demonstrated significant reductions in hazardous alcohol use while using the system (56% of days spent hazardously drinking at baseline vs. 25% while using the LBMI-A) and drinks per day diminished by 52%. Conclusions: Implications for system improvement as well as suggestions for designing ecological momentary assessment and intervention systems for substance use disorders are discussed. C1 [Dulin, Patrick L.; Gonzalez, Vivian M.] Univ Alaska Anchorage, Dept Psychol, Anchorage, AK 99508 USA. [Campbell, Kendra] San Francisco VA Med Ctr, Dept Family Med, San Francisco, CA USA. RP Dulin, PL (reprint author), Univ Alaska Anchorage, Dept Psychol, 3211 Providence Dr, Anchorage, AK 99508 USA. EM afpld@uaa.alaska.edu RI Emchi, Karma/Q-1952-2016 FU National Institute of Alcohol Abuse and Alcoholism (NIAAA) [RC2 AA019422-02] FX This project was funded by the National Institute of Alcohol Abuse and Alcoholism (NIAAA), grant RC2 AA019422-02. NR 31 TC 19 Z9 20 U1 5 U2 18 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2014 VL 35 IS 2 BP 168 EP 175 DI 10.1080/08897077.2013.821437 PG 8 WC Substance Abuse SC Substance Abuse GA AI9HY UT WOS:000337244900014 PM 24821354 ER PT J AU Kertesz, SG Austin, EL Pollio, DE Holmes, SK White, B Lukas, CV AF Kertesz, S. G. Austin, E. L. Pollio, D. E. Holmes, S. K. White, B. Lukas, C. VanDeusen TI Housing, Housing Vouchers, and the H-SOLVE Study: Homeless Solutions in a VA Environment SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Kertesz, S. G.; Austin, E. L.] Birmingham VAMC, Birmingham, AL USA. [Pollio, D. E.] Univ Alabama, Tuscaloosa, AL 35487 USA. [Holmes, S. K.; White, B.; Lukas, C. VanDeusen] Boston VAMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2014 VL 35 IS 2 BP 194 EP 195 PG 2 WC Substance Abuse SC Substance Abuse GA AI9HY UT WOS:000337244900020 ER PT J AU Merlin, J Turan, J Herbey, I Westfall, A Starrels, J Kertesz, S Mugavero, M Saag, M Ritchie, C AF Merlin, Jessica Turan, Janet Herbey, Ivan Westfall, Andrew Starrels, Joanna Kertesz, Stefan Mugavero, Michael Saag, Michael Ritchie, Christine TI Provider Documentation of Aberrant Drug-Related Behaviors in Patients Referred to an HIV/Chronic Pain Clinic SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Merlin, Jessica; Turan, Janet; Herbey, Ivan; Westfall, Andrew; Kertesz, Stefan; Mugavero, Michael; Saag, Michael] Univ Alabama Birmingham, Birmingham, AL USA. [Starrels, Joanna] Albert Einstein Coll Med, New York, NY USA. [Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2014 VL 35 IS 2 BP 199 EP 199 PG 1 WC Substance Abuse SC Substance Abuse GA AI9HY UT WOS:000337244900033 ER PT J AU Broyles, LM Wieland, M Confer, A Youk, A Gordon, A AF Broyles, Lauren Matukaitis Wieland, Melissa Confer, Andrea Youk, Ada Gordon, Adam TI Holes in the Pipeline: Addressing Recruitment Challenges for an Alcohol Brief Intervention Trial in the Acute Care Setting SO SUBSTANCE ABUSE LA English DT Meeting Abstract C1 [Broyles, Lauren Matukaitis; Gordon, Adam] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2014 VL 35 IS 2 BP 208 EP 208 PG 1 WC Substance Abuse SC Substance Abuse GA AI9HY UT WOS:000337244900058 ER PT J AU Morrel, WG Ge, L Ward, A Zhang, ZH Pantoja, J Gulati, S Grossi, EA Ratcliffe, MB AF Morrel, William G. Ge, Liang Ward, Alison Zhang, Zhihong Pantoja, Joe Gulati, Sarthak Grossi, Eugene A. Ratcliffe, Mark B. TI Effect of Mitral Annuloplasty Ring Shape and Size on Leaflet and Myofiber Stress Following Repair of Posterior Leaflet Prolapse: A Patient-Specific Finite-Element Simulation SO CARDIOLOGY LA English DT Meeting Abstract C1 [Morrel, William G.; Ge, Liang; Pantoja, Joe; Ratcliffe, Mark B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ward, Alison; Grossi, Eugene A.] NYU Sch Med, New York, NY USA. [Zhang, Zhihong] San Francisco VA Med Ctr, San Francisco, CA USA. [Gulati, Sarthak] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2014 VL 128 IS 2 BP 161 EP 162 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AI0GB UT WOS:000336523100122 ER PT J AU Bauman, WA La Fountaine, MF Spungen, AM AF Bauman, William A. La Fountaine, Michael F. Spungen, Ann M. TI Age-related prevalence of low testosterone in men with spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injuries; Testosterone replacement therapy; Paraplegia; Tetraplegia; Aging ID HORMONE-BINDING-GLOBULIN; CARDIOVASCULAR-DISEASE RISK; SERUM TESTOSTERONE; BODY-COMPOSITION; OLDER MEN; PITUITARY; PARAPLEGIA; DEFICIENCY; AXIS; HYPOGONADISM AB Objective: To describe the relationship of advancing age in persons with chronic spinal cord injury (SCI) on the prevalence of low testosterone in men with SCI compared to historical normative data from able-bodied men in the general population. Design: Retrospective, cross-sectional study. Two hundred forty-three healthy, non-ambulatory outpatient men with chronic SCI from age of 21 to 78 years were included in this retrospective analysis. Results: Forty-six percent of men with SCI were identified as having low serum total testosterone concentrations (total testosterone <11.3 nmol/l). The age-related decline in SCI for total serum testosterone concentration was 0.6%/year compared to 0.4%/year in the Massachusetts Male Aging Study. Between the third and eighth decade of life, men with SCI had a 15, 39, 50, 53, 58, and 57% prevalence rate of low serum total testosterone, which is higher than values reported for each decade of life for able-bodied men in the Baltimore Longitudinal Study on Aging. Conclusion: Compared with the general population, low serum total testosterone concentration occurs earlier in life in men with SCI, at a higher prevalence by decade of life, and their age-related decline in circulating total testosterone concentration is greater. Studies of T replacement therapy in men with SCI should assist in determining the possible functional and clinical benefits from reversing low serum total testosterone concentration. C1 [Bauman, William A.; La Fountaine, Michael F.; Spungen, Ann M.] James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Dept Vet Affairs, Rehabil Res & Dev Serv, Bronx, NY USA. [Bauman, William A.; La Fountaine, Michael F.; Spungen, Ann M.] James J Peters VA Med Ctr, Med Serv, Bronx, NY USA. [Bauman, William A.; La Fountaine, Michael F.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, Dept Phys Therapy, S Orange, NJ 07079 USA. RP Bauman, WA (reprint author), VA RR&D Natl Ctr Excellence Med Consequences Spin, Bronx, NY 10468 USA. EM william.bauman@va.gov FU Rehabilitation Research & Development (RR& D) Center of Excellence for the Medical Consequences of Spinal Cord Injury [B2648C, B9212C]; Department of Veterans Affairs Rehabilitation Research & Development Service FX The authors thank the James J Peters VA Medical Center, Bronx, NY, and the Department of Veterans Affairs Rehabilitation Research & Development Service for their support. This work was funded by a Rehabilitation Research & Development (RR& D) Center of Excellence for the Medical Consequences of Spinal Cord Injury (# B2648C and B9212C). NR 39 TC 11 Z9 13 U1 1 U2 2 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JAN PY 2014 VL 37 IS 1 BP 32 EP 39 DI 10.1179/2045772313Y.0000000122 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA AI8CJ UT WOS:000337132500005 PM 24090163 ER PT S AU Akl, TJ Wilson, MA Ericson, MN Cote, GL AF Akl, Tony J. Wilson, Mark A. Ericson, M. Nance Cote, Gerard L. BE Cote, GL TI Photoplethysmography beyond Perfusion and Oxygenation Monitoring: Pulse Wave Analysis for Hepatic Graft Monitoring SO OPTICAL DIAGNOSTICS AND SENSING XIV: TOWARD POINT-OF-CARE DIAGNOSTICS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Diagnostics and Sensing XIV - Toward Point-of-Care Diagnostics CY FEB 03-06, 2014 CL San Francisco, CA SP SPIE DE Photoplethysmography; Pulse waveform; Pulse analysis; Compliance; Graft monitoring ID LIVER-TRANSPLANTATION; IMPLANTABLE SENSOR; CONTOUR ANALYSIS; DISEASE; MICROCIRCULATION; QUANTIFICATION; ELASTOGRAPHY; FIBROSIS; FINGER AB Photoplethysmography is a technique widely used in monitoring perfusion and blood oxygen saturation based on the amplitude of the pulsatile signal at one or multiple wavelengths. However, the pulsatile signal carries in its waveform a substantial amount of information about the mechanical properties of the tissue and vasculature under investigation that is still yet to be utilized to its full potential. In this work, we present the feasibility of pulse wave analysis for the application of monitoring hepatic implants and diagnosing graft complications. In particular, we demonstrate the utility of computing the slope of the pulse during the diastole phase to assess compliance changes in tissue. This hypothesis was tested in a series of in vitro experiments using a polydimethylsiloxane based phantom mimicking the optical and mechanical properties of the portal vein. The emptying time decreased from 148.1 ms for phantoms with compliance of 12 KPa to 97.5 ms for phantoms with compliance of 61 KPa. These compliance levels mimic those seen for normal and fibrotic hepatic tissue respectively. C1 [Akl, Tony J.; Cote, Gerard L.] Texas A&M Univ, Dept Biomed Engn, College Stn, TX 77843 USA. [Wilson, Mark A.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Wilson, Mark A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ericson, M. Nance] Oak Ridge Natl Lab, Oak Ridge, TN USA. RP Akl, TJ (reprint author), Texas A&M Univ, Dept Biomed Engn, College Stn, TX 77843 USA. RI Ericson, Milton/H-9880-2016 OI Ericson, Milton/0000-0002-6628-4865 FU bioengineering research partnership (BRP); NIH [5R01-GM077150] FX This research was funded by a bioengineering research partnership (BRP) grant from NIH, (#5R01-GM077150). NR 28 TC 0 Z9 0 U1 0 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-0-8194-9864-9 J9 PROC SPIE PY 2014 VL 8951 AR UNSP 895103 DI 10.1117/12.2039611 PG 6 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BA5JX UT WOS:000336740800002 ER PT S AU Finn, NA Kemp, ML AF Finn, Nnenna A. Kemp, Melissa L. BE Nagar, S Argikar, UA Tweedie, DJ TI Systems Biology Approaches to Enzyme Kinetics: Analyzing Network Models of Drug Metabolism SO ENZYME KINETICS IN DRUG METABOLISM: FUNDAMENTALS AND APPLICATIONS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Doxorubicin; Systems biology; Network model; P-glycoprotein; Sensitivity analysis ID P-GLYCOPROTEIN; REDOX-REGULATION; STATE; CELL; THIOREDOXIN; GLUTATHIONE AB Intracellular drug metabolism involves transport, bioactivation, conjugation, and other biochemical steps. The dynamics of these steps are each dependent on a number of other cellular factors that can ultimately lead to unexpected behavior. In this review, we discuss the confounding processes and coupled reactions within bioactivation networks that require a systems-level perspective in order to fully understand the time-varying behavior. When converting known in vitro characteristics of drug-enzyme interactions into descriptions of cellular systems, features such as substrate availability, cell-to-cell variability, and intracellular redox state deserve special focus. An example of doxorubicin bioactivation is used for discussing points of consideration when constructing and analyzing network models of drug metabolism. C1 [Finn, Nnenna A.] Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USA. [Finn, Nnenna A.] US Dept Vet Affairs, Atlanta VA Med Ctr, Decatur, GA USA. [Kemp, Melissa L.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA. [Kemp, Melissa L.] Emory Univ, Atlanta, GA 30322 USA. RP Finn, NA (reprint author), Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USA. NR 27 TC 0 Z9 0 U1 0 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-62703-757-0; 978-1-62703-758-7 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2014 VL 1113 BP 317 EP 334 DI 10.1007/978-1-62703-758-7_15 D2 10.1007/978-1-62703-758-7 PG 18 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology GA BA2LX UT WOS:000333653000017 PM 24523119 ER PT J AU Hook, G Yu, J Toneff, T Kindy, M Hook, V AF Hook, Gregory Yu, Jin Toneff, Thomas Kindy, Mark Hook, Vivian TI Brain Pyroglutamate Amyloid-beta is Produced by Cathepsin B and is Reduced by the Cysteine Protease Inhibitor E64d, Representing a Potential Alzheimer's Disease Therapeutic SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Pyroglutamate amyloid-beta; cathepsin B; BACE1; A beta PP; protease; transgenic AD mice; inhibitor; cysteine protease; secretion ID REGULATED SECRETORY VESICLES; IMPROVES MEMORY DEFICITS; APP TRANSGENIC MICE; PRECURSOR PROTEIN; WILD-TYPE; A-BETA; MOUSE MODEL; IN-VIVO; CHROMAFFIN CELLS; SELECTIVE INHIBITOR AB Pyroglutamate amyloid-beta peptides (pGlu-A beta) are particularly pernicious forms of amyloid-beta peptides (A beta) present in Alzheimer's disease (AD) brains. pGlu-A beta peptides are N-terminally truncated forms of full-length A beta peptides (flA beta((1-40/42))) in which the N-terminal glutamate is cyclized to pyroglutamate to generate pGlu-A beta((3-40/42)). beta-secretase cleavage of amyloid-beta precursor protein (A beta PP) produces flA beta((1-40/42)), but it is not yet known whether the beta-secretase BACE1 or the alternative beta-secretase cathepsin B (CatB) participate in the production of pGlu-A beta. Therefore, this study examined the effects of gene knockout of these proteases on brain pGlu-A beta levels in transgenic A beta PPLon mice, which express A beta PP isoform 695 and have the wild-type (wt) beta-secretase activity found in most AD patients. Knockout or overexpression of the CatB gene reduced or increased, respectively, pGlu-A beta((3-40/42)), flA beta((1-40/42)), and pGlu-A beta plaque load, but knockout of the BACE1 gene had no effect on those parameters in the transgenic mice. Treatment of A beta PPLon mice with E64d, a cysteine protease inhibitor of CatB, also reduced brain pGlu-A beta((3-42)), flA beta((1-40/42)), and pGlu-A beta plaque load. Treatment of neuronal-like chromaffin cells with CA074Me, an inhibitor of CatB, resulted in reduced levels of pGlu-A beta((3-40)) released from the activity-dependent, regulated secretory pathway. Moreover, CatB knockout and E64d treatment has been previously shown to improve memory deficits in the A beta PPLon mice. These data illustrate the role of CatB in producing pGlu-A beta and flA beta that participate as key factors in the development of AD. The advantages of CatB inhibitors, especially E64d and its derivatives, as alternatives to BACE1 inhibitors in treating AD patients are discussed. C1 [Hook, Gregory] Amer Life Sci Pharmaceut, La Jolla, CA USA. [Yu, Jin; Kindy, Mark] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Yu, Jin; Kindy, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Toneff, Thomas; Hook, Vivian] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Neurosci, La Jolla, CA 92093 USA. [Toneff, Thomas; Hook, Vivian] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmacol, La Jolla, CA 92093 USA. RP Hook, V (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0744, La Jolla, CA 92093 USA. EM vhook@ucsd.edu FU NIH [R44AG032784, R01ES016774-02, R21AG042828]; VA Merit Review [1I01RX000331-01]; Alzheimer's Association award FX The authors wish to thank Christoph Peters, MD, of the Albert Ludwig University, Freiburg, Germany for providing the cathepsin B deficient mice and to Steven Jacobsen at AstraZeneca Neuroscience for his critical thinking and insightful comments on the work. This work was supported in part by grants from the NIH, composed of R44AG032784 to American Life Science Pharmaceuticals (ALSP) (GH), R01ES016774-02 (MSK), and R21AG042828 (VH), as well as a VA Merit Review 1I01RX000331-01 (MSK) and an Alzheimer's Association award (VH). G. Hook has equity interest in ALSP. V. Hook is the Chair of ALSP's Scientific Advisory Board and holds equity in ALSP, and the relationship has been disclosed to the Univ. of Calif., San Diego. NR 123 TC 18 Z9 18 U1 0 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 41 IS 1 BP 129 EP 149 DI 10.3233/JAD-131370 PG 21 WC Neurosciences SC Neurosciences & Neurology GA AI5PH UT WOS:000336921000010 PM 24595198 ER PT J AU Harris, CJ Voss, K Murchison, C Ralle, M Frahler, K Carter, R Rhoads, A Lind, B Robinson, E Quinn, JF AF Harris, Christopher J. Voss, Kellen Murchison, Charles Ralle, Martina Frahler, Kate Carter, Raina Rhoads, Allison Lind, Betty Robinson, Emily Quinn, Joseph F. TI Oral Zinc Reduces Amyloid Burden in Tg2576 Mice SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta protein; copper; transgenic mice ID TARGETING A-BETA; ALZHEIMERS-DISEASE; TRANSGENIC MICE; PRECURSOR PROTEIN; WILSON-DISEASE; 3XTG-AD MICE; DOUBLE-BLIND; MOUSE MODEL; COPPER; BRAIN AB The aggregation of amyloid-beta in Alzheimer's disease can be affected by free transition metals such as copper and zinc in the brain. Addition of copper and zinc with amyloid acts to increase aggregation and copper additionally promotes the formation of reactive oxygen species. We propose that reduction of brain copper by blocking uptake of copper from the diet is a viable strategy to regulate the formation of insoluble amyloid-beta in the brain of Tg2576 mice. Mice were treated with regimens of zinc acetate, which acts with metallothionein to block copper uptake in the gut, at various times along their lifespan to model prevention and treatment paradigms. We found that the mice tolerated zinc acetate well over the six month course of study. While we did not observe significant changes in cognition and behavior, there was a reduction in insoluble amyloid-beta in the brain. This observation coincided with a reduction in brain copper and interestingly no change in brain zinc. Our findings show that blocking copper uptake from the diet can redistribute copper from the brain and reduce amyloid-beta aggregation. C1 [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. [Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR USA. [Harris, Christopher J.; Voss, Kellen; Murchison, Charles; Frahler, Kate; Carter, Raina; Rhoads, Allison; Lind, Betty; Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Ralle, Martina; Robinson, Emily] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. RP Quinn, JF (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, CR-131,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM quinnj@ohsu.edu FU U.S. Department of Veterans Affairs Merit Review; NIH/NIA [T32AG023477]; NINDS NeuroNext [1U10NS077350, S10RR025512-01] FX This work is supported in part by the U.S. Department of Veterans Affairs Merit Review (JFQ), NIH/NIA T32AG023477 (KV) (P.I. Dr. Henryk Urbanski), NINDS NeuroNext 1U10NS077350 (CM) and S10RR025512-01 (MR). We would also like to acknowledge Nora Gray for her critical reading of the manuscript. NR 43 TC 6 Z9 6 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 41 IS 1 BP 179 EP 192 DI 10.3233/JAD-131703 PG 14 WC Neurosciences SC Neurosciences & Neurology GA AI5PH UT WOS:000336921000014 PM 24595193 ER PT J AU Teodorescu, M Xie, AL Sorkness, CA Robbins, J Reeder, S Gong, YS Fedie, JE Sexton, A Miller, B Huard, T Hind, J Bioty, N Peterson, E Kunselman, SJ Chinchilli, VM Soler, X Ramsdell, J Loredo, J Israel, E Eckert, DJ Malhotra, A AF Teodorescu, Mihaela Xie, Ailiang Sorkness, Christine A. Robbins, JoAnne Reeder, Scott Gong, Yuanshen Fedie, Jessica E. Sexton, Ann Miller, Barb Huard, Tiffany Hind, Jaqueline Bioty, Nora Peterson, Emily Kunselman, Susan J. Chinchilli, Vernon M. Soler, Xavier Ramsdell, Joe Loredo, Jose Israel, Elliott Eckert, Danny J. Malhotra, Atul TI Effects of Inhaled Fluticasone on Upper Airway during Sleep and Wakefulness in Asthma: A Pilot Study SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE Asthma; lung; inhaled corticosteroid; genioglossus; sleep apnea; obstructive ID OF-LIFE QUESTIONNAIRE; WATER-FAT SEPARATION; DAYTIME SLEEPINESS; LUNG-VOLUME; APNEA; IDEAL; PRESSURE; AGE; COLLAPSIBILITY; POPULATION AB Study Objective: Obstructive sleep apnea is prevalent among people with asthma, but underlying mechanisms remain unknown. Inhaled corticosteroids may contribute. We tested the effects of orally inhaled fluticasone propionate (FP) on upper airway (UAW) during sleep and wakefulness. Study design: 16-week single-arm study. Participants: 18 (14 females, mean [+/- SD] age 26 +/- 6 years) corticosteroid-naive subjects with mild asthma (FEV1 89 +/- 8% predicted). Interventions: High dose (1,760 mcg/day) inhaled FP. Measurements: (1) UAW collapsibility (passive critical closing pressure [Pcrit]); (2) tongue strength (maximum isometric pressure-Pmax, in KPa) and endurance-time (in seconds) able to maintain 50% Pmax across 3 trials (Ttot)-at anterior and posterior locations; (3) fat fraction and volume around UAW, measured by magnetic resonance imaging in three subjects. Results: Pcrit overall improved (became more negative) (mean +/- SE) (-8.2 +/- 1.1 vs. -12.2 +/- 2.2 cm H2O, p = 0.04); the response was dependent upon baseline characteristics, with older, male gender, and worse asthma control predicting Pcrit deterioration (less negative). Overall, Pmax increased (anterior p = 0.02; posterior p = 0.002), but Ttot generally subsided (anterior p = 0.0007; posterior p = 0.06), unrelated to Pcrit response. In subjects studied with MRI, fat fraction and volume increased by 20.6% and 15.4%, respectively, without Pcrit changes, while asthma control appeared improved. Conclusions: In this study of young, predominantly female, otherwise healthy subjects with well-controlled asthma and stiff upper airways, 16-week high dose FP treatment elicited Pcrit changes which may be dependent upon baseline characteristics, and determined by synchronous and reciprocally counteracting local and lower airway effects. The long-term implications of these changes on sleep disordered breathing severity remain to be determined. C1 [Teodorescu, Mihaela] William S Middleton Mem Vet Adm Med Ctr, Med Serv, James B Skatrud Pulm Sleep Res Lab, Madison, WI USA. [Teodorescu, Mihaela; Sorkness, Christine A.; Robbins, JoAnne; Sexton, Ann; Miller, Barb; Huard, Tiffany; Hind, Jaqueline] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. [Teodorescu, Mihaela] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Sleep Med & Sleep Res Wisconsin Sleep, Madison, WI 53792 USA. [Xie, Ailiang; Gong, Yuanshen; Fedie, Jessica E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53792 USA. [Robbins, JoAnne; Hind, Jaqueline] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Reeder, Scott] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI 53792 USA. [Reeder, Scott] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI 53792 USA. [Reeder, Scott] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomed Engn, Madison, WI 53792 USA. [Bioty, Nora; Peterson, Emily; Kunselman, Susan J.; Chinchilli, Vernon M.] Penn State Univ, Coll Med, Hershey, PA USA. [Soler, Xavier; Ramsdell, Joe; Loredo, Jose; Malhotra, Atul] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Israel, Elliott; Eckert, Danny J.; Malhotra, Atul] Harvard Univ, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Eckert, Danny J.] Neurosci Res Australia, Sydney, NSW, Australia. RP Teodorescu, M (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA. EM mt3@medicine.wisc.edu RI Eckert, Danny/A-6145-2012 OI Eckert, Danny/0000-0003-3503-2363; Reeder, Scott/0000-0003-4728-8171 FU NIH-NHLBI Asthma Clinical Research Network, University of Wisconsin Clinical Skills Development Core [1 U10 HL074212-01]; Clinical and Translational Science Award (CTSA) through NIH/NCRR [UL1RR025011, UL1TR000427]; William S. Middleton Memorial VA Hospital, Madison FX This was not an industry supported study. This work was performed at the University of Wisconsin and William S. Middleton Memorial VA Hospital, Madison, Wisconsin. This work was funded by the 1 U10 HL074212-01 NIH-NHLBI Asthma Clinical Research Network, University of Wisconsin Clinical Skills Development Core; the Clinical and Translational Science Award (CTSA) program, formerly through NIH/NCRR UL1RR025011, and now through NIH/NCATS UL1TR000427; additional resources from the William S. Middleton Memorial VA Hospital, Madison. The content of this article is solely the responsibility of the authors and does not represent the views of the Department of Veterans Affairs, NIH or the United States Government. The authors have indicated no financial conflicts of interest. NR 59 TC 6 Z9 7 U1 1 U2 3 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2014 VL 10 IS 2 BP 183 EP + DI 10.5664/jcsm.3450 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA AH9VY UT WOS:000336494300010 PM 24533002 ER PT J AU Geary, K Keller, A Knaub, L Reusch, J AF Geary, K. Keller, A. Knaub, L. Reusch, J. TI IMPAIRED MITOCHONDRIAL DYNAMICS IN DIABETIC VASCULATURE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 23-25, 2014 CL Carmel, CA SP Amer Federat Med Res C1 [Geary, K.; Keller, A.; Knaub, L.; Reusch, J.] Univ Colorado, Aurora, CO USA. [Geary, K.; Keller, A.; Knaub, L.; Reusch, J.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2014 VL 62 IS 1 MA 14 BP 147 EP 148 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AH7AP UT WOS:000336284900027 ER PT J AU Ballon-Landa, E Bergman, J Lorenz, KA Saucedo, J Saigal, C Bennett, CJ Litwin, MS AF Ballon-Landa, E. Bergman, J. Lorenz, K. A. Saucedo, J. Saigal, C. Bennett, C. J. Litwin, M. S. TI COMMUNITY-PARTNERED COLLABORATION TO BUILD AN INTEGRATED PALLIATIVE CARE CLINIC: THE VIEW FROM UROLOGY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 23-25, 2014 CL Carmel, CA SP Amer Federat Med Res C1 [Ballon-Landa, E.] UC Irvine Sch Med, Irvine, CA USA. [Bergman, J.; Saucedo, J.; Saigal, C.; Bennett, C. J.; Litwin, M. S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Bergman, J.; Lorenz, K. A.; Saigal, C.; Bennett, C. J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lorenz, K. A.; Saigal, C.] RAND Corp, Santa Monica, CA USA. [Ballon-Landa, E.; Litwin, M. S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2014 VL 62 IS 1 MA 148 BP 188 EP 188 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AH7AP UT WOS:000336284900160 ER PT J AU Utzschneider, KM Largajolli, A Bertoldo, A Leonetti, D McNeely, M Fujimoto, W Cobelli, C Kahn, SE Boyko, E AF Utzschneider, K. M. Largajolli, A. Bertoldo, A. Leonetti, D. McNeely, M. Fujimoto, W. Cobelli, C. Kahn, S. E. Boyko, E. TI OGTT MODELED BETA-CELL FUNCTION MEASURES PREDICT INCIDENT DIABETES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 23-25, 2014 CL Carmel, CA SP Amer Federat Med Res C1 [Utzschneider, K. M.; Kahn, S. E.; Boyko, E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Utzschneider, K. M.; Leonetti, D.; McNeely, M.; Fujimoto, W.; Kahn, S. E.; Boyko, E.] Univ Washington, Seattle, WA 98195 USA. [Largajolli, A.; Bertoldo, A.; Cobelli, C.] Univ Padua, Padua, Italy. NR 0 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2014 VL 62 IS 1 MA 201 BP 203 EP 203 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AH7AP UT WOS:000336284900211 ER PT J AU Tashjian, VC Kaiser, W Spiegel, B AF Tashjian, V. C. Kaiser, W. Spiegel, B. TI ANALYSIS OF ABDOMINAL ACOUSTIC AND MOTOR PROFILES OF PATIENTS WITH POSTOPERATIVE ILEUS USING THE NOVEL ABSTATS MONITORING SYSTEM SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 23-25, 2014 CL Carmel, CA SP Amer Federat Med Res C1 [Tashjian, V. C.; Spiegel, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Spiegel, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kaiser, W.; Spiegel, B.] UCLA VA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2014 VL 62 IS 1 MA 212 BP 207 EP 207 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AH7AP UT WOS:000336284900222 ER PT J AU Bayona, E Keller, T Clavijo, R Shelton, J Bergman, J Bennett, CJ AF Bayona, E. Keller, T. Clavijo, R. Shelton, J. Bergman, J. Bennett, C. J. TI THE USE OF REMOTE ACCESS CLINICS TO TREAT AND INFORM MEN WITH SEXUAL DYSFUNCTION SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 23-25, 2014 CL Carmel, CA SP Amer Federat Med Res C1 [Bayona, E.; Clavijo, R.; Shelton, J.; Bergman, J.; Bennett, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Keller, T.; Clavijo, R.; Shelton, J.; Bergman, J.; Bennett, C. J.] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2014 VL 62 IS 1 MA 278 BP 226 EP 226 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AH7AP UT WOS:000336284900288 ER PT J AU Cooper, LA Page, ST Amory, JK Anawalt, BD Matsumoto, AM AF Cooper, L. A. Page, S. T. Amory, J. K. Anawalt, B. D. Matsumoto, A. M. TI BODY MASS INDEX HAS A GREATER INFLUENCE THAN AGING ON SERUM SHBG AND TOTAL TESTOSTERONE IN MEN: IMPLICATIONS FOR THE BIOCHEMICAL DIAGNOSIS OF HYPOGONADISM IN OLDER OBESE MEN SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 23-25, 2014 CL Carmel, CA SP Amer Federat Med Res C1 [Cooper, L. A.; Page, S. T.; Amory, J. K.; Anawalt, B. D.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA. [Cooper, L. A.; Matsumoto, A. M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2014 VL 62 IS 1 MA 354 BP 249 EP 249 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AH7AP UT WOS:000336284900364 ER PT J AU Gray, AM Banks, WA AF Gray, A. M. Banks, W. A. TI MECHANISMS OF INFLAMMATION IN BLOOD-BRAIN BARRIER DISRUPTION SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 23-25, 2014 CL Carmel, CA SP Amer Federat Med Res C1 [Gray, A. M.; Banks, W. A.] Univ Washington, Sch Med, Seattle, WA USA. [Gray, A. M.; Banks, W. A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2014 VL 62 IS 1 MA 469 BP 283 EP 284 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AH7AP UT WOS:000336284900479 ER PT J AU Falcone, JA Salameh, TS Banks, WA AF Falcone, J. A. Salameh, T. S. Banks, W. A. TI INTRANASAL ADMINISTRATION AS A ROUTE FOR DRUG DELIVERY TO THE BRAIN: EVIDENCE FOR A UNIQUE PATHWAY FOR ALBUMIN SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CY JAN 23-25, 2014 CL Carmel, CA SP Amer Federat Med Res C1 [Salameh, T. S.; Banks, W. A.] VA Puget Sound, Seattle, WA USA. [Falcone, J. A.; Salameh, T. S.; Banks, W. A.] Univ Washington, Sch Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2014 VL 62 IS 1 MA 471 BP 284 EP 284 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA AH7AP UT WOS:000336284900481 ER PT J AU Fischer, BL Hoyt, WT Maucieri, L Kind, AJ Gunter-Hunt, G Swader, TC Gangnon, RE Gleason, CE AF Fischer, Barbara L. Hoyt, William T. Maucieri, Lawrence Kind, Amy J. Gunter-Hunt, Gail Swader, Teresa Chervenka Gangnon, Ronald E. Gleason, Carey E. TI Performance-based assessment of falls risk in older veterans with executive dysfunction SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE American Geriatrics Society falls-risk guidelines; cognitive impairment; executive function; falls; falls-risk identification; falls prevention; older adults; physical therapy; Timed Up and Go test; veterans ID COGNITIVE IMPAIRMENT; NORMATIVE DATA; GO TEST; GAIT; ATTENTION; AGE; VALIDATION; EDUCATION; MOBILITY; ADULTS AB Falling is a serious hazard for older veterans that may lead to severe injury, loss of independence, and death. While the American Geriatrics Society (AGS) provides guidelines to screen individuals at risk for falls, the guidelines may be less successful with specific subgroups of patients. In a veteran sample, we examined whether the Timed Up and Go (TUG) test, including a modified version, the TUG-Cognition, effectively detected potential fallers whose risk was associated with cognitive deficits. Specifically, we sought to determine whether TUG tasks and AGS criteria were differentially associated with executive dysfunction, whether the TUG tasks identified potential fallers outside of those recognized by AGS criteria, and whether these tasks distinguished groups of fallers. Participants included 120 mostly male patients referred to the Memory Assessment Clinic because of cognitive impairment. TUG-Cognition scores were strongly associated with executive dysfunction and differed systematically between fallers grouped by number of falls. These findings suggest that the TUG-Cognition shows promise in identifying fallers whose risk is related to or compounded by cognitive impairment. Future research should study the predictive validity of these measures by following patients prospectively. C1 [Fischer, Barbara L.; Kind, Amy J.; Gunter-Hunt, Gail; Swader, Teresa Chervenka; Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Hoyt, William T.] Univ Wisconsin, Dept Counseling Psychol, Madison, WI USA. [Maucieri, Lawrence] Governors State Univ, Dept Psychol & Counseling, University Pk, PA USA. [Kind, Amy J.; Gleason, Carey E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Gangnon, Ronald E.] Univ Wisconsin, Dept Biostat, Madison, WI USA. [Gangnon, Ronald E.] Univ Wisconsin, Dept Med Informat & Populat Hlth Sci, Madison, WI USA. RP Fischer, BL (reprint author), Wm S Middleton Mem VA Hosp, GRECC, 2500 Overlook Terrace, Madison, WI 53705 USA. EM Barbara.fischer@va.gov FU Wisconsin Alzheimer Disease Research Center; VA GRECC Advanced Fellowship FX Dr. Gleason's time was supported by the Wisconsin Alzheimer Disease Research Center. Dr. Fischer's time was supported by a VA GRECC Advanced Fellowship. NR 29 TC 2 Z9 2 U1 2 U2 11 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2014 VL 51 IS 2 BP 263 EP 274 DI 10.1682/JRRD.2013.03.0075 PG 12 WC Rehabilitation SC Rehabilitation GA AI3ZM UT WOS:000336804700011 PM 24933724 ER PT J AU Shorkey, CT Uebel, M AF Shorkey, Clayton T. Uebel, Michael TI History and Development of Instructional Technology and Media in Social Work Education SO JOURNAL OF SOCIAL WORK EDUCATION LA English DT Article ID TELEVISION; TAPE; INTERVIEWS; CLASSROOM; STUDENTS; RECALL AB Since the mid-20th century, instructional technologies and educational media in social work education have undergone significant development with the goals of improving learning and performance and enhancing access. This growth has been marked by technical advances in hardware and by innovations in media, or so-called soft formats. Current distance education and Web-based instructional programs allow for the enrichment of onsite instructional activities as well as open possibilities for the ever-expanding outreach of social work educational programs. The article describes the evolution of instructional technology and media in social work and reviews the historical contributions of 8 pioneering schools. C1 [Shorkey, Clayton T.] Univ Texas Austin, Austin, TX 78712 USA. [Uebel, Michael] US Dept Vet Affairs, Cent Texas Vet Hlth Care Syst, Washington, DC USA. RP Shorkey, CT (reprint author), Univ Texas Austin, Sch Social Work, 1 Univ Stn D3500, Austin, TX 78712 USA. EM cshorkey@mail.utexas.edu NR 100 TC 2 Z9 2 U1 4 U2 15 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1043-7797 EI 2163-5811 J9 J SOC WORK EDUC JI J. Soc. Work Educ. PY 2014 VL 50 IS 2 BP 247 EP 261 DI 10.1080/10437797.2014.885248 PG 15 WC Education & Educational Research; Social Work SC Education & Educational Research; Social Work GA AI2JV UT WOS:000336684800005 ER PT J AU Longmire, CVF Drye, LT Frangakis, CE Martin, BK Meinert, CL Mintzer, JE Munro, CA Porsteinsson, AP Rabins, PV Rosenberg, PB Schneider, LS Weintraub, D Lyketsos, CG AF Longmire, Crystal V. Flynn Drye, Lea T. Frangakis, Constantine E. Martin, Barbara K. Meinert, Curtis L. Mintzer, Jacobo E. Munro, Cynthia A. Porsteinsson, Anton P. Rabins, Peter V. Rosenberg, Paul B. Schneider, Lon S. Weintraub, Daniel Lyketsos, Constantine G. CA DIADS-2 Res Grp TI Is Sertraline Treatment or Depression Remission in Depressed Alzheimer Patients Associated with Improved Caregiver Well Being? Depression in Alzheimer's Disease Study 2 SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Sertraline; depression; Alzheimer disease; caregivers; DIADS-2 ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; NEUROPSYCHIATRIC SYMPTOMS; PHARMACOLOGICAL-TREATMENT; COGNITIVE IMPAIRMENT; FAMILY CAREGIVERS; DEMENTIA PATIENTS; DOUBLE-BLIND; BURDEN; HEALTH AB Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being. Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease in five clinical research sites across the United States. Participants were caregivers of patients enrolled in the Depression in Alzheimer's Disease Study 2 (N = 131). All caregivers received standardized psychosocial support throughout the study. Caregiver outcome measures included depression (Beck Depression Inventory), distress (Neuropsychiatric Inventory), burden (Zarit Burden Interview), and quality of life (Medical Outcomes Study Short Form Health Survey). Results: Fifty-nine percent of caregivers were spouses, 63.4% were women, and 64.1% were white. Caregivers of patients in both treatment groups had significant reductions in distress scores over the 24-week study period, but there was not a greater benefit for caregivers of patients taking sertraline. However, caregivers of patients whose depression was in remission at week 12 had greater declines in distress scores over the 24 weeks than caregivers of patients whose depression did not remit by week 12. Conclusion: Patient treatment with sertraline was not associated with significantly greater reductions in caregiver distress than placebo treatment. Distress but not level of depression or burden lessened for all caregivers regardless of remission status and even more so for those who cared for patients whose depression remitted. Results imply an interrelationship between caregiver distress and patient psychiatric outcomes. C1 [Longmire, Crystal V. Flynn] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Mintzer, Jacobo E.] Med Univ S Carolina, Coll Hlth Sci, Charleston, SC 29425 USA. [Drye, Lea T.; Frangakis, Constantine E.; Martin, Barbara K.; Meinert, Curtis L.; Lyketsos, Constantine G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Mintzer, Jacobo E.] Ralph H Johnson Vet Affairs Med Ctr, Div Psychiat, Charleston, SC USA. [Munro, Cynthia A.; Rabins, Peter V.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Porsteinsson, Anton P.] Univ Rochester, Sch Med, Rochester, NY USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Schneider, Lon S.] Univ So Calif, Dept Psychiat & Behav Sci, Los Angeles, CA USA. [Schneider, Lon S.] Univ So Calif, Dept Neurol, Los Angeles, CA USA. [Schneider, Lon S.] Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Longmire, CVF (reprint author), Med Univ S Carolina, Dept Neurosci, Alzheimers Res Program, 5900 Core Rd,Ste 203, N Charleston, SC 29406 USA. EM crystalflynn@hotmail.com NR 44 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JAN PY 2014 VL 22 IS 1 BP 14 EP 24 DI 10.1016/j.jagp.2013.02.014 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA AH3UJ UT WOS:000336050800003 ER PT J AU Nair, BG Horibe, M Newman, SF Wu, WY Peterson, GN Schwid, HA AF Nair, Bala G. Horibe, Mayumi Newman, Shu-Fang Wu, Wei-Ying Peterson, Gene N. Schwid, Howard A. TI Anesthesia Information Management System- Based Near Real-Time Decision Support to Manage Intraoperative Hypotension and Hypertension SO ANESTHESIA AND ANALGESIA LA English DT Article ID NONCARDIAC SURGERY; DOCUMENTATION; ALERTS; NOTIFICATION; DEFINITIONS; PERFORMANCE; MORTALITY; DURATION; QUALITY; RECORDS AB BACKGROUND: Intraoperative hypotension and hypertension are associated with adverse clinical outcomes and morbidity. Clinical decision support mediated through an anesthesia information management system (AIMS) has been shown to improve quality of care. We hypothesized that an AIMS-based clinical decision support system could be used to improve management of intraoperative hypotension and hypertension. METHODS: A near real-time AIMS-based decision support module, Smart Anesthesia Manager (SAM), was used to detect selected scenarios contributing to hypotension and hypertension. Specifically, hypotension (systolic blood pressure <80 mm Hg) with a concurrent high concentration (>1.25 minimum alveolar concentration [MAC]) of inhaled drug and hypertension (systolic blood pressure >160 mm Hg) with concurrent phenylephrine infusion were detected, and anesthesia providers were notified via pop-up computer screen messages. AIMS data were retrospectively analyzed to evaluate the effect of SAM notification messages on hypotensive and hypertensive episodes. RESULTS: For anesthetic cases 12 months before (N = 16913) and after (N = 17132) institution of SAM messages, the median duration of hypotensive episodes with concurrent high MAC decreased with notifications (Mann Whitney rank sum test, P = 0.031). However, the reduction in the median duration of hypertensive episodes with concurrent phenylephrine infusion was not significant (P = 0.47). The frequency of prolonged episodes that lasted >6 minutes (sampling period of SAM), represented in terms of the number of cases with episodes per 100 surgical cases (or percentage occurrence), declined with notifications for both hypotension with >1.25 MAC inhaled drug episodes ( = -0.26% [confidence interval, -0.38% to -0.11%], P < 0.001) and hypertension with phenylephrine infusion episodes ( = -0.92% [confidence interval, -1.79% to -0.04%], P = 0.035). For hypotensive events, the anesthesia providers reduced the inhaled drug concentrations to <1.25 MAC 81% of the time with notifications compared with 59% without notifications (P = 0.003). For hypertensive episodes, although the anesthesia providers' reduction or discontinuation of the phenylephrine infusion increased from 22% to 37% (P = 0.030) with notification messages, the overall response was less consistent than the response to hypotensive episodes. CONCLUSIONS: With automatic acquisition of arterial blood pressure and inhaled drug concentration variables in an AIMS, near real-time notification was effective in reducing the duration and frequency of hypotension with concurrent >1.25 MAC inhaled drug episodes. However, since phenylephrine infusion is manually documented in an AIMS, the impact of notification messages was less pronounced in reducing episodes of hypertension with concurrent phenylephrine infusion. Automated data capture and a higher frequency of data acquisition in an AIMS can improve the effectiveness of an intraoperative clinical decision support system. C1 [Nair, Bala G.; Newman, Shu-Fang; Peterson, Gene N.; Schwid, Howard A.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Horibe, Mayumi] VA Puget Sound Hlth Care Syst, Dept Anesthesiol, Seattle, WA USA. [Wu, Wei-Ying] Natl Dong Hwa Univ, Dept Appl Math, Hualien, Taiwan. RP Nair, BG (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, BB-1469 Hlth Sci Bldg,Mail Box 356540, Seattle, WA 98195 USA. EM nairbg@uw.edu FU University of Washington FX This research was partly supported by Laura Cheney Patient Safety Grant provided by the University of Washington. NR 27 TC 16 Z9 17 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 EI 1526-7598 J9 ANESTH ANALG JI Anesth. Analg. PD JAN PY 2014 VL 118 IS 1 BP 206 EP 214 DI 10.1213/ANE.0000000000000027 PG 9 WC Anesthesiology SC Anesthesiology GA AG4NC UT WOS:000335395700024 PM 24247227 ER PT J AU Morasco, BJ O'Neil, ME Duckart, JP Ganzini, L AF Morasco, Benjamin J. O'Neil, Maya E. Duckart, Jonathan P. Ganzini, Linda TI Comparison of Health Service Use Among Veterans With Methamphetamine Versus Alcohol Use Disorders SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE health service utilization; comorbidity; medical care; alcohol abuse; methamphetamine abuse ID MEDICAL ADVICE; ADMINISTRATIVE DATA; COMORBIDITY; SYMPTOMS; LEAVE; CARE; CONSUMPTION; IMPROVEMENT; PREVALENCE; RETENTION AB Objectives: Methamphetamine use disorders (MUD) are associated with severe health effects and psychiatric comorbidities, but little is known about the health care utilization of patients with MUD. The goal of this study was to describe health service use among veterans with MUD relative to a group of veterans with an alcohol use disorder (AUD). Methods: Using Veterans Affairs (VA) administrative data, we identified 718 patients who were diagnosed with MUD and had confirmatory drug testing. Data were compared with those of 744 patients who had diagnoses of an AUD also with confirmatory testing. We examined diagnoses and medical utilization for 5 years after their index date. Results: Patients with MUD and laboratory-confirmed recent use were younger and more likely to be diagnosed with a mood disorder, posttraumatic stress disorder, and a psychotic-spectrum disorder (all P values < 0.05). After statistical controls, patients with MUD were more likely to have an inpatient hospitalization (80% vs 70%, odds ratio [OR] = 1.8; 95% confidence interval [CI] = 1.4-2.3), discharge from an inpatient admission against medical advice (23.4% vs 8.3%, OR = 2.6, 95% CI = 1.9-3.7), receive care at 3 or more VA medical centers (13.1% vs 5.4%, OR = 2.3, 95% CI = 1.5-3.5), have a behavioral flag in the medical record (5.6% vs 1.1%, OR = 4.6, 95% CI = 2.1-10.6), and have more total missed appointments in the 5-year study period (M = 33.1 vs M = 23.5, P < 0.001). Conclusions: Among veterans with substance use disorders, those with MUD and laboratory-confirmed recent use have additional behavioral, health care utilization, and psychiatric characteristics that need to be considered in developing programs of care. C1 [Morasco, Benjamin J.; O'Neil, Maya E.; Ganzini, Linda] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Morasco, Benjamin J.; O'Neil, Maya E.; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Morasco, Benjamin J.; O'Neil, Maya E.; Duckart, Jonathan P.; Ganzini, Linda] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr R&D99, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM benjamin.morasco@va.gov FU National Institute on Drug Abuse as part of the Methamphetamine Research Center at the Portland VA Medical Center [018165]; Oregon Health & Science University; VA Health Services Research and Development service [REA 06-174]; National Institute on Drug Abuse [K23DA023467] FX Supported in part by award 018165 from the National Institute on Drug Abuse to Drs. Ganzini and Morasco, as part of the Methamphetamine Research Center at the Portland VA Medical Center and Oregon Health & Science University. Dr Ganzini, Dr O'Neil, and Mr Duckart were supported in part by grant REA 06-174 from the VA Health Services Research and Development service. Dr Morasco received funding from grant K23DA023467 from the National Institute on Drug Abuse. NR 25 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD JAN-FEB PY 2014 VL 8 IS 1 BP 47 EP 52 DI 10.1097/ADM.0000000000000005 PG 6 WC Substance Abuse SC Substance Abuse GA AG8UB UT WOS:000335692600007 PM 24365802 ER PT J AU Morley, JF Duda, JE AF Morley, James F. Duda, John E. TI Use of Hyposmia and Other Non-Motor Symptoms to Distinguish between Drug-Induced Parkinsonism and Parkinson's Disease SO JOURNAL OF PARKINSONS DISEASE LA English DT Review DE Autonomic nervous system diseases; cognitive disorders; olfaction disorders; Parkinson disease; Parkinsonian syndrome; secondary ID NEUROLEPTIC-INDUCED PARKINSONISM; OLFACTORY DYSFUNCTION; IDENTIFICATION; SCINTIGRAPHY; ASSOCIATION; PERSISTENT; DISORDER; RISK AB Drug-induced Parkinsonism (DIP) secondary to antipsychotics and other dopamine antagonists is common and can be clinically indistinguishable from idiopathic Parkinson's disease (PD). Making the correct diagnosis is essential as it has important implications both for management of the underlying psychiatric condition and potentially lifelong therapy with antiparkinsonian agents. Additionally, because Parkinsonism does not always resolve with withdrawal of the offending agent or can recur years later, DIP may sometimes represent unmasking of incipient PD. The problem is increasing in scope as antipsychotic drugs are prescribed for a widening variety of indications, and understanding the factors that distinguish pharmacologic from degenerative Parkinsonism represents a significant unmet need. In this review, we discuss the rationale and evidence for using pre-clinical manifestations of PD, particularly non-motor symptoms, to distinguish between the conditions. C1 [Morley, James F.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Duda, John E.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. RP Morley, JF (reprint author), Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, 3900 Woodland Ave,Mail Stop 127, Philadelphia, PA 19104 USA. EM James.morley@va.gov NR 38 TC 2 Z9 2 U1 2 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 EI 1877-718X J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2014 VL 4 IS 2 BP 169 EP 173 DI 10.3233/JPD-130299 PG 5 WC Neurosciences SC Neurosciences & Neurology GA AH8SW UT WOS:000336409500006 PM 24284418 ER PT J AU Farr, SA Erickson, MA Niehoff, ML Banks, WA Morley, JE AF Farr, Susan A. Erickson, Michelle A. Niehoff, Michael L. Banks, William A. Morley, John E. TI Central and Peripheral Administration of Antisense Oligonucleotide Targeting Amyloid-beta Protein Precursor Improves Learning and Memory and Reduces Neuroinflammatory Cytokines in Tg2576 (A beta PPswe) Mice SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Antisense oligonucleotide; Tg2576; learning; memory; T-maze; object recognition; oxidative stress; blood brain barrier; cytokines ID BLOOD-BRAIN-BARRIER; RECEPTOR-RELATED PROTEIN-1; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; COGNITIVE DEFICITS; OXIDATIVE STRESS; SPATIAL MEMORY; SAMP8 MICE; IN-VIVO AB Alzheimer's disease (AD) is a progressive neurodegenerative disease. Currently, there are no therapies to stop or reverse the symptoms of AD. We have developed an antisense oligonucleotide (OL-1) against the amyloid-beta protein precursor (A beta PP) that can decrease A beta PP expression and amyloid-beta protein (A beta) production. This antisense rapidly crosses the blood-brain barrier, reverses learning and memory impairments, reduces oxidative stress, and restores brain-to-blood efflux of A beta in SAMP8 mice. Here, we examined the effects of this A beta PP antisense in the Tg2576 mouse model of AD. We administered the OL-1 antisense into the lateral ventricle 3 times at 2week intervals. Seventy-two hours after the third injection, we tested learning and memory in T-maze foot shock avoidance. In the second study, we injected the mice with OL-1 antisense 3 times at 2-week intervals via the tail vein. Seventy-two hours later, we tested learning and memory T-maze, novel object recognition, and elevated plus maze. At the end of behavioral testing, brain tissue was collected. OL-1 antisense administered centrally improved acquisition and retention of T-maze foot shock avoidance. OL-1 antisense administered via tail vein improved learning and memory in both T-maze foot shock avoidance and novel object-place recognition. In the elevated plus maze, the mice which received OL-1 antisense spent less time in the open arms and had fewer entries into the open arms indicating reduced disinhibitation. Biochemical analyses reveal significant reduction of A beta PP signal and a reduction of measures of neuroinflammation. The current findings support the therapeutic potential of OL-1 A beta PP antisense. C1 [Farr, Susan A.] VA Med Ctr, Res & Dev Serv, St Louis, MO USA. [Farr, Susan A.; Niehoff, Michael L.; Morley, John E.] St Louis Univ, Sch Med, Div Geriatr Med, Dept Internal Med, St Louis, MO 63106 USA. [Erickson, Michelle A.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Erickson, Michelle A.; Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Morley, John E.] St Louis Univ, Sch Med, Dept Internal Med, Div Endocrinol, St Louis, MO 63106 USA. RP Farr, SA (reprint author), St Louis Univ, Sch Med, VA Med Ctr St Louis, 915 North Grand Blvd,151-JC, St Louis, MO 63106 USA. EM farrsa@slu.edu FU VA Merit Review FX This work was supported by VA Merit Review. NR 48 TC 11 Z9 11 U1 0 U2 6 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 40 IS 4 BP 1005 EP 1016 DI 10.3233/JAD-131883 PG 12 WC Neurosciences SC Neurosciences & Neurology GA AH6SW UT WOS:000336262000018 PM 24577464 ER PT J AU Block, C Fabrizio, K Bagley, B Hannah, J Camp, S Mindingall, N Labbe, D Lokken, K AF Block, Cady Fabrizio, Katherine Bagley, Beau Hannah, Joanna Camp, Susan Mindingall, Nazaren Labbe, Don Lokken, Kristine TI Assessment of Veteran and Caregiver Knowledge About Mild Traumatic Brain Injury in a VA Medical Center SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE attitudes; knowledge; practice; health knowledge; veterans; military personnel; brain injuries ID POSTCONCUSSION SYNDROME; INFORMATIONAL CASCADES; WAR VETERANS; MISCONCEPTIONS; CONCUSSION; IRAQ; AFGHANISTAN; SURVIVORS; TERMINOLOGY; DEPLOYMENT AB Objective: To examine the accuracy of knowledge about mild traumatic brain injury (TBI) of veterans and their friends/family members. Setting: VA Medical Center. Participants: One hundred veterans and 50 of their friends/family members. Design: Cross-sectional survey. Main Measures: A 60-item questionnaire was created by drawing both from the Neurobehavioral Symptom Inventory and from a brain injury knowledge survey developed for use with the general public. Results: Both groups were equally able to identify true mild TBI items, but both also endorsed numerous items not typical of a mild injury. Self-reported prior TBI and receipt of TBI education were unrelated to the level of knowledge. For both groups, knowing another individual with TBI was unrelated to other aspects of mild TBI knowledge. Only 1 in 5 veterans endorsed receiving brain injury education while in the military. Conclusion: Results of this study may assist in the development of targeted TBI educational interventions for veterans and their friends/family members within the Veterans Affairs system. Ultimately, increased knowledge about mild TBI improves the likelihood that veterans receive care congruent with their needs and may potentially improve outcomes for those with mild TBI. C1 [Block, Cady; Fabrizio, Katherine; Labbe, Don] Univ Alabama Birmingham, Div Med Clin Psychol, Dept Psychol, Birmingham, AL 35294 USA. [Bagley, Beau; Hannah, Joanna; Camp, Susan; Mindingall, Nazaren; Lokken, Kristine] Birmingham Vet Affairs Med Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA. RP Block, C (reprint author), Univ Alabama Birmingham, Div Med Clin Psychol, CH 201,1530 3rd Ave S, Birmingham, AL 35294 USA. EM cblock@uab.edu RI Block, Cady/I-3078-2014 OI Block, Cady/0000-0001-7168-6116 NR 48 TC 2 Z9 2 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD JAN-FEB PY 2014 VL 29 IS 1 BP 76 EP 88 DI 10.1097/HTR.0b013e3182886d78 PG 13 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA AH1OC UT WOS:000335889400013 PM 23524877 ER PT J AU Chen, JJ Marsh, L AF Chen, Jack J. Marsh, Laura TI Anxiety in Parkinson's disease: identification and management SO THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS LA English DT Review DE Anxiety; neurology; Parkinson's disease; psychiatry ID COGNITIVE-BEHAVIORAL THERAPY; ON-OFF PHENOMENON; NONMOTOR SYMPTOMS; DEPRESSION SCALE; HOSPITAL ANXIETY; DIAGNOSTIC-CRITERIA; CONTROLLED-TRIAL; RATING-SCALES; RISK; COMORBIDITY AB Anxiety disturbances are recognized as common psychiatric comorbidities in Parkinson's disease (PD) and contribute to significant impairments in areas of cognitive, functional, motor and social performance. Anxiety in PD results in reduced quality of life, higher levels of care dependency and increased caregiver burden. Surprisingly, there is a paucity of treatment data. In one randomized, controlled study, bromazepam was found to be effective for anxiety in PD. However, usage of benzodiazepines in the PD population is limited by potential risk of confusion and falls. There are no controlled studies of selective serotonin reuptake inhibitors (SSRIs) for anxiety in PD. However, results from uncontrolled studies suggest that SSRIs are effective for anxiety in PD, although in these studies anxiety outcomes were secondary. This review underscores that, given the high prevalence of anxiety disturbances in PD, there is a significant paucity of treatment data for this population. Additional studies are warranted. In the meantime, clinicians should rely on empiric assessments of known risks and putative benefits to guide treatment decisions. Cognitive and behavioral therapies (with or without pharmacotherapy) have demonstrated efficacy and warrant consideration. When feasible, a targeted and individualized multimodal approach utilizing psychotherapeutic interventions along with pharmacologic therapies should be considered. C1 [Chen, Jack J.] Loma Linda Univ, Sch Med, Loma Linda, CA 92350 USA. [Chen, Jack J.] Loma Linda Univ, Sch Pharm, Loma Linda, CA 92350 USA. [Marsh, Laura] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Marsh, Laura] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. [Marsh, Laura] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. RP Chen, JJ (reprint author), Loma Linda Univ, Sch Med, Shyrock Hall 225, Loma Linda, CA 92350 USA. EM jjchen@llu.edu NR 66 TC 23 Z9 23 U1 4 U2 11 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1756-2856 EI 1756-2864 J9 THER ADV NEUROL DISO JI Ther. Adv. Neurol. Disord. PD JAN PY 2014 VL 7 IS 1 BP 52 EP 59 DI 10.1177/1756285613495723 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA AH0SD UT WOS:000335829700005 PM 24409202 ER PT J AU Ricardo, AC Yang, W Lora, CM Gordon, EJ Diamantidis, CJ Ford, V Kusek, JW Lopez, A Lustigova, E Nessel, L Rosas, SE Steigerwalt, S Theurer, J Zhang, XM Fischer, MJ Lash, JP Investigators, C AF Ricardo, Ana C. Yang, Wei Lora, Claudia M. Gordon, Elisa J. Diamantidis, Clarissa J. Ford, Virginia Kusek, John W. Lopez, Amada Lustigova, Eva Nessel, Lisa Rosas, Sylvia E. Steigerwalt, Susan Theurer, Jacqueline Zhang, Xiaoming Fischer, Michael J. Lash, James P. Investigators, C. R. I. C. TI Limited health literacy is associated with low glomerular filtration in the Chronic Renal Insufficiency Cohort (CRIC) study SO CLINICAL NEPHROLOGY LA English DT Article DE chronic kidney disease; health literacy ID CHRONIC KIDNEY-DISEASE; MANAGED CARE ENROLLEES; DIALYSIS PATIENTS; SELF-MANAGEMENT; KNOWLEDGE; PREVALENCE; MORTALITY; OUTCOMES; RISK; LINE AB Background: Low health literacy in the general population is associated with increased risk of death and hospitalization. The evaluation of health literacy in individuals with predialysis chronic kidney disease (CKD) is limited. Methods: We conducted a cross-sectional study to evaluate the associations of limited health literacy with kidney function and cardiovascular disease (CVD) risk factors in 2,340 non-Hispanic (NH) Whites and Blacks aged 21 - 74 years with mild-to-moderate CKD. Limited health literacy was defined as a Short Test of Functional Health Literacy in Adults (STOFHLA) score <= 22. Outcomes evaluated included estimated glomerular filtration rate (eGFR), 24-hour urine protein excretion, and CVD risk factors. Results: The prevalence of limited health literacy was 28% in NH-Blacks and 5% in NH-Whites. Compared with participants with adequate health literacy, those with limited health literacy were more likely to have lower eGFR (34 vs. 42 mL/min/1.73 m(2)); higher urine protein/24-hours (0.31 vs. 0.15 g); and higher self-reported CVD (61 vs. 37%); and were less likely to have BP < 130/80 mmHg (51 vs. 58%); p <= 0.01 for each comparison. After adjustment, limited health literacy was associated with self-reported CVD (OR 1.51, 95% CI 1.13 - 2.03) and lower eGFR (beta -2.47, p = 0.03). Conclusion: In this CKD cohort, limited health literacy was highly prevalent, especially among NH-Blacks, and it was associated with lower eGFR and a less favorable CVD risk factor profile. Further studies are needed to better understand these associations and inform the development of health literacy interventions among individuals with CKD. C1 [Ricardo, Ana C.; Lora, Claudia M.; Lopez, Amada; Fischer, Michael J.; Lash, James P.] Univ Illinois, Dept Med, Chicago, IL 60616 USA. [Yang, Wei; Ford, Virginia; Nessel, Lisa; Zhang, Xiaoming] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gordon, Elisa J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Diamantidis, Clarissa J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Kusek, John W.] NIDDK, NIH, Bethesda, MD 20892 USA. [Lustigova, Eva] Tulane Univ, New Orleans, LA 70118 USA. [Rosas, Sylvia E.] Univ Penn, Philadelphia VA Med Ctr, Dept Med, Philadelphia, PA 19104 USA. [Steigerwalt, Susan] St Johns Hlth Syst, Detroit, MI USA. [Theurer, Jacqueline] MetroHlth Med Ctr, Dept Med, Div Nephrol, Cleveland, OH USA. [Fischer, Michael J.] Jesse Brown VA Med Ctr, Ctr Management Complex Chron Care, Chicago, IL USA. RP Ricardo, AC (reprint author), Univ Illinois, Nephrol Sect, 820 South Wood St,Room 470, Chicago, IL 60616 USA. EM aricar2@uic.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028, 5U01DK60980, 5U01DK060963, 5U01DK060902]; HCRIC [R01 DK072231]; institutional Clinical Translational Science Awards (CTSA); National Institutes of Health (NIH) [UL1 RR-025005, GRCR M01 RR-16500, UL1 RR-024989, GCRC M01 RR-000042, CTSA UL1 RR-024986, M01 RR-013987-06, RR-05096, UCSF-CTSI UL1 RR-024131, 5K24DK002651]; National Center for Minority Health and Health Disparities, NIH; Department of Veterans Affairs Health Services Research and Development Service (MJF Career Development Award) FX This work was funded under a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028, 5U01DK60980, 5U01DK060963, 5U01DK060902) and an R01 DK072231 (HCRIC). In addition, this work was supported in part by institutional Clinical Translational Science Awards (CTSA) and other National Institutes of Health (NIH) grants: Johns Hopkins University UL1 RR-025005; University of Maryland GRCR M01 RR-16500; Case Western Reserve University Clinical and Translational Science Collaborative (University Hospitals of Cleveland, Cleveland Clinic Foundation, and MetroHealth) UL1 RR-024989; University of Michigan GCRC M01 RR-000042, CTSA UL1 RR-024986; University of Illinois at Chicago Clinical Research Center, M01 RR-013987-06; Tulane/LSU/Charity Hospital General Clinical Research Center RR-05096; University of Pennsylvania CTSA UL1 RR-024134; Kaiser NIH/NCRR UCSF-CTSI UL1 RR-024131, 5K24DK002651. Additional support was provided by the National Center for Minority Health and Health Disparities, NIH, and Department of Veterans Affairs Health Services Research and Development Service (MJF Career Development Award). NR 38 TC 11 Z9 12 U1 5 U2 12 PU DUSTRI-VERLAG DR KARL FEISTLE PI DEISENHOFEN-MUENCHEN PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY SN 0301-0430 J9 CLIN NEPHROL JI Clin. Nephrol. PD JAN PY 2014 VL 81 IS 1 BP 30 EP 37 DI 10.5414/CN108062 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA AG5FL UT WOS:000335444800004 PM 24219913 ER PT B AU McClintic, SM Shapiro, B Tam, DY Naseri, A AF McClintic, Scott M. Shapiro, Brett Tam, Diamond Y. Naseri, Ayman BE Henderson, BA TI INCISION CONSTRUCTION SO ESSENTIALS OF CATARACT SURGERY, SECOND EDITION LA English DT Article; Book Chapter ID CORNEAL CATARACT INCISIONS; INTRAOCULAR-LENS IMPLANTATION; SCLERAL TUNNEL INCISION; SELF-SEALING INCISIONS; CLEAR CORNEAL; RETROBULBAR ANESTHESIA; ANTERIOR-CHAMBER; COHERENCE TOMOGRAPHY; INDUCED ASTIGMATISM; TOPICAL ANESTHESIA C1 [McClintic, Scott M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shapiro, Brett] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Tam, Diamond Y.] Univ Toronto, Toronto, ON, Canada. [Naseri, Ayman] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP McClintic, SM (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 84 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-067-2 PY 2014 BP 51 EP 67 PG 17 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BA1TA UT WOS:000333060600006 ER PT B AU Edgington, BD Mahesh, S Goldstein, MH AF Edgington, Bryan D. Mahesh, Sankaranarayana Goldstein, Michael H. BE Henderson, BA TI SUTURED INTRAOCULAR LENSES SO ESSENTIALS OF CATARACT SURGERY, SECOND EDITION LA English DT Article; Book Chapter ID FIXATION; IMPLANTATION; SUPPORT; ABSENCE C1 [Edgington, Bryan D.] Portland VA Med Ctr, Casey Eye Inst, Portland, OR 97239 USA. [Mahesh, Sankaranarayana] George Washington Univ, Washington, DC USA. [Goldstein, Michael H.] New England Eye Ctr, Cornea & External Dis Serv, Boston, MA USA. [Goldstein, Michael H.] Tufts Univ, Sch Med, Boston, MA 02111 USA. RP Edgington, BD (reprint author), Portland VA Med Ctr, Casey Eye Inst, Portland, OR 97239 USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-61711-067-2 PY 2014 BP 193 EP 206 PG 14 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA BA1TA UT WOS:000333060600019 ER PT J AU Jotwani, V Scherzer, R Abraham, A Estrella, MM Bennett, M Devarajan, P Anastos, K Cohen, MH Nowicki, M Sharma, A Young, M Tien, PC Grunfeld, C Parikh, CR Shlipak, MG AF Jotwani, Vasantha Scherzer, Rebecca Abraham, Alison Estrella, Michelle M. Bennett, Michael Devarajan, Prasad Anastos, Kathryn Cohen, Mardge H. Nowicki, Marek Sharma, Anjali Young, Mary Tien, Phyllis C. Grunfeld, Carl Parikh, Chirag R. Shlipak, Michael G. TI Does HIV infection promote early kidney injury in women? SO ANTIVIRAL THERAPY LA English DT Article ID GELATINASE-ASSOCIATED LIPOCALIN; RENAL-DISEASE; MOLECULE-1 KIM-1; CARDIAC-SURGERY; CYSTATIN-C; ANTIRETROVIRAL THERAPY; URINE NGAL; BIOMARKER; NEPHROPATHY; INTERLEUKIN-18 AB Background: In HIV-infected women, urine concentrations of novel tubulointerstitial injury markers, interleukin-18 (IL-18) and kidney injury marker-1 (KIM-1), are associated with kidney function decline and all-cause mortality. We hypothesized that HIV-infected individuals with preserved kidney filtration function would have more extensive kidney injury, as determined by urine injury markers, compared to the uninfected controls, and that risk factors for tubulointerstitial injury would differ from risk factors for albuminuria. Methods: In this cross-sectional study, we compared urine concentrations of IL-18, KIM-1 and albumin-tocreatinine ratio (ACR) in 908 HIV-infected and 289 HIV-uninfected women enrolled in the Women's Interagency HIV Study, utilizing stored urine specimens from visits between 1999 and 2000. Results: After multivariate-adjusted linear regression analysis, mean urine concentrations were higher in HIV-infected individuals by 38% for IL-18 (P<0.0001), 12% for KIM-1 (P=0.081) and 47% for ACR (P<0.0001). Higher HIV RNA level (15% per 10-fold increase; P<0.0001), lower CD4(+) lymphocyte count (8% per doubling; P=0.0025), HCV infection (30%; P=0.00018) and lower high-density lipoprotein (5% per 10 mg/dl; P=0.0024) were each associated with higher IL-18 concentrations. In contrast, hypertension (81%; P<0.0001) and diabetes (47%; P=0.018) were among the strongest predictors of higher ACR, though HIV RNA level (15% per 10-fold increase; P=0.0004) was also associated with higher ACR. Conclusions: HIV-infected women had more extensive tubulointerstitial and glomerular injury than uninfected women, but the associated factors differed among the urine biomarkers. Combinations of urinary biomarkers should be investigated to further characterize early kidney injury in HIV-infected women. C1 [Jotwani, Vasantha; Scherzer, Rebecca; Tien, Phyllis C.; Grunfeld, Carl; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. [Jotwani, Vasantha; Scherzer, Rebecca; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Abraham, Alison] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Estrella, Michelle M.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Bennett, Michael; Devarajan, Prasad] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA. [Anastos, Kathryn] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Chicago, IL 60612 USA. [Nowicki, Marek] Univ So Calif, Dept Med, Los Angeles, CA USA. [Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Div Infect Dis, Brooklyn, NY 11203 USA. [Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Div Infect Dis & Travel Med, Washington, DC 20007 USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA. [Parikh, Chirag R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. EM Michael.Shlipak@ucsf.edu FU NCRR NIH HHS [UL1 RR024131]; NIA NIH HHS [1R01 AG034853-01A2, R01 AG034853]; NIAID NIH HHS [P30 AI027763, U01 AI031834, U01 AI034989, U01 AI034993, U01 AI034994, U01 AI035004, U01 AI042590, U01-AI-31834, U01-AI-34989, U01-AI-34993, U01-AI-34994, U01-AI-35004]; NICHD NIH HHS [U01 HD032632, U01-HD-32632, U01-HD-42590]; NIDDK NIH HHS [P50 DK096418, T32 DK007219] NR 52 TC 5 Z9 5 U1 0 U2 2 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2014 VL 19 IS 1 BP 79 EP 87 DI 10.3851/IMP2677 PG 9 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA AG2FP UT WOS:000335231800008 PM 23970313 ER PT J AU Young, S Vos, SS Cantrell, M Shaw, R AF Young, Shardae Vos, Susan S. Cantrell, Matthew Shaw, Robert TI Factors Associated With Students' Perception of Preceptor Excellence SO AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION LA English DT Article DE preceptor; experiential education; evaluation; quality assurance ID PHARMACY EDUCATION; QUALITY AB Objectives. To identify factors associated with preceptor excellence as rated by student pharmacists and to assess the correlation of excellent ratings with years as pharmacist, specialty certification, and faculty appointment status. Methods. A retrospective analysis of student pharmacist evaluations of preceptors from May 2009 to May 2012 was completed to determine factors associated with preceptor excellence. Results. Preceptors who showed an interest in teaching, related to the student as an individual, encouraged discussion, were accessible, provided feedback, served as a role model, were organized, and/or spent increased time with students were more likely to be rated excellent. Conclusion. Serving as role models and showing an interest in teaching demonstrated the strongest association with being an excellent preceptor. Identifying factors students associate with preceptor excellence may result in enhanced preceptor recruitment, development, and training. C1 [Young, Shardae] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Vos, Susan S.] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA. [Cantrell, Matthew; Shaw, Robert] Univ Iowa, Iowa City VA Healthcare Syst, Iowa City, IA USA. RP Vos, SS (reprint author), Univ Iowa, Coll Pharm, Dept Pharm Practice & Sci, 115 S Grand Ave,S413 PHAR, Iowa City, IA 52242 USA. EM susan-vos@uiowa.edu NR 20 TC 6 Z9 6 U1 1 U2 6 PU AMER ASSOC COLL PHARMACY PI ALEXANDRIA PA 1426 PRINCE STREET, ALEXANDRIA, VA 22314-2815 USA SN 0002-9459 EI 1553-6467 J9 AM J PHARM EDUC JI Am. J. Pharm. Educ. PY 2014 VL 78 IS 3 AR 53 PG 6 WC Education, Scientific Disciplines; Pharmacology & Pharmacy SC Education & Educational Research; Pharmacology & Pharmacy GA AF8ZK UT WOS:000335004300006 PM 24761014 ER PT J AU Dobkin, BHK Nadeau, SE Behrman, AL Wu, SS Rose, DK Bowden, M Studenski, S Lu, XM Duncan, PW AF Dobkin, Bruce H. K. Nadeau, Stephen E. Behrman, Andrea L. Wu, Samuel S. Rose, Dorian K. Bowden, Mark Studenski, Stephanie Lu, Xiaomin Duncan, Pamela W. TI Prediction of responders for outcome measures of Locomotor Experience Applied Post Stroke trial SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE community ambulation; exercise; functional walking level; gait speed; LEAPS; outcome measures; physical therapy; quality of life; stroke rehabilitation; walking ID GAIT; REHABILITATION; SPEED; HETEROGENEITY; INTERVENTION; RELIABILITY; MANAGEMENT AB The Locomotor Experience Applied Post Stroke rehabilitation trial found equivalent walking outcomes for body weight-supported treadmill plus overground walking practice versus home-based exercise that did not emphasize walking. From this large database, we examined several clinically important questions that provide insights into recovery of walking that may affect future trial designs. Using logistic regression analyses, we examined predictors of response based on a variety of walking speed-related outcomes and measures that captured disability, physical impairment, and quality of life. The most robust predictor was being closer at baseline to the primary outcome measure, which was the functional walking speed thresholds of 0.4 m/s (household walking) and 0.8 m/s (community walking). Regardless of baseline walking speed, a younger age and higher Berg Balance Scale score were relative predictors of responding, whether operationally defined by transitioning beyond each speed boundary or by a continuous change or a greater than median increase in walking speed. Of note, the cutoff values of 0.4 and 0.8 m/s had no particular significance compared with other walking speed changes despite their general use as descriptors of functional levels of walking. No evidence was found for any difference in predictors based on treatment group. C1 [Dobkin, Bruce H. K.] Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Nadeau, Stephen E.] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA. [Nadeau, Stephen E.; Rose, Dorian K.] Malcom Randall Dept Vet Affairs VA Med Ctr, Res Serv, Gainesville, FL USA. [Behrman, Andrea L.] Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA. [Wu, Samuel S.; Lu, Xiaomin] Univ Florida, Dept Biostat, Gainesville, FL USA. [Rose, Dorian K.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA. [Bowden, Mark] Med Univ S Carolina, Dept Hlth Sci, Charleston, SC 29425 USA. [Bowden, Mark] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Bowden, Mark] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Studenski, Stephanie] Univ Pittsburgh, Dept Internal Med, Pittsburgh, PA USA. [Studenski, Stephanie] VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Duncan, Pamela W.] Wake Forest Univ, Dept Neurol, Winston Salem, NC 27109 USA. RP Dobkin, BHK (reprint author), Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA. EM bdobkin@mednet.ucla.edu FU National Institute of Neurologic Diseases and Stroke; National Center for Medical Rehabilitation Research [RO1 NS050506] FX Funding/Support: This material was based on work supported by the National Institute of Neurologic Diseases and Stroke and the National Center for Medical Rehabilitation Research (grant RO1 NS050506). NR 23 TC 11 Z9 11 U1 1 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2014 VL 51 IS 1 BP 39 EP 50 DI 10.1682/JRRD.2013.04.0080 PG 12 WC Rehabilitation SC Rehabilitation GA AF8GB UT WOS:000334952600004 PM 24805892 ER PT J AU Alhosaini, M Walter, JS Singh, S Dieter, RS Hsieh, AM Leehey, DJ AF Alhosaini, Mohamad Walter, James S. Singh, Sanjay Dieter, Robert S. Hsieh, Annming Leehey, David J. TI Hypomagnesemia in Hemodialysis Patients:Role of Proton Pump Inhibitors SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Magnesium; Hemodialysis; Proton pump inhibitors ID SERUM MAGNESIUM CONCENTRATION; PERITONEAL-DIALYSIS PATIENTS; PARATHYROID-HORMONE SECRETION; CHRONIC KIDNEY-DISEASE; ADYNAMIC BONE-DISEASE; MAINTENANCE HEMODIALYSIS; SIGNIFICANT PREDICTOR; PHOSPHATE BINDER; RENAL FAILURE; CALCIUM AB Background: Recent observations have associated hypomagnesemia with increased risk of cardiovascular morbidity and mortality in hemodialysis patients. Methods: We did a 3-month chart review of 62 chronic hemodialysis patients at a single US hospital. All were dialyzed using a dialysate [Mg] of 0.75-1.0 mEq/1. Patients were divided into two groups: hypomagnesemic (mean predialysis plasma [Mg] <1.5 mEq/1) and non-hypomagnesemic (mean predialysis plasma [Mg] >= 1.5 mEq/1). Results: All patients were male; mean age was 64.3 +/- 8.7 years and the majority (73%) diabetic. 24 patients (39%) had hypomagnesemia and 38 (61%) were not hypomagnesemic. There were no significant differences between the two groups in age, diabetes status, blood pressure, duration of dialysis, plasma calcium, phosphorus, albumin, intact parathyroid hormone (PTH), dialysis adequacy (Kt/V), or dietary protein intake (as estimated by normalized protein catabolic rate, nPCR). However, use of proton pump inhibitors (PPIs) was significantly associated with hypomagnesemia (plasma [Mg] 1.48 +/- 0.16 mEq/1 in the PPI group vs. 1.65 +/- 0.26 mEq/I in the non-PPI group, p = 0.007). Adjustment for age, diabetes status, duration of dialysis, plasma albumin, Kt/V, nPCR, and diuretic use did not affect the association between PPI use and hypomagnesemia. Conclusions: Use of PPIs in patients dialyzed using a dialysate [Mg] of 0.75-1.0 mEq/1 is associated with hypomagnesemia. We suggest monitoring plasma [Mg] in patients taking PPIs, with discontinuation of the medication if possible and/or adjustment of dialysate [Mg] to normalize plasma [Mg]. (C) 2014 S. Karger AG, Basel C1 [Alhosaini, Mohamad; Dieter, Robert S.; Hsieh, Annming; Leehey, David J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Med, Hines, IL 60141 USA. [Walter, James S.; Singh, Sanjay] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Res, Hines, IL 60141 USA. [Singh, Sanjay] East West Univ, Chicago, IL USA. RP Leehey, DJ (reprint author), Vet Affairs Hosp, 111-L, Hines, IL 60141 USA. EM dleehey@lumc.edu NR 44 TC 14 Z9 14 U1 0 U2 10 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 EI 1421-9670 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2014 VL 39 IS 3 BP 204 EP 209 DI 10.1159/000360011 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA AE7DK UT WOS:000334156700003 PM 24577494 ER PT J AU Cooper, JN Evans, RW Brooks, MM Fried, L Holmes, C Barinas-Mitchell, E Sutton-Tyrrell, K AF Cooper, Jennifer N. Evans, Rhobert W. Brooks, Maria Mori Fried, Linda Holmes, Chris Barinas-Mitchell, Emma Sutton-Tyrrell, Kim TI Associations between arterial stiffness and platelet activation in normotensive overweight and obese young adults SO CLINICAL AND EXPERIMENTAL HYPERTENSION LA English DT Article DE Arterial stiffness; obesity; platelet activation; pulse wave velocity; weight loss ID INTIMA-MEDIA THICKNESS; PULSE-WAVE VELOCITY; ALL-CAUSE MORTALITY; CARDIOVASCULAR-DISEASE; BETA-THROMBOGLOBULIN; URINARY SODIUM; PLASMA-LEVELS; SHEAR-STRESS; VOLUME; ATHEROSCLEROSIS AB Obese individuals have elevated platelet activation and arterial stiffness, but the strength and temporality of the relationship between these factors remain unclear. We aimed to determine the effect of increased arterial stiffness on circulating platelet activity in overweight/obese young adults. This analysis included 92 participants (mean age 40 years, 60 women) in the Slow Adverse Vascular Effects of excess weight (SAVE) trial, a clinical trial examining the effects of a lifestyle intervention with or without sodium restriction on vascular health in normotensive overweight/obese young adults. Carotid-femoral (cf), brachial-ankle (ba) and femoral-ankle (fa) pulse wave velocity (PWV) served as measures of arterial stiffness and were measured at baseline and 6, 12 and 24 months follow-up. Platelet activity was measured as plasma b-thromboglobulin (beta-TG) at 24 months. Higher plasma beta-TG was correlated with greater exposure to elevated cfPWV (p = 0.02) and baPWV (p = 0.04) during the preceding two years. After adjustment for serum leptin, greater exposure to elevated baPWV remained significant (p = 0.03) and exposure to elevated cfPWV marginally significant (p = 0.054) in predicting greater plasma b-TG. Greater arterial stiffness, particularly central arterial stiffness, predicts greater platelet activation in overweight/obese individuals. This relationship might partly explain the association between increased arterial stiffness and incident atherothrombotic events. C1 [Cooper, Jennifer N.; Evans, Rhobert W.; Brooks, Maria Mori; Fried, Linda; Barinas-Mitchell, Emma; Sutton-Tyrrell, Kim] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Cooper, Jennifer N.; Brooks, Maria Mori] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Cooper, Jennifer N.] Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, Columbus, OH 43205 USA. [Fried, Linda] VA Pittsburgh Healthcare Syst, Univ Drive Div, Pittsburgh, PA USA. [Holmes, Chris] Univ Vermont, Coll Med, Colchester Res Facil, Pittsburgh, PA USA. RP Cooper, JN (reprint author), Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, JWest 4915, Columbus, OH 43205 USA. EM jennifer.cooper@nationwidechildrens.org OI Barinas-Mitchell, Emma/0000-0002-7280-7781; Brooks, Maria/0000-0002-2030-7873 FU National Heart, Lung, and Blood Institute of the National Institutes of Health [R01 HL077525, F31 HL106986] FX Grant Support: This work was supported by grants R01 HL077525 and F31 HL106986 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. NR 34 TC 1 Z9 1 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1064-1963 EI 1525-6006 J9 CLIN EXP HYPERTENS JI Clin. Exp. Hypertens. PY 2014 VL 36 IS 3 BP 115 EP 122 DI 10.3109/10641963.2013.789045 PG 8 WC Pharmacology & Pharmacy; Peripheral Vascular Disease SC Pharmacology & Pharmacy; Cardiovascular System & Cardiology GA AF2AT UT WOS:000334515700001 PM 23654212 ER PT J AU Bras, LED Toba, H Baicu, CF Zile, MR Weintraub, ST Lindsey, ML Bradshaw, AD AF Bras, Lisandra E. de Castro Toba, Hiroe Baicu, Catalin F. Zile, Michael R. Weintraub, Susan T. Lindsey, Merry L. Bradshaw, Amy D. TI Age and SPARC Change the Extracellular Matrix Composition of the Left Ventricle SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID RAT LEFT-VENTRICLE; VI COLLAGEN; IV COLLAGEN; MYOCARDIAL FIBROSIS; BASEMENT-MEMBRANES; FIBRILLAR COLLAGEN; HYPERTROPHY; PRESSURE; NETWORK; STIFFNESS AB Secreted protein acidic and rich in cysteine (SPARC), a collagen-binding matricellular protein, has been implicated in procollagen processing and deposition. The aim of this study was to investigate age-and SPARC-dependent changes in protein composition of the cardiac extracellular matrix (ECM). We studied 6 groups of mice (n = 4/group): young (4-5 months old), middle-aged (11-12 m.o.), and old (18-29 m.o.) C57BL/6J wild type (WT) and SPARC null. The left ventricle (LV) was decellularized to enrich for ECM proteins. Protein extracts were separated by SDS-PAGE, digested in-gel, and analyzed by HPLC-ESI-MS/MS. Relative quantification was performed by spectral counting, and changes in specific proteins were validated by immunoblotting. We identified 321 proteins, of which 44 proteins were extracellular proteins. Of these proteins, collagen III levels were lower in the old null mice compared to WT, suggestive of a role for SPARC in collagen deposition. Additionally, fibrillin showed a significant increase in the null middle-aged group, suggestive of increased microfibril deposition in the absence of SPARC. Collagen VI increased with age in both genotypes (>3-fold), while collagen IV showed increased age-associated levels only in the WT animals (4-fold, P < 0.05). These changes may explain the previously reported age-associated increases in LV stiffness. In summary, our data suggest SPARC is a possible therapeutic target for aging induced LV dysfunction. C1 [Bras, Lisandra E. de Castro; Toba, Hiroe; Lindsey, Merry L.] Univ Mississippi, Med Ctr, Mississippi Ctr Heart Res, Jackson, MS 39216 USA. [Bras, Lisandra E. de Castro; Toba, Hiroe; Weintraub, Susan T.; Lindsey, Merry L.] Univ Texas Hlth Sci Ctr San Antonio UTHSCA, San Antonio Cardiovasc Prote Ctr, San Antonio, TX 78229 USA. [Toba, Hiroe] Kyoto Pharmaceut Univ, Dept Clin Pharmacol, Div Pathol Sci, Kyoto 607, Japan. [Baicu, Catalin F.; Zile, Michael R.; Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Zile, Michael R.; Bradshaw, Amy D.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Weintraub, Susan T.] UTHSCSA, Dept Biochem, San Antonio, TX 78229 USA. [Lindsey, Merry L.] GV Sonny Montgomery Vet Affairs Med Ctr, Res Serv, Jackson, MS 39216 USA. RP Lindsey, ML (reprint author), Univ Mississippi, Med Ctr, Mississippi Ctr Heart Res, Jackson, MS 39216 USA. EM mllindsey@umc.edu; bradshad@musc.edu FU AHA [14SDG18860050]; NIH/NHLBI HHSN [268201000036C (N01-HV-00244)]; Biomedical Laboratory Research, Development Service of the Veterans Affairs Office of Research and Development Awards [5I01BX000505, 1I01BX001385]; [HL075360]; [HL51971] FX The authors acknowledge support from AHA for 14SDG18860050 to LEDCB, from NIH/NHLBI HHSN 268201000036C (N01-HV-00244) for the San Antonio Cardiovascular Proteomics Center, HL075360, and HL51971 to MLL, and from the Biomedical Laboratory Research, Development Service of the Veterans Affairs Office of Research and Development Awards 5I01BX000505 to MLL and 1I01BX001385 to ADB. Mass spectrometry analyses were conducted in the UTHSCSA Institutional Mass Spectrometry Laboratory. The expert technical assistance of Kevin W. Hakala, Trevi A. Ramirez, and Elizabeth Flynn is gratefully acknowledged. NR 40 TC 0 Z9 0 U1 0 U2 3 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2014 AR 810562 DI 10.1155/2014/810562 PG 7 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA AE3YK UT WOS:000333914200001 ER PT S AU Swenson, ER AF Swenson, Erik R. BE Frost, SC McKenna, R TI Carbonic Anhydrase Inhibitors and High Altitude Illnesses SO CARBONIC ANHYDRASE: MECHANISM, REGULATION, LINKS TO DISEASE, AND INDUSTRIAL APPLICATIONS SE Subcellular Biochemistry LA English DT Article; Book Chapter DE Hypoxia; Acid-base; Pulmonary edema; Cerebral edema; Erythrocytosis; Carbonic anhydrase inhibitors ID ACUTE MOUNTAIN-SICKNESS; HYPOXIC PULMONARY VASOCONSTRICTION; ARTERIAL SMOOTH-MUSCLE; CEREBRAL-BLOOD-FLOW; VENTILATORY RESPONSE; EXERCISE CAPACITY; CHOROID-PLEXUS; GAS-EXCHANGE; CAROTID-BODY; NITRIC-OXIDE AB Carbonic anhydrase (CA) inhibitors, particularly acetazolamide, have been used at high altitude for decades to prevent or reduce acute mountain sickness (AMS), a syndrome of symptomatic intolerance to altitude characterized by headache, nausea, fatigue, anorexia and poor sleep. Principally CA inhibitors act to further augment ventilation over and above that stimulated by the hypoxia of high altitude by virtue of renal and endothelial cell CA inhibition which oppose the hypocapnic alkalosis resulting from the hypoxic ventilatory response (HVR), which acts to limit the full expression of the HVR. The result is even greater arterial oxygenation than that driven by hypoxia alone and greater altitude tolerance. The severity of several additional diseases of high attitude may also be reduced by acetazolamide, including high altitude cerebral edema (HACE), high altitude pulmonary edema (HAPE) and chronic mountain sickness (CMS), both by its CA-inhibiting action as described above, but also by more recently discovered non-CA inhibiting actions, that seem almost unique to this prototypical CA inhibitor and are of most relevance to HAPE. This chapter will relate the history of CA inhibitor use at high altitude, discuss what tissues and organs containing carbonic anhydrase play a role in adaptation and maladaptation to high altitude, explore the role of the enzyme and its inhibition at those sites for the prevention and/or treatment of the four major forms of illness at high altitude. C1 [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Swenson, Erik R.] Univ Washington, Dept Med, Seattle, WA USA. RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM eswenson@u.washington.edu NR 119 TC 12 Z9 12 U1 0 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 0306-0225 BN 978-94-007-7359-2; 978-94-007-7358-5 J9 SUBCELL BIOCHEM JI Subcell. Biochem. PY 2014 VL 75 BP 361 EP 386 DI 10.1007/978-94-007-7359-2_18 D2 10.1007/978-94-007-7359-2 PG 26 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA BA0QY UT WOS:000332111800018 PM 24146388 ER PT J AU Wharton, W Gleason, CE Dowling, NM Carlsson, CM Brinton, EA Santoro, MN Neal-Perry, G Taylor, H Naftolin, F Lobo, RA Merriam, G Manson, JE Cedars, MI Miller, VM Black, DM Budoff, M Hodis, HN Harman, SM Asthana, S AF Wharton, Whitney Gleason, Carey E. Dowling, N. Maritza Carlsson, Cynthia M. Brinton, Eliot A. Santoro, M. Nanette Neal-Perry, Genevieve Taylor, Hugh Naftolin, Frederick Lobo, Rogerio A. Merriam, George Manson, Joann E. Cedars, Marcelle I. Miller, Virginia M. Black, Dennis M. Budoff, Matthew Hodis, Howard N. Harman, S. Mitchell Asthana, Sanjay TI The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Attention; blood pressure; clinical trial; cognition; estradiol; estrogen; hormone therapy; memory; vascular risk ID MIDLIFE BLOOD-PRESSURE; ALZHEIMERS-DISEASE; MENOPAUSAL TRANSITION; MEMORY PERFORMANCE; HYPERTENSION; DEMENTIA; LIFE; AGE; ESTROGEN; INDIVIDUALS AB Midlife vascular risk factors influence later cognitive decline and Alzheimer's disease (AD). The decrease in serum estradiol levels during menopause has been associated with cognitive impairment and increased vascular risk, such as high blood pressure (BP), which independently contributes to cognitive dysfunction and AD. We describe the extent to which vascular risk factors relate to cognition in healthy, middle-aged, recently postmenopausal women enrolled in the Kronos Early Estrogen Prevention Cognitive and Affective Study (KEEPS-Cog) at baseline. KEEPS-Cog is a double-blind, randomized, placebo-controlled, parallel group, clinical trial, investigating the efficacy of low-dose, transdermal 17 beta-estradiol and oral conjugated equine estrogen on cognition. All results are cross-sectional and represent baseline data only. Analyses confirm that the KEEPS-Cog cohort (n = 571) was middle aged (mean 52.7 years, range 42-59 years), healthy, and free of cognitive dysfunction. Higher systolic BP was weakly related to poorer performance in auditory working memory and attention (p = 0.004; adjusted for multiple comparisons p = 0.10). This relationship was not associated with endogenous hormone levels, and systolic BP was not related to any other cognitive domain. BP levels may be more sensitive than other vascular risk factors in detecting subtle differences in cognitive task performance in healthy, recently menopausal women. Lower BP early in menopause may affect cognitive domains known to be associated with AD. C1 [Wharton, Whitney] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30329 USA. [Wharton, Whitney] Emory Alzheimers Dis Res Ctr, Adrc Atlanta, GA USA. [Gleason, Carey E.; Dowling, N. Maritza; Carlsson, Cynthia M.; Asthana, Sanjay] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Gleason, Carey E.; Carlsson, Cynthia M.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Gleason, Carey E.; Dowling, N. Maritza; Carlsson, Cynthia M.; Asthana, Sanjay] Wisconsin Alzheimers Dis Res Ctr, Adrc Madison, WI USA. [Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Brinton, Eliot A.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Santoro, M. Nanette] Univ Colorado, Sch Med, Aurora, CO USA. [Neal-Perry, Genevieve] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Taylor, Hugh] Yale Univ, Sch Med, New Haven, CT USA. [Naftolin, Frederick] NYU, New York, NY USA. [Lobo, Rogerio A.] Columbia Univ, Sch Med, New York, NY USA. [Merriam, George] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Merriam, George] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Manson, Joann E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Cedars, Marcelle I.; Black, Dennis M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Miller, Virginia M.] Mayo Clin, Rochester, MN USA. [Budoff, Matthew] Los Angeles Biomed Res Inst, Torrance, CA USA. [Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA. [Harman, S. Mitchell] Kronos Longev Res Inst, Phoenix, AZ USA. [Harman, S. Mitchell] Phoenix VA Med Ctr, Phoenix, AZ USA. RP Wharton, W (reprint author), Emory Univ, Wesley Woods Hlth Ctr, Emory Alzheimers Dis Res Ctr, Dept Neurol, 1841 Clifton Rd NE, Atlanta, GA 30329 USA. EM w.wharton@emory.edu FU Aurora Foundation; Bayer Health Care Pharmaceuticals, Inc. FX We gratefully acknowledge the dedicated efforts of all the investigators and staff at the KEEPS clinical centers, the KEEPS Data Coordinating Center at KLRI, and the NIH Institutes supporting ancillary studies. The KEEPS investigators would like to thank the Aurora Foundation for study support and Bayer Health Care Pharmaceuticals, Inc. and Abbott Laboratories for providing study medications. Above all, we recognize and thank the KEEPS participants for their dedication and commitment to the KEEPS research program. NR 52 TC 9 Z9 10 U1 0 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 40 IS 2 BP 331 EP 341 DI 10.3233/JAD-130245 PG 11 WC Neurosciences SC Neurosciences & Neurology GA AD9LX UT WOS:000333587700011 PM 24430001 ER PT J AU Gray, NE Morre, J Kelley, J Maier, CS Stevens, JF Quinn, JF Soumyanath, A AF Gray, Nora E. Morre, Jeff Kelley, Jeremiah Maier, Claudia S. Stevens, Jan F. Quinn, Joseph F. Soumyanath, Amala TI Caffeoylquinic Acids in Centella asiatica Protect against Amyloid-beta Toxicity SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Amyloid-beta toxicity; caffeoylquinic acids; Centella asiatica; neuroprotection; tau ID ABNORMALLY PHOSPHORYLATED-TAU; ALZHEIMER-DISEASE BRAIN; OXIDATIVE STRESS; PRECURSOR PROTEIN; CORTICAL-NEURONS; CONDITIONAL EXPRESSION; INDUCED NEUROTOXICITY; SIGNALING PATHWAY; L. URBAN; IN-VITRO AB The accumulation of amyloid-beta (A beta) is a hallmark of Alzheimer's disease and is known to result in neurotoxicity both in vivo and in vitro. We previously demonstrated that treatment with the water extract of Centella asiatica (CAW) improves learning and memory deficits in Tg2576 mice, an animal model of A beta accumulation. However the active compounds in CAW remain unknown. Here we used two in vitro models of A beta toxicity to confirm this neuroprotective effect and identify several active constituents of the CAW extract. CAW reduced A beta-induced cell death and attenuated A beta-induced changes in tau expression and phosphorylation in both the MC65 and SH-SY5Y neuroblastoma cell lines. We confirmed and quantified the presence of several mono-and dicaffeoylquinic acids (CQAs) in CAW using chromatographic separation coupled to mass spectrometry and ultraviolet spectroscopy. Multiple dicaffeoylquinic acids showed efficacy in protecting MC65 cells against A beta-induced cytotoxicity. Isochlorogenic acid A and 1,5-dicaffeoylquinic acid were found to be the most abundant CQAs in CAW, and the most active in protecting MC65 cells from A beta-induced cell death. Both compounds showed neuroprotective activity in MC65 and SH-SY5Y cells at concentrations comparable to their levels in CAW. Each compound not only mitigated A beta-induced cell death, but was able to attenuate A beta-induced alterations in tau expression and phosphorylation in both cell lines, as seen with CAW. These data suggest that CQAs are active neuroprotective components in CAW, and therefore are important markers for future studies on CAW standardization, bioavailability, and dosing. C1 [Gray, Nora E.; Quinn, Joseph F.; Soumyanath, Amala] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Morre, Jeff; Kelley, Jeremiah; Maier, Claudia S.] Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA. [Stevens, Jan F.] Oregon State Univ, Dept Pharmaceut Sci, Corvallis, OR 97331 USA. [Stevens, Jan F.] Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Dept Neurol, Portland, OR USA. [Quinn, Joseph F.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Care Ctr PADRECC, Portland, OR USA. RP Soumyanath, A (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM soumyana@ohsu.edu OI Maier, Claudia S./0000-0003-0743-8956 FU NIH [P50 AT00066]; Oregon Alzheimer's Disease Center 5 [P30 AG008017 24]; T32 grant [NCCAM AT002688]; Department of Veterans Affairs Merit Review grant; Bio-Analytical Shared Resource/Pharmacokinetics Core in the Department of Physiology and Pharmacology at Oregon Health & Science University; Biomolecular Mass Spectrometry Core of the Environmental Health Sciences Core Center at Oregon State University (NIH) [P30ES000210, S10RR027878] FX This work was funded by a grant awarded to A. Soumyanath from NIH P50 AT00066 and to N. Gray from the Oregon Alzheimer's Disease Center 5 P30 AG008017 24, a T32 grant on which N. Gray is a trainee from NIH-NCCAM AT002688, and by a Department of Veterans Affairs Merit Review grant awarded to J. Quinn. HPLC and LCMS work was supported by the Bio-Analytical Shared Resource/Pharmacokinetics Core in the Department of Physiology and Pharmacology at Oregon Health & Science University. The authors also acknowledge the Biomolecular Mass Spectrometry Core of the Environmental Health Sciences Core Center at Oregon State University (NIH grant P30ES000210) for LC-HRMS and LC-MS analyses (NIH grant S10RR027878). NR 64 TC 13 Z9 13 U1 1 U2 12 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 40 IS 2 BP 359 EP 373 DI 10.3233/JAD-131913 PG 15 WC Neurosciences SC Neurosciences & Neurology GA AD9LX UT WOS:000333587700014 PM 24448790 ER PT J AU Du, YPP Chu, RX Tregellas, JR AF Du, Yiping P. Chu, Renxin Tregellas, Jason R. TI Enhancing the Detection of BOLD Signal in fMRI by Reducing the Partial Volume Effect SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE LA English DT Article ID HIGH-RESOLUTION FMRI; HUMAN AUDITORY-CORTEX; HIGH MAGNETIC-FIELDS; SMOOTH-PURSUIT; ACTIVATION; BRAIN; ECHO; SENSITIVITY; ANGIOGRAPHY; CONTRAST AB Purpose. To investigate the advantages of reducing the partial volume effect (PVE) to enhance the detection of the BOLD signal in fMRI. Methods. A linear phase term was added in k-space to obtain half-voxel shifting of 64 x 64 T-2*-weighted echo-planar images. Three sets of image data shifted in the x, y, and diagonal direction, respectively, are combined with the original 64 x 64 data to form the 128 x 128 voxel-shifted interpolated data. Results. A simulation of a synthetic fMRI dataset shows that the voxel-shifted interpolation (VSI) can increase the t-score up to 50% in single-voxel activations. An fMRI study (n = 7) demonstrates that 20.4% of the interpolated voxels have higher t-scores than their nearest neighboring voxels in the original maps. The average increase of the t-score in these interpolated voxels is 13.3%. Conclusion. VSI yields increased sensitivity in detecting voxel-size BOLD activations, improved spatial accuracy of activated regions, and improved detection of the peak BOLD signal of an activated region. VSI can potentially be used as an alternative to the high-resolution fMRI studies in which reduction in SNR and increase in imaging time become prohibitive. C1 [Du, Yiping P.] Zhejiang Univ, Dept Biomed Engn, Hangzhou 310027, Peoples R China. [Du, Yiping P.] Educ Minist China, Key Lab Biomed Engn, Beijing, Peoples R China. [Du, Yiping P.; Chu, Renxin; Tregellas, Jason R.] Univ Colorado, Sch Med, Dept Psychiat, Brain Imaging Ctr, Aurora, CO USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. RP Du, YPP (reprint author), Zhejiang Univ, Dept Biomed Engn, Hangzhou 310027, Peoples R China. EM yipingdu@zju.edu.cn RI Tregellas, Jason/J-3637-2015 FU National Key Basic Research Program of China [2013CB329501]; National Natural Science Foundation of China [81371518, 81261120411]; Ministry of Science and Technology [2011BAI12B01] FX This work was partially supported by the National Key Basic Research Program of China (2013CB329501), the National Natural Science Foundation of China (81371518, 81261120411), and the Ministry of Science and Technology (2011BAI12B01). The Brain and Behavior Research Foundation, and the Blowitz-Ridgeway Foundation. NR 23 TC 0 Z9 0 U1 1 U2 9 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1748-670X EI 1748-6718 J9 COMPUT MATH METHOD M JI Comput. Math. Method Med. PY 2014 AR 973972 DI 10.1155/2014/973972 PG 9 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA AD5LA UT WOS:000333293100001 ER PT J AU Ross, SA Allen, DN Goldstein, G AF Ross, Sylvia An Allen, Daniel N. Goldstein, Gerald TI Factor Structure of the Halstead-Reitan Neuropsychological Battery for Children: A Brief Report Supplement SO APPLIED NEUROPSYCHOLOGY-CHILD LA English DT Article DE factor analysis; Halstead-Reitan Neuropsychological Battery for Older Children; neuropsychological assessment; Reitan-Indiana Neuropsychological Battery ID OLDER CHILDREN; TESTS; PLASTICITY; VALIDITY; MOTOR AB The Halstead-Reitan Neuropsychological Battery (HRNB) is the first factor-analyzed neuropsychological battery and consists of three batteries for young children, older children, and adults. Halstead's original factor analysis extracted four factors from the adult version of the battery, which were the basis for his theory of biological intelligence. These factors were called Central Integrative Field, Abstraction, Power, and Directional. Since this original analysis, Reitan's additions to the battery, and the development of the child versions of the test, this factor-analytic research continued. An introduction and the adult literature are reviewed in Ross, Allen, and Goldstein (in press). In this supplemental article, factor-analytic studies of the HRNB with children are reviewed. It is concluded that factor analysis of the HRNB or Reitan-Indiana Neuropsychological Battery with children does not replicate the extensiveness of the adult literature, although there is some evidence that when the traditional battery for older children is used, the factor structure is similar to what is found in adult studies. Reitan's changes to the battery appear to have added factors including language and sensory-perceptual factors. When other tests and scoring methods are used in addition to the core battery, differing solutions are produced. C1 [Ross, Sylvia An; Allen, Daniel N.] Univ Nevada, Dept Psychol, Las Vegas, NV 89154 USA. [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Allen, DN (reprint author), Univ Nevada, Dept Psychol, 4505 Maryland Pkwy, Las Vegas, NV 89154 USA. EM Daniel.allen@unlv.edu FU Mental Illness Research, Education, and Clinical Center, VA Pittsburgh Healthcare System; Medical Research Service, Department of Veterans Affairs FX Indebtedness is expressed to the Mental Illness Research, Education, and Clinical Center, VA Pittsburgh Healthcare System, and the Medical Research Service, Department of Veterans Affairs, for support of this research. NR 30 TC 0 Z9 0 U1 1 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 2162-2965 EI 2162-2973 J9 APPL NEUROPSYCH-CHIL JI Appl. Neuropsychol.-Child PY 2014 VL 3 IS 1 BP 1 EP 9 DI 10.1080/21622965.2012.695882 PG 9 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA AD0TI UT WOS:000332946600001 PM 24236936 ER PT J AU Niess, MA Prochazka, A AF Niess, Meredith A. Prochazka, Allan TI Preoperative Chest X-rays A Teachable Moment SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Niess, Meredith A.] Univ Colorado, Sch Med, Aurora, CO 80045 USA. [Prochazka, Allan] Denver VA Med Ctr, Dept Ambulatory Care, Denver, CO USA. RP Niess, MA (reprint author), Univ Colorado, Sch Med, Internal Med Residency Program, 12631 E 17th Ave,B177, Aurora, CO 80045 USA. EM meredith.niess@ucdenver.edu NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2014 VL 174 IS 1 BP 12 EP 12 DI 10.1001/jamainternmed.2013.10531 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AD2EM UT WOS:000333046500004 PM 24081219 ER PT J AU Brownell, J Wang, J Smith, A Stephens, C Hsia, RY AF Brownell, Julia Wang, Joseph Smith, Alexander Stephens, Caroline Hsia, Renee Y. TI Trends in Emergency Department Visits for Ambulatory Care Sensitive Conditions by Elderly Nursing Home Residents, 2001 to 2010 SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Brownell, Julia; Hsia, Renee Y.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94110 USA. [Wang, Joseph] Univ Calif San Francisco, Sch Med, San Francisco, CA 94110 USA. [Smith, Alexander] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94110 USA. [Smith, Alexander; Stephens, Caroline] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94110 USA. [Stephens, Caroline] Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA 94110 USA. RP Brownell, J (reprint author), Univ Calif San Francisco, Dept Emergency Med, 1001 Potrero Ave,Room 1E2, San Francisco, CA 94110 USA. EM julia.brownell@emergency.ucsf.edu FU NCATS NIH HHS [KL2 TR000143] NR 5 TC 8 Z9 8 U1 2 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2014 VL 174 IS 1 BP 156 EP 158 DI 10.1001/jamainternmed.2013.11821 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA AD2EM UT WOS:000333046500044 PM 24166099 ER PT J AU Stickrath, C Anderson, M AF Stickrath, Chad Anderson, Mel TI Considerations for Attending Rounds Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Stickrath, Chad; Anderson, Mel] Univ Colorado, Sch Med, Dept Med, Denver, CO USA. [Stickrath, Chad; Anderson, Mel] Denver Vet Affairs Med Ctr, Med Serv, Denver, CO USA. RP Stickrath, C (reprint author), Univ Colorado, Sch Med, Denver VA Med Ctr, Med Serv, 1055 Clermont St,Box 111, Denver, CO 80220 USA. EM Chad.stickrath@va.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JAN PY 2014 VL 174 IS 1 BP 162 EP 162 DI 10.1001/jamainternmed.2013.11085 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AD2EM UT WOS:000333046500048 PM 24394927 ER PT J AU Dutton, CE Adams, T Bujarski, S Badour, CL Feldner, MT AF Dutton, Courtney E. Adams, Thomas Bujarski, Sarah Badour, Christal L. Feldner, Matthew T. TI Posttraumatic stress disorder and alcohol dependence: Individual and combined associations with social network problems SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE PTSD; Alcohol dependence; Social support; Social conflict ID NATIONAL COMORBIDITY SURVEY; SUBSTANCE-ABUSE PATIENTS; REPLICATION NCS-R; AGGRESSION PERPETRATION; INTIMATE PARTNER; PTSD; SYMPTOMS; SUPPORT; TRAUMA; VETERANS AB People with either posttraumatic stress disorder (PTSD) or alcohol dependence (AD) are apt to report problems in their social networks, including low perceived support and elevated conflict. However, little research has examined social networks among people with comorbid PTSD/AD despite evidence suggesting these two conditions commonly co-occur and are linked to particularly severe problems. To test the hypothesis that people with comorbid PTSD/AD experience particularly elevated social network problems, individuals with lifetime diagnoses of PTSD, AD, comorbid PTSD/AD, or no lifetime history of Axis I psychopathology in the National Comorbidity Survey-Replication were compared on four dimensions of social networks: (I) Closeness, (2) Conflict, (3) Family Support, and (4) Apprehension. Persons with PTSD, AD, or comorbid PTSD/AD endorsed more problems with the Conflict, Family Support, and Apprehension factors compared to people with no history of Axis I psychopathology. Moreover, individuals with comorbid PTSD/AD endorsed greater Apprehension and significantly less Family Support compared to the other three groups. Results suggest people with comorbid PTSD/AD experience increased problems with their family as well as greater concerns about enlisting social support than even people with PTSD or AD alone. Treatments for people suffering from comorbid PTSD/AD should consider assessing for and possibly targeting family support and apprehension about being close to others. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Dutton, Courtney E.; Adams, Thomas; Bujarski, Sarah; Badour, Christal L.; Feldner, Matthew T.] Univ Arkansas, Fayetteville, AR 72701 USA. [Adams, Thomas; Badour, Christal L.] Med Univ S Carolina, Charleston, SC 29425 USA. [Adams, Thomas; Badour, Christal L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Feldner, Matthew T.] Laureate Inst Brain Res, Tulsa, OK 74136 USA. RP Dutton, CE (reprint author), Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA. EM cedutton@uark.edu; mfeldne@uark.edu NR 62 TC 6 Z9 6 U1 2 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD JAN PY 2014 VL 28 IS 1 BP 67 EP 74 DI 10.1016/j.janxdis.2013.11.010 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AD2MT UT WOS:000333070500009 PM 24462749 ER PT J AU Folmer, RL Theodoroff, SM Martin, WH Shi, YB AF Folmer, Robert L. Theodoroff, Sarah M. Martin, William Hal Shi, Yongbing TI Experimental, Controversial, and Futuristic Treatments for Chronic Tinnitus SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY LA English DT Review DE Auditory rehabilitation; management; tinnitus; therapy; treatment ID TRANSCRANIAL MAGNETIC STIMULATION; PLACEBO-CONTROLLED TRIAL; DEEP BRAIN-STIMULATION; HAIR CELL REGENERATION; 8TH CRANIAL NERVE; LOW-LEVEL LASER; MICROVASCULAR DECOMPRESSION; DOUBLE-BLIND; SUBJECTIVE TINNITUS; AUDITORY-CORTEX AB Background: Because chronic tinnitus is a condition that negatively impacts the quality of life of millions of people worldwide, a safe and effective treatment for tinnitus has been sought for millennia. However, effective treatments for tinnitus are greatly outnumbered by ineffective strategies, medications, devices, and surgeries that continue to be developed and promoted for the condition. Purpose: This article describes and critiques experimental, controversial, and potential treatments for chronic tinnitus. The purpose of this review is to provide information that should help patients and clinicians to select tinnitus treatment and management strategies most likely to be effective for each set of symptoms and circumstances. Research Design: PubMed and MEDLINE databases (National Center for Biotechnology Information, U.S. National Library of Medicine) were searched for the term tinnitus in articles published from 1940 to 2012. Other historical documents and publications were also reviewed as needed for particular topics. Study Sample: Studies included in this review were selected to represent a sampling of treatment methodologies that have been used for tinnitus. Data Collection and Analysis: Due to the heterogeneity of the studies reviewed, it was not appropriate to perform a meta-analysis. A selective review of the literature was conducted to summarize and critique published research results. Results: Most invasive treatments for tinnitus should be avoided because (1) at best, there is scant evidence that any of these treatments is effective, and (2) the risk to patients for most invasive procedures is much greater than the risk posed by the tinnitus perception. Effective and non-invasive treatments for tinnitus include acoustic therapy (which includes hearing aids and other types of environmental sound enrichment); cognitive-behavioral therapy; psychological counseling; hypnosis; biofeedback; and relaxation training. Over-the-counter or prescription medications may be used as needed to facilitate sleep and to reduce anxiety, depression, or obsessive-compulsiveness. Conclusions: Patients and clinicians should be especially cautious when considering invasive (and potentially harmful) treatments for tinnitus, which is a non-life-threatening symptom. Unless well-designed clinical trials verify that a tinnitus therapy demonstrates effectiveness above and beyond the placebo effect, consumers should be wary of medications, devices, or procedures promoted as a "cure." Although a true cure for tinnitus has not yet been found, effective and noninvasive tinnitus management strategies are available now. If progress is made to medically (or genetically) treat sensorineural hearing loss in humans, this breakthrough should also help to simultaneously reduce the perception of tinnitus for many patients. C1 [Folmer, Robert L.; Theodoroff, Sarah M.] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA. [Folmer, Robert L.; Theodoroff, Sarah M.; Martin, William Hal; Shi, Yongbing] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA. RP Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM Robert.Folmer@va.gov FU U.S. Department of Veterans Affairs Rehabilitation Research and Development (RR&D) Service (VA RRD) [C74481]; National Center for Rehabilitative Auditory Research; [C9230C] FX This research was supported by a grant from the U.S. Department of Veterans Affairs Rehabilitation Research and Development (RR&D) Service (VA RR&D grant #C74481). Additional support was provided by the National Center for Rehabilitative Auditory Research (funded by VA RR&D grant #C9230C) at Portland VA Medical Center. NR 145 TC 7 Z9 7 U1 3 U2 40 PU AMER ACAD AUDIOLOGY PI RESTON PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA SN 1050-0545 EI 2157-3107 J9 J AM ACAD AUDIOL JI J. Am. Acad. Audiol. PD JAN PY 2014 VL 25 IS 1 SI SI BP 106 EP 125 DI 10.3766/jaaa.25.1.7 PG 20 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA AC7BX UT WOS:000332683100007 PM 24622863 ER PT J AU Farrell, SR Sargoy, A Brecha, NC Barnes, S AF Farrell, Spring R. Sargoy, Allison Brecha, Nicholas C. Barnes, Steven TI Modulation of voltage-gated Ca2+ channels in rat retinal ganglion cells by gabapentin SO VISUAL NEUROSCIENCE LA English DT Article DE alpha(2)delta Ca channel subunit; Alpha2delta subunit; Cacna2d1; Retinal ganglion cell; Gabapentin ID CALCIUM-CHANNEL; ALPHA(2)DELTA SUBUNIT; PROTEIN-KINASE; NEURONS; CURRENTS; TRAFFICKING; PREGABALIN; LOCALIZATION; INHIBITION; RECEPTORS AB The alpha (2) delta auxiliary subunits of voltage-gated Ca2+ channels (VGCCs) are important modulators of VGCC function. Gabapentin interacts with alpha (2) delta (1) and alpha (2) delta (2) subunits and is reported to reduce Ca2+ channel current amplitude (I (Ca)). This study aimed to determine the effects of gabapentin on VGCCs in retinal ganglion cells (RGCs). Whole cell patch clamp was used to record I (Ca) in isolated RGCs, and calcium imaging was used to measure Ca2+ transients from RGCs in situ. Immunohistochemistry was used to detect the presence of alpha (2) delta (1)-containing VGCCs in isolated RGCs in the absence and presence of gabapentin pretreatment. Acute administration of gabapentin reduced I (Ca) and Ca2+ transients compared to control conditions. In isolated RGCs, pretreatment with gabapentin (4-18 h) reduced I (Ca), and cell surface alpha (2) delta (1) staining was reduced compared to nonpretreated cells. Acute administration of gabapentin to isolated RGCs that had been pretreated further reduced I (Ca). These results show that gabapentin has both short-term and long-term mechanisms to reduce I (Ca) in isolated RGCs. Some Ca2+ channel blockers have been shown to protect RGCs in retinal trauma suggesting that modulation of VGCCs by gabapentin may prevent the deleterious effects of elevated Ca2+ levels in RGCs in trauma and disease. C1 [Farrell, Spring R.; Barnes, Steven] Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS B3H 4R2, Canada. [Sargoy, Allison; Brecha, Nicholas C.; Barnes, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Dept Med, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Brecha, Nicholas C.; Barnes, Steven] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [Barnes, Steven] Dalhousie Univ, Inst Neurosci, Halifax, NS B3H 4R2, Canada. [Barnes, Steven] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 4R2, Canada. RP Farrell, SR (reprint author), Dalhousie Univ, Dept Physiol & Biophys, POB 15000, Halifax, NS B3H 4R2, Canada. EM sbarnes@dal.ca FU Canadian Institutes of Health Research; Nova Scotia Health Research Foundation; NIH [EY04067]; VA Merit Review; [W81XWH-10-2-0077] FX The authors would like to thank Dr. William Baldridge and Janette Nason for the preparation of postnatal retinal ganglion cell cultures. Funding for this work was provided by a Canadian Institutes of Health Research and Nova Scotia Health Research Foundation Regional Partnership Program grant to S.B. Part of this research and development project was conducted at the David Geffen School of Medicine at UCLA and is made possible by a contract agreement that was awarded to N.C.B. and administered by the U.S. Army Medical Research & Materiel Command (USAMRMC) and the Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD under Contract Number W81XWH-10-2-0077. Support for these studies also came from NIH EY04067, and a VA Merit Review was awarded to N.C.B. N.C.B. is a VA Career Research Scientist. NR 30 TC 2 Z9 2 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0952-5238 EI 1469-8714 J9 VISUAL NEUROSCI JI Visual Neurosci. PD JAN PY 2014 VL 31 IS 1 BP 47 EP 55 DI 10.1017/S0952523813000588 PG 9 WC Neurosciences; Ophthalmology SC Neurosciences & Neurology; Ophthalmology GA AD1DY UT WOS:000332975300005 PM 24801623 ER PT J AU Paruch, JL Ko, CY Bilimoria, KY AF Paruch, Jennifer L. Ko, Clifford Y. Bilimoria, Karl Y. TI An Opportunity to Improve Informed Consent and Shared Decision Making: The Role of the ACS NSQIP Surgical Risk Calculator in Oncology SO ANNALS OF SURGICAL ONCOLOGY LA English DT Editorial Material C1 [Paruch, Jennifer L.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Paruch, Jennifer L.] Univ Chicago, Pritzker Sch Med, Dept Surg, Chicago, IL 60637 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Los Angeles, CA USA. [Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Northwestern Inst Comparat Effectiveness Res Onco, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA. RP Bilimoria, KY (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. EM kbilimoria@facs.org NR 5 TC 22 Z9 22 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 EI 1534-4681 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD JAN PY 2014 VL 21 IS 1 BP 5 EP 7 DI 10.1245/s10434-013-3345-3 PG 3 WC Oncology; Surgery SC Oncology; Surgery GA AC6YE UT WOS:000332671700002 PM 24197763 ER PT J AU Karlin, BE Cross, G AF Karlin, Bradley E. Cross, Gerald TI From the Laboratory to the Therapy Room National Dissemination and Implementation of Evidence-Based Psychotherapies in the U.S. Department of Veterans Affairs Health Care System SO AMERICAN PSYCHOLOGIST LA English DT Article DE evidence-based psychotherapy; dissemination; implementation; sustainability; veterans ID COGNITIVE-BEHAVIORAL THERAPY; POSTTRAUMATIC-STRESS-DISORDER; PATIENT-LEVEL OUTCOMES; MENTAL-HEALTH; PRACTICE GUIDELINES; COMMITMENT THERAPY; DEPRESSION; KNOWLEDGE; ATTITUDES; IMPROVE AB Despite their established efficacy and recommendation-often as first-line treatments-in clinical practice guidelines, evidence-based psychotherapies (EBPs) have largely failed to make their way into mainstream clinical settings. Numerous attempts over the years to promote the translation of EBPs from science to practice, typically relying on one-dimensional dissemination approaches, have yielded limited success. As part of the transformation of its mental health care system, the Veterans Health Administration (VHA) of the U.S. Department of Veterans Affairs (VA) is working to disseminate and implement a number of EBPs for various mental and behavioral health conditions throughout the VA health care system. This article examines VHA's multidimensional model and specific strategies, involving policy, provider, local systems, patient, and accountability levels, for promoting the national dissemination and implementation of EBPs in VHA. In addition, the article identifies key lessons learned and next steps for further promoting EBP delivery and sustainability in the VA health care system. Beyond promoting the availability of effective treatments for veterans returning from Iraq and Afghanistan and for veterans of previous combat eras, VHA's EBP dissemination and implementation model and key lessons learned may help to inform other private and public health care systems interested in disseminating and implementing EBPs. C1 [Karlin, Bradley E.; Cross, Gerald] US Dept Vet Affairs, Cent Off, Washington, DC 20420 USA. [Karlin, Bradley E.] Johns Hopkins Univ, Baltimore, MD 21218 USA. RP Karlin, BE (reprint author), US Dept Vet Affairs, Natl Mental Hlth Director Psychotherapy & Psychog, Mental Hlth Serv 10P4M, Cent Off, 810 Vermont Ave NW, Washington, DC 20420 USA. EM bradley.karlin2@va.gov NR 88 TC 63 Z9 64 U1 1 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X EI 1935-990X J9 AM PSYCHOL JI Am. Psychol. PD JAN PY 2014 VL 69 IS 1 BP 19 EP 33 DI 10.1037/a0033888 PG 15 WC Psychology, Multidisciplinary SC Psychology GA AB5AX UT WOS:000331802400002 PM 24001035 ER PT J AU Hinrichsen, GA Brickman, AM Edelstein, B Vacha-Haase, T Hiroto, K Zweig, R AF Hinrichsen, Gregory A. Brickman, Adam M. Edelstein, Barry Vacha-Haase, Tammi Hiroto, Kimberly Zweig, Richard CA Amer Psychological Assoc TI Guidelines for Psychological Practice With Older Adults SO AMERICAN PSYCHOLOGIST LA English DT Article ID PRIMARY-CARE PATIENTS; MENTAL-HEALTH-SERVICES; NURSING-HOME RESIDENTS; LONG-TERM-CARE; COMORBIDITY SURVEY REPLICATION; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; PROBLEM-SOLVING THERAPY; LATE-LIFE DEPRESSION; ALZHEIMERS-DISEASE C1 [Hinrichsen, Gregory A.] Icahn Sch Med, Mt Sinai, NY USA. [Brickman, Adam M.] Columbia Univ, New York, NY 10027 USA. [Edelstein, Barry] W Virginia Univ, Morgantown, WV 26506 USA. [Vacha-Haase, Tammi] Colorado State Univ, Ft Collins, CO 80523 USA. [Hiroto, Kimberly] US Dept Vet Affairs, Puget Sound Hlth Care Syst, Washington, DC USA. [Zweig, Richard] Yeshiva Univ, New York, NY 10033 USA. RP Hinrichsen, GA (reprint author), Amer Psychol Assoc, Publ Interest Directorate, Off Aging, 750 First St NE, Washington, DC 20002 USA. NR 420 TC 14 Z9 15 U1 4 U2 22 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X EI 1935-990X J9 AM PSYCHOL JI Am. Psychol. PD JAN PY 2014 VL 69 IS 1 BP 34 EP 65 DI 10.1037/a0035063 PG 32 WC Psychology, Multidisciplinary SC Psychology GA AB5AX UT WOS:000331802400003 ER PT J AU Murray, PS Kirkwood, CM Gray, MC Fish, KN Ikonomovic, MD Hamilton, RL Kofler, JK Klunk, WE Lopez, OL Sweet, RA AF Murray, Patrick S. Kirkwood, Caitlin M. Gray, Megan C. Fish, Kenneth N. Ikonomovic, Milos D. Hamilton, Ronald L. Kofler, Julia K. Klunk, William E. Lopez, Oscar L. Sweet, Robert A. TI Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; Braak stage; Mini-Mental State Examination; psychosis; tau ID A-BETA OLIGOMERS; NEUROFIBRILLARY TANGLES; NATIONAL INSTITUTE; SYNAPSE LOSS; NEUROPATHOLOGIC ASSESSMENT; NEUROPSYCHIATRIC SYMPTOMS; COGNITIVE IMPAIRMENT; ENDOGENOUS TAU; RISK-FACTORS; LEWY BODIES AB Psychosis occurs in 40-60% of Alzheimer's disease (AD) subjects, is heritable, and indicates a more rapidly progressive disease phenotype. Neuroimaging and postmortem evidence support an exaggerated prefrontal cortical synaptic deficit in AD with psychosis. Microtubule-associated protein tau is a key mediator of amyloid-beta-induced synaptotoxicity in AD, and differential mechanisms of progressive intraneuronal phospho-tau accumulation and interneuronal spread of tau aggregates have recently been described. We hypothesized that psychosis in AD would be associated with greater intraneuronal concentration of phosphotau and greater spread of tau aggregates in prefrontal cortex. We therefore evaluated prefrontal cortex phospho-tau in a cohort of 45 AD cases with and without psychosis. Intraneuronal phospho-tau concentration was higher in subjects with psychosis, while a measure of phospho-tau spread, volume fraction, was not. Across groups both measures were associated with lower scores on the Mini-Mental State Examination and Digit Span Backwards test. These novel findings indicate that tau phosphorylation may be accelerated in AD with psychosis, indicating a more dynamic, exaggerated pathology in AD with psychosis. C1 [Murray, Patrick S.; Kirkwood, Caitlin M.; Gray, Megan C.; Fish, Kenneth N.; Ikonomovic, Milos D.; Klunk, William E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Murray, Patrick S.; Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr, VISN Mental Illness Res 4, Pittsburgh, PA USA. [Ikonomovic, Milos D.; Klunk, William E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hamilton, Ronald L.; Kofler, Julia K.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,W1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu OI Murray, Patrick/0000-0002-6525-2888 FU Veterans Health Administration [BX000452]; National Institute of Mental Health [MH071533, MH019986]; National Institute on Aging [AG005133, AG027224] FX This work was supported by the Veterans Health Administration [BX000452 to R. A. S]; the National Institute of Mental Health [MH071533 to R. A. S.]; and the National Institute on Aging [AG005133 to O.L.L., AG027224 to R. A. S.]. P. S. M. is supported by the National Institute of Mental Health [MH019986] and seed grant funding from the National Institute on Aging [AG005133]. NR 70 TC 10 Z9 10 U1 4 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 39 IS 4 BP 759 EP 773 DI 10.3233/JAD-131166 PG 15 WC Neurosciences SC Neurosciences & Neurology GA AB5QD UT WOS:000331842500007 PM 24270207 ER PT J AU Isenhart, C Dieperink, E Thuras, P Fuller, B Stull, L Koets, N Lenox, R AF Isenhart, Carl Dieperink, Eric Thuras, Paul Fuller, Bret Stull, Laura Koets, Nancy Lenox, Rebecca TI Training and maintaining motivational interviewing skills in a clinical trial SO JOURNAL OF SUBSTANCE USE LA English DT Article DE Consultation; training; motivational interviewing; implementation AB Motivational interviewing (MI) is an evidence-based practice that is being implemented in a wide range of settings. Research supports the importance of ongoing coaching and feedback sessions following initial training in MI to implement and sustain MI-adherent competencies. This article describes the development and preliminary testing of a group feedback and consultation process where clinicians code each others' clinical samples of MI sessions and provide feedback to each other regarding the level of adherence to MI fidelity measures. Preliminary results suggest that group feedback may help clinicians develop and sustain MI skills. C1 [Isenhart, Carl; Dieperink, Eric; Thuras, Paul] Minneapolis VA Hlth Care Syst, Mental Hlth Serv Line, Minneapolis, MN 55417 USA. [Isenhart, Carl] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. [Isenhart, Carl; Dieperink, Eric; Thuras, Paul] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Fuller, Bret; Lenox, Rebecca] Portland VA Med Ctr, Portland, OR USA. [Stull, Laura] Anderson Univ, Dept Psychol, Indiana, PA USA. [Koets, Nancy] Wright Patterson Med Ctr, Fairborn, OH USA. RP Isenhart, C (reprint author), Minneapolis VA Hlth Care Syst, One Vet Dr, Minneapolis, MN 55417 USA. EM Carl.Isenhart@va.gov NR 12 TC 1 Z9 1 U1 2 U2 6 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1465-9891 EI 1475-9942 J9 J SUBST USE JI J. Subst. Use PY 2014 VL 19 IS 1-2 BP 164 EP 170 DI 10.3109/14659891.2013.765514 PG 7 WC Substance Abuse SC Substance Abuse GA AB6XM UT WOS:000331933000025 ER PT J AU Wan, JY Edwards, KL Hutter, CM Mata, IF Samii, A Roberts, JW Agarwal, P Checkoway, H Farin, FM Yearout, D Zabetian, CP AF Wan, Jia Y. Edwards, Karen L. Hutter, Carolyn M. Mata, Ignacio F. Samii, Ali Roberts, John W. Agarwal, Pinky Checkoway, Harvey Farin, Federico M. Yearout, Dora Zabetian, Cyrus P. TI Association mapping of the PARK10 region for Parkinson's disease susceptibility genes SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE PARK10; Parkinson's disease; Replication; GWAS ID GENOME-WIDE ASSOCIATION; CANDIDATE GENES; RISK-FACTORS; ONSET; POPULATION; ELAVL4; AGE; IDENTIFICATION; GENETICS; LOCI AB Background: Previous studies indicate that as many as six genes within the PARK10 region (RNF11, UQCRH, HIVEP3, EIF2B3, USP24, ELAVL4) might modify susceptibility or age at onset in Parkinson's disease (PD). Methods: We sought to identify new PD susceptibility genes and to validate previously nominated candidate genes within the PARK10 region using a two-stage design. We used data from a large, publicly-available genome-wide association study (GWAS) in the discovery stage (n = 2000 cases and 1986 controls) and data from three independent studies for the replication stage (total n = 2113 cases and 2095 controls). Marker density was increased by imputation using HapMap 3 and 1000 Genomes reference panels, and over 40,000 single nucleotide polymorphisms (SNPs) were used in the final analysis. The association between each SNP and PD was modeled using logistic regression with an additive allele dosage effect and adjusted for sex, age, and axes of geographical variation. Results: Although the discovery stage yielded promising findings for SNPs in several novel genes, including DAB1, none of the results were validated in the replication stage. Furthermore, in meta-analyses across all datasets no genes within PARK10 reached significance after accounting for multiple testing. Conclusion: Our results suggest that common variation in the PARK10 region is not associated with PD risk. However, additional studies are needed to assess the role of PARK10 in modifying age at onset and to determine whether rare variants in this region might affect PD susceptibility. Published by Elsevier Ltd. C1 [Wan, Jia Y.; Edwards, Karen L.; Hutter, Carolyn M.; Checkoway, Harvey] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Mata, Ignacio F.; Samii, Ali; Yearout, Dora; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Mata, Ignacio F.; Samii, Ali; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Roberts, John W.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Agarwal, Pinky] Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Kirkland, WA USA. [Checkoway, Harvey; Farin, Federico M.] Univ Washington, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu OI Zabetian, Cyrus/0000-0002-7739-4306 FU Allergan; Prana Biotechnology Limited; MERZ; NeuroSearch; Solstice Neurosciences; Ipsen; Adamas; CHDI; HP Therapeutics Foundation, Inc; Addex Therapeutics; NIH; Multiple Sclerosis Society; Department of Veterans Affairs; American Parkinson Disease Association; Parkinson's Disease Foundation FX Ms. Wan receives salary support from the NIH.; Dr. Edwards is funded by grants from the NIH.; Dr. Hutter received funding from University of Washington Royalty Research Fund and grants from the NIH.; Dr. Mata is funded by grants from the Department of Veterans Affairs, NIH, and Parkinson's Disease Foundation. Dr. Agarwal has received honoraria as a speaker for Teva, GSK, UCB, Impax, and consultancy for Merz and has been provided research support from Allergan, Prana Biotechnology Limited, MERZ, NeuroSearch, Solstice Neurosciences, Ipsen, Adamas, CHDI, HP Therapeutics Foundation, Inc., Addex Therapeutics, and the NIH.; Dr. Checkoway is funded by grants from the NIH and the Multiple Sclerosis Society. He also serves as a paid consultant for the Alcoa Co., Pittsburgh, PA, the Electric Power Research Institute, Palo Alto, CA, ENVIRON, Amherst, MA, and the University of Minnesota Dept. of Environmental Health, Minneapolis, MN.; Dr. Farin is funded by grants from the NIH.; Ms. Yearout receives salary support from the Department of Veterans Affairs and NIH.; Dr. Zabetian is funded by grants from the Department of Veterans Affairs, NIH, the American Parkinson Disease Association, Department of Veterans Affairs, NIH, and Parkinson's Disease Foundation. NR 30 TC 6 Z9 6 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD JAN PY 2014 VL 20 IS 1 BP 93 EP 98 DI 10.1016/j.parkreldis.2013.10.001 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA AB0VU UT WOS:000331511000018 PM 24156912 ER PT J AU Campos, GM Ziemelis, M Paparodis, R Ahmed, M Davis, DB AF Campos, Guilherme M. Ziemelis, Martynas Paparodis, Rodis Ahmed, Muhammed Davis, Dawn Belt TI Laparoscopic reversal of Roux-en-Y gastric bypass: Technique and utility for treatment of endocrine complications SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Hypoglycemia; Hyperinsulinemic hypoglycemia; Hypocalcemia; Gastric bypass; Reversal; Sleeve gastrectomy; GLP-1; Hypoparathyroidism; Nesidioblastosis; Laparoscopic reversal; Bariatric surgery ID BARIATRIC SURGERY; HYPERINSULINEMIC HYPOGLYCEMIA; PANCREATIC RESECTION; ISLET HYPERPLASIA; MANAGEMENT; NESIDIOBLASTOSIS; MECHANISMS; RESOLUTION; RESPONSES; OBESITY AB Background: The anatomic and physiologic changes with Roux-en-Y gastric bypass (RYGB) may lead to uncommon but occasionally difficult to treat complications such as hyperinsulinemic hypoglycemia with neuroglycopenia and recalcitrant hypocalcemia associated to hypoparathyroidism. Medical management of these complications is challenging. Laparoscopic reversal of RYGB anatomy with restoration of pyloric function and duodenal continuity is a potential treatment. The objective of this study was to present the indications, surgical technique, and clinical outcomes of laparoscopic reversal of RYGB. Methods: Prospective study of consecutive patients offered laparoscopic reversal of RYGB. Results: Five patients with remote laparoscopic RYGB underwent laparoscopic reversal of RYGB to normal anatomy (n = 2) or modified sleeve gastrectomy (n = 3). Indications were medically refractory hyperinsulinemic hypoglycemia with neuroglycopenia (n = 3), recalcitrant hypocalcemia with hypoparathyroidism (n = 1), and both conditions simultaneously (n = 1). Before reversal, all patients had a gastrostomy tube placed in the excluded stomach to document improvement of symptom's. Laparoscopic reversal was accomplished successfully in all patients. Three postoperative complications occurred: bleeding that required transfusion, gallstone pancreatitis, and a superficial trocar site infection. Average length of stay was 3 days. At a mean follow-up of 12 months (range 3 to 22), no additional episodes of neuroglycopenia occurred, average number of hypoglycemic episodes per week decreased from 18.5 +/- 12.4 to 1.5 +/- 1.9 (P = .05), and hypocalcemia became responsive to oral replacement therapy in both patients. Conclusions: Laparoscopic reversal of RYGB to normal anatomy or modified sleeve gastrectomy is feasible and may be a therapeutic option for selected patients with medically refractory hyperinsulinemic hypoglycemia and/or recalcitrant hypocalcemia associated with hypoparathyroidism. (C) 2014 American Society for Metabolic and Bariatric Surgery. All rights reserved. C1 [Campos, Guilherme M.; Ziemelis, Martynas] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Div Gen Surg,Sect Foregut & Bariatr Surg, Madison, WI 53792 USA. [Paparodis, Rodis; Ahmed, Muhammed; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Endocrinol Diabet & Metab, Madison, WI 53792 USA. [Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Campos, GM (reprint author), Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, 600 Highland Av,K4-730 CSC, Madison, WI 53792 USA. EM campos@surgery.wisc.edu RI Davis, Dawn/B-1624-2013 OI Paparodis, Rodis/0000-0003-2804-0859 FU Clinical and Translational Science Award (CTSA) program, through the National Institutes of Health National Center for Advancing Translational Sciences (NCATS) [UL1TR000427] FX This study was supported by the Clinical and Translational Science Award (CTSA) program, through the National Institutes of Health National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the federal government. NR 35 TC 23 Z9 24 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD JAN-FEB PY 2014 VL 10 IS 1 BP 36 EP 43 DI 10.1016/j.soard.2013.05.012 PG 8 WC Surgery SC Surgery GA AB4QA UT WOS:000331773800006 PM 24120983 ER PT J AU Givertz, MM Postmus, D Hillege, HL Mansoor, GA Massie, BM Davison, BA Ponikowski, P Metra, M Teerlink, JR Cleland, JGF Dittrich, HC O'Connor, CM Cotter, G Voors, AA AF Givertz, Michael M. Postmus, Douwe Hillege, Hans L. Mansoor, George A. Massie, Barry M. Davison, Beth A. Ponikowski, Piotr Metra, Marco Teerlink, John R. Cleland, John G. F. Dittrich, Howard C. O'Connor, Christopher M. Cotter, Gad Voors, Adriaan A. TI Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE cardiorenal syndrome; heart failure; hospitalization; mortality ID IN-HOSPITAL MORTALITY; MEDICARE BENEFICIARIES; ROLOFYLLINE; PROTECT; DYSFUNCTION; ANTAGONIST; PRESSURE; IMPACT; MODEL; TRIAL AB Background Prior studies have demonstrated adverse risk associated with baseline and worsening renal function in acute heart failure, but none has modeled the trajectories of change in renal function and their impact on outcomes. Methods and Results We used linear mixed models of serial measurements of blood urea nitrogen and creatinine to describe trajectories of renal function in 1962 patients with acute heart failure and renal dysfunction enrolled in the Placebo-Controlled Randomized Study of the Selective A(1) Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function study. We assessed risk of 180-day mortality and 60-day cardiovascular or renal readmission and used Cox regression to determine association between renal trajectories and outcomes. Compared with patients alive at 180 days, patients who died were older, had lower blood pressure and ejection fraction, and higher creatinine levels at baseline. On average for the entire cohort, creatinine rose from days 1 to 3 and increased further after discharge, with the trajectory dependent on the day of discharge. Blood urea nitrogen, creatinine, and the rate of change in creatinine from baseline were the strongest independent predictors of 180-day mortality and 60-day readmission, whereas the rate of change of blood urea nitrogen from baseline was not predictive of outcomes. Baseline blood urea nitrogen >35 mg/dL and increase in creatinine >0.1 mg/dL per day increased the risk of mortality, whereas stable or decreasing creatinine was associated with reduced risk. Conclusions Patients with acute heart failure and renal dysfunction demonstrate variable rise and fall in renal indices during and immediately after hospitalization. Risk of morbidity and mortality can be predicted based on baseline renal function and creatinine trajectory during the first 7 days. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00328692 and NCT00354458. C1 [Givertz, Michael M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc,Dept Med, Boston, MA 02115 USA. [Postmus, Douwe; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Mansoor, George A.] Merck Res Labs, Rahway, NJ USA. [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco VAMC, San Francisco, CA 94143 USA. [Davison, Beth A.; Cotter, Gad] Momentum Res Inc, Durham, NC USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Metra, Marco] Univ Brescia, Brescia, Italy. [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England. [Dittrich, Howard C.] Univ Iowa, Dept Med, Iowa City, IA 52242 USA. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. RP Givertz, MM (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. EM mgivertz@partners.org RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568; Davison, Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016 FU NovaCardia, Inc. FX This study was originally funded by NovaCardia, Inc. In September 2007, NovaCardia became a wholly owned subsidiary of Merck & Co, Inc. NR 44 TC 22 Z9 22 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JAN PY 2014 VL 7 IS 1 BP 59 EP 67 DI 10.1161/CIRCHEARTFAILURE.113.000556 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AA4ND UT WOS:000331071800009 PM 24281137 ER PT J AU Cleland, JG Chiswell, K Teerlink, JR Stevens, S Fiuzat, M Givertz, MM Davison, BA Mansoor, GA Ponikowski, P Voors, AA Cotter, G Metra, M Massie, BM O'Connor, CM AF Cleland, John G. Chiswell, Karen Teerlink, John R. Stevens, Susanna Fiuzat, Mona Givertz, Michael M. Davison, Beth A. Mansoor, George A. Ponikowski, Piotr Voors, Adriaan A. Cotter, Gad Metra, Marco Massie, Barry M. O'Connor, Christopher M. TI Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure A Report From the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study SO CIRCULATION-HEART FAILURE LA English DT Article DE acute heart failure; mortality; randomized controlled trial ID BLOOD UREA NITROGEN; INITIATE LIFESAVING TREATMENT; BRAIN NATRIURETIC PEPTIDE; PROGNOSTIC VALUE; OPTIMIZE-HF; VASOPRESSIN ANTAGONIST; INTRAVENOUS MILRINONE; SYSTOLIC DYSFUNCTION; RISK STRATIFICATION; ORGANIZED PROGRAM AB Background Acute heart failure is a common reason for admission, and outcome is often poor. Improved prognostic risk stratification may assist in the design of future trials and in patient management. Using data from a large randomized trial, we explored the prognostic value of clinical variables, measured at hospital admission for acute heart failure, to determine whether a few selected variables were inferior to an extended data set. Methods and Results The prognostic model included 37 clinical characteristics collected at baseline in PROTECT, a study comparing rolofylline and placebo in 2033 patients admitted with acute heart failure. Prespecified outcomes at 30 days were death or rehospitalization for any reason; death or rehospitalization for cardiovascular or renal reasons; and, at both 30 and 180 days, all-cause mortality. No variable had a c-index >0.70, and few had values >0.60; c-indices were lower for composite outcomes than for mortality. Blood urea was generally the strongest single predictor. Eighteen variables contributed independent prognostic information, but a reduced model using only 8 items (age, previous heart failure hospitalization, peripheral edema, systolic blood pressure, serum sodium, urea, creatinine, and albumin) performed similarly. For prediction of all-cause mortality at 180 days, the model c-index using all variables was 0.72 and for the simplified model, also 0.72. Conclusions A few simple clinical variables measured on admission in patients with acute heart failure predict a variety of adverse outcomes with accuracy similar to more complex models. However, predictive models were of only moderate accuracy, especially for outcomes that included nonfatal events. Better methods of risk stratification are required. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00328692 and NCT00354458. C1 [Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England. [Chiswell, Karen; Stevens, Susanna; Fiuzat, Mona; O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ponikowski, Piotr] Kardiol Klin, Wroclaw, Poland. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Davison, Beth A.; Cotter, Gad] Momentum Res Inc, Durham, NC USA. [Metra, Marco] Univ Brescia, Pzza Spedali Civili, Brescia, Italy. [Mansoor, George A.] Merck Res Labs, Rahway, NJ USA. RP Cleland, JG (reprint author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England. EM j.cleland@imperial.ac.uk RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland, John/0000-0002-1471-7016 FU Merck Research Laboratories, Rahway, NJ FX The study and analyses were funded by Merck Research Laboratories, Rahway, NJ. NR 45 TC 44 Z9 44 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JAN PY 2014 VL 7 IS 1 BP 76 EP 87 DI 10.1161/CIRCHEARTFAILURE.113.000284 PG 12 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AA4ND UT WOS:000331071800011 PM 24281134 ER PT J AU Zheng, JY Yancey, DM Ahmed, MI Wei, CC Powell, PC Shanmugam, M Gupta, H Lloyd, SG McGiffin, DC Schiros, CG Denney, TS Babu, GJ Dell'Italia, LJ AF Zheng, Junying Yancey, Danielle M. Ahmed, Mustafa I. Wei, Chih-Chang Powell, Pamela C. Shanmugam, Mayilvahanan Gupta, Himanshu Lloyd, Steven G. McGiffin, David C. Schiros, Chun G. Denney, Thomas S., Jr. Babu, Gopal J. Dell'Italia, Louis J. TI Increased Sarcolipin Expression and Adrenergic Drive in Humans With Preserved Left Ventricular Ejection Fraction and Chronic Isolated Mitral Regurgitation SO CIRCULATION-HEART FAILURE LA English DT Article DE heart ventricles; mitral valve insufficiency ID CARDIAC-SPECIFIC OVEREXPRESSION; RETICULUM CALCIUM-TRANSPORT; DILATED CARDIOMYOPATHY; EXTRACELLULAR-MATRIX; RECEPTOR BLOCKADE; VOLUME OVERLOAD; HEART-FAILURE; CONTRACTILITY; PROTEIN; ABNORMALITIES AB Background There is currently no therapy proven to attenuate left ventricular (LV) dilatation and dysfunction in volume overload induced by isolated mitral regurgitation (MR). To better understand molecular signatures underlying isolated MR, we performed LV gene expression analyses and overlaid regulated genes into ingenuity pathway analysis in patients with isolated MR. Methods and Results Gene arrays from LV tissue of 35 patients, taken at the time of surgical repair for isolated MR, were compared with 13 normal controls. Cine-MRI was performed in 31 patients before surgery to measure LV function and volume from serial short-axis summation. LV end-diastolic volume was 2-fold (P=0.005) higher in MR patients than in normal controls, and LV ejection fraction was 647% (50%-79%) in MR patients. Ingenuity pathway analysis identified significant activation of pathways involved in -adrenergic, cAMP, and G-protein-coupled signaling, whereas there was downregulation of pathways associated with complement activation and acute phase response. SERCA2a and phospholamban protein were unchanged in MR versus control left ventricles. However, mRNA and protein levels of the sarcoplasmic reticulum Ca2+ ATPase (SERCA) regulatory protein sarcolipin, which is predominantly expressed in normal atria, were increased 12- and 6-fold, respectively. Immunofluorescence analysis confirmed the absence of sarcolipin in normal left ventricles and its marked upregulation in MR left ventricles. Conclusions These results demonstrate alterations in multiple pathways associated with -adrenergic signaling and sarcolipin in the left ventricles of patients with isolated MR and LV ejection fraction >50%, suggesting a beneficial role for -adrenergic blockade in isolated MR. C1 [Wei, Chih-Chang; Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Zheng, Junying; Yancey, Danielle M.; Ahmed, Mustafa I.; Wei, Chih-Chang; Powell, Pamela C.; Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [McGiffin, David C.] Univ Alabama Birmingham, Div Cardiovasc Surg, Birmingham, AL 35294 USA. [Schiros, Chun G.; Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, Auburn, AL 36849 USA. [Shanmugam, Mayilvahanan; Babu, Gopal J.] Univ Med & Dent New Jersey NJMS, Dept Cell Biol & Mol Med, Newark, NJ USA. RP Dell'Italia, LJ (reprint author), Univ Alabama Birmingham, UAB Comprehens Cardiovasc Ctr, Dept Med, Div Cardiol, 434 BMR2,901 19th St S, Birmingham, AL 35294 USA. EM loudell@uab.edu FU National Institutes of Health Specialized Center of Clinically Oriented Research in Cardiac Dysfunction [50-HL077100] FX This work was supported by National Institutes of Health Specialized Center of Clinically Oriented Research in Cardiac Dysfunction 50-HL077100. NR 33 TC 10 Z9 10 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JAN PY 2014 VL 7 IS 1 BP 194 EP 202 DI 10.1161/CIRCHEARTFAILURE.113.000519 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AA4ND UT WOS:000331071800024 PM 24297688 ER PT J AU Johnson, JM Minson, CT Kellogg, DL AF Johnson, John M. Minson, Christopher T. Kellogg, Dean L., Jr. TI Cutaneous Vasodilator and Vasoconstrictor Mechanisms in Temperature Regulation SO COMPREHENSIVE PHYSIOLOGY LA English DT Article ID SKIN BLOOD-FLOW; NITRIC-OXIDE SYNTHASE; AGED HUMAN SKIN; VASOACTIVE-INTESTINAL-PEPTIDE; ACTIVE THERMOREGULATORY VASODILATION; CYCLASE-ACTIVATING POLYPEPTIDE; TYPE-2 DIABETES-MELLITUS; LASER-DOPPLER FLOWMETRY; HUMAN FINGER SKIN; POSTURAL TACHYCARDIA SYNDROME AB In this review, we focus on significant developments in our understanding of the mechanisms that control the cutaneous vasculature in humans, with emphasis on the literature of the last half-century. To provide a background for subsequent sections, we review methods of measurement and techniques of importance in elucidating control mechanisms for studying skin blood flow. In addition, the anatomy of the skin relevant to its thermoregulatory function is outlined. The mechanisms by which sympathetic nerves mediate cutaneous active vasodilation during whole body heating and cutaneous vasoconstriction during whole body cooling are reviewed, including discussions of mechanisms involving cotransmission, NO, and other effectors. Current concepts for the mechanisms that effect local cutaneous vascular responses to local skin warming and cooling are examined, including the roles of temperature sensitive afferent neurons as well as NO and other mediators. Factors that can modulate control mechanisms of the cutaneous vasculature, such as gender, aging, and clinical conditions, are discussed, as are nonthermoregulatory reflex modifiers of thermoregulatory cutaneous vascular responses. (C) 2014 American Physiological Society. C1 [Johnson, John M.; Kellogg, Dean L., Jr.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Minson, Christopher T.] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA. [Kellogg, Dean L., Jr.] Univ Texas Hlth Sci Ctr San Antonio, Geriatr Res Educ & Clin Ctr, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Kellogg, Dean L., Jr.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Minson, CT (reprint author), Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA. EM minson@uoregon.edu FU National Institutes of Health FX The authors acknowledge the contributions of colleagues world-wide whose research contributed to this synthesis. This includes those who provided the important groundwork (John Shepherd and Loring Rowell among many others) and those who made many of the more recent contributions (Lacy Holowatz, Larry Kenney, Craig Crandall, Gary Hodges, and Nicholas Flavahan also among many others). We also acknowledge our colleagues who participated in research in our laboratories. We acknowledge Vienna Brunt and Molly Geiger for their invaluable assistance in the preparation of this review. We also gratefully acknowledge support for the research in our laboratories from the National Institutes of Health. NR 460 TC 53 Z9 53 U1 6 U2 43 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2040-4603 J9 COMPR PHYSIOL JI Compr. Physiol. PD JAN PY 2014 VL 4 IS 1 BP 33 EP 89 DI 10.1002/cphy.c130015 PG 57 WC Physiology SC Physiology GA AA6HL UT WOS:000331199300002 PM 24692134 ER PT J AU Simon, LS Strand, V Bingham, CO Singh, JA AF Simon, Lee S. Strand, Vibeke Bingham, Clifton O., III Singh, Jasvinder A. TI OMERACT 11-International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials Introduction SO JOURNAL OF RHEUMATOLOGY LA English DT Editorial Material C1 [Strand, Vibeke] Stanford Univ, Portola Valley, CA USA. [Bingham, Clifton O., III] Johns Hopkins Univ, Baltimore, MD USA. [Singh, Jasvinder A.] Univ Birmingham, Birmingham VA Med Ctr, Birmingham, MD USA. [Singh, Jasvinder A.] Univ Birmingham, Birmingham VA Med Ctr, Birmingham, MD USA. [Singh, Jasvinder A.] Univ Birmingham, Div Rheumatol, Dept Med, Birmingham, MD USA. [Singh, Jasvinder A.] Univ Birmingham, Div Epidemiol, Birmingham, MD USA. EM lssconsult@aol.com NR 0 TC 1 Z9 1 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD JAN PY 2014 VL 41 IS 1 BP 147 EP 149 DI 10.3899/jrheum.130937 PG 3 WC Rheumatology SC Rheumatology GA AA5QF UT WOS:000331154000024 PM 24382928 ER PT J AU O'Neill, J Rader, T Guillemin, F Boonen, A Christensen, R Lyddiatt, A Pardo, JP Welch, V Singh, JA Tugwell, P AF O'Neill, Jennifer Rader, Tamara Guillemin, Francis Boonen, Annelies Christensen, Robin Lyddiatt, Anne Pardo, Jordi Pardo Welch, Vivian Singh, Jasvinder A. Tugwell, Peter TI Including Health Equity Considerations in Development of Instruments for Rheumatology Research: An Introduction to a Novel OMERACT Paradigm SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE HEALTH EQUITY; MUSCULOSKELETAL CONDITIONS; RHEUMATOLOGY ID CROSS-CULTURAL ADAPTATION; ASSESSMENT QUESTIONNAIRE; ARTHRITIS; GUIDELINES; QUALITY; GOUT; CARE AB The Outcome Measures in Rheumatology (OMERACT) Equity Special Interest Group (SIG) was established in 2008 to create a preliminary core set of outcome measures for clinical trials that can assess equity gaps in healthcare and the effectiveness of interventions to close or narrow gaps between advantaged and disadvantaged populations with musculoskeletal (MSK) conditions. At the OMERACT 11 meeting in 2012, the Equity SIG workshop focused on health assessment scales and their applicability for disadvantaged patients with MSK conditions. The intent was to determine whether the items and domains in 2 common questionnaires, the Health Assessment Questionnaire and the Medical Outcome Study Short Form-36 Survey, are appropriate for the activities and life experiences of certain disadvantaged populations, and whether completion of any of the scales would present a challenge to disadvantaged persons. To generate discussion, we considered the reading level of items in these questionnaires and whether they would be accessible to people with different levels of literacy. The group concluded that the choice of measurement instrument may contribute to "outcome measure generated inequalities" because disadvantaged groups might have difficulty understanding some of the questions. The future work of the Equity SIG will explore the appropriateness of different measurement scales as they relate to inequities in arthritis as well as the risk of exacerbating disadvantages for patients with low literacy. C1 [O'Neill, Jennifer] Univ Ottawa, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada. Univ Lorraine, Nancy, France. Maastricht Univ, Med Ctr, Maastricht, Netherlands. Copenhagen Univ Hosp, Parker Inst, Dept Rheumatol, Copenhagen, Denmark. Birmingham VA Med Ctr, Birmingham, MD USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. Univ Ottawa, Inst Populat Hlth, Clin Epidemiol Program,Dept Med, Ottawa Hosp,Res Inst,Fac Med,Dept Epidemiol & Com, Ottawa, ON K1N 6N5, Canada. RP O'Neill, J (reprint author), Univ Ottawa, Inst Populat Hlth, 1 Stewart St, Ottawa, ON K1N 6N5, Canada. EM Jennifer.ONeill@uottawa.ca OI Tugwell, Peter/0000-0001-5062-0556 FU Canadian Institutes of Health Research; Allergan; Ardea; Savient; Novartis; Takeda FX P. Tugwell is supported in part by the Canadian Institutes of Health Research. J. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Allergan, Ardea, Savient, and Novartis; and (more than $10,000) from Takeda; and an investigator-initiated grant from Savient and Takeda. NR 21 TC 3 Z9 3 U1 0 U2 6 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD JAN PY 2014 VL 41 IS 1 BP 150 EP 152 DI 10.3899/jrheum.130812 PG 3 WC Rheumatology SC Rheumatology GA AA5QF UT WOS:000331154000025 PM 24128775 ER PT J AU Kozlenkov, A Roussos, P Timashpolsky, A Barbu, M Rudchenko, S Bibikova, M Klotzle, B Byne, W Lyddon, R Di Narzo, AF Hurd, YL Koonin, EV Dracheva, S AF Kozlenkov, Alexey Roussos, Panos Timashpolsky, Alisa Barbu, Mihaela Rudchenko, Sergei Bibikova, Marina Klotzle, Brandy Byne, William Lyddon, Rebecca Di Narzo, Antonio Fabio Hurd, Yasmin L. Koonin, Eugene V. Dracheva, Stella TI Differences in DNA methylation between human neuronal and glial cells are concentrated in enhancers and non-CpG sites SO NUCLEIC ACIDS RESEARCH LA English DT Article ID BODY-SPECIFIC METHYLATION; GENOME BROWSER DATABASE; HUMAN PREFRONTAL CORTEX; CENTRAL-NERVOUS-SYSTEM; HUMAN BRAIN; GENE-EXPRESSION; EPIGENETIC MECHANISMS; HISTONE MODIFICATIONS; MAMMALIAN DEVELOPMENT; NETWORK ANALYSIS AB We applied Illumina Human Methylation450K array to perform a genomic-scale single-site resolution DNA methylation analysis in neuronal and nonneuronal (primarily glial) nuclei separated from the orbitofrontal cortex of postmortem human brain. The findings were validated using enhanced reduced representation bisulfite sequencing. We identified thousands of sites differentially methylated (DM) between neuronal and nonneuronal cells. The DM sites were depleted within CpG-island-containing promoters but enriched in predicted enhancers. Classification of the DM sites into those undermethylated in neurons (neuronal type) and those undermethylated in nonneuronal cells (glial type), combined with findings of others that methylation within control elements typically negatively correlates with gene expression, yielded large sets of predicted neuron-specific and nonneuron-specific genes. These sets of predicted genes were in excellent agreement with the available direct measurements of gene expression in human and mouse. We also found a distinct set of DNA methylation patterns that were unique for neuronal cells. In particular, neuronal-type differential methylation was overrepresented in CpG island shores, enriched within gene bodies but not in intergenic regions, and preferentially harbored binding motifs for a distinct set of transcription factors, including neuron-specific activity-dependent factors. Finally, non-CpG methylation was substantially more prevalent in neurons than in nonneuronal cells. C1 [Kozlenkov, Alexey; Roussos, Panos; Timashpolsky, Alisa; Byne, William; Lyddon, Rebecca; Dracheva, Stella] James J Peters VA Med Ctr, Educ & Clin Ctr MIRECC, VISN Mental Illness Res 3, Bronx, NY 10468 USA. [Kozlenkov, Alexey; Roussos, Panos; Byne, William; Lyddon, Rebecca; Hurd, Yasmin L.; Dracheva, Stella] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY USA. [Kozlenkov, Alexey; Roussos, Panos; Byne, William; Lyddon, Rebecca; Hurd, Yasmin L.; Dracheva, Stella] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. [Roussos, Panos; Di Narzo, Antonio Fabio] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA. [Barbu, Mihaela; Rudchenko, Sergei] Hosp Special Surg, Div Res, New York, NY 10021 USA. [Bibikova, Marina; Klotzle, Brandy] Illumina Inc, San Diego, CA USA. [Koonin, Eugene V.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA. RP Dracheva, S (reprint author), James J Peters VA Med Ctr, Educ & Clin Ctr MIRECC, VISN Mental Illness Res 3, Bronx, NY 10468 USA. EM Stella.Dracheva@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU National Institute on Drug Abuse [R21DA031557]; National Institute of Mental Health [R21MH090352]; Hope for Depression Research Foundation; VISN 3 Mental Illness Research, Education and Clinical Center (MIRECC); US Department of Health and Human Services FX National Institute on Drug Abuse [R21DA031557 to S. D.]; National Institute of Mental Health [R21MH090352 to S. D.]; Hope for Depression Research Foundation grants (to S. D.); VISN 3 Mental Illness Research, Education and Clinical Center (MIRECC) (to S. D.). The work was also supported with resources and the use of facilities at the James J Peters VA Medical Center, Bronx, NY; Supported by intramural funds of the US Department of Health and Human Services (to National Library of Medicine) (to E. V. K.). Funding for open access charge: Authors' funding. NR 107 TC 46 Z9 46 U1 4 U2 18 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD JAN PY 2014 VL 42 IS 1 BP 109 EP 127 DI 10.1093/nar/gkt838 PG 19 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AA5KF UT WOS:000331136000016 PM 24057217 ER PT J AU Parikh, NG Junaid, I Sheinkopf, L Randhawa, I Santiago, SM Klaustermeyer, WB AF Parikh, Neil G. Junaid, Imran Sheinkopf, Lee Randhawa, Inderpal Santiago, Silverio M. Klaustermeyer, William B. TI Clinical control in the dual diagnosis of obstructive sleep apnea syndrome and rhinitis: A prospective analysis SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID PERENNIAL ALLERGIC RHINITIS; NASAL OBSTRUCTION; INFLAMMATION; PREVALENCE; RESISTANCE; SURGERY AB Background: Obstructive sleep apnea syndrome (OSAS) and allergic rhinitis (AR) are common coexisting disorders. Upper airway, specifically nasal resistance, is thought to increase during exacerbations of AR and nonallergic rhinitis (NAR), as well as in OSAS. The study objective was to determine if a correlation exists between clinical control of rhinitis and OSAS. Methods: This prospective study followed 43 patients with concurrent OSAS and AR or NAR. OSAS was diagnosed by polysomnography, and AR or NAR was diagnosed by history, skin testing, serum-specific IgE, and total IgE levels. Measurements of control of OSAS included the Epworth Sleepiness Scale (ESS) survey and compliance with continuous positive airway pressure (CPAP) device. Measurements of rhinitis control included Assessment of Nasal Symptom Severity and Assessment of Nonnasal Symptom Severity (NSS refers to both) and Global Assessment of Nasal and Nonnasal Symptom Severity surveys (GSS). Higher NSS scores correlate with more rhinitis symptoms, whereas higher GSS scores correlate with less symptoms. Results: All patients completed the study. There was a positive correlation between ESS and NSS scores (p < 0.001), inverse correlation between ESS and GSS scores (p < 0.001), inverse correlation between CPAP compliance and NSS scores (p < 0.001), and positive correlation between CPAP compliance and GSS scores (p < 0.001). There was no statistically significant difference between the AR, NAR, and AR/NAR groups. Conclusion: Our study showed a statistically significant positive correlation between clinical control of rhinitis symptoms and clinical control of OSAS. This study emphasizes the importance of achieving concurrent optimal control of both OSAS and AR/NAR. C1 [Parikh, Neil G.; Junaid, Imran; Sheinkopf, Lee; Randhawa, Inderpal; Santiago, Silverio M.; Klaustermeyer, William B.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Div Allergy & Immunol, Los Angeles, CA 90073 USA. RP Parikh, NG (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Allergy Immunol 111R, Los Angeles, CA 90073 USA. EM nparikh2009@gmail.com NR 25 TC 6 Z9 6 U1 2 U2 13 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD JAN-FEB PY 2014 VL 28 IS 1 BP E52 EP E55 DI 10.2500/ajra.2014.28.3977 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA AA2WC UT WOS:000330953900010 PM 24717883 ER PT J AU O'Keefe, VM Wingate, LR Tucker, RP Rhoades-Kerswill, S Slish, ML Davidson, CL AF O'Keefe, Victoria M. Wingate, LaRicka R. Tucker, Raymond P. Rhoades-Kerswill, Sarah Slish, Meredith L. Davidson, Collin L. TI Interpersonal Suicide Risk for American Indians: Investigating Thwarted Belongingness and Perceived Burdensomeness SO CULTURAL DIVERSITY & ETHNIC MINORITY PSYCHOLOGY LA English DT Article DE American Indian; Native American; suicide; interpersonal ID PSYCHOLOGICAL THEORY; SOCIAL NETWORKS; SCREENING TOOL; YOUNG-ADULTS; OLDER-ADULTS; IDEATION; ADOLESCENTS; VALIDITY; BEHAVIOR; QUESTIONNAIRE AB American Indians (AIs) experience increased suicide rates compared with other groups in the United States. However, no past studies have examined AI suicide by way of a recent empirically supported theoretical model of suicide. The current study investigated whether AI suicidal ideation can be predicted by two components: thwarted belongingness and perceived burdensomeness, from the Interpersonal-Psychological Theory of Suicide (T. E. Joiner, 2005, Why people die by suicide. Cambridge, MA: Harvard University Press). One hundred seventy-one AIs representing 27 different tribes participated in an online survey. Hierarchical regression analyses showed that perceived burdensomeness significantly predicted suicidal ideation above and beyond demographic variables and depressive symptoms; however, thwarted belongingness did not. Additionally, the two-way interaction between thwarted belongingness and perceived burdensomeness significantly predicted suicidal ideation. These results provide initial support for continued research on the components of the Interpersonal-Psychological Theory of Suicide, an empirically supported theoretical model of suicide, to predict suicidal ideation among AI populations. C1 [O'Keefe, Victoria M.; Wingate, LaRicka R.; Tucker, Raymond P.; Rhoades-Kerswill, Sarah; Slish, Meredith L.] Oklahoma State Univ, Dept Psychol, Stillwater, OK 74078 USA. [Davidson, Collin L.] Denver VA Med Ctr, VISN MIRECC 19, Denver, CO USA. RP Wingate, LR (reprint author), Oklahoma State Univ, Dept Psychol, 116 North Murray Hall, Stillwater, OK 74078 USA. EM laricka.wingate@okstate.edu NR 39 TC 14 Z9 14 U1 2 U2 11 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1099-9809 EI 1939-0106 J9 CULT DIVERS ETHN MIN JI Cult. Divers. Ethn. Minor. Psychol. PD JAN PY 2014 VL 20 IS 1 BP 61 EP 67 DI 10.1037/a0033540 PG 7 WC Ethnic Studies; Psychology, Social SC Ethnic Studies; Psychology GA AA1SN UT WOS:000330876100008 PM 24041264 ER PT J AU Wojnar, DM Katzenmeyer, A AF Wojnar, Danuta M. Katzenmeyer, Amy TI Experiences of Preconception, Pregnancy, and New Motherhood for Lesbian Nonbiological Mothers SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING LA English DT Article DE nonbiological lesbian mothers; pregnancy; descriptive phenomenology ID POSTPARTUM DEPRESSION; CO-MOTHERS; PARENTHOOD; FAMILIES; COUPLES; CHILDBEARING; NEEDS; ADOLESCENTS; TRANSITION; INTERVIEWS AB ObjectiveTo describe the experiences of preconception, pregnancy, and new motherhood from the perspective of lesbian nonbiological mothers. DesignDescriptive phenomenology. SettingA private room at the study site and participants' homes. ParticipantsTwenty-four self-identified lesbian nonbiological mothers in a committed relationship and whose partner gave birth within the past 2years participated. All of the participants were from urban or suburban areas in the Pacific Northwest. MethodsWomen participated in semistructured in person interviews that were audio recorded and transcribed verbatim for analysis. Coliazzi's method guided the process. ResultsAn overarching theme of feeling different permeated the experiences of preconception, pregnancy, and new motherhood for the participants. The women's narratives revealed seven themes that illustrated their experiences: (a) Launching pregnancy: A roller coaster ride; (b) Having legal and biological concerns: Biology prevails; (c) There is a little person in there: Dealing with pregnancy issues; (d) Losing relationships over pregnancy: The elephant in the room; (e) Feeling incomplete as a mother; (f) Carving a unique role: There are very few of us out there; and (g) Sadness and regret: Nonbiological mothers get the postpartum blues, too. ConclusionsThe experience of preconception, pregnancy, and new motherhood for nonbiological lesbian mothers is complicated by the lack of biological and legal substantiation to the infant, few role models, and limited social support. Nurses and health care providers cognizant of these issues can play an important role in facilitating a positive transition to motherhood for this population. C1 [Wojnar, Danuta M.] Seattle Univ, Coll Nursing, Dept Maternal Child & Family Nursing, Seattle, WA 98122 USA. [Katzenmeyer, Amy] VA Puget Sound Hlth Care Syst, Dept Orthoped, Seattle, WA USA. RP Wojnar, DM (reprint author), Seattle Univ, Coll Nursing, 901 12th Ave,POB 222000, Seattle, WA 98122 USA. EM wojnard@seattleu.edu NR 42 TC 7 Z9 7 U1 0 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-2175 EI 1552-6909 J9 JOGNN-J OBST GYN NEO JI JOGNN PD JAN PY 2014 VL 43 IS 1 BP 50 EP 60 DI 10.1111/1552-6909.12270 PG 11 WC Nursing; Obstetrics & Gynecology SC Nursing; Obstetrics & Gynecology GA AA1GI UT WOS:000330844200007 PM 24354595 ER PT J AU Kisiel, C Fehrenbach, T Torgersen, E Stolbach, B McClelland, G Griffin, G Burkman, K AF Kisiel, Cassandra L. Fehrenbach, Tracy Torgersen, Elizabeth Stolbach, Brad McClelland, Gary Griffin, Gene Burkman, Kristine TI Constellations of Interpersonal Trauma and Symptoms in Child Welfare: Implications for a Developmental Trauma Framework SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE Complex trauma; Developmental trauma disorder; Posttraumatic stress; Child; Youth; Caregiver ID POLY-VICTIMIZATION; COMPLEX TRAUMA; POSTTRAUMATIC-STRESS; NATIONAL SAMPLE; YOUNG-CHILDREN; MALTREATMENT; ADOLESCENTS; DISORDER; EXPERIENCES; PREVALENCE AB Patterns of trauma exposure and symptoms were examined in a sample of 16,212 children in Illinois child welfare. Data were collected on trauma histories, child and caregiver needs and strengths, and analyzed in light of the proposed Developmental Trauma Disorder diagnostic criteria. Youth exposed to both interpersonal violence and attachment-based ("non-violent") traumas within the caregiving system had significantly higher levels of affective/physiological, attentional/behavioral, and self/relational dysregulation in addition to posttraumatic stress symptoms compared to youth with either type of trauma alone or in relation to other trauma experiences. These complexly traumatized children exhibited higher levels of functional impairment and were more likely to have placement disruptions and psychiatric hospitalizations. Findings suggest a developmental trauma framework can more adequately capture the spectrum of needs of these multiply traumatized youth than existing diagnostic formulations. Utilizing this framework for assessment, treatment planning, and intervention can lead to more targeted and effective services for these children. C1 [Kisiel, Cassandra L.; Fehrenbach, Tracy; Torgersen, Elizabeth; McClelland, Gary; Griffin, Gene] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA. [Stolbach, Brad] Univ Chicago, Pritzker Sch Med, Dept Pediat, Chicago, IL 60637 USA. [Burkman, Kristine] San Francisco VA Med Ctr, Dept Psychol, San Francisco, CA USA. RP Kisiel, C (reprint author), Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, 710 N Lake Shore Dr,12th Floor, Chicago, IL 60611 USA. EM c-kisiel@northwestern.edu NR 55 TC 8 Z9 8 U1 2 U2 21 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 EI 1573-2851 J9 J FAM VIOLENCE JI J. Fam. Violence PD JAN PY 2014 VL 29 IS 1 BP 1 EP 14 DI 10.1007/s10896-013-9559-0 PG 14 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA AA4QU UT WOS:000331081800001 ER PT J AU Vu, JP Million, M Larauche, M Luong, L Norris, J Waschek, JA Pothoulakis, C Pisegna, JR Germano, PM AF Vu, John P. Million, Mulugeta Larauche, Muriel Luong, Leon Norris, Joshua Waschek, James A. Pothoulakis, Charalabos Pisegna, Joseph R. Germano, Patrizia M. TI Inhibition of Vasoactive Intestinal Polypeptide (VIP) Induces Resistance to Dextran Sodium Sulfate (DSS)-Induced Colitis in Mice SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE VIP; Colitis; VIP antagonist: IBD ID INFLAMMATORY-BOWEL-DISEASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DIFFERENTIAL EXPRESSION; CROHNS-DISEASE; RECEPTOR ANTAGONIST; ULCERATIVE-COLITIS; CANCER GROWTH; PEPTIDE VIP; IN-VIVO; CELLS AB VIP is highly expressed in the colon and regulates motility, vasodilatation, and sphincter relaxation. However, its role in the development and progress of colitis is still controversial. Our aim was to determine the participation of VIP on dextran sodium sulfate (DSS)-induced colonic mucosal inflammation using VIP-/- and WT mice treated with VIP antagonists. Colitis was induced in 32 adult VIP-/- and 14 age-matched WT litter-mates by giving 2.5 % DSS in the drinking water. DSS-treated WT mice were injected daily with VIP antagonists, VIPHyb (n = 22), PG 97-269 (n = 9), or vehicle (n = 31). After euthanasia, colons were examined; colonic cytokines mRNA were quantified. VIP-/- mice were remarkably resistant to DSS-induced colitis compared to WT. Similarly, DSS-treated WT mice injected with VIPHyb (1 mu M) or PG 97-269 (1 nM) had significantly reduced clinical signs of colitis. Furthermore, colonic expression of IL-1I, TNF-alpha, and IL-6 was significantly lower in VIP-/- and VIPHyb or PG 97-269 compared to vehicle-treated WT. Genetic deletion of VIP or pharmacological inhibition of VIP receptors resulted in resistance to colitis. These data demonstrate a pro-inflammatory role for VIP in murine colitis and suggest that VIP antagonists may be an effective clinical treatment for human inflammatory bowel diseases. C1 [Vu, John P.; Million, Mulugeta; Larauche, Muriel; Luong, Leon; Norris, Joshua; Waschek, James A.; Pothoulakis, Charalabos; Pisegna, Joseph R.; Germano, Patrizia M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Vu, John P.; Million, Mulugeta; Larauche, Muriel; Luong, Leon; Norris, Joshua; Waschek, James A.; Pothoulakis, Charalabos; Pisegna, Joseph R.; Germano, Patrizia M.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Waschek, James A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA. [Germano, Patrizia M.] VA Greater Los Angeles Healthcare Syst, Div Pulm & Crit Care, Dept Med, Los Angeles, CA USA. [Pothoulakis, Charalabos] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90095 USA. [Pisegna, Joseph R.] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Dept Med, Los Angeles, CA USA. [Germano, Patrizia M.] CURE UCLA West Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Germano, PM (reprint author), CURE UCLA West Los Angeles VA Healthcare Syst, Bldg 115,Rm 313, Los Angeles, CA USA. EM pgermano@ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU Department of Veterans Affairs Merit Review; NIH [DK-41301]; RO1 [DK-078676] FX Department of Veterans Affairs Merit Review (PG, JP) NIH DK-41301 & RO1 DK-078676 (MM) NR 46 TC 8 Z9 8 U1 0 U2 5 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 EI 1559-1166 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD JAN PY 2014 VL 52 IS 1 BP 37 EP 47 DI 10.1007/s12031-013-0205-3 PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA AA1LN UT WOS:000330857900005 PM 24395090 ER PT J AU Stappenbeck, CA Hellmuth, JC Simpson, T Jakupcak, M AF Stappenbeck, Cynthia A. Hellmuth, Julianne C. Simpson, Tracy Jakupcak, Matthew TI The Effects of Alcohol Problems, PTSD, and Combat Exposure on Nonphysical and Physical Aggression Among Iraq and Afghanistan War Veterans SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE Iraq and Afghanistan war veterans; aggression; PTSD; combat exposure; alcohol problems ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; MILITARY VETERANS; VIETNAM VETERANS; UNITED-STATES; INTERPERSONAL VIOLENCE; CONCEPTUAL-FRAMEWORK; HISPANIC COUPLES; CONDUCT PROBLEMS; PERPETRATION AB Aggression among combat veterans is of great concern. Although some studies have found an association between combat exposure and aggressive behavior following deployment, others conclude that aggression is more strongly associated with symptoms of posttraumatic stress disorder (PTSD), and that alcohol misuse may influence this association. Many of these studies have assessed aggression as a single construct, whereas the current study explored both nonphysical aggression only and physical aggression in a sample of Iraq and Afghanistan war veterans (N = 337; 91% male). We found that alcohol problems interacted with PTSD symptom severity to predict nonphysical aggression only. At low levels of PTSD symptoms, veterans with alcohol problems were more likely to perpetrate nonphysical aggression only, as compared with no aggression, than veterans without an alcohol problem. There was no difference in the likelihood of nonphysical aggression only between those with and without alcohol problems at high levels of PTSD symptoms. The likelihood of nonphysical aggression only, as compared with no aggression, was also greater among younger veterans. Greater combat exposure and PTSD symptom severity were associated with an increased likelihood of perpetrating physical aggression, as compared with no aggression. Ethnic minority status and younger age were also associated with physical aggression, as compared with no aggression. Findings suggest that a more detailed assessment of veterans' aggressive behavior, as well as their alcohol problems and PTSD symptoms, by researchers and clinicians is needed in order to determine how best to intervene. C1 [Stappenbeck, Cynthia A.; Hellmuth, Julianne C.; Simpson, Tracy; Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Stappenbeck, Cynthia A.; Simpson, Tracy; Jakupcak, Matthew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA. RP Stappenbeck, CA (reprint author), Univ Washington, Dept Psychiat & Behav Sci, 1107 NE 45th St Suite 201, Seattle, WA 98105 USA. EM cstappen@uw.edu FU NIDA NIH HHS [T32 DA019426] NR 66 TC 6 Z9 6 U1 3 U2 13 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD JAN PY 2014 VL 6 IS 1 BP 65 EP 72 DI 10.1037/a0031468 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AA1HN UT WOS:000330847300008 PM 25225593 ER PT J AU Jakupcak, M Blais, RK Grossbard, J Garcia, H Okiishi, J AF Jakupcak, Matthew Blais, Rebecca K. Grossbard, Joel Garcia, Hector Okiishi, John TI "Toughness" in Association With Mental Health Symptoms Among Iraq and Afghanistan War Veterans Seeking Veterans Affairs Health Care SO PSYCHOLOGY OF MEN & MASCULINITY LA English DT Article DE Iraq/Afghanistan Veterans; emotional toughness; gender norms ID HELP-SEEKING; SELF-REPORT; MASCULINITY; COMBAT; PTSD; STRESS; NORMS AB The association between endorsement of emotional "toughness" (i.e., extreme self-reliance and the suppression of outward displays of emotional distress) and likelihood for screening positive for mental health conditions was examined in a male sample of 198 Iraq and Afghanistan veterans presenting for postdeployment Veteran Affairs health care. After accounting for relevant covariates, veterans endorsing higher levels of emotional toughness were more likely to screen positive for posttraumatic stress disorder and depression. There was also a nonsignificant trend (p = .08) associated with a positive relationship between toughness and likelihood of self-reported alcohol abuse. Results are discussed in terms of identifying and addressing toughness norms among returning veterans to promote effective use of mental health services. C1 [Jakupcak, Matthew; Blais, Rebecca K.; Grossbard, Joel] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Jakupcak, Matthew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Blais, Rebecca K.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA. [Grossbard, Joel] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Garcia, Hector] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Garcia, Hector] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. [Okiishi, John] Joint Base Lewis McCord, Tacoma, WA USA. RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, 1660 South Columbia Way, Seattle, WA 98108 USA. EM matthew.jakupcak@va.gov NR 29 TC 7 Z9 7 U1 1 U2 3 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1524-9220 EI 1939-151X J9 PSYCHOL MEN MASCULIN JI Psychol. Men Masculinity PD JAN PY 2014 VL 15 IS 1 BP 100 EP 104 DI 10.1037/a0031508 PG 5 WC Psychology, Social SC Psychology GA AA1GW UT WOS:000330845600013 ER PT J AU Kaunitz, JD AF Kaunitz, Jonathan D. TI Introduction to the 80th Anniversary Issue SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material C1 Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA. RP Kaunitz, JD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA. EM Jonathan.Kaunitz@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JAN PY 2014 VL 59 IS 1 BP 1 EP 1 DI 10.1007/s10620-013-3009-y PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 302ES UT WOS:000330585500001 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI Dental Implant Cone Beam Scans of Older Individuals Often Reveal Potentially Life-Threatening Atherosclerotic Disease SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS LA English DT Editorial Material ID STROKE C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 7 TC 0 Z9 0 U1 0 U2 1 PU QUINTESSENCE PUBLISHING CO INC PI HANOVER PARK PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA SN 0882-2786 EI 1942-4434 J9 INT J ORAL MAX IMPL JI Int. J. Oral Maxillofac. Implants PD JAN-FEB PY 2014 VL 29 IS 1 BP 19 EP 20 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 304ME UT WOS:000330750200001 PM 24451850 ER PT J AU Tsai, TT Patel, UD Chang, TI Kennedy, KF Masoudi, FA Matheny, ME Kosiborod, M Amin, AP Messenger, JC Rumsfeld, JS Spertus, JA AF Tsai, Thomas T. Patel, Uptal D. Chang, Tara I. Kennedy, Kevin F. Masoudi, Frederick A. Matheny, Michael E. Kosiborod, Mikhail Amin, Amit P. Messenger, John C. Rumsfeld, John S. Spertus, John A. TI Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE acute kidney injury; PCI; stent(s) ID CONTRAST-INDUCED NEPHROPATHY; ACUTE MYOCARDIAL-INFARCTION; ACUTE-RENAL-FAILURE; CARDIOVASCULAR DATA REGISTRY; INTENSIVE-CARE-UNIT; SERUM CREATININE; REQUIRING DIALYSIS; HOSPITALIZED-PATIENTS; REPLACEMENT THERAPY; RISK-FACTORS AB Objectives This study sought to examine the contemporary incidence, predictors and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions. Background Acute kidney injury (AKI) is a serious and potentially preventable complication of percutaneous coronary interventions (PCIs) that is associated with adverse outcomes. The contemporary incidence, predictors, and outcomes of AKI are not well defined, and clarifying these can help identify high-risk patients for proactive prevention. Methods A total of 985,737 consecutive patients underwent PCIs at 1,253 sites participating in the National Cardiovascular Data Registry Cath-PCI registry from June 2009 through June 2011. AKI was defined on the basis of changes in serum creatinine level in the hospital according to the Acute Kidney Injury Network (AKIN) criteria. Using multivariable regression analyses with generalized estimating equations, we identified patient characteristics associated with AKI. Results Overall, 69,658 (7.1%) patients experienced AKI, with 3,005 (0.3%) requiring new dialysis. On multivariable analyses, the factors most strongly associated with development of AKI included ST-segment elevation myocardial infarction (STEMI) presentation (odds ratio [OR]: 2.60; 95% confidence interval [CI]: 2.53 to 2.67), severe chronic kidney disease (OR: 3.59; 95% CI: 3.47 to 3.71), and cardiogenic shock (OR: 2.92; 95% CI: 2.80 to 3.04). The in-hospital mortality rate was 9.7% for patients with AKI and 34% for those requiring dialysis compared with 0.5% for patients without AKI (p < 0.001). After multivariable adjustment, AKI (OR: 7.8; 95% CI: 7.4 to 8.1, p< 0.001) and dialysis (OR: 21.7; 95% CI: 19.6 to 24.1; p< 0.001) remained independent predictors of in-hospital mortality. Conclusions Approximately 7% of patients undergoing a PCI experience AKI, which is strongly associated with in-hospital mortality. Defining strategies to minimize the risk of AKI in patients undergoing PCI are needed to improve the safety and outcomes of the procedure. (C) 2014 by the American College of Cardiology Foundation C1 [Tsai, Thomas T.; Masoudi, Frederick A.; Messenger, John C.; Rumsfeld, John S.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Tsai, Thomas T.] Univ Colorado, Denver, CO 80202 USA. [Patel, Uptal D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Chang, Tara I.] Stanford Sch Med, Palo Alto, CA USA. [Kennedy, Kevin F.; Kosiborod, Mikhail; Amin, Amit P.; Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Kennedy, Kevin F.; Kosiborod, Mikhail; Amin, Amit P.; Spertus, John A.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Matheny, Michael E.] Tennesse Vallry Hlth Syst VA, Nashville, TN USA. [Matheny, Michael E.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. RP Tsai, TT (reprint author), Univ Colorado Denver, Kaiser Permanente Colorado, Inst Hlth Res, 280 Exempla Circle, Lafayette, CO 80026 USA. EM thomas.tsai@coloradooutcomes.org FU NIDDK NIH HHS [T32 DK007357] NR 45 TC 76 Z9 81 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JAN PY 2014 VL 7 IS 1 BP 1 EP 9 DI 10.1016/j.jcin.2013.06.016 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AA2VU UT WOS:000330953100003 PM 24456715 ER PT J AU Alcalay, RN Caccappolo, E Mejia-Santana, H Tang, MX Rosado, L Reilly, MO Ruiz, D Louis, ED Comella, CL Nance, MA Bressman, SB Scott, WK Tanner, CM Mickel, SF Waters, CH Fahn, S Cote, LJ Frucht, SJ Ford, B Rezak, M Novak, KE Friedman, JH Pfeiffer, RF Marsh, L Hiner, B Payami, H Molho, E Factor, SA Nutt, JG Serrano, C Arroyo, M Ottman, R Pauciulo, MW Nichols, WC Clark, LN Marder, KS AF Alcalay, Roy N. Caccappolo, Elise Mejia-Santana, Helen Tang, Ming Xin Rosado, Llency Reilly, Martha Orbe Ruiz, Diana Louis, Elan D. Comella, Cynthia L. Nance, Martha A. Bressman, Susan B. Scott, William K. Tanner, Caroline M. Mickel, Susan F. Waters, Cheryl H. Fahn, Stanley Cote, Lucien J. Frucht, Steven J. Ford, Blair Rezak, Michael Novak, Kevin E. Friedman, Joseph H. Pfeiffer, Ronald F. Marsh, Laura Hiner, Bradley Payami, Haydeh Molho, Eric Factor, Stewart A. Nutt, John G. Serrano, Carmen Arroyo, Maritza Ottman, Ruth Pauciulo, Michael W. Nichols, William C. Clark, Lorraine N. Marder, Karen S. TI Cognitive and Motor Function in Long-Duration PARKIN-Associated Parkinson Disease SO JAMA NEUROLOGY LA English DT Article ID EARLY-ONSET PD; MUTATIONS; FREQUENCY; DEMENTIA; DECLINE; ENTITY; GENE AB IMPORTANCE Data on the long-term cognitive outcomes of patients with PARKIN-associated Parkinson disease (PD) are unknown but may be useful when counseling these patients. OBJECTIVE Among patients with early-onset PD of long duration, we assessed cognitive and motor performances, comparing homozygotes and compound heterozygotes who carry 2 PARKIN mutations with noncarriers. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of 44 participants at 17 different movement disorder centers who were in the Consortium on Risk for Early-Onset PD study with a duration of PD greater than the median duration (>14 years): 4 homozygotes and 17 compound heterozygotes (hereafter referred to as carriers) and 23 noncarriers. MAIN OUTCOMES AND MEASURES Unified Parkinson Disease Rating Scale Part III (UPDRS-III) and Clinical Dementia Rating scores and neuropsychological performance. Linear regression models were applied to assess the association between PARKIN mutation status and cognitive domain scores and UPDRS-III scores. Models were adjusted for age, education, disease duration, language, and levodopa equivalent daily dose. RESULTS Carriers had an earlier age at onset of PD (P < .001) and were younger (P = .004) at time of examination than noncarriers. They performed better than noncarriers on the Mini-Mental State Examination (P = .010) and were more likely to receive lower scores on the Clinical Dementia Rating (P = .003). In multivariate analyses, carriers performed better than noncarriers on the UPDRS-III (P = .02) and on tests of attention (P = .03), memory (P = .03), and visuospatial (P = .02) cognitive domains. CONCLUSIONS AND RELEVANCE In cross-sectional analyses, carriers demonstrated better cognitive and motor performance than did noncarriers with long disease duration, suggesting slower disease progression. A longitudinal follow-up study is required to confirm these findings. C1 [Alcalay, Roy N.; Caccappolo, Elise; Mejia-Santana, Helen; Tang, Ming Xin; Rosado, Llency; Reilly, Martha Orbe; Ruiz, Diana; Louis, Elan D.; Waters, Cheryl H.; Fahn, Stanley; Cote, Lucien J.; Frucht, Steven J.; Ford, Blair; Ottman, Ruth; Marder, Karen S.] Columbia Univ, Dept Neurol, Coll Phys & Surg, New York, NY 10032 USA. [Alcalay, Roy N.; Tang, Ming Xin; Louis, Elan D.; Clark, Lorraine N.; Marder, Karen S.] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, Coll Phys & Surg, New York, NY 10032 USA. [Louis, Elan D.; Cote, Lucien J.; Ottman, Ruth; Marder, Karen S.] Columbia Univ, Gertrude H Sergievsky Ctr, Coll Phys & Surg, New York, NY 10032 USA. [Louis, Elan D.; Ottman, Ruth] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Comella, Cynthia L.] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. [Nance, Martha A.] Struthers Parkinsons Ctr, Pk Nicollet Clin, Golden Valley, MN USA. [Bressman, Susan B.] Beth Israel Deaconess Med Ctr, Alan & Barbara Mirken Dept Neurol, New York, NY 10003 USA. [Bressman, Susan B.] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA. [Scott, William K.] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn, Dept Human Genet,Miami Inst Human Genom, Miami, FL 33136 USA. [Tanner, Caroline M.] Parkinsons Inst, Sunnyvale, CA USA. [Tanner, Caroline M.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. [Mickel, Susan F.] Marshfield Clin Fdn Med Res & Educ, Dept Neurol, Marshfield Clin, Marshfield, WI 54449 USA. [Rezak, Michael] Cent DuPage Hosp, Inst Neurosci, Movement Disorders Ctr, Winfield, IL USA. [Novak, Kevin E.] NorthShore Univ Hlth Syst, Dept Neurol, Evanston, IL USA. [Novak, Kevin E.] Univ Chicago, Dept Neurol, Pritzker Sch Med, Chicago, IL 60637 USA. [Friedman, Joseph H.] Butler Hosp, Dept Neurol, Providence, RI 02906 USA. [Friedman, Joseph H.] Brown Univ, Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA. [Pfeiffer, Ronald F.] Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Coll Med, Memphis, TN USA. [Marsh, Laura] Johns Hopkins Univ, Sch Med, Morris K Udall Parkinsons Dis Res Ctr Excellence, Baltimore, MD USA. [Marsh, Laura] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Marsh, Laura] Johns Hopkins Univ, Sch Med, Dept Neurol & Neurol Sci, Baltimore, MD USA. [Hiner, Bradley] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA. [Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Molho, Eric] Albany Med Ctr, Parkinsons Dis & Movement Disorders Ctr, Albany, NY USA. [Factor, Stewart A.] Emory Univ, Dept Neurol, Atlanta, GA USA. [Nutt, John G.] Parkinson Dis Res Educ & Clin Ctr, Portland VA Med Ctr, Portland, OR USA. [Nutt, John G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Serrano, Carmen; Arroyo, Maritza] Univ Puerto Rico, Dept Neurol, San Juan, PR 00936 USA. [Ottman, Ruth] New York State Psychiat Inst & Hosp, Div Epidemiol, New York, NY 10032 USA. [Pauciulo, Michael W.; Nichols, William C.] Univ Cincinnati, Coll Med, Div Human Genet, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA. [Pauciulo, Michael W.; Nichols, William C.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA. [Clark, Lorraine N.] Columbia Univ, Dept Pathol & Cell Biol, Coll Phys & Surg, New York, NY 10032 USA. [Clark, Lorraine N.] Columbia Univ, Ctr Human Genet, Coll Phys & Surg, New York, NY 10032 USA. [Marder, Karen S.] Columbia Univ, Dept Psychiat, Med Ctr, New York, NY 10032 USA. RP Alcalay, RN (reprint author), Columbia Univ, Dept Neurol, Coll Phys & Surg, 710 W 168th St, New York, NY 10032 USA. EM rna2104@columbia.edu RI Ottman, Ruth/O-2371-2013 OI Ottman, Ruth/0000-0001-7074-242X FU Scott; Marder; Clark; Payami; Fahn FX Obtained funding: Scott, Fahn, Payami, Clark, Marder. NR 28 TC 14 Z9 15 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD JAN PY 2014 VL 71 IS 1 BP 62 EP 67 DI 10.1001/jamaneurol.2013.4498 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 301YH UT WOS:000330567700010 PM 24190026 ER PT J AU Lu, PH Lee, GJ Shapira, J Jimenez, E Mather, MJ Thompson, PM Bartzokis, G Mendez, MF AF Lu, Po H. Lee, Grace J. Shapira, Jill Jimenez, Elvira Mather, Michelle J. Thompson, Paul M. Bartzokis, George Mendez, Mario F. TI Regional Differences in White Matter Breakdown Between Frontotemporal Dementia and Early-Onset Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; behavioral variant; diffusion tensor imaging; early onset; frontotemporal dementia; magnetic resonance imaging; myelin; white matter ID MYELINATED NERVE-FIBERS; MILD COGNITIVE IMPAIRMENT; DIFFUSION TENSOR MRI; LOBAR DEGENERATION; HUMAN BRAIN; RHESUS-MONKEY; AGE; ATROPHY; CORTEX; HUMANS AB Background: White matter abnormalities have been associated with both behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD). Objective: Using MRI diffusion tensor imaging (DTI) measures, we compared white matter integrity between patients with bvFTD and those with early-onset AD and correlated these biomarkers with behavioral symptoms involving emotional blunting. Methods: We studied 8 bvFTD and 12 AD patients as well as 12 demographically-matched healthy controls (NCs). Using four DTI metrics (fractional anisotropy, axial diffusivity, radial diffusivity, and mean diffusivity), we assessed the frontal lobes (FWM) and genu of the corpus callosum (GWM), which are vulnerable late-myelinating regions, and a contrasting early-myelinating region (splenium of the corpus callosum). The Scale for Emotional Blunting Scale (SEB) was used to assess emotional functioning of the study participants. Results: Compared to AD patients and NCs, the bvFTD subjects exhibited significantly worse FWM and GWM integrity on all four DTI metrics sensitive to myelin and axonal integrity. In contrast, AD patients showed a numerical trend toward worse splenium of the corpus callosum integrity than bvFTD and NC groups. Significant associations between SEB ratings and GWM DTI measures were demonstrated in the combined bvFTD and AD sample. When examined separately, these relationships remained robust for the bvFTD group but not the AD group. Conclusions: The regional DTI alterations suggest that FTD and AD are each associated with a characteristic distribution of white matter degradation. White matter breakdown in late-myelinating regions was associated with symptoms of emotional blunting, particularly within the bvFTD group. C1 [Lu, Po H.; Shapira, Jill; Jimenez, Elvira; Thompson, Paul M.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Lee, Grace J.] Loma Linda Univ, Sch Behav Hlth, Dept Psychol, Loma Linda, CA 92350 USA. [Shapira, Jill; Jimenez, Elvira; Mather, Michelle J.; Mendez, Mario F.] Greater Los Angeles VA Healthcare Syst, West Los Angeles, CA USA. [Thompson, Paul M.; Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuroimaging, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Lu, PH (reprint author), 710 Westwood Plaza,RNRC 2-258, Los Angeles, CA 90095 USA. EM plu@mednet.ucla.edu FU NIH from the National Institute of Aging (NIA) [K23-AG028727, R01-AG034499]; Alzheimer's Disease Research Center [P50 AG-16570]; California Alzheimer's Disease Centers; Department of Veterans Affairs FX This work was supported by NIH grants K23-AG028727 and R01-AG034499 from the National Institute of Aging (NIA), the Alzheimer's Disease Research Center grant P50 AG-16570, California Alzheimer's Disease Centers, and the Department of Veterans Affairs. NR 59 TC 8 Z9 8 U1 0 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2014 VL 39 IS 2 BP 261 EP 269 DI 10.3233/JAD-131481 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 304HZ UT WOS:000330739000006 PM 24150110 ER PT J AU Maggiore, RJ Gorawara-Bhat, R Levine, SK Dale, W AF Maggiore, Ronald J. Gorawara-Bhat, Rita Levine, Stacie K. Dale, William TI Perceptions, attitudes, and experiences of hematology/oncology fellows toward incorporating geriatrics in their training SO JOURNAL OF GERIATRIC ONCOLOGY LA English DT Article DE Geriatrics; Education; Training; Hematology/Oncology; Fellowship ID INTERNAL-MEDICINE-RESIDENTS; CANCER; KNOWLEDGE; COMPETENCES; CURRICULUM; CONSENSUS; OLDER AB The aging of the U.S. population continues to highlight emerging issues in providing care generally for older adults and specifically for older adults with cancer. The majority of patients with cancer in the U.S. are currently 65 years of age or older; therefore, training and research in geriatrics and geriatric oncology are viewed to be integral in meeting the needs of this vulnerable population. Yet, the ways to develop and integrate best geriatrics training within the context of hematology/oncology fellowship remain unclear. Toward this end, the current study seeks to evaluate the prior and current geriatric experiences and perspectives of hematology/oncology fellows. To gain insight into these experiences, focus groups of hematology/oncology fellows were conducted. Emergent themes included: 1) perceived lack of formal geriatric oncology didactics among fellows; 2) a considerable amount of variability exists in pre-fellowship geriatric experiences; 3) shared desire to participate in a geriatric oncology-based clinic; 4) differences across training levels in confidence in managing older adults with cancer; and 5) identification of specific criteria on how best to approach older adults with cancer in a particular clinical scenario. The present findings will help guide future studies in evaluating geriatrics among hematology/oncology fellows across institutions. They will also have implications in the development of geriatrics curricula and competencies specific to hematology/oncology training. Published by Elsevier Ltd. C1 [Maggiore, Ronald J.; Gorawara-Bhat, Rita; Levine, Stacie K.; Dale, William] Univ Chicago, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA. [Maggiore, Ronald J.; Dale, William] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA. RP Maggiore, RJ (reprint author), Portland VA Med Ctr, 3710 US Vet Hosp Rd,P3MED, Portland, OR 97239 USA. EM maggiore@ohsu.edu; stacie.levine@uchospitals.edu FU John A. Hartford Foundation of Center of Excellence in Geriatrics FX Supported by the auspices from the John A. Hartford Foundation of Center of Excellence in Geriatrics. NR 18 TC 3 Z9 3 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1879-4068 EI 1879-4076 J9 J GERIATR ONCOL JI J. Geriatr. Oncol. PD JAN PY 2014 VL 5 IS 1 BP 106 EP 115 DI 10.1016/j.jgo.2013.10.003 PG 10 WC Oncology; Geriatrics & Gerontology SC Oncology; Geriatrics & Gerontology GA AA0XJ UT WOS:000330820400014 PM 24484724 ER PT J AU Sadasivam, RS Luger, TM Coley, HL Taylor, BB Padir, T Ritchie, CS Houston, TK AF Sadasivam, Rajani S. Luger, Tana M. Coley, Heather L. Taylor, Benjamin B. Padir, Taskin Ritchie, Christine S. Houston, Thomas K. TI Robot-assisted home hazard assessment for fall prevention: a feasibility study SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID OLDER-ADULTS; CARE; TECHNOLOGY; IMPAIRMENT; SIMULATION; MOBILITY; DESIGN AB We examined the feasibility of using a remotely manoeuverable robot to make home hazard assessments for fall prevention. We employed use-case simulations to compare robot assessments with in-person assessments. We screened the homes of nine elderly patients (aged 65 years or more) for fall risks using the HEROS screening assessment. We also assessed the participants' perspectives of the remotely-operated robot in a survey. The nine patients had a median Short Blessed Test score of 8 (interquartile range, IQR 2-20) and a median Life-Space Assessment score of 46 (IQR 27-75). Compared to the in-person assessment (mean = 4.2 hazards identified per participant), significantly more home hazards were perceived in the robot video assessment (mean = 7.0). Only two checklist items (adequate bedroom lighting and a clear path from bed to bathroom) had more than 60% agreement between in-person and robot video assessment. Participants were enthusiastic about the robot and did not think it violated their privacy. The study found little agreement between the in-person and robot video hazard assessments. However, it identified several research questions about how to best use remotely-operated robots. C1 [Sadasivam, Rajani S.; Houston, Thomas K.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA 01655 USA. [Sadasivam, Rajani S.; Luger, Tana M.; Houston, Thomas K.] Bedford VAMC, VA E Hlth Qual Enhancement Res Initiat, Bedford, MA USA. [Luger, Tana M.; Houston, Thomas K.] Bedford VAMC, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Coley, Heather L.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL USA. [Taylor, Benjamin B.] Univ Alabama Birmingham, Div Gen Internal Med, Dept Med, Birmingham, AL USA. [Padir, Taskin] Worcester Polytech Inst, Dept Elect & Comp Engn, Worcester, MA USA. [Ritchie, Christine S.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA. [Ritchie, Christine S.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Sadasivam, RS (reprint author), Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, 368 Plantat St, Worcester, MA 01655 USA. EM Rajani.Sadasivam@umassmed.edu FU National Institute on Aging [P30AG031054]; National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000161]; National Cancer Institute Career Development Award [K07CA172677] FX The work was supported by the National Institute on Aging (award number P30AG031054) and the National Center for Advancing Translational Sciences of the National Institutes of Health (award number UL1TR000161). Dr Sadasivam is also funded by a National Cancer Institute Career Development Award (K07CA172677). The paper does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health, or the Department of Veterans Affairs or the United States government. NR 19 TC 3 Z9 3 U1 4 U2 10 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1357-633X EI 1758-1109 J9 J TELEMED TELECARE JI J. Telemed. Telecare PD JAN PY 2014 VL 20 IS 1 BP 3 EP 10 DI 10.1177/1357633X13517350 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 302OE UT WOS:000330613200001 PM 24352900 ER PT J AU Karavan, M Compton, N Knezevich, S Raugi, G Kodama, S Taylor, L Reiber, GE AF Karavan, Mahsa Compton, Nicholas Knezevich, Stevan Raugi, Gregory Kodama, Samantha Taylor, Leslie Reiber, Gayle E. TI Teledermatology in the diagnosis of melanoma SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID CUTANEOUS MALIGNANT-MELANOMA; FORWARD TELEDERMATOLOGY; MANAGEMENT; DERMATOLOGISTS; LESIONS; TRIAGE AB We conducted a retrospective chart review of US Veterans in the Pacific Northwest area to compute melanoma incidence and Breslow depth at diagnosis. We compared Veterans with access to teledermatology (TD) and those without (non-TD). We identified pathology-confirmed primary melanomas in Veterans who had had at least one encounter at a VA facility during a 3-year study period. The age-adjusted melanoma incidence for all, TD and non-TD Veterans was 36, 15 and 57 per 100,000, respectively. The mean Breslow depth was significantly greater in the TD group (P = 0.03). Although a higher proportion of thin (Breslow depth <= 1 mm) TD melanomas were mitotically active, this difference was not significant. We also found that 180 (40%) of the non-TD (face-to-face) diagnosed melanomas were from Veterans living in areas where TD was available. This suggests that the higher melanoma incidence in the non-TD group was mainly due to under-utilization of TD services. The study demonstrated that the TD service was not fully utilized in the VISN20 region, although the reasons for this are not clear. Where TD was utilized it tended to diagnose more advanced melanomas with worse initial prognosis. C1 [Karavan, Mahsa; Kodama, Samantha; Taylor, Leslie; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA. [Compton, Nicholas; Raugi, Gregory] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Div Dermatol, Specialty Care Serv, Seattle, WA USA. [Knezevich, Stevan] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Div Pathol, Seattle, WA USA. [Karavan, Mahsa; Compton, Nicholas; Raugi, Gregory] Univ Washington, Sch Med, Seattle, WA USA. [Knezevich, Stevan] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Reiber, GE (reprint author), 1100 Olive Way 1400, Seattle, WA 98101 USA. EM Gayle.Reiber@va.gov FU US Department of Veterans Affairs; VISN20 Office of Rural Health Services; Health Services Research and Development Center of Excellence; VA Puget Sound Health Care System; Career Scientist Award of Dr Gayle Reiber [RCS 98-353] FX The work was supported by the US Department of Veterans Affairs, VISN20 Office of Rural Health Services, Health Services Research and Development Center of Excellence, VA Puget Sound Health Care System, and the Career Scientist Award of Dr Gayle Reiber (RCS 98-353). NR 21 TC 2 Z9 2 U1 0 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1357-633X EI 1758-1109 J9 J TELEMED TELECARE JI J. Telemed. Telecare PD JAN PY 2014 VL 20 IS 1 BP 18 EP 23 DI 10.1177/1357633X13517354 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 302OE UT WOS:000330613200003 PM 24352898 ER PT J AU Iyer, RS Lam, DL Bhargava, P Stern, EJ Wood, BP Paladin, AM AF Iyer, Ramesh S. Lam, Diana L. Bhargava, Puneet Stern, Eric J. Wood, Beverly P. Paladin, Angelisa M. TI Implementing and Refining a Faculty-Resident Mentorship Program SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material ID ACADEMIC MEDICINE; RADIOLOGY C1 [Iyer, Ramesh S.; Paladin, Angelisa M.] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA. [Lam, Diana L.; Stern, Eric J.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA. [Wood, Beverly P.] Univ So Calif, Dept Radiol, Keck Sch Med, Los Angeles, CA USA. RP Iyer, RS (reprint author), Univ Washington, Sch Med, Seattle Childrens Hosp, 4800 Sand Point Way NE, Seattle, WA 98105 USA. EM riyer@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 14 TC 0 Z9 0 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JAN PY 2014 VL 11 IS 1 BP 85 EP 87 DI 10.1016/j.jacr.2013.02.006 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 303NS UT WOS:000330681800020 PM 23583083 ER PT J AU Daskalakis, NP Diamantopoulou, A Claessens, SEF Remmers, E Tjalve, M Oitzl, MS Champagne, DL de Kloet, ER AF Daskalakis, Nikolaos P. Diamantopoulou, Anastasia Claessens, Sanne E. F. Remmers, Elisa Tjalve, Marika Oitzl, Melly S. Champagne, Danielle L. de Kloet, E. Ronald TI Early experience of a novel-environment in isolation primes a fearful phenotype characterized by persistent amygdala activation SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Maternal separation; Novelty stress; Amygdala; c-Fos; ACTH; Corticosterone; Social play; Short-term memory; Fear-conditioning ID PITUITARY-ADRENAL AXIS; EARLY-LIFE STRESS; MATERNAL-CARE; SPATIAL MEMORY; POSTNATAL-DEVELOPMENT; NATURAL VARIATIONS; NEONATAL-RATS; BRAIN-REGIONS; SOCIAL PLAY; ADULT RATS AB Prolonged maternal separation (MS) activates the neonate's hypothalamus-pituitary-adrenal axis causing elevated basal and stress-induced corticosterone levels that may initiate amygdala-dependent fear learning. Here we test the hypothesis that the adult fearful phenotype is programmed by the pup's stressful experience during prolonged MS rather than by prolonged maternal absence per se. For this purpose, Wistar rat pups were exposed, on postnatalday (pnd) 3, to: (i) repeated-MS in home-environment (HOME-SEP), 8h-MS daily for three days with the pups remaining together in the home-cage; (ii) repeated-MS in a novel-environment (NOVEL-SEP), with the same separation procedure, but now the pups were individually housed in a novel-environment during the 8 h dam's absence; (iii) repeated handling, which consisted of daily brief (15 min instead of 8 h) MS in the home-altogether or in a novel-environment individually (HOME-HAN and NOVEL-HAN, respectively); (iv) no-separation/no-handling (NON-SEP/NON-HAN) control condition, in which pups were left undisturbed in their home-cage. Compared to HOME-SEP rats, the NOVEL-SEP rats showed one day after the last MS enhanced stress-induced amygdala c-Fos expression and ACTH-release, despite of reduced adrenal corticosterone secretion. The higher amygdala c-Fos expression, ACTH-release and reduced corticosterone output observed postnatally, persisted into adulthood of the NOVEL-SEP animals. Behaviorally, NOVEL-SEP juvenile rats displayed deficits in social play, had intact spatial memory in the pen-pubertal period and showed more contextual fear memory compared to HOME-SEP in adulthood. Finally, NOVEL-HAN, compared to HOME-HAN, displayed increased stress-induced corticosterone output, no deficits in social play and reduced contextual fear. In conclusion, programming of an adult fearful phenotype linked to amygdala priming develops if pups are repeatedly isolated from peers in a novel-environment, while away from the dam for a prolonged period of time. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Daskalakis, Nikolaos P.; Diamantopoulou, Anastasia; Claessens, Sanne E. F.; Remmers, Elisa; Tjalve, Marika; Oitzl, Melly S.; Champagne, Danielle L.; de Kloet, E. Ronald] Leiden Univ, Leiden Univ Med Ctr, Leiden Acad Ctr Drug Res, Div Med Pharmacol, Leiden, Netherlands. [Daskalakis, Nikolaos P.; de Kloet, E. Ronald] Leiden Univ, Leiden Univ Med Ctr, Dept Endocrinol & Metab, Leiden, Netherlands. [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY 10029 USA. [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, New York, NY 10029 USA. [Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, PTSD Clin Res Program, Bronx, NY USA. [Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Lab Clin Neuroendocrinol & Neurochem, Bronx, NY USA. [Diamantopoulou, Anastasia] Univ Athens, Sch Hlth Sci, Fac Nursing, Lab Biol Biochem, GR-10679 Athens, Greece. [Diamantopoulou, Anastasia] Columbia Univ, Dept Psychiat, New York, NY USA. RP Daskalakis, NP (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, 1 Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM nikolaos.daskalakis@mssm.edu RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 FU Dutch TI-Pharma [T5-209]; Royal Netherlands Academy of Sciences FX The support by Dutch TI-Pharma T5-209 grant (to NPD and ERdK) and the Royal Netherlands Academy of Sciences (to ERdK) is gratefully acknowledged. We would like to thank Servane Lachize and Maaike van der Mark for the technical assistance with RIA; Wesley Fung, Marjolein Koller and Jasper Laboyrie for help in brain cryosectioning and/or in situ hybridization; Wout Meelis for the technical assistance with animal sampling and decapitation; Ricardo Llorente and Rixt van der Veen for help with maternal care observations; Rixt van der Veen for scientific input; the anonymous reviewers of this manuscript for their fruitful suggestions on the interpretation of the data. NR 88 TC 15 Z9 15 U1 0 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD JAN PY 2014 VL 39 BP 39 EP 57 DI 10.1016/j.psyneuen.2013.09.021 PG 19 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA AA0WM UT WOS:000330818100005 PM 24275003 ER PT J AU Rowland, NC Miller, KJ Starr, PA AF Rowland, Nathan C. Miller, Kai J. Starr, Philip A. TI Three-Dimensional Accuracy of ECOG Strip Electrode Localization Using Coregistration of Preoperative MRI and Intraoperative Fluoroscopy SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY LA English DT Article DE Coregistration; Fluoroscopic radiography; Magnetic resonance imaging; Normalized mutual information; Statistical parametric mapping; X-ray radiography ID DEEP BRAIN-STIMULATION; SUBDURAL ELECTRODES; IMPLANTED ELECTRODES; SENSORIMOTOR CORTEX; PARKINSONS-DISEASE; FOCAL EPILEPSY AB Background/Aims: Algorithms that estimate implanted cortical strip electrode coordinates using postoperative skull X-ray coregistration with preoperative magnetic resonance imaging (MRI) have been proposed. However, when cortical strip electrodes are inserted for temporary use and removed prior to closure, intraoperative imaging either fluoroscopy or computed tomography (CT) must be substituted. Objectives:To measure the accuracy of temporarily inserted su bdural strip electrode coordinates using intraoperative fluoroscopic coregistration with preoperative MRI compared to intraoperative CT coregistration with preoperative MRI. Methods: In 5 patients undergoing movement disorder surgery, preoperative MRI was used to generate a three-dimensional cortical surface manually scaled to fit an intraoperative skull fluorogrann with an in situ six-contact subdural electrode strip. Individual contact coordinates were estimated using subjacent gyral and sulcal patterns. Estimated co- ordinates were compared to reference coordinates obtained by preoperative MRI coregistration with intraoperative CT in the same patients. Results: Mean electrode coordinate distances between estimated and reference locations were 6.0 +/- 0.8 (x-axis, mediolateral), 3.3 +/- 0.5 (y-axis, anterior-posterior) and 4.0 +/- 0.5 mm (z-axis, superior-inferior; n = 30). Conclusions: Localization of temporarily inserted subdural electrodes can be accomplished using preoperative MRI and intraoperative fluoroscopy. The accuracy of this approach is verified by preoperative MRI and intraoperative CT coregistration in the same patients. (C) 2013 S. Karger AG, Basel C1 [Rowland, Nathan C.; Starr, Philip A.] Univ Calif San Francisco, UCSF Surg Movement Disorders Ctr, San Francisco, CA 94143 USA. [Starr, Philip A.] Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Neurol Surg, San Francisco, CA 94143 USA. [Miller, Kai J.] Stanford Univ, Sch Med, Dept Neurosurg, Palo Alto, CA 94304 USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Room M-779, San Francisco, CA 94143 USA. EM StarrP@neurosurg.ucsf.edu NR 23 TC 1 Z9 1 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1011-6125 EI 1423-0372 J9 STEREOT FUNCT NEUROS JI Stereotact. Funct. Neurosurg. PY 2014 VL 92 IS 1 BP 8 EP 16 DI 10.1159/000350027 PG 9 WC Neurosciences; Neuroimaging; Surgery SC Neurosciences & Neurology; Surgery GA 295YH UT WOS:000330151800002 PM 24216603 ER PT J AU Vaid, M Singh, T Prasad, R Katiyar, SK AF Vaid, Mudit Singh, Tripti Prasad, Ram Katiyar, Santosh K. TI Intake of high-fat diet stimulates the risk of ultraviolet radiation-induced skin tumors and malignant progression of papillomas to carcinoma in SKH-1 hairless mice SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE High-fat diet; Malignant progression; Skin tumor; Photocarcinogenesis; Cyclooxygenase-2; Prostaglandins ID NF-KAPPA-B; MOUSE SKIN; INFLAMMATORY RESPONSES; CANCER; INHIBITION; PHOTOCARCINOGENESIS; CYCLOOXYGENASE-2; ACTIVATION; MECHANISMS; EXPRESSION AB Previously, we showed that administration of a high-fat diet (HF-diet) to C57BL/6 mice exacerbates their response to short-term UVB radiation-induced inflammation in the skin. To explore the effects of an HF-diet on UVB-induced tumorigenesis, we have used the SKH-1 hairless mouse model in which the mice are exposed to UVB radiation (180 mJ/cm(2)) three times a week for 24 weeks. The development of UVB-induced skin tumors was rapid and the tumor multiplicity and tumor size were significantly higher (P < 0.01-0.005) in the mice fed an HF-diet than the mice fed a control-diet (C-diet). Moreover, the malignant progression of UVB-induced papillomas to carcinomas was higher in HF-diet-fed mice. On analysis of tumors and tumor-uninvolved skin samples from the tumor-bearing mice, we found that administration of an HF-diet significantly enhanced the levels of UVB-induced expression of cyclooxygenase-2 (COX-2), prostaglandin E-2 (P < 0.01), and PGE(2) receptors, and activation of NF-KB in the UVB-exposed skin as well as in tumors. In addition the HF-diet enhanced the expression of proinflammatory cytokines, including tumor necrosis factor-alpha (P < 0.01), interleukin (IL)-1 beta (P < 0.01) and IL-6 (P < 0.05) in the UVB-exposed skin as well as in tumors. Western blot analysis revealed that HF-diet enhanced the levels of epidermal cell proliferation, phosphatidylinositol 3-kinase and phosphorylation of Akt at Ser(473) in UVB-exposed skin and skin tumors. Collectively, these data demonstrate that the regular consumption of an HF-diet increases the risk of photocarcinogenesis in mice and that this is associated with enhanced expression of inflammatory mediators in the UVB-exposed skin and tumors. (C) 2013 Elsevier Inc. All rights reserved. C1 [Vaid, Mudit; Singh, Tripti; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award [1I01BX001410] FX This work was supported by the funds from the Veterans Administration Merit Review Award (1I01BX001410, S.K.K.). The content of this manuscript does not necessarily represent the official views of the Department of Veterans Administration. We thank Dr. Fiona Hunter for editorial assistance. NR 35 TC 4 Z9 4 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X EI 1096-0333 J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD JAN 1 PY 2014 VL 274 IS 1 BP 147 EP 155 DI 10.1016/j.taap.2013.10.030 PG 9 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 297LD UT WOS:000330256000016 PM 24211275 ER PT J AU Minces, LR Nguyen, MH Mitsani, D Shields, RK Kwak, EJ Silveira, FP Abdel-Massih, R Pilewski, JM Crespo, MM Bermudez, C Bhama, JK Toyoda, Y Clancy, CJ AF Minces, Lucio R. Hong Nguyen, M. Mitsani, Dimitra Shields, Ryan K. Kwak, Eun J. Silveira, Fernanda P. Abdel-Massih, Rima Pilewski, Joseph M. Crespo, Maria M. Bermudez, Christian Bhama, Jay K. Toyoda, Yoshiya Clancy, Cornelius J. TI Ganciclovir-Resistant Cytomegalovirus Infections among Lung Transplant Recipients Are Associated with Poor Outcomes despite Treatment with Foscarnet-Containing Regimens SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID VALGANCICLOVIR PROPHYLAXIS; INTRAVENOUS GANCICLOVIR; PREVENT CYTOMEGALOVIRUS; DRUG-RESISTANCE; IMMUNE GLOBULIN; CMV INFECTION; SINGLE-CENTER; DISEASE; EMERGENCE; EXPERIENCE AB Ganciclovir-resistant cytomegalovirus (CMV) infections are reported infrequently among lung transplant recipients receiving extended valganciclovir prophylaxis. We performed a single-center, retrospective review of ganciclovir-resistant CMV infections in a program that employed valganciclovir prophylaxis for >= 6 months after lung transplant. CMV infections were diagnosed in 28% (170/607) of patients. UL97 mutations were detected in 9.4% (16/170) of CMV-infected patients at a median of 8.5 months posttransplant (range, 5 to 21) and despite prophylaxis for a median of 7 months (range, 4 to 21). UL97 mutations were canonical; 25% (4/16) of strains carried concurrent UL54 mutations. Ganciclovir-resistant CMV was more likely with breakthrough infections (75% [12/16] versus 19% [30/154]; P = 0.00001) and donor positive/recipient negative (D+/R-) serostatus (75% versus 45% [69/154]; P = 0.03). The median whole-blood CMV load was 4.13 log(10) copies/cm(3) (range, 2.54 to 5.53), and 93% (14/15) of patients had low-moderate immune responses (Cylex Immunoknow). Antiviral therapy was successful, failed, or eradicated viremia followed by relapse in 12% (2/16), 31% (5/16), and 56% (9/16) of patients, respectively. Eighty-seven percent (14/16) of patients were treated with foscarnet-containing regimens; toxicity developed in 78% (11/14) of these. Median viral load half-life and time to viremia eradication among foscarnet-treated patients were 2.6 and 23 days, respectively, and did not correlate with protection from relapse. Sixty-nine percent (11/16) of patients developed CMV pneumonitis, and 25% (4/16) died of it. Serum viral load was independently associated with death among foscarnet-treated patients (P = 0.04). In conclusion, ganciclovir-resistant CMV infections remained a major cause of morbidity and mortality following lung transplantation. Foscarnet-based regimens often eradicated viremia rapidly but were ineffective in the long term and limited by toxicity. C1 [Minces, Lucio R.; Hong Nguyen, M.; Mitsani, Dimitra; Shields, Ryan K.; Kwak, Eun J.; Silveira, Fernanda P.; Abdel-Massih, Rima; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA. [Pilewski, Joseph M.; Crespo, Maria M.] Univ Pittsburgh, Dept Med, Dept Pulm Med, Pittsburgh, PA USA. [Bermudez, Christian; Bhama, Jay K.; Toyoda, Yoshiya] Univ Pittsburgh, Dept Cardiothorac Surg, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA. EM mhn5@pitt.edu NR 44 TC 12 Z9 12 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2014 VL 58 IS 1 BP 128 EP 135 DI 10.1128/AAC.00561-13 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 287ZL UT WOS:000329581100016 PM 24145525 ER PT J AU Wiederhold, NP Pennick, GJ Dorsey, SA Furmaga, W Lewis, JS Patterson, TF Sutton, DA Fothergill, AW AF Wiederhold, Nathan P. Pennick, Gennethel J. Dorsey, Sheryl A. Furmaga, Wieslaw Lewis, James S., II Patterson, Thomas F. Sutton, Deanna A. Fothergill, Annette W. TI A Reference Laboratory Experience of Clinically Achievable Voriconazole, Posaconazole, and Itraconazole Concentrations within the Bloodstream and Cerebral Spinal Fluid SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID INVASIVE FUNGAL-INFECTIONS; CELL TRANSPLANT RECIPIENTS; VERSUS-HOST-DISEASE; PULMONARY ASPERGILLOSIS; ANTIFUNGAL PROPHYLAXIS; NEUTROPENIC PATIENTS; CONTROLLED-TRIAL; EXPOSURE-RESPONSE; ADVERSE EVENTS; MURINE MODEL AB Interest in antifungal therapeutic-drug monitoring has increased due to studies demonstrating associations between concentrations and outcomes. We reviewed the antifungal drug concentration database at our institution to gain a better understanding of achievable triazole drug levels. Antifungal concentrations were measured by high-performance liquid chromatography (HPLC), ultraperformance liquid chromatography and single-quadrupole mass spectrometry (UPLC/MS), or a bioassay. For this study, only confirmed human bloodstream (serum or plasma) and cerebral spinal fluid (CSF) concentrations of voriconazole, posaconazole, and itraconazole were analyzed. The largest numbers of bloodstream and CSF samples were found for voriconazole (14,370 and 173, respectively). Voriconazole bloodstream concentrations within the range of 1 to 5.5 mu g/ml represented 50.6% of samples. Levels below the lower limit of quantification (0.2 mu g/ml) were observed in 14.6% of samples, and 10.4% of samples had levels of >= 5.5 mu g/ml. CSF voriconazole levels ranged from undetectable to 15.3 mu g/ml and were <0.2 mu g/ml in 11% of samples. Posaconazole bloodstream concentrations were >= 0.7 and >= 1.25 mu g/ml in 41.6% and 18.9% of samples, respectively. Posaconazole was detected in only 4 of 22 CSF samples (undetectable to 0.56 mu g/ml). Itraconazole levels, as measured by UPLC/MS, were >= 0.5 mu g/ml in 43.3% and were undetectable in 33.9% of bloodstream samples. In contrast, when measured by a bioassay, itraconazole/hydroxyitraconazole bloodstream concentrations were >= 1.0 mu g/ml in 72.9% of samples and were undetectable in 18% of samples. These results indicate that there is marked variability in bloodstream concentrations achieved with these three azoles. In addition, many levels within the bloodstream for each azole and for voriconazole and posaconazole in the CSF were undetectable or below thresholds associated with efficacy. C1 [Wiederhold, Nathan P.; Pennick, Gennethel J.; Dorsey, Sheryl A.; Furmaga, Wieslaw; Lewis, James S., II; Patterson, Thomas F.; Sutton, Deanna A.; Fothergill, Annette W.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lewis, James S., II] Univ Hlth Syst, San Antonio, TX USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wiederhold, NP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. EM wiederholdn@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU Merck; Astellas; bioMerieux; Viamet; Medicis; Merz; F2G FX N.P.W. has received research support from Merck, Astellas, bioMerieux, Viamet, Medicis, Merz, and F2G and has served on advisory boards for Merck, Astellas, Toyama, and Viamet. NR 57 TC 15 Z9 16 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2014 VL 58 IS 1 BP 424 EP 431 DI 10.1128/AAC.01558-13 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 287ZL UT WOS:000329581100054 PM 24189246 ER PT J AU Luoh, SW Ramsey, B Park, B Keenan, E AF Luoh, Shiuh-Wen Ramsey, Betsy Park, Byung Keenan, Edward TI Quantitative Progesterone Receptor Expression and Efficacy of Anti-estrogen Therapy in Breast Cancer SO BREAST JOURNAL LA English DT Article DE anti-estrogen therapy; predictive marker; progesterone receptor ID ADJUVANT ENDOCRINE THERAPY; LIGAND-BINDING ASSAY; ESTROGEN-RECEPTOR; PREDICTING RESPONSE; IMMUNOHISTOCHEMISTRY; TAMOXIFEN; HER2; IMPROVES; ER AB The central role of estrogen receptor (ER) presence in predicting which breast cancer patients are likely to benefit from anti-estrogen therapies is well-established, but the added benefit of progesterone receptor (PR) and in particular low levels of PR is less well understood. The objective of this study was to determine the quantitative relationship between borderline levels of PR and subsequent benefit from anti-estrogen therapy. We examined data from 447 patients, age 50 or older. ER and PR levels were quantitated by conventional ligand binding assay and Scatchard plot analysis or by enzyme-linked immunoassay. Comparison of clinical outcome in relation with ER and PR status was calculated using Kaplan-Meier actuarial survival analysis and the log-rank test. Subpopulation treatment effect pattern plot (STEPP) analysis was used to explore the interaction between treatment effects and ER or PR levels for the 409 patients with ER values greater than 0. For anti-estrogen treated patients, when the ER and PR positivity cut-off was set at 1.0fmole/mg protein, there was a statistically significant advantage for patients with ER+PR+ over ER+ PR- tumors for both breast cancer-free interval (BCFI) and overall survival (OS). STEPP analysis found no overall interaction between treatment outcome (5year survival probability) and levels of hormone receptor. However, patients with borderline PR levels did not appear to benefit from anti-estrogen therapy. PR levels above borderline in addition to the presence of ER predicts an increased probability of benefit from anti-estrogen therapy in breast cancer patients. C1 [Luoh, Shiuh-Wen] Portland VA Med Ctr, Portland, OR USA. [Luoh, Shiuh-Wen; Ramsey, Betsy; Park, Byung; Keenan, Edward] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA. [Ramsey, Betsy; Keenan, Edward] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. [Park, Byung] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Luoh, SW (reprint author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, 3181 SW Sam,Jackson Pk Rd,MC L586, Portland, OR 97239 USA. EM luohs@ohsu.edu NR 24 TC 3 Z9 3 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1075-122X EI 1524-4741 J9 BREAST J JI Breast J. PD JAN PY 2014 VL 20 IS 1 BP 46 EP 52 DI 10.1111/tbj.12200 PG 7 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 291EQ UT WOS:000329810900008 PM 24261828 ER PT J AU Kangovi, S Grande, D AF Kangovi, Shreya Grande, David TI Transitional Care Management Reimbursement to Reduce COPD Readmission SO CHEST LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; NATIONAL DEMONSTRATION PROJECT; PATIENT SAFETY STRATEGY; FOLLOW-UP; SOCIOECONOMIC-STATUS; HOSPITAL DISCHARGE; MEDICAL HOME; AMBULATORY-CARE; HEART-FAILURE AB Reducing preventable readmissions for COPD is an important national health policy goal. Thus far, Centers for Medicare & Medicaid Services (CMS) policies focused on incentivizing improvements in inpatient quality have had variable success. In its 2013 physician-payment rule, CMS announced new payments that reimburse ambulatory care providers for timely posthospital visits and transitional care management services. CMS hopes that posthospital transitional care and services will substitute for readmission, but the evidence supporting this hypothesis is mixed. In this article, we discuss ways for ambulatory pulmonologists to leverage transitional care management payments to enhance access for their patients with COPD while minimizing the risk of a paradoxic increase in readmission rates. C1 [Kangovi, Shreya] Univ Penn, Philadelphia Vet Affairs Med Ctr, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kangovi, Shreya; Grande, David] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Kangovi, S (reprint author), 13th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM kangovi@mail.med.upenn.edu NR 59 TC 3 Z9 3 U1 3 U2 14 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2014 VL 145 IS 1 BP 149 EP 155 DI 10.1378/chest.13-0787 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 293JD UT WOS:000329966300031 PM 24394826 ER PT J AU Bastawrous, S Hirschmann, JV AF Bastawrous, Sarah Hirschmann, Jan V. TI A Man in His Early 70s With Progressive Dyspnea and Abnormal Fundoscopic Examination SO CHEST LA English DT Editorial Material ID DRUG-ABUSERS; TALCOSIS C1 [Bastawrous, Sarah] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Hirschmann, Jan V.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. [Bastawrous, Sarah] Univ Washington, Dept Radiol, UW Med, Seattle, WA 98195 USA. [Hirschmann, Jan V.] Univ Washington, Dept Med, UW Med, Seattle, WA USA. RP Bastawrous, S (reprint author), VA Puget Sound Hlth Care Syst, Dept Radiol, Mail Box 358280,S-114,1660 S Columbian Way, Seattle, WA 98108 USA. EM ssheikh@u.washington.edu OI Bastawrous, Sarah/0000-0002-7690-3121 NR 7 TC 1 Z9 1 U1 1 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2014 VL 145 IS 1 BP 178 EP 181 DI 10.1378/chest.13-1277 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 293JD UT WOS:000329966300036 PM 24394831 ER PT J AU Berg, AT Loddenkemper, T Baca, CB AF Berg, Anne T. Loddenkemper, Tobias Baca, Christine B. TI Diagnostic delays in children with early onset epilepsy: Impact, reasons, and opportunities to improve care SO EPILEPSIA LA English DT Article DE Health services; Barriers to care; Pediatrics; Development ID ADAPTIVE-BEHAVIOR; SEIZURE; EEG; SURGERY; TIME; OUTCOMES; INFANCY; ACCESS; AGE AB PurposeDelayed diagnosis of early onset epilepsy is a potentially important and avoidable complication in epilepsy care. We examined the frequency of diagnostic delays in young children with newly presenting epilepsy, their developmental impact, and reasons for delays. MethodsChildren who developed epilepsy before their third birthday were identified in a prospective community-based cohort. An interval 1month from second seizure to diagnosis was considered a delay. Testing of development at baseline and for up to 3years after and of intelligence quotient (IQ) 8-9years later was performed. Detailed parental baseline interview accounts and medical records were reviewed to identify potential reasons for delays. Factors associated with delays included the parent, child, pediatrician, neurologist, and scheduling. ResultsDiagnostic delays occurred in 70 (41%) of 172 children. Delays occurred less often if children had received medical attention for the first seizure (p<0.0001), previously had neonatal or febrile seizures (p=0.02), had only convulsions before diagnosis (p=0.005), or had a college-educated parent (p=0.01). A 1month diagnostic delay was associated with an average 7.4 point drop (p=0.02) in the Vineland Scales of Adaptive Behavior motor score. The effect was present at diagnosis, persisted for at least 3years, and was also apparent in IQ scores 8-9years later, which were lower in association with a diagnostic delay by 8.4 points (p=0.06) for processing speed up to 14.5 points (p=0.004) for full scale IQ, after adjustment for parental education and other epilepsy-related clinical factors. Factors associated with delayed diagnosis included parents not recognizing events as seizures (N=47), pediatricians missing or deferring diagnosis (N=15), neurologists deferring diagnosis (N=7), and scheduling problems (N=11). SignificanceDiagnostic delays occur in many young children with epilepsy. They are associated with substantial decrements in development and IQ later in childhood. Several factors influence diagnostic delays and may represent opportunities for intervention and improved care. C1 [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat, Epilepsy Ctr, Chicago, IL USA. [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Northwestern Mem Feinberg Sch Med, Chicago, IL USA. [Loddenkemper, Tobias] Harvard Univ, Sch Med, Div Epilepsy & Clin Neurophysiol, Dept Neurol,Boston Childrens Hosp, Boston, MA 02115 USA. [Baca, Christine B.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Baca, Christine B.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. RP Berg, AT (reprint author), Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, 225 East Chicago Ave,Box 29, Chicago, IL 60611 USA. EM atberg@luriechildrens.org FU National Institute of Neurological Disorders and Stroke [R37-NS31146] FX This study was funded by a grant from the National Institute of Neurological Disorders and Stroke R37-NS31146. NR 38 TC 7 Z9 7 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD JAN PY 2014 VL 55 IS 1 BP 123 EP 132 DI 10.1111/epi.12479 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 292HX UT WOS:000329893900016 PM 24313635 ER PT J AU Chen, DK Maheshwari, A Franks, R Trolley, GC Robinson, JS Hrachovy, RA AF Chen, David K. Maheshwari, Atul Franks, Romay Trolley, Gregory C. Robinson, Jordan S. Hrachovy, Richard A. TI Brief group psychoeducation for psychogenic nonepileptic seizures: A neurologist-initiated program in an epilepsy center SO EPILEPSIA LA English DT Article DE Psychogenic nonepileptic seizures; Psychotherapy; Psychoeducation; Work and Social Adjustment Scale; Psychosocial functioning ID SOCIAL-ADJUSTMENT SCALE; QUALITY-OF-LIFE; DIAGNOSIS; PSEUDOSEIZURE; DISORDERS; WORK; COMMUNICATION; COMORBIDITY; PERSONALITY; RELIABILITY AB ObjectiveTo evaluate therapeutic efficacy upon augmenting the initial communication to patients regarding the diagnosis of psychogenic nonepileptic seizures (PNES) with a novel, brief group psychoeducation administered by the same team that provided the video-electroencephalography (VEEG) confirmed diagnosis and within 4weeks of the diagnosis. MethodsPrior to discharge from the epilepsy monitoring unit (EMU), a standardized communication strategy was utilized to explain the diagnosis of PNES to all patients prior to enrollment. Enrolled patients were then randomized to either participation in three successive and monthly group psychoeducational sessions (intervention group), or routine seizure clinic follow-up visits (control group). Both groups completed questionnaires at time of enrollment, and then at approximately 3months (follow-up 1) and 6months (follow-up 2) after discharge, assessing for: (1) primary outcomes that include a measure of psychosocial functioning, as well as interval difference in seizure frequency/intensity; and (2) secondary outcomes that include interval seizure-related emergency room visits or hospitalizations, development of new and medically unexplained symptoms, and results of an internal measure of knowledge and perception outcomes. ResultsThe majority (73%) of patients from the intervention group commenced on therapy sessions within 4weeks after learning of the diagnosis. Although we did not observe significant group difference in seizure frequency/intensity, patients from the intervention group showed significant improvement on the Work and Social Adjustment Scale (WSAS) scores at both follow-up 1 (p=0.013) and follow-up 2 (p=0.038) after discharge from the EMU. In addition, we observed a trend toward lesser likelihood for seizure-related emergency room visits or hospitalizations for the intervention group (p=0.184), as well as meaningful insights from an internal measure of intervention outcomes. SignificanceThese findings suggest that our cost/resource effective, brief group psychoeducational program, when administered early and by the same team who confirmed and communicated the diagnosis of PNES, may contribute to significant functional improvement among participating patients. C1 [Chen, David K.; Maheshwari, Atul; Hrachovy, Richard A.] Baylor Coll Med, Dept Neurol, Peter Kellaway Sect Neurophysiol, Houston, TX 77030 USA. [Chen, David K.; Franks, Romay; Hrachovy, Richard A.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Trolley, Gregory C.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Robinson, Jordan S.] Baylor Coll Med, Dept Psychol & Behav Sci, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Chen, DK (reprint author), MEDVAMC, 2002 Holcombe Blvd,NCL 127, Houston, TX 77030 USA. EM dkchen@bcm.edu FU Department of Veteran Affairs, Epilepsy Centers of Excellence (ECoE) FX The authors are grateful to the staff and patients of the epilepsy monitoring unit at Michael E. DeBakey VA Medical Center for their involvement in this study. This research is based on work supported in part by the Department of Veteran Affairs, Epilepsy Centers of Excellence (ECoE). NR 40 TC 18 Z9 18 U1 2 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD JAN PY 2014 VL 55 IS 1 BP 156 EP 166 DI 10.1111/epi.12481 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 292HX UT WOS:000329893900020 PM 24446955 ER PT B AU Murray, D AF Murray, David BE Rahko, PS TI Left Ventricular Dysfunction and Associated Renal Failure: The Cardiorenal Syndrome SO HEART FAILURE: A CASE-BASED APPROACH LA English DT Article; Book Chapter ID DECOMPENSATED HEART-FAILURE; VENOUS-PRESSURE; INTRAABDOMINAL PRESSURE; ULTRAFILTRATION; DIURETICS; MORTALITY; DOPAMINE; NESIRITIDE; KIDNEY; DEATH C1 [Murray, David] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Murray, David] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Murray, David] William S Middleton Mem Vet Adm Med Ctr, Cardiol Sect, Madison, WI USA. RP Murray, D (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. NR 45 TC 0 Z9 0 U1 0 U2 2 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-51-2 PY 2014 BP 229 EP 239 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA BJL42 UT WOS:000328866100017 ER PT J AU Iskandrian, AE Hage, FG Shaw, LJ Mahmarian, JJ Berman, DS AF Iskandrian, Ami E. Hage, Fadi G. Shaw, Leslee J. Mahmarian, John J. Berman, Daniel S. TI Serial Myocardial Perfusion Imaging Defining a Significant Change and Targeting Management Decisions SO JACC-CARDIOVASCULAR IMAGING LA English DT Article DE coronary artery disease; myocardial ischemia; myocardial perfusion imaging; single-photon emission tomography; stress testing ID CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; AMERICAN-HEART-ASSOCIATION; INTENSIVE MEDICAL THERAPY; LEFT-VENTRICULAR FUNCTION; PLACEBO-CONTROLLED TRIAL; QUANTITATIVE-ANALYSIS; EXERCISE ELECTROCARDIOGRAPHY; NUCLEAR CARDIOLOGY; ISCHEMIA DETECTION AB Myocardial perfusion imaging (MPI) with gated single-photon emission tomography provides important information on the extent and severity of myocardial perfusion abnormalities, including myocardial ischemia. The availability of software for automated quantitative assessment of myocardial perfusion in an objective and more reproducible manner than visual assessment has allowed MPI to be particularly effective in serial evaluation. Serial testing using MPI is widely used in guiding patient care despite the lack of well-defined appropriateness use criteria. This should not be surprising because ischemic heart disease is a life-long malady subject to dynamic changes throughout its natural course and particularly following man-made interventions that may improve or worsen the disease process, such as medical therapy and coronary revascularization. Serial MPI has filled an important clinical gap by providing crucial information for managing patients with changes in clinical presentations or in anticipation of such changes in patients with stable symptoms. In the research arena, serial MPI has been widely applied in randomized controlled trials to study the impact of various medical and interventional therapies on myocardial perfusion, as well as the relative merits of new imaging procedures (hardware and/or software), radiotracers, and stressor agents. Serial testing, however, unlike initial or 1-time testing, has more stringent requirements and is subject to variability because of technical, procedural, interpretational, and biological factors. The intrinsic variability of MPI becomes important in interpreting serial tests in order to define a true change in a given patient and to guide clinical decision making. The purpose of this first comprehensive review on this subject is to illustrate where serial MPI may be useful clinically and in research studies, and to highlight strategies for addressing the various issues that are unique to serial testing in order to derive more valid and robust data from the serial scans. (C) 2014 by the American College of Cardiology Foundation C1 [Iskandrian, Ami E.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35242 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [Shaw, Leslee J.] Emory Univ, Sch Med, Emory Clin Cardiovasc Res Inst, Atlanta, GA USA. [Mahmarian, John J.] Methodist Hosp, Methodist DeBakey Heart & Vasc Ctr, Houston, TX 77030 USA. [Berman, Daniel S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Iskandrian, AE (reprint author), Univ Alabama Birmingham, Div Cardiol, Dept Med, 318 LHRB,1900 Univ Blvd, Birmingham, AL 35242 USA. EM aiskand@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 58 TC 20 Z9 20 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD JAN PY 2014 VL 7 IS 1 BP 79 EP 96 DI 10.1016/j.jcmg.2013.05.022 PG 18 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 293EF UT WOS:000329953500011 PM 24433711 ER PT J AU Alam, MA Kumar, S McGinty, D Alam, MN Szymusiak, R AF Alam, Md. Aftab Kumar, Sunil McGinty, Dennis Alam, Md. Noor Szymusiak, Ronald TI Neuronal activity in the preoptic hypothalamus during sleep deprivation and recovery sleep SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE adenosine; median preoptic nucleus; REM sleep; sleep homeostasis; ventrolateral preoptic area ID EYE-MOVEMENT SLEEP; BASAL FOREBRAIN NEURONS; PERIFORNICAL LATERAL HYPOTHALAMUS; VENTROLATERAL PERIAQUEDUCTAL GRAY; WAKING DISCHARGE PATTERNS; FOS PROTEIN EXPRESSION; GABAERGIC NEURONS; C-FOS; REM-SLEEP; HOMEOSTATIC REGULATION AB The preoptic hypothalamus is implicated in sleep regulation. Neurons in the median preoptic nucleus (MnPO) and the ventrolateral preoptic area (VLPO) have been identified as potential sleep regulatory elements. However, the extent to which MnPO and VLPO neurons are activated in response to changing homeostatic sleep regulatory demands is unresolved. To address this question, we continuously recorded the extracellular activity of neurons in the rat MnPO, VLPO and dorsal lateral preoptic area (LPO) during baseline sleep and waking, during 2 h of sleep deprivation (SD) and during 2 h of recovery sleep (RS). Sleep-active neurons in the MnPO (n = 11) and VLPO (n = 13) were activated in response to SD, such that waking discharge rates increased by 95.8 +/- 29.5% and 59.4 +/- 17.3%, respectively, above waking baseline values. During RS, non-rapid eye movement (REM) sleep discharge rates of MnPO neurons initially increased to 65.6 +/- 15.2% above baseline values, then declined to baseline levels in association with decreases in EEG delta power. Increase in non-REM sleep discharge rates in VLPO neurons during RS averaged 40.5 +/- 7.6% above baseline. REM-active neurons (n = 16) in the LPO also exhibited increased waking discharge during SD and an increase in non-REM discharge during RS. Infusion of A(2A) adenosine receptor antagonist into the VLPO attenuated SD-induced increases in neuronal discharge. Populations of LPO wake/REM-active and state-indifferent neurons and dorsal LPO sleep-active neurons were unresponsive to SD. These findings support the hypothesis that sleep-active neurons in the MnPO and VLPO, and REM-active neurons in the LPO, are components of neuronal circuits that mediate homeostatic responses to sustained wakefulness. C1 [Alam, Md. Aftab; Kumar, Sunil; McGinty, Dennis; Alam, Md. Noor; Szymusiak, Ronald] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA USA. [McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Alam, Md. Noor; Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Szymusiak, Ronald] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM rszym@ucla.edu FU Department of Veterans Affairs; National Institute of Mental Health [MH-63323] FX This study was supported by the Department of Veterans Affairs and National Institute of Mental Health Grant MH-63323. NR 55 TC 12 Z9 13 U1 0 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD JAN PY 2014 VL 111 IS 2 BP 287 EP 299 DI 10.1152/jn.00504.2013 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 292SM UT WOS:000329922600006 PM 24174649 ER PT J AU Hildenbrand, AK Alderfer, MA Deatrick, JA Marsac, ML AF Hildenbrand, Aimee K. Alderfer, Melissa A. Deatrick, Janet A. Marsac, Meghan L. TI A Mixed Methods Assessment of Coping with Pediatric Cancer SO JOURNAL OF PSYCHOSOCIAL ONCOLOGY LA English DT Article DE coping; coping assistance; pediatric cancer; mixed methods; childhood cancer ID MEDICAL PROCEDURES; CHILDREN; STRESS; ADOLESCENTS; ADJUSTMENT; SYMPTOMS; STRATEGIES; DISTRESS; AVOIDANT; PARENTS AB The purpose of this study was to describe child coping and parent coping assistance with cancer-related stressors during treatment. Fifteen children (age 6-12) with cancer and their parents (N = 17) completed semistructured interviews and self-report measures to assess coping and coping assistance. Results suggest families utilized a broad array of approach and avoidance strategies to manage cancer and its treatment. Quantitative and qualitative assessments provided complementary and unique contributions to understanding coping among children with cancer and their parents. Using a mixed methods approach to assess coping provides a richer understanding of families' experiences, which can better inform clinical practice. C1 [Hildenbrand, Aimee K.; Marsac, Meghan L.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA. [Alderfer, Melissa A.] Childrens Hosp Philadelphia, Ctr Canc, Philadelphia, PA 19104 USA. [Alderfer, Melissa A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. RP Hildenbrand, AK (reprint author), Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, 3535 Market,Suite 1150, Philadelphia, PA 19104 USA. EM hildenbranda@email.chop.edu FU NIMH NIH HHS [1K23MH093618-01A1, K23 MH093618] NR 67 TC 5 Z9 5 U1 2 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0734-7332 EI 1540-7586 J9 J PSYCHOSOC ONCOL JI J. Psychosoc. Oncol. PD JAN 1 PY 2014 VL 32 IS 1 BP 37 EP 58 DI 10.1080/07347332.2013.855960 PG 22 WC Psychology, Social SC Psychology GA 289NI UT WOS:000329688800002 PM 24428250 ER PT J AU Dzierzewski, JM Fung, CH Jouldjian, S Alessi, CA Irwin, MR Martin, JL AF Dzierzewski, Joseph M. Fung, Constance H. Jouldjian, Stella Alessi, Cathy A. Irwin, Michael R. Martin, Jennifer L. TI Decrease in Daytime Sleeping Is Associated with Improvement in Cognition After Hospital Discharge in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE sleep; cognition; longitudinal change; inpatient hospitalization; older adults ID POST-ACUTE REHABILITATION; ILLNESS RATING-SCALE; NURSING-HOME; DECLINE; POPULATION; VALIDATION; PATTERNS; INSOMNIA; LIFE; CARE AB ObjectivesTo examine the relationship between changes in objectively assessed sleep and global cognitive functioning from inpatient postacute rehabilitation to 6-month follow-up. DesignSecondary analysis of two prospective, longitudinal studies. SettingInpatient rehabilitation units at a Veterans Affairs Medical Center. ParticipantsOlder adults (mean age 73.89.4) undergoing inpatient rehabilitation (n=192). MeasurementsAll participants completed 7 nights and days of ambulatory sleep monitoring using wrist actigraphy (yielding an estimate of nighttime wakefulness and daytime sleep) and the Mini-Mental State Examination (MMSE) during a postacute inpatient rehabilitation stay and 6months after discharge. The 5-item Geriatric Depression Scale, Geriatric Pain Measure, and Cumulative Illness Rating Scale for Geriatrics were completed during inpatient rehabilitation. ResultsGrowth curve modeling (controlling for baseline age, education, sex, body mass index, depression, pain, and comorbidity burden) revealed that individuals whose amount of daytime sleep decreased from inpatient postacute rehabilitation to 6-month follow-up also experienced improvements in MMSE score (=-0.01, t(80=-3.22, P=.002)). Change in nighttime wakefulness was not a significant predictor of change in MMSE score. ConclusionOlder adults whose daytime sleeping decreased after hospital discharge also experienced improvements in cognitive functioning at 6month follow-up. As such, daytime sleep may represent a promising candidate for targeted interventions aimed at promoting cognitive recovery after hospital discharge. C1 [Dzierzewski, Joseph M.; Fung, Constance H.; Jouldjian, Stella; Alessi, Cathy A.; Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA 91343 USA. [Dzierzewski, Joseph M.; Fung, Constance H.; Alessi, Cathy A.; Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Irwin, Michael R.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA 90024 USA. RP Martin, JL (reprint author), VA Greater Los Angeles Healthcare Syst, 16111 Plummer St 11E, North Hills, CA 91343 USA. EM jennifer.martin@va.gov RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431 FU National Institute on Aging [K23 AG028452]; University of California at Los Angeles (UCLA) Claude D. Pepper Older Americans Independence Center [NIA 5P30 AG028748]; UCLA Cousins Center for Psychoneuroimmunology, VA Health Services Research Development [IIR 04-321-3]; VA Advanced Geriatrics Fellowship Program; American Sleep Medicine Foundation; VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center FX This work was supported by the National Institute on Aging (K23 AG028452; PI Martin), University of California at Los Angeles (UCLA) Claude D. Pepper Older Americans Independence Center (NIA 5P30 AG028748, Career Development Award and Pilot Award, Martin; Inflammatory Biology Core, Irwin), UCLA Cousins Center for Psychoneuroimmunology, VA Health Services Research & Development (IIR 04-321-3, Alessi), VA Advanced Geriatrics Fellowship Program (Dzierzewski and Fung), American Sleep Medicine Foundation (Physician Scientist Training Award, Fung), and VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center. NR 41 TC 3 Z9 3 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2014 VL 62 IS 1 BP 47 EP 53 DI 10.1111/jgs.12622 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 292AS UT WOS:000329874600006 PM 25093233 ER PT J AU Hurd, YL Michaelides, M Miller, ML Jutras-Aswad, D AF Hurd, Yasmin L. Michaelides, Michael Miller, Michael L. Jutras-Aswad, Didier TI Trajectory of adolescent cannabis use on addiction vulnerability SO NEUROPHARMACOLOGY LA English DT Review DE Marijuana; Cannabinoid; Opioid neuropeptide; Nucleus accumbens; Prefrontal cortex ID RECEPTOR MESSENGER-RNA; ILLICIT DRUG-USE; PROENKEPHALIN GENE-EXPRESSION; BRAIN GLUCOSE-METABOLISM; POPULATION-BASED SAMPLE; MARIJUANA USE; RAT-BRAIN; ENVIRONMENTAL-INFLUENCES; DOPAMINE-D-2 RECEPTORS; GATEWAY HYPOTHESIS AB The adolescent brain is a period of dynamic development making it vulnerable to environmental factors such as drug exposure. Of the illicit drugs, cannabis is most used by teenagers since it is perceived by many to be of little harm. This perception has led to a growing number of states approving its legalization and increased accessibility. Most of the debates and ensuing policies regarding cannabis were done without consideration of its impact on one of the most vulnerable population, namely teens, or without consideration of scientific data. We provide an overview of the endocannabinoid system in relation to adolescent cannabis exposure and provide insights regarding factors such as genetics and behavioral traits that confer risk for subsequent addiction. While it is clear that more systematic scientific studies are needed to understand the long-term impact of adolescent cannabis exposure on brain and behavior, the current evidence suggests that it has a far-reaching influence on adult addictive behaviors particularly for certain subsets of vulnerable individuals. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Hurd, Yasmin L.; Michaelides, Michael; Miller, Michael L.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Hurd, Yasmin L.; Michaelides, Michael; Miller, Michael L.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA. [Hurd, Yasmin L.] James J Peters Vet Adm, Bronx, NY USA. [Jutras-Aswad, Didier] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada. [Jutras-Aswad, Didier] Ctr Hosp Univ Montreal, CRCHUM, Montreal, PQ, Canada. RP Hurd, YL (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM Yasmin.hurd@mssm.edu OI Miller, Michael/0000-0002-6350-5706 FU NIDA [DA030359, DA023214] FX This work was funded by NIDA DA030359 and DA023214. NR 124 TC 25 Z9 26 U1 7 U2 50 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 EI 1873-7064 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD JAN PY 2014 VL 76 SI SI BP 416 EP 424 DI 10.1016/j.neuropharm.2013.07.028 PN B PG 9 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA 294YK UT WOS:000330083600022 PM 23954491 ER PT J AU Moshiri, M Zaidi, SF Robinson, TJ Bhargava, P Siebert, JR Dubinsky, TJ Katz, DS AF Moshiri, Mariam Zaidi, Sadaf F. Robinson, Tracy J. Bhargava, Puneet Siebert, Joseph R. Dubinsky, Theodore J. Katz, Douglas S. TI Comprehensive Imaging Review of Abnormalities of the Umbilical Cord SO RADIOGRAPHICS LA English DT Review ID PRENATAL ULTRASOUND DIAGNOSIS; OF-THE-LITERATURE; NUCHAL CORD; VEIN VARIX; COILING INDEX; RISK-FACTORS; SONOGRAPHIC EVALUATION; CLINICAL IMPORTANCE; DOPPLER SONOGRAPHY; PERINATAL OUTCOMES AB A complete fetal ultrasonographic (US) study includes assessment of the umbilical cord for possible abnormalities. Knowledge of the normal appearance of the umbilical cord is necessary for the radiologist to correctly diagnose pathologic conditions. Umbilical cord abnormalities can be related to cord coiling, length, and thickness; the placental insertion site; in utero distortion; vascular abnormalities; and primary tumors or masses. These conditions may be associated with other fetal anomalies and aneuploidies, and their discovery should prompt a thorough fetal US examination. Further workup and planning for a safe fetal delivery may include fetal echocardiography and karyotype analysis. Doppler US is a critical tool for assessment and diagnosis of vascular cord abnormalities. US also can be used for follow-up serial imaging evaluation of conditions that could result in fetal demise. Recent studies suggest that three- or four-dimensional Doppler US of the fetal umbilical cord and abdominal vasculature allows more accurate diagnosis of vascular abnormalities. Doppler US also is invaluable in assessment of fetal growth restriction since hemodynamic changes in the placenta or fetus would appear as a spectral pattern of increased resistance to forward flow in the fetal umbilical artery. Early detection of umbilical cord abnormalities and close follow-up can reduce the risk of morbidity and mortality and assist in decision making. (C)RSNA, 2014 C1 [Moshiri, Mariam; Zaidi, Sadaf F.; Robinson, Tracy J.; Bhargava, Puneet; Dubinsky, Theodore J.] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA. [Siebert, Joseph R.] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA. [Katz, Douglas S.] Winthrop Univ Hosp, Dept Radiol, Mineola, NY 11501 USA. RP Moshiri, M (reprint author), Univ Washington, Sch Med, Dept Radiol, 1959 NE Pacific St, Seattle, WA 98195 USA. EM moshiri@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 70 TC 6 Z9 6 U1 0 U2 12 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD JAN-FEB PY 2014 VL 34 IS 1 BP 179 EP 196 DI 10.1148/rg.341125127 PG 18 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 292QP UT WOS:000329917500020 PM 24428290 ER PT J AU Asch, DA Nicholson, S Srinivas, SK Herrin, J Epstein, AJ AF Asch, David A. Nicholson, Sean Srinivas, Sindhu K. Herrin, Jeph Epstein, Andrew J. TI How Do You Deliver a Good Obstetrician? Outcome-Based Evaluation of Medical Education SO ACADEMIC MEDICINE LA English DT Editorial Material AB The goal of medical education is the production of a workforce capable of improving the health and health care of patients and populations, but it is hard to use a goal that lofty, that broad, and that distant as a standard against which to judge the success of schools or training programs or particular elements within them. For that reason, the evaluation of medical education often focuses on elements of its structure and process, or on the assessment of competencies that could be considered intermediate outcomes. These measures are more practical because they are easier to collect, and they are valuable when they reflect activities in important positions along the pathway to clinical outcomes. But they are all substitutes for measuring whether educational efforts produce doctors who take good care of patients. The authors argue that the evaluation of medical education can become more closely tethered to the clinical outcomes medical education aims to achieve. They focus on a specific clinical outcomematernal complications of obstetrical deliveryand show how examining various observable elements of physicians' training and experience helps reveal which of those elements lead to better outcomes. Does it matter where obstetricians trained? Does it matter how much experience they have? Does it matter how good they were to start? Each of these questions reflects a component of the production of a good obstetrician and, most important, defines a good obstetrician as one whose patients in the end do well. C1 [Asch, David A.; Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Asch, David A.; Epstein, Andrew J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA. [Nicholson, Sean] Cornell Univ, Dept Policy Anal & Management, Ithaca, NY USA. [Nicholson, Sean] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Srinivas, Sindhu K.] Univ Penn, Div Maternal Fetal Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Herrin, Jeph] Yale Univ, Sch Med, New Haven, CT USA. [Herrin, Jeph] Hlth Res Educ Trust, Chicago, IL USA. RP Asch, DA (reprint author), Ctr Innovat, 423 Guardian Dr Blockley Hall 1123, Philadelphia, PA 19104 USA. EM asch@wharton.upenn.edu OI Asch, David/0000-0002-7970-286X NR 3 TC 14 Z9 14 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD JAN PY 2014 VL 89 IS 1 BP 24 EP 26 DI 10.1097/ACM.0000000000000067 PG 3 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 282RI UT WOS:000329189900011 PM 24280859 ER PT J AU Fox, E AF Fox, Ellen TI Developing a Certifying Examination for Health Care Ethics Consultants: Bioethicists Need Help SO AMERICAN JOURNAL OF BIOETHICS LA English DT Editorial Material ID NATIONAL-SURVEY; HOSPITALS C1 [Fox, Ellen] Natl Ctr Eth Hlth Care, US Dept Vet Affairs, Washington, DC 20420 USA. RP Fox, E (reprint author), Natl Ctr Eth Hlth Care, US Dept Vet Affairs VA, 810 Vermont Ave,NW 10P6, Washington, DC 20420 USA. EM foxe2@comcast.net NR 12 TC 4 Z9 4 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1526-5161 EI 1536-0075 J9 AM J BIOETHICS JI Am. J. Bioeth. PD JAN 1 PY 2014 VL 14 IS 1 BP 1 EP 4 DI 10.1080/15265161.2014.873243 PG 4 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA 288IH UT WOS:000329604700002 PM 24422919 ER PT J AU Gilley, SK Stenbit, AE Pasek, RC Sas, KM Steele, SL Amria, M Bunni, MA Estell, KP Schwiebert, LM Flume, P Gooz, M Haycraft, CJ Yoder, BK Miller, C Pavlik, JA Turner, GA Sisson, JH Bell, PD AF Gilley, Sandra K. Stenbit, Antine E. Pasek, Raymond C. Sas, Kelli M. Steele, Stacy L. Amria, May Bunni, Marlene A. Estell, Kimberly P. Schwiebert, Lisa M. Flume, Patrick Gooz, Monika Haycraft, Courtney J. Yoder, Bradley K. Miller, Caroline Pavlik, Jacqueline A. Turner, Grant A. Sisson, Joseph H. Bell, P. Darwin TI Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE bronchiectasis; hyperreactivity; lung; respiratory ID POLYCYSTIC KIDNEY-DISEASE; SMOOTH-MUSCLE-CELLS; CALCIUM; MODEL; LUNG; INTRAFLAGELLAR; TRANSPORT; SPECTRUM; BIOLOGY; PROTEIN AB The mechanisms for the development of bronchiectasis and airway hyperreactivity have not been fully elucidated. Although genetic, acquired diseases and environmental influences may play a role, it is also possible that motile cilia can influence this disease process. We hypothesized that deletion of a key intraflagellar transport molecule, IFT88, in mature mice causes loss of cilia, resulting in airway remodeling. Airway cilia were deleted by knockout of IFT88, and airway remodeling and pulmonary function were evaluated. In IFT88(-) mice there was a substantial loss of airway cilia on respiratory epithelium. Three months after the deletion of cilia, there was clear evidence for bronchial remodeling that was not associated with inflammation or apparent defects in mucus clearance. There was evidence for airway epithelial cell hypertrophy and hyperplasia. IFT88(-) mice exhibited increased airway reactivity to a methacholine challenge and decreased ciliary beat frequency in the few remaining cells that possessed cilia. With deletion of respiratory cilia there was a marked increase in the number of club cells as seen by scanning electron microscopy. We suggest that airway remodeling may be exacerbated by the presence of club cells, since these cells are involved in airway repair. Club cells may be prevented from differentiating into respiratory epithelial cells because of a lack of IFT88 protein that is necessary to form a single nonmotile cilium. This monocilium is a prerequisite for these progenitor cells to transition into respiratory epithelial cells. In conclusion, motile cilia may play an important role in controlling airway structure and function. C1 [Gilley, Sandra K.; Stenbit, Antine E.; Sas, Kelli M.; Steele, Stacy L.; Amria, May; Bunni, Marlene A.; Flume, Patrick; Gooz, Monika; Haycraft, Courtney J.; Bell, P. Darwin] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Bell, P. Darwin] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Miller, Caroline] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA. [Pasek, Raymond C.; Estell, Kimberly P.; Schwiebert, Lisa M.; Yoder, Bradley K.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [Pavlik, Jacqueline A.; Turner, Grant A.; Sisson, Joseph H.] Univ Nebraska, Med Ctr, Dept Internal Med, Pulm Crit Care Sleep & Allergy Div, Omaha, NE USA. RP Bell, PD (reprint author), Med Univ S Carolina, 70 President St,DDB520, Charleston, SC 29425 USA. EM Bellpd@musc.edu OI Pasek, Raymond/0000-0002-1817-8697 FU Veterans Affairs Merit Grant; Core C of the UAB [P30-DK-074038, DK-32032, DK-065655, RO1-AA-008769]; Dialysis Clinic FX This project was supported by a Veterans Affairs Merit Grant (P. D. Bell), Core C of the UAB P30-DK-074038, DK-32032 (P. D. Bell), DK-065655 (B. K. Yoder), RO1-AA-008769 (J. H. Sisson), and funds from Dialysis Clinic. NR 38 TC 8 Z9 9 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD JAN PY 2014 VL 306 IS 2 BP L162 EP L169 DI 10.1152/ajplung.00095.2013 PG 8 WC Physiology; Respiratory System SC Physiology; Respiratory System GA 291VC UT WOS:000329858000006 PM 24213915 ER PT J AU Rice, LA Smith, I Kelleher, AR Greenwald, K Boninger, ML AF Rice, Laura A. Smith, Ian Kelleher, Annmaire R. Greenwald, Karen Boninger, Michael L. TI Impact of a Wheelchair Education Protocol Based on Practice Guidelines for Preservation of Upper-Limb Function: A Randomized Trial SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Medical education; Wheelchair; Rehabilitation; Spinal cord injuries ID SPINAL-CORD-INJURY; CARPAL-TUNNEL-SYNDROME; CLINICAL-PRACTICE GUIDELINES; BEARING UPPER EXTREMITY; PAIN RATING-SCALES; SHOULDER PAIN; RISK-FACTORS; PUSHRIM BIOMECHANICS; PARAPLEGIC PATIENTS; AXLE POSITION AB Objectives: To determine if strict use of the Paralyzed Veterans of America's Clinical Practice Guidelines for Preservation of Upper Limb Function affects wheelchair setup, selection, propulsion biomechanics, pain, satisfaction with life, and participation of individuals with new spinal cord injuries (SCIs). Design: Single blinded, randomized controlled trial. Setting: Model SCI systems rehabilitation facility and community. Participants: Volunteer sample of manual wheelchair users with new SCIs (N=37). Intervention: The intervention group was strictly educated on the clinical practice guideline by a physical therapist and an occupational therapist in an inpatient rehabilitation facility. The standard of care group received standard therapy services. Main Outcome Measures: Comparison of wheelchair setup, selection, propulsion biomechanics, pain, and Satisfaction With Life Scale and Craig Handicap Assessment and Reporting Technique scores at the time of discharge from inpatient rehabilitation and at 6 months and 1 year postdischarge. Results: Participants in the intervention group pushed on tile with significantly lower push frequency (P=.02) at the discharge visit. On the ramp, the intervention group used a significantly larger push length (P =.03) across all time points. No significant differences were found between groups related to wheelchair setup, selection, pain, satisfaction with life, and participation. Conclusions: The intervention group showed better skills on key wheelchair propulsion biomechanics variables related to upper-limb health. Use of a structured education program may be an effective method of educating new manual wheelchair users to prevent the development of upper-limb impairments in an inpatient setting. Additional follow-up testing is necessary to determine whether the differences seen in propulsion skills translate into decreased pain and improved quality of life in the long term. Archives of Physical Medicine and Rehabilitation 2014;95:10-9 (c) 2014 by the American Congress of Rehabilitation Medicine C1 [Boninger, Michael L.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA. [Smith, Ian; Greenwald, Karen; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Kelleher, Annmaire R.; Boninger, Michael L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Kelleher, Annmaire R.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. RP Rice, LA (reprint author), 2003 Huff Hall,M-C-586,1206 South 4th St, Champaign, IL 61820 USA. EM ricela@illinois.edu OI Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research; Office of Special Education and Rehabilitation Services; US Department of Education [H133N000019, H133N060019] FX Supported by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, US Department of Education (grant no. H133N000019/ H133N060019). The material presented hem is solely the responsibility of the authors and does not necessarily reflect the opinions of the funding agency or the US Department of Education. NR 52 TC 0 Z9 0 U1 1 U2 19 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JAN PY 2014 VL 95 IS 1 BP 10 EP 19 DI 10.1016/j.apmr.2013.06.028 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 289KI UT WOS:000329681000002 PM 23856151 ER PT J AU Switzer, GE Bruce, JG Harrington, D Haagenson, M Drexler, R Foley, A Confer, D Bishop, M Anderlini, P Rowley, S Leitman, SF Anasetti, C Wingard, JR AF Switzer, Galen E. Bruce, Jessica G. Harrington, Donna Haagenson, Michael Drexler, Rebecca Foley, Amy Confer, Dennis Bishop, Michelle Anderlini, Paolo Rowley, Scott Leitman, Susan F. Anasetti, Claudio Wingard, John R. TI Health-related Quality of Life of Bone Marrow versus Peripheral Blood Stem Cell Donors: A Prespecified Subgroup Analysis from a Phase III RCT-BMTCTN Protocol 0201 SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Marrow versus peripheral blood stem cell donation; Unrelated hematopoietic stem cell donation; Randomized trial ID UNRELATED DONORS; PROSPECTIVE TRIAL; MOOD STATES; DONATION; EXPERIENCE; PROGRAM; TRANSPLANTATION; SAFETY; PRODUCT; PROFILE AB Hematopoietic stem cells can be procured from unrelated donors via either the bone marrow (BM) aspiration or peripheral blood stem cell (PBSC) collection methods. There is no evidence from prospective randomized trials in the unrelated donor setting about the relative health-related quality-of-life (HRQoL) benefits/costs to donors. The goals of this prospective longitudinal investigation were to describe and compare the donation-related HRQoL experiences of 332 BM and PBSC donors. Donors were interviewed before donation, 48 hours after donation, weekly until fully recovered, and at 6 and 12 months after donation. Before donation, BM donors had lower confusion, fewer concerns, and were more prepared for donation. Shortly after donation, BM donors reported more physical side effects. BM donors also reported more donation-related impact on their social activities. However, BM donors reported somewhat better psychological status and were more likely to indicate that the donation made their lives more meaningful. There were virtually no longer term differences in the experiences of the 2 donor groups, including no recovery time difference beginning 3 weeks after donation. Although BM donors may experience the process as more physically stressful and more psychologically beneficial in the short term, the longer term HRQoL consequences of BM and PBSC donors are similar. Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation. C1 [Switzer, Galen E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA. [Switzer, Galen E.; Bruce, Jessica G.; Harrington, Donna] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA 15213 USA. [Haagenson, Michael; Drexler, Rebecca; Foley, Amy; Confer, Dennis] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Haagenson, Michael] Natl Marrow Donor Program, Minneapolis, MN USA. [Bishop, Michelle; Wingard, John R.] Univ Florida, Coll Med, Gainesville, FL USA. [Anderlini, Paolo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Rowley, Scott] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Leitman, Susan F.] NIH, Ctr Clin, Bethesda, MD 20892 USA. [Anasetti, Claudio] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. RP Switzer, GE (reprint author), Univ Pittsburgh, 3501 Forbes Ave,Oxford Bld Suite 410, Pittsburgh, PA 15213 USA. EM SwitzerGE@upmc.edu FU National Heart, Lung, and Blood Institute; National Cancer Institute [U10HL069294]; Office of Naval Research; National Marrow Donor program FX Financial disclosure: Supported by a grant from the National Heart, Lung, and Blood Institute and the National Cancer Institute (U10HL069294), by the Office of Naval Research, and by the National Marrow Donor program. NR 24 TC 9 Z9 9 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD JAN PY 2014 VL 20 IS 1 BP 118 EP 127 DI 10.1016/j.bbmt.2013.10.024 PG 10 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 289LG UT WOS:000329683400018 PM 24184336 ER PT J AU Bandeali, SJ Daye, J Virani, SS AF Bandeali, Salman J. Daye, Jad Virani, Salim S. TI Novel Therapies for Treating Familial Hypercholesterolemia SO CURRENT ATHEROSCLEROSIS REPORTS LA English DT Article DE Familial hypercholesterolemia; Mipomersen; Proprotein convertase subtilisin/kexin 9 inhibitors; Lomitapide ID DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; B SYNTHESIS INHIBITOR; VIVO GENE-THERAPY; TRIGLYCERIDE TRANSFER PROTEIN; PLACEBO-CONTROLLED TRIAL; MONOCLONAL-ANTIBODY; LDL CHOLESTEROL; DOUBLE-BLIND; PLASMA-CHOLESTEROL AB Familial hypercholesterolemia is an inherited disorder associated with early accelerated atherosclerosis with morbidity and mortality resulting from premature cardiovascular disease. Affected individuals have extreme elevations in low-density lipoprotein cholesterol levels. Patients usually do not achieve target reductions in cholesterol levels with conventional antihyperlipidemic pharmacotherapy. This unmet need has resulted in the recent development and approval of novel therapies targeting different cholesterol pathways. This article briefly summarizes familial hypercholesterolemia and then discusses the newer pharmacotherapies available in the management of familial hypercholesterolemia. C1 [Bandeali, Salman J.] St Lukes Episcopal Hosp, Texas Heart Inst, Cardiol Sect, Dept Med, Houston, TX 77030 USA. [Daye, Jad; Virani, Salim S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Virani, Salim S.] Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy Qual & Informat Program, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA. [Virani, Salim S.] Houston Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX 77030 USA. [Virani, Salim S.] Michael E DeBakey VA Med Ctr, Cardiol Sect, Houston, TX 77030 USA. [Virani, Salim S.] Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev 152, Houston, TX 77030 USA. RP Virani, SS (reprint author), Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM salmanbandeali@hotmail.com; eldaye@bcm.edu; virani@bcm.edu FU Department of Veterans Affairs Health Services Research and Development Service Career Development Award FX Salim S. Virani is supported by a Department of Veterans Affairs Health Services Research and Development Service Career Development Award. NR 52 TC 2 Z9 2 U1 0 U2 3 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1523-3804 EI 1534-6242 J9 CURR ATHEROSCLER REP JI Curr. Atheroscleros. Rep. PD JAN PY 2014 VL 16 IS 1 AR 382 DI 10.1007/s11883-013-0382-0 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 288LY UT WOS:000329614700006 PM 24293346 ER PT J AU Villani, V Milanesi, A Sedrakyan, S Da Sacco, S Angelow, S Conconi, MT Di Liddo, R De Filippo, R Perin, L AF Villani, Valentina Milanesi, Anna Sedrakyan, Sargis Da Sacco, Stefano Angelow, Susanne Conconi, Maria Teresa Di Liddo, Rosa De Filippo, Roger Perin, Laura TI Amniotic fluid stem cells prevent beta-cell injury SO CYTOTHERAPY LA English DT Article DE amniotic fluid; beta-cell; pancreas; regeneration; stem cells; type 1 diabetes mellitus ID INSULIN-PRODUCING CELLS; TYPE-1 DIABETES-MELLITUS; BONE-MARROW; IN-VITRO; VASCULAR MATURATION; PANCREATIC-ISLETS; GENE-EXPRESSION; DIFFERENTIATION; MICE; PROLIFERATION AB Background aims. The contribution of amniotic fluid stem cells (AFSC) to tissue protection and regeneration in models of acute and chronic kidney injuries and lung failure has been shown in recent years. In the present study, we used a chemically induced mouse model of type 1 diabetes to determine whether AFSC could play a role in modulating beta-cell injury and restoring beta-cell function. Methods. Streptozotocin-induced diabetic mice were given intracardial injection of AFSC; morphological and physiological parameters and gene expression profile for the insulin pathway were evaluated after cell transplantation. Results. AFSC injection resulted in protection from beta-cell damage and increased beta-cell regeneration in a subset of mice as indicated by glucose and insulin levels, increased islet mass and preservation of islet structure. Moreover, beta-cell preservation/regeneration correlated with activation of the insulin receptor/Pi3K/Akt signaling pathway and vascular endothelial growth factor-A expression involved in maintaining beta-cell mass and function. Conclusions. Our results suggest a therapeutic role for AFSC in preserving and promoting endogenous beta-cell functionality and proliferation. The protective role of AFSC is evident when stem cell transplantation is performed before severe hyperglycemia occurs, which suggests the importance of early intervention. The present study demonstrates the possible benefits of the application of a non-genetically engineered stem cell population derived from amniotic fluid for the treatment of type 1 diabetes mellitus and gives new insight on the mechanism by which the beneficial effect is achieved. C1 [Villani, Valentina; Sedrakyan, Sargis; Da Sacco, Stefano; Angelow, Susanne; De Filippo, Roger; Perin, Laura] Univ So Calif, Childrens Hosp Los Angeles, Dept Urol, Los Angeles, CA USA. [Milanesi, Anna] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA. [Conconi, Maria Teresa; Di Liddo, Rosa] Univ Padua, Dept Pharmaceut Sci, Padua, Italy. RP Perin, L (reprint author), Childrens Hosp Los Angeles, Dept Urol, 4661 Sunset Blvd,Mailstop 35, Los Angeles, CA 90027 USA. EM lperin@chla.usc.edu FU Fondazione Ing Aldo Gini (University of Padua); Iacocca foundation; GOFARR FX We thank Fondazione Ing Aldo Gini (University of Padua) for funding support to the present research. We also would like to thank Dr Habibian for providing the human amniotic fluid samples. This work was supported by The Iacocca foundation and GOFARR. NR 46 TC 6 Z9 6 U1 2 U2 11 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1465-3249 EI 1477-2566 J9 CYTOTHERAPY JI Cytotherapy PD JAN PY 2014 VL 16 IS 1 BP 41 EP 55 DI 10.1016/j.jcyt.2013.08.010 PG 15 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine GA 288DS UT WOS:000329592800005 PM 24210784 ER PT J AU Quinn, LS Anderson, BG Conner, JD Wolden-Hanson, T Marcell, TJ AF Quinn, LeBris S. Anderson, Barbara G. Conner, Jennifer D. Wolden-Hanson, Tami Marcell, Taylor J. TI IL-15 Is Required for Postexercise Induction of the Pro-Oxidative Mediators PPAR delta and SIRT1 in Male Mice SO ENDOCRINOLOGY LA English DT Article ID HUMAN SKELETAL-MUSCLE; ENDURANCE EXERCISE; GENE-EXPRESSION; INTERLEUKIN-15; RECEPTOR; PGC-1-ALPHA; PROTEIN; FAT; MASS; OVEREXPRESSION AB Physical exercise induces transient upregulation of the pro-oxidative mediators peroxisome proliferator-activated receptor-delta (PPAR delta), silent information regulator of transcription (sirtuin)-1 (SIRT1), PPAR gamma coactivator 1 alpha (PGC-1 alpha), and PGC-1 beta in skeletal muscle. To determine the role of the cytokine IL-15 in acute postexercise induction of these molecules, expression of these factors after a bout of exhaustive treadmill running was examined in the gastrocnemius muscle of untrained control and IL-15-knockout (KO) mice. Circulating IL-15 levels increased transiently in control mice after exercise. Control mice, but not IL-15-KO mice, upregulated muscle PPAR delta and SIRT1 protein after exercise, accompanied by a complex pattern of mRNA expression for these factors. However, in exhaustive exercise, control mice ran significantly longer than IL-15-KO mice. Therefore, in a second experiment, mice were limited to a 20-minute run, after which a similar pattern of induction of muscle PPAR delta and SIRT1 protein by control mice only was observed. In a separate experiment, IL-15-KO mice injected systemically with recombinant IL-15 upregulated muscle PPAR delta and SIRT1 mRNA within 30 minutes and also exhibited increased muscle PPAR delta protein levels by 3 hours. After exercise, both control and IL-15-KO mice downregulated IL-15 receptor-alpha (IL-15R alpha) mRNA, whereas IL-15R alpha-deficient mice exhibited constitutively elevated circulating IL-15 levels. These observations indicate IL-15 release after exercise is necessary for induction of PPAR delta and SIRT1 at the protein level in muscle tissue and suggest that exercise releases IL-15 normally sequestered by the IL-15R alpha in the resting state. These findings could be used to develop an IL-15-based strategy to induce many of the metabolic benefits of physical exercise. C1 [Quinn, LeBris S.; Anderson, Barbara G.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Quinn, LeBris S.; Conner, Jennifer D.; Wolden-Hanson, Tami] VA Puget Sound Hlth Care Syst, Res Serv, Seattle, WA 98108 USA. [Quinn, LeBris S.; Conner, Jennifer D.] Seattle Inst Biomed & Clin Res, Seattle, WA 98108 USA. [Quinn, LeBris S.; Anderson, Barbara G.] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98195 USA. [Marcell, Taylor J.] Calif State Univ Stanislaus, Dept Kinesiol, Turlock, CA 95382 USA. RP Quinn, LS (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM quinnL@uw.edu FU Department of Veterans Affairs [BX001026] FX This work was supported by Merit Review BX001026 from the Department of Veterans Affairs (to L. S. Q.) and use of resources and facilities including the Rodent Metabolic and Behavioral Phenotyping Core at VA Puget Sound Health Care System, the Transgenic Resource Core at the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging (NIA 5P30AG-013280), and the University of Washington Diabetes Endocrinology Research Center (NIH P30 DK-17047). NR 45 TC 13 Z9 13 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2014 VL 155 IS 1 BP 143 EP 155 DI 10.1210/en.2013-1645 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 279NU UT WOS:000328967500020 PM 24169546 ER PT J AU Sibila, O Mortensen, EM Anzueto, A Laserna, E Restrepo, MI AF Sibila, Oriol Mortensen, Eric M. Anzueto, Antonio Laserna, Elena Restrepo, Marcos I. TI Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; OBSTRUCTIVE PULMONARY-DISEASE; ACUTE CORONARY SYNDROMES; UNITED-STATES; CARE; HOSPITALIZATIONS; COMORBIDITY; INFECTION; PATTERNS; OUTCOMES AB There is controversy regarding the impact of chronic obstructive pulmonary disease (COPD) in clinical outcomes in elderly patients with pneumonia. Comorbidities such as cardiovascular disease have been reported to play an important role in patients with acute exacerbations of COPD. However, limited data are available regarding the impact of cardiovascular disease in elderly COPD patients who require hospitalisation for pneumonia. We examined a cohort of subjects with pneumonia and pre-existing COPD. Prior cardiovascular disease was defined as history of myocardial infarction, congestive heart failure, cardiac arrhythmia, unstable angina or stroke. Outcomes examined included 30-day, 90-day, 6-month and 1-year mortality. We included 17 140 elderly COPD patients who were hospitalised for pneumonia. Prior cardiovascular disease was present in 10 240 (59.7%) patients. Prior cardiovascular disease was independently associated with 90-day mortality (21.3% versus 19.4%; hazard ratio (HR) 1.29, 95% CI 1.02-1.17), 6-month mortality (29.0% versus 26.1%; HR 1.28, 95% CI 1.07-1.50) and 12-month mortality (39.2% versus 34.5%; HR 1.33, 95% CI 1.15-1.54) when compared to no prior cardiovascular disease. The temporal differential effect between groups increases from 1.0% at 30 days to 4.7% at 1 year. Prior cardiovascular disease is associated with increased long-term mortality in elderly COPD patients with pneumonia. Differences in mortality rates increased over time. C1 [Sibila, Oriol; Anzueto, Antonio; Laserna, Elena; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Mortensen, Eric M.] Vet Affairs North Texas Hlth Care Syst, San Antonio, TX USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Anzueto, Antonio; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, Marcos I.] Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. [Sibila, Oriol] Hosp Santa Creu & Sant Pau, Serv Pneumol, Barcelona, Spain. [Laserna, Elena] Hosp Comarcal Mollet, Mollet Del Valles, Spain. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst ALMD, VERDICT 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 FU Howard Hughes Medical Institute faculty-start up grant [00378-001]; Dept of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant; Instituto de Salud Carlos III [BAE11/00102]; Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR); Societat Catalana de Pneumologia (SOCAP); Fundacio Catalana de Pneumologia (FUCAP); National Heart, Lung, and Blood Institute [K23HL096054] FX This research was supported by Howard Hughes Medical Institute faculty-start up grant 00378-001 and a Dept of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant. O. Sibila is supported by Instituto de Salud Carlos III (BAE11/00102). O. Sibila and E. Laserna are supported by Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR), Societat Catalana de Pneumologia (SOCAP) and Fundacio Catalana de Pneumologia (FUCAP). M.I. Restrepo's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The funding agencies had no role in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the author and do not necessarily represent the views of the Dept of Veterans Affairs. NR 31 TC 8 Z9 8 U1 0 U2 4 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD JAN PY 2014 VL 43 IS 1 BP 36 EP 42 DI 10.1183/09031936.00117312 PG 7 WC Respiratory System SC Respiratory System GA 287ON UT WOS:000329552200009 PM 23598950 ER PT J AU Pizzirusso, M Lin, J Head, C Marcus, SM Ahmed, S Brau, N Weiss, JJ AF Pizzirusso, Maria Lin, Jenny Head, Cory Marcus, Sue M. Ahmed, Samia Braeu, Norbert Weiss, Jeffrey J. TI Impact of Hepatitis C Treatment Initiation on Adherence to Concomitant Medications SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE LA English DT Article DE adherence; concomitant medications; HCV; HIV; treatment initiation ID SELF-REPORTED ADHERENCE; CHRONIC HCV INFECTION; GENOTYPE 1 INFECTION; VISUAL ANALOG SCALE; ANTIRETROVIRAL ADHERENCE; PEGYLATED INTERFERON; HIV PATIENTS; THERAPY; BOCEPREVIR; TELAPREVIR AB Our study investigated whether initiating hepatitis C virus (HCV) treatment affected adherence to concomitant medications. Mixed-effects linear regression was used to analyze data from 57 patients (29 co-infected with HIV) in a prospective study of HCV treatment-naive patients initiating HCV treatment. Adherence was assessed using structured selfreport at the time of treatment initiation, and at 12 weeks and 24 weeks into treatment. There was no change in adherence to concomitant medications over the first 24 weeks of HCV treatment. There was a significant interaction effect such that the change in adherence to concomitant medications between baseline and 12 weeks differed between the HIV-infected and HIV-uninfected patients. Adherence to concomitant medications in the HIV-infected patients was found to decrease, whereas adherence in the HIV-uninfected patients was found to increase. HIVinfected patients may be more at risk for adherence problems in the first 12 weeks of HCV treatment as compared to HIV-uninfected patients. Copyright (C) 2014 Association of Nurses in AIDS Care C1 [Pizzirusso, Maria; Lin, Jenny; Braeu, Norbert; Weiss, Jeffrey J.] Icahn Sch Med Mt Sinai, New York, NY USA. [Head, Cory] New York City Childrens Ctr, Bronx, NY USA. [Marcus, Sue M.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Marcus, Sue M.] Columbia Coll Phys & Surg, New York, NY USA. [Ahmed, Samia; Braeu, Norbert] Bronx Vet Affairs Med Ctr, Bronx, NY USA. RP Pizzirusso, M (reprint author), Icahn Sch Med Mt Sinai, New York, NY USA. FU National Institute of Mental Health of the National Institutes of Health [MH071177] FX This study was funded by the National Institute of Mental Health of the National Institutes of Health, grant number MH071177. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. NR 30 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1055-3290 EI 1552-6917 J9 J ASSOC NURSE AIDS C JI J. Assoc. Nurses Aids Care PD JAN-FEB PY 2014 VL 25 IS 1 BP 23 EP 31 DI 10.1016/j.jana.2013.07.004 PG 9 WC Nursing SC Nursing GA 287FG UT WOS:000329526500005 PM 24070644 ER PT J AU Basile, JN Bloch, MJ AF Basile, Jan N. Bloch, Michael J. TI Analysis of Recent Papers in Hypertension Treatment of Hypertension in the Setting of Acute Intracerebral Hemorrhage: Still No Clear Answer on the Best BP Level to Intervene or What BP Goal to Achieve SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article C1 [Basile, Jan N.] Med Univ S Carolina, Div Gen Internal Med Geriatr, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA. [Basile, Jan N.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA. [Bloch, Michael J.] Renown Reg Med Ctr, Renown Inst Heart & Vasc Hlth, Reno, NV USA. RP Bloch, MJ (reprint author), Univ Hlth Syst, 1500 East Second St,Suite 302, Reno, NV 89502 USA. EM michael@bluesprucemed.com NR 3 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD JAN PY 2014 VL 16 IS 1 BP 1 EP 3 DI 10.1111/jch.12233 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 286SA UT WOS:000329487800006 PM 24325638 ER PT J AU Gujral, UP Narayan, KMV Kahn, SE Kanaya, AM AF Gujral, Unjali P. Narayan, K. M. Venkat Kahn, Steven E. Kanaya, Alka M. TI The relative associations of beta-cell function and insulin sensitivity with glycemic status and incident glycemic progression in migrant Asian Indians in the United States: The MASALA study SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Type 2 diabetes mellitus; Asian Indians; Insulin sensitivity; beta-cell dysfunction; Ethnicity; Incidence; Impaired glucose tolerance; Impaired fasting glucose ID POPULATION-BASED INCIDENCE; SOUTH ASIANS; RESISTANCE; DYSFUNCTION; PREVALENCE; GLUCOSE; ATHEROSCLEROSIS; MODEL; RISK; US AB Aims: We assessed the relative associations of beta-cell dysfunction and insulin sensitivity with baseline glycemic status and incident glycemic progression among Asian Indians in the United States. Methods: A 5-sample oral glucose tolerance test was obtained at baseline. Normoglycemia, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and type 2 diabetes (T2DM) were defined by ADA criteria. The Matsuda Index (ISIM) estimated insulin sensitivity, and the Disposition Index (DIo) estimated beta-cell function. Visceral fat was measured by abdominal CT. After 2.5 years, participants underwent a 2-sample oral glucose tolerance test. Standardized polytomous logistic regression was used to examine associations with prevalent and incident glycemia. Results: Mean age was 57 +/- 8 years and BMI 26.1 +/- 4.6 kg/m(2). Log ISIM and log DIo were associated with prediabetes and T2DM after adjusting for age, sex, BMI, family history of diabetes, hypertension, and smoking. After adjusting for visceral fat, only DIo remained associated with prediabetes (OR per SD 0.17, 95% CI: 0.70, 0.41) and T2DM (OR 0.003, 95% CI: 0.0001, 0.03). Incidence rates (per 1,000 person-years) were: normoglycemia to IGT: 82.0, 95% CI (40, 150); to IFG: 8.4, 95% CI (0, 41); to T2DM: 8.6, 95% CI (0, 42); IGT to T2DM: 55.0, 95% CI (17, 132); IFG to T2DM: 64.0, 95% CI (3, 316). The interaction between sex and the change in waist circumference (OR 1.8, per SD 95% CI: 1.22, 2.70) and the change in log HOMA-beta (OR 0.37, per SD 95% CI: 0.17, 0.81) were associated with glycemic progression. Conclusions: The association of DIo with baseline glycemia after accounting for visceral fat as well as the association of the change in log HOMA-beta with incident glycemic progression implies innate beta-cell susceptibility in Asian Indians for glucose intolerance or dysglycemia. (C) 2014 Elsevier Inc. All rights reserved. C1 [Gujral, Unjali P.; Narayan, K. M. Venkat] Emory Univ, Laney Grad Sch, Grad Div Biomed & Biol Sci, Nutr & Hlth Sci Program, Atlanta, GA 30329 USA. [Narayan, K. M. Venkat] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30329 USA. [Narayan, K. M. Venkat] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30329 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Kanaya, Alka M.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94115 USA. RP Kanaya, AM (reprint author), Univ Calif San Francisco, Box 0320,1545 Divisadero St,Suite 311, San Francisco, CA 94115 USA. EM alka.kanaya@ucsf.edu RI Narayan, K.M. Venkat /J-9819-2012 OI Narayan, K.M. Venkat /0000-0001-8621-5405 FU NIH [K23 HL080026-01]; American Heart Association [0855069F]; NIH/NCRR UCSF-CTSI [UL1 RR024131]; Fulbright Nehru Scholars Program; United States Department of Veterans Affairs FX The MASALA study were supported by the NIH [grant no. K23 HL080026-01] and the American Heart Association (Western States Affiliate award #0855069F). This project was supported by NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131.UP Gujral was funded by the Fulbright Nehru Scholars Program. SE Kahn was supported by the United States Department of Veterans Affairs. NR 28 TC 8 Z9 8 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD JAN-FEB PY 2014 VL 28 IS 1 BP 45 EP 50 DI 10.1016/j.jdiacomp.2013.10.002 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 288DL UT WOS:000329592100011 PM 24211090 ER PT J AU Ismail-Beigi, F Lombardero, MS Escobedo, J Genuth, S Green, J Massaro, E Mooradian, AD Ovalle, F Whitehouse, F Zonszein, J AF Ismail-Beigi, Faramarz Lombardero, Manuel S. Escobedo, Jorge Genuth, Saul Green, Jennifer Massaro, Elaine Mooradian, Arshag D. Ovalle, Fernando Whitehouse, Fred Zonszein, Joel CA Bari 2D Study Grp TI Determinants of successful glycemic control among participants in the BARI 2D Trial: A Post-hoc Analysis SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Cardiovascular disease; Plasma insulin levels; Predictors of glycemic control ID BETA-CELL FUNCTION; TYPE-2 DIABETES-MELLITUS; INSULIN-SECRETION; GLUCOSE; AGE; SENSITIVITY; AMERICANS; METFORMIN; THERAPY; DESIGN AB Objective: The BARI 2D trial compared insulin provision (IP) versus insulin sensitization (IS) for the primary outcome of total mortality in participants with T2DM and cardiovascular disease (CVD). In this analysis we examine baseline characteristics that are associated with successful long-term glycemic control. Research design and methods: In a 2 x 2 factorial design, 2368 participants were randomized to either IP or IS therapy, and to either prompt revascularization with medical therapy or medical therapy alone. Successful long-term glycemic control (success) was defined by simultaneously meeting 1) a mean HbA1c level of <7.0% after each participant's third year of follow-up period, and 2) adherence with medications only from the assigned glycemic treatment arm during >80% of the BARI 2D follow-up. The association between baseline variables and success was determined using unadjusted and adjusted logistic regression models. Results: 1917 participants (962 IP and 955 IS participants) had sufficiently long follow-up and data for this analysis. Among these IP and IS participants, 235 and 335 participants met both criteria of success, respectively (p<0.001). Those not on insulin at entry had higher odds of success (OR 2.25; CI 1.79-2.82) when treated with IS versus IP medications, irrespective of baseline HbA1c levels. Younger age, shorter duration of T2DM, and lower HbA1c at baseline were also each independently associated with higher success when treated with IS versus IP medications. Conclusion: Patients similar to those in the BARI 20 trial may have a higher chance of achieving success with IS versus IP medications if they are younger, have shorter duration of T2DM, have lower HbA1c levels, have moderate or strenuous physically activity, and are not on insulin. In contrast, increasing age, longer duration of T2DM, higher HbA1c, and insulin therapy are associated with increased chance of success if treated with IP medications. (C) 2014 Elsevier Inc. All rights reserved. C1 [Ismail-Beigi, Faramarz; Genuth, Saul] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Ismail-Beigi, Faramarz] Cleveland VA Med Ctr, Cleveland, OH USA. [Lombardero, Manuel S.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Escobedo, Jorge] Reg Hosp 1, Clin Res Ctr, Mexican Inst Social Secur, Benito Juarez 03100, DF, Mexico. [Green, Jennifer] Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27710 USA. [Green, Jennifer] Durham VA Med Ctr, Durham, NC 27710 USA. [Massaro, Elaine] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Mooradian, Arshag D.] Univ Florida, Coll Med, Jacksonville, FL USA. [Ovalle, Fernando] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Ovalle, Fernando] Birmingham VA Med Ctr, Birmingham, AL USA. [Whitehouse, Fred] Henry Ford Hlth Syst, Diabet & Bone & Mineral Dis, Div Endocrinol, Detroit, MI USA. [Zonszein, Joel] Albert Einstein Coll Med, Montefiore Clin Diabet Ctr, Bronx, NY 10467 USA. RP Ismail-Beigi, F (reprint author), Case Western Reserve Univ, Dept Med, 10900 Euclid Ave, Cleveland, OH 44106 USA. EM fxi2@case.edu FU National Heart, Lung and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases [U01 HL061744, U01 HL061746, U01 HL061748, U01 HL063804]; GlaxoSmithKline; Lantheus Medical Imaging, Inc.; Astellas Pharma US, Inc.; Merck Co., Inc.; Abbott Laboratories, Inc.; Pfizer, Inc. FX The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 20) is funded by the National Heart, Lung and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (U01 HL061744, U01 HL061746, U01 HL061748, U01 HL063804).; BARI 2D receives significant supplemental funding from GlaxoSmithKline, and additional funding from Lantheus Medical Imaging, Inc. (formerly Bristol-Myers Squibb Medical Imaging, Inc.), Astellas Pharma US, Inc., Merck & Co., Inc., Abbott Laboratories, Inc. and Pfizer, Inc. Medications and supplies were donated by Abbott Laboratories Ltd., MediSense Products, Bayer Diagnostics, Becton, Dickinson and Company, J. R. Carlson Labs, Centocor, Inc., Eli Lilly and Company, LipoScience, Inc., Merck Sante, Novartis Pharmaceuticals Corporation, and Novo Nordisk, Inc. NR 32 TC 1 Z9 1 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD JAN-FEB PY 2014 VL 28 IS 1 BP 101 EP 109 DI 10.1016/j.jdiacomp.2013.01.006 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 288DL UT WOS:000329592100021 PM 23478173 ER PT J AU Linzer, M Levine, R Meltzer, D Poplau, S Warde, C West, CP AF Linzer, Mark Levine, Rachel Meltzer, David Poplau, Sara Warde, Carole West, Colin P. TI 10 Bold Steps to Prevent Burnout in General Internal Medicine SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Linzer, Mark; Poplau, Sara] Hennepin Cty Med Ctr, Div Gen Internal Med, Minneapolis, MN 55415 USA. [Linzer, Mark] Univ Minnesota, Minneapolis, MN USA. [Levine, Rachel] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Meltzer, David] Univ Chicago, Chicago, IL 60637 USA. [Warde, Carole] Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA. [Warde, Carole] Univ Calif Los Angeles, Los Angeles, CA USA. [West, Colin P.] Mayo Clin, Rochester, MN USA. RP Linzer, M (reprint author), Hennepin Cty Med Ctr, Div Internal Med, 701 Pk Ave, Minneapolis, MN 55415 USA. EM Mark.linzer@hcmed.org FU AHRQ HHS [R18 HS018160]; NIA NIH HHS [K24 AG031326] NR 5 TC 31 Z9 31 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2014 VL 29 IS 1 BP 18 EP 20 DI 10.1007/s11606-013-2597-8 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 284WR UT WOS:000329352900008 PM 24002633 ER PT J AU Westergaard, RP Beach, MC Saha, S Jacobs, EA AF Westergaard, Ryan P. Beach, Mary Catherine Saha, Somnath Jacobs, Elizabeth A. TI Racial/Ethnic Differences in Trust in Health Care: HIV Conspiracy Beliefs and Vaccine Research Participation SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE trust in health care; HIV vaccine research; conspiracy beliefs ID AFRICAN-AMERICANS; CLINICAL-TRIALS; MALE CIRCUMCISION; INFECTED PATIENTS; UNITED-STATES; FOLLOW-UP; DISPARITIES; PREVENTION; MEN; HIV/AIDS AB Prior research has documented a high prevalence of conspiracy beliefs about the origin of the human immunodeficiency virus (HIV) and the role of the government in the acquired immunodeficiency syndrome (AIDS) epidemic, particularly among racial and ethnic minorities in the United States. Whether such beliefs are a barrier to participation in HIV prevention research is not known. To understand the prevalence of HIV conspiracy beliefs and their relationship to willingness to participate in HIV vaccine research among three racial/ethnic groups. Cross-sectional survey. Six hundred and one community-recruited volunteers (33.0 % White, 32.5 % Mexican American, and 34.5 % African American). We evaluated the level of agreement with six previously described HIV conspiracy beliefs, trust in medical research, and willingness to participate in HIV vaccine research. Multivariate models were used to compare these parameters among the three racial/ethnic groups while controlling for the potential confounding effects of socioeconomic status, access to health care, and other demographic factors. African Americans, Mexican Americans, and whites had similar levels of distrust in medical research. African and Mexican Americans were more likely to endorse one or more of six HIV conspiracy beliefs than whites (59.0 % and 58.6 % versus 38.9 %, respectively, P < 0.001), but were significantly more willing to participate in HIV vaccine research (ORs 1.58, CI 1.10-2.25 and 2.53, CI 1.75-3.66, respectively). Among respondents of all racial/ethnic groups, endorsing HIV conspiracy beliefs was not associated with willingness to participate in research. HIV conspiracy beliefs, while common among all racial and ethnic groups in the United States, do not preclude willingness to participate in HIV prevention research. C1 [Westergaard, Ryan P.; Jacobs, Elizabeth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53715 USA. [Westergaard, Ryan P.; Jacobs, Elizabeth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Beach, Mary Catherine] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR USA. [Jacobs, Elizabeth A.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Madison, WI USA. RP Westergaard, RP (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, MFCB 5220, Madison, WI 53715 USA. EM rpw@medicine.wisc.edu FU National Institutes of Health [1R21HD057473-01A1]; NIH [K23DA032306]; Department of Medicine; Wisconsin Partnership Program [NCATS9_U54_TR000021]; Health Innovation Program at the University of Wisconsin School of Medicine and Public Health; Department of Veterans Affairs FX This research was funded by the National Institutes of Health (1R21HD057473-01A1). Dr. Westergaard received support from NIH grant K23DA032306. Dr. Jacobs has received additional support from the Department of Medicine, the Wisconsin Partnership Program (NCATS9_U54_TR000021), and the Health Innovation Program at the University of Wisconsin School of Medicine and Public Health. Dr. Saha was supported by the Department of Veterans Affairs. The opinions expressed in this paper are those of the authors and not necessarily those of the U.S. Department of Veterans Affairs. NR 46 TC 7 Z9 7 U1 3 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2014 VL 29 IS 1 BP 140 EP 146 DI 10.1007/s11606-013-2554-6 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 284WR UT WOS:000329352900028 PM 23979684 ER PT J AU Oslin, DW Lynch, KG Maisto, SA Lantinga, LJ McKay, JR Possemato, K Ingram, E Wierzbicki, M AF Oslin, David W. Lynch, Kevin G. Maisto, Stephen A. Lantinga, Larry J. McKay, James R. Possemato, Kyle Ingram, Erin Wierzbicki, Michael TI A Randomized Clinical Trial of Alcohol Care Management Delivered in Department of Veterans Affairs Primary Care Clinics Versus Specialty Addiction Treatment SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE addiction; primary care; treatment; randomized clinical trial ID BRIEF INTERVENTIONS; USE DISORDERS; DEPENDENCE; NALTREXONE; METAANALYSIS; POPULATIONS; RELIABILITY; ACAMPROSATE; EFFICACY; MISUSE AB Alcohol use disorder is one of the leading causes of disability worldwide. Despite the availability of efficacious treatments, few individuals with an alcohol use disorder are actively engaged in treatment. Available evidence suggests that primary care may play a crucial role in the identification of patients with an alcohol use disorder, delivery of interventions, and the success of treatment. The principal aims of this study were to test the effectiveness of a primary care-based Alcohol Care Management (ACM) program for alcohol use disorder and treatment engagement in veterans. The design of the study was a 26-week single-blind randomized clinical trial. The study was conducted in the primary care practices at three VA medical centers. Participants were randomly assigned to treatment in ACM or standard treatment in a specialty outpatient addiction treatment program. One hundred and sixty-three alcohol-dependent veterans were randomized. ACM focused on the use of pharmacotherapy and psychosocial support. ACM was delivered in-person or by telephone within the primary care clinic. Engagement in treatment and heavy alcohol consumption. The ACM condition had a significantly higher proportion of participants engaged in treatment over the 26 weeks [OR = 5.36, 95 % CI = (2.99, 9.59)]. The percentage of heavy drinking days were significantly lower in the ACM condition [OR = 2.16, 95 % CI = (1.27, 3.66)], while overall abstinence did not differ between groups. Results demonstrate that treatment for an alcohol use disorder can be delivered effectively within primary care, leading to greater rates of engagement in treatment and greater reductions in heavy drinking. C1 [Oslin, David W.; McKay, James R.; Ingram, Erin] Univ Penn, Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Oslin, David W.; Lynch, Kevin G.; McKay, James R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Maisto, Stephen A.; Lantinga, Larry J.; Possemato, Kyle] Syracuse Univ, Dept Psychol, Syracuse, NY USA. [Maisto, Stephen A.; Lantinga, Larry J.; Possemato, Kyle] VISN2, Dept Vet Affairs, Ctr Integrated Healthcare, Syracuse, NY USA. [Wierzbicki, Michael] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Oslin, DW (reprint author), Univ Penn, Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. EM oslin@upenn.edu FU Health Services Research and Development Program of the Department of Veteran Affairs (IIR); VISN 4 Mental Illness Research, Education, and Clinical Center at the Philadelphia VA Medical Center; VISN 2 Center for Integrated Healthcare; Career Development Award [K05 AA16928]; NIDA [K24 DA029062]; NIAAA [P01-AA016821] FX Supported, for the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript, by the following sources:; Health Services Research and Development Program of the Department of Veteran Affairs (IIR); The VISN 4 Mental Illness Research, Education, and Clinical Center at the Philadelphia VA Medical Center; The VISN 2 Center for Integrated Healthcare; Career Development Award [K05 AA16928 (Dr. Maisto)]; NIDA (K24 DA029062) and NIAAA (P01-AA016821) (Dr. McKay) NR 33 TC 24 Z9 24 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2014 VL 29 IS 1 BP 162 EP 168 DI 10.1007/s11606-013-2625-8 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 284WR UT WOS:000329352900031 PM 24052453 ER PT J AU Malte, CA AF Malte, Carol A. TI Capsule Commentary on Oslin et al., A Randomized Clinical Trial of Alcohol Care Management Delivered in Department of Veterans Affairs Primary Care Clinics Versus Specialty Addiction Treatment SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID BRIEF INTERVENTION; DEPENDENCE C1 VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. RP Malte, CA (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. EM Carol.malte@va.gov NR 5 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2014 VL 29 IS 1 BP 184 EP 184 DI 10.1007/s11606-013-2656-1 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 284WR UT WOS:000329352900041 PM 24129861 ER PT J AU Ranard, BL Ha, YP Meisel, ZF Asch, DA Hill, SS Becker, LB Seymour, AK Merchant, RM AF Ranard, Benjamin L. Ha, Yoonhee P. Meisel, Zachary F. Asch, David A. Hill, Shawndra S. Becker, Lance B. Seymour, Anne K. Merchant, Raina M. TI Crowdsourcing-Harnessing the Masses to Advance Health and Medicine, a Systematic Review SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE crowdsourcing; crowd sourcing; citizen scientist; citizen science; human computing ID DISTRIBUTED HUMAN INTELLIGENCE; FOLDING GAME PLAYERS; CT COLONOGRAPHY; ONLINE GAME AB Crowdsourcing research allows investigators to engage thousands of people to provide either data or data analysis. However, prior work has not documented the use of crowdsourcing in health and medical research. We sought to systematically review the literature to describe the scope of crowdsourcing in health research and to create a taxonomy to characterize past uses of this methodology for health and medical research. PubMed, Embase, and CINAHL through March 2013. Primary peer-reviewed literature that used crowdsourcing for health research. Two authors independently screened studies and abstracted data, including demographics of the crowd engaged and approaches to crowdsourcing. Twenty-one health-related studies utilizing crowdsourcing met eligibility criteria. Four distinct types of crowdsourcing tasks were identified: problem solving, data processing, surveillance/monitoring, and surveying. These studies collectively engaged a crowd of > 136,395 people, yet few studies reported demographics of the crowd. Only one (5 %) reported age, sex, and race statistics, and seven (33 %) reported at least one of these descriptors. Most reports included data on crowdsourcing logistics such as the length of crowdsourcing (n = 18, 86 %) and time to complete crowdsourcing task (n = 15, 71 %). All articles (n = 21, 100 %) reported employing some method for validating or improving the quality of data reported from the crowd. Gray literature not searched and only a sample of online survey articles included. Utilizing crowdsourcing can improve the quality, cost, and speed of a research project while engaging large segments of the public and creating novel science. Standardized guidelines are needed on crowdsourcing metrics that should be collected and reported to provide clarity and comparability in methods. C1 [Ranard, Benjamin L.; Ha, Yoonhee P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.; Merchant, Raina M.] Univ Penn, Penn Med Ctr Innovat, Philadelphia, PA 19104 USA. [Meisel, Zachary F.; Asch, David A.; Merchant, Raina M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Meisel, Zachary F.; Becker, Lance B.; Merchant, Raina M.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Asch, David A.; Hill, Shawndra S.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Seymour, Anne K.] Univ Penn, Univ Penn Lib, Philadelphia, PA 19104 USA. RP Merchant, RM (reprint author), Univ Penn, Perelman Sch Med, 423 Guardian Dr,Blockley Hall, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu OI Seymour, Anne/0000-0002-4285-7702; Asch, David/0000-0002-7970-286X FU NIH, K23 grant [10714038] FX NIH, K23 grant 10714038 (Merchant). NR 37 TC 57 Z9 57 U1 5 U2 54 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2014 VL 29 IS 1 BP 187 EP 203 DI 10.1007/s11606-013-2536-8 PG 17 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 284WR UT WOS:000329352900044 PM 23843021 ER PT J AU Anaya, A Plantmason, L Dhaliwal, G AF Anaya, Andres Plantmason, Lee Dhaliwal, Gurpreet TI Back Attack SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE decision making; clinical problem solving; back pain ID PARASPINAL COMPARTMENT SYNDROME; PAIN; RHABDOMYOLYSIS C1 [Anaya, Andres] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Plantmason, Lee] Univ So Calif, Dept Emergency Med, Los Angeles, CA 90033 USA. [Plantmason, Lee] Univ So Calif, Los Angeles Cty Med Ctr, Los Angeles, CA 90033 USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Plantmason, L (reprint author), Univ So Calif, Dept Emergency Med, 2051 Marengo St Inpatient Tower Room C1A100, Los Angeles, CA 90033 USA. EM lplantma@gmail.com NR 12 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2014 VL 29 IS 1 BP 255 EP 259 DI 10.1007/s11606-013-2487-0 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 284WR UT WOS:000329352900056 PM 23733373 ER PT J AU Guo, FJ Moellering, DR Garvey, WT AF Guo, Fangjian Moellering, Douglas R. Garvey, W. Timothy TI The progression of cardiometabolic disease: Validation of a new cardiometabolic disease staging system applicable to obesity SO OBESITY LA English DT Article ID CORONARY-HEART-DISEASE; TREATMENT PANEL-III; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; WEIGHT-LOSS; FOLLOW-UP; RISK AB Objective To validate a Cardiometabolic Disease Staging (CMDS) system for assigning risk level for diabetes, and all-cause and cardiovascular disease (CVD) mortality. Design and Methods Two large national cohorts, CARDIA and NHANES III, were used to validate CMDS. CMDS: Stage 0: metabolically healthy; Stage 1: one or two metabolic syndrome risk factors [other than impaired fasting glucose (IFG)]; Stage 2: IFG or impaired glucose tolerance (IGT) or metabolic syndrome (without IFG); Stage 3: two of three (IFG, IGT, and/or metabolic syndrome); and Stage 4: type 2 diabetes mellitus/CVD. Results In the CARDIA study, compared with Stage 0 metabolically healthy subjects, adjusted risk for diabetes exponentially increased from Stage 1 [hazard ratio (HR) 2.83, 95% confidence interval (CI): 1.76-4.55], to Stage 2 (HR 8.06, 95% CI 4.91-13.2), to Stage 3 (HR 23.5, 95% CI 13.7-40.1) (P for trend <0.001). In NHANES III, both cumulative incidence and multivariable adjusted HRs markedly increased for both all-cause and CVD mortality with advancement of the risk stage from Stages 0 to 4. Adjustment for body mass index (BMI) minimally affected the risks for diabetes and all-cause/CVD mortality using CMDS. Conclusion CMDS can discriminate a wide range of risk for diabetes, CVD mortality, and all-cause mortality independent of BMI, and should be studied as a risk assessment tool to guide interventions that prevent and treat cardiometabolic disease. C1 [Guo, Fangjian; Moellering, Douglas R.; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Guo, FJ (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. EM ilovedd@uab.edu; garveyt@uab.edu RI Guo, Fangjian/B-7705-2015 OI Guo, Fangjian/0000-0003-3729-2724 FU Merit Review program of the Department of Veterans Affairs; National Institutes of Health [DK-038765, DK-083562]; UAB Diabetes Research Center [P60-DK079626] FX The Merit Review program of the Department of Veterans Affairs, National Institutes of Health (DK-038765 and DK-083562), and the UAB Diabetes Research Center (P60-DK079626). NR 37 TC 17 Z9 19 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD JAN PY 2014 VL 22 IS 1 BP 110 EP 118 DI 10.1002/oby.20585 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 288LN UT WOS:000329613600020 PM 23894121 ER PT J AU McCarthy, JF Ilgen, MA Austin, K Blow, FC Katz, IR AF McCarthy, John F. Ilgen, Mark A. Austin, Karen Blow, Frederic C. Katz, Ira R. TI Associations between body mass index and suicide in the veterans affairs health system SO OBESITY LA English DT Article ID DEATH REPORTING SYSTEM; GENERAL-POPULATION; DEPRESSIVE SYMPTOMS; COMPLETED SUICIDE; RISK-FACTORS; US ADULTS; OBESITY; OVERWEIGHT; MEN; MORTALITY AB Objectives Associations between BMI and suicide risks and methods for individuals receiving care in the Veterans Health Administration (VHA) health system were evaluated. Design and Methods For 4,005,640 patients in fiscal years 2001-2002, multivariable survival analyses assessed associations between BMI and suicide, through FY2009. Covariates included demographics, psychiatric, and nonpsychiatric diagnoses, receipt of VHA mental health encounters, and regional network. Among suicide decedents, multivariable Generalized Estimating Equations (GEE) regression examined associations between BMI and suicide method. Results 1.3% of patients were underweight, 24.3% normal weight, 40.6% overweight, and 33.8% obese. Underweight was associated with increased suicide risk (adjusted hazard ratio [AHR] = 1.17, 95% CI: 1.01, 1.36) compared to normal. Overweight and obese status were associated with lower risk (AHR = 0.78, 95% CI: 0.74, 0.82; AHR = 0.63, 95% CI: 0.60, 0.66, respectively). Among suicide decedents, high lethality methods were most common among underweight and least common among obese individuals. Adjusting for covariates, BMI was not associated with method lethality, yet some associations were observed between BMI and specific methods. Conclusion Among VHA patients, BMI was negatively associated with suicide risks. These differences may partly relate to choice of suicide method. Low BMI offers an additional resource for clinical suicide risk assessments. C1 [McCarthy, John F.; Ilgen, Mark A.; Austin, Karen; Blow, Frederic C.; Katz, Ira R.] US Dept Vet Affairs, Off Mental Hlth Operat, Washington, DC 20420 USA. [McCarthy, John F.; Ilgen, Mark A.; Blow, Frederic C.] VA OMHO Serious Mental Illness Treatment Resource, Ann Arbor, MI USA. [McCarthy, John F.; Ilgen, Mark A.; Austin, Karen; Blow, Frederic C.] VA Ctr Clin Management Res, Washington, DC USA. [McCarthy, John F.; Ilgen, Mark A.; Blow, Frederic C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. RP McCarthy, JF (reprint author), US Dept Vet Affairs, Off Mental Hlth Operat, Washington, DC 20420 USA. EM john.mccarthy2@va.gov NR 40 TC 6 Z9 7 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD JAN PY 2014 VL 22 IS 1 BP 269 EP 276 DI 10.1002/oby.20422 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 288LN UT WOS:000329613600039 PM 23512622 ER PT J AU Metraux, S Stino, M Culhane, DP AF Metraux, Stephen Stino, Magdi Culhane, Dennis P. TI Validation of Self-Reported Veteran Status Among Two Sheltered Homeless Populations SO PUBLIC HEALTH REPORTS LA English DT Article ID INDIVIDUALS; TRUST AB Objectives. We assessed the accuracy of self-reported veteran status among sheltered homeless adults to assess the reliability of using self-report to determine the number of veterans in homeless populations and examine whether there are demographic correlates to inaccurate reporting of veteran status. Methods. Records on 5,860 sheltered adults from Columbus, Ohio, and 16,346 sheltered adults from New York City (NYC) were matched with U.S. Department of Veterans Affairs (VA) records. We analyzed the agreement between veteran,self-reporting and official records using descriptive measures, diagnostic tests, and logistic regression. Results. The degree of concordance was moderate. Using VA records rather than self-report data to determine veteran status increased homeless veteran prevalence rates by 27% in Columbus and 39% in NYC. Veterans with discordant veteran status (i.e., false positive or false negative) showed lower levels of services use in the VA (both cities) and in the municipal shelter system (NYC only). Younger veterans and women were at higher risk of not being identified as veterans. Conclusion. Administrative records can help to more accurately identify homeless veterans and to connect them to available services and benefits. C1 [Metraux, Stephen; Stino, Magdi; Culhane, Dennis P.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA 19104 USA. [Metraux, Stephen; Stino, Magdi] Allegheny Univ Hlth Sci, Dept Hlth Policy & Publ Hlth, Philadelphia, PA 19102 USA. [Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Metraux, S (reprint author), US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4101 Chester Ave, Philadelphia, PA 19104 USA. EM stephen.metraux@va.gov NR 23 TC 1 Z9 1 U1 0 U2 3 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JAN-FEB PY 2014 VL 129 IS 1 BP 73 EP 77 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 288BL UT WOS:000329586900010 PM 24381362 ER PT J AU van Erp, TGM Preda, A Nguyen, D Faziola, L Turner, J Bustillo, J Belger, A Lim, KO McEwen, S Voyvodic, J Mathalon, DH Ford, J Potkin, SG AF van Erp, Theo G. M. Preda, Adrian Dana Nguyen Faziola, Lawrence Turner, Jessica Bustillo, Juan Belger, Aysenil Lim, Kelvin O. McEwen, Sarah Voyvodic, James Mathalon, Daniel H. Ford, Judith Potkin, Steven G. CA FBIRN TI Converting positive and negative symptom scores between PANSS and SAPS/SANS SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Symptoms; Marder; Conversion; Meta; Multi-center ID SYNDROME-SCALE; RATING-SCALE; SCHIZOPHRENIA; DIMENSIONS; RECOMMENDATIONS; RELIABILITY; VALIDATION; TRIALS; MODEL AB The Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS), and the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) are the most widely used schizophrenia symptom rating scales, but despite their co-existence for 25 years no easily usable between-scale conversion mechanism exists. The aim of this study was to provide equations for between-scale symptom rating conversions. Two-hundred-and-five schizophrenia patients [mean age +/- SD = 39.5 +/- 11.6, 156 males] were assessed with the SANS, SAPS, and PANSS. Pearson's correlations between symptom scores from each of the scales were computed. Linear regression analyses, on data from 176 randomly selected patients, were performed to derive equations for converting ratings between the scales. Intraclass correlations, on data from the remaining 29 patients, not part of the regression analyses, were performed to determine rating conversion accuracy. Between-scale positive and negative symptom ratings were highly correlated. Intraclass correlations between the original positive and negative symptom ratings and those obtained via conversion of alternative ratings using the conversion equations were moderate to high (ICCs = 0.65 to 0.91). Regression-based equations may be useful for conversion between schizophrenia symptom severity as measured by the SANS/SAPS and PANSS, though additional validation is warranted. This study's conversion equations, implemented at http:/converteasy.org, may aid in the comparison of medication efficacy studies, in meta- and mega-analyses examining symptoms as moderator variables, and in retrospective combination of symptom data in multi-center data sharing projects that need to pool symptom rating data when such data are obtained using different scales. (C) 2013 Elsevier B.V. All rights reserved. C1 [van Erp, Theo G. M.; Preda, Adrian; Dana Nguyen; Faziola, Lawrence; Potkin, Steven G.; FBIRN] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92617 USA. [Turner, Jessica] Mind Res Network, Albuquerque, NM 87106 USA. [Turner, Jessica; Bustillo, Juan] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA. [Turner, Jessica; Bustillo, Juan] Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA. [Belger, Aysenil] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA. [Belger, Aysenil] Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA. [Lim, Kelvin O.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55454 USA. [McEwen, Sarah] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Voyvodic, James] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC 27710 USA. [Mathalon, Daniel H.; Ford, Judith] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Ford, Judith] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. RP van Erp, TGM (reprint author), Univ Calif Irvine, Sch Med, Dept Psychiat & Human Behav, 5251 Calif Ave,Suite 240C, Irvine, CA 92617 USA. RI Faziola, Lawrence/P-7686-2014; Turner, Jessica/H-7282-2015; Preda, Adrian /K-8889-2013 OI Faziola, Lawrence/0000-0002-0376-3586; Mathalon, Daniel/0000-0001-6090-4974; Turner, Jessica/0000-0003-0076-8434; Preda, Adrian /0000-0003-3373-2438; Belger, Aysenil/0000-0003-2687-1966; Potkin, Steven/0000-0003-1028-1013 FU National Center for Research Resources at the National Institutes of Health [NIH 1 U24 U24 RR021992]; National Institutes of Health (NIH) [1 U24 RR025736-01] FX This work was supported by the National Center for Research Resources at the National Institutes of Health (grant numbers: NIH 1 U24 U24 RR021992 (Function Biomedical Informatics Research Network) and National Institutes of Health (NIH) 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org). NR 34 TC 14 Z9 14 U1 2 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD JAN PY 2014 VL 152 IS 1 BP 289 EP 294 DI 10.1016/j.schres.2013.11.013 PG 6 WC Psychiatry SC Psychiatry GA 283AR UT WOS:000329217000042 PM 24332632 ER PT J AU Ishida, JH Johansen, KL AF Ishida, Julie H. Johansen, Kirsten L. TI Iron and Infection in Hemodialysis Patients SO SEMINARS IN DIALYSIS LA English DT Review ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; INTRAVENOUS IRON; POLYMORPHONUCLEAR LEUKOCYTES; MAINTENANCE HEMODIALYSIS; DIALYSIS PATIENTS; FERRIC GLUCONATE; YERSINIA-ENTEROCOLITICA; BACTERICIDAL FUNCTION; PRACTICE GUIDELINES AB Intravenous iron is an important component of the treatment of anemia of end-stage renal disease (ESRD), but it is biologically plausible that iron could increase the risk of infection through impairment of neutrophil and T-cell function and promotion of microbial growth. Any such increase in risk would be particularly important because infection is a significant cause of mortality and morbidity in dialysis patients. The overall evidence favors an association between iron and infection in hemodialysis patients, but the optimal iron management strategy to minimize infection risk has yet to be identified. There is a need for further research on this topic, particularly in light of increased utilization of intravenous iron following implementation of the bundled ESRD reimbursement system. C1 [Ishida, Julie H.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco VA Med Ctr, Dept Med, Div Nephrol, San Francisco, CA USA. RP Ishida, JH (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, Box 0532,521 Parnassus Ave,Clin Sci C443, San Francisco, CA 94143 USA. EM julie.ishida@ucsf.edu FU American Society of Nephrology; NIDDK [K24DK085153] FX Dr. Ishida is supported by the American Society of Nephrology Dr. Johansen is supported by the NIDDK (K24DK085153). NR 78 TC 17 Z9 18 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD JAN PY 2014 VL 27 IS 1 BP 26 EP 36 DI 10.1111/sdi.12168 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 286XH UT WOS:000329502100013 PM 24329610 ER PT J AU Grandner, MA Chakravorty, S Perlis, ML Oliver, L Gurubhagavatula, I AF Grandner, Michael A. Chakravorty, Subhajit Perlis, Michael L. Oliver, Linden Gurubhagavatula, Indira TI Habitual sleep duration associated with self-reported and objectively determined cardiometabolic risk factors SO SLEEP MEDICINE LA English DT Article DE Sleep duration; Epidemiology; Obesity; Cardiovascular disease; Hypertension; Cholesterol; Diabetes ID HEALTH INTERVIEW SURVEY; CARDIOVASCULAR-DISEASE; UNITED-STATES; LONG-SLEEP; NATIONAL-HEALTH; INSULIN-RESISTANCE; BLOOD-PRESSURE; METABOLIC CONSEQUENCES; HYPERTENSION INCIDENCE; INFLAMMATORY MARKERS AB Background: Self-reported short or long sleep duration has been associated with adverse cardiometabolic health outcomes in laboratory and epidemiologic studies, but interpretation of such data has been limited by methodologic issues. Methods: Adult respondents of the 2007-2008 US National Health and Nutrition Examination Survey (NHANES) were examined in a cross-sectional analysis (N = 5649). Self-reported sleep duration was categorized as very short (< 5 h), short (5-6 h), normal (7-8 h), or long (>= 9 h). Obesity, diabetes mellitus (DM), hypertension, and hyperlipidemia were objectively assessed by self-reported history. Statistical analyses included univariate comparisons across sleep duration categories for all variables. Binary logistic regression analyses and cardiometabolic factor as outcome, with sleep duration category as predictor, were assessed with and without covariates. Observed relationships were further assessed for dependence on race/ethnicity. Results: In adjusted analyses, very short sleep was associated with self-reported hypertension (odds ratio [OR], 2.02, [95% confidence interval {CI}, 1.45-2.81]; P < 0.0001), self-reported hyperlipidemia (OR, 1.96 [95% CI, 1.43-2.69]; P < 0.0001), objective hyperlipidemia (OR, 1.41 [95% CI, 1.04-1.91]; P = 0.03), self-reported DM (OR, 1.76 [95% CI, 1.13-2.74]; P = 0.01), and objective obesity (OR, 1.53 [95% CI, 1.03-1.43]; P = 0.005). Regarding short sleep (5-6 h), in adjusted analyses, elevated risk was seen for self-reported hypertension (OR, 1.22 [95% CI, 1.02-1.45]; P = 0.03) self-reported obesity (OR, 1.21 [95% CI, 1.03-1.43]; P = 0.02), and objective obesity (OR, 1.17 [95% CI, 1.00-1.38]; P < 0.05). Regarding long sleep (>= 9 h), no elevated risk was found for any outcomes. Interactions with race/ethnicity were significant for all outcomes; race/ethnicity differences in patterns of risk varied by outcome studied. In particular, the relationship between very short sleep and obesity was strongest among blacks and the relationship between short sleep and hypertension is strongest among non-Hispanic whites, blacks, and non-Mexican Hispanics/Latinos. Conclusions: Short sleep duration is associated with self-reported and objectively determined adverse cardiometabolic outcomes, even after adjustment for many covariates. Also, these patterns of risk depend on race/ethnicity. (C) 2013 Elsevier B. V. All rights reserved. C1 [Grandner, Michael A.; Chakravorty, Subhajit; Perlis, Michael L.; Oliver, Linden] Univ Penn, Perelman Sch Med, Dept Psychiat, Behav Sleep Med Program, Philadelphia, PA 19104 USA. [Grandner, Michael A.; Chakravorty, Subhajit; Perlis, Michael L.; Gurubhagavatula, Indira] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Chakravorty, Subhajit; Gurubhagavatula, Indira] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Gurubhagavatula, Indira] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Grandner, MA (reprint author), Univ Penn, Ctr Sleep & Circadian Neurobiol, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA. EM grandner@upenn.edu FU NCRR NIH HHS [UL1 RR024134]; NHLBI NIH HHS [K23 HL110216]; NIEHS NIH HHS [R21 ES022931] NR 128 TC 52 Z9 53 U1 4 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 EI 1878-5506 J9 SLEEP MED JI Sleep Med. PD JAN PY 2014 VL 15 IS 1 BP 42 EP 50 DI 10.1016/j.sleep.2013.09.012 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 283BW UT WOS:000329220600008 PM 24333222 ER PT J AU Brent, GA AF Brent, Gregory A. TI Commentary on: "American Thyroid Association Guide to Investigating Thyroid Hormone Economy and Action in Rodent and Cell Models," Bianco et al. SO THYROID LA English DT Editorial Material ID THERMOGENESIS; MUTATION C1 [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA. RP Brent, GA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu NR 10 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PD JAN 1 PY 2014 VL 24 IS 1 BP 1 EP 2 DI 10.1089/thy.2013.0679 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 285YM UT WOS:000329431000001 PM 24303889 ER EF